Grant ID,Grant Number,Title,Funding Amount in USD,Start Date,Start Year,End Date,End Year,Research Organization - standardized,GRID ID,Country of Research organization,Funder,Funder Country,pubs,patents,clinical_trials
grant.8172033,30410203277,疫苗－整体方案,1208,2004-11-30,2004.0,2004-12-31,2004,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,0,0,0
grant.7715379,620792,Engineering Inhalable Vaccines,26956,2017-04-01,2017.0,2018-03-31,2018,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6962629,599115,Engineering Inhalable Vaccines,26403,2016-04-01,2016.0,2017-03-31,2017,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6723913,251564,HIV Vaccine research,442366,2003-01-01,2003.0,2007-12-31,2007,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6722306,334174,HIV Vaccine Development,236067,2005-01-01,2005.0,2009-12-31,2009,Monash University,grid.1002.3,Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6716312,910292,Dengue virus vaccine.,130890,1991-01-01,1991.0,1993-12-31,1993,Royal Children's Hospital,grid.416107.5,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.5526688,578221,Engineering Inhalable Vaccines,27386,2015-04-01,2015.0,2016-03-31,2016,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.3733803,IC18980360,Schistosomiasis Vaccine Network.,0,1998-11-01,1998.0,2000-10-31,2000,Pasteur Institute of Lille; University of Edinburgh; Kenya Medical Research Institute; Ghent University; University of York; Centre de Recherche Médicale et Sanitaire; Oswaldo Cruz Foundation; Institute of Tropical Medicine Antwerp,grid.8970.6; grid.4305.2; grid.33058.3d; grid.5342.0; grid.5685.e; grid.452260.7; grid.418068.3; grid.11505.30,France; United Kingdom; Kenya; Belgium; United Kingdom; Niger; Brazil; Belgium,European Commission,Belgium,0,0,0
grant.3274273,7621798,Pneumococcal Ribosomal Vaccines,46000,1977-08-01,1977.0,1980-01-31,1980,University of Iowa,grid.214572.7,United States,Directorate for Biological Sciences,United States,0,0,0
grant.2936015,255890,Rational vaccine design,7138,2003-04-01,2003.0,2004-03-31,2004,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2863615,275254,Rational vaccine design,13447,2004-04-01,2004.0,2005-03-31,2005,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2815666,280679,Aquaticulture vaccines,23051,2004-04-01,2004.0,2005-03-31,2005,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2807651,295878,Aquaticulture vaccines,24761,2005-04-01,2005.0,2006-03-31,2006,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2800991,468513,Vaccines for aquaculture,4363,2010-04-01,2010.0,2011-03-31,2011,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2710461,Z01BC010456,Cancer Vaccine Development,0,2002-01-01,2002.0,2002-12-31,2002,,,,National Cancer Institute,United States,0,0,0
grant.2657659,R44AI033256,CRYPTOSPORIDIUM RECOMBINANT VACCINES,0,1992-08-01,1992.0,1996-10-30,1996,ImmuCell (United States),grid.420912.c,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2640369,R43AI040514,ANTIRETROVIAL DNA VACCINE,0,1996-09-30,1996.0,1997-08-14,1997,Cambridge Scientific (United States),grid.423337.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640228,R43AI036810,VACCINE FOR LEISHMANIASIS,0,1996-05-01,1996.0,1996-10-31,1996,Corixa Corporation,grid.284594.6,United States,National Institute of Allergy and Infectious Diseases,United States,8,1,0
grant.2426045,N01CB021155,CANCER VACCINE PRODUCTION,0,1992-08-30,1992.0,1993-12-07,1993,Sanofi (United States),grid.417555.7,United States,National Cancer Institute,United States,0,0,0
grant.2426044,N01CB021154,CANCER VACCINE PRODUCTION,0,1992-06-30,1992.0,1993-10-15,1993,,,,National Cancer Institute,United States,0,0,0
grant.2426039,N01CB021026,CANCER VACCINE PRODUCTION,0,1992-09-30,1992.0,1993-07-31,1993,,,,National Cancer Institute,United States,0,0,0
grant.2425936,N01BC021155,CANCER VACCINE PRODUCTION,0,1992-08-30,1992.0,1996-10-15,1996,Sanofi (United States),grid.417555.7,United States,National Cancer Institute,United States,0,0,0
grant.2425935,N01BC021154,CANCER VACCINE PRODUCTION,0,1992-06-30,1992.0,1993-10-15,1993,,,,National Cancer Institute,United States,0,0,0
grant.2425932,N01BC021026,CANCER VACCINE PRODUCTION,0,1992-09-30,1992.0,1996-12-31,1996,,,,National Cancer Institute,United States,0,0,0
grant.2425010,N01AI095375,HIV VACCINE PRODUCTION,61313,1999-06-30,1999.0,2006-06-29,2006,SRI International,grid.98913.3a,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2424436,N01AI015093,VACCINES FOR SAIDS,0,1990-12-31,1990.0,1996-09-30,1996,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.8068979,2813100406,Entwicklung viraler Vektorvakzinen/Markervakzinen,1136603,2006-10-01,2006.0,2010-12-31,2010,Friedrich Loeffler Institute,grid.417834.d,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.7106480,2010-00636,Herpes Vaccine project,29617,2010-06-01,2010.0,2011-12-01,2011,Chalmersinvest,grid.451683.d,Sweden,VINNOVA,Sweden,0,0,0
grant.2639983,R43AI030577,VACCINE DELIVERY SYSTEM FOR LIVE ROTAVIRUS VACCINES,0,1990-09-30,1990.0,1991-05-31,1991,CytRx (United States),grid.422976.c,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2355874,F05TW003686,IMMUNOLOGICAL STUDIES IN VACCINES OF RABIES VACCINE,0,1986-05-21,1986.0,1986-12-31,1986,Johns Hopkins University,grid.21107.35,United States,Fogarty International Center,United States,1,0,0
grant.7566903,IRLX0703,Vaccine adjuvant commercialisation project,22635,2007-12-07,2007.0,2008-05-07,2008,Callaghan Innovation,grid.418016.a,New Zealand,"Ministry of Business, Innovation and Employment",New Zealand,0,0,0
grant.7042623,SE1202,Shelf life of vaccines,67917,1990-04-01,1990.0,1993-03-31,1993,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7040393,OD0302,Duck viral Hepatitis vaccine,6767,1992-04-01,1992.0,1993-03-31,1993,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.6731478,946099,Novel vaccines against AIDS,70976,1994-01-01,1994.0,1995-12-31,1995,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6728996,980664,Synthetic peptides as vaccines,447769,1998-01-01,1998.0,2002-12-31,2002,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,4,0,0
grant.6723289,145882,Klebsiella Vaccines and Immunotherapeutics,63197,2002-01-01,2002.0,2004-12-31,2004,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6718929,943201,Malaria and Vaccine Research,1750550,1994-01-01,1994.0,1998-12-31,1998,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6713873,930849,Vaccines for complex organisms,36032,1993-01-01,1993.0,1993-12-31,1993,,,,National Health and Medical Research Council,Australia,0,0,0
grant.4442512,,DENGUE VACCINE DEVELOPMENT,50000,1985-10-01,1985.0,1986-09-30,1986,Hawaii Biotech (United States),grid.420613.2,United States,United States Department of the Army,United States,0,0,0
grant.4035473,2196,Novel Vaccines for Measles,86356,2008-10-01,2008.0,2010-09-30,2010,University of Saskatchewan,grid.25152.31,Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.2987461,79426,Streptococcal mastitis vaccine development,20686,1992-04-01,1992.0,1993-03-31,1993,University of Saskatchewan; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada,grid.25152.31; grid.55614.33; grid.55614.33,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2972379,153466,Bovine adenovirus vectored vaccines,259061,1997-04-01,1997.0,2000-03-31,2000,University of Saskatchewan; Vétoquinol (Canada),grid.25152.31; grid.450582.e,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2964974,388654,Vaccine formulation and delivery,178772,2005-04-01,2005.0,2009-03-31,2009,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2957579,60520,Streptococcal mastitis vaccine development,38760,1993-04-01,1993.0,1994-03-31,1994,University of Saskatchewan; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada,grid.25152.31; grid.55614.33; grid.55614.33,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2950584,519469,Vaccins thérapeutiques anti-cancer,4498,2012-04-01,2012.0,2013-03-31,2013,GlaxoSmithKline (Canada),grid.420846.c,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2920553,464727,Subunit vaccines for aquaculture,31616,2010-04-01,2010.0,2011-03-31,2011,Pfizer (Canada),grid.421137.2,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2915638,366693,Pan-PRovincial Vaccine ENTerprise,3230548,2007-04-01,2007.0,2008-03-31,2008,Pan-Provincial Vaccine Enterprise,grid.440055.0,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2912254,285269,Vaccine formulation and delivery,49951,2004-04-01,2004.0,2005-03-31,2005,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2880945,379652,Vaccines for farm fish,4184,2007-04-01,2007.0,2008-03-31,2008,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2877426,516321,Vaccins thérapeutiques anti-cancer,4498,2012-04-01,2012.0,2013-03-31,2013,GlaxoSmithKline (Canada),grid.420846.c,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2828580,495065,Vaccins thérapeutiques anti-cancer,4546,2011-04-01,2011.0,2012-03-31,2012,GlaxoSmithKline (Canada),grid.420846.c,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2805504,379651,Vaccines for farm fish,4184,2007-04-01,2007.0,2008-03-31,2008,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2795214,330169,Improving cancer vaccine efficacy,15247,2006-04-01,2006.0,2007-03-31,2007,McMaster University,grid.25073.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2692263,U01IP000464,NEW VACCINE SURVEILLANCE NETWORK,3455122,2011-08-01,2011.0,2017-07-31,2017,Vanderbilt University,grid.152326.1,United States,Centers for Disease Control and Prevention,United States,4,0,0
grant.2688631,U01CA061398,MACROPHAGE-BASED MELANOMA VACCINE,0,1993-09-01,1993.0,1997-09-04,1997,University of Connecticut Health Center,grid.208078.5,United States,National Cancer Institute,United States,10,0,0
grant.2657670,R44AI034679,HELICOBACTER PYLORI MUCOSAL VACCINE,0,1993-09-30,1993.0,1997-08-31,1997,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2640366,R43AI040433,MALARIA VACCINE ADJUVANT DEVELOPMENT,0,1996-09-30,1996.0,1997-03-31,1997,Corixa Corporation,grid.284594.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2597598,R21AI045391,HIV GP120 GLYCOCONJUGATE VACCINES,485633,2000-02-15,2000.0,2004-01-31,2004,Brigham and Women's Hospital,grid.62560.37,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2424826,N01AI065303,SIMIAN VACCINE EVALUATION UNITS,838646,1996-06-30,1996.0,2001-06-29,2001,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2424691,N01AI052576,TESTING VACCINES IN CHILDREN,0,1985-02-01,1985.0,1990-02-03,1990,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2424653,N01AI045240,HLA AND VACCINES (BAA),0,1994-09-30,1994.0,1999-09-29,1999,Mayo Clinic,grid.66875.3a,United States,National Institute of Allergy and Infectious Diseases,United States,19,0,0
grant.2424634,N01AI045211,AIDS VACCINE EVALUATION UNITS,52371,1994-05-31,1994.0,2000-05-31,2000,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,27,0,0
grant.2424633,N01AI045210,AIDS VACCINE EVALUATION UNITS,113783,1994-05-31,1994.0,2000-05-31,2000,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,22,0,0
grant.2424632,N01AI045209,AIDS VACCINE EVALUATION UNITS,378543,1994-05-31,1994.0,2000-05-31,2000,University of Alabama at Birmingham,grid.265892.2,United States,National Institute of Allergy and Infectious Diseases,United States,17,0,0
grant.2424631,N01AI045208,AIDS VACCINE EVALUATION UNITS,113000,1994-05-31,1994.0,2000-05-31,2000,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,20,0,0
grant.2424630,N01AI045207,AIDS VACCINE EVALUATION UNITS,534630,1994-05-27,1994.0,2000-05-31,2000,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,15,0,0
grant.2424629,N01AI045206,AIDS VACCINE EVALUATION UNITS,39000,1994-05-31,1994.0,2000-05-31,2000,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,15,0,0
grant.2424455,N01AI015114,EVALUATION OF CANDIDATE VACCINES,0,1991-06-18,1991.0,1996-09-30,1996,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424372,N01AI005065,AIDS VACCINE EVALUATION UNITS,0,1990-02-01,1990.0,1995-01-31,1995,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,16,0,0
grant.2393802,H23IP000735,IMMUNIZATION & VACCINES FOR CHILDREN,8807296,2013-01-01,2013.0,2017-12-31,2017,Philadelphia Department of Public Health,grid.280512.c,United States,Centers for Disease Control and Prevention,United States,1,0,0
grant.2393756,H23IP000689,Hepatatis B Vaccine Pilot,1265722,2012-09-30,2012.0,2015-06-29,2015,Virginia Department of Health,grid.280313.b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.7987079,0311300 /8,Verbundprojekt: Verfahren zur Impfstoffentwicklung: Rekombinante Impfstoffe Impfstoffe gegen virale Erkrankungen von Salmoniden,183534,1996-07-01,1996.0,1999-06-30,1999,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.8217971,39789010,基因工程疫苗的机理,120798,1998-01-01,1998.0,2000-12-31,2000,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,2,0,0
grant.8176576,31210103063,坏死杆菌重组亚单位疫苗研究,1901,2012-11-09,2012.0,2012-12-31,2012,,,,National Natural Science Foundation of China,China,0,0,0
grant.8175344,30910303037,2009亚洲DNA疫苗国际年会,5854,2009-07-01,2009.0,2009-12-31,2009,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,0,0,0
grant.8172020,30410203257,2004年DNA疫苗国际会议,1691,2004-11-16,2004.0,2004-12-31,2004,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8166566,30010427,第三届疫苗研究年会,1086,2000-01-01,2000.0,2000-12-31,2000,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.7988463,0313170,BioChancePLUS: Therapeutische Vakzinierung gegen Multiple Sklerose,512009,2004-07-01,2004.0,2007-06-30,2007,EMC microcollections (Germany),grid.424419.e,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7821014,BCTR9831,Improved Vaccines for Breast Cancer Immunotherapy,200000,1998-05-01,1998.0,2001-04-30,2001,"University of California, Berkeley",grid.47840.3f,United States,Susan G. Komen Breast Cancer Foundation,United States,0,0,0
grant.7688859,,Sterilization Vaccine for Cattle,0,2006-07-01,2006.0,2006-12-01,2006,Washington State University; Washington State University; Yüzüncü Yıl University,grid.30064.31; grid.30064.31; grid.411703.0,United States; United States; Turkey,Council for International Exchange of Scholars,United States,0,0,0
grant.7685445,,Vaccine Production in Plants,0,2011-01-01,2011.0,2011-09-30,2011,Pitzer College; Pitzer College; Pitzer College; Pitzer College; University of Botswana; University of Botswana; University of Botswana,grid.418658.6; grid.418658.6; grid.418658.6; grid.418658.6; grid.7621.2; grid.7621.2; grid.7621.2,United States; United States; United States; United States; Botswana; Botswana; Botswana,Council for International Exchange of Scholars,United States,0,0,0
grant.7666696,,Novel vaccine formulations against tuberculosis,295003,2002-10-01,2002.0,2005-09-30,2005,McMaster University,grid.25073.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7664870,,Development of recombinant TB vaccine,101459,1999-06-01,1999.0,2003-05-31,2003,McMaster University,grid.25073.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7628231,,Hepatitis C: Vaccines and Immunotherapy,9841,2000-04-01,2000.0,2001-10-31,2001,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7623308,,DNA vaccine for chlamydia,67329,1999-04-01,1999.0,2001-03-31,2001,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7575791,211347,nd,1514,2016-04-01,2016.0,2017-03-31,2017,Université de Sherbrooke,grid.86715.3d,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.7568437,VIRX0201,New Generation Recombinant Viral Vaccine Vectors,81841,2002-07-01,2002.0,2003-06-30,2003,,,,"Ministry of Business, Innovation and Employment",New Zealand,0,0,0
grant.7567590,SWSS0402,The automated synthesis of tuberculosis vaccines,182350,2004-07-01,2004.0,2007-08-31,2007,Malaghan Institute of Medical Research,grid.250086.9,New Zealand,"Ministry of Business, Innovation and Employment",New Zealand,0,0,0
grant.7456676,2010-0029242,신변종 인플루엔자 바이러스 제어 연구,0,2010-01-01,2010.0,2011-01-01,2011,Korea University,grid.222754.4,South Korea,National Research Foundation of Korea,South Korea,7,0,0
grant.7437133,762208,Mucosal Vaccine against HIV-1 Infection,66584,2008-04-01,2008.0,2010-03-31,2010,University of Hong Kong,grid.194645.b,China,University Grants Committee,China,4,0,0
grant.7167590,AF/090/97,Oral DNA Vaccines,638466,1997-01-01,1997.0,1999-01-31,1999,University of Hong Kong; University of Hong Kong,grid.194645.b; grid.194645.b,China; China,Innovation and Technology Commission,China,0,0,0
grant.7149998,,Microcontainers for oral vaccine delivery,579532,2014-01-01,2014.0,2014-12-31,2014,Technical University of Denmark,grid.5170.3,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7148384,,Microcontainers for oral vaccine delivery,88992,2014-01-01,2014.0,2014-12-31,2014,Technical University of Denmark,grid.5170.3,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7043734,VM0108,EC collaborative study for tetanus vaccines,23691,1992-04-01,1992.0,1993-03-31,1993,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042974,SE2805,Antigenic properties of vaccine virus strains,230794,1996-04-01,1996.0,1999-03-31,1999,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042624,SE1203,Alternative methods of formulating FMDV vaccines,74889,1990-04-01,1990.0,1993-03-31,1993,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042622,SE1201,To maintain the footandmouth vaccine bank,552165,1990-04-01,1990.0,1993-03-31,1993,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.6972056,609967,Vaccins et adjuvants pour la vache laitière,3391,2016-04-01,2016.0,2017-03-31,2017,Université de Sherbrooke,grid.86715.3d,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6968725,606399,Prototype vaccine against sea lice,3391,2016-04-01,2016.0,2017-03-31,2017,University of Prince Edward Island,grid.139596.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6966722,604388,Thermal Stabilization of Phage and Vaccines,3391,2016-04-01,2016.0,2017-03-31,2017,McMaster University,grid.25073.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6844591,159106,A DNA Vaccine to Prevent Schistosomiasis,71382,2001-01-01,2001.0,2004-12-31,2004,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6735165,890745,Immune response to malaria vaccine candidate,229287,1989-01-01,1989.0,1991-12-31,1991,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6732885,900006,Development of a contraceptive vaccine,46740,1990-01-01,1990.0,1991-12-31,1991,Royal North Shore Hospital,grid.412703.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6731341,920969,Challenging the malaria vaccine development strategy,78134,1992-01-01,1992.0,1998-12-31,1998,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6730713,596899,Diabetes Vaccine Development Centre (DVDC),5147415,2010-01-01,2010.0,2017-12-31,2017,Melbourne Health; Melbourne Health; Melbourne Health,grid.429299.d; grid.429299.d; grid.429299.d,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6729465,900655,Vivax malaria sporozoite vaccine development,84188,1990-01-01,1990.0,1992-12-31,1992,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6729082,920275,New vaccines produced by genetic engineering,136593,1992-01-01,1992.0,1994-12-31,1994,Macquarie University,grid.1004.5,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6726453,997640,A Mucosal HIV Polytype Vaccine,33003,1999-01-01,1999.0,2001-12-31,2001,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6725165,960338,HIV (AIDS) vaccine delivery vectors,120675,1996-01-01,1996.0,1998-12-31,1998,,,,National Health and Medical Research Council,Australia,1,0,0
grant.6725082,920330,A vaccine for cervical cancer,133297,1992-01-01,1992.0,1994-12-31,1994,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6725032,910123,Development of an oral pneumococcal vaccine.,68538,1991-01-01,1991.0,1993-12-31,1993,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6724834,910471,Development of new types of vaccines.,116900,1991-01-01,1991.0,1993-12-31,1993,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6723804,209187,DNA and avipox vaccines for HIV.,64693,2002-01-01,2002.0,2007-12-31,2007,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6723056,456152,Characterisation of Neisseria meningitidis vaccine candidates,298213,2007-01-01,2007.0,2013-12-31,2013,Griffith University,grid.1022.1,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6716599,950876,Towards a vaccine against hepatitis e,96548,1995-01-01,1995.0,1997-12-31,1997,Burnet Institute,grid.1056.2,Australia,National Health and Medical Research Council,Australia,4,0,0
grant.6714669,880246,A modern vaccine against leptospirosis,158968,1988-01-01,1988.0,1990-12-31,1990,Monash University,grid.1002.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6714037,900820,Development of an improved pneumococcal vaccine,148678,1990-01-01,1990.0,1992-12-31,1992,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6713255,971030,Additional vaccine antigens for chlamydia,109364,1997-01-01,1997.0,1999-12-31,1999,Menzies School of Health Research,grid.271089.5,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6582874,OPP3431,To support the Vaccine Leadership Conference,40000,2000-06-01,2000.0,2001-06-01,2001,University of Southern California,grid.42505.36,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6370857,X46120----570027,風診生ワクチンに関する研究,5523,1971-01-01,1971.0,1971-12-31,1971,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6363940,X45120-----70027,風疹生ワクチンに関する研究,5523,1970-01-01,1970.0,1970-12-31,1970,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6363488,X44120----371029,流行性耳下腺炎生ワクチンに関する研究,6907,1969-01-01,1969.0,1969-12-31,1969,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6343961,X41120-----71094,インフルエンザ生ワクチンに関する研究,6907,1966-01-01,1966.0,1966-12-31,1966,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6317005,X00120----187045,インフルエンザ生ワクチンに関する研究,8978,1976-01-01,1976.0,1976-12-31,1976,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6315891,X00120----287054,インフルエンザ生ワクチンに関する研究,11050,1977-01-01,1977.0,1977-12-31,1977,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6233441,61771809,合成マラリアワクチンの開発研究,6907,1986-01-01,1986.0,1986-12-31,1986,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6193400,E 50,Biochemical characterization of a vaccine,0,2000-07-01,2000.0,2002-06-30,2002,University of Natural Resources and Life Sciences; University of Natural Resources and Life Sciences,grid.5173.0; grid.5173.0,Austria; Austria,FWF Austrian Science Fund,Austria,0,0,0
grant.6171313,56770791,単純ヘルペスウイルスワクチンの研究,6559,1981-01-01,1981.0,1981-12-31,1981,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6169577,56870047,パラインフルエンザウイルスワクチンの開発,12430,1981-01-01,1981.0,1981-12-31,1981,Nagoya University,grid.27476.30,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5896926,16922177,新規腫瘍ワクチンの作製,6934,2004-01-01,2004.0,2004-12-31,2004,Mirai Hospital,grid.505850.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5526642,583834,Anti-Vaccine Blog Annotation Project,3518,2015-04-01,2015.0,2016-03-31,2016,Concordia University,grid.410319.e,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5502450,hrc_aae0a049,Vaccine-based immunotherapy of cancer,3578777,2010-01-01,2010.0,2015-01-01,2015,Malaghan Institute of Medical Research,grid.250086.9,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5246711,N01AI95367-0-0-0,HIV VACCINE PRODUCTION,126906,1999-07-09,1999.0,2008-08-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246674,N01AI60019-4-0-1,Therapeutics/Vaccine Teams,5519281,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246626,N01AI50040-5-0-1,Tularemia Vaccine Development,0,2005-09-30,2005.0,2010-09-29,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5070451,Y2080775,幽门螺杆菌磷酸钙纳米疫苗的研究,0,2008-01-01,2008.0,2013-12-31,2013,Hangzhou Normal University,grid.410595.c,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5061344,DRT-S98-93,Anti-tick Vaccines,50929,1999-06-30,1999.0,2001-06-30,2001,"University of California, Irvine",grid.266093.8,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.4641309,189030,SEVAPLANT - Secure Vaccine Production in Plants,8860,2008-01-01,2008.0,2008-12-31,2008,,,,The Research Council of Norway,Norway,0,0,0
grant.4168271,561325,Development of Novel Vaccines through Glycoengineering,4071,2014-04-01,2014.0,2015-03-31,2015,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.3739684,BIO4980503,Mucosal vaccines against autoimmune disease,0,1998-09-01,1998.0,2000-08-31,2000,French Institute of Health and Medical Research; University of Gothenburg; Paris Descartes University; Novo Nordisk (Denmark),grid.7429.8; grid.8761.8; grid.10992.33; grid.425956.9,France; Sweden; France; Denmark,European Commission,Belgium,0,0,0
grant.3706272,TS1*0347,DEVELOPMENT OF MALARIA VACCINE,0,1985-01-01,1985.0,1987-07-31,1987,State Serum Institute,grid.6203.7,Denmark,European Commission,Belgium,0,0,0
grant.3702523,TS2*0103,VACCINES AGAINST TROPICAL THEILERIOSIS,0,1989-02-01,1989.0,1993-06-30,1993,University of Edinburgh,grid.4305.2,United Kingdom,European Commission,Belgium,0,0,0
grant.3652600,540031,Creation of an anti-diarrhea vaccine,4364,2013-04-01,2013.0,2014-03-31,2014,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.3309929,8026742,Fish Biologics Symposium: Serodiagnostics and Vaccines,6536,1981-02-15,1981.0,1981-08-31,1981,United States Fish and Wildlife Service; United States Fish and Wildlife Service,grid.462979.7; grid.462979.7,United States; United States,Directorate for Engineering,United States,0,0,0
grant.2986898,217170,Oral delievery of vaccines to salmonids,19106,2002-04-01,2002.0,2003-03-31,2003,,,,Natural Sciences and Engineering Research Council,Canada,1,0,0
grant.2985999,304464,Tumor associated carbohydrates and vaccine design,96926,2003-04-01,2003.0,2006-03-31,2006,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2984549,10244,Vaccines for bovine respiratory disease,10998,1996-04-01,1996.0,1997-03-31,1997,University of Saskatchewan; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada,grid.25152.31; grid.55614.33; grid.55614.33,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2974921,42673,Vaccines for bovine respiratory disease,21960,1994-04-01,1994.0,1995-03-31,1995,University of Saskatchewan; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada,grid.25152.31; grid.55614.33; grid.55614.33,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2971636,153531,Développement_d'un vaccin contre Streptococcus suis,64288,1999-04-01,1999.0,2000-03-31,2000,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2963297,134249,Development of subunit Streptococcus suis vaccines,45902,1997-04-01,1997.0,1999-03-31,1999,University of Saskatchewan; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada,grid.25152.31; grid.55614.33; grid.55614.33; grid.55614.33; grid.55614.33; grid.55614.33,Canada; Canada; Canada; Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2953859,29549,Development of subunit Streptococcus suis vaccines,23952,1995-04-01,1995.0,1996-03-31,1996,University of Saskatchewan; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada,grid.25152.31; grid.55614.33; grid.55614.33; grid.55614.33; grid.55614.33; grid.55614.33,Canada; Canada; Canada; Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2951075,137414,Développement_dun vaccin contre Streptococcus suis,66739,1998-04-01,1998.0,1999-03-31,1999,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2945193,454883,Carbohydrate-based anti cancer vaccines,193054,2006-04-01,2006.0,2011-03-31,2011,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2937592,511553,Vaccines comprising heat-sensitive transgenes,4998,2012-04-01,2012.0,2013-03-31,2013,University of Victoria,grid.143640.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2937042,309395,A vaccine to inhibit tick feeding,79436,2004-04-01,2004.0,2006-03-31,2006,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2935778,175434,Porcine cicovirus pathogenesis and vaccine development,105178,1998-04-01,1998.0,2001-03-31,2001,University of Saskatchewan; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada,grid.25152.31; grid.55614.33; grid.55614.33,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2914065,408200,DNA vaccine for avian influenza,4216,2008-04-01,2008.0,2009-03-31,2009,University of Manitoba,grid.21613.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2910038,240059,Oral delivery of vaccines and immunomodulators,72085,2000-04-01,2000.0,2004-03-31,2004,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2899455,421077,Bioinformatics and intelligent vaccine design,102599,2005-04-01,2005.0,2010-03-31,2010,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2898752,192792,Tumor Associated Carbohydrates and Vaccine design,52765,2000-04-01,2000.0,2002-03-31,2002,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2896132,410332,Developing plant based vaccines from forages,4216,2008-04-01,2008.0,2009-03-31,2009,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2869083,294165,Bovine adenovirus-3 vectored vaccines,580948,2003-04-01,2003.0,2006-03-31,2006,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2835164,372295,Possible peptide vaccine candidtates for leishmania,16102,2007-04-01,2007.0,2008-03-31,2008,University of Toronto,grid.17063.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2824183,404453,Recombinant vaccine development for tenacibaculum maritimum,4216,2008-04-01,2008.0,2009-03-31,2009,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2813726,255717,Oral delievery of vaccines to salmonids,1634,2003-04-01,2003.0,2004-03-31,2004,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2694848,U13FD003568,Annual Conference on Vaccine Research,15000,2008-08-15,2008.0,2013-07-31,2013,,,,United States Food and Drug Administration,United States,0,0,0
grant.2692184,U01IP000019,Varicella and Viral Vaccine Preventable Disease,752462,2004-09-30,2004.0,2011-09-29,2011,Philadelphia Department of Public Health,grid.280512.c,United States,Centers for Disease Control and Prevention,United States,5,0,0
grant.2687621,U01AI056438,Alphavirus Replicon Vaccines to Encephalitis Viruses,7497149,2003-09-01,2003.0,2009-12-31,2009,AlphaVax (United States),grid.422340.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,6,0
grant.2687368,U01AI037546,MALARIA VACCINE RESEARCH AND DEVELOPMENT PROJECT,0,1994-09-01,1994.0,1996-08-31,1996,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687218,U01AI030238,STRATEGIES FOR HIV VACCINE DEVELOPMENT,0,1990-06-15,1990.0,1996-11-30,1996,"University of California, San Diego",grid.266100.3,United States,National Institute of Allergy and Infectious Diseases,United States,13,1,0
grant.2687093,U01AI024762,LIPOSOME MICROENCAPSULATION OF VACCINE ANTIGENS,0,1987-06-01,1987.0,1990-05-31,1990,University of Tennessee at Knoxville,grid.411461.7,United States,National Institute of Allergy and Infectious Diseases,United States,14,0,0
grant.2666074,R56AI064745,MULTIVALENT VACCINE FOR LYMPHATIC FILARIASIS,310000,2006-07-15,2006.0,2007-07-31,2007,University of Illinois at Chicago,grid.185648.6,United States,National Institute of Allergy and Infectious Diseases,United States,20,0,0
grant.2665915,R56AI052012,An Envelope Containing HIV Pseudovirion Vaccine,247200,2002-05-01,2002.0,2008-08-31,2008,Brentwood Biomedical Research Institute,grid.280472.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2664798,R55DC004583,MICROBIAL POPULATION STRATEGY FOR VACCINE DEVELOPMENT,100000,2001-02-01,2001.0,2003-01-31,2003,Boston Medical Center,grid.239424.a,United States,National Institute on Deafness and Other Communication Disorders,United States,9,0,0
grant.2643578,R43CA069969,THERAPEUTIC TUMOR VACCINE AGAINST MUC-1,0,1996-05-24,1996.0,1996-11-23,1996,Corixa Corporation,grid.284594.6,United States,National Cancer Institute,United States,0,0,0
grant.2643577,R43CA069967,SYNTHESIS OF RNA CANCER VACCINES,0,1996-03-10,1996.0,1997-08-31,1997,Ambion Diagnostics,grid.281037.f,United States,National Cancer Institute,United States,0,0,0
grant.2643549,R43CA068957,DEVELOPMENT OF SYNTHETIC CANCER VACCINES,0,1996-08-15,1996.0,1997-10-31,1997,,,,National Cancer Institute,United States,0,0,0
grant.2640348,R43AI039909,NOVEL VACCINE FOR HELICOBACTER PYLORI,0,1996-09-01,1996.0,1997-02-28,1997,Panorama Research (United States),grid.429970.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640344,R43AI039894,HIV-1 VACCINE FOR DEVELOPING COUNTRIES,0,1996-09-01,1996.0,1997-02-28,1997,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640324,R43AI039346,DEVELOPMENT OF CAMPYLOBACTER FLAGELLIN SUBUNIT VACCINE,0,1996-09-30,1996.0,1997-07-31,1997,Hawaii Biotech (United States),grid.420613.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640316,R43AI039324,DEVELOPMENT OF A NOVEL VACCINE STRATEGY,0,1996-09-01,1996.0,1997-02-28,1997,Bristol-Myers Squibb (United States),grid.419971.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640237,R43AI037354,SUSTAINED RELEASE FOR VACCINES AND ADJUVANTS,0,1996-09-30,1996.0,1997-05-31,1997,Lynntech,grid.280661.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640236,R43AI037352,BIODEGRADABLE MINERAL MICROSPHERE ADJUVANTS FOR VACCINES,0,1996-09-01,1996.0,1998-02-28,1998,BioTek (United States),grid.288134.4,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2639795,R43AI024371,SYNTHETIC VACCINES UTILIZING BACULOVIRUS POLYHEDRA,0,1987-05-01,1987.0,1987-10-31,1987,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2636315,R41AI040449,DEVELOPMENT OF ROTAVIRUS DNA VACCINES,0,1996-09-01,1996.0,1997-08-31,1997,Antigen Express (United States),grid.417452.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2636304,R41AI038606,BIVALENT CONJUGATED RSV PNEUMOCOCCUS VACCINE,0,1995-08-07,1995.0,1997-02-06,1997,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2636298,R41AI036585,AVIRULENT SALMONELLA HOST-VECTOR VACCINE SYSTEMS,0,1994-09-01,1994.0,1996-02-29,1996,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2625146,R29AI032463,SALMONELLA/HUMAN IMMUNODEFICIENCY VIRUS VACCINE VECTOR,0,1992-07-01,1992.0,1997-04-30,1997,University of Colorado Anschutz Medical Campus,grid.430503.1,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2608574,R21DK057122,A VACCINE FOR IMMUNE MEDIATED DIABETES,160465,1999-09-30,1999.0,2002-08-31,2002,Cornell University,grid.5386.8,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,1,0,0
grant.2602929,R21CA082869,CHIMERIC HER-2 PEPTIDE VACCINE,130785,1999-09-01,1999.0,2002-08-31,2002,University of Alabama at Birmingham,grid.265892.2,United States,National Cancer Institute,United States,0,0,0
grant.2597635,R21AI046259,CYTOMEGALOVIRUS VECTORS FOR HIV VACCINE DEVELOPMENT,239250,1999-09-30,1999.0,2002-09-29,2002,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2572211,R03DE011313,A RECOMBINANT PORPHYROMONAS GINGIVALIS VACCINE,0,1995-02-01,1995.0,1997-01-31,1997,"University at Buffalo, State University of New York",grid.273335.3,United States,National Institute of Dental and Craniofacial Research,United States,1,0,0
grant.2566750,R03AI031994,INDO-US VACCINE ACTION PROGRAM,0,1991-09-15,1991.0,1993-08-31,1993,University of Colorado Anschutz Medical Campus,grid.430503.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2566749,R03AI030994,INDO-US VACCINE ACTION PROGRAM,0,1990-06-01,1990.0,1994-05-31,1994,Texas Tech University Health Sciences Center,grid.416992.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2566740,R03AI030346,INDO-US VACCINE ACTION PROGRAM,0,1990-02-01,1990.0,1993-10-31,1993,Stanford University,grid.168010.e,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2566739,R03AI030345,INDO-US VACCINE ACTION PROGRAM,0,1990-02-01,1990.0,1993-01-31,1993,University of Colorado Anschutz Medical Campus,grid.430503.1,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2566738,R03AI030344,INDO-US VACCINE ACTION PROGRAM,0,1990-02-01,1990.0,1993-01-31,1993,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2489689,R01DE006153,CHILDHOOD VACCINES AND DENTAL CARIES IMMUNITY,0,1982-08-01,1982.0,2003-04-30,2003,Harvard University,grid.38142.3c,United States,National Institute of Dental and Craniofacial Research,United States,32,4,0
grant.2474868,R01CA085868,ENHANCING TUMOR VACCINE IMMUNOGENICITY BY ANTIGAL,409875,1999-08-01,1999.0,2002-07-31,2002,Rush University Medical Center,grid.240684.c,United States,National Cancer Institute,United States,7,0,0
grant.2471363,R01CA058484,IMMUNOLOGICAL EFFECTS OF MELANOMA VACCINE THERAPY,0,1993-03-25,1993.0,1997-02-28,1997,New York University,grid.137628.9,United States,National Cancer Institute,United States,7,0,0
grant.2471277,R01CA057820,BREAST TUMOR SPECIFIC IMMUNITY--VACCINE DESIGN,0,1992-08-07,1992.0,1998-05-31,1998,University of Pittsburgh,grid.21925.3d,United States,National Cancer Institute,United States,11,0,0
grant.2471271,R01CA057778,ANTITUMOR ARTIFICIAL RECEPTORS AS CANCER VACCINES,0,1992-07-16,1992.0,1997-06-30,1997,University of Wisconsin–Madison,grid.14003.36,United States,National Cancer Institute,United States,4,0,0
grant.2454716,R01AI046164,IMMUNOLOGICALLY FOCUSED APPROACH TO AIDS VACCINE,858983,1999-06-01,1999.0,2004-05-31,2004,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,12,1,0
grant.2453176,R01AI037256,VACCINE INTERVENTION FOR LYME BORRELIOSIS,1709592,1994-09-30,1994.0,2004-08-31,2004,Brookhaven National Laboratory,grid.202665.5,United States,National Institute of Allergy and Infectious Diseases,United States,23,9,0
grant.2452868,R01AI035027,SECOND-GENERATION VACCINES AGAINST LYME DISEASE,0,1993-12-01,1993.0,1998-02-28,1998,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,6,4,0
grant.2452627,R01AI033544,MICROSPHERES TO ENHANCE VACCINE IMMUNOGENICITY,0,1992-09-30,1992.0,1998-05-31,1998,University of Alabama at Birmingham,grid.265892.2,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2452157,R01AI031064,RATIONALE FOR SPOROZOITE MALARIA VACCINE DEVELOPMENT,0,1992-02-01,1992.0,1997-01-31,1997,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2450816,R01AI023269,NONLIVING VACCINE AGAINST S MANSONI,0,1986-09-01,1986.0,1991-04-30,1991,George Washington University,grid.253615.6,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2433676,N43CM057766,MONOCLONAL ANTIBODY ANTI-IDIOTYPE TUMOR VACCINES,0,1985-09-23,1985.0,1985-12-31,1985,Biogen (United States),grid.417832.b,United States,National Cancer Institute,United States,0,0,0
grant.2433640,N43AI095018,ADENOVIRUS RECOMBINANTS FOR VACCINE EFFICACY,0,1989-06-01,1989.0,1989-12-31,1989,SeraCare Life Sciences (United States),grid.422121.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2433628,N43AI052603,DEVELOP LIVE ATTENUATED CYTOMEGALOVIRUS VACCINES,0,1985-08-01,1985.0,1985-12-31,1985,Mallinckrodt (United States),grid.421513.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2428617,N01DE012430,INVESTIGATION OF ANTICARIES VACCINE IN PRIMATES,0,1981-07-01,1981.0,1986-06-30,1986,Covance (United States),grid.417600.4,United States,National Institute of Dental and Craniofacial Research,United States,0,0,0
grant.2428003,N01CP050529,MODELS FOR AIDS VACCINE RESEARCH,0,1994-11-30,1994.0,1998-11-29,1998,Bioqual,grid.282501.c,United States,National Cancer Institute,United States,0,0,0
grant.2425945,N01BC050529,MODELS FOR AIDS VACCINE RESEARCH,0,1994-11-30,1994.0,1998-11-29,1998,Bioqual,grid.282501.c,United States,National Cancer Institute,United States,0,0,0
grant.2425777,N01AO082722,OPERATE EXPERIMENTAL VIRUS VACCINE LABORATORY,740515,1997-12-01,1997.0,2002-11-30,2002,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425765,N01AO052710,MFG OF YEAST-PRODUCED MALARIA VACCINES,0,1995-09-29,1995.0,1999-09-28,1999,Amgen (United States),grid.417886.4,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425738,N01AO015095,"INFECTIOUS AGENTS, VACCINES &ANTIMICROBIALS IN HUMANS",0,1990-12-01,1990.0,1996-01-15,1996,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424919,N01AI082681,EXPERIMENTAL VIRUS VACCINE PRODUCTION LABORATORY,0,1987-12-01,1987.0,1992-11-30,1992,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424708,N01AI052593,EFFICACY TRIAL OF COLD-ADAPTED VACCINES,0,1985-08-15,1985.0,1991-02-14,1991,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2424692,N01AI052577,TESTING VACCINES IN ADOLESCENTS AND ADULTS,0,1985-02-01,1985.0,1990-02-03,1990,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2424627,N01AI045204,HIV VACCINE TRIALS AND EPIDEMIOLOGY REPOSITORY,229246,1994-06-01,1994.0,1999-11-30,1999,Biomedical Research Institute,grid.418352.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424600,N01AI042534,DEVELOP A VACCINE FOR GONORRHEA,0,1983-12-19,1983.0,1985-01-01,1985,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2424554,N01AI032518,DEVELOP AN ACELLULAR BORDETELLA PERTUSSIS VACCINE,0,1983-09-01,1983.0,1986-08-31,1986,Michigan Department of Health and Human Services,grid.467944.c,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2424491,N01AI025137,INVESTIGATIONAL NEW DRUGS AND VACCINES,0,1992-03-02,1992.0,1995-06-30,1995,McKesson (United States),grid.418450.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424469,N01AI015130,ADVERSE REACTIONS OF CHILDHOOD VACCINES,0,1991-09-30,1991.0,1994-06-30,1994,National Academy of Sciences,grid.275752.0,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2424424,N01AI005421,MALARIA VACCINE PRODUCTION &SUPPORT SERVICES,6077974,2000-09-22,2000.0,2007-09-21,2007,Science Applications International Corporation (United States),grid.419669.5,United States,National Institute of Allergy and Infectious Diseases,United States,9,1,0
grant.2424340,N01AI002639,CLINICAL EVALUATION OF LIVE HERPESVIRUS VACCINE,0,1979-12-28,1979.0,1985-12-27,1985,New York University,grid.137628.9,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2406847,K04AI001087,ACELLULAR VACCINES AGAINST BACTERIAL PATHOGENS,0,1992-07-01,1992.0,1997-06-30,1997,Medical College of Wisconsin,grid.30760.32,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2393916,H23IP922549,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,12176449,2003-01-01,2003.0,2012-12-31,2012,Nevada Department of Health and Human Services,grid.410400.1,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393915,H23IP922545,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,28595532,2003-01-01,2003.0,2012-12-31,2012,Arizona Department of Health Services,grid.413872.b,United States,Centers for Disease Control and Prevention,United States,1,0,0
grant.2393914,H23IP922535,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,4359668,2003-01-01,2003.0,2012-12-31,2012,Department of Public Health and Social Services,grid.420533.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393913,H23IP922533,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,3559620,2003-01-01,2003.0,2012-12-31,2012,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393912,H23IP922518,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,12787854,2003-01-01,2003.0,2012-12-31,2012,Hawaii Department of Health,grid.280337.d,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393911,H23IP922507,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,132483632,2003-01-01,2003.0,2012-12-31,2012,California Department of Public Health,grid.236815.b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393910,H23IP922505,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,4848248,2003-01-01,2003.0,2012-12-31,2012,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393909,H23IP922504,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,2354105,2003-01-01,2003.0,2012-12-31,2012,American Samoa Government,grid.423259.b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393908,H23IP922503,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,1027633,2003-01-01,2003.0,2012-12-31,2012,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393907,H23IP922502,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,3370321,2003-01-01,2003.0,2012-12-31,2012,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393906,H23IP822564,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,22485676,2003-01-01,2003.0,2012-12-31,2012,Colorado Department of Public Health and Environment,grid.410375.4,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393905,H23IP822560,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,5545506,2003-01-01,2003.0,2012-12-31,2012,Montana Department of Environmental Quality,grid.470606.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393904,H23IP822552,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,6238876,2003-01-01,2003.0,2012-12-31,2012,North Dakota Department of Health,grid.280457.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393903,H23IP822546,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,4581647,2003-01-01,2003.0,2012-12-31,2012,Wyoming State Department of Health,grid.280415.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393902,H23IP822520,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13332202,2003-01-01,2003.0,2012-12-31,2012,Utah Department of Health,grid.280326.d,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393901,H23IP822510,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,5265499,2003-01-01,2003.0,2012-12-31,2012,South Dakota Department of Health,grid.280514.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393900,H23IP722562,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,9078858,2003-01-01,2003.0,2012-12-31,2012,Nebraska Department of Health and Human Services,grid.280417.8,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393899,H23IP722543,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,19171620,2003-01-01,2003.0,2012-12-31,2012,Missouri Department of Health and Senior Services,grid.280361.e,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393898,H23IP722542,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13750234,2003-01-01,2003.0,2012-12-31,2012,Iowa Department of Public Health,grid.280302.b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393897,H23IP722509,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,12782071,2003-01-01,2003.0,2012-12-31,2012,Kansas Department of Health and Environment,grid.280429.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393896,H23IP622571,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,84654136,2003-01-01,2003.0,2012-12-31,2012,Texas Department of State Health Services,grid.287260.9,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393895,H23IP622566,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,9773650,2003-01-01,2003.0,2012-12-31,2012,Louisiana State Department of Health and Hospitals,grid.280395.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393893,H23IP622541,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,18633488,2003-01-01,2003.0,2012-12-31,2012,Oklahoma State Department of Health,grid.238667.e,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393892,H23IP622532,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,11954660,2003-01-01,2003.0,2012-12-31,2012,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393891,H23IP622523,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13452676,2003-01-01,2003.0,2012-12-31,2012,Arkansas State Department of Human Services,grid.280559.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393890,H23IP622512,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,9133450,2003-01-01,2003.0,2012-12-31,2012,San Antonio Metropolitan Health District,grid.421798.1,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393889,H23IP522568,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,27272696,2003-01-01,2003.0,2012-12-31,2012,Illinois Department of Public Health,grid.280362.d,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393888,H23IP522565,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,19894560,2003-01-01,2003.0,2012-12-31,2012,Chicago Department of Public Health,grid.410374.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393887,H23IP522563,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,20886180,2003-01-01,2003.0,2012-12-31,2012,Wisconsin Department of Health Services,grid.280246.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393886,H23IP522556,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,36897780,2003-01-01,2003.0,2012-12-31,2012,Michigan Department of Health and Human Services,grid.467944.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393885,H23IP522551,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,23057106,2003-01-01,2003.0,2012-12-31,2012,Minnesota Department of Health,grid.280248.4,United States,Centers for Disease Control and Prevention,United States,1,0,0
grant.2393884,H23IP522537,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,30695332,2003-01-01,2003.0,2012-12-31,2012,Ohio Department of Health,grid.410403.2,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393883,H23IP522522,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,14725251,2003-01-01,2003.0,2012-12-31,2012,Indiana State Department of Health,grid.429033.f,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393882,H23IP422554,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,32415946,2003-01-01,2003.0,2012-12-31,2012,North Carolina Department of Environment and Natural Resources,grid.422784.f,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393881,H23IP422544,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,20465260,2003-01-01,2003.0,2012-12-31,2012,South Carolina Department of Health and Environmental Control,grid.280471.8,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393880,H23IP422536,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,18486918,2003-01-01,2003.0,2012-12-31,2012,Alabama Department of Public Health,grid.236631.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393879,H23IP422528,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,16958976,2003-01-01,2003.0,2012-12-31,2012,Tennessee Department of Health,grid.416951.e,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393878,H23IP422527,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,14506256,2003-01-01,2003.0,2012-12-31,2012,Kentucky Cabinet For Health and Family Services,grid.280376.8,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393877,H23IP422524,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13074784,2003-01-01,2003.0,2012-12-31,2012,Mississippi State Department of Health,grid.280409.7,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393876,H23IP422521,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,35935876,2003-01-01,2003.0,2012-12-31,2012,Georgia Department of Public Health,grid.420388.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393875,H23IP422511,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,58067576,2003-01-01,2003.0,2012-12-31,2012,Florida Department of Health,grid.410382.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393874,H23IP322572,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,7377398,2003-01-01,2003.0,2012-12-31,2012,West Virginia State Department of Health and Human Resources,grid.280350.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393873,H23IP322570,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,19605318,2003-01-01,2003.0,2012-12-31,2012,Maryland Department of Health,grid.416491.f,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393872,H23IP322567,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,6612114,2003-01-01,2003.0,2012-12-31,2012,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393871,H23IP322561,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,6472027,2003-01-01,2003.0,2012-12-31,2012,Department of Human Services,grid.410331.4,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393870,H23IP322559,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,36378536,2003-01-01,2003.0,2012-12-31,2012,Pennsylvania Department of Health,grid.280365.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393869,H23IP322538,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,11256214,2003-01-01,2003.0,2012-12-31,2012,Philadelphia Department of Public Health,grid.280512.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393868,H23IP322519,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,22522020,2003-01-01,2003.0,2012-12-31,2012,Virginia Department of Health,grid.280313.b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393867,H23IP222576,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,25629016,2003-01-01,2003.0,2012-12-31,2012,New Jersey Department of Health and Senior Services,grid.238434.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393866,H23IP222575,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,51502832,2003-01-01,2003.0,2012-12-31,2012,Health Research,grid.465226.1,United States,Centers for Disease Control and Prevention,United States,1,0,0
grant.2393865,H23IP222539,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,39530888,2003-01-01,2003.0,2012-12-31,2012,New York City Department of Health and Mental Hygiene,grid.238477.d,United States,Centers for Disease Control and Prevention,United States,1,0,0
grant.2393864,H23IP222534,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,5346605,2003-01-01,2003.0,2012-12-31,2012,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393863,H23IP222501,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,13795530,2003-01-01,2003.0,2012-12-31,2012,Puerto Rico Department of Health,grid.280499.e,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393862,H23IP122558,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,11807857,2003-01-01,2003.0,2012-12-31,2012,State of Maine Department of Health and Human Services,grid.280289.9,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393861,H23IP122555,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,7599557,2003-01-01,2003.0,2012-12-31,2012,New Hampshire Department of Health and Human Services,grid.422654.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393860,H23IP122540,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,24289670,2003-01-01,2003.0,2012-12-31,2012,Massachusetts Department of Public Health,grid.416511.6,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393859,H23IP122530,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,7587053,2003-01-01,2003.0,2012-12-31,2012,Rhode Island Department of Health,grid.280336.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393858,H23IP122529,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,6787449,2003-01-01,2003.0,2012-12-31,2012,Vermont Department of Mental Health,grid.280536.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393857,H23IP122525,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,16585636,2003-01-01,2003.0,2012-12-31,2012,Connecticut Department of Public Health,grid.280310.8,United States,Centers for Disease Control and Prevention,United States,1,0,0
grant.2393856,H23IP022569,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,7824550,2003-01-01,2003.0,2012-12-31,2012,Idaho Department of Health and Welfare,grid.280384.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393855,H23IP022550,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,18607916,2003-01-01,2003.0,2012-12-31,2012,,,,Centers for Disease Control and Prevention,United States,1,0,0
grant.2393854,H23IP022548,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,31860150,2003-01-01,2003.0,2012-12-31,2012,South Carolina Department of Alcohol and Other Drug Abuse Services,grid.422383.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393853,H23IP022531,IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,9059135,2003-01-01,2003.0,2012-12-31,2012,Alaska Department of Health and Social Services,grid.413533.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393852,H23IP000790,MISSISSIPPI IMMUNIZATION AND VACCINE GRANT,10058390,2013-01-01,2013.0,2017-12-31,2017,Mississippi State Department of Health,grid.280409.7,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393844,H23IP000778,Immunization and Vaccines for Children Program,14692051,2013-01-01,2013.0,2017-12-31,2017,South Carolina Department of Health and Environmental Control,grid.280471.8,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393841,H23IP000775,IMMUNIZATION AND VACCINES FOR CHILDREN GRANT,5550667,2013-01-01,2013.0,2017-12-31,2017,Rhode Island Department of Health,grid.280336.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393821,H23IP000755,IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAM,4430576,2013-01-01,2013.0,2017-12-31,2017,Montana Department of Public Health and Human Services,grid.410447.2,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393817,H23IP000751,IMMUNIZATIONS AND VACCINE FOR CHILDREN,19247618,2013-01-01,2013.0,2017-12-31,2017,Massachusetts Department of Public Health,grid.416511.6,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393814,H23IP000748,IMMUNIZATIONS AND VACCINES FOR CHILDREN GRANTS,10479382,2013-01-01,2013.0,2017-12-31,2017,Kansas Department of Health and Environment,grid.280429.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393808,H23IP000741,Immunization and Vaccines for Children Program,41633856,2013-01-01,2013.0,2017-12-31,2017,Florida Department of Health,grid.410382.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393804,H23IP000737,MINNESOTA STATEWIDE IMMUNIZATION & VACCINES PROGRAM,15583782,2013-01-01,2013.0,2017-12-31,2017,Minnesota Department of Health,grid.280248.4,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393800,H23IP000733,ARIZONA IMMUNIZATION AND VACCINE FOR CHILDREN,21286744,2013-01-01,2013.0,2017-12-31,2017,Arizona Department of Health Services,grid.413872.b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393799,H23IP000732,IMMUNIZATION AND VACCINES FOR CHILDREN,14626625,2013-01-01,2013.0,2017-12-31,2017,Chicago Department of Public Health,grid.410374.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393797,H23IP000730,IMMUNIZATION AND VACCINES FOR CHILDREN GRANT,8323787,2013-01-01,2013.0,2017-12-31,2017,Alaska Department of Health and Social Services,grid.413533.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393795,H23IP000728,NEW JERSEY VACCINE PREVENTABLE DISEASE PROGRAM,22845980,2013-01-01,2013.0,2017-09-30,2017,New Jersey Department of Health and Senior Services,grid.238434.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393794,H23IP000727,NEVADA IMMUNIZATION AND VACCINES FOR CHILDREN,9981773,2013-01-01,2013.0,2017-12-31,2017,Nevada Division of Public and Behavioral Health,grid.422589.0,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393790,H23IP000723,IMMUNIZATIONS AND VACCINES FOR CHILDREN,16824272,2013-01-01,2013.0,2017-12-13,2017,Indiana State Department of Health,grid.429033.f,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393786,H23IP000719,IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAM,14710428,2013-01-01,2013.0,2017-12-31,2017,Colorado Department of Public Health and Environment,grid.410375.4,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2375051,F32DK008072,EVALUATION OF GENETICALLY ENGINEERED ROTAVIRUS VACCINES,0,1987-09-10,1987.0,1988-01-01,1988,Baylor College of Medicine,grid.39382.33,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,0,0,0
grant.2369583,F32AI008222,GROUP B STREPTOCOCCAL OLIGOSACCHARIDE-CONJUGATE VACCINE,0,1991-02-01,1991.0,1991-12-31,1991,Brigham and Women's Hospital,grid.62560.37,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2356619,F05TW005055,NOVEL APPROACH TOWARD RETROVIRAL VACCINE DESIGN,0,1994-09-30,1994.0,1995-01-01,1995,"Rutgers, The State University of New Jersey",grid.430387.b,United States,Fogarty International Center,United States,0,0,0
grant.8460157,,"Develop low-cost prophylactic vaccines against HCV, and therapeutic vaccines against HBV",9100510,2010-06-01,2010.0,2017-05-31,2017,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8446709,2013-01797,Development of diagnostic tools and vaccines,447887,2013-01-01,2013.0,2015-12-31,2015,National Veterinary Institute,grid.419788.b,Sweden,Swedish Research Council for Environment Agricultural Sciences and Spatial Planning,Sweden,0,0,0
grant.8033537,13025B10,Potenzierung von Impfstoffen durch gezieltes Design der Glykosylierung - IPoGly (Impfstoffpotenzierung durch Glykosylierung),377233,2010-07-01,2010.0,2014-06-30,2014,Technical University of Applied Sciences Wildau,grid.438275.f,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7951286,01KA1301,"EDCTP: Malaria Vakzine, vorbereitende Arbeiten zur Entwicklung zweier Malaria Impfstoffe",93832,2013-05-01,2013.0,2014-12-31,2014,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7942547,01GU0708,Verbundprojekt: Innovative bakterielle Tumorimpfstoffe - Teilprojekt 1: Bakterielles Prostatakrebsvakzin,766222,2008-01-01,2008.0,2011-06-30,2011,Aeterna Zentaris (Germany),grid.476147.7,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7608089,SERB_45c964ebaf,Development of Porphyric Intracellular Leishmania Parasite for the Effect vaccine and Vaccine Delivery System,36686,2016-04-01,2016.0,2017-03-31,2017,Invertis University,grid.449122.8,India,Science and Engineering Research Board,India,0,0,0
grant.7502141,2015R1D1A4A01020761,DNA 백신 및 백신보조제 전달을 위한 효율적이고 스마트한 마이크니들시스템 개발,0,2015-01-01,2015.0,2016-01-01,2016,Sungkyunkwan University,grid.264381.a,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7498852,2015M3A9B5030116,인유두종바이러스 백신 제품화 및 차세대 인유두종바이러스 백신 개발,0,2015-01-01,2015.0,2016-01-01,2016,SK Chemicals (South Korea),grid.474515.6,South Korea,National Research Foundation of Korea,South Korea,2,0,0
grant.7498851,2015M3A9B5030142,인유두종바이러스 4가 백신의 제품화 및 인유두종바이러스 10가 백신 개발,0,2015-01-01,2015.0,2016-01-01,2016,SK Chemicals (South Korea),grid.474515.6,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7475580,2014R1A6A3A01055315,저온적응 약독 생백신형 만능독감백신 개발 연구,0,2014-01-01,2014.0,2015-01-01,2015,Yonsei University,grid.15444.30,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7167585,AF/138/96,Vaccine Biotechnology: Genetically Engineered Chimeric Protein Vaccine Against Foot-and-Mouth Disease,454005,1996-01-01,1996.0,2000-01-28,2000,Hong Kong University of Science and Technology,grid.24515.37,China,Innovation and Technology Commission,China,0,0,0
grant.7104247,2010-00481,Therapeutic cancer vaccine for test in human,526155,2010-10-01,2010.0,2014-03-31,2014,Immunicum (Sweden),grid.451730.4,Sweden,VINNOVA,Sweden,0,0,0
grant.7062940,156524,The Vaccine Project,15896,2016-04-01,2016.0,2017-03-31,2017,University of Alberta; University of Alberta; University of Alberta,grid.17089.37; grid.17089.37; grid.17089.37,Canada; Canada; Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.6967906,605578,Ingénierie d'un plateforme vaccinale et développement d'un vaccin vétérinaire contre la gripp,3391,2016-04-01,2016.0,2017-03-31,2017,Laval University,grid.23856.3a,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6728271,630754,Hepatitis C vaccine preparedness: feasibility of field-based vaccine trials,56978,2010-01-01,2010.0,2012-12-31,2012,UNSW Sydney,grid.1005.4,Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6500725,272201600035C-0-0-1,A MUCOSAL PROPHYLACTIC VACCINE AGAINST COCCIDIOIDOMYCOSIS,449984,2016-08-31,2016.0,2018-08-30,2018,Applied Biotechnology Institute,grid.426798.6,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.6259132,97F00421,魚類寄生虫に対する遺伝子組換えワクチンおよびDNAワクチンの開発,18068,1998-01-01,1998.0,1999-12-31,1999,Tokyo University of Marine Science and Technology,grid.412785.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5892064,16380123,魚類ウイルスを用いたDNAワクチンに代わる新たなRNAワクチンの開発,36058,2004-01-01,2004.0,2004-12-31,2004,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5761631,11771116,組み換えBCGワクチンシステムを用いた、う蝕予防ワクチンの開発,9665,1999-01-01,1999.0,1999-12-31,1999,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5551429,00J01507,新規粘膜ワクチンキャリアーの開発およびエイズワクチンへの応用,17502,2000-01-01,2000.0,2001-12-31,2001,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5246672,N01AI60018-0-0-1,HIV Vaccine Design and Dev. Teams Part A - Preventative Vaccines,3352012,2006-09-30,2006.0,2011-09-29,2011,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246671,N01AI60018-0-0-0,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS PART A - PREVENTATIVE VACCINES,3352012,2006-09-30,2006.0,2011-09-29,2011,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246586,N01AI50010-0-0-0,"HIV VACCINE DESIGN AND DEVELOPMENT TEAMS, PART B-THERAPEUTIC VACCINES",5042594,2005-09-12,2005.0,2010-09-11,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246584,N01AI50009-4-0-0,HIV VACCINES DESIGN &DEVELOPMENT TEAMS-PART B-THERAPEUTIC VACCINE,3418543,2005-06-15,2005.0,2010-06-14,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246583,N01AI50008-6-0-1,HIV Vaccines Design and Dev. Teams Part A - Preventative Vaccine,3200598,2008-01-01,2008.0,2008-12-31,2008,Children's Hospital of Philadelphia,grid.239552.a,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246582,N01AI50008-6-0-0,HIV VACCINES DESIGN AND DEVELOPMENT TEAMS PART A - PREVENTATIVE VACCINE,7976947,2005-08-31,2005.0,2010-08-30,2010,,,,National Institute of Allergy and Infectious Diseases,United States,1,3,0
grant.5246581,N01AI50007-0-0-1,"HIV Vaccine Design and Development, Part A-Preventative Vaccines",1700000,2005-08-31,2005.0,2010-08-30,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.4632144,J3-6363 (D),Priprava tumorskih vakcin: hibridomi in gensko spremenjene vakcine (basic research project),0,2004-01-07,2004.0,2007-06-30,2007,Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana,grid.418872.0; grid.418872.0; grid.418872.0; grid.418872.0; grid.418872.0; grid.418872.0; grid.418872.0; grid.418872.0; grid.418872.0,Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia,Slovenian Research Agency,Slovenia,0,0,0
grant.3802932,H23IP000851,"Economics of Vaccines and Immunization Policies, Programs, and Practices for Adults: Prioritysetting for adult vaccines",149989,2014-08-31,2014.0,2016-08-30,2016,University of South Carolina,grid.254567.7,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2936797,213682,Nanoparticle delivery systems for cancer vaccines - applications to a MUC1 lipopeptide cancer vaccine,294474,2000-04-01,2000.0,2003-03-31,2003,University of Alberta; Oncothyreon (Canada),grid.17089.37; grid.418358.3,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2424522,N01AI025480,Millenium Vaccine Initiative-Novel Vaccines for TB and Malaria-26625480,0,2004-01-01,2004.0,2004-12-31,2004,Takeda (United States),grid.419849.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6315092,X00120----187043,"現行ワクチンにかわる副作用のない破傷風ワクチンの作成法と, その二種(ジフテリア・破傷風)混合ワクチンへの応用",12432,1976-01-01,1976.0,1976-12-31,1976,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.8505364,G023511N,Evaluatie van afgiftesystemen voor mRNA kanker vaccins,0,2011-01-01,2011.0,2014-12-31,2014,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8495954,G007614N,Naar een universeel op mRNA-gebaseerd therapeutisch vaccin tegen HIV,0,2014-01-01,2014.0,2017-12-31,2017,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8489605,1210812N,Ontwikkeling van een generische microparticulaire vaccin formulatie,0,2011-10-01,2011.0,2014-09-30,2014,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8487606,G003008N,Ontwikkeling van een vaccin tegen Ascaris suum bij het varken.,0,2008-01-01,2008.0,2011-12-31,2011,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8352947,81581240327,感染免疫、疫苗与治疗性抗体双边研讨会,12042,2015-07-01,2015.0,2015-12-31,2015,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,0,0,0
grant.8328815,80011764,用转基因植物生产口服疫苗,845,2000-05-01,2000.0,2000-05-14,2000,,,,National Natural Science Foundation of China,China,0,0,0
grant.8290380,60410106426,扫描探针显微学研制细胞免疫疫苗,2053,2004-07-20,2004.0,2004-10-31,2004,,,,National Natural Science Foundation of China,China,0,0,0
grant.8219416,39940006,疫苗防治人类乳头瘤病毒感染及宫颈癌的研究,6039,1999-01-01,1999.0,1999-12-31,1999,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,0,0,0
grant.8219108,39880043,人免疫缺陷病毒多肽疫苗的研究,21740,1999-01-01,1999.0,2001-12-31,2001,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,10,0,0
grant.8217961,39780032,肝片吸虫DNA疫苗研究,14488,1998-01-01,1998.0,2000-12-31,2000,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,0,0,0
grant.8216804,39680018,新型肝炎病毒基因克隆与DNA疫苗研究,17863,1997-01-01,1997.0,1999-12-31,1999,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8214678,39480022,BCG多价疫苗免疫保护作用的实验研究,11414,1995-01-01,1995.0,1997-12-31,1997,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,0,0,0
grant.8209272,39060057,脑包虫细胞系疫苗的研究,5168,1991-01-01,1991.0,1993-12-31,1993,,,,National Natural Science Foundation of China,China,0,0,0
grant.8209093,39000001,乙型脑炎活疫苗毒株的基因分析,8618,1991-01-01,1991.0,1993-12-31,1993,National Institutes for Food and Drug Control,grid.410749.f,China,National Natural Science Foundation of China,China,0,0,0
grant.8205967,38671111,猪伪狂犬病病毒重组疫苗的研究,6024,1987-01-01,1987.0,1993-12-31,1993,Sichuan Agricultural University,grid.80510.3c,China,National Natural Science Foundation of China,China,0,0,0
grant.8173982,30711220434,艾滋病疫苗新型策略与相关免疫学研究,2103,2007-10-28,2007.0,2007-11-02,2007,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,0,0,0
grant.8173409,30610103103,疟疾疫苗及其相关基础免疫学的研究,27526,2007-01-01,2007.0,2008-12-31,2008,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8172930,30531160053,鼻咽癌多肽疫苗研究及临床疗效评价,37887,2005-01-01,2005.0,2007-12-31,2007,South China University of Technology,grid.79703.3a,China,National Natural Science Foundation of China,China,0,0,0
grant.8169476,30210103222,新的疟疾疫苗靶点基因的功能研究,3262,2002-10-18,2002.0,2002-10-28,2002,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8167666,30080020,丙型肝炎病毒样颗粒疫苗的基础研究,16909,2001-01-01,2001.0,2003-12-31,2003,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8034776,1356X09,Entwicklung optimaler Herstellungsprozesse artifizieller Malariavakzine,365392,2009-07-01,2009.0,2012-12-31,2012,Hamburg University of Applied Sciences,grid.11500.35,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8033536,13025A10,Potenzierung von Impfstoffen durch gezieltes Design der Glykosylierung,357548,2010-07-01,2010.0,2013-12-31,2013,Beuth University of Applied Sciences,grid.440921.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8019012,03VP00510,Kreuzprotektive und thermostabile Humane Papillomavirus Vakzine - T-panHPVvac,1172455,2016-06-01,2016.0,2019-03-31,2019,German Cancer Research Center,grid.7497.d,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8018668,03V0347,Therapeutischer Impfstoff zur Behandlung von Zervixdysplasien,2215626,2012-05-01,2012.0,2016-04-30,2016,,,,Federal Ministry of Education and Research,Germany,2,0,0
grant.8005184,03FO2211,ForMaT: Diagnostika- und Impfstoffentwicklung für vernachlässigte Infektionskrankheiten,131436,2008-11-01,2008.0,2009-04-30,2009,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.8000977,03EFT2BW12,EXIST-Forschungstranfer: Entwicklung eines Impfstoffes gegen Malaria.,569700,2009-01-01,2009.0,2010-12-31,2010,Heidelberg University,grid.7700.0,Germany,Federal Ministry for Economic Affairs and Energy,Germany,0,0,0
grant.7993576,031A521,Individualisierte Tumorimpfstoffe mittels eines viralen Vektors,571409,2014-08-01,2014.0,2016-12-31,2016,University of Tübingen,grid.10392.39,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992850,031A144,GO-Bio 5: VEROVACCINES - Tierimpfstoffe auf Hefebasis,3935142,2013-06-01,2013.0,2018-03-31,2018,Martin Luther University Halle-Wittenberg,grid.9018.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989648,0315241,"BioPharma: Allianz für Antiinfektiva, Chemotherapeutika und Impfstoffe",146344,2008-03-01,2008.0,2008-06-30,2008,Helmholtz Centre for Infection Research,grid.7490.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7951296,01KA1501,EDCTP: Malaria-Impfstoff-Entwicklung: zwei EDCTP Projekte,15864,2015-07-01,2015.0,2015-09-30,2015,,,,Federal Ministry of Education and Research,Germany,1,0,0
grant.7851731,SERB_968aca715e,Identification Of Novel Targets For Effective Drugs/Vaccines Against,43096,2017-04-01,2017.0,2018-03-31,2018,,,,Science and Engineering Research Board,India,0,0,0
grant.7821052,BCTR9903159,MUC1 as a Potential Breast Cancer Vaccine,248741,1999-05-01,1999.0,2002-04-30,2002,Mayo Clinic,grid.417468.8,United States,Susan G. Komen Breast Cancer Foundation,United States,0,0,0
grant.7741443,,Centre for Nano-vaccines (sagsnr.: 09-067052),4424845,2010-03-01,2010.0,2015-02-28,2015,State Serum Institute,grid.6203.7,Denmark,Danish Ministry of Higher Education and Science,Denmark,0,0,0
grant.7721825,627315,Oncolytic virus vaccine to cure different kinds of cancer,3463,2017-04-01,2017.0,2018-03-31,2018,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7721778,627268,Screening for immunogenic antigens for Zika virus vaccine,3463,2017-04-01,2017.0,2018-03-31,2018,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7721598,627088,Oncolytic virus vaccine to cure different kinds of cancer,3463,2017-04-01,2017.0,2018-03-31,2018,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7721597,627087,Oncolytic virus vaccine to cure different kinds of cancer,3463,2017-04-01,2017.0,2018-03-31,2018,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7715670,621083,Single-walled carbon nanotubes as delivery vehicle of vaccines,16174,2017-04-01,2017.0,2018-03-31,2018,Carnegie Mellon University,grid.147455.6,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7709652,642507,Bioprocess Sciences and Technology of Viral Vaccines,154056,2017-04-01,2017.0,2018-03-31,2018,McGill University,grid.14709.3b,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7695510,,Antigen Discovery for Human Helminth Vaccines Using Immunomics,0,2012-08-01,2012.0,2012-10-01,2012,"University of California, Irvine; James Cook University",grid.266093.8; grid.1011.1,United States; Australia,Council for International Exchange of Scholars,United States,0,0,0
grant.7693092,,Vaccines That Induce Broadly Protective Antibodies Against Influenza,0,2017-08-01,2017.0,2017-12-01,2017,Scripps Research Institute; University of Oslo,grid.214007.0; grid.5510.1,United States; Norway,Council for International Exchange of Scholars,United States,0,0,0
grant.7692313,,Quillaja Saponin Adjuvants in Carbohydrate Cancer Vaccines,0,2010-09-01,2010.0,2012-09-01,2012,Memorial Sloan Kettering Cancer Center; University of La Rioja,grid.51462.34; grid.119021.a,United States; Spain,Council for International Exchange of Scholars,United States,0,0,0
grant.7687496,,Indo-U.S. Asthma Research Collaborative Group: Asthma Vaccine,0,2008-03-01,2008.0,2008-07-01,2008,The University of Texas Medical Branch at Galveston; The University of Texas Medical Branch at Galveston; Rama Hospital & Research Centre,grid.176731.5; grid.176731.5; grid.502108.e,United States; United States; India,Council for International Exchange of Scholars,United States,0,0,0
grant.7685141,,Quillaja Saponin Adjuvants in Carbohydrate Cancer Vaccines,0,2010-09-15,2010.0,2012-09-14,2012,Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of La Rioja,grid.51462.34; grid.51462.34; grid.119021.a,United States; United States; Spain,Council for International Exchange of Scholars,United States,0,0,0
grant.7684827,,Development of a Recombinant DNA Vaccine Against Blackleg,0,2011-10-01,2011.0,2012-10-20,2012,Cornell University; Cornell University; Cornell University; Cornell University; Ahmadu Bello University; Ahmadu Bello University; Ahmadu Bello University,grid.5386.8; grid.5386.8; grid.5386.8; grid.5386.8; grid.411225.1; grid.411225.1; grid.411225.1,United States; United States; United States; United States; Nigeria; Nigeria; Nigeria,Council for International Exchange of Scholars,United States,0,0,0
grant.7683420,,Toward Enhanced Pulmonary Delivery of Vaccines,0,2006-08-01,2006.0,2007-02-01,2007,"Indian Institute of Technology Bombay; University of Maryland, College Park",grid.417971.d; grid.164295.d,India; United States,Council for International Exchange of Scholars,United States,0,0,0
grant.7668688,O3/IN3/B364STAR05,Developing a prototype MMR vaccine,15347,2005-06-01,2005.0,2005-08-30,2005,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7666767,,Lactococcus lactis live vaccines against leishmaniasis,14769,2005-08-01,2005.0,2006-07-31,2006,McGill University,grid.14709.3b,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665207,,Strategic training program in vaccine development and delivery,3184,2002-10-01,2002.0,2002-12-31,2002,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665048,,Needle-free Vaccines for Respiratory Viruses,346628,2002-07-01,2002.0,2004-06-30,2004,Montreal General Hospital,grid.416099.3,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665045,,Development of proteosome-based vaccines for protozoan pathogens,63651,2001-03-01,2001.0,2003-02-28,2003,Montreal General Hospital,grid.416099.3,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665032,,Mechanisms of dendritic cell-based cancer vaccines,235501,2002-07-01,2002.0,2007-06-30,2007,McMaster University,grid.25073.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7658271,,CIHR Team in Structure-Based Vaccine Design,7556,2006-06-01,2006.0,2006-11-30,2006,University of Calgary,grid.22072.35,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7658269,,Transferring binding regions as vaccine agents,71400,2003-03-01,2003.0,2004-02-29,2004,University of Calgary,grid.22072.35,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7653038,,Structural studies on antiidiotypic antibody vaccines,27317,1998-05-01,1998.0,2001-04-30,2001,University of Ottawa,grid.28046.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7648001,,Vaccine antigens for C. pneumoniae atherosclerosis,28049,1999-05-01,1999.0,2000-12-31,2000,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7647714,,Development of a Vaccine Against Canine Leishmaniasis,64572,2001-11-15,2001.0,2002-11-14,2002,McGill University,grid.14709.3b,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7645631,,Novel Dendritic Cell-based Vaccine of Cancer,66623,2004-10-01,2004.0,2008-03-31,2008,University of Saskatchewan,grid.25152.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7644460,,Human alloimmune responses and HIV-1 vaccine development,0,1998-04-01,1998.0,2001-03-31,2001,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7632409,,Transdermal delivery systems for protein medicines and vaccines,107932,2004-04-01,2004.0,2006-03-31,2006,University of Saskatchewan,grid.25152.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7629669,,Towards a Type 1 Diabetes Vaccine,63697,2002-03-01,2002.0,2003-02-28,2003,Hospital for Sick Children,grid.42327.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7628997,,Cancer Vaccines: Targeting Cancer Genes for Immunotherapy,3017,2016-03-06,2016.0,2016-03-10,2016,McGill University,grid.14709.3b,Canada,Canadian Cancer Society,Canada,0,0,0
grant.7628517,,The role of Alloimmunization in HIV vaccine design,35506,1996-01-01,1996.0,2001-12-31,2001,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7624786,,Development of a novel intranasal vaccine against measles,68775,2003-05-01,2003.0,2005-04-30,2005,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.7623304,,A DNA vaccine for chlamydia trachomatis,103437,2001-07-01,2001.0,2004-06-30,2004,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7622447,,Delivery of genetic vaccines through Microporated Skin,32616,2002-05-01,2002.0,2003-04-30,2003,McMaster University,grid.25073.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7620072,,Post-genomic studies of BCG vaccines,332091,1999-10-01,1999.0,2005-09-30,2005,Montreal General Hospital,grid.416099.3,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7618695,,Transcutaneous vaccines: Delivery and mechanisms of immune induction,56581,2000-04-01,2000.0,2002-09-30,2002,University of Saskatchewan,grid.25152.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7608908,SERB_44e315abd3,Aptamer-mRNA Chimera-The Next Generation RNA vaccine,60383,2016-04-01,2016.0,2017-03-31,2017,University of Delhi,grid.8195.5,India,Science and Engineering Research Board,India,0,0,0
grant.7576541,211394,nd,1514,2016-04-01,2016.0,2017-03-31,2017,Université de Sherbrooke,grid.86715.3d,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.7575474,34259,Déterminants des couvertures vaccinales chez les enfants âgés de 1 an et 2 ans au Québec et impact épidémiologique des retards vaccinaux,29817,2016-04-01,2016.0,2017-03-31,2017,Institut National de Santé Publique du Québec,grid.434819.3,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.7550264,9955,DEVELOPMENT OF DNA VACCINES AGAINST CUTANEOUS T CELL LYMPHOMA,113067,2000-03-27,2000.0,2003-03-26,2003,University of Southampton,grid.5491.9,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.7550133,9803,DNA VACCINES AS INDUCERS OF IMMUNITY AGAINST  HAEMATOLOGICAL MALIGNANCIES,746244,1998-08-01,1998.0,1999-07-31,1999,University of Southampton,grid.5491.9,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.7501980,2015R1D1A1A02062348,미세막상 구조물을 이용한 비세포 항암 백신,0,2015-01-01,2015.0,2016-01-01,2016,Chungnam National University,grid.254230.2,South Korea,National Research Foundation of Korea,South Korea,4,0,0
grant.7497479,2015K1A3A7A03073714,차세대 결핵백신의 방어면역 바이오마커 발굴,0,2015-01-01,2015.0,2016-01-01,2016,International Tuberculosis Research Center,grid.495992.a,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7487475,2013R1A2A1A03069903,다제내성 결핵을 표적으로 하는 치료백신 개발연구,0,2013-01-01,2013.0,2014-01-01,2014,Chungnam National University,grid.254230.2,South Korea,National Research Foundation of Korea,South Korea,5,0,0
grant.7486078,2012R1A1A1042735,다공성 실리카 나노입자를 이용한 암백신 전달체 연구,0,2012-01-01,2012.0,2013-01-01,2013,Sungkyunkwan University,grid.264381.a,South Korea,National Research Foundation of Korea,South Korea,6,0,0
grant.7485113,2012R1A2A2A06045773,스마트 백신 경피 제형 및 레이저 면역보조제 개발,0,2012-01-01,2012.0,2013-01-01,2013,Pohang University of Science and Technology,grid.49100.3c,South Korea,National Research Foundation of Korea,South Korea,17,0,0
grant.7480407,2013K1A2A1043459,개발 도상국을 위한 백신 개발 지원 프로그램,0,2013-01-01,2013.0,2014-01-01,2014,International Vaccine Institute,grid.30311.30,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7475943,2014R1A2A1A11051899,유산균 항원운반체를 매개로 하는 급여형어류백신 개발 연구,0,2014-01-01,2014.0,2015-01-01,2015,Handong Global University,grid.411957.f,South Korea,National Research Foundation of Korea,South Korea,4,0,0
grant.7466232,2010-00167,새로운 결핵 생백신 후보 물질의 개발 및 분석,0,2010-01-01,2010.0,2011-01-01,2011,Institut Pasteur Korea,grid.418549.5,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7456985,2011-0009339,Terpene 성분을 이용한 진균백신 개발,0,2011-01-01,2011.0,2012-01-01,2012,Dongduk Women's University,grid.412059.b,South Korea,National Research Foundation of Korea,South Korea,2,0,0
grant.7453708,2011-0015258,새로운 결핵 생백신 후보 물질의 개발 및 분석,0,2011-01-01,2011.0,2012-01-01,2012,Institut Pasteur Korea,grid.418549.5,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7451192,2010-0030044,신규 결핵예방백신 개발사업 기획연구,0,2010-01-01,2010.0,2011-01-01,2011,Sejong University,grid.263333.4,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7445407,2010-00713,새로운 결핵 생백신 후보 물질의 개발 및 분석,0,2010-01-01,2010.0,2011-01-01,2011,Institut Pasteur Korea,grid.418549.5,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7172800,2015361,H. pylori infection and oral enteric vaccines,60000,2015-01-01,2015.0,2017-01-01,2017,Tel Aviv University,grid.12136.37,Israel,United States-Israel Binational Science Foundation,Israel,0,0,0
grant.7164693,InP/038/15,A New Therapeutic Vaccine for HIV/AIDS,26697,2015-01-30,2015.0,2016-01-29,2016,University of Hong Kong,grid.194645.b,China,Innovation and Technology Commission,China,0,0,0
grant.7162576,ITS/194/13,A New Therapeutic Vaccine for HIV/AIDS,179388,2014-01-01,2014.0,2016-01-31,2016,University of Hong Kong,grid.194645.b,China,Innovation and Technology Commission,China,0,0,0
grant.7150415,,Generation of HyperImmunogenic vaccines against human viral pathogens,881665,2013-01-01,2013.0,2013-12-31,2013,Aarhus University,grid.7048.b,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7148703,,Delivery of vaccine antigens on virus like particles,385160,2016-01-01,2016.0,2016-12-31,2016,University of Copenhagen,grid.5254.6,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7148315,,Less is more in TB vaccines,449644,2017-01-01,2017.0,2017-12-31,2017,State Serum Institute,grid.6203.7,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7043730,VM0104,Development of a potency test for leptospira vaccines,292991,1993-04-01,1993.0,1996-03-31,1996,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043113,SE3218,"Bovine TB vaccine programme advisor, Prof Douglas Young",105796,2003-09-01,2003.0,2011-03-31,2011,,,,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042995,SE2912,Improved selection methods for emergency FMD vaccines,810873,1997-04-01,1997.0,2000-06-30,2000,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042984,SE2901,Improved selection methods for emergency FMD vaccines,652432,1994-04-01,1994.0,1996-12-31,1996,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042973,SE2804,Protective immune responses induced by FMDV vaccine,256438,1996-04-01,1996.0,1999-03-31,1999,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042972,SE2803,Antigenic properties of vaccine virus strains,232602,1993-04-01,1993.0,1996-03-31,1996,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7040781,OZ0131,Live salmonella vaccines for the protection of poultry,185946,1997-04-01,1997.0,1998-03-31,1998,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7040770,OZ0115,"`The development of live, rationallyattenuated salmonella vaccines`",653455,1994-04-01,1994.0,1997-03-31,1997,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.6973472,617355,Bioprocess Sciences and Technology of Viral Vaccines,150889,2016-04-01,2016.0,2017-03-31,2017,McGill University,grid.14709.3b,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6968429,606102,Synthesis of a Potential Lyme Disease Vaccine,3391,2016-04-01,2016.0,2017-03-31,2017,Dalhousie University,grid.55602.34,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6964936,602424,Oncolytic virus vaccine to cure different kinds of cancer,3391,2016-04-01,2016.0,2017-03-31,2017,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6964935,602423,Oncolytic virus vaccine to cure different kinds of cancer,3391,2016-04-01,2016.0,2017-03-31,2017,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6964934,602422,Oncolytic virus vaccine to cure different kinds of cancer,3391,2016-04-01,2016.0,2017-03-31,2017,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6962076,598373,Targeted microneedle insertion for epidermal vaccine delivery and biosensing,37718,2016-04-01,2016.0,2017-03-31,2017,University of British Columbia,grid.17091.3e,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6860200,LY13H100003,FcR介导的具有特异免疫保护作用新型RSV粘膜疫苗的研究,0,2013-01-01,2013.0,2017-12-31,2017,Wenzhou Medical University,grid.268099.c,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.6841646,17K16224,Development of RNA vaccine against dengue virus infection,37533,2017-04-01,2017.0,2019-03-31,2019,Kobe University,grid.31432.37,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6733351,940158,Construction of designer immunogens for use as vaccines,441609,1994-01-01,1994.0,1998-12-31,1998,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6733063,890035,Development of a possible vaccine for gonorrhoea,72348,1989-01-01,1989.0,1991-12-31,1991,Monash University,grid.1002.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6732161,880846,Designing novel chemicals as potential influenza vaccines,70796,1988-01-01,1988.0,1990-12-31,1990,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6731087,930141,An improved vaccine for hepatitis B virus,111817,1993-01-01,1993.0,1995-12-31,1995,Royal Children's Hospital,grid.416107.5,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6730637,971242,Schistosome proteolytic enzymes as drug and vaccine tar gets,69224,1997-01-01,1997.0,1997-12-31,1997,,,,National Health and Medical Research Council,Australia,1,0,0
grant.6729362,900170,Development of a vaccine to prevent malaria transmissio n,197208,1990-01-01,1990.0,1992-12-31,1992,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6728479,910347,Development of AIDS vaccine using synthesized peptides.,123855,1991-01-01,1991.0,1994-12-31,1994,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6727741,8118,Factors affecting the immunogenicity of pertussis vaccines,29704,2000-01-01,2000.0,2001-12-31,2001,Women's and Children's Hospital,grid.1694.a,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6727472,900771,Search for active components for a malaria vaccine,203274,1990-01-01,1990.0,1992-12-31,1992,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6727351,930123,The development of a safer whooping cough vaccine,99460,1993-01-01,1993.0,1995-12-31,1995,University of Wollongong,grid.1007.6,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6727129,950472,Towards a vaccine against infantile diarrhoeal disease,171630,1995-01-01,1995.0,1998-12-31,1998,Macquarie University,grid.1004.5,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6726943,990037,Development of a Plant-Derived Oral Vaccine for Measles,111784,1999-01-01,1999.0,2001-12-31,2001,Monash University,grid.1002.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6726066,987521,Development of a nucleic acid vaccine for schistosomiasis,37292,1998-01-01,1998.0,2001-12-31,2001,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6724082,284535,"Intestinal adapatation, Intususspection and rotavirus vaccine, applied clinical nutrition",170570,2004-01-01,2004.0,2008-12-31,2008,Murdoch Childrens Research Institute,grid.1058.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6724070,284475,Bacterial delivery of DNA vaccines: salmonella - endosome interactions,8896,2004-01-01,2004.0,2004-12-31,2004,Monash University,grid.1002.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6722617,437000,Clinical trials of RV3 oral human neonatal rotavirus vaccine,160408,2007-01-01,2007.0,2011-12-31,2011,Murdoch Childrens Research Institute,grid.1058.c,Australia,National Health and Medical Research Council,Australia,2,0,0
grant.6722495,418108,CD8+ T cell immunity to viruses and recombinant vaccines,414742,2007-01-01,2007.0,2011-12-31,2011,Australian National University,grid.1001.0,Australia,National Health and Medical Research Council,Australia,9,0,0
grant.6719794,930841,How to turn malaria proteins into a vaccine,60047,1993-01-01,1993.0,1993-12-31,1993,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6717775,981340,A cytotoxic T cell epitope based vaccine for HIV,199095,1998-01-01,1998.0,2000-12-31,2000,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6716449,970804,The development of an oral whooping cough vaccine,106640,1997-01-01,1997.0,1999-12-31,1999,University of Wollongong,grid.1007.6,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6715829,890949,Why are live vaccines often better than killed?,109212,1989-01-01,1989.0,1991-12-31,1991,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6715708,931125,Relevance of bacterial surface structure to vaccine dev elopment,149976,1993-01-01,1993.0,1995-12-31,1995,University of Adelaide,grid.1010.0,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6584428,OPP1025596,To develop and test a DNA vaccine for HIV,100000,2010-11-01,2010.0,2012-11-01,2012,Catholic University of America,grid.39936.36,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584014,OPP1070514,To develop novel vesicle-derived vaccines against Mycobacterium tuberculosis.,440000,2012-11-01,2012.0,2015-11-01,2015,Yeshiva University,grid.268433.8,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6583657,OPP37868,To develop nanoemulsions and adjuvants for nasal-spray vaccines,6294086,2005-07-01,2005.0,2012-01-01,2012,University of Michigan,grid.214458.e,United States,Bill & Melinda Gates Foundation,United States,7,0,0
grant.6582621,OPP1094567,To support CMV vector-based Vaccine Concept,2871805,2013-10-01,2013.0,2016-05-01,2016,Oregon Health & Science University,grid.5288.7,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6582605,OPP37881,To develop an inexpensive therapeutic vaccine for human papillomavirus,3543549,2005-07-01,2005.0,2013-01-01,2013,University of Colorado Anschutz Medical Campus,grid.430503.1,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582373,OPP1154635,To produce better and cheaper vaccines against polio,1847820,2016-09-01,2016.0,2018-11-01,2018,Fraunhofer Society,grid.4561.6,Germany,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581732,OPP38637,To fund a vaccine discovery (antibody) consortium,25293370,2006-07-01,2006.0,2013-07-01,2013,University College London,grid.83440.3b,United Kingdom,Bill & Melinda Gates Foundation,United States,17,0,0
grant.6581497,OPP1084286,To conduct a pneumococcal vaccine impact assessment in Bangladesh,6376130,2013-09-01,2013.0,2019-08-01,2019,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6581487,OPP38580,To develop a Global HIV Vaccine Research Cryorepository (GHRC),7782675,2006-08-01,2006.0,2009-08-01,2009,Fraunhofer Society,grid.4561.6,Germany,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6581045,OPP1148786,To test a novel universal influenza vaccine,385144,2016-06-01,2016.0,2017-06-01,2017,Pirbright Institute,grid.63622.33,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580935,OPP633,To develop a genetically engineered recombinant hookworm vaccine,18000000,2000-04-01,2000.0,2006-04-01,2006,Sabin Vaccine Institute,grid.452766.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580931,OPP33112,To conduct an analysis of pediatric enteric vaccine development,807080,2004-07-01,2004.0,2005-07-01,2005,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580858,OPP1002555,To develop a unique delivery system for vaccines whose major health impact is in high burden countries allowing the conversion of existing injectable vaccines into oral and/or inhalation vaccines and expedite development of novel mucosal vaccines,804741,2011-10-01,2011.0,2014-10-01,2014,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6373203,X46120-----70030,狂犬病日卵ワクチンの改良,5178,1971-01-01,1971.0,1971-12-31,1971,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6371736,X46120-----70025,ボツリヌス中毒の経口ワクチンに関する研究,8287,1971-01-01,1971.0,1971-12-31,1971,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6371621,X46120-----70036,インフルエンザワクチンの改善に関する研究,11740,1971-01-01,1971.0,1971-12-31,1971,Nippon Medical School,grid.410821.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6354558,X42120-----71124,インフルエンザ生ワクチンに関する研究(継2年),6768,1967-01-01,1967.0,1967-12-31,1967,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6352300,X43120-----71029,流行性耳下膜炎生ワクチンに関する研究,6906,1968-01-01,1968.0,1968-12-31,1968,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6326766,X00120----670025,ボッリヌス中毒の経口ワクチンに関する研究,6906,1972-01-01,1972.0,1972-12-31,1972,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6322556,X00120----670036,インフルエンザワクチンの改善に関する研究,8978,1972-01-01,1972.0,1972-12-31,1972,Nippon Medical School,grid.410821.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6320876,X00120----787028,精製三種混合(D.T.P)ワクチンの試験的研究,17265,1972-01-01,1972.0,1973-12-31,1973,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6315181,X00120----387007,精製狂犬病ワクチンによる咬傷後免疫法の研究,17956,1978-01-01,1978.0,1979-12-31,1979,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6312481,X00120----187046,水痘生ワクチンの開発に関する研究,10360,1976-01-01,1976.0,1976-12-31,1976,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6312424,X00120----087080,水痘生ワクチンの開発に関する研究,12914,1975-01-01,1975.0,1975-12-31,1975,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6309272,X00120----587054,大腸菌K1株のワクチン開発研究,24172,1980-01-01,1980.0,1980-12-31,1980,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6300254,X00090----856161,緑膿菌の溶解ワクチンに関する研究,9323,1973-01-01,1973.0,1973-12-31,1973,Kagoshima University,grid.258333.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6269166,99J03631,SHIVを用いたAIDS弱毒生ワクチンの間発,31546,1999-01-01,1999.0,2001-12-31,2001,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6265050,98F00138,腸管寄生虫に対する粘膜ワクチンの開発,16256,1999-01-01,1999.0,2000-12-31,2000,University of Miyazaki,grid.410849.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6199903,58771559,HB ワクチンによる歯科医師のB型肝炎予防対策について,6213,1983-01-01,1983.0,1983-12-31,1983,Nihon University,grid.260969.2,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6184528,58480395,抗齲蝕ワクチン開発に関する基礎的研究,42130,1983-01-01,1983.0,1984-12-31,1984,Kagoshima University,grid.258333.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6172495,56870053,肺炎球菌ワクチンの実用化に関する研究,11740,1981-01-01,1981.0,1981-12-31,1981,Toho University,grid.265050.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6168194,57015012,抗原特異的抗腫瘍ワクチンの開発とその応用,22102,1982-01-01,1982.0,1982-12-31,1982,Chiba University,grid.136304.3,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6053442,22790870,DNAワクチンによる自己免疫性糖尿病の寛解,14803,2010-01-01,2010.0,2010-12-31,2010,Keio University,grid.26091.3c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6035398,22240057,Programmed Activationに基づく人工DNAワクチンの創製,183583,2010-01-01,2010.0,2010-12-31,2010,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5988918,19790430,乳幼児におけるインフルエンザワクチンに対する免疫原性に関する研究,11034,2007-01-01,2007.0,2007-12-31,2007,Osaka City University,grid.261445.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5608798,04760137,遺伝子組換えによるせっそう病トキソイドワクチンの開発,7104,1992-01-01,1992.0,1992-12-31,1992,Kitasato University,grid.410786.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5592504,03857253,MHC非拘束性合成う蝕ワクチンの研究,6688,1991-01-01,1991.0,1991-12-31,1991,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5569183,02857269,蛋白質工学を利用した蝕ワクチンの分子設計,7597,1990-01-01,1990.0,1990-12-31,1990,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5565949,02856074,鶏コクシジウムのコンポーネント・ワクチンに関する基礎的研究,4833,1990-01-01,1990.0,1990-12-31,1990,Ibaraki University,grid.410773.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5565166,01790488,家禽に対する遺伝子組み換えウィルスワクチン用ベクターに関する研究,13118,1989-01-01,1989.0,1990-12-31,1990,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5533552,592381,Bioprocess Sciences and Technology of Viral Vaccines,156508,2015-04-01,2015.0,2016-03-31,2016,McGill University,grid.14709.3b,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5531348,580413,Stability of a dry whole cell malaria vaccine,3518,2015-04-01,2015.0,2016-03-31,2016,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5528462,581150,Excipient investigation for improving Herpes simpex II vaccine processing,3518,2015-04-01,2015.0,2016-03-31,2016,University of Waterloo,grid.46078.3d,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5527258,577324,Targeted microneedle insertion for epidermal vaccine delivery and biosensing,39124,2015-04-01,2015.0,2016-03-31,2016,University of British Columbia,grid.17091.3e,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5502385,hrc_7d782a16,Novel vaccine approaches for protecting against helminth parasites,927884,2010-01-01,2010.0,2013-01-01,2013,Malaghan Institute of Medical Research,grid.250086.9,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5502275,hrc_85e8ff70,Immunisation disparities and vaccine-preventable diseases in New Zealand,90826,2008-01-01,2008.0,2011-01-01,2011,University of Auckland,grid.9654.e,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5325527,ASTHMARF02L,T cell vaccines for asthma and allergic rhinitis,435809,2001-03-09,2001.0,2006-03-08,2006,McMaster University,grid.25073.33,Canada,Asthma UK,United Kingdom,0,0,0
grant.5246712,N01AI95367-0-0-1,Clinical Grade H9N2 Influenza Vaccine,0,1999-07-09,1999.0,2008-08-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.5246675,N01AI60023-3-0-0,NIAID HIV VACCINE RESEARCH EDUCATION INITIATIVE,2685906,2006-09-30,2006.0,2008-09-29,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246655,N01AI60007-4-0-1,Simian Vaccine Evaluation Units,4388000,2008-01-01,2008.0,2008-12-31,2008,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246654,N01AI60007-4-0-0,SIMIAN VACCINE EVALUATION UNIT,2090968,2006-06-22,2006.0,2013-06-21,2013,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246653,N01AI60006-4-0-1,Simian Vaccine Evaluation Unit (SVEU),3464000,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246652,N01AI60006-4-0-0,SIMIAN VACCINE EVALUATION UNIT,6720850,2006-06-22,2006.0,2013-06-21,2013,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246651,N01AI60005-5-0-1,Simian Vaccine Evaluation Unit (SVEU),6369000,2008-01-01,2008.0,2008-12-31,2008,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246650,N01AI60005-5-0-0,SIMIAN VACCINE EVALUATION UNIT,4640567,2006-06-15,2006.0,2013-06-21,2013,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246628,N01AI50041-5-0-1,Tularemia Vaccine Development Team,0,2005-09-30,2005.0,2010-09-29,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246627,N01AI50041-5-0-0,TULAREMIA VACCINE DEVELOPMENT TEAM,6978780,2005-09-30,2005.0,2010-09-29,2010,,,,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.5246625,N01AI50040-5-0-0,TULAREMIA VACCINE DEVELOPMENT TEAM,4000000,2005-09-30,2005.0,2010-09-29,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246587,N01AI50010-0-0-1,HIV Vaccine Design and Development Teams,5042594,2005-09-12,2005.0,2010-09-11,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246557,N01AI40091-8-0-1,Tuberculosis Research Materials and Vaccine Testing,515844,2008-01-01,2008.0,2008-12-31,2008,Colorado State University,grid.47894.36,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246556,N01AI40091-8-0-0,TUBERCULOSIS RESEARCH MATERIALS AND VACCINE TESTING,4270280,2004-09-24,2004.0,2011-09-23,2011,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246416,N01AI30053-0-0-1,Production and Testing of Anthrax Vaccine,0,2003-09-30,2003.0,2007-04-03,2007,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246378,N01AI30031-0-0-1,HIV Vaccine Design and Development Teams,1300000,2003-09-26,2003.0,2008-09-25,2008,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.5246376,N01AI30030-0-0-1,HIV Vaccine Design and Development Teams,2600000,2003-09-26,2003.0,2008-09-25,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246333,N01AI25464-13-0-2,Vaccine and Treatment Evaluation Unit,791496,2002-06-01,2002.0,2008-12-31,2008,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246326,N01AI25453-2-0-1,Vaccine and Treatment Evaluation Unit,17271,2001-11-01,2001.0,2006-10-31,2006,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246292,N01AI05421-27-0-1,Malaria Vaccine Production and Support Services,5293544,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246291,N01AI05421-27-0-0,MALARIA VACCINE PRODUCTION AND SUPPORT SERVICES,4312612,2000-09-22,2000.0,2014-09-21,2014,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5206028,52068,Molecular analysis of immune responses to malaria peptide vaccines,149592,1998-03-01,1998.0,2000-03-31,2000,University of Basel; Swiss Tropical and Public Health Institute,grid.6612.3; grid.416786.a,Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,4,0,0
grant.5202152,66442,Immunologische Kontrolle der Zeckeninduzierten Immunmodulation: Eine Vakzinestrategie.,0,2001-08-01,2001.0,2002-07-31,2002,University of Connecticut Health Center,grid.208078.5,United States,Swiss National Science Foundation,Switzerland,0,0,0
grant.5196804,40199,Conserved CTL Epitopes in HIV-1 as Potential Vaccines.,29019,1994-04-01,1994.0,1995-03-31,1995,University of Lausanne,grid.9851.5,Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5195740,37440,Biodegradable microspheres as a novel vaccine delivery system,142572,1994-04-01,1994.0,1997-03-31,1997,Swiss Federal Institute of Technology in Zurich; University of Lausanne; Swiss Federal Institute of Technology in Zurich,grid.5801.c; grid.9851.5; grid.5801.c,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,3,0,0
grant.5195025,36349,Development of a vaccine against HELICOBACTER PYLORI infection,307034,1993-04-01,1993.0,1995-12-31,1995,University of Lausanne; University of Lausanne; Cabinet Gastroenterology La Source-Beaulieu; University of Lausanne,grid.9851.5; grid.9851.5; grid.482966.7; grid.9851.5,Switzerland; Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5138636,CRUK-A7825,Robo4 protein as a cancer vaccine,0,2007-01-01,2007.0,2008-12-31,2008,University of Birmingham,grid.6572.6,United Kingdom,Cancer Research UK,United Kingdom,1,0,0
grant.5069446,Y205749,肾综合征出血热基因工程疫苗的研制,0,2005-01-01,2005.0,2013-12-31,2013,Chinese Center For Disease Control and Prevention,grid.198530.6,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5068098,Y204458,麻疹流行株的抗原变异对疫苗效果影响的研究,0,2004-01-01,2004.0,2012-12-31,2012,Chinese Center For Disease Control and Prevention,grid.198530.6,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5066344,LQ13C180002,基于蛋白质组学的兔支气管败血波氏杆菌反向疫苗学研究,0,2013-01-01,2013.0,2016-12-31,2016,ZheJiang Academy of Agricultural Sciences,grid.410744.2,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5064871,Y305031,PRRS多价基因工程疫苗研究的新策略,0,2005-01-01,2005.0,2009-12-31,2009,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5061881,DRT-S97-19,Breast Cancer Vaccines from Plants,51865,1998-06-01,1998.0,2000-05-31,2000,"University of California, San Francisco",grid.266102.1,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.5061466,DRT-S96-10,Basic Studies in Super Vaccines,54650,1997-01-01,1997.0,1998-12-31,1998,New York University,grid.137628.9,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.5061185,DRT-biostar00-10098,Vaccines Based on DNA Adenine Methylase Technology,127444,2001-08-10,2001.0,2002-12-10,2002,"University of California, Santa Barbara",grid.133342.4,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.5060853,DRT-S97-25,Mechanism of action of DNA vaccines,212413,1998-06-01,1998.0,2000-05-31,2000,"University of California, San Francisco",grid.266102.1,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.4845632,3853,Development of a novel carrier/adjuvant for intranasal vaccines,117981,2004-01-01,2004.0,2006-12-31,2006,Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem,grid.9619.7; grid.9619.7; grid.9619.7,Israel; Israel; Israel,Israel Science Foundation,Israel,0,0,0
grant.4695298,9-2000-1012,Australia III - DVDC  (Diabetes Vaccine Development Center),8965963,2004-01-01,2004.0,2014-03-31,2014,National Health and Medical Research Council,grid.431143.0,Australia,Juvenile Diabetes Research Foundation,United States,0,0,0
grant.4682414,141321,Improving whole-organism vaccines against malaria by genetic modification,0,2016-01-01,2016.0,2018-12-31,2018,University of Lisbon,grid.9983.b,Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.4661480,208297,AquaSolve: Nanobead vaccine delivery platform for aquaculture,355035,2011-01-01,2011.0,2012-12-31,2012,Inven2 (Norway),grid.458116.f,Norway,The Research Council of Norway,Norway,0,0,0
grant.4644142,217391,Effective vaccine against winter ulcer in salmon.,272177,2012-01-01,2012.0,2013-12-31,2013,Kjeller Innovation,grid.458253.d,Norway,The Research Council of Norway,Norway,0,0,0
grant.4641075,187664,Low cost production of biopharmaceuticals and vaccines in plants,8529,2007-01-01,2007.0,2007-12-31,2007,,,,The Research Council of Norway,Norway,0,0,0
grant.4636462,M1-0150 (C),Rekombinantno cepivo proti aviarni influenci,0,2006-01-06,2006.0,2007-05-31,2007,University of Ljubljana; National Institute of Chemistry; University of Ljubljana; University of Ljubljana; Ljubljana University Medical Centre; National Institute of Chemistry; University of Ljubljana,grid.8954.0; grid.454324.0; grid.8954.0; grid.8954.0; grid.29524.38; grid.454324.0; grid.8954.0,Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia,Slovenian Research Agency,Slovenia,0,0,0
grant.4562339,96/11539-0,Development of a recombinant BCG vaccine - DPT,0,1997-04-01,1997.0,2000-12-31,2000,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4510775,94/05878-1,Peptides and proteins for vaccines and therapeutics,0,1995-04-01,1995.0,1996-03-31,1996,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4453044,CBD99-020,Development of Naked DNA Vaccine: Brucella,70000,1998-10-01,1998.0,1999-09-30,1999,,,,United States Department of Defense,United States,0,0,0
grant.4362089,5578,Preparation of liquid live vaccine against rubella,233401,2008-04-01,2008.0,2010-03-31,2010,Imuna Pharm (Slovakia); Slovak Academy of Sciences; Slovak Academy of Sciences,grid.455080.c; grid.419303.c; grid.419303.c,Slovakia; Slovakia; Slovakia,Slovak Research and Development Agency,Slovakia,0,0,0
grant.4192377,72284,Construction and characterization of live-attenuated enterobacterial vaccine candidates,55902,2008-09-01,2008.0,2011-09-30,2011,University of Pecs; University of Pecs; University of Pecs,grid.9679.1; grid.9679.1; grid.9679.1,Hungary; Hungary; Hungary,Hungarian Scientific Research Fund,Hungary,1,0,0
grant.4171416,561463,Evaluation of an oncolytic vaccine in dogs,4071,2014-04-01,2014.0,2015-03-31,2015,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.4167878,557753,Bioprocess Sciences and Technology of Viral Vaccines,90554,2014-04-01,2014.0,2015-03-31,2015,McGill University,grid.14709.3b,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.4167438,563155,Targeted microneedle insertion for epidermal vaccine delivery and biosensing,45275,2014-04-01,2014.0,2015-03-31,2015,University of British Columbia,grid.17091.3e,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.4106519,150026,Controlled Release Nanoparticle vaccines,2736860,2005-09-30,2005.0,2010-09-29,2010,Xenetic Biosciences (United Kingdom); University of Cambridge; Public Health England,grid.505583.e; grid.5335.0; grid.271308.f,United Kingdom; United Kingdom; United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.4035526,2101,Novel dendritic cell-based vaccine of cancer,67080,2004-10-01,2004.0,2007-09-30,2007,University of Saskatchewan; University of Saskatchewan,grid.25152.31; grid.25152.31,Canada; Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.4035380,2093,Transdermal delivery systems for protein medicines and vaccines,72594,2004-04-01,2004.0,2006-03-31,2006,University of Saskatchewan,grid.25152.31,Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.4035377,2094,Transdermal delivery systems for protein medicines and vaccines,37264,2004-04-01,2004.0,2005-03-31,2005,University of Saskatchewan,grid.25152.31,Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.3749684,QLK2-CT-1999-01321,European vaccine effort against hiv/aids,9080219,2000-01-01,2000.0,2005-01-01,2005,Karolinska Institute; Covance (United Kingdom); University of Lausanne; Swiss Federal Institute of Technology in Lausanne; Jean Monnet University; French National Centre for Scientific Research; Biomedical Primate Research Centre; Academic Medical Center; University of Insubria; University of Bern; Public Health England; Crucell (Switzerland); San Raffaele Hospital; Medical Research Council; University of Lausanne; King's College London; Spanish National Research Council; University of Naples Federico II; University of Regensburg; French Institute of Health and Medical Research; Imperial College London; Sanofi (France),grid.4714.6; grid.417605.1; grid.9851.5; grid.5333.6; grid.6279.a; grid.4444.0; grid.11184.3d; grid.5650.6; grid.18147.3b; grid.5734.5; grid.271308.f; grid.432742.4; grid.18887.3e; grid.14105.31; grid.9851.5; grid.13097.3c; grid.4711.3; grid.4691.a; grid.7727.5; grid.7429.8; grid.7445.2; grid.417924.d,Sweden; United Kingdom; Switzerland; Switzerland; France; France; Netherlands; Netherlands; Italy; Switzerland; United Kingdom; Switzerland; Italy; United Kingdom; Switzerland; United Kingdom; Spain; Italy; Germany; France; United Kingdom; France,European Commission,Belgium,27,0,0
grant.3733024,BIO4980031,Biosafety of vaccines based on self-replicating recombinant alphavirus,0,1998-09-01,1998.0,2000-08-31,2000,"Enterprise Ireland; Imperial College London; Queen's University Belfast; Karolinska Institute; National University of Ireland, Maynooth; National University of Ireland",grid.7088.7; grid.7445.2; grid.4777.3; grid.4714.6; grid.95004.38; grid.9344.a,Ireland; United Kingdom; United Kingdom; Sweden; Ireland; Ireland,European Commission,Belgium,0,0,0
grant.3731136,IC18980387,Selection of P. Falciparum antigene for MPES vaccine development,0,1999-02-01,1999.0,2001-02-28,2001,Pasteur Institute; Biomedical Primate Research Centre; University of Valle; Radboud University Nijmegen; Institute of Tropical Medicine Antwerp,grid.428999.7; grid.11184.3d; grid.8271.c; grid.5590.9; grid.11505.30,France; Netherlands; Colombia; Netherlands; Belgium,European Commission,Belgium,0,0,0
grant.3729873,CIPA940230,New approaches for the development of enterobacterial vaccine strains,0,1995-01-01,1995.0,1997-12-31,1997,University of Würzburg; National Center of Infectious and Parasitic Diseases; University of Pecs,grid.8379.5; grid.419273.a; grid.9679.1,Germany; Bulgaria; Hungary,European Commission,Belgium,0,0,0
grant.3728490,CIPE926123,Development of vaccines against coccidiosis through biotechnology,0,1993-05-01,1993.0,1994-04-30,1994,,,,European Commission,Belgium,0,0,0
grant.3726127,TS3*930255,Oral vaccine against cholera with Built-in adjuvanticity,0,1994-04-01,1994.0,1997-04-30,1997,Novartis (Italy); Pasteur Institute; University of Sao Paulo,grid.15585.3c; grid.428999.7; grid.11899.38,Italy; France; Brazil,European Commission,Belgium,1,0,0
grant.3708086,TS1*0026,CHEMICAL SYNTHESIS OF HEPATITIS B VACCINES,0,1984-01-01,1984.0,1986-12-31,1986,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,European Commission,Belgium,0,0,0
grant.3706490,MR4*0027,DEVELOPMENT OF AN EFFICIENT VACCINE (AIDS),0,1987-09-01,1987.0,1988-12-31,1988,Medical Research Council,grid.14105.31,United Kingdom,European Commission,Belgium,0,0,0
grant.3702872,TS2*0188,DEVELOPMENT OF SYNTHETIC VACCINES AGAINST NEMATODE INFECTIONS,0,1989-07-01,1989.0,1993-06-30,1993,National Research Council,grid.5326.2,Italy,European Commission,Belgium,0,0,0
grant.3700936,TS2*0218,DEVELOPMENT OF VACCINE AGAINST CHAGAS' DISEASE,0,1989-02-01,1989.0,1992-06-30,1992,Pasteur Institute of Lille,grid.8970.6,France,European Commission,Belgium,0,0,0
grant.3535230,U01CK000350,EVAL OF IMPCT OF JAPANESE ENCEPHALITIS VACCINE IN CAMBODIA,75190,2014-04-01,2014.0,2015-03-31,2015,National Center for Immunization and Respiratory Diseases,grid.419260.8,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3532347,101143,Rational design of an AIP56-based anti-pasteurellosis vaccine,145174,2010-05-01,2010.0,2013-10-31,2013,University of Porto; University of Porto; University of Porto; University of Porto; University of Porto; University of Porto; University of Porto,grid.5808.5; grid.5808.5; grid.5808.5; grid.5808.5; grid.5808.5; grid.5808.5; grid.5808.5,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3529500,103484,Exploring pathogen diversity in disease epidemiology and vaccine research,217382,2010-02-01,2010.0,2013-01-31,2013,Instituto Gulbenkian de Ciência; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Brooklyn College; Universidade Nova de Lisboa; Instituto Gulbenkian de Ciência; Atlantic University; University of Porto; Oswaldo Cruz Foundation; Instituto Gulbenkian de Ciência,grid.418346.c; grid.10772.33; grid.10772.33; grid.183006.c; grid.10772.33; grid.418346.c; grid.410920.e; grid.5808.5; grid.418068.3; grid.418346.c,Portugal; Portugal; Portugal; United States; Portugal; Portugal; Portugal; Portugal; Brazil; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3528280,113650,Melhoramento da imunogenicidade de vacinas de DNA,163587,2011-01-01,2011.0,2013-12-31,2013,University of Lisbon; University of Lisbon; University of Lisbon; University of Lisbon; University of Lisbon; University of Lisbon; University of Lisbon,grid.9983.b; grid.9983.b; grid.9983.b; grid.9983.b; grid.9983.b; grid.9983.b; grid.9983.b,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3528140,61090,Development of DNA vaccine prototypes for veterinary trypanosomiasis,83746,2005-07-01,2005.0,2007-12-31,2007,University of Lisbon; University of Lisbon; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa,grid.9983.b; grid.9983.b; grid.10772.33; grid.10772.33; grid.10772.33,Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,4,0,0
grant.3527854,82211,Development of DNA vaccine prototypes for veterinary trypanosomiasis,32656,2007-01-01,2007.0,2009-02-28,2009,University of Lisbon; University of Lisbon; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa,grid.9983.b; grid.9983.b; grid.10772.33; grid.10772.33; grid.10772.33,Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3527599,126635,Anti-ghrelin vaccine: a feasible alternative for obesity treatment?,66351,2013-05-01,2013.0,2014-10-31,2014,University of Porto; University of Porto; University of Porto; University of Porto; University of Porto,grid.5808.5; grid.5808.5; grid.5808.5; grid.5808.5; grid.5808.5,Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3526938,116097,Smart porous particles for pulmonary drug and vaccine delivery,116280,2011-04-01,2011.0,2014-07-31,2014,Universidade Nova de Lisboa; Universidade Nova de Lisboa; University of Beira Interior; Rede de Química e Tecnologia,grid.10772.33; grid.10772.33; grid.7427.6; grid.421461.4,Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3526242,65048,Impact of the conjugate pneumococcal vaccines on pneumococcal ecology,208503,2009-01-01,2009.0,2012-06-30,2012,Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Hospital de Santa Maria,grid.10772.33; grid.10772.33; grid.10772.33; grid.10772.33; grid.10772.33; grid.10772.33; grid.411265.5,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3524632,70275,Vaccine potential of different Leishmania infantum proteins,148018,2007-10-15,2007.0,2011-04-14,2011,University of Porto; Universidade Nova de Lisboa; University of Porto; University of Porto; University of Porto; Universidade Nova de Lisboa; University of Porto,grid.5808.5; grid.10772.33; grid.5808.5; grid.5808.5; grid.5808.5; grid.10772.33; grid.5808.5,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,4,0,0
grant.2987656,152995,Development of subunit anti-viral vaccines for salmonid fish,142445,1998-04-01,1998.0,2000-03-31,2000,"University of British Columbia; Innovation, Science and Economic Development Canada; Innovation, Science and Economic Development Canada",grid.17091.3e; grid.435030.1; grid.435030.1,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2985050,84171,Towards a live vaccine against cryptobiosis in salmonids,9540,1991-04-01,1991.0,1993-03-31,1993,University of Guelph; Fisheries and Oceans Canada,grid.34429.38; grid.23618.3e,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2984254,111908,Développement d'un vaccin contre Streptococcus suis,52358,1997-04-01,1997.0,1998-03-31,1998,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2982723,54872,Enhancing vaccine efficacy by molecular chimerization to cytokines,15503,1993-04-01,1993.0,1994-03-31,1994,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2978220,66199,"Development of vaccines for BVDV, BRSV and PI-3",78576,1991-04-01,1991.0,1993-03-31,1993,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2971136,214798,Development of vaccine vector for human immunodeficiency virus,22291,2002-04-01,2002.0,2003-03-31,2003,"University of California, San Francisco",grid.266102.1,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2968761,325113,Identification of tumor-associated antigens as cancer vaccine targets,129424,2005-04-01,2005.0,2007-03-31,2007,University of Toronto,grid.17063.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2968075,176289,Design of a glycoconjugate vaccine against group A streptococcus,129905,1999-04-01,1999.0,2001-03-31,2001,Simon Fraser University,grid.61971.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2967309,98132,Development of a subunit vaccine for haemophilus somnus,43628,1991-04-01,1991.0,1992-03-31,1992,University of Saskatchewan; Agriculture and Agriculture-Food Canada; Agriculture and Agriculture-Food Canada,grid.25152.31; grid.55614.33; grid.55614.33,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2960882,54871,Increasing vaccine efficiency through defined adjuvant use,128223,1992-04-01,1992.0,1994-03-31,1994,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2958728,212544,Design of a glycoconjugate vaccine against group A streptococcus,23745,2002-04-01,2002.0,2003-03-31,2003,Simon Fraser University,grid.61971.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2957327,78064,Development of a multivalent recombinant fowlpox virus vaccine,161733,1991-04-01,1991.0,1993-03-31,1993,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2942407,9534,Development of a molecularly defined vaccine for Myxosporean parasites,116966,1995-04-01,1995.0,1997-03-31,1997,University of Victoria,grid.143640.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2939650,472024,Role of TLR4 binding adjuvant in improving cancer vaccines,4090,2010-04-01,2010.0,2011-03-31,2011,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2937046,298504,Attenuating West Nile: The search for a Love Vaccine,14278,2005-04-01,2005.0,2006-03-31,2006,University of Manitoba,grid.21613.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2936941,240074,Development of porcine adenovirus-3 as a vaccine vector,373818,2000-04-01,2000.0,2004-03-31,2004,University of Saskatchewan; Vétoquinol (Canada),grid.25152.31; grid.450582.e,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2932210,330272,Attenuating West Nile: The search for a Love Vaccine,15247,2006-04-01,2006.0,2007-03-31,2007,University of Manitoba,grid.21613.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2928975,408862,Recombinant fowl adenovirus based vaccine against avian influenza,4216,2008-04-01,2008.0,2009-03-31,2009,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2923314,372020,Novel biodegradeable hydrogel for hiv vaccine delivery,16102,2007-04-01,2007.0,2008-03-31,2008,Case Western Reserve University,grid.67105.35,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2921906,53574,Human adenovirus-based vaccines and mammalian expression vectors,351165,1991-04-01,1991.0,1994-03-31,1994,McMaster University,grid.25073.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2912514,239917,Oral vaccines: Targetting to improve induction of mucosal immunity,298383,1999-04-01,1999.0,2004-03-31,2004,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2911669,442602,Diagnostics of fish diseases and development of vaccines,3939,2009-04-01,2009.0,2010-03-31,2010,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2901085,51493,Development of a recombinant vaccine for porcine transmissible gastroenteritis,243286,1991-04-01,1991.0,1994-03-31,1994,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2899804,57603,Development of an effective recombinant Actinobacillus pleuropneumoniae vaccine,206369,1991-04-01,1991.0,1994-03-31,1994,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2892553,152504,Liposome-cytokine formulations as vaccine delivery systems,59485,1996-04-01,1996.0,2000-03-31,2000,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2875627,518456,Synthesis of cyclic oligonucleotide analogues as mucosal vaccine adjuvants,3654,2012-04-01,2012.0,2013-03-31,2013,Brock University,grid.411793.9,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2874597,368324,Creating edible forage-based vaccines against bovine pneumonic pasteurellosis,408329,2004-04-01,2004.0,2008-03-31,2008,University of Guelph; Dow Agrosciences (Canada); Dow Agrosciences (Canada); Dow Agrosciences (Canada),grid.34429.38; grid.292666.f; grid.292666.f; grid.292666.f,Canada; Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2874082,429473,Novel Multi-Strain Vaccines against HIV-1,17520,2009-04-01,2009.0,2010-03-31,2010,Variation Biotechnologies (Canada),grid.438914.3,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2857726,254432,Development of vaccine vector for human immunodeficiency virus,292,2003-04-01,2003.0,2004-03-31,2004,"University of California, San Francisco",grid.266102.1,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2853909,327282,Novel Multi-Strain Vaccines against HIV-1,8812,2006-04-01,2006.0,2007-03-31,2007,Variation Biotechnologies (Canada),grid.438914.3,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2846899,492,Development of a bovine adenovirus vaccine vector,216848,1994-04-01,1994.0,1997-03-31,1997,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2845378,369571,Novel Multi-Strain Vaccines against HIV-1,27926,2007-04-01,2007.0,2008-03-31,2008,Variation Biotechnologies (Canada),grid.438914.3,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2835397,467118,In vitro qualification of a SPIO labeled vaccine,4090,2010-04-01,2010.0,2011-03-31,2011,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2834880,470801,Evaluation of fowl adenovirus based recombinant vaccines for poultry,4363,2010-04-01,2010.0,2011-03-31,2011,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2821820,187874,Development of vaccine vector for human immunodeficiency virus,22598,2001-04-01,2001.0,2002-03-31,2002,"University of California, San Francisco",grid.266102.1,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2817654,328626,Development of Synthetic Glycoconjugate Vaccines for Active Tumor Immunotherapy,18511,2006-04-01,2006.0,2007-03-31,2007,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2807465,370582,Development of Synthetic Glycoconjugate Vaccines for Active Tumor Immunotherapy,19546,2007-04-01,2007.0,2008-03-31,2008,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2798941,502258,Optimization of vaccine production in algae using engineered bioreactors,17498,2012-04-01,2012.0,2013-03-31,2013,University of Calgary,grid.22072.35,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2795749,467031,Développement d'un vaccin atténué contre la colibacillose aviaire,29109,2010-04-01,2010.0,2011-03-31,2011,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2791038,293470,The Effects of Chemotherapy on Gene-Based Cancer Vaccines,14442,2005-04-01,2005.0,2006-03-31,2006,McMaster University,grid.25073.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2789593,487216,Développement d'un vaccin atténué contre la colibacillose aviaire,30328,2011-04-01,2011.0,2012-03-31,2012,,,,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2722085,Z01RR010444,UPDATING COMPUTER FACILITIES FOR THE VACCINE LABORATORY,0,1994-01-01,1994.0,1994-12-31,1994,,,,National Center for Advancing Translational Sciences,United States,0,0,0
grant.2706159,Y1AI2642-11-0-1,HIV Vaccine Research and Development,22663000,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2698714,U51IP000821,INTRODUCING THE USE OF SEASONAL INFLUENZA VACCINES,696000,2013-09-01,2013.0,2016-08-31,2016,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2697537,U38IP522352,Enhanced surveillance for newly vaccine preventable disease,0,2002-09-30,2002.0,2007-09-29,2007,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2695257,U18FD004012,Discovery of Biological and Immunological Biomarkers for TB Vaccines,299525,2010-09-17,2010.0,2014-03-31,2014,Aeras,grid.432518.9,United States,United States Food and Drug Administration,United States,9,0,0
grant.2693731,U10CI923373,STUDYING THE MEASLES INFECTIONS &DEVELOPMENT OF MEASLES VACCINES,0,2003-09-30,2003.0,2007-09-29,2007,"University of California, Davis",grid.27860.3b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2690783,U01FD004575,Innovations in Vaccine Clinical Trials and Pharmacovigilance,1492900,2012-09-05,2012.0,2017-08-31,2017,World Health Organization,grid.3575.4,Switzerland,United States Food and Drug Administration,United States,3,0,0
grant.2690760,U01FD004248,SUPPORTING INFLUENZA VACCINE INTRODUCTION IN LOW-MIDDLE INCOME COUNTRIES,1373500,2011-09-15,2011.0,2017-08-31,2017,World Health Organization,grid.3575.4,Switzerland,United States Food and Drug Administration,United States,0,0,0
grant.2687365,U01AI037543,EPITOPE POLYMORPHISM IN P FALCIPARUM VACCINE ANIGENS,0,1994-08-23,1994.0,1997-01-31,1997,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2687364,U01AI037542,DESIGN AND IMMUNE MECHANISMS OF P FALCIPARUM CS VACCINE,0,1994-07-01,1994.0,1997-06-30,1997,New York University,grid.137628.9,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2687357,U01AI036467,ANTIGENIZED ANTIBODY AND GENE IN MALARIA VACCINE,0,1994-09-15,1994.0,1997-08-31,1997,"University of California, San Diego",grid.266100.3,United States,National Institute of Allergy and Infectious Diseases,United States,7,5,0
grant.2687347,U01AI035365,LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS,0,1994-02-15,1994.0,1998-03-31,1998,Harvard University,grid.38142.3c,United States,National Institute of Allergy and Infectious Diseases,United States,17,0,0
grant.2687156,U01AI026507,COMBINED VACCINE STRATEGIES FOR THE PREVENTION OF AIDS,0,1989-03-01,1989.0,1998-07-30,1998,,,,National Institute of Allergy and Infectious Diseases,United States,12,0,0
grant.2687154,U01AI026503,NOVEL IMDEF VIRUS VACCINES IN NHP MODELS,0,1988-03-01,1988.0,1998-05-14,1998,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2666046,R56AI063396,Development of multi-antigen subunit SARS vaccines,284375,2006-08-01,2006.0,2008-07-31,2008,University of Massachusetts Medical School,grid.168645.8,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2664366,R55AI040302,STRUCTURAL AND CONFORMATIONAL ASPECTS IN PEPTIDE VACCINE,0,1996-09-30,1996.0,1997-03-31,1997,The Ohio State University,grid.261331.4,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2664365,R55AI039427,RECOMBINANT L MONOCYTOGENES AS AN SIV VACCINE,0,1996-09-30,1996.0,1996-11-30,1996,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657660,R44AI033301,CELL CULTURE PRODUCTION OF T GONDII T 263 VACCINE,0,1992-09-03,1992.0,1997-03-31,1997,Heska (United States),grid.418541.d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657656,R44AI032847,VACCINE TO TREAT HEPATITIS B VIRUS INFECTION,0,1992-04-01,1992.0,1997-04-30,1997,Cytel (United States),grid.417720.7,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2657579,R44AI026028,ATTENUATION OF THE NYCBH VACCINE STRAIN OF VACCINIA,0,1988-04-01,1988.0,1993-07-31,1993,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2647175,R43DK050890,ADHESIN BASED VACCINE TO PREVENT URINARY TRACT INFECTION,0,1996-05-01,1996.0,1996-10-31,1996,AstraZeneca (United States),grid.418152.b,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,0,0,0
grant.2643697,R43CA074665,DEVELOPMENT OF TUMOR VACCINES USING GPI LINKED MOLECULES,0,1997-09-30,1997.0,1999-06-30,1999,,,,National Cancer Institute,United States,0,0,0
grant.2643565,R43CA069885,THERAPEUTIC TUMOR VACCINE AGAINST HER 2/NEU,0,1996-05-06,1996.0,1996-10-31,1996,Corixa Corporation,grid.284594.6,United States,National Cancer Institute,United States,0,0,0
grant.2641009,R43AI054075,Allergy Protection by Active IgE B Cell Vaccines,552946,2003-01-01,2003.0,2004-12-31,2004,IGE Therapeutics (United States),grid.435522.7,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2640640,R43AI046212,EPITOPE-DRIVEN HIV VACCINE TARGETING DENDRITIC CELLS,0,1999-09-30,1999.0,2000-03-31,2000,EpiVax (United States),grid.421087.8,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2640550,R43AI044532,ORAL DELIVERY OF ENCAPSULATED MULTIMERIC AIDS VACCINES,0,1999-09-30,1999.0,2001-09-29,2001,TSRL (United States),grid.281449.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640356,R43AI040397,DEVELOPMENT OF A VACCINE FOR CLOSTRIDIUM DIFFICILE,0,1996-09-30,1996.0,1997-03-31,1997,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640346,R43AI039906,UBIQUITIN FUSION FOR PEPTIDE IMMUNE DISPLAY AND VACCINES,0,1996-06-01,1996.0,1996-11-30,1996,,,,National Institute of Allergy and Infectious Diseases,United States,0,3,0
grant.2640336,R43AI039865,LYME VACCINE BASED ON BORRELIA DECORIN ADHESIN,0,1996-04-15,1996.0,1996-10-14,1996,AstraZeneca (United States),grid.418152.b,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2640319,R43AI039334,PEPTIDE ANTIIGE VACCINE FOR IMMUNOTHERAPY OF ALLERGY,0,1996-09-30,1996.0,1997-10-15,1997,United Biomedical (United States),grid.421974.d,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2640315,R43AI039318,LYME VACCINE BASED ON BORRELIA TRANSFERIN RECEPTORS,0,1996-06-01,1996.0,1996-11-30,1996,AstraZeneca (United States),grid.418152.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640305,R43AI039276,ORAL HIV-1 VACCINE TECHNOLOGIES USING OPTIVAX COPOLYMER,0,1996-08-01,1996.0,1997-07-31,1997,Vaxcel (United States),grid.438928.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640255,R43AI038081,PEPTIDE BASED VACCINE FOR PRIMATE MODEL OF AIDS,0,1996-08-01,1996.0,1997-01-31,1997,Cytel (United States),grid.417720.7,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2640187,R43AI036003,"ORAL, LIVE, ATTENUATED VIBRIO VECTORED SSONNEI VACCINE",0,1996-09-30,1996.0,1997-03-31,1997,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2639832,R43AI026028,ATTENUATION OF THE NYCBH VACCINE STRAIN OF VACCINIA,0,1988-04-01,1988.0,1988-09-30,1988,Nuclea Biotechnologies (United States),grid.432723.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2624939,R29AI027332,CS PROTEIN T-EPITOPE POLYMORPHISM--MALARIA VACCINE,0,1988-12-01,1988.0,1989-06-15,1989,Biomedical Research Institute,grid.418352.9,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2608583,R21DK057206,A TARGETED PLANT-BASED VACCINE FOR TYPE I DIABETES,163941,1999-09-30,1999.0,2002-08-31,2002,Loma Linda University,grid.43582.38,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,3,1,0
grant.2608571,R21DK057113,APC-TARGETING VACCINE FOR PREVENTION OF TYPE I DIABETES,164000,1999-09-30,1999.0,2002-02-28,2002,Loma Linda University,grid.43582.38,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,0,0,0
grant.2597656,R21AI046329,DEVELOPMENT/EVALUATION OF HYBRID NOVEL MUCOSAL VACCINES,150000,1999-09-30,1999.0,2002-02-28,2002,University of Queensland,grid.1003.2,Australia,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2597626,R21AI046184,NEW STRATEGIES FOR BACTERIAL DELIVERY OF DNA VACCINES,237750,1999-09-30,1999.0,2002-09-29,2002,University of Pennsylvania,grid.25879.31,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2597599,R21AI045396,HIV VACCINE STRATEGIES BASED ON A GOAT LENTIVIRUS--CAEV,368846,1999-05-01,1999.0,2005-08-31,2005,University of Southern California,grid.42505.36,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2597536,R21AI044369,DEVELOPMENT OF ENHANCED HIV 1 PSEUDOVIRION VACCINES,181850,1999-06-01,1999.0,2002-05-31,2002,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2597279,R21AI040261,DEVELOPMENT OF AN ORAL MULTIVALENT SHIGELLA/ETEC VACCINE,0,1996-09-15,1996.0,1997-09-14,1997,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,2,1,0
grant.2597266,R21AI040090,DEVELOPMENT OF A GENETIC VACCINE FOR M TUBERCULOSIS,0,1996-09-01,1996.0,1998-08-31,1998,The University of Texas Southwestern Medical Center,grid.267313.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2597222,R21AI038979,DETOXIFIED BACTERIAL TOXINS AS CTL VACCINE MOLECULES,0,1997-09-30,1997.0,1999-09-29,1999,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2590181,R15AI037777,MUCOSAL VACCINES--HEAT LABILE TOXIN/ANTIGEN FUSIONS,0,1995-06-01,1995.0,1997-05-31,1997,University of Montana,grid.253613.0,United States,National Institute of Allergy and Infectious Diseases,United States,1,3,0
grant.2583049,R13CA067131,INTERNATIONAL CONFERENCE ON VACCINES FOR CANCER AND AIDS,0,1995-03-15,1995.0,1996-02-28,1996,Saint Francis Memorial Hospital,grid.416496.8,United States,National Cancer Institute,United States,0,0,0
grant.2579292,R03OH003255,HEPATITIS B VACCINE ACCEPTANCE BY NURSING HOME WORKERS,0,1995-07-01,1995.0,1997-06-30,1997,Johns Hopkins University,grid.21107.35,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2567035,R03AI058222,DNA/MVA HIV Vaccine for India,100000,2003-08-15,2003.0,2005-07-31,2005,GeoVax (United States),grid.434905.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2566836,R03AI045084,MUCOSAL IMMUNITY TO VIRULENT AND VACCINE-STRAIN CMV,142814,1999-09-30,1999.0,2003-08-31,2003,Eastern Virginia Medical School,grid.255414.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2566752,R03AI033668,EVALUATION OF ARI ORGANISMS FOR VACCINE DEVELOPMENT,0,1992-07-01,1992.0,1995-06-30,1995,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2564456,R01RR008552,DEVELOPMENT OF SUBUNIT VACCINE FOR M PULMONIS IN MICE,0,1993-08-01,1993.0,1997-07-31,1997,The University of Texas Southwestern Medical Center,grid.267313.2,United States,National Center for Advancing Translational Sciences,United States,2,0,0
grant.2508306,R01FD002545,DC TUMOR CONJUGATE VACCINE FOR IMMUNOTHERAPY,0,2005-09-30,2005.0,2007-09-29,2007,University of Pittsburgh,grid.21925.3d,United States,United States Food and Drug Administration,United States,0,0,0
grant.2454434,R01AI044592,EVALUATION STUDIES--DNA VACCINE EXPRESSING SIVSM VLP,1010353,1999-05-01,1999.0,2003-04-30,2003,"University of Puerto Rico, Medical Sciences Campus",grid.267034.4,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2453161,R01AI037166,DNA VACCINES-RESPONSES TO VECTORS WITH RABIES ANTIGENS,1273968,1994-09-30,1994.0,2006-05-31,2006,The Wistar Institute,grid.251075.4,United States,National Institute of Allergy and Infectious Diseases,United States,2,1,0
grant.2452894,R01AI035196,DEVELOPMENT OF A POX-VECTORED MEASLES VACCINE,0,1993-09-30,1993.0,1998-06-30,1998,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2452879,R01AI035137,MEASLES &MEASLES VACCINES--MECHANISMS OF IMMUNE INJURY,0,1993-09-30,1993.0,1997-06-30,1997,Montreal General Hospital,grid.416099.3,Canada,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2452193,R01AI031224,GENE EXPRESSION FOR S MANSONI VACCINE ANTIGEN,0,1991-05-01,1991.0,1997-04-30,1997,Brown University,grid.40263.33,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2450320,R01AI021024,PREVENTION OF NEONATAL BACTEREMIA WITH PILUS VACCINE,0,1984-09-01,1984.0,1987-08-31,1987,Boston Children's Hospital,grid.2515.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2435123,P01AI056356,HSV-1 Amplicon Vectors for HIV Vaccine Delivery,11606890,2003-07-15,2003.0,2009-12-31,2009,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,11,1,0
grant.2435096,P01AI052816,"HIV, TB, and Malaria Vaccine Development for Africa",14490691,2003-08-01,2003.0,2009-07-31,2009,Duke University,grid.26009.3d,United States,National Institute of Allergy and Infectious Diseases,United States,22,6,0
grant.2434876,P01AI024009,HSV VACCINE DESIGN--ABLATION OF VIRULENCE AND LATENCY,0,1987-07-01,1987.0,1997-05-31,1997,University of Chicago,grid.170205.1,United States,National Institute of Allergy and Infectious Diseases,United States,28,7,0
grant.2433623,N43AI052598,DNA TECHNIQUES FOR PRODUCTION OF A VACCINE TO AIDS,0,1985-08-01,1985.0,1986-01-01,1986,SeraCare Life Sciences (United States),grid.422121.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2430978,N01HD953226,EVALUATE SAFETY OF VACCINES TO PREVENT SHIGELLOSIS-275953226,0,2004-01-01,2004.0,2004-12-31,2004,Sheba Medical Center,grid.413795.d,Israel,National Institute of Child Health and Human Development,United States,0,0,0
grant.2430831,N01HD073269,CONJUGATE VACCINES DESIGNED TO PREVENT TYPHOID FEVER-275973269,217249,1997-09-30,1997.0,2000-03-31,2000,Institut Pasteur in Ho Chi Minh City,grid.452689.4,Vietnam,National Institute of Child Health and Human Development,United States,0,0,0
grant.2430826,N01HD073264,KILLED ORAL CHOLERA VACCINE EFFECTIVENESS TRIAL--VIETNAM-275973264,0,1996-12-01,1996.0,2001-11-30,2001,World Health Organization,grid.3575.4,Switzerland,National Institute of Child Health and Human Development,United States,1,0,0
grant.2430821,N01HD072923,TEST OF ACELLULAR PERTUSSIS VACCINE IN INFANTS,0,1987-09-30,1987.0,1988-01-01,1988,,,,National Institute of Child Health and Human Development,United States,0,0,0
grant.2430718,N01HD053225,EVALUATION OF TYPHOID FEVER VI CONJUGATE VACCINE,0,1995-06-02,1995.0,1997-01-01,1997,Institut Pasteur in Ho Chi Minh City,grid.452689.4,Vietnam,National Institute of Child Health and Human Development,United States,1,0,0
grant.2430614,N01HD033187,U.S. CLINICAL TRIAL OF ACELLULAR PERTUSSIS VACCINE,0,1993-06-01,1993.0,1995-09-30,1995,Carolinas Medical Center,grid.239494.1,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.2430613,N01HD033186,U.S. CLINICAL TRIAL OF ACELLULAR PERTUSSIS VACCINE,0,1993-06-01,1993.0,1995-09-30,1995,San Antonio Metropolitan Health District,grid.421798.1,United States,National Institute of Child Health and Human Development,United States,2,0,0
grant.2430542,N01HD023151,PRODUCTION OF NICHD DPT VACCINE FOR U.S. CLINICAL TRIALS,0,1992-03-01,1992.0,1993-11-30,1993,,,,National Institute of Child Health and Human Development,United States,0,0,0
grant.2425744,N01AO035154,OPERATION OF &EXPERIMENTAL VIRUS VACCINE PRODUCTION LAB,0,1992-11-30,1992.0,1997-11-30,1997,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424990,N01AI095041,ADVERSE CONSEQUENCES OF PERTUSSIS AND RUBELLA VACCINES,0,1989-09-27,1989.0,1991-12-31,1991,National Academy of Sciences,grid.275752.0,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2424954,N01AI085343,PRIMATE IMMUNOLOGY LABORATORY FOR AIDS VACCINE R&D,411574,1998-08-01,1998.0,2003-07-31,2003,Beth Israel Deaconess Medical Center,grid.239395.7,United States,National Institute of Allergy and Infectious Diseases,United States,44,2,0
grant.2424953,N01AI085342,Evaluation of Vaccines and Therapies in Adults/Elderly-26685342,0,1998-07-01,1998.0,2003-06-30,2003,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2424952,N01AI085341,LAB SUP. FOR AIDS VACCINE &OTHER PREVENT. CLINICAL TRIA,750000,1998-07-01,1998.0,2005-06-30,2005,SeraCare Life Sciences (United States),grid.422121.6,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2424951,N01AI085340,PHASE II PNEUMOCOCCAL CONJUGATE VACCINE STUDY IN THE GAM,0,1998-09-25,1998.0,2000-03-24,2000,Medical Research Council,grid.14105.31,United Kingdom,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424889,N01AI075320,TB Research Materials and Vaccine testing-26675320,979767,1997-07-01,1997.0,2004-06-30,2004,Colorado State University System,grid.42752.36,United States,National Institute of Allergy and Infectious Diseases,United States,174,2,0
grant.2424801,N01AI062553,STUDY OF MALARIA VACCINES IN HUMAN VOLUNTEERS,0,1986-05-25,1986.0,1992-03-24,1992,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2424782,N01AI062528,FACILITY FOR STUDY OF INFECTIOUS DISEASE AND VACCINES,0,1985-11-30,1985.0,1992-07-01,1992,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,30,0,0
grant.2424743,N01AI055263,MAO/EVALUATION OF AIDS VACCINES IN NONHUMAN PRIMATE,0,1995-08-15,1995.0,1998-04-14,1998,Harvard University,grid.38142.3c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424740,N01AI055260,EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MODELS,0,1995-02-08,1995.0,1999-08-06,1999,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2424712,N01AI052630,EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MODELS,0,1995-04-10,1995.0,1997-04-09,1997,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424651,N01AI045237,VACCINE DEVELOPMENT--ESTABLISHMENT OF PRIORITIES FOR U S,0,1994-09-01,1994.0,1999-06-30,1999,National Academy of Sciences,grid.275752.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424636,N01AI045218,CORRELATE IMMUNE PROTECTION IN AIDS VACCINE RECIPIENTS,0,1994-06-30,1994.0,1997-06-30,1997,Northwestern University,grid.16753.36,United States,National Institute of Allergy and Infectious Diseases,United States,21,2,0
grant.2424626,N01AI045202,CENTRAL LAB FOR AIDS/HIV VACCINE EFFICACY TRIALS,0,1994-03-15,1994.0,2000-03-14,2000,Public Health Foundation Enterprises,grid.280537.b,United States,National Institute of Allergy and Infectious Diseases,United States,17,0,0
grant.2424597,N01AI040072,Production and Testing of a MVA Vaccine-266040072,0,2005-01-01,2005.0,2005-12-31,2005,,,,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2424596,N01AI040069,Population Genetics Analysis Program: Immunity to Vaccines/Infections--266040069,0,2005-01-01,2005.0,2006-01-01,2006,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2424595,N01AI040068,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266040068,0,2006-01-01,2006.0,2006-12-31,2006,University of Alabama at Birmingham,grid.265892.2,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2424594,N01AI040067,POPULATION GENETICS ANALYSIS PROGRAM:  IMMUNITY TO VACCINES/INFECTIONS-266040067,0,2006-01-01,2006.0,2006-12-31,2006,RTI International,grid.62562.35,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2424592,N01AI040064,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266040064,0,2006-01-01,2006.0,2006-12-31,2006,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424552,N01AI032512,HAEMOPHILUS INFLUENZA TYPE B VACCINE IN HIGH RISK INFANT,0,1983-09-01,1983.0,1986-08-31,1986,Harbor–UCLA Medical Center,grid.239844.0,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2424540,N01AI030042,HIV Vaccine Design and Development Teams /HVDDT/-26630042,0,2003-01-01,2003.0,2004-01-01,2004,Novavax (United States),grid.436677.7,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2424537,N01AI030030,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS (HVDDT)-266030030,0,2003-01-01,2003.0,2003-12-31,2003,Progenics Pharmaceuticals (United States),grid.280766.d,United States,National Institute of Allergy and Infectious Diseases,United States,15,5,0
grant.2424536,N01AI030029,HIV Vaccine Design and Development Teams /HVDDT/-26630029,0,2004-01-01,2004.0,2004-12-31,2004,AlphaVax (United States),grid.422340.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2424527,N01AI025494,DEVELOPMENT AND TESTING OF VACCINES AGAINST ANTHRAX-266025494,0,2002-01-01,2002.0,2004-01-01,2004,Diadexus (United States),grid.438929.d,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2424526,N01AI025492,Development and Testing of Vaccines Against Anthrax-266025492,0,2002-01-01,2002.0,2005-01-01,2005,,,,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2424512,N01AI025458,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS-266025458,0,2003-01-01,2003.0,2005-01-01,2005,Pfizer (United States),grid.410513.2,United States,National Institute of Allergy and Infectious Diseases,United States,13,2,0
grant.2424487,N01AI022678,STUDY ISSUES AND PRIORITIES FOR NEW VACCINE DEVELOPMENT,0,1982-09-20,1982.0,1985-01-01,1985,National Academy of Sciences,grid.275752.0,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2424463,N01AI015124,EVAL OF VACCINE PROPH AGAINST INFECT DISEASES IN CHILDRN,0,1991-09-30,1991.0,1996-09-29,1996,,,,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2424448,N01AI015106,CENTRAL LAB FOR AIDS VACCINE CLINICAL TRIALS,0,1991-03-12,1991.0,1996-04-16,1996,Duke University,grid.26009.3d,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2424437,N01AI015094,EVALUATION IN MONKEYS OF VACCINES FOR SAIDS,0,1990-12-31,1990.0,1996-06-30,1996,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424431,N01AI012674,DEVELOP AN H INFLUENZAE TYPE B VACCINE,0,1981-06-01,1981.0,1985-01-01,1985,Pfizer (United States),grid.410513.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424428,N01AI012666,"FACILITY FOR STUDY OF INFECTIOUS DISEASES, VACCINES",0,1980-11-30,1980.0,1985-11-29,1985,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,26,0,0
grant.2424403,N01AI005397,HIV Vaccine Design and Development Teams-26605397,3773578,2000-06-26,2000.0,2005-06-25,2005,,,,National Institute of Allergy and Infectious Diseases,United States,17,2,0
grant.2424402,N01AI005396,HIV Vaccine Design and Development Teams-26605396,7545418,2000-06-05,2000.0,2005-06-04,2005,Novartis (United States),grid.418424.f,United States,National Institute of Allergy and Infectious Diseases,United States,29,13,0
grant.2424401,N01AI005395,HIV Vaccine Design and Development Teams-26605395,3213894,2000-06-26,2000.0,2005-06-25,2005,UNSW Sydney,grid.1005.4,Australia,National Institute of Allergy and Infectious Diseases,United States,65,0,0
grant.2424400,N01AI005394,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS-266005394,2527964,2000-06-26,2000.0,2005-06-25,2005,,,,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2424360,N01AI005053,DEVELOP LIVE ATTENTUATED COLD ADAPTED INFLUENZA VACCINE,0,1989-10-25,1989.0,1993-04-24,1993,University of Michigan,grid.214458.e,United States,National Institute of Allergy and Infectious Diseases,United States,3,2,0
grant.2424343,N01AI002645,TEST RESPIRATORY VIRUS AND BACTERIAL VACCINES IN INFANTS,0,1980-06-30,1980.0,1985-01-31,1985,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,39,0,0
grant.2424333,N01AI000068,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266000068,0,2004-01-01,2004.0,2005-01-01,2005,University of Arkansas at Little Rock,grid.265960.e,United States,National Institute of Allergy and Infectious Diseases,United States,15,0,0
grant.2424332,N01AI000067,POPULATION GENETICS ANALYSIS PROGRAM:  IMMUNITY TO VACCINES/INFECTIONS-266000067,0,2004-01-01,2004.0,2005-01-01,2005,RTI International,grid.62562.35,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424330,N01AI000065,POPULATION GENETICS ANALYSIS PROGRAM: IMMUNITY TO VACCINES/INFECTIONS--266000065,0,2004-01-01,2004.0,2006-01-01,2006,Mayo Clinic,grid.66875.3a,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424329,N01AI000064,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266000064,0,2004-01-01,2004.0,2005-01-01,2005,deCODE Genetics (Iceland),grid.421812.c,Iceland,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2415704,K11AI001061,IMMUNE INTERACTIONS OF GONORRHEA AND VACCINE DEVELOPMENT,0,1991-09-30,1991.0,1996-08-31,1996,Boston Public Health Commission,grid.236741.5,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2409426,K08AG000548,"ANTIBODY DIVERSITY, AGE AND INFLUENZA VACCINE EFFICACY",0,1992-01-27,1992.0,1998-08-31,1998,Eastern Virginia Medical School,grid.255414.3,United States,National Institute on Aging,United States,18,0,0
grant.2405500,K01OH000131,HEALTH CARE WORKER COMPLIANCE WITH HEPATITIS B VACCINE,0,1993-04-01,1993.0,1997-03-31,1997,University of Iowa,grid.214572.7,United States,Centers for Disease Control and Prevention,United States,8,0,0
grant.2393833,H23IP000767,PREVENTING AND MITIGATING VACCINE PREVENTABLE DISEASE THROUGH IMMUNIZATION,12239874,2013-01-01,2013.0,2017-12-31,2017,,,,Centers for Disease Control and Prevention,United States,1,0,0
grant.2393831,H23IP000765,TO PREVENT VACCINE-PREVENTABLE DISEASE THROUGH MAINTAINING IMMUNIZATION STRUCTURE,24666320,2013-01-01,2013.0,2017-12-31,2017,Ohio Department of Health,grid.410403.2,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393828,H23IP000762,Immunization Grant and Vaccines for Children's Program,23776040,2013-01-01,2013.0,2017-12-31,2017,Washington State Department of Health,grid.1658.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393822,H23IP000756,NEBRASKA IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAM,6919041,2013-01-01,2013.0,2017-12-31,2017,Nebraska Department of Health and Human Services,grid.280417.8,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393812,H23IP000746,GUAM IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAMS,3954801,2013-01-01,2013.0,2017-12-31,2017,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393810,H23IP000744,GEORGIA IMMUNIZATIONS AND VACCINES FOR CHILDREN GRANTS,26897364,2013-01-01,2013.0,2017-12-31,2017,Georgia Department of Public Health,grid.420388.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393809,H23IP000742,FSM IMMUNIZATION AND VACCINES FOR CHILDREN GRANTS,3732639,2013-01-01,2013.0,2017-12-31,2017,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393798,H23IP000731,PREVENTION & CONTROL OF COMMUNICABLE AND VACCINE PREVENTABLE DISEASES,10030916,2013-01-01,2013.0,2017-12-31,2017,Arkansas State Department of Human Services,grid.280559.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393792,H23IP000725,KY IMMUNIZATION PROGRAM IMMUNIZATION & VACCINE FOR CHILDREN PROGRAM,13007636,2013-01-01,2013.0,2017-12-31,2017,Kentucky Cabinet For Health and Family Services,grid.280376.8,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393788,H23IP000721,HAWAII IMMUNIZATION AND VACCINES FOR CHILDREN PROGRAM,9628383,2013-01-01,2013.0,2017-12-31,2017,Hawaii Department of Health,grid.280337.d,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393775,H23IP000708,Building Capacity for Immunization Billing and Vaccine Barcode Reading,835028,2012-09-30,2012.0,2015-03-29,2015,Nebraska Department of Health and Human Services,grid.280417.8,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2390878,F33AI008851,NEISSERIA MENINGITIDIS GROUP B;IDIOTYPES AND VACCINES,0,1993-03-29,1993.0,1993-12-31,1993,UCSF Benioff Children's Hospital,grid.414016.6,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2375603,F32DK009360,ATTENUATED SHIGELLA AS TOXIGENIC E COLI VACCINE,0,1996-03-01,1996.0,1996-12-31,1996,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,0,0,0
grant.2369988,F32AI009773,VACCINE POTENTIAL OF PAR PROTEINS OF TRYPANOSOMA CRUZI,0,1997-05-31,1997.0,1999-01-01,1999,"University of California, Irvine",grid.266093.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2369821,F32AI008991,LIVE AND ATTENUATED VIBRIO CHOLERAE VACCINE STRAINS,0,1994-01-31,1994.0,1995-01-01,1995,Massachusetts General Hospital,grid.32224.35,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2369813,F32AI008965,DEVELOPMENT OF A SINGLE DOSE TETANUS VACCINE,0,1994-03-30,1994.0,1994-12-31,1994,Massachusetts Institute of Technology,grid.116068.8,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2359845,F31AI010487,SALMONELLA AS A VACCINE TOOL AGAINST HIV,113650,2000-08-31,2000.0,2002-01-01,2002,Rockefeller University,grid.134907.8,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2356296,F05TW004386,FACTORS INFLUENCING HIB DISEASE AND VACCINE EFFICACY,0,1990-09-30,1990.0,1991-01-01,1991,Johns Hopkins University,grid.21107.35,United States,Fogarty International Center,United States,1,0,0
grant.2355713,F05TW003315,DEVELOPMENT OF VACCINE AGAINST GROUP B STREPTOCOCCI,0,1985-03-01,1985.0,1985-12-31,1985,Harvard University,grid.38142.3c,United States,Fogarty International Center,United States,1,0,0
grant.2346752,272200800057C-1-0-2,Vaccine and Treatment Evaluation Units,2723435,2007-11-01,2007.0,2014-10-31,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346751,272200800057C-1-0-1,Vaccine and Treatment Evaluation Units,371377,2007-11-01,2007.0,2014-10-31,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,12,0,0
grant.2346748,272200800056C-0-0-1,Advanced Development of Multivalent Filovirus Vaccines,13496364,2008-09-30,2008.0,2013-09-29,2013,Janssen (Netherlands),grid.497529.4,Netherlands,National Institute of Allergy and Infectious Diseases,United States,3,2,0
grant.2346743,272200800051C-0-0-1,Development of an Anthrax Vaccine,13072863,2008-09-25,2008.0,2011-09-24,2011,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2346629,272200800008C-2-0-2,Vaccine and Treatment Evaluation Units,2809421,2008-01-01,2008.0,2008-12-31,2008,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346628,272200800008C-2-0-1,Vaccine and Treatment Evaluation Units,383103,2008-01-01,2008.0,2008-12-31,2008,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,21,0,0
grant.2346595,272200800007C-1-0-2,Vaccine and Treatment Evaluation Units,2729831,2007-11-01,2007.0,2014-10-31,2014,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346594,272200800007C-1-0-1,Vaccine and Treatment Evaluation Units,372250,2007-11-01,2007.0,2014-10-31,2014,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,14,0,0
grant.2346582,272200800006C-2-0-2,Vaccine and Treatment Evaluation Units,2628793,2007-11-01,2007.0,2014-10-31,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346581,272200800006C-2-0-1,Vaccine and Treatment Evaluation Units,358447,2007-11-01,2007.0,2014-10-31,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,21,0,0
grant.2346548,272200800005C-1-0-2,Vaccine and Treatment Evaluation Units,2746553,2007-11-01,2007.0,2014-10-31,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346547,272200800005C-1-0-1,Vaccine and Treatment Evaluation Units,374527,2007-11-01,2007.0,2014-10-31,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,19,0,0
grant.2346527,272200800004C-1-0-2,Vaccine and Treatment Evaluation Units,2634897,2007-11-01,2007.0,2014-10-31,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346526,272200800004C-1-0-1,Vaccine and Treatment Evaluation Units,359304,2007-11-01,2007.0,2014-10-31,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,19,0,0
grant.2346510,272200800003C-2-0-1,Vaccine and Treatment Evaluation Units,337232,2007-11-01,2007.0,2014-10-31,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,29,0,0
grant.2346485,272200800002C-1-0-2,Vaccine and Treatment Evaluation Units,2758811,2007-11-01,2007.0,2014-10-31,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346484,272200800002C-1-0-1,Vaccine and Treatment Evaluation Unit,376202,2007-11-01,2007.0,2014-10-31,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,22,0,0
grant.2346449,272200700056C-0-0-1,Global HIV AIDS Vaccine Enterprise Secretariat,1735409,2007-09-12,2007.0,2009-09-11,2009,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346448,272200700056C-0-0-0,GLOBAL HIV VACCINE ENTERPRISE,1735409,2007-09-12,2007.0,2009-09-11,2009,,,,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.100070653,7262-08,Translational Development of Novel Vaccine Therapies,6250000,2007-10-01,2007.0,2012-09-30,2012,The University of Texas Health Science Center at Houston,grid.267308.8,United States,Leukemia and Lymphoma Society,United States,0,0,0
grant.100069317,09PH-008-961-2596,Rotavirus vaccine and prevention of hospitalization,20000,2010-01-01,2010.0,2011-12-31,2011,Yale University,grid.47100.32,United States,Gerber Foundation,United States,0,0,0
grant.7992220,0319223B/3,Verbundprojekt: EUREKA-Projekt: Malaria-Impfstoff (EU 101) - Teilvorhaben: Gentechnologische Entwicklung einer Malaria-Vakzine - Phase 2,2247441,1988-07-01,1988.0,1991-06-30,1991,Sanofi (Germany),grid.420214.1,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7951289,01KA1304,"'EDCTP-Malaria Impfstoff: Biometrie und Parasiten-Quantifizierung zur Entwicklung neuer malariaimpfstoffe, -medikamente und -miagnostika in Afrika.'",79683,2013-09-01,2013.0,2014-06-30,2014,University of Tübingen,grid.10392.39,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7951265,01KA0802,"EDCTP-HIV-Vakzine I: Durchführung eine Phase IB HIV Impfstoffstudie (DNA / NYVAC) in Mbeya, Tansania.",211751,2008-10-01,2008.0,2012-05-31,2012,Ludwig Maximilian University of Munich,grid.5252.0,Germany,Federal Ministry of Education and Research,Germany,2,0,0
grant.7616858,,Investigation of Novel Vaccine Strategies for Influenza: Targeting Innate and Adaptive Immunity for Cross-protective Vaccines,1102716,2008-04-01,2008.0,2011-03-31,2011,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7496086,2015R1C1A1A02037060,일반백신 또는 긴급백신제제의 뇌구조 및 기능에 대한 안전성 신속검정,0,2015-01-01,2015.0,2016-01-01,2016,Soonchunhyang University,grid.412674.2,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7472216,2013R1A1A2061340,비만 마우스에서의 호흡기 바이러스에 대한 백신의 효능 측정 및 비만 개선을 통한 백신 역량 강화 평가,0,2013-01-01,2013.0,2014-01-01,2014,Ewha Womans University,grid.255649.9,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7446874,2010-00240,마우스 모델에서 모체의 결핵 감염이 신생아의 결핵 백신 효과에 미치는 영향 및 신규 결핵 백신 효능 검증,0,2010-01-01,2010.0,2011-01-01,2011,International Vaccine Institute,grid.30311.30,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.6723340,194341,Development of vaccine strategies for measles and malaria using oral bacterial vectors and edible plant vaccines,46858,2002-01-01,2002.0,2005-12-31,2005,Monash University,grid.1002.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6584684,OPP51764,To test a new bacterial synthesis method to produce glycoconjugate vaccines to generate an improved vaccine against pneumococcal disease.,100000,2008-10-01,2008.0,2009-10-01,2009,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584355,OPP1036030,To produce more poliovirus vaccine supply by silencing non-essential virus resistance genes to develop enhanced vaccine cell lines.,99632,2011-04-01,2011.0,2012-10-01,2012,University System of Georgia,grid.298187.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582323,OPP41427,To support the AIDS Vaccine 2006 conference which will bring together scientists in the field of HIV vaccine research.,357500,2006-05-01,2006.0,2007-05-01,2007,Academic Medical Center,grid.5650.6,Netherlands,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581899,OPP1060868,To develop and field test a durable liner for vaccine carriers to protect vaccines from freezing.,98231,2012-04-01,2012.0,2013-11-01,2013,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580202,OPP1033096,To develop an envelope vaccine antigen that allows immune recognition and is an effective vaccine antigen,896490,2011-09-01,2011.0,2015-12-01,2015,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6499488,272201600039C-0-0-1,DEVELOPMENT OF A NOVEL SALMONELLA PARATYPHI A VACCINE,449620,2016-08-26,2016.0,2018-08-25,2018,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5710170,09671687,ヒト精子抗原を用いた経口ワクチン及び遺伝子ワクチンの開発に関する生殖免疫学的研究,4956,1997-01-01,1997.0,1997-12-31,1997,University of Tokushima,grid.267335.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5502095,hrc_04bb2ea4,RV3 Rotavirus Vaccine: A Phase II clinical trial for a human neonatal rotavirus vaccine for the global community,322481,2009-01-01,2009.0,2011-09-01,2011,University of Otago,grid.29980.3a,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5246360,N01AI30023-14-0-1,Development of a Coronavirus Vaccine,1000,2003-09-26,2003.0,2012-11-30,2012,Protein Sciences (United States),grid.437366.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5141545,BW-08028,Insights into CD4+ T cell responses against cancer vaccines from analysis of responses to a conventional vaccine,0,2008-08-01,2008.0,2014-06-01,2014,University of Southampton,grid.5491.9,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.4486180,09/16282-0,Adjuvant properties of cellular vaccines: combination of cellular pertussis vaccine and BCG with Streptococcus pneumoniae antigens,0,2010-03-01,2010.0,2012-02-29,2012,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.3984586,00/PI.1/B045,Pathogen-derived immunomodulatory molecules: future immunotherapeutics and vaccines,9265633,2001-10-01,2001.0,2006-12-04,2006,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,8,0,0
grant.3983756,06/RFP/GEN028,Can plant plastids produce a candidate flu vaccine,327096,2006-09-01,2006.0,2009-08-31,2009,"National University of Ireland, Maynooth",grid.95004.38,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.3899759,62863,Information dissemination on the human papillomavirus vaccine,16141,2008-04-01,2008.0,2009-03-31,2009,McMaster University,grid.25073.33,Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.3858644,N01AI30023-13-0-1,Development of a Coronavirus Vaccine,25831,2003-09-26,2003.0,2012-11-30,2012,Protein Sciences (United States),grid.437366.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856963,272201200003I-1-27200008-1,Task X8: Efficacy Testing of Ebola Virus Vaccines,1644104,2013-09-24,2013.0,2016-03-31,2016,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3529314,72624,USE OF THE VACCINE ADJUVANT FOR IMMUNOMODULATION OF THE INFECTION CAUSED BY TRYPANOSOMA BRUCEI: AN APPROACH TO VACCINE DESIGN,152343,2007-08-01,2007.0,2010-12-31,2010,Universidade Nova de Lisboa; University of Lisbon; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa,grid.10772.33; grid.9983.b; grid.10772.33; grid.10772.33; grid.10772.33; grid.10772.33,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,3,0,0
grant.2972456,111077,Development of DNA-based vaccines for bovine viral diarrhoea virus. Développement des vaccins à base d'ADN le virus de diarrhée bovine.,170773,1996-04-01,1996.0,1998-03-31,1998,Université de Sherbrooke,grid.86715.3d,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2424690,N01AI052575,TESTING VACCINES IN CHILDREN,0,1985-02-01,1985.0,1990-02-01,1990,Marshall University,grid.259676.9,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.100069716,71998,Frameshifts as a Cancer Vaccine,1200000,2007-07-01,2007.0,2010-06-30,2010,Arizona State University,grid.215654.1,United States,W. M. Keck Foundation,United States,0,0,0
grant.2424837,N01AI065314,SIMIAN VACCINE EVALUATION UNITS,2560239,1996-09-30,1996.0,2001-09-29,2001,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.8169343,30200246,HPV双启动子DNA疫苗和重组腺病毒疫苗的联合应用研究,23024,2003-01-01,2003.0,2005-12-31,2005,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,0,0,0
grant.6783638,5395449580,Vaccines against helminth infections (acronym PARAVAC),0,2011-04-01,2011.0,2015-03-31,2015,Ghent University; Ghent University,grid.5342.0; grid.5342.0,Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6127074,25830115,The mechanisms of macrophage dependent vaccine,39940,2013-04-01,2013.0,2015-03-31,2015,Mie University,grid.260026.0,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.2708529,Z01AI000416,Recombinant Vaccines for Prevention of AIDS and Other Diseases,3320228,1985-01-01,1985.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,63,0,0
grant.8248988,50343004,SARS疫苗高分子载体的模拟研究,12078,2003-06-01,2003.0,2004-12-31,2004,Changchun Institute of Applied Chemistry,grid.453213.2,China,National Natural Science Foundation of China,China,0,0,0
grant.6734414,1031473,Characterisation of rotavirus vaccine escape - potential for significant impact on vaccination program,514201,2012-01-01,2012.0,2014-12-31,2014,Murdoch Childrens Research Institute; Murdoch Childrens Research Institute,grid.1058.c; grid.1058.c,Australia; Australia,National Health and Medical Research Council,Australia,5,0,0
grant.4640689,185875,Conference: Genetic vaccines - benefits and challenges,33782,2007-01-01,2007.0,2009-12-31,2009,Norwegian Biotechnology Advisory Board,grid.457588.3,Norway,The Research Council of Norway,Norway,0,0,0
grant.5356862,10-04-09827,Участие в GENE-BASED VACCINES - GBV2010 Conference,0,2010-01-01,2010.0,2010-12-31,2010,,,,Russian Foundation for Basic Research,Russia,0,0,0
grant.6586399,OPP1117200,To development of a new safer Oral Polio Vaccine against type 2 strain (nOPV2) with lower risk of circulating vaccine derived polio virus (cVDVP) or vaccine associated paralytic poliomyelitis (VAPP) than existing Sabin mOPV 2,3081165,2014-11-01,2014.0,2018-11-01,2018,PT Bio Farma (Indonesia),grid.479536.a,Indonesia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585096,OPP1015149,"To test a new vaccine technology that modulates a host cytokine response to HIV vaccines. If successful, this technology may also enhance T-cell mediated immunity to other vaccine antigens, such as Tuberculosis.",100000,2010-04-01,2010.0,2011-04-01,2011,Australian National University,grid.1001.0,Australia,Bill & Melinda Gates Foundation,United States,7,0,0
grant.6583693,OPP1068031,To produce new and more potent vaccines with increased stability by testing a vaccine platform based on protein crystals (MicroCubes) produced by insect viruses for developing a candidate vaccine against HIV.,428770,2013-03-01,2013.0,2016-06-01,2016,Monash University,grid.1002.3,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582991,OPP1045902,To develop better polio vaccines by researching whether adding immune pressure against proteins found in the attenuated strains of the oral polio vaccine leads to the emergence of recombinant circulating vaccine-derived polioviruses,100000,2011-10-01,2011.0,2014-05-01,2014,Pasteur Institute,grid.428999.7,France,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582151,OPP1025568,"To develop and test a vaccine combining a novel placental malaria vaccine candidate with the cervical cancer vaccine, with the potential of inducing a strong protective response against both diseases simultaneously",100000,2010-11-01,2010.0,2012-05-01,2012,University of Copenhagen,grid.5254.6,Denmark,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581800,OPP1109210,"To bring together African researchers, vaccine implementers and public health academics to share information regarding rotavirus vaccines within Africa, and to exchange information and lessons regarding the impact of the vaccines",98212,2014-05-01,2014.0,2014-08-01,2014,Centre for Infectious Disease Research in Zambia,grid.418015.9,Zambia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.3869376,64571,"Sometimes it's take that hill, sometimes it's take that vaccine:  the Persian Gulf war and the anthrax vaccine controversy",16141,2008-04-01,2008.0,2009-03-31,2009,University of Alberta,grid.17089.37,Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.3765762,QLK4-CT-1999-50407,Training in vaccine research: vaccine against peptic ulcer,234957,2001-09-01,2001.0,2005-08-31,2005,Novartis (Italy),grid.15585.3c,Italy,European Commission,Belgium,1,0,0
grant.2425528,N01AI50040-19-0-1,Tularemia Vaccine Development,336464,2005-09-30,2005.0,2012-12-31,2012,University of New Mexico,grid.266832.b,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.6784476,7190763100,Polymeric microparticulate vaccine formulations based on hydrogen bonding,0,2014-01-10,2014.0,2017-09-30,2017,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8595342,26_4129,Production of a recombinant vaccine against human cytomegalovirus in plant cells,0,2014-05-01,2014.0,2017-10-31,2017,University of Liège,grid.4861.b,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8589748,30_24854,GSK VACCINES - COURS INTRO MIN PME Convention -Course with Minor Entrepreneurschip,0,2015-02-27,2015.0,2018-02-28,2018,Catholic University of Louvain,grid.7942.8,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8458531,,Vaccine Effectiveness: An integrated approach for monitoring influenza vaccine effectiveness to inform public health policy and influenza immunization program implementation,1790,2016-04-01,2016.0,2017-03-31,2017,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8458109,,Vaccine Effectiveness: An integrated approach for monitoring influenza vaccine effectiveness to inform public health policy and influenza immunization program implementation,1777,2016-04-01,2016.0,2017-03-31,2017,Marshfield Clinic,grid.280718.4,United States,Canadian Institutes of Health Research,Canada,0,0,0
grant.8458054,,Vaccine Effectiveness: An integrated approach for monitoring influenza vaccine effectiveness to inform public health policy and influenza immunization program implementation,1159,2016-04-01,2016.0,2017-03-31,2017,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.8457212,,Vaccine Effectiveness: An integrated approach for monitoring influenza vaccine effectiveness to inform public health policy and influenza immunization program implementation,2328,2016-04-01,2016.0,2017-03-31,2017,BC Centre for Disease Control,grid.418246.d,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8054101,16IN0171,"Verbundprojekt: Integriertes, patientennahes Verfahren zur Herstellung einer therapeutischen zellulären Vakzine im geschlossenen System, Teilvorhaben: Genetisch modifizierte DC-Vakzine mit verbesserter Antigenpräsentation",142191,2003-04-01,2003.0,2006-03-31,2006,University Hospital Ulm,grid.410712.1,Germany,Federal Ministry for Economic Affairs and Energy,Germany,0,0,0
grant.8054100,16IN0170,"Verbundprojekt: Integriertes, patientennahes Verfahren zur Herstellung einer therapeutischen zellulären Vakzine im geschlossenen System, Teilvorhaben: Geschlossenes, GMP-fähiges Verfahren für DC-Vakzine",654734,2003-07-01,2003.0,2006-06-30,2006,Helmholtz Centre for Infection Research,grid.7490.a,Germany,Federal Ministry for Economic Affairs and Energy,Germany,0,0,0
grant.7999630,03 8689 /0,Verbundprojekt: Impfstoffentwicklung Gegen Herpesviren: Ein flexibles System zur gezielten Antigen-Variation bei Humanen Influenza-Viren für die Herstellung von Vakzinen,174044,1985-08-01,1985.0,1988-10-31,1988,University of Giessen,grid.8664.c,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989715,0315281A,ERA Net EuroTransBio-2: Neue Technologie für erfolgreiche Impfstoffstrategien: Crossbeta Adjuvanz-Technologie am Beispiel von Protein-basierten Impfstoffen gegen Influenza H5N1 Viren,277036,2008-04-01,2008.0,2010-03-31,2010,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7963379,01QE1522,"Verbundprojekt: Entwicklung eines low-cost intranasalen Vaccines mit universellem Schutz gegen Pneumococcus Infektionen, Teilprojekt: Sicherheits- und Wirksamkeitsuntersuchungen des Vaccines",69213,2015-09-01,2015.0,2018-08-31,2018,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7951267,01KA0804,"EDCTP - Malariaimpfstoffe I: Förderung der immunologischen und der klinischen Forschungs-Kompetenz im Rahmen multizentrischer, internationaler klinischer Studien an Malariavakzinen der Phasen I bis IIb",1443557,2008-09-01,2008.0,2013-08-31,2013,University of Tübingen,grid.10392.39,Germany,Federal Ministry of Education and Research,Germany,6,0,0
grant.7951264,01KA0801,EDCTP-HIV-Vakzine I: Bestimmung der zellulären Immunantwort nach Impfung mit einer DNA / MVA HIV Vakzine bei 70 Freiwilligen.,541177,2008-10-01,2008.0,2012-05-31,2012,Ludwig Maximilian University of Munich,grid.5252.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7942548,01GU0709,Verbundprojekt: Innovative bakterielle Tumorimpfstoffe - Teilprojekt 2/3: Entwicklung eines oralen rekombinanten Salmonellenvakzins der zweiten Generation für die Tumortherapie,873846,2008-01-01,2008.0,2011-06-30,2011,University of Würzburg,grid.8379.5,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7635223,,"Best Brains Exchange: 'Achievement of Optimal Vaccine Coverage Rates in Canada: Identifying and Addressing the Problem of Vaccine Hesitancy', February 3, 2015, Ottawa.",932,2014-04-01,2014.0,2015-03-31,2015,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7631633,,"Best Brains Exchange: 'Achievement of Optimal Vaccine Coverage Rates in Canada: Identifying and Addressing the Problem of Vaccine Hesitancy', February 3, 2015, Ottawa.",2129,2014-04-01,2014.0,2015-03-31,2015,British Columbia Children's Hospital,grid.414137.4,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7630003,,"Best Brains Exchange: 'Achievement of Optimal Vaccine Coverage Rates in Canada: Identifying and Addressing the Problem of Vaccine Hesitancy', February 3, 2015, Ottawa.",1954,2014-04-01,2014.0,2015-03-31,2015,Institut National de Santé Publique du Québec,grid.434819.3,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7626821,,"Best Brains Exchange: 'Achievement of Optimal Vaccine Coverage Rates in Canada: Identifying and Addressing the Problem of Vaccine Hesitancy', February 3, 2015, Ottawa.",957,2014-04-01,2014.0,2015-03-31,2015,University of Ottawa,grid.28046.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7620636,,"Best Brains Exchange: 'Achievement of Optimal Vaccine Coverage Rates in Canada: Identifying and Addressing the Problem of Vaccine Hesitancy', February 3, 2015, Ottawa.",1433,2014-04-01,2014.0,2015-03-31,2015,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.7608947,SERB_8acf8d2d03,Investigation of the role of envelope glycoprotein in virulence/attenulation of live japanese encephalitis virus (JEV) vaccine SA14-14-2insights into rational design of flaviviral vaccines,86605,2016-04-01,2016.0,2017-03-31,2017,Indian Institute of Science Bangalore,grid.34980.36,India,Science and Engineering Research Board,India,0,0,0
grant.7590516,161134,The nature and extent of vaccine hesitancy among chiropractors and naturopaths:  identifying how vaccination views impact practice,7168,2017-04-01,2017.0,2018-03-31,2018,Laval University; Laval University; Laval University; Laval University; Laval University; Laval University; Laval University; Laval University,grid.23856.3a; grid.23856.3a; grid.23856.3a; grid.23856.3a; grid.23856.3a; grid.23856.3a; grid.23856.3a; grid.23856.3a,Canada; Canada; Canada; Canada; Canada; Canada; Canada; Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.7501851,2015R1D1A1A02062126,경제동물용 백신 제조에 있어 포르말린 대체제 발굴 및 이를 활용한 신 개념 사균 백신 개발에 관한 기초 연구,0,2015-01-01,2015.0,2016-01-01,2016,Chonbuk National University,grid.411545.0,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7475151,2014R1A2A1A10053662,현재 백신의 한계를 극복한 새로운 대상포진 백신후보 발굴 및 작용기전 규명,0,2014-01-01,2014.0,2015-01-01,2015,Korea Advanced Institute of Science and Technology,grid.37172.30,South Korea,National Research Foundation of Korea,South Korea,11,0,0
grant.7390075,OPP1180809,To develop new synthetic DNA vaccines encoding designed CSP antigens to provide a new generation advanced CSP component for a prophylactic malaria vaccine,1494972,2017-11-01,2017.0,2019-06-01,2019,The Wistar Institute,grid.251075.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7390050,OPP1180137,To develop a plan for the identification of immune correlates of vaccine efficacy that will enable vaccine product development and licensure to improve global population health,328953,2017-12-01,2017.0,2019-07-01,2019,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7389866,OPP1174124,To evaluate benefits of inactivated vaccine as a booster following vaccination with live attenuated influenza vaccine in young children in developing countries,333428,2017-07-01,2017.0,2019-09-01,2019,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7161820,S/P033/06,Production of High Efficiency Recombinant Foot-and-mouth Disease Vaccine for Pre-clinical and Clinical Trials and Commercial Vaccine Production,51269,2007-01-01,2007.0,2007-01-30,2007,,,,Innovation and Technology Commission,China,0,0,0
grant.7149494,,Evaluation of the effect of vaccines on overall health in Danish children: Changing the paradigm of vaccine policy in high-income countries,247887,2015-01-01,2015.0,2015-12-31,2015,State Serum Institute,grid.6203.7,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7099889,2010-00999,Antigen targeting and activation of dendritic cells for vaccine design,449950,2010-12-01,2010.0,2014-12-31,2014,Karolinska Institute,grid.4714.6,Sweden,VINNOVA,Sweden,3,0,0
grant.6782435,2460888340,Chlamydophila psittaci recombinant vaccine development,0,2012-03-01,2012.0,2014-01-31,2014,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6585998,OPP1084574,To optimize the process of WHO biannual influenza vaccine virus selection towards appropriate influenza vaccine composition recommendations for tropical countries,1299500,2013-10-01,2013.0,2016-11-01,2016,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6585935,OPP1039139,To determine whether mucosal immunity against poliovirus can be enhanced by providing an additional dose of inactivated poliovirus vaccine to children previously immunized with oral poliovirus vaccine,501069,2011-10-01,2011.0,2014-12-01,2014,Christian Medical College & Hospital,grid.11586.3b,India,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6585926,OPP1111073,"To reduce child mortality through increasing vaccine visibility in 6 states, and through increasing availability of vaccines in Lagos state.",510006,2014-08-01,2014.0,2016-09-01,2016,Clinton Health Access Initiative,grid.452345.1,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585903,OPP53273,To test whether injection of a vaccine into laser-exposed skin can significantly enhance immune responses stimulated by the vaccine,100000,2009-05-01,2009.0,2010-11-01,2010,Massachusetts General Hospital,grid.32224.35,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6585869,OPP1113282,"To convene professionals from developing countries working in research, development, manufacturing and supply of vaccines, towards the common goal of increasing the availability of high-quality vaccines",54970,2014-09-01,2014.0,2014-12-01,2014,Developing Countries Vaccine Manufactures Network,grid.479199.b,Switzerland,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6585273,OPP1058969,To test for use in a vaccine a live single-cycle poliovirus that has been modified to eliminate its ability to re-emerge as vaccine-derived poliovirus.,100000,2012-04-01,2012.0,2013-11-01,2013,,,,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584991,OPPGH5162,To advocate for HIV vaccines research and development and facilitate the African AIDS Vaccine Programme's transition to an independent operational African program outside of WHO,487273,2009-06-01,2009.0,2012-07-01,2012,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584904,OPP1060879,To develop new architectural and construction guidelines for vaccine storage rooms in hot climates that incorporate passive solar thermal technologies to keep vaccines at recommended temperatures.,100000,2012-10-01,2012.0,2014-11-01,2014,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584557,OPP1033104,To develop a novel HIV-1 RV144-like vaccine regimen using an improved vaccine vector Mycobacterium bovis Bacillus Calmette-Guerin,8958936,2011-10-01,2011.0,2018-01-01,2018,Beth Israel Deaconess Medical Center,grid.239395.7,United States,Bill & Melinda Gates Foundation,United States,10,0,0
grant.6584345,OPP38619,To establish a global laboratory support network that will benefit AIDS vaccine development as it relates to vaccine-elicited antibody responses,33736704,2006-06-01,2006.0,2012-08-01,2012,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,67,0,0
grant.6584272,OPP1039137,To produce more poliovirus vaccine supply while reducing production costs by silencing non-essential virus resistance genes to develop enhanced vaccine cell lines,222411,2011-10-01,2011.0,2013-03-01,2013,University of Georgia,grid.213876.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583987,OPP1060827,To develop cell phone sensors that monitor refrigerated vaccine stocks and generate geo-tagged alerts when vaccines reach critical temperatures.,100000,2012-04-01,2012.0,2013-11-01,2013,Nexleaf Analytics,grid.479530.c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583104,OPP51960,To study whether reducing the ability of lysomes to digest protein antigens in vaccines could enhance the vaccine’s ability to elicit antibody and T cell responses.,100000,2008-10-01,2008.0,2009-10-01,2009,New York University,grid.137628.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583069,OPP1119024,"To employ novel, rational design strategies to generate an oral/mucosal vaccine formulation that could significantly contribute to developing vaccines to improve global health",800000,2014-12-01,2014.0,2017-12-01,2017,,,,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6582938,OPP1097705,To investigate the use of lyophilized Salk IPV to serve as basis for a combination vaccine strategy with a pentavalent vaccine,382750,2013-11-01,2013.0,2015-01-01,2015,Intravacc (Netherlands),grid.452495.b,Netherlands,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581894,OPP1061344,"To develop a vaccine platform that uses bacteriophages that are structurally stable in extreme environments to manufacture inexpensive, stable, and easy-to-produce vaccines.",100000,2012-04-01,2012.0,2014-11-01,2014,University of Southern Maine,grid.267189.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581427,OPP1058684,To test the hypothesis that selling vaccines through medicine shops in emerging markets can lead to profits for both vaccine developers and the small business owners.,100000,2012-04-01,2012.0,2013-11-01,2013,Epsilon Therapeutics (United States),grid.479088.a,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581288,OPP1054013,"To develop an affordable, easy-to-use, and effective stable liquid multi-dose rotavirus vaccine delivery system for introduction to vaccine partners in developing countries",2325773,2012-11-01,2012.0,2017-01-01,2017,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581141,OPP1046170,To test the feasibility of using microneedle patches to deliver the inactivated polio vaccine (IPV) instead of using intramuscular vaccine shots.,100000,2011-10-01,2011.0,2013-11-01,2013,Georgia Institute of Technology,grid.213917.f,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580969,OPP1033438,"To reduce severe illness and death among infants and children by evaluating non-replicating rotavirus vaccine candidates as viable alternatives to oral, live attenuated rotavirus vaccines",19901076,2011-11-01,2011.0,2018-07-01,2018,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580705,OPP1046318,To engineer an adenovirus vaccine vector that could be used in an HIV vaccine to elicit the strong immune response.,100000,2011-11-01,2011.0,2013-05-01,2013,Jenner Institute,grid.418731.8,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580376,OPP53055,"To design a novel vaccine platform based on protein microcrystals produced by insect viruses, to induce a vigorous immune response without the need for refrigerated vaccine storage.",100000,2009-05-01,2009.0,2010-11-01,2010,Monash University,grid.1002.3,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6576981,31516,Développement d'une plateforme vaccinale hautement versatile basée sur les nanoparticules du virus mosaïque de la papaye,11631,2015-04-01,2015.0,2016-03-31,2016,Centre Hospitalier Universitaire de Québec,grid.411081.d,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.6501535,272201600038C-0-0-1,A HUMAN TOXOPLASMA GONDII VACCINE,438932,2016-08-31,2016.0,2018-08-30,2018,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500969,272201600037C-0-0-1,DEVELOPMENT OF A PROPHYLACTIC ONCHOCERCIASIS VACCINE,441905,2016-08-31,2016.0,2018-08-30,2018,PAI Life Sciences (United States),grid.423437.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500765,272201600036C-0-0-1,COMBINING PARASITE AND VECTOR COMPONENTS FOR DEVELOPMENT OF A LEISHMANIA VACCINE,444428,2016-08-31,2016.0,2018-08-30,2018,PAI Life Sciences (United States),grid.423437.5,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.6118127,25670479,A basic study on combination vaccines of rotavirus and norovirus,34797,2013-04-01,2013.0,2016-03-31,2016,Nihon University,grid.260969.2,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5857550,15H04723,Malaria vaccine development based on multifunctional hybrid vaccine platform,155419,2015-04-01,2015.0,2018-03-31,2018,Kanazawa University,grid.9707.9,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.5849868,15F15415,多機能型ワクチンプラットフォームを基盤としたマラリアワクチンの開発研究,20711,2015-11-09,2015.0,2018-03-31,2018,Kanazawa University,grid.9707.9,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.5128659,LP160100633,Enhanced multivalent vaccine responses using a novel vaccine vector system,272219,2016-01-01,2016.0,2018-12-31,2018,University of South Australia,grid.1026.5,Australia,Australian Research Council,Australia,3,0,0
grant.4672399,185133,Caractérisation et évaluation du potentiel immunostimulant de saponines triterpéniques naturelles et hémisynthétiques comme adjuvants potentiels de vaccins,11666,2014-04-01,2014.0,2015-03-31,2015,Université du Québec à Chicoutimi,grid.265696.8,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4656617,164677,Mise au point d'un vaccin sous-unitaire contre les infections à Salmonella et Streptococcus suis chez le porc.,10079,2011-04-01,2011.0,2012-03-31,2012,University of Montreal,grid.14848.31,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4651170,180808,Effets des capsules polysaccharidiques sialylées de bactéries Gram Positif sur la capacité immunogénique de vaccins conjugués,17503,2014-04-01,2014.0,2015-03-31,2015,University of Montreal,grid.14848.31,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4649198,192489,Development of a sub-unit vaccine to protect swine against the infections caused by Streptococcus suis,4374,2014-04-01,2014.0,2015-03-31,2015,University of Montreal,grid.14848.31,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4047540,NA16RG1607,SIGNATURE-TAGGED MUTAGENESIS: A NOVEL AND RAPID APPROACH FOR DEVELOPMENT OF AQUACULTURE VACCINES,190050,2001-07-01,2001.0,2004-03-31,2004,Kent SeaTech Corporation (United States),grid.420657.2,United States,National Oceanic and Atmospheric Administration,United States,0,0,0
grant.3983507,08/RFP/BMT1363,Harnessing the immunostimulatory activity of chitosan to produce potent vaccine adjuvants,294426,2008-09-01,2008.0,2012-08-31,2012,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,6,0,0
grant.3926442,41994,HIV vaccine acceptability among vulnerable communities in Thailand,104331,2005-04-01,2005.0,2008-03-31,2008,University of Toronto,grid.17063.33,Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.3869522,56415,Pan-PRovincial Vaccine ENTerprise (PREVENT) / Prévention de la propagation de l'insuffisance fonctionnelle des organes (PPIFO),2318236,2007-04-01,2007.0,2008-03-31,2008,Pan-Provincial Vaccine Enterprise,grid.440055.0,Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.3856976,272201200005I-2-27200003-1,Task X3: Production and Testing of Conjugate Cholera Vaccine,1323948,2012-09-25,2012.0,2018-10-08,2018,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856958,272201200003I-1-27200004-1,Task X 4: Assessment of Simple Adjuvants to Enhance Anthrax Vaccines,196323,2013-09-11,2013.0,2014-09-10,2014,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3636168,093608/Z/10/A,Heterogeneous prime boost vaccines for Chlamydia trachomatis.,30458,2012-02-01,2012.0,2014-09-30,2014,Imperial College London,grid.7445.2,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3636164,093608/Z/10/Z,Heterogeneous prime boost vaccines for Chlamydia trachomatis.,243699,2010-10-01,2010.0,2014-09-30,2014,Imperial College London,grid.7445.2,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.2707046,Y2AI9456-1-0-3,Targeting the hydrophobic domain of biothreat pathogens for vaccine development,99667,2009-01-01,2009.0,2009-12-31,2009,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706133,Y1AI0664-2-0-1,Development of Assays to Evaluate Filovirus Vaccines,261000,2011-01-01,2011.0,2011-12-31,2011,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706132,Y1AI0664-1-0-1,Development of Assays to Evaluate Filovirus Vaccines,261000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706121,Y1AI0632-2-0-1,Preclinical Development of Oral Anthrax Vaccine,165000,2011-01-01,2011.0,2011-12-31,2011,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706120,Y1AI0632-1-0-1,Preclinical Development of Oral Anthrax Vaccine,88000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425329,N01AI40031-4-0-1,Development and Production of Inactivated H5N1 Influenza Vaccine,263474,2004-05-17,2004.0,2007-06-17,2007,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425152,N01AI30023-11-0-1,Development of a Recombinant SARS Vaccine,10718,2003-05-22,2003.0,2012-11-30,2012,Protein Sciences (United States),grid.437366.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2346454,272200700056C-9-0-1,GLOBAL HIV VACCINE ENTERPRISE,1077813,2013-09-12,2013.0,2014-09-11,2014,Global HIV Vaccine Enterprise,grid.420432.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346453,272200700056C-8-0-1,GLOBAL HIV VACCINE ENTERPRISE,1270842,2012-09-12,2012.0,2013-09-11,2013,Global HIV Vaccine Enterprise,grid.420432.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346452,272200700056C-4-0-1,GLOBAL HIV VACCINE ENTERPRISE,517816,2007-09-12,2007.0,2014-09-11,2014,Global HIV Vaccine Enterprise,grid.420432.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346451,272200700056C-3-0-1,GLOBAL HIV VACCINE ENTERPRISE,1060037,2007-09-12,2007.0,2014-09-11,2014,Global HIV Vaccine Enterprise,grid.420432.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346450,272200700056C-2-0-1,GLOBAL HIV VACCINE ENTERPRISE,985801,2007-09-12,2007.0,2014-09-11,2014,Global HIV Vaccine Enterprise,grid.420432.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7194761,31402346,迟缓爱德华氏菌弱毒载体疫苗的异源抗原呈递和免疫保护,31104,2015-01-01,2015.0,2016-12-31,2016,Chinese Academy of Fishery Sciences,grid.43308.3c,China,National Natural Science Foundation of China,China,1,0,0
grant.7172017,272201300003I-1-27200012-1,SIMIAN VACCINE EVALUATION UNITS - Animal Maintenance and Care,233204,2016-05-01,2016.0,2018-04-30,2018,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500978,272201300002I-3-27200008-1,SVEU - Efficacy of HIV Clade C Vaccine Candidate with GP120 Boost,23078,2013-08-30,2013.0,2016-04-30,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500814,272201300002I-0-27200015-1,IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS,1576546,2016-08-15,2016.0,2019-08-14,2019,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500392,272201300003I-0-27200011-1,IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS,157372,2016-05-01,2016.0,2017-07-31,2017,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500217,272201300003I-0-27200010-1,IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS,1624996,2016-04-15,2016.0,2018-07-14,2018,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499433,272201300002I-0-27200014-1,IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS,1369907,2016-05-01,2016.0,2018-04-30,2018,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499403,272201300003I-0-27200012-1,IGF::OT::IGF SIMIAN VACCINE EVALUATION UNITS,223386,2016-05-01,2016.0,2017-04-30,2017,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245883,272201300004I-0-27200005-1,SIMIAN VACCINE EVALUATION UNITS: Conduct Study P190,1286013,2015-08-25,2015.0,2018-08-24,2018,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2723025,ZIAAI000416,Recombinant Vaccines for Prevention of AIDS and Other Diseases,7281277,2009-01-01,2009.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,81,0,0
grant.2347707,272201300002I-0-27200008-1,SVEU - Efficacy of HIV Clade C Vaccine Candidate with GP120 Boost,1685828,2013-08-30,2013.0,2015-08-29,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6246546,62570439,STUDIES ON ENZYME-LINKED IMMUNOSORBENT ASSAY FOR EVALUATION OF IMMUNIZATION,13116,1987-01-01,1987.0,1989-12-31,1989,Tokai University,grid.265061.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5012180,81000748,基于同种异型（Heterologous prime－boost）疫苗免疫策略增强日本血吸虫病疫苗免疫保护作用及其机理的研究,31631,2011-01-01,2011.0,2013-12-31,2013,,,,National Natural Science Foundation of China,China,6,0,0
grant.5009549,31001049,中国EIAV疫苗免疫原的多样性构成与诱导保护性免疫的相关性研究,30049,2011-01-01,2011.0,2013-12-31,2013,Harbin Veterinary Research Institute,grid.38587.31,China,National Natural Science Foundation of China,China,3,0,0
grant.2581616,R13AI069828,"2nd Annual Vaccine Renaissance Conference, RI",17500,2006-06-01,2006.0,2007-05-31,2007,EpiVax (United States),grid.421087.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.8564619,BT/PR21553/ADV/90/244/2016,Validation of Molecular Diagnostics and Vaccine for Classical Swine Fever,51355,2017-08-01,2017.0,2019-08-01,2019,University of Madras,grid.413015.2,India,Department of Biotechnology,India,0,0,0
grant.8564045,BT/HRD/NBA/37/01/2014 (v),Development of auxotrophic vaccines against M. tuberculosis.,7421,2016-08-17,2016.0,2019-08-17,2019,Translational Health Science and Technology Institute,grid.464764.3,India,Department of Biotechnology,India,0,0,0
grant.8563756,BT/Indo-Aus/08/05/2014,Preclinical trials of a quadrivalent hepatitis C virus vaccine,63483,2015-06-02,2015.0,2018-06-02,2018,Indian Institute of Science Bangalore,grid.34980.36,India,Department of Biotechnology,India,0,0,0
grant.8563659,BT/PR9674/ADV/90/160/2013,Development of oral pellet Fowl Cholera Vaccine,36587,2015-09-29,2015.0,2017-03-29,2017,Tamil Nadu Veterinary and Animal Sciences University,grid.412908.6,India,Department of Biotechnology,India,0,0,0
grant.8563658,BT/PR8495/ADV/90/162/2014,Development of a Live Attenuated Vaccine against Hemorrhagic Septicemia,46728,2016-03-07,2016.0,2019-03-07,2019,Chaudhary Sarwan Kumar Himachal Pradesh Krishi Vishvavidyalaya,grid.411939.7,India,Department of Biotechnology,India,0,0,0
grant.8563337,BT/PR11807/MED/29/871/2014,Development of envelope based dengue tetravalent all-in-one vaccine,117550,2014-07-18,2014.0,2017-07-18,2017,International Centre for Genetic Engineering and Biotechnology,grid.425195.e,India,Department of Biotechnology,India,0,0,0
grant.8563045,BT/ADV/90/SP10837/2014,Status of Veterinary Vaccines and Diagnostics in India A comprehensive review,49584,2014-07-21,2014.0,2016-07-21,2016,Tamil Nadu Veterinary and Animal Sciences University,grid.412908.6,India,Department of Biotechnology,India,0,0,0
grant.8563043,BT/ADV/90/SP11556/2014,Nano-Newcastle disease virus vaccine pathway to commercialization,43453,2014-06-20,2014.0,2016-06-20,2016,Tamil Nadu Veterinary and Animal Sciences University; Hester,grid.412908.6; grid.506006.5,India; India,Department of Biotechnology,India,0,0,0
grant.8563042,BT/PR5796/ADV/90/146/2013,Development of recombinant vaccine for control of salmonellosis in poultry,62245,2014-12-19,2014.0,2016-12-19,2016,Indian Veterinary Research Institute; Kerala Veterinary and Animal Sciences University,grid.417990.2; grid.459722.f,India; India,Department of Biotechnology,India,0,0,0
grant.8563041,BT/ADV/90/SP11580/2014,DEVELOPMENT OF RECOMBINANT FUSION PROTEIN VACCINE FOR,17397,2014-06-23,2014.0,2015-06-23,2015,Tamil Nadu Veterinary and Animal Sciences University,grid.412908.6,India,Department of Biotechnology,India,0,0,0
grant.8562912,BT/PR6611/GBD/27/443/2012,Modulation of TLR5 mediated T regulatory functions in cholera vaccine,39505,2013-08-07,2013.0,2016-08-07,2016,Indian Institute of Advanced Research,grid.429014.a,India,Department of Biotechnology,India,0,0,0
grant.8562432,BT/Bio-CARe/07/634/2011-12,Development of vaccines and diagnostics against hospital acquired infections:,68810,2013-11-22,2013.0,2017-05-22,2017,,,,Department of Biotechnology,India,0,0,0
grant.8562161,BT/MB/01/VAP/2012,Predictors of Poor Immune Response to Rotavirus Vaccine in Infants.,73800,2012-08-27,2012.0,2014-08-27,2014,Society for Applied Studies; Christian Medical College & Hospital,grid.465049.a; grid.11586.3b,India; India,Department of Biotechnology,India,0,0,0
grant.8561665,BT/PR15176/GBD/27/358/2011,Identification of the potential vaccine candidate antigens of clostridium chauvoei,41174,2011-06-06,2011.0,2014-12-06,2014,Indian Veterinary Research Institute,grid.417990.2,India,Department of Biotechnology,India,0,0,0
grant.8561576,BT/PR5164/MED/15/80/2012,Development of Malaria Vaccines Using the Influenza,327733,2012-03-29,2012.0,2013-03-29,2013,International Centre for Genetic Engineering and Biotechnology; International Centre for Genetic Engineering and Biotechnology,grid.425195.e; grid.425195.e,India; India,Department of Biotechnology,India,0,0,0
grant.8561573,BT/PR5136/MED/15/86/2012,Development of a Recombinant Combination Blood Stage Vaccine,1073308,2012-03-28,2012.0,2015-03-28,2015,International Centre for Genetic Engineering and Biotechnology; International Centre for Genetic Engineering and Biotechnology,grid.425195.e; grid.425195.e,India; India,Department of Biotechnology,India,0,0,0
grant.8561429,BT/PR441/MED/15/71/2011,DEVELOPMENT OF NEW LIVE ATTENUATED VACCINE CANDIDATES FOR KALA - AZAR,311686,2011-09-29,2011.0,2015-03-29,2015,National Institute of Pathology; Institute of Molecular Medicine,grid.418901.5; grid.464859.2,India; India,Department of Biotechnology,India,0,0,0
grant.8560657,BT/PR13125/GBD/27/193/2009,Construction of multivalent protein vaccine against Staphylococuss aureus and immunogenicity,56582,2009-12-29,2009.0,2013-06-29,2013,Tata Institute of Fundamental Research,grid.22401.35,India,Department of Biotechnology,India,0,0,0
grant.8560624,BT/PR10382/GBD/27/105/2007,Adenovirus vectored vaccines for foot and mouth disease.,39299,2009-01-09,2009.0,2012-01-09,2012,Bharat Biotech (India),grid.497429.5,India,Department of Biotechnology,India,0,0,0
grant.8560476,BT/PR12871/NNT/28/449/2009,Development of smart nano carriers for oral vaccine delivery,51907,2010-03-16,2010.0,2015-03-16,2015,Indian Institute of Science Education and Research Mohali,grid.458435.b,India,Department of Biotechnology,India,0,0,0
grant.8560405,BT/MB/VGCP/CVRU-CMC/2009,Establishment of the Core Vaccine Research Unit (CVRU),156211,2010-02-18,2010.0,2013-02-18,2013,Christian Medical College & Hospital,grid.11586.3b,India,Department of Biotechnology,India,0,0,0
grant.8560221,BT/PR14797/MED/30/578/2010,Development of HPV 18 Chimaeric vaccine candidate,54452,2011-01-27,2011.0,2013-01-27,2013,All India Institute of Medical Sciences,grid.413618.9,India,Department of Biotechnology,India,0,0,0
grant.8560117,BT/PR9277/MED/29/16/2007,DEVELOPMENT OF CHIKUNGUNYA VACCINE CANDIDATE,81445,2008-03-24,2008.0,2011-03-24,2011,Translational Health Science and Technology Institute,grid.464764.3,India,Department of Biotechnology,India,0,0,0
grant.8559105,BT/AAQ/Indo-Norway/183204/2007,Indo Norwegian platform on fish and shellfish vaccine development.,870473,2009-08-11,2009.0,2013-08-11,2013,Thiruvalluvar University; Karnataka Veterinary Animal and Fisheries Sciences University; Tata Institute of Fundamental Research,grid.449556.f; grid.418768.4; grid.22401.35,India; India; India,Department of Biotechnology,India,0,0,0
grant.8559074,BT/PR9912/AAQ/03/359/2007,Development of DNA based vaccine against,157697,2008-05-26,2008.0,2012-05-26,2012,Central Institute of Fisheries Education,grid.444582.b,India,Department of Biotechnology,India,0,0,0
grant.8559052,BT/PR7882/AAQ/01/309/2006,Development of Vaccine for control of bovine tuberculosis.,480900,2007-07-02,2007.0,2011-11-02,2011,All India Institute of Medical Sciences; University of Delhi; National JALMA Institute for Leprosy & Other Mycobacterial Diseases,grid.413618.9; grid.8195.5; grid.417722.5,India; India; India,Department of Biotechnology,India,0,0,0
grant.8559051,BT/PR12518/ADV/57/01/2009,Development of Recombinant Vaccine for Infectious bursal disease virus.,63231,2009-12-24,2009.0,2013-12-24,2013,Indian Veterinary Research Institute,grid.417990.2,India,Department of Biotechnology,India,0,0,0
grant.8559050,BT/PR9992/AAQ/57/7/2007,Development of Recombinant Fusion Protein Vaccine for Mycobacterium avium subsp.Paratuberculosis.,93480,2008-12-31,2008.0,2011-12-31,2011,University of Madras,grid.413015.2,India,Department of Biotechnology,India,0,0,0
grant.8515700,1119007N,Recombinante expressie van door middel van RNAi geselecteerde kandidaatvaccin antigenen van Ostertagia ostertagi in Caenorhabditis elegans,0,2006-10-01,2006.0,2008-09-30,2008,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8515699,1119005N,Recombinante expressie van door middel van RNAi geselecteerde kandidaat-vaccin antigenen van Ostertagia ostertagi in Caenorhabditis elegans.,0,2004-10-01,2004.0,2006-09-30,2006,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8514844,1800310N,Een geïntegreerde preklinische strategie voor het ontwikkelen van verbeterde dendritische cel vaccins tegen longkanker,0,2009-10-01,2009.0,2014-09-30,2014,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8513725,1530997N,Ontwikkeling van een Chlamydia psittaci DNA vaccin voor de bestrijding van chlamydiosis bij kalkoenen.,0,1996-07-01,1996.0,1998-12-31,1998,KU Leuven,grid.5596.f,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8513721,G041207N,Ontwikkeling van een Chlamydia trachomatis kandidaat recombinant vaccin voor mucosale toediening.,0,2007-01-01,2007.0,2010-12-31,2010,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8513720,G008605N,"""Biomics"" als innovatieve benadering voor Chlamydia trachomatis vaccin ontwikkeling.",0,2005-01-01,2005.0,2005-12-31,2005,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8512475,1137704N,Ontwikkeling van F1- en P-gebaseerde subunit vaccins tegen aviaire escherichia coli infectie (APEC).,0,2003-10-01,2003.0,2005-09-30,2005,KU Leuven,grid.5596.f,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8512474,1137702N,Ontwikkeling van F1-gebaseerde subunit vaccins tegen aviaire E. coli infectie.,0,2001-10-01,2001.0,2003-09-30,2003,KU Leuven,grid.5596.f,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8512461,1181792N,De rol van interferon-gamma in de immuniteit geïnduceerd door het sporozoïet malaria vaccin.,0,1991-10-01,1991.0,1993-09-30,1993,KU Leuven,grid.5596.f,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8511997,1235905N,Preklinische ontwikkeling van RNA-gemodifieerde dendritische celvaccins voor kanker en HIV.,0,2004-10-01,2004.0,2007-09-30,2007,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8511996,1235902N,Preklinische ontwikkeling van RNA gemodifieerde dendritische celvaccins voor kanker en HIV.,0,2001-10-01,2001.0,2004-09-30,2004,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8509953,G013497N,Studie van de variabiliteit van humaan immunodeficiëntie virussen. Implicaties voor vaccin en antivirale interventie strategieën.,0,1996-12-01,1996.0,2000-12-31,2000,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8509657,1135410N,Ontwikkeling en validering van een oraal influenza A vaccin gebaseerd op M2e-uitdrukkende fagen,0,2009-10-01,2009.0,2011-09-30,2011,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8509656,1135408N,Ontwikkeling en validering van een oraal influenza A vaccin gebaseerd op M2e-uitdrukkende fagen,0,2007-10-01,2007.0,2009-09-30,2009,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8506007,1S52016N,Production of immunogenic tumor lysate loaded mesoporous silica nanoparticles as anti-cancer vaccine,0,2016-01-01,2016.0,2017-12-31,2017,KU Leuven,grid.5596.f,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8505275,1509809N,Identificatie van het immunologisch werkingsmechanisme van het influenza matrixeiwit-2 ectodomein vaccin.,0,2009-01-01,2009.0,2009-12-31,2009,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8504517,G017013N,Formulatie van vaccin antigenen in intelligente stimuli-responsieve ultra-kleine nanpoartikels,0,2013-01-01,2013.0,2016-12-31,2016,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8504516,G073012N,Ontwikkeling van microparticulaire kanker vaccins door formulatie van tumor-specifieke antigenen met immuno-modulerende polymeren.,0,2012-01-01,2012.0,2015-12-31,2015,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8497993,1187907N,Ontwikkeling en evaluatie van een recombinant vaccin tegen malaria bij het rund veroorzaakt door Theileria parva,0,2006-10-01,2006.0,2008-09-30,2008,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8497992,1187905N,Ontwikkeling en evaluatie van een recombinant vaccin tegen malaria bij het rund veroorzaakt door Theileria parva.,0,2004-10-01,2004.0,2006-09-30,2006,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8497452,G035597N,Een nieuw tuberculose vaccin gebaseerd op genetische vaccinatie met cultuurfiltraat-antigenen.,0,1996-12-01,1996.0,2000-12-31,2000,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8495457,1110317N,RNA synthetische biologie voor de genetische aanmaak van een programmeerbaar éénmaal toe te dienen slim RNA vaccin,0,2016-10-01,2016.0,2018-09-30,2018,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8494876,1111506N,Vaccins tegen tuberculose: identificatie en karakterisatie van de immunologische parameters die immune bescherming verlenen.,0,2005-10-01,2005.0,2007-09-30,2007,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8494875,1111504N,Vaccins tegen tuberculose : identificatie en karakterisatie van de immunolo- gische parameters die immune bescherming verlenen.,0,2003-10-01,2003.0,2005-09-30,2005,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8485215,G031301N,Ontwikkeling van een tumorvaccin gebruikmakend van antigeen getransfecteerde dendritische cellen: een ex vivo studie.,0,2001-01-01,2001.0,2006-12-31,2006,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8445296,2018-04942,Vaccine for all,11191,2019-04-01,2019.0,2019-08-30,2019,,,,VINNOVA,Sweden,0,0,0
grant.8220284,39980038,以减毒沙门氏菌为载体的HCV多表位核酸疫苗的研究,15698,2000-01-01,2000.0,2002-12-31,2002,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8220277,39980031,利用转基因紫花苜蓿研究肝片吸虫食用疫苗,16906,2000-01-01,2000.0,2002-12-31,2002,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,0,0,0
grant.8220260,39980014,MAF-J6-1及其受体融合基因疫苗构建及实验研究,16906,2000-01-01,2000.0,2002-12-31,2002,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,2,0,0
grant.8219111,39880046,新城病毒在肿瘤疫苗制备中的作用,16909,1999-01-01,1999.0,2000-12-31,2000,Shanghai Municipal Center For Disease Control Prevention,grid.430328.e,China,National Natural Science Foundation of China,China,0,0,0
grant.8217953,39780024,恶性疟基因在人伤寒杆菌疫苗株中进行四环素诱导表达,14488,1998-01-01,1998.0,2000-12-31,2000,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8217940,39780011,HPV16基因工程预防疫苗及其作用的细胞与分子生物研究,16907,1998-01-01,1998.0,2000-12-31,2000,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8217931,39780002,丙型肝炎复合多价基因工程口服活菌苗的实验研究,14488,1998-01-01,1998.0,2000-12-31,2000,Southern Medical University,grid.284723.8,China,National Natural Science Foundation of China,China,0,0,0
grant.8216797,39680011,抗乳头瘤病毒感染的嵌合基因工程疫苗的细胞分子生物学,14483,1997-01-01,1997.0,1999-12-31,1999,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8211499,39180026,家畜病毒基因工程疫苗通用载体的构建,6150,1992-01-01,1992.0,1994-12-31,1994,Wuhan University,grid.49470.3e,China,National Natural Science Foundation of China,China,0,0,0
grant.8211072,39170536,香蕉病毒病血清学快速检验技术及抗病毒疫苗筛选的研究,5380,1992-01-01,1992.0,1994-12-31,1994,South China Institute of Botany,grid.458495.1,China,National Natural Science Foundation of China,China,0,0,0
grant.8209941,39070654,牛传染性鼻气管炎单克隆抗体诊断试剂及亚单位疫苗研制,5168,1991-01-01,1991.0,1993-12-31,1993,Huazhong Agricultural University,grid.35155.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8208830,38970657,霍乱高效疫苗的研制及其免疫机制的探讨,4303,1990-01-01,1990.0,1993-12-31,1993,Nanjing Medical University,grid.89957.3a,China,National Natural Science Foundation of China,China,0,0,0
grant.8208822,38970649,福氏志贺氏菌抗独特型抗体作为疫苗的可行性研究,5168,1990-01-01,1990.0,1992-12-31,1992,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,0,0,0
grant.8207779,38870716,恶性疟原虫配子疫苗基础研究--配子靶抗原分析,3442,1989-01-01,1989.0,1992-12-31,1992,Peking University,grid.11135.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8207091,38870027,口蹄疫疫苗研制的新技术及其应用基础研究,5169,1989-01-01,1989.0,1991-12-31,1991,,,,National Natural Science Foundation of China,China,0,0,0
grant.8206776,38770681,应用基因工程技术制备恙虫病立克次体抗原及疫苗的研究,5168,1988-01-01,1988.0,1990-12-31,1990,Sun Yat-sen University,grid.12981.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8206012,38671156,杂交细胞活瘤苗抗白血病作用的研究,5164,1987-01-01,1987.0,1990-12-31,1990,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8205580,38670724,轮状病毒基因工程疫苗的研制及其临床应用,5169,1977-01-01,1977.0,1979-12-31,1979,Dalian Medical University,grid.411971.b,China,National Natural Science Foundation of China,China,0,0,0
grant.8176372,31110103064,三甲基壳聚糖新城疫DNA疫苗纳米粒的制备及其理化特性,3094,2011-11-01,2011.0,2011-12-31,2011,,,,National Natural Science Foundation of China,China,1,0,0
grant.8173991,30711220443,T细胞疫苗诱导的CD4+调节性T细胞应答(免疫双边会),2103,2007-10-28,2007.0,2007-11-03,2007,,,,National Natural Science Foundation of China,China,0,0,0
grant.8172695,30510103151,增强IgA应答抗成人牙周炎DNA疫苗的实验研究,976,2005-07-01,2005.0,2005-09-01,2005,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8172132,30410403264,用双歧杆菌做载体构建ETEC定居因子I重组载体疫苗,604,2004-12-15,2004.0,2004-12-31,2004,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,0,0,0
grant.8169730,30220140635,马铃薯晚疫苗持久抗性与加工品质改良,84702,2002-06-01,2002.0,2005-06-30,2005,Huazhong Agricultural University,grid.35155.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8069030,2813400307,Verbundprojekt: Entwicklung eines Rotlauf-Impfstoffs für Geflügel - Teilprojekt 2,548392,2008-09-01,2008.0,2012-12-31,2012,Free University of Berlin,grid.14095.39,Germany,Federal Ministry of Food and Agriculture,Germany,1,0,0
grant.8069029,2813400207,Verbundprojekt: Entwicklung eines Rotlauf-Impfstoffs für Geflügel - Teilprojekt 1,118430,2008-09-01,2008.0,2012-12-31,2012,Lohmann Tierzucht (Germany),grid.435896.5,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8069028,2813400107,Entwicklung eines Impfstoffes zur Prophylaxe der Chlamydiose des Rindes,234734,2008-03-04,2008.0,2010-02-28,2010,IDT Biologika (Germany),grid.498615.7,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8068980,2813100506,Pilotstudie zum Einsatz kommerziell erhältlicher AIV H5-Impfstoffe,1294061,2006-08-01,2006.0,2008-07-31,2008,Friedrich Loeffler Institute,grid.417834.d,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8048328,13N9198,Verbundprojekt: Topische Vakzinierung mit funktionalen Nanopartikeln - Teilvorhaben: Getriggerte Freisetzung von Vakzinen aus LbL-Nanopartikeln,279496,2007-04-01,2007.0,2009-09-30,2009,,,,Federal Ministry of Education and Research,Germany,1,0,0
grant.8048326,13N9196,Verbundprojekt: Topische Vakzinierung mit funktionalen Nanopartikeln - Teilvorhaben: Synthese und Analyse von Vakzinkomponenten,299989,2007-04-01,2007.0,2010-09-30,2010,EMC microcollections (Germany),grid.424419.e,Germany,Federal Ministry of Education and Research,Germany,3,0,0
grant.8034489,131A022,CI3: Präklinische Entwicklung einer prophylaktischen RNA Vakzine gegen Influenza,747533,2012-10-01,2012.0,2016-03-31,2016,BioNTech (Germany),grid.434484.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8034470,131A010A,"CI3: Tumorimpfstoffe basierend auf onkolytischen Masernviren, Teilprojekt Ribological",155782,2012-10-01,2012.0,2016-03-31,2016,BioNTech (Germany),grid.434484.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8034462,131A004B,"CI3: IVAC - Individualisierte Vakzine zur Therapie des malignen Melanoms, Teilprojekt Ribological",2581731,2012-04-01,2012.0,2016-03-31,2016,BioNTech (Germany),grid.434484.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8034461,131A004A,CI3: IVAC - Individualisierte Vakzine zur Therapie des malignen Melanoms - Teilprojekt TRON,806049,2012-04-01,2012.0,2016-03-31,2016,University Medical Center of the Johannes Gutenberg University Mainz,grid.410607.4,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.8005612,03FPB00248,Forschungsprämie: Vom Forschungsergebnis zum pharmazeutischen Produkt - Entwicklung von Aufreinigungsprozessen für eine Impfstoffplattform,18539,2009-07-01,2009.0,2010-06-30,2010,Otto-von-Guericke University Magdeburg,grid.5807.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8001843,03EGSBY005,EXIST-Gründerstipendium: Pylorix - Neue Impfstoffe und Antibiotika gegen Helicobacter pylori,136301,2007-09-01,2007.0,2008-08-31,2008,Rechts der Isar Hospital,grid.15474.33,Germany,Federal Ministry for Economic Affairs and Energy,Germany,0,0,0
grant.7999578,03 8615 /9,Verbundprojekt: Entwicklung von Impfstoffen Gegen Viren der Herpesgruppe - Teil 1,915606,1985-01-01,1985.0,1987-12-31,1987,Sanofi (Germany),grid.420214.1,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7993965,031B0082,KMU-innovativ-16: Entwicklung mRNA-basierter mukosaler Impfstoffe - 'MukoVak',281182,2015-10-01,2015.0,2017-12-31,2017,CureVac (Germany),grid.476259.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7993361,031A397,GO-Bio 4B: Imevax - Neue Impfstoffe gegen Erreger chronischer Infektionen,6792983,2014-09-01,2014.0,2018-06-30,2018,,,,Federal Ministry of Education and Research,Germany,14,0,0
grant.7992821,031A115B,ERA Net EuroTransBIO-5: Neue DC-basierte Vakzine gegen Brustkrebs (PDC-VAC),38579,2012-10-01,2012.0,2015-05-31,2015,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992820,031A115A,ERA Net EuroTransBIO-5: Neue DC-basierte Vakzine gegen Brustkrebs (PDC-Vac),696583,2012-10-01,2012.0,2014-12-31,2014,Center for Experimental and Clinical Infection Research,grid.452370.7,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992218,0319220B/0,"Verbundprojekt: Prüfprogramm eines Synthetischen, veterinärmedizinisch Einsetzbaren Peptid-Impfstoffes",71909,1988-04-01,1988.0,1989-06-30,1989,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992040,0318913A/7,Arbeiten zur Entwicklung einer Vaccine und Immuntherapie Gegen AIDS,775776,1986-09-01,1986.0,1989-08-31,1989,Sanofi (Germany),grid.420214.1,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7991987,0318836A/9,Gentechnologische Gewinnung von AIDS-Antigenen - neue Wege zur AIDS-Diagnostik und zur Impfstoffentwicklung,549251,1986-08-01,1986.0,1989-07-31,1989,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7990907,0315974,GO-Bio 4: Entwicklung neuer Impfstoffe gegen Erreger chronischer und nosokomialer Infektionen,5681136,2011-08-01,2011.0,2014-08-31,2014,Technical University Munich,grid.6936.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7990549,0315802,KMU-innovativ-5: Entwicklung einer panspezifischen RNA Vakzine gegen Influenza A - FluVac,897548,2010-03-01,2010.0,2012-02-29,2012,CureVac (Germany),grid.476259.b,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7990456,0315723,ERA-Net EuroTransBIO-4: Entwicklung eines DNA-Impfstoffes gegen Hepatitis B.,373761,2010-01-01,2010.0,2012-12-31,2012,Mologen (Germany),grid.476508.8,Germany,Federal Ministry of Education and Research,Germany,2,0,0
grant.7990362,0315640E,"Verbundprojekt: Optimierung der industriellen zellkulturbasierten Herstellung von Influenza Vakzinen, TP: 5",91725,2013-07-01,2013.0,2016-12-31,2016,IDT Biologika (Germany),grid.498615.7,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7990358,0315640A,"Verbundprojekt: Optimierung der industriellen zellkulturbasierten Herstellung von Influenza Vakzinen, TP 1",786127,2013-07-01,2013.0,2016-12-31,2016,Sartorius (Germany),grid.425849.6,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7990357,0315640,Go-Bio 1B: Pharmakologisch optimierte Ribonukleinsäuren als rekombinante Impfstoffe und Immunadjuvantien,3854579,2010-03-01,2010.0,2013-12-31,2013,BioNTech (Germany),grid.434484.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989450,0315120B,BioChancePLUS-4: Entwicklung eines immunologisch wirksamen therapeutischen Impfstoffs zur Behandlung von Glioblastomen.,123733,2007-08-01,2007.0,2009-06-30,2009,Heidelberg University,grid.7700.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989449,0315120A,BioChancePLUS-4: Entwicklung eines immunologisch wirksamen therapeutischen Impfstoffs zur Behandlung von Glioblastomen,718296,2007-08-01,2007.0,2009-06-30,2009,Immatics Biotechnologies (Germany),grid.434836.e,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7989070,0313886,GO-Bio1: Pharmakologisch optimierte Ribonukleinsäuren als rekombinante Impfstoffe und Immunadjuvantien,1745503,2007-03-01,2007.0,2010-02-28,2010,University Medical Center of the Johannes Gutenberg University Mainz,grid.410607.4,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7988831,0313702,BioChancePLUS: Entwicklung eines Sequenz-stabilisierten RNA-Impfstoffs (RNActiveTM) gegen Krebserkrankungen,324227,2005-09-01,2005.0,2007-08-31,2007,CureVac (Germany),grid.476259.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7988536,0313312,BioChancePLUS: Neuartige Verfahren zur Entwicklung verbesserter Lebendimpfstoffe,330698,2004-08-01,2004.0,2006-06-30,2006,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7988249,0313037,Verbundprojekt: BioProfile Braunschweig/Göttingen/Hannover: Entwicklung von bakteriellen Negativmarker-Impfstoffen für landwirtschaftliche Nutztiere,593649,2003-10-01,2003.0,2006-09-30,2006,University of Veterinary Medicine Hanover,grid.412970.9,Germany,Federal Ministry of Education and Research,Germany,3,0,0
grant.7987929,0312589,BioChance: Synthetische Gene: Verbessertes Sicherheits- und Wirksamkeitsprofil von DNA-Impfstoffen und Gentherapie-Vektoren,561875,2001-05-01,2001.0,2004-04-30,2004,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7979234,02PK2178,KMU-innovativ: Entwicklung eines Produktionsverfahrens zur Herstellung stabiler RNA-Impfstoffe (StabiRNA),519040,2011-05-01,2011.0,2013-04-30,2013,CureVac (Germany),grid.476259.b,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7953162,01KV9911/2,Herstellung und Erprobung genmodifizierter Tumorzellvakzine,376405,2000-01-01,2000.0,2004-03-31,2004,Max Delbrück Center for Molecular Medicine,grid.419491.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7953078,01KV9506/2,Herstellung und Erprobung genmodifizierter Tumorzellvakzine,339022,1995-10-01,1995.0,1999-12-31,1999,Max Delbrück Center for Molecular Medicine,grid.419491.0,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7952422,01KI9209/8,Aktive und Passive Immunisierung Gegen Pseudomonas Aeruginosa mit Gentechnisch Gewonnenen Vaccinen,164629,1993-11-01,1993.0,1997-02-28,1997,University of Freiburg,grid.5963.9,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7952403,01KI8910/4,Aktive und Passive Immunisierung Gegen Pseudomonas Aeruginosa mit Gentechnologisch Gewonnenen Vaccinen,394723,1990-01-01,1990.0,1993-10-31,1993,University of Freiburg,grid.5963.9,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7952013,01KI0210,Förderung einer Initiative zur Entwicklung und Verwertung von Impfstoffen,32871900,2002-04-01,2002.0,2011-12-31,2011,Helmholtz Centre for Infection Research,grid.7490.a,Germany,Federal Ministry of Education and Research,Germany,3,0,0
grant.7942597,01GU1103B,"Verbundprojekt: Individualisierte Tumorimpfstoffe - Individualized Vaccines for Cancer (IVAC), Teilprojekt (TP) 2",544826,2012-02-01,2012.0,2015-01-31,2015,BioNTech (Germany),grid.434484.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7942596,01GU1103A,"Verbundprojekt: Individualisierte Tumorimpfstoffe - Individualized Vaccines for Cancer (IVAC), Teilprojekt (TP) 1",1039442,2012-02-01,2012.0,2015-01-31,2015,University Medical Center of the Johannes Gutenberg University Mainz,grid.410607.4,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7940840,01GM0873,Verbundprojekt Translationales Sarkom-Netzwerk (TranSaRNet): Verbesserung der Tumorvakzine-Therapie,210836,2009-02-01,2009.0,2012-01-31,2012,Heinrich Heine University Düsseldorf,grid.411327.2,Germany,Federal Ministry of Education and Research,Germany,3,0,0
grant.7939785,01GE9913,Verbundprojekt: Entwicklung einer RNA-DC Vakzine im Melanommodell,31240,2000-09-01,2000.0,2002-12-31,2002,University Medical Center of the Johannes Gutenberg University Mainz,grid.410607.4,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7934359,01DN12004,Entwicklung und Validierung von prophylaktischen und therapeutischen Impfstoffkandidaten gegen die Chagas Krankheit,14023,2012-01-01,2012.0,2013-03-31,2013,Helmholtz Centre for Infection Research,grid.7490.a,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7933704,01DJ11003,"ERA-Net: Selbst-replizierender RNA-Impfstoff gegen Hepatitis C Genotyp 2, zielgerichtet auf dendritische Zellen",120251,2012-01-01,2012.0,2014-03-31,2014,Helmholtz Centre for Infection Research,grid.7490.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7917520,,Does a Customized Website Affect HPV Vaccine Use among Latino Adolescents and Young Adults?,1575648,2012-01-01,2012.0,2017-11-30,2017,,,,Patient-Centered Outcomes Research Institute,United States,0,0,0
grant.7915417,LY14H160013,肿瘤微环境中EPCs裂解物致敏的DC疫苗抗肿瘤血管生成的研究,0,2014-01-01,2014.0,2018-12-31,2018,Zhejiang Cancer Hospital,grid.417397.f,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.7915152,LY13C080001,携带登革病毒CTL表位的嵌合VLP疫苗的构建及免疫效应研究,0,2013-01-01,2013.0,2018-12-31,2018,Wenzhou Medical University,grid.268099.c,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.7850866,SERB_21ad732498,Animal Challenge study of novel shigella vaccine antigens common to multiple serotypes,45224,2017-04-01,2017.0,2018-03-31,2018,,,,Science and Engineering Research Board,India,0,0,0
grant.7821641,K96010,Mucin-Based Breast Tumor Vaccine-Can Help Be Generated Where Help is Needed?,105000,1996-05-01,1996.0,1999-04-30,1999,,,,Susan G. Komen Breast Cancer Foundation,United States,0,0,0
grant.7821008,BCTR9825,Development of a Novel Vaccine with Fusions of Human Dendritic and Breast Cancer Cells,200000,1998-05-01,1998.0,2001-04-30,2001,Dana-Farber Cancer Institute,grid.65499.37,United States,Susan G. Komen Breast Cancer Foundation,United States,0,0,0
grant.7821001,BCTR9640,Development of Human Dendritic Cell Vaccines for Treatment of Breast Cancer,150000,1996-05-01,1996.0,1999-04-30,1999,University of Pennsylvania,grid.25879.31,United States,Susan G. Komen Breast Cancer Foundation,United States,0,0,0
grant.7820997,BCTR2000 440 AFF,DNA-Based Vaccine for Treatment of Breast Cancer,40000,2001-08-06,2001.0,2003-03-31,2003,University of Illinois at Chicago,grid.185648.6,United States,Susan G. Komen Breast Cancer Foundation,United States,0,0,0
grant.7743584,,Dansk titel: En plante-produceret vaccine mod grise PRRS,2387117,2014-01-01,2014.0,2018-12-31,2018,,,,Danish Ministry of Higher Education and Science,Denmark,0,0,0
grant.7742854,,Dansk titel: Produktion af allergivacciner målrettet mod antigen præsenterende celler,2204022,2013-01-01,2013.0,2016-01-01,2016,University of Copenhagen,grid.5254.6,Denmark,Danish Ministry of Higher Education and Science,Denmark,0,0,0
grant.7736921,DST_4f921659da,"Probiotics For Food Preservation, Functional Foods As Vaccine And Vector For Delivery Systems",8388,2005-04-01,2005.0,2008-04-01,2008,Central Food Technological Research Institute,grid.417629.f,India,Department of Science and Technology,India,0,0,0
grant.7723182,619383,"NSERC/Sanofi Industrial Research Chair in vaccine mathematics, modelling and manufacturing",154056,2017-04-01,2017.0,2018-03-31,2018,York University,grid.21100.32,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7721815,627305,Vaccine-induced protection against bacterial infections in Arctic charr (Salvelinus alpinus),13477,2017-04-01,2017.0,2018-03-31,2018,University of Prince Edward Island,grid.139596.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7717098,622588,Bilan de masse permettant le développement de nouveaux vaccins et anticorps à base de plantes,3030,2017-04-01,2017.0,2018-03-31,2018,SNC-Lavalin (Canada),grid.410465.2,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7716935,622425,Interactions Between Vaccines and Excipients Affecting Thermal Stability After Spray-Drying,13477,2017-04-01,2017.0,2018-03-31,2018,McMaster University,grid.25073.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7715161,620574,Development of Orf virus (ORFV) as a multivalent vaccine vector platform against Toxoplasma gondii,26956,2017-04-01,2017.0,2018-03-31,2018,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7698924,,Characterization of Rotavirus Strains and Development of Candidate Vaccine Derived From Children With Diarrhea.,0,2012-10-01,2012.0,2013-10-01,2013,Centers for Disease Control and Prevention; National Research Centre,grid.416738.f; grid.419725.c,United States; Egypt,Council for International Exchange of Scholars,United States,0,0,0
grant.7697763,,Development of Dendritic Cell-Based Vaccines With Osteotropism for Treatment of Bone Metastasis,0,2013-01-01,2013.0,2013-06-01,2013,Harvard University; Universidade Nova de Lisboa,grid.38142.3c; grid.10772.33,United States; Portugal,Council for International Exchange of Scholars,United States,0,0,0
grant.7695709,,Characterization and Development of CELiD for Gene Transfer and DNA Vaccine Purposes,0,2015-08-01,2015.0,2016-07-01,2016,University of Massachusetts Medical School; University of Eastern Finland,grid.168645.8; grid.9668.1,United States; Finland,Council for International Exchange of Scholars,United States,0,0,0
grant.7694896,,Identification and Development of Potential Subunit Vaccine Candidates Against Leptospirosis,0,2013-01-01,2013.0,2014-01-01,2014,Cornell University; Kasetsart University,grid.5386.8; grid.9723.f,United States; Thailand,Council for International Exchange of Scholars,United States,0,0,0
grant.7694534,,Immunomodulation of Neu5Gc Glycopeptides with Biomaterials: A Potential Vaccine Platform.,0,2017-10-01,2017.0,2018-06-01,2018,"University of California, San Diego; Indian Institute of Science Education and Research Pune",grid.266100.3; grid.417959.7,United States; India,Council for International Exchange of Scholars,United States,0,0,0
grant.7694487,,Programming Protective Efficacy of BCG-Vaccine Using Novel TLRs Adjuvant Nano-Formulations,0,2016-11-01,2016.0,2017-07-01,2017,Cornell University; University of Hyderabad,grid.5386.8; grid.18048.35,United States; India,Council for International Exchange of Scholars,United States,0,0,0
grant.7687875,,Animal Model Malaria: Its Application to Preclinical Trials of Adenoviral Anti-Malaria Vaccine,0,2007-09-01,2007.0,2008-05-01,2008,"University of Pittsburgh; University of Pittsburgh; University of Nigeria, Nsukka",grid.21925.3d; grid.21925.3d; grid.10757.34,United States; United States; Nigeria,Council for International Exchange of Scholars,United States,0,0,0
grant.7686772,,Designing an Effective T-Cell Vaccine for Rheumatic Fever and Rheumatic Heart Disease,0,2009-01-01,2009.0,2009-09-01,2009,University of Cincinnati; University of Cincinnati; City of Scientific Research and Technological Applications,grid.24827.3b; grid.24827.3b; grid.420020.4,United States; United States; Egypt,Council for International Exchange of Scholars,United States,0,0,0
grant.7686658,,Development of Therapeutic Vaccine Against Bovine Papilloma Virus Induced Equine Sarcoids,0,2008-10-01,2008.0,2009-09-01,2009,University of Southern California; University of Southern California; Ghent University,grid.42505.36; grid.42505.36; grid.5342.0,United States; United States; Belgium,Council for International Exchange of Scholars,United States,0,0,0
grant.7686599,,Control of Contagious Bovine Pleuropneumonia: The Need for Vaccine Development,0,2008-09-01,2008.0,2009-05-01,2009,Iowa State University; Iowa State University; University of Ibadan,grid.34421.30; grid.34421.30; grid.9582.6,United States; United States; Nigeria,Council for International Exchange of Scholars,United States,0,0,0
grant.7670238,03/IN3/B364ur07,Analysis of the immune response in mice to Semliki Forest-based vaccine vectors,8757,2007-05-08,2007.0,2007-07-31,2007,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7669718,08/RFP/BMT1363s1,Harnessing the immunostimluatory activity of chitosan to produce potent vaccine adjuvants,26734,2008-11-01,2008.0,2011-08-18,2011,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7668452,15/TIDA/2918,Validation of lipoproteins/lipopeptides as adjuvants and antigens for a new pertussis vaccine,143822,2016-01-01,2016.0,2016-12-31,2016,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7667057,,Recombinant human papillomavirus 16 vaccine against cervical cancer in women,118381,2000-04-01,2000.0,2003-03-31,2003,Centre Hospitalier Universitaire Sainte-Justine,grid.411418.9,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7666943,,Immunogenecity and functional analysis of an amoebic vaccine candidate,75264,1996-09-01,1996.0,2001-08-31,2001,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665268,,Leishmania vaccine development II: Transition from in vitro studies to clinical trials,140407,1999-10-01,1999.0,2003-03-31,2003,University of Ottawa,grid.28046.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665027,,A Nano-on-micro Delivery System for a Vaccine/Adjuvant againts Helicobacter pylori,407088,2014-04-01,2014.0,2017-03-31,2017,Western University,grid.39381.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7658619,,Canadian network for vaccines and immunotherapeutics of cancer and chronic viral diseases (CANVAC),8135774,2003-04-01,2003.0,2006-03-31,2006,University of Montreal,grid.14848.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7658608,,Immune correlates of protection in SIV and HIV vaccine development,116837,1999-10-01,1999.0,2002-09-30,2002,University of Montreal,grid.14848.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7658433,,Antibody libraries for discovering vaccine leads against HIV-1,52134,2001-09-01,2001.0,2002-09-30,2002,Simon Fraser University,grid.61971.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7658042,,Initiative to develop a Canada-wide vaccine epidemiology and clinical trials consortium,26446,2000-01-01,2000.0,2000-03-31,2000,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7654329,,Developing novel vaccines for respiratory syncytial virus and parainfluenza virus type 3,395105,2014-04-01,2014.0,2017-03-31,2017,University of Saskatchewan,grid.25152.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7652669,,Novel molecular approaches for the development of live vaccines against leishmaniasis,13261,1996-10-01,1996.0,1999-09-30,1999,Laval University,grid.23856.3a,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7647878,,Nanoparticle delivery of cancer vaccines and immunomodulators for overcoming immunosuppression,36949,2005-10-01,2005.0,2007-09-30,2007,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7646358,,MHC supertypes and epitope-based HIV-1 vaccine design,291086,2003-04-01,2003.0,2006-03-31,2006,Sinai Health System,grid.492573.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7646357,,MHC supertypes and epitopes-based HIV-1 vaccine design,30684,1998-10-01,1998.0,2002-03-31,2002,Sinai Health System,grid.492573.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7642061,,Development of a neonatal pertussis vaccine: One shot for life,34445,2007-11-01,2007.0,2008-10-31,2008,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7632456,,Development of a vaccine for Chlamydia pneumoniae infection in a rabbit model,13762,1997-12-01,1997.0,1999-11-30,1999,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.7626776,,HIV therapy trials:  Assessment of antiretroviral drug treatments and vaccine development,31616,2001-07-01,2001.0,2002-06-30,2002,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7625380,,Topical toll-like receptor activation for optimization of vaccine immune responses,16338,2007-09-01,2007.0,2008-08-31,2008,British Columbia Children's Hospital,grid.414137.4,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7625186,,Analysis of genetic variations between strains of the Bacille Calmette-Guerin vaccine.,100615,2002-01-01,2002.0,2007-12-31,2007,McGill University,grid.14709.3b,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7623484,,Targeted cancer vaccines: Synthesis and evaluation of clustered cancer associated carbohydrate antigens,225876,2001-04-01,2001.0,2004-03-31,2004,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7623431,,Generation of a novel therapeutic dendritic cell- based HIV vaccine,15330,2009-09-01,2009.0,2010-08-31,2010,Western University,grid.39381.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7618679,,Innovative vaccine development and delivery to induce mucosal immunity,1418041,2002-01-01,2002.0,2006-12-31,2006,University of Saskatchewan,grid.25152.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7618672,,Linking Innate and Specific Immunity to Develop Single Dose Vaccine for Neonates,1266966,2005-07-01,2005.0,2010-06-30,2010,University of Saskatchewan,grid.25152.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7606416,SERB_120c3f8827,Development of oral parvo virus vaccine combined with probiotics as spray,59322,2016-04-01,2016.0,2017-03-31,2017,,,,Science and Engineering Research Board,India,0,0,0
grant.7594392,,Do Pentavalent vaccines have sex-differential non-specific effects?,22798,2018-01-01,2018.0,2018-12-31,2018,State Serum Institute,grid.6203.7,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7578413,,Elucidating the therapeutic potential of plasmacytoid dendritic cells in cell-based vaccines.,410418,2018-01-01,2018.0,2018-12-31,2018,Aarhus University,grid.7048.b,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7575561,210872,Centre de recherche en infectiologie porcine et avicole (CRIPA),11370,2016-04-01,2016.0,2017-03-31,2017,University of Montreal,grid.14848.31,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.7550363,0083,Phase I/II clinical trial of DNA idiotype vaccines in untreated stage A CLL,86733,2001-04-18,2001.0,2003-04-17,2003,University of Southampton,grid.5491.9,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.7549515,8529,Analysis of molecules important for vaccine protection against EBV infection,36257,1986-04-01,1986.0,1989-03-31,1989,St Michael's Hospital,grid.416544.6,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.7549488,8501,Analysis of molecules important for vaccine protection against EBV infection,2500,1985-04-01,1985.0,1986-03-31,1986,St Michael's Hospital,grid.416544.6,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.7545804,18H00459,単球の接着機構の解明および樹状細胞療法ワクチン製造技術への応用,4818,2018-04-01,2018.0,2019-03-31,2019,Shinshu University,grid.263518.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.7502338,2015R1D1A1A01060327,혐기적조건에서 배양된 신개념의 콜레라 백신 개발 및 효능평가,0,2015-01-01,2015.0,2016-01-01,2016,International Vaccine Institute,grid.30311.30,South Korea,National Research Foundation of Korea,South Korea,4,0,0
grant.7501589,2015R1D1A1A02061577,나노 기반 Bioparticle의 신개념 백신 전달체 개발 및 방어 면역 연구,0,2015-01-01,2015.0,2016-01-01,2016,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,6,0,0
grant.7498870,2015M3A9B5030157,인유두종바이러스 10가 백신의 면역학적 기전 및 분석법 개발,0,2015-01-01,2015.0,2016-01-01,2016,Catholic University of Korea,grid.411947.e,South Korea,National Research Foundation of Korea,South Korea,7,0,0
grant.7497586,2015R1A2A1A14001011,신개념 delivery system과 Secretory 발현 vector를 이용한 감염병예방용 백신개발,0,2015-01-01,2015.0,2016-01-01,2016,Chonbuk National University,grid.411545.0,South Korea,National Research Foundation of Korea,South Korea,27,0,0
grant.7496354,2015R1A2A1A16074914,바이러스 질병 예방과 치료를 위한 차세대 유니버설 백신개발,0,2015-01-01,2015.0,2016-01-01,2016,Korea University,grid.222754.4,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7496127,2015R1A2A2A01007209,TM4SF5를 표적으로 하는 췌장암 예방 및 치료백신의 효능 및 작용기전 규명,0,2015-01-01,2015.0,2016-01-01,2016,Chungbuk National University,grid.254229.a,South Korea,National Research Foundation of Korea,South Korea,6,0,0
grant.7496124,2015R1A2A2A01007297,콜레라 독소바이러스 CTX phage의 진화와 콜레라 백신 디자인에 관한 연구,0,2015-01-01,2015.0,2016-01-01,2016,Hanyang University,grid.49606.3d,South Korea,National Research Foundation of Korea,South Korea,6,0,0
grant.7493180,2015H1A2A1029732,"분해성 고분자 PLGA를 이용한 어류 백신의 약리적, 면역학적 평가",0,2015-01-01,2015.0,2016-01-01,2016,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,3,0,0
grant.7492793,2014K1A3A9A01033755,네팔 고산지역 신재생 에너지원을 이용한 원거리 백신 전달 시스템의 구축,0,2014-01-01,2014.0,2015-01-01,2015,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,3,0,0
grant.7492787,2014K1B1A1073861,면역원성이 강화된 항원을 이용한 뎅기 바이러스 방어용 경구백신 기술 연구,0,2014-01-01,2014.0,2015-01-01,2015,Chonbuk National University,grid.411545.0,South Korea,National Research Foundation of Korea,South Korea,12,0,0
grant.7491681,2014M3A9E4064580,감염성 질환 예방 백신의 마이크로니들 기반 패치로의 응용 및 실용화 연구,0,2014-01-01,2014.0,2015-01-01,2015,Korea Advanced Institute of Science and Technology,grid.37172.30,South Korea,National Research Foundation of Korea,South Korea,28,0,0
grant.7491122,2014R1A1A1004469,악성뇌종양에서 Branched multipeptide vaccine의 활성기전 연구 및 응용,0,2014-01-01,2014.0,2015-01-01,2015,Chonnam National University,grid.14005.30,South Korea,National Research Foundation of Korea,South Korea,7,0,0
grant.7490400,2014R1A1A2055842,난치성암 치료용 면역세포 백신 개발을 위한 종양 면역학적 연구,0,2014-01-01,2014.0,2015-01-01,2015,,,,National Research Foundation of Korea,South Korea,1,0,0
grant.7490008,2014R1A1A2055172,결핵만성감염 특이항원을 이용한 결핵예방백신 개발,0,2014-01-01,2014.0,2015-01-01,2015,Yonsei University,grid.15444.30,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7488330,2013R1A1A2013297,아메바성 수막뇌염 백신을 위한 특이 유전자 및 벡터 시스템 개발,0,2013-01-01,2013.0,2014-01-01,2014,Gyeongsang National University,grid.256681.e,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7487607,2013R1A2A2A01004355,백신 플랫폼 적용을 위한 돼지 파라인플루엔자 바이러스 기반 벡터 개발,0,2013-01-01,2013.0,2014-01-01,2014,Kyungpook National University,grid.258803.4,South Korea,National Research Foundation of Korea,South Korea,5,0,0
grant.7483093,2012S1A5B5A07037869,한일 여류작가의   비교연구  -히라바야시 다이코와 백신애 을 중심으로,0,2012-01-01,2012.0,2013-01-01,2013,Ewha Womans University,grid.255649.9,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7482716,2013R1A1A2073197,체적변동측정장치 기반 비주사형 백신전달 원천기술개발,0,2013-01-01,2013.0,2014-01-01,2014,Sungshin Women's University,grid.264383.8,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7480563,2013K1A3A1A25038276,나노백신: 항원 특이 면역반응 증진을 위한 새로운 전략,0,2013-01-01,2013.0,2014-01-01,2014,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7479983,2013R1A1A2064735,프로테오믹스와 DNA 백신기술을 이용한 효과적인 돌돔 이리도바이러스 항원 탐색,0,2013-01-01,2013.0,2014-01-01,2014,Jeju National University,grid.411277.6,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7479288,2013R1A1A1062435,면역조절분자를 발현하는 바이러스 유사입자 기반 백신 플랫폼 개발,0,2013-01-01,2013.0,2014-01-01,2014,Sungshin Women's University,grid.264383.8,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7477822,2012R1A1A2038430,종양치료백신 및 유전자/항체/단백질 치료제의 복합 항종양치료효과 규명,0,2012-01-01,2012.0,2013-01-01,2013,Kangwon National University,grid.412010.6,South Korea,National Research Foundation of Korea,South Korea,5,0,0
grant.7477815,2012R1A1A2005675,폐구균 협막 다당체의 생합성 기전을 이용한 협막 다당 백신 유도체 개발,0,2012-01-01,2012.0,2013-01-01,2013,Ewha Womans University,grid.255649.9,South Korea,National Research Foundation of Korea,South Korea,4,0,0
grant.7477713,2012R1A1A2021731,조직이식시 면역거부반응을 억제하기 위한 수지상 세포 백신제작,0,2012-01-01,2012.0,2013-01-01,2013,Seoul National University Bundang Hospital,grid.412480.b,South Korea,National Research Foundation of Korea,South Korea,2,0,0
grant.7476579,2014R1A1A3049897,백신 효능 증가를 위해 CD8+ T 세포 에피토프의 우선 순위를 신생아 마우스와 성체 마우스에서 비교 연구,0,2014-01-01,2014.0,2015-01-01,2015,International Vaccine Institute,grid.30311.30,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7475646,2014R1A2A2A01004899,바이러스 유사입자를 이용하여 호흡기 세포융합 바이러스 백신 개발을 위한 근간 연구,0,2014-01-01,2014.0,2015-01-01,2015,Kyung Hee University,grid.289247.2,South Korea,National Research Foundation of Korea,South Korea,14,0,0
grant.7475018,2014R1A2A1A10049622,폴리감마글루탐산 나노 아쥬번트 소재를 이용한 인플루엔자 대유행 대응 백신 연구,0,2014-01-01,2014.0,2015-01-01,2015,Korea Research Institute of Bioscience and Biotechnology,grid.249967.7,South Korea,National Research Foundation of Korea,South Korea,3,0,0
grant.7473902,2013R1A6A3A01018510,메커니즘 기반 독감바이러스 약독화 생백신 개발에 관한 연구,0,2013-01-01,2013.0,2014-01-01,2014,Yonsei University,grid.15444.30,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7473160,2013R1A6A3A01023678,항원보조제(adjuvant)로서 나노백신전달시스템의 기전 및 효능 연구,0,2013-01-01,2013.0,2014-01-01,2014,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7472051,2013R1A1A2060008,설하접종에 의한 RSV 백신 유도 호산구증의 발생기전 연구,0,2013-01-01,2013.0,2014-01-01,2014,Ewha Womans University,grid.255649.9,South Korea,National Research Foundation of Korea,South Korea,3,0,0
grant.7470759,2013R1A1A2063064,합성 결핵단백을 이용한 항결핵 면역기작 분석과 백신 개발,0,2013-01-01,2013.0,2014-01-01,2014,Chungnam National University,grid.254230.2,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7466607,2012H1B8A2025495,암/정소 항원 CAGE 단백질을 이용한 항암 백신 개발에 관한 연구,0,2012-01-01,2012.0,2013-01-01,2013,Kangwon National University,grid.412010.6,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7466586,2012H1A8003044,박테리아 원형질체 유래 나노소포체를 이용한 패혈증 및 암백신 개발과 면역학적 기작 연구,0,2012-01-01,2012.0,2013-01-01,2013,Pohang University of Science and Technology,grid.49100.3c,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7466408,2012R1A1A4A01015303,새로운 약독화변이주를 이용한 소 브루셀라병 예방용 생균 백신주 개발,0,2012-01-01,2012.0,2013-01-01,2013,Kangwon National University,grid.412010.6,South Korea,National Research Foundation of Korea,South Korea,4,0,0
grant.7461778,2011-0022798,개 인플루엔자 바이러스의 면역병리 기전 연구 및 백신 개발,0,2011-01-01,2011.0,2012-01-01,2012,Konkuk University,grid.258676.8,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7460590,2011-0001808,한국의 알러젠을 이용한 재조합 알러지 백신 개발,0,2010-01-01,2010.0,2011-01-01,2011,Daejeon University,grid.411948.1,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7457969,351-2009-2-F00047,양식어류의 비브리오증에 대한 재조합 cadaver 백신 개발,0,2009-01-01,2009.0,2010-01-01,2010,Pukyong National University,grid.412576.3,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7456810,2010-0022232,항우식 백신으로서 S. mutans에 대한 단일항체의 효과,0,2010-01-01,2010.0,2011-01-01,2011,Chonbuk National University,grid.411545.0,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7455882,2010-0029917,B 세포를 항원 제시세포로 활용한 자궁경부암 치료백신 개발 기획,0,2010-01-01,2010.0,2011-01-01,2011,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7454862,2011-0024912,신재조합 벡터 시스템을 적용한 노로바이러스 백신개발에 관한 연구,0,2011-01-01,2011.0,2012-01-01,2012,Mokwon University,grid.411817.a,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7453221,2009-0089873,식중독 발생감소를 위한 Salmonella Typhimurium의 예방 백신 개발,0,2009-01-01,2009.0,2010-01-01,2010,Kangwon National University,grid.412010.6,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7452629,2010-0002810,차세대 백신개발을 위한 수지상세포 subset targeting strategy와 면역제어 메카니즘 연구,0,2010-01-01,2010.0,2011-01-01,2011,Ulsan National Institute of Science and Technology,grid.42687.3f,South Korea,National Research Foundation of Korea,South Korea,2,0,0
grant.7452447,2010-0008060,종양치료용 유전자백신의 개발 및 치료기전 규명,0,2010-01-01,2010.0,2011-01-01,2011,Kangwon National University,grid.412010.6,South Korea,National Research Foundation of Korea,South Korea,3,0,0
grant.7448161,2009-0076413,Streptococcus parauberis 병원성관련 세포 표면 fibronectin-binding adhesins의 기능해석 및 vaccine 개발,0,2009-01-01,2009.0,2010-01-01,2010,Chonnam National University,grid.14005.30,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7446869,2010-00159,고병원성 W-Beijing 결핵균주를 이용한 결핵예방백신후보들의 예방효과평가,0,2010-01-01,2010.0,2011-01-01,2011,Sun Moon University,grid.412859.3,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7446551,2009-0078785,첨단 유전공학기법을 이용한 살모넬라 백신의 개발 및 효능연구,0,2009-01-01,2009.0,2010-01-01,2010,Chonbuk National University,grid.411545.0,South Korea,National Research Foundation of Korea,South Korea,3,0,0
grant.7446325,2011-0029000,사육온도관리에 의한 어류 바이러스의 병독성 제어와 생백신 개발,0,2011-01-01,2011.0,2012-01-01,2012,Chonnam National University,grid.14005.30,South Korea,National Research Foundation of Korea,South Korea,5,0,0
grant.7445767,2009-0080246,노로바이러스 VLPs 및 synthetic peptides를 이용한 감염 및 백신 연구,0,2009-01-01,2009.0,2010-01-01,2010,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7437134,762209,Role of the PD-1/PD-L pathway in HIV-1 vaccine design,121627,2009-04-01,2009.0,2012-11-30,2012,University of Hong Kong,grid.194645.b,China,University Grants Committee,China,5,0,0
grant.7389994,OPP1178691,To convene global experts to address RSV vaccine research and development issues,113300,2017-08-01,2017.0,2018-03-01,2018,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7174252,2003171,Novel Idiotype-Based Genetic Vaccines for the Treatment of Lymphoid Malignancies,120540,2003-01-01,2003.0,2007-01-01,2007,Tel Hai Academic College; Stanford University; Tel Hai Academic College,grid.443193.8; grid.168010.e; grid.443193.8,Israel; United States; Israel,United States-Israel Binational Science Foundation,Israel,0,0,0
grant.7167621,AF/045/96,Manufacturing Technology Centre for Human Vaccines and Pharmaceuticals,4684442,1996-01-01,1996.0,1999-01-30,1999,Hong Kong Institute of Biotechnology,grid.493670.f,China,Innovation and Technology Commission,China,0,0,0
grant.7167575,AF/072/96,Development of DNA Vaccine Biotechnology in Hong Kong,386100,1996-01-01,1996.0,2000-01-30,2000,University of Hong Kong,grid.194645.b,China,Innovation and Technology Commission,China,0,0,0
grant.7167421,AF/023/98,IND Filing and Phase I Clinical Trial of a Malaria Vaccine TBV25H,743073,1998-01-01,1998.0,2000-01-30,2000,Hong Kong Institute of Biotechnology,grid.493670.f,China,Innovation and Technology Commission,China,0,0,0
grant.7164928,InP/146/14,Liver Cancer Vaccine Development:- Cell Culture Scale-Up Prototype Production Prior IND Application,40362,2014-01-25,2014.0,2016-01-24,2016,Hong Kong Institute of Biotechnology,grid.493670.f,China,Innovation and Technology Commission,China,0,0,0
grant.7164864,InP/195/14,Liver Cancer Vaccine Development:- Cell Culture Scale-Up Prototype Production Prior IND Application,40620,2014-01-25,2014.0,2016-01-31,2016,Hong Kong Institute of Biotechnology,grid.493670.f,China,Innovation and Technology Commission,China,0,0,0
grant.7162955,ITS/173/08,Development of Novel Second Generation Broad-spectrum hTERTC27-based Therapeutic Tumor Vaccine,124074,2008-01-01,2008.0,2010-01-31,2010,University of Hong Kong; University of Hong Kong,grid.194645.b; grid.194645.b,China; China,Innovation and Technology Commission,China,0,0,0
grant.7162624,ITS/360/13FX,Liver Cancer Vaccine Development:- Cell Culture Scale-Up Prototype Production Prior IND Application,128841,2014-01-02,2014.0,2016-01-01,2016,Hong Kong Institute of Biotechnology,grid.493670.f,China,Innovation and Technology Commission,China,0,0,0
grant.7161695,UIM/182,Development of HPV Therapeutic Vaccine and Related Immunotherapy for Treating Cervical Cancer,202342,2008-01-15,2008.0,2010-01-14,2010,Chinese University of Hong Kong; Chinese University of Hong Kong,grid.10784.3a; grid.10784.3a,China; China,Innovation and Technology Commission,China,0,0,0
grant.7161678,UIM/191,Development of Recombinant Vaccine Candidates for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV),177902,2009-01-01,2009.0,2012-01-31,2012,Hong Kong University of Science and Technology; Hong Kong University of Science and Technology,grid.24515.37; grid.24515.37,China; China,Innovation and Technology Commission,China,0,0,0
grant.7150246,,Generation of an adenovirus-based vaccine against infection with cytomegalovirus,446022,2013-01-01,2013.0,2013-12-31,2013,University of Copenhagen,grid.5254.6,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7150219,,The effect of early measles vaccine on pneumococcal carriage,38448,2013-01-01,2013.0,2013-12-31,2013,State Serum Institute,grid.6203.7,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7149996,,"LOW-TOX: Enabling Highly Efficient, Low-Toxicity Fish Vaccines",629535,2014-01-01,2014.0,2014-12-31,2014,University of Copenhagen,grid.5254.6,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7149920,,Accelerating development of vaccines against cancer with pigs as a large animal model (CANVACPIG),1007992,2014-01-01,2014.0,2014-12-31,2014,Technical University of Denmark,grid.5170.3,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7149707,,Structure-based design of a vaccine to prevent severe childhood malaria,1251342,2014-01-01,2014.0,2014-12-31,2014,University of Copenhagen,grid.5254.6,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7149706,,The cellular immunogenicity of HPV-vaccines in adults with HIV infection,22020,2014-01-01,2014.0,2014-12-31,2014,Aarhus University Hospital,grid.154185.c,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7149341,,Vaccine induced T cell responses at respiratory surfaces – the requirement for long-term protection,376648,2015-01-01,2015.0,2015-12-31,2015,University of Copenhagen,grid.5254.6,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7148379,,Developing a therapeutic TB vaccine through molecular design and immunization route,372787,2017-01-01,2017.0,2017-12-31,2017,State Serum Institute,grid.6203.7,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7148301,,Design of a microfluidics method for preparation of the liposomal vaccine adjuvant CAF09,205046,2017-01-01,2017.0,2017-12-31,2017,State Serum Institute,grid.6203.7,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7132364,W81XWH-11-2-0184,Malaria Vaccine Development: Protecting Our Troops,3495000,2009-10-01,2009.0,2010-09-01,2010,Center for Infectious Disease Research,grid.53964.3d,United States,Congressionally Directed Medical Research Programs,United States,6,0,0
grant.7132354,W81XWH-10-1-0377,Tulane/Xavier Vaccine Peptide Program,1328340,2008-10-01,2008.0,2009-09-01,2009,Tulane University,grid.265219.b,United States,Congressionally Directed Medical Research Programs,United States,8,1,0
grant.7132057,W81XWH-07-1-0136,Tulane/Xavier Vaccine Development/Engineering Project,1788000,2005-10-01,2005.0,2006-09-01,2006,Tulane University,grid.265219.b,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7092364,462,DNA Vaccine-Mediated Immunotherapy for an Animal Model for Rheumatois Arthritis,70000,2001-07-01,2001.0,2003-06-30,2003,Stanford University,grid.168010.e,United States,Arthritis Foundation,United States,0,0,0
grant.7092356,1764,Reverse Genomics: Portin Microarrays to Guide Tolerizing DNA Vaccine Treatment of Rheumatoid Arthritis,375000,2003-10-01,2003.0,2008-10-01,2008,Stanford University,grid.168010.e,United States,Arthritis Foundation,United States,0,0,0
grant.7092198,1638,Outer Surface Protein (Osp) C Vaccine for Lyme Disease,74767,1995-07-01,1995.0,1998-07-01,1998,University of Connecticut,grid.63054.34,United States,Arthritis Foundation,United States,0,0,0
grant.7067163,,Pilot Project: Using Parent Preferences in Decisions about Childhood Vaccines,641817,2012-01-01,2012.0,2014-12-31,2014,Kaiser Permanente,grid.280062.e,United States,Patient-Centered Outcomes Research Institute,United States,0,0,0
grant.7043745,VM0119,Evaluation of alternative methods for the detection of porcine cytomegalovirus in veterinary vaccines,79486,1997-04-01,1997.0,1999-03-31,1999,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043744,VM0118,The development of a monoclonal antibodybased ELISA for measuring antibodies to leptospira vaccines,511097,1996-04-01,1996.0,1999-03-31,1999,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043740,VM0114,Validation of tests used in the quality control of vaccines [was VM0107],66051,1995-04-01,1995.0,1996-03-31,1996,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043737,VM0111,Development of in vitro tests for the determination of the potency of Clostridial vaccines,425772,1993-04-01,1993.0,1997-03-31,1997,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043735,VM0109,Evaluation of the immunosuppression test for live infectious bursal disease vaccines,172317,1992-04-01,1992.0,1995-03-31,1995,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043733,VM0107,Validation of tests used in the quality control of vaccines [became VM0114],150186,1992-04-01,1992.0,1995-03-31,1995,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043732,VM0106,Development of methods for detecting retroviruses and other viruses in cell lines and vaccines,105840,1991-04-01,1991.0,1994-03-31,1994,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043729,VM0103,Development of methods for detecting chicken anaemia virus in vaccines,332693,1990-04-01,1990.0,1995-03-31,1995,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043727,VM0101,Development & evaluation of standards to assess QC methods for cat & dog vaccines [became VM0112],351204,1991-04-01,1991.0,1995-03-31,1995,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043100,SE3205,Development of vaccine candidates for protection of badgers against infection with Mycobacterium bovis,409410,1998-04-01,1998.0,1999-03-31,1999,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042971,SE2802,Protective immune responses induced by FMDV vaccine,252737,1993-04-01,1993.0,1996-03-31,1996,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042970,SE2801,Maintenance and quality control of the vaccine bank,416405,1993-04-01,1993.0,1995-03-31,1995,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042592,SE1003,Identification of the origin of footandmouth Disease outbreaks and improved selection methods for vaccines,793905,1991-04-01,1991.0,1994-03-31,1994,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042330,SE0123,Development of vaccines to protect badgers against M. bovis [was part SE0110],420331,1995-04-01,1995.0,1997-03-31,1997,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7040790,OZ0142,Live Salmonella vaccines for the protection of poultry (continuation of OZ0131),194121,1998-04-01,1998.0,1999-03-31,1999,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7034048,AW1138,Development of a vaccine to control the poultry red mite & improve laying hen welfare.,960309,2006-10-01,2006.0,2009-09-30,2009,Moredun Foundation; Scotland's Rural College,grid.420013.4; grid.426884.4,United Kingdom; United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,1,0,0
grant.6967805,605476,Engineering the Surface of Transferrin Binding Protein B for Vaccine,3391,2016-04-01,2016.0,2017-03-31,2017,University of Toronto,grid.17063.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6967534,605204,Mechanism of action of a novel respiratory syncytial virus subunit vaccine formulation.,3391,2016-04-01,2016.0,2017-03-31,2017,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6967408,605078,Application of a new small RNA molecule as a vaccine adjuvant,13200,2016-04-01,2016.0,2017-03-31,2017,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6962426,598873,Effects of sialylated capsular polysaccharides from Streptococci on the immunogenic capacity ofconjugate vaccines,26403,2016-04-01,2016.0,2017-03-31,2017,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6953177,R44AI134267,Development of live attenuated respiratory syncytial virus vaccines with novel thermal stable fusion protein,1563412,2017-07-01,2017.0,2019-07-31,2019,Meissa Vaccines (United States),grid.504806.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6946159,036.001.177,93518024,0,2010-08-27,2010.0,2011-03-31,2011,Utrecht University; Utrecht University,grid.5477.1; grid.5477.1,Netherlands; Netherlands,Netherlands Organisation for Scientific Research,Netherlands,0,0,0
grant.6946050,971520,New Application of a DNA-nanorod Platform for Vaccine Development,507796,2017-04-30,2017.0,2018-03-30,2018,University of Strathclyde,grid.11984.35,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.6945935,971527,"Serological Vaccine Standards for Ebola, Zika and MersCoV",643644,2017-03-31,2017.0,2018-04-29,2018,National Institute for Biological Standards and Control,grid.70909.37,United Kingdom,Innovate UK,United Kingdom,1,0,0
grant.6945300,971518,Development of inducible expression-inactivated Leishmania as vaccine carries,642366,2017-04-30,2017.0,2018-04-29,2018,GeneFirst (United Kingdom),grid.450809.0,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.6945026,971526,Adjuvant free vaccines and companion diagnostics to control emerging flaviviruses,493002,2017-04-30,2017.0,2018-05-30,2018,Liverpool School of Tropical Medicine,grid.48004.38,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.6944786,971525,Using engineered gut bacteria-derived microvesicles for plague vaccines,643391,2017-04-30,2017.0,2018-04-29,2018,University of East Anglia,grid.8273.e,United Kingdom,Innovate UK,United Kingdom,1,0,0
grant.6860319,OPP1164271,To support the pre-clinical development of a measles and rubella vaccine microarray patch,1238633,2017-06-01,2017.0,2019-07-01,2019,Georgia Institute of Technology,grid.213917.f,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6860300,OPP1174698,"This grant will enable vaccine experts from developing countries to participate in the Vaccine Bioprocess and Commercialization three-day workshop in June 2017. The skills learned will improve technology transfer and improve local vaccine development and manufacturing so that vaccines can be provided at an affordable price, which will, in turn, lead to local employment.",30692,2017-05-01,2017.0,2017-07-01,2017,Massachusetts Institute of Technology,grid.116068.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6818448,17F17035,細胞内標的化スマートナノＤＤＳを用いた効率的かつ安全ながんワクチンの開発,20757,2017-04-26,2017.0,2019-03-31,2019,Innovation Center of NanoMedicine,grid.493442.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6734648,1041832,Research fellowship to study HIV vaccines,682359,2013-01-01,2013.0,2017-12-31,2017,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,11,0,0
grant.6731388,890849,Diagnostic probes and vaccines against dysentry due to shigella flexneri,109023,1989-01-01,1989.0,1991-12-31,1991,University of Adelaide,grid.1010.0,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6731147,930146,Will Synthetic T cell determinants be a useful componen t of influenza vaccines?,155631,1993-01-01,1993.0,1995-12-31,1995,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6730760,910523,An animal model to test vaccines against cervical cance r,150234,1991-01-01,1991.0,1993-12-31,1993,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6729550,990144,Genetically disabled murine cytomegalovirus vaccines: efficacy of single-cycle replication mutants,98359,1999-01-01,1999.0,2002-12-31,2002,University of Western Australia,grid.1012.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6728861,900620,Vaccine to be taken by mothers to prevent rotaviral dia rrhoea in children,173588,1990-01-01,1990.0,1992-12-31,1992,University of Adelaide,grid.1010.0,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6728001,607203,Identification of novel stage-specific vaccine candidates for schistosomes using local antibody secreting cell probes,101922,2010-01-01,2010.0,2013-12-31,2013,Monash University,grid.1002.3,Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6725574,402920,A model for evidence based introduction of a new vacine to Australia - human papillomavirus vaccine,34250,2006-01-01,2006.0,2007-12-31,2007,University of Sydney,grid.1013.3,Australia,National Health and Medical Research Council,Australia,6,0,0
grant.6725405,359353,Preparing for group A streptococcal vaccines: epidemiology and immunology of group A streps in Fiji,86172,2005-01-01,2005.0,2010-12-31,2010,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6725179,951076,Studies on a recombinant attenuated salmonella vaccine carrying HIV antigens,106134,1995-01-01,1995.0,1997-12-31,1997,Australian National University,grid.1001.0,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6724329,297110,Evidence-based health policy and modelling research in vaccine preventable diseases,355284,2004-01-01,2004.0,2008-12-31,2008,UNSW Sydney,grid.1005.4,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6724106,290245,Secretory and Surface Proteins of Blood-feeding Helminths: Roles in Parasitism and Effacies as Vaccines,348763,2004-01-01,2004.0,2008-12-31,2008,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6723172,166001,"The epidemiology and economic impact of vaccine preventable, childhood respiratory infections in the community",64748,2001-01-01,2001.0,2010-12-31,2010,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6722974,458780,Immuno-epidemiological studies of vaccine responses in developing world populations,314526,2007-01-01,2007.0,2010-12-31,2010,University of Western Australia,grid.1012.2,Australia,National Health and Medical Research Council,Australia,6,0,0
grant.6722602,410200,Enhancing and evaluating T cell responses to candidate HIV prime-boost vaccines,137939,2006-01-01,2006.0,2008-12-31,2008,Australian National University,grid.1001.0,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6720807,960014,Assessment of a surface component of the malaria parasi te for use in a vaccine,128758,1996-01-01,1996.0,1998-12-31,1998,Monash University,grid.1002.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6720035,880198,Immunisation with an oral vaccine against bronchitis mode of action,56550,1988-01-01,1988.0,1990-12-31,1990,University of Newcastle Australia,grid.266842.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6718348,991266,Phase variation of LPS expression in Neisseria meningitidis; role in pathogenesis and vaccine development.,101151,1999-01-01,1999.0,2001-12-31,2001,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6718034,891025,"Box jellyfish venom toxins: how they act,study of vaccines and specific antitoxin",84345,1989-01-01,1989.0,1991-12-31,1991,Deakin University,grid.1021.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6716733,950887,Devlopment of a vaccine against hookworm infection in d ogs and humans,107886,1995-01-01,1995.0,1997-12-31,1997,,,,National Health and Medical Research Council,Australia,1,0,0
grant.6716718,964161,Testing vaccine to prevent pneumonia in high risk child ren,139249,1996-01-01,1996.0,1997-12-31,1997,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,4,0,0
grant.6716680,961084,Meningococcal surface structures: role in disease and p otential as a vaccine candidates,214282,1996-01-01,1996.0,1998-12-31,1998,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,2,0,0
grant.6715381,930309,"A model for understanding human papillomavirus infectio n, and a vaccine",127081,1993-01-01,1993.0,1995-12-31,1995,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6715100,960184,The potential of influenza vaccines designed to stimulate crossreactive T-cell immunity,400427,1996-01-01,1996.0,2000-12-31,2000,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6713671,990396,Development of mucosal anti-adhesive vaccines against group A streptococci,174132,1999-01-01,1999.0,2001-12-31,2001,University of Wollongong,grid.1007.6,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6712624,910404,A novel type of vaccine for use against sexually transm itted chlamydial disease,67638,1991-01-01,1991.0,1994-12-31,1994,Queensland University of Technology,grid.1024.7,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6663780,412518,Humanized melanoma mouse models for translational assessment of neoantigen-based vaccines,2000000,2015-11-01,2015.0,2019-10-31,2019,Icahn School of Medicine at Mount Sinai,grid.59734.3c,United States,Melanoma Research Alliance,United States,0,0,0
grant.6663543,OPP1166297,To assess the impact of pneumococcal conjugate vaccine used in a 3+0 schedule,535445,2017-01-01,2017.0,2018-11-01,2018,Medical Research Council,grid.14105.31,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6616218,311488,Therapeutic CD8 vaccines against conserved E7 HPV epitopes identified by MS,1515000,2014-07-01,2014.0,2019-06-30,2019,Dana-Farber Cancer Institute; Dana-Farber Cancer Institute,grid.65499.37; grid.65499.37,United States; United States,American Association For Cancer Research,United States,0,0,0
grant.6586479,OPP1118289,To explore development of a nimble and focused experimental medicine (EM) approach to vaccine research,257314,2014-11-01,2014.0,2016-12-01,2016,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586475,OPP37862,To develop single dose vaccines for neonates by linking innate and specific immunity,4510133,2005-07-01,2005.0,2011-07-01,2011,University of Saskatchewan,grid.25152.31,Canada,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586470,OPP1187,To develop a stealth measles vaccine which can be administered safely to young infants,20360592,2000-08-01,2000.0,2005-08-01,2005,"University of Maryland, Baltimore",grid.411024.2,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586428,OPP23197,To fund effective and affordable dengue vaccines for children in dengue-endemic areas,49680144,2003-06-01,2003.0,2012-12-01,2012,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,7,0,0
grant.6586415,OPP48416,To further explore an innovative strategy to develop a vaccine against HIV pathogenesis.,463650,2008-07-01,2008.0,2010-09-01,2010,French Institute of Health and Medical Research,grid.7429.8,France,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6586392,OPP1104756,To develop more accurate and timely measurement of population immunity generated by polio vaccines,1547782,2014-03-01,2014.0,2019-07-01,2019,Dartmouth–Hitchcock Medical Center,grid.413480.a,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6586326,OPP1084257,To develop a bivalent conjugate vaccine against S. Typhi and S. Paratyphi A,406436,2013-08-01,2013.0,2015-08-01,2015,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586273,OPP1149896,To support phase I clinical trials with the new oral polio vaccine-2 formulation,7730969,2016-11-01,2016.0,2019-08-01,2019,University of Antwerp,grid.5284.b,Belgium,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6586259,OPP1039135,To improve the effectiveness of oral poliovirus vaccine in lower-income settings,3018257,2012-05-01,2012.0,2017-04-01,2017,Imperial College London,grid.7445.2,United Kingdom,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6586159,OPP32636,To support the think tank: HIV Vaccines for Developing Countries: Initiation of Trials in Africa,40000,2004-03-01,2004.0,2005-03-01,2005,Harvard University,grid.38142.3c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586008,OPP38580_01,To continue support of the Global HIV Vaccine Research Cryorepository (GHRC),5988943,2009-07-01,2009.0,2016-08-01,2016,Fraunhofer Society,grid.4561.6,Germany,Bill & Melinda Gates Foundation,United States,8,0,0
grant.6585987,OPP29789_01,To develop and license an improved vaccine against tuberculosis for use in high burden countries,200665216,2007-07-01,2007.0,2012-10-01,2012,Aeras,grid.432518.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585866,OPP43057,To conduct a landscape analysis of potential pandemic flu vaccine technologies,2182670,2006-11-01,2006.0,2008-01-01,2008,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585814,OPP51061,To conduct research related to the influence of adenovirus infections on HIV-1 vaccine performance,6455989,2009-04-01,2009.0,2015-08-01,2015,University of Pennsylvania,grid.25879.31,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6585424,OPP1148170,To test a potentially novel vaccine target towards malaria eradication,399912,2016-07-01,2016.0,2019-04-01,2019,Instituto Gulbenkian de Ciência,grid.418346.c,Portugal,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585377,OPP1109864,To support broad literacy and current awareness around vaccines and global health,105000,2014-04-01,2014.0,2017-12-01,2017,New York University,grid.137628.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585159,OPP1084292,To assess the dengue vaccine development efforts underway at Chengdu Institute of Biological Products (CDIBP),198725,2013-09-01,2013.0,2015-10-01,2015,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585141,OPP26748_02,To evaluate the effect of pneumococcal conjugate vaccine given in the routine infant schedule,785326,2009-04-01,2009.0,2010-03-01,2010,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585127,OPP37872,To develop a novel delivery strategy for HIV vaccine antigens,10628405,2005-07-01,2005.0,2013-04-01,2013,"St George's, University of London",grid.264200.2,United Kingdom,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6585062,OPP1107775,"For the creation of ""The State of Vaccine Confidence Report” and web-based supplemental resources",125000,2014-05-01,2014.0,2015-04-01,2015,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585020,OPP42381,"To support a conference entitled ""Vaccines for viruses in developing countries""",49720,2006-07-01,2006.0,2007-07-01,2007,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584897,OPP1001143,To provide conference support for the Global Vaccine Research Forum,400000,2009-07-01,2009.0,2010-12-01,2010,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584861,OPP1153439,To develop “single-shot” ultra-stable vaccine formulations that reduce costs for vaccinations,1169363,2016-10-01,2016.0,2019-07-01,2019,University of Colorado Boulder,grid.266190.a,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584856,OPP1069890,To develop global consensus on regulatory specifications for evaluation of second generation HPV vaccines,1672400,2012-09-01,2012.0,2017-04-01,2017,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584640,OPP1146356,To support the development of a preventive vaccine against HIV-1,697763,2016-05-01,2016.0,2019-05-01,2019,University of Montreal,grid.14848.31,Canada,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584506,OPP1024205,To evaluate and develop a cross-species synthetic saccharide vaccine for malaria,999385,2011-10-01,2011.0,2013-11-01,2013,Walter and Eliza Hall Institute of Medical Research,grid.1042.7,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584389,OPP1033112,To develop an effective HIV vaccine to control the transmission of human immodeficiency viruses,2595505,2011-09-01,2011.0,2017-01-01,2017,University of Massachusetts Medical School,grid.168645.8,United States,Bill & Melinda Gates Foundation,United States,8,0,0
grant.6584320,OPP1153370,To develop an effective and safer poliovirus vaccine to prevent paralytic poliomyelitis,121000,2016-07-01,2016.0,2018-07-01,2018,"University of California, San Francisco",grid.266102.1,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584287,OPP52812,To research Human Polyomavirus BKV as a HIV Vaccine Vector,100000,2009-05-01,2009.0,2010-11-01,2010,City Of Hope National Medical Center,grid.410425.6,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6584260,OPP46405,To fund a conference called Stop Cervical Cancer: Accelerating Global Access to HPV Vaccines,50000,2006-10-01,2006.0,2007-10-01,2007,International AIDS Vaccine Initiative,grid.420368.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584213,OPP1025190,To co-sponsor a scientific workshop to discuss immune correlates of protection on HIV vaccines,25536,2010-10-01,2010.0,2011-01-01,2011,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584100,OPP1008284,To develop technology for rapid low cost delivery of malaria vaccine,100000,2009-11-01,2009.0,2010-11-01,2010,TetraGenetics (United States),grid.479566.f,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584093,OPP1099497,"To develop safe, effective, and affordable vaccines for introduction into the developing world",8000000,2013-10-01,2013.0,2019-01-01,2019,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584078,OPP1051827,To develop a reduced antigen and reduced dose inulin-adjuvanted inactivated poliovirus vaccine.,587998,2012-10-01,2012.0,2014-02-01,2014,Australian Respiratory and Sleep Medicine Institute,grid.475062.2,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584077,OPP1007287,To use polymeric nanoparticles and engineered proteins to deliver vaccines to immune cells,100000,2009-11-01,2009.0,2011-05-01,2011,The University of Texas at Austin,grid.89336.37,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584012,OPP37863,"To develop a live, recombinant, attenuated Salmonella anti-pneumococcal vaccine for newborns",15178461,2005-07-01,2005.0,2012-07-01,2012,Arizona State University,grid.215654.1,United States,Bill & Melinda Gates Foundation,United States,33,0,0
grant.6583923,OPP38856,To convene an international symposium to discuss enteric diseases vaccines.,45795,2005-05-01,2005.0,2005-11-01,2005,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583828,OPP1117543,To provide estimates of vaccine impact across relevant countries and under various scenarios,181868,2014-10-01,2014.0,2017-01-01,2017,Imperial College London,grid.7445.2,United Kingdom,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6583741,OPP46319,To convene an international symposium to discuss the latest information on ETEC vaccines,52382,2006-10-01,2006.0,2007-02-01,2007,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583613,OPP41789,To convene an international symposium to discuss upstream rotavirus vaccine candidates and worldwide supply issues.,65707,2006-03-01,2006.0,2006-09-01,2006,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583610,OPP1039141,To facilitate the eradication of polio by understanding mechanisms of protection afforded by vaccines,323499,2011-10-01,2011.0,2014-01-01,2014,Dartmouth College,grid.254880.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583559,OPP1015572,To engineer a live virus with a self-destruct sequence for use in a vaccine,100000,2010-04-01,2010.0,2011-04-01,2011,Monash University,grid.1002.3,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583471,OPP1061231,To produce antigens for use in edible vaccines against infectious diseases.,100000,2012-04-01,2012.0,2013-11-01,2013,University of Natural Resources and Life Sciences,grid.5173.0,Austria,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6583359,OPP1024421,To design an effective vaccine against HIV: An Alternative Hypothesis,997235,2011-04-01,2011.0,2014-04-01,2014,"University of California, San Francisco",grid.266102.1,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6583353,OPP1091919,To application of epidemiological models to guide and evaluate control of vaccine-preventable infections,1300000,2013-07-01,2013.0,2019-01-01,2019,Princeton University,grid.16750.35,United States,Bill & Melinda Gates Foundation,United States,13,0,0
grant.6583250,OPP37870,To create novel mouse models for testing live attenuated vaccines,17405098,2005-07-01,2005.0,2011-07-01,2011,Yale University,grid.47100.32,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583171,OPP37875,To reduce the time and cost for trials of vaccines against bacterial pneumonia,8097894,2005-07-01,2005.0,2012-06-01,2012,National Institute for Health and Welfare,grid.14758.3f,Finland,Bill & Melinda Gates Foundation,United States,7,0,0
grant.6583079,OPP47029,To develop immunogens for a vaccine that will prevent pregnancy malaria globally,8998623,2007-10-01,2007.0,2014-05-01,2014,Center for Infectious Disease Research,grid.53964.3d,United States,Bill & Melinda Gates Foundation,United States,7,0,0
grant.6583022,OPP51701,To use newly identified intracellular signaling molecules as components of DNA vaccines against malaria.,100000,2008-10-01,2008.0,2010-10-01,2010,Osaka University,grid.136593.b,Japan,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582921,OPP1132049,To evaluate efficiency of PnuVax's novel conjugation chemistry for making pneumococcal conjugate vaccine,3298464,2015-08-01,2015.0,2016-11-01,2016,,,,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6582895,OPP1035181,To complete the development of a novel vaccine against cholera,695413,2011-10-01,2011.0,2013-10-01,2013,University of Gothenburg,grid.8761.8,Sweden,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582745,OPP37871,To create novel mouse models for testing HIV and HCV vaccines,6885862,2005-07-01,2005.0,2011-07-01,2011,Peking University,grid.11135.37,China,Bill & Melinda Gates Foundation,United States,19,0,0
grant.6582691,OPP29789,To develop and license an improved TB vaccine for use in high burden countries,82906200,2004-02-01,2004.0,2009-02-01,2009,Aeras,grid.432518.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582558,OPP30505,To support the development and evaluation of HPV vaccines and related diagnostics,3692385,2004-12-01,2004.0,2012-09-01,2012,Harvard University,grid.38142.3c,United States,Bill & Melinda Gates Foundation,United States,25,0,0
grant.6582368,OPP50654,"To develop needleless vaccines for tuberculosis that are safe, stable and effective",979908,2008-09-01,2008.0,2012-08-01,2012,Harvard University,grid.38142.3c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582345,OPP38614,"To develop novel recombinant adenovirus, plasmid DNA, and mycobacteria vector-based vaccines for HIV-1",17121364,2006-07-01,2006.0,2012-07-01,2012,Beth Israel Deaconess Medical Center,grid.239395.7,United States,Bill & Melinda Gates Foundation,United States,15,0,0
grant.6582286,OPP1088268,To evaluate the impact of pnuemococcal conjugate vaccine in Togo,2032736,2013-11-01,2013.0,2018-05-01,2018,Agence de Médecine Préventive,grid.417713.7,France,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582270,OPP51990,To research use of a nanopatch delivery of DNA-based malaria vaccines to skin,100000,2008-10-01,2008.0,2010-11-01,2010,University of Queensland,grid.1003.2,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582237,OPP38988,"To produce an effective, manufacturable, affordable and sustainable Human Hookworm Vaccine (HHV)",13791587,2006-08-01,2006.0,2011-08-01,2011,Sabin Vaccine Institute,grid.452766.4,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6582215,OPP1088249,To fund a partnership for influenza vaccine introduction in low and lower middle-income countries,622196,2013-08-01,2013.0,2016-01-01,2016,Emory University,grid.189967.8,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6581950,OPP40062,To convene an international symposium on enteric disease vaccine development,38500,2005-09-01,2005.0,2006-03-01,2006,Boston University,grid.189504.1,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581943,OPP1040741,To develop a novel vector/protein HIV-1 Env vaccine for the developing world,5935024,2012-09-01,2012.0,2017-01-01,2017,Beth Israel Deaconess Medical Center,grid.239395.7,United States,Bill & Melinda Gates Foundation,United States,16,0,0
grant.6581933,OPP1070067,To develop a technology platform for the production of highly immunogenic and affordable polysaccharide vaccines.,100000,2012-10-01,2012.0,2014-11-01,2014,Novartis (Italy),grid.15585.3c,Italy,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6581770,OPP29202,To identify and validate new antigens for a vaccine to prevent malaria in pregnant women,10390332,2003-12-01,2003.0,2006-12-01,2006,Center for Infectious Disease Research,grid.53964.3d,United States,Bill & Melinda Gates Foundation,United States,15,0,0
grant.6581662,OPP26748_01,To evaluate the effect of pneumococcal conjugate vaccine given in the routine infant schedule,294422,2005-10-01,2005.0,2007-10-01,2007,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581623,OPP1036009,To determine if preexisting gut immunity predicts shedding of poliovirus vaccine.,100000,2011-04-01,2011.0,2013-05-01,2013,Dartmouth College,grid.254880.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581600,OPP48805,To support research and development of new influenza vaccines to address pandemic influenza,38750000,2007-12-01,2007.0,2015-04-01,2015,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6581572,OPP31337,To support components of the Annual Conference on Vaccine Research,341619,2004-03-01,2004.0,2006-03-01,2006,National Foundation for Infectious Diseases,grid.475534.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581544,OPP1006841,To prevent exportation of pneumococcal surface GAPDH and create an attenuated vaccine,100000,2009-11-01,2009.0,2011-05-01,2011,The Ohio State University,grid.261331.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581351,OPP43387,To fund pre-emptive use of a cholera vaccine in vulnerable populations at risk,5504889,2006-10-01,2006.0,2012-07-01,2012,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581329,OPP1126862,To develop and validate a novel vaccine for Animal African Trypanosomiasis,2610892,2015-08-01,2015.0,2019-08-01,2019,University of Wisconsin System,grid.28803.31,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6581172,OPP1114721,To define the protective nature of antibodies that emerge after boosting of the RV144 vaccines,3940062,2014-10-01,2014.0,2018-01-01,2018,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6581167,OPP1107657,To reduce manufacturing costs of mass-immunization vaccine candidates and simultaneously improve manufacturing efficiencies..,14998390,2014-08-01,2014.0,2019-01-01,2019,Inventprise (United States),grid.479385.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581010,OPP1065429,To convene an international conference on global progress regarding the development of new TB vaccines,25000,2012-07-01,2012.0,2013-05-01,2013,University of Cape Town,grid.7836.a,South Africa,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580958,OPP1031438,To improve delivery and efficacy of vaccines for children in less developed countries..,738589,2011-06-01,2011.0,2015-01-01,2015,Tulane University,grid.265219.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580957,OPP1113279,To provide training and guidance to developing country vaccine manufacturers through their Network organization,2626088,2014-10-01,2014.0,2019-01-01,2019,Developing Countries Vaccine Manufactures Network,grid.479199.b,Switzerland,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580938,OPP51832,To work to design components of an HIV vaccine using groups of related envelope sequences.,100000,2008-10-01,2008.0,2009-10-01,2009,Oregon Health & Science University,grid.5288.7,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580830,OPP1024202,For protein glycan coupling technology and the development of novel conjugate vaccines,917380,2011-04-01,2011.0,2014-03-01,2014,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580809,OPP3522,To develop a stealth measles vaccine that is safe and effective in immunizing young infants,12840000,2000-08-01,2000.0,2010-02-01,2010,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580712,OPP53111,To identify new vaccines that induce broadly neutralizing antibodies against HIV,98734,2009-05-01,2009.0,2011-04-01,2011,University of New Mexico,grid.266832.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580342,OPP53131,To develop a novel arthropod-based vaccine system against leishmaniasis,100000,2009-05-01,2009.0,2010-11-01,2010,Colorado State University,grid.47894.36,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580316,OPP51724,To research whether the immune responses to DNA vaccines can be enhanced with novel adjuvants.,100000,2008-10-01,2008.0,2009-10-01,2009,University of Sheffield,grid.11835.3e,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580274,OPP1151372,To identify antibody correlates of protection for efficacious vaccines to enable product development,4631720,2016-07-01,2016.0,2019-07-01,2019,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580244,OPP28666,To measure the impact of Hib vaccine introduction in Senegal,3211791,2005-06-01,2005.0,2009-08-01,2009,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580193,OPP38639,To use novel recombinant Adenovirus (Ad) vector technologies to develop an HIV vaccine,9185813,2006-07-01,2006.0,2013-03-01,2013,Imperial College London,grid.7445.2,United Kingdom,Bill & Melinda Gates Foundation,United States,4,0,0
grant.6504939,201500299,Extension Submission - Pre-Clinical Development of a Malaria Vaccine,9858,2015-12-01,2015.0,2016-06-30,2016,University of Alberta,grid.17089.37,Canada,Alberta Innovates,Canada,0,0,0
grant.6504851,201301197,Pre-Clinical Development of a Malaria Vaccine,12118,2014-10-01,2014.0,2015-04-30,2015,University of Alberta,grid.17089.37,Canada,Alberta Innovates,Canada,0,0,0
grant.6368111,X44060------0422,ウイルスワクチンの基礎的問題の研究,4142,1969-01-01,1969.0,1969-12-31,1969,Sapporo Medical University,grid.263171.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6366318,X45120-----70026,狂犬病鶏卵ワクチンの改良に関する研究,5178,1970-01-01,1970.0,1970-12-31,1970,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6340767,X40120-----67014,ニューカッスル病生ワクチン株に関する研究(継2年),4039,1965-01-01,1965.0,1965-12-31,1965,Nippon Institute for Biological Science,grid.420033.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6336065,X00210----576120,アユのビブリオ病不活化経口ワクチンの免疫機構に関する研究,6076,1980-01-01,1980.0,1980-12-31,1980,Kōchi University,grid.278276.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6335184,X00210----577221,Salmonella typhimurium のリボゾームワクチンの免疫原性の解明,5454,1980-01-01,1980.0,1980-12-31,1980,Nara Medical University,grid.410814.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6328118,X00120----987027,緑膿菌のワクチン及び血清診断液の開発改良に関する研究,33564,1974-01-01,1974.0,1975-12-31,1975,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6318414,X00120----487006,"アレルギー副作用のない, プルラン結合トキソイドワクチンの開発研究",33151,1979-01-01,1979.0,1980-12-31,1980,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6313954,X00120----087154,百日ぜき菌感染防御抗原分画ワクチンの試作的研究,5662,1975-01-01,1975.0,1975-12-31,1975,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6313345,X00120----286039,魚類の免疫ワクチン開発に関する基礎的研究,17266,1977-01-01,1977.0,1977-12-31,1977,Kōchi University,grid.278276.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6313002,X00120----287053,培養細胞ワクチンによる狂犬病予防方式の確立,12430,1977-01-01,1977.0,1977-12-31,1977,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6310572,X00120----087031,狂犬病組織培養ワクチンの実用化に関する研究,11740,1975-01-01,1975.0,1975-12-31,1975,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6310525,X00120----586045,噴霧法による魚類の免疫ワクチン開発に関する基礎的研究,40061,1980-01-01,1980.0,1981-12-31,1981,Kōchi University,grid.278276.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6310227,X00120----386014,魚類の細菌感染症に対するワクチン開発に関する研究,29008,1978-01-01,1978.0,1979-12-31,1979,University of Miyazaki,grid.410849.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6309820,X00120----487066,細胞壁関連合成アジュバントを用いた新しいワクチン開発のための基礎的研究,41439,1979-01-01,1979.0,1980-12-31,1980,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6308457,X00095----267117,緑膿菌型別ワクチンに関する基礎的臨床的研究,2932,1977-01-01,1977.0,1977-12-31,1977,Fukushima Medical University,grid.411582.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6300678,X00095----267155,白血病患者及び悪性固型腫瘍患者に於ける水痘生ワクチンの接種について,2900,1977-01-01,1977.0,1977-12-31,1977,Mie University,grid.260026.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6294950,X00090----057107,ワクチンアウイルス血球凝集素による細胞膜修飾の研究,4833,1975-01-01,1975.0,1975-12-31,1975,Niigata University,grid.260975.f,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6285974,X00080----348074,鶏のロイコチトゾーン病の予防に関する研究特にスポロゾイト・ワクチンについて,29698,1978-01-01,1978.0,1979-12-31,1979,Okayama University,grid.261356.5,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6272688,99J09455,イヌヘルペスウイルスをベクターとして用いたネオスポーラ原虫のワクチン開発,16256,1999-01-01,1999.0,2000-12-31,2000,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6272293,99F00358,粘膜免疫を用いたA群レンサ球菌ワクチンの開発,11128,2000-01-01,2000.0,2000-12-31,2000,Kagoshima University,grid.258333.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6270561,X00021----801546,マレック病ワクチンの腫瘍形成防御機構の研究,13814,1973-01-01,1973.0,1973-12-31,1973,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6269227,99F00442,マレック病に対するワクチンの作用機構の解析,16625,2000-01-01,2000.0,2001-12-31,2001,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6268936,98J00777,人工合成遺伝子を用いたレコンビナントSERA蛋白質によるマラリアワクチンの実用化,30844,1998-01-01,1998.0,2000-12-31,2000,Keio University,grid.26091.3c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6267466,96F00331,熱帯タイレリア症に対するサブユニットワクチン開発 ― 有効な抗原の同定と精製,9169,1998-01-01,1998.0,1998-12-31,1998,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6266897,63770291,抗イディオタイプ抗体を用いた新しい日本脳炎ウィルスワクチン開発のための基礎研究,6214,1988-01-01,1988.0,1988-12-31,1988,Tokyo Metropolitan Institute of Medical Science,grid.272456.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6265249,98J05380,組換えワクチンの抗原特異的免疫誘導能の解析と転換,30844,1998-01-01,1998.0,2000-12-31,2000,Yamaguchi University,grid.268397.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6264328,98J05111,ネコヘルペスウイルス1型をベクターとして用いたネコ免疫不全ウイルスのワクチン開発,23133,1998-01-01,1998.0,2000-12-31,2000,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6245628,62760278,各種病原性腸内細菌と癌に対するYersiniaの死菌の経口ワクチン効果,5523,1987-01-01,1987.0,1987-12-31,1987,University of Tsukuba,grid.20515.33,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6241900,62770500,HBワクチンに対する抗pre-S抗体のresponseに関する研究,6213,1987-01-01,1987.0,1987-12-31,1987,Tokyo Women's Medical University,grid.410818.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6238029,61770692,百日咳コンポーネントワクチンの予防効果に関する研究,5523,1986-01-01,1986.0,1986-12-31,1986,Keio University,grid.26091.3c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6236810,61770315,水痘ウイルス弱毒生ワクチン株のDNAマーカーに関する解析,6907,1986-01-01,1986.0,1986-12-31,1986,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6235447,61771761,"新たに分離した1,6-α-D-glucan synthaseのう蝕ワクチン利用",6907,1986-01-01,1986.0,1986-12-31,1986,Kyushu Dental University,grid.411238.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6221933,60770345,水痘ウイルス-弱毒生ワクチン株の DNA マーカーの構造解析,6213,1985-01-01,1985.0,1985-12-31,1985,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6213659,59771714,コレラ菌リポ多糖(LPS)とコレラ外毒素の化学的結合による新コレラワクチンの開発,5524,1984-01-01,1984.0,1984-12-31,1984,Josai University,grid.411949.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6212038,59770497,"コレラワクチン改良のための, モノクローナル抗体によるコレラ菌外膜の抗原性の解析",3452,1984-01-01,1984.0,1984-12-31,1984,University of the Ryukyus,grid.267625.2,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6205842,59015003,ウシ白血病の特異抗体による診断とワクチンによる予防,19338,1984-01-01,1984.0,1984-12-31,1984,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6192396,J 1598,Development of molecular adjuvants for DNA vaccines in the malaria model,0,1998-03-09,1998.0,1999-03-09,1999,United States Army Medical Research and Materiel Command,grid.420210.5,United States,FWF Austrian Science Fund,Austria,0,0,0
grant.6186191,57760154,アユのビブリオ病不活化経口ワクチンの免疫機構に関する研究,5868,1982-01-01,1982.0,1982-12-31,1982,Kōchi University,grid.278276.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6184222,57770352,ヒトロタウイルスの培養細胞による分離と生ワクチン作製の試み,5523,1982-01-01,1982.0,1982-12-31,1982,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6181805,57870046,"インフルエンザワクチンの効果に関する研究(特に, 地域集団を対象として)",41442,1982-01-01,1982.0,1983-12-31,1983,Nippon Medical School,grid.410821.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6180998,57760236,Yersiniaの経口死菌ワクチンによるマウス腸管定着阻止に関する研究,5523,1982-01-01,1982.0,1982-12-31,1982,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6180034,57870037,破傷風毒素の迅速高度純化法とその精製三種混合ワクチンへの応用,22792,1982-01-01,1982.0,1982-12-31,1982,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6179947,58430023,合成ペプチドによるB型肝炎ウイルスワクチンの基礎的研究,216196,1983-01-01,1983.0,1984-12-31,1984,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6168559,57015056,成人T細胞白血病・リンパ腫(ATL)ウイルスワクチンの基礎的研究,50422,1982-01-01,1982.0,1982-12-31,1982,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6164015,56570165,自由生活性絨毛虫ワクチンによる原虫感染防御効果,13814,1981-01-01,1981.0,1981-12-31,1981,Jikei University,grid.411898.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6163599,56570162,幼若マウスにおけるトリパノソーマ症の研究:ワクチン効果に及ぼす修飾要因,15194,1981-01-01,1981.0,1982-12-31,1982,Nagoya City University,grid.260433.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6158872,56570213,レプトスピラ症ワクチンの新しい検定用実験動物としてのスナネズミに関する研究,16574,1981-01-01,1981.0,1982-12-31,1982,Tokyo Medical and Dental University,grid.265073.5,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6158686,56480333,S.mutans の精製菌体抗原をワクチンとする抗う蝕免疫に関する研究,58704,1981-01-01,1981.0,1983-12-31,1983,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6134788,25861424,新規前立腺癌マウス実験モデルの確立と癌ワクチンの創成,41803,2013-04-01,2013.0,2014-03-31,2014,Okayama University,grid.261356.5,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6066977,23659606,SSXa1を標的とするマウス自家抗原癌ワクチンモデルの構築と免疫解析,47274,2011-04-28,2011.0,2012-03-31,2012,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5963633,18580287,プロテオーム解析によるトキソプラズマ原虫の新規ワクチン・薬剤標的分子の探索,16333,2006-01-01,2006.0,2006-12-31,2006,Obihiro University of Agriculture and Veterinary Medicine,grid.412310.5,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5934697,16K20195,安全かつ有効な粘膜アジュバントを用いた、経鼻ワクチンによる効果的な膣内免疫誘導,35586,2016-04-01,2016.0,2017-03-31,2017,University of Tokushima,grid.267335.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5929096,16K21240,キラーT細胞とヘルパーT細胞を活性化する、がんペプチドワクチンの臨床応用,38848,2016-04-01,2016.0,2019-03-31,2019,Kumamoto University,grid.274841.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5924338,16K11192,PolyICをアジュバントにした舌下免疫によるインフルエンザ菌ワクチン開発の研究,29431,2016-04-01,2016.0,2019-03-31,2019,Wakayama Medical University,grid.412857.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5895865,16658078,クルマエビ類のWSSウイルス感染症に対するワクチンの開発,12942,2004-01-01,2004.0,2004-12-31,2004,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5860041,15H06349,The potential of self-polymerizing Spy0128 as vaccine adjuvant,26755,2015-08-28,2015.0,2017-03-31,2017,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5850910,15790877,ヒトパピローマウイルス感染に対する新規L2ペプチドワクチンの開発に関する研究,15521,2003-01-01,2003.0,2003-12-31,2003,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5811526,13922142,インスリンB鎖ペプチド連結MHCclassII遺伝子を用いたDNAワクチン療法,1972,2001-01-01,2001.0,2001-12-31,2001,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5809369,13877206,癌細胞―アロ樹状細胞融合による癌ワクチン療法システムの開発,4113,2001-01-01,2001.0,2001-12-31,2001,Kobe University,grid.31432.37,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5795950,13671316,消化器癌に対する癌ワクチン療法の開発,15633,2001-01-01,2001.0,2001-12-31,2001,Sapporo Medical University,grid.263171.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5721027,09770199,成人T細胞白血病ウイルスに対するDNAワクチンの感染予防効果の検討,11568,1997-01-01,1997.0,1997-12-31,1997,University of Tsukuba,grid.20515.33,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5716163,09770177,リステリア・モノサイドゲネスに対するDNAワクチンの開発とその高効率化,9915,1997-01-01,1997.0,1997-12-31,1997,Hamamatsu University School of Medicine,grid.505613.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5703840,08771058,悪性神経膠腫に対するサイトカイン発現腫瘍ワクチン療法の開発,9190,1996-01-01,1996.0,1996-12-31,1996,Tokyo Medical and Dental University,grid.265073.5,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5612658,04770640,インフルエンザ経鼻噴霧ワクチンの抗体反応に関する研究,4734,1992-01-01,1992.0,1992-12-31,1992,Tokai University,grid.265061.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5610847,04857296,B30-MDPインフルエンザウイルス人工腺ワクチンの感染防御能,6314,1992-01-01,1992.0,1992-12-31,1992,Teikyo University,grid.264706.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5592399,03770255,ヒトサイトメガロウイルス(HCMV)遺伝子組み換えワクチンの研究,6688,1991-01-01,1991.0,1991-12-31,1991,Kanazawa Medical University,grid.411998.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5588292,03857341,B30-MDPインフルエンザウィルス人工膜ワクチンにより誘導されたCTLの特徴,5944,1991-01-01,1991.0,1991-12-31,1991,Teikyo University,grid.264706.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5577894,02857357,B30-MPPインフルエンザウイルス人工膜ワクチンの細胞性免疫,5523,1990-01-01,1990.0,1990-12-31,1990,Teikyo University,grid.264706.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5571242,02770216,トキンプラズマ感染防御ワクチンの開発に関する基礎的研究,7597,1990-01-01,1990.0,1990-12-31,1990,Jikei University,grid.411898.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5569035,02760166,マレック病ワクチン株の発病防御に関わる遺伝子のクローニング,6907,1990-01-01,1990.0,1990-12-31,1990,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5557987,01771544,合成ペプチドを用いたう蝕ワクチンの開発,6213,1989-01-01,1989.0,1989-12-31,1989,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5546953,00J60703,癌ペプチドワクチン療法に有用な樹状細胞サブセットの解析,9873,2001-01-01,2001.0,2001-12-31,2001,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5533198,587142,The development and production of recombinant Parapoxvirus vectors for viral vaccine therapy and cancer immunotherapy,4692,2015-04-01,2015.0,2016-03-31,2016,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5529646,583511,Mechanism of action of a novel respiratory syncytial virus subunit vaccine formulation.,3518,2015-04-01,2015.0,2016-03-31,2016,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5528720,577935,Effects of sialylated capsular polysaccharides from Streptococci on the immunogenic capacity of conjugate vaccines,27386,2015-04-01,2015.0,2016-03-31,2016,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5524673,579889,Signaling mechanisms of dectin-1 endosomes and anti-fungal vaccine optimization,3518,2015-04-01,2015.0,2016-03-31,2016,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5502747,hrc_650f8f04,The use of virus-like particles as vaccines and therapies against cancer,368354,2009-01-01,2009.0,2013-01-01,2013,University of Otago,grid.29980.3a,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5502458,hrc_0e4873f9,Targeting vaccines to human antigen-presenting cells with synthetic glycopeptides,759468,2007-01-01,2007.0,2010-01-01,2010,University of Auckland,grid.9654.e,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5502068,hrc_311b036b,Experimental bacterial infections: improved models for vaccine and treatment development,368354,2009-01-01,2009.0,2013-01-01,2013,University of Auckland,grid.9654.e,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5502035,hrc_a2065fd1,Increasing the potency of dendritic cell based vaccines for treatment of cancer,391043,2006-01-01,2006.0,2009-01-01,2009,Malaghan Institute of Medical Research,grid.250086.9,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5502020,hrc_b50fe0f7,The impact of pneumococcal vaccine on hospital admission in young children with pneumonia,220699,2008-01-01,2008.0,2011-11-01,2011,Middlemore Clinical Trials,grid.472254.2,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5501712,hrc_dc3eee69,Phase 3 Clinical Trial for Stage 4 Melanoma using the Dendritic Cell Vaccine,139427,2006-01-01,2006.0,2011-08-01,2011,Malaghan Institute of Medical Research,grid.250086.9,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5491140,35630,Development and evaluation of a MERS-virus epitope based vaccine,222135,2016-01-01,2016.0,2018-12-31,2018,Tel Aviv University,grid.12136.37,Israel,Israel Science Foundation,Israel,0,0,0
grant.5430432,99-04-58889,"Участие в Международной конференции ""Liposome advances: progress in drug and vaccine delivery""",0,1999-01-01,1999.0,1999-12-31,1999,,,,Russian Foundation for Basic Research,Russia,0,0,0
grant.5330014,12-04-31397,Стабильность гемагглютинина - фактор низкой иммуногенности вакцин против высокопатогенных вирусов гриппа,0,2012-01-01,2012.0,2012-12-31,2012,,,,Russian Foundation for Basic Research,Russia,0,0,0
grant.5329652,12-04-31794,Разработка  ДНК–вакцин для применения в биомедицине,0,2012-01-01,2012.0,2012-12-31,2012,,,,Russian Foundation for Basic Research,Russia,0,0,0
grant.5246899,N01CP11005-14-0-1,HPV TYPE 16 VACCINE TRIAL IN COSTA RICA,0,2001-04-30,2001.0,2011-10-31,2011,,,,National Cancer Institute,United States,0,0,0
grant.5246898,N01CP11005-14-0-0,HPV TYPE 16 VACCINE TRIAL IN COSTA RICA,3893007,2001-04-30,2001.0,2011-10-31,2011,,,,National Cancer Institute,United States,0,0,0
grant.5246737,N01AO60026-8-0-1,NIAID Vaccine Immune T-cell and Antibody Laboratory (NVITAL),2475253,2008-01-01,2008.0,2008-12-31,2008,Henry M. Jackson Foundation,grid.201075.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246678,N01AI60024-3-0-1,Evaluation of NIAID's HIV Vaccine Research Education Initiative,300244,2008-01-01,2008.0,2008-12-31,2008,Nova Research Company (United States),grid.281579.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246677,N01AI60024-3-0-0,EVALUATION OF NIAID'S HIV VACCINE RESEARCH EDUCATION INITIATIVE,300132,2006-09-30,2006.0,2008-07-28,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246676,N01AI60023-3-0-1,Evaluation of NIAID's HIV Vaccine Research Education Initiative,2605933,2008-01-01,2008.0,2008-12-31,2008,Academy for Educational Development,grid.420327.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246673,N01AI60019-4-0-0,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS - PART B,4504514,2006-09-30,2006.0,2011-09-29,2011,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246585,N01AI50009-4-0-1,HIV Vaccine Design and Dev. Teams for Preventation and Treatment,1807525,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246580,N01AI50007-0-0-0,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS FOR PREVENTION AND TREATMENT,1700000,2005-08-31,2005.0,2010-08-30,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246573,N01AI40100-0-0-1,Assessing Safety of Cell Substrates and Vaccine Components,0,2004-09-24,2004.0,2009-09-23,2009,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246572,N01AI40100-0-0-0,ASSESSING THE SAFETY OF CELL SUBSTRATES AND VACCINE COMPONENTS,1063489,2004-09-24,2004.0,2009-09-23,2009,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246528,N01AI40072-5-0-1,Production and Testing of a Modified Vaccinia Ankara (MVA) Vaccine,4850824,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246523,N01AI40069-5-0-1,Population Genetics Analysis Program: Immunity to Vaccines/Infections,1136659,2004-09-30,2004.0,2009-09-29,2009,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246522,N01AI40068-4-0-1,Population Genetics Analysis Program: Immunity to Vaccines/Infections,833523,2004-09-29,2004.0,2009-09-29,2009,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246520,N01AI40066-5-0-1,Population Genetics Analysis Program: Immunity to Vaccines/Infections,2095686,2004-09-30,2004.0,2009-09-29,2009,McMaster University,grid.25073.33,Canada,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246519,N01AI40065-5-0-1,Population Genetics Analysis Program: Immunity to Vaccines/Infections,970149,2008-01-01,2008.0,2008-12-31,2008,Mayo Clinic,grid.66875.3a,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.5246518,N01AI40065-5-0-0,POPULATION GENETICS ANALYSIS PROGRAM: IMMUNITY TO VACCINES/INFECTIONS,895126,2004-09-30,2004.0,2009-09-29,2009,,,,National Institute of Allergy and Infectious Diseases,United States,61,0,0
grant.5246517,N01AI40064-8-0-1,Population Genetics Analysis Program: Immunity to Vaccines/Infections,2426364,2008-01-01,2008.0,2008-12-31,2008,deCODE Genetics (Iceland),grid.421812.c,Iceland,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246516,N01AI40064-8-0-0,POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION,2426364,2004-09-30,2004.0,2009-09-29,2009,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246471,N01AI40016-7-0-1,Malaria Vaccines:  Clinical Research &Trial Sites in Endemic Areas,0,2004-06-01,2004.0,2011-05-31,2011,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246470,N01AI40016-7-0-0,MALARIA VACCINES: CLINICAL RESEARCH AND TRIAL SITES IN ENDEMIC AREAS,3945003,2004-06-01,2004.0,2011-05-31,2011,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246460,N01AI40002-7-0-1,"Development, Testing and Evaluation of a Live Attenuated (LVS) Vaccine",0,2003-10-30,2003.0,2010-09-30,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246415,N01AI30053-0-0-0,PRODUCTION AND TESTING OF ANTHRAX RECOMBINANT PROTECTIVE ANTIGEN (RPA) VACCINE,2415964,2003-09-30,2003.0,2007-04-03,2007,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246414,N01AI30052-11-0-1,Production and Testing of Anthrax rPA Vaccine,0,2003-09-30,2003.0,2013-08-31,2013,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246413,N01AI30052-11-0-0,PRODUCTION AND TESTING OF ANTHRAX RECOMBINANT PROTECTIVE ANTIGEN (RPA) VACCINE,38000000,2003-09-30,2003.0,2013-08-31,2013,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246377,N01AI30031-0-0-0,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS (HVDDT),1300000,2003-09-26,2003.0,2008-09-25,2008,,,,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.5246375,N01AI30030-0-0-0,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS (HVDDT),2600000,2003-09-26,2003.0,2008-09-25,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246374,N01AI30029-0-0-1,HIV Vaccine Design and Development Teams (HVDDT),1136715,2003-09-26,2003.0,2008-09-25,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246373,N01AI30029-0-0-0,HIV VACCINE DESIGN AND DEVELOPMENT TEAMS (HVVDT),1136715,2003-09-26,2003.0,2008-09-25,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246362,N01AI30024-0-0-1,HLA Typing and Epitope Mapping Relative to HIV Vaccine Design,127482,2003-08-01,2003.0,2008-07-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246361,N01AI30024-0-0-0,HLA TYPING AND EPITOPE MAPPING RELATIVE TO HIV VACCINE DESIGN,127482,2003-08-01,2003.0,2008-07-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5246355,N01AI30018-8-0-0,REAGENT RESOURCE SUPPORT FOR AIDS VACCINE DEVELOPMENT,3090667,2003-04-14,2003.0,2010-04-13,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5216155,103172,Rational optimization of peptide vaccines for immunotherapy of cancer (SCORE),515907,2004-03-01,2004.0,2009-02-28,2009,Swiss Institute of Bioinformatics,grid.419765.8,Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5215901,112702,Probing Hierarchical Self-Assemblies Relevant for Drug and Vaccine Design by Employing Scanning Tunnelling Microscopy,176449,2006-03-01,2006.0,2010-02-28,2010,Swiss Federal Institute of Technology in Zurich,grid.5801.c,Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5214123,104318,Virus Like Particles and Salmonella-based Vaccines against Human papillomavirus and Cervical Cancer,526055,2004-05-01,2004.0,2006-04-30,2006,University of Lausanne; University Hospital of Basel; University Hospital of Lausanne,grid.9851.5; grid.410567.1; grid.8515.9,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,5,0,0
grant.5213219,109033,Development of approaches to rapidly assess engineered HIV vaccine candidates,0,2005-09-01,2005.0,2007-08-31,2007,Scripps Research Institute,grid.214007.0,United States,Swiss National Science Foundation,Switzerland,1,0,0
grant.5211010,100622,Therapeutic vaccination against chronic Hepatitis B by intralymphatic administration of a naked DNA vaccine,202761,2003-10-01,2003.0,2007-09-30,2007,University of Manitoba; University Hospital of Zurich; University of Zurich; University Hospital of Zurich; University Hospital of Zurich; University Hospital of Zurich; University Hospital of Zurich; University Hospital of Zurich; University Hospital of Zurich,grid.21613.37; grid.412004.3; grid.7400.3; grid.412004.3; grid.412004.3; grid.412004.3; grid.412004.3; grid.412004.3; grid.412004.3,Canada; Switzerland; Switzerland; Switzerland; Switzerland; Switzerland; Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5210364,102026,DDoSVax - in search of a vaccine for distributed denial of service attacks,99374,2003-10-01,2003.0,2006-09-30,2006,Swiss Federal Institute of Technology in Zurich,grid.5801.c,Switzerland,Swiss National Science Foundation,Switzerland,1,0,0
grant.5208623,111391,Antigen processing and presentation via vaccine adjuvants in the antigen-presenting cells,1373,2005-08-01,2005.0,2005-08-31,2005,University of Zurich; University of Zurich,grid.7400.3; grid.7400.3,Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5207729,52892,Immune responses to salmonella-based and subunit human papilloma-virus type 16 (HPV 16) vaccines,175294,1998-08-01,1998.0,2000-07-31,2000,University of Lausanne; University Hospital of Lausanne; Agroscope,grid.9851.5; grid.8515.9; grid.417771.3,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,2,0,0
grant.5202017,56936,Antigen sampling and presentation in mucosal tissues: implications for mucosal vaccine design,254095,1999-10-01,1999.0,2003-02-28,2003,Swiss Federal Institute of Technology in Lausanne,grid.5333.6,Switzerland,Swiss National Science Foundation,Switzerland,10,0,0
grant.5201826,59075,Combinatorial biomimetic chemistry - A source of new reagents forchemical biology and drug and vaccine discovery,104559,2000-06-01,2000.0,2002-05-31,2002,"University of Zurich; Boston Biomedical Research Institute; University of California, Irvine",grid.7400.3; grid.280432.f; grid.266093.8,Switzerland; United States; United States,Swiss National Science Foundation,Switzerland,0,0,0
grant.5200653,52901,The outer membrane protein UspA1 of Moraxella catarrhalis as a vaccine candidate,134026,1998-04-01,1998.0,2002-09-30,2002,University of Bern; University of Bern; University of Zurich,grid.5734.5; grid.5734.5; grid.7400.3,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,4,0,0
grant.5200583,53469,In vitro und in vivo Charakterisierung von CpG Oligonukleotiden als Adjuvantien für einen FIV-DNA Impfstoff.,0,1999-04-01,1999.0,2001-06-30,2001,,,,Swiss National Science Foundation,Switzerland,5,0,0
grant.5200284,57014,Decyphering distinctive features of early life immune responses to vaccine antigens,234160,1999-10-01,1999.0,2002-09-30,2002,University of Geneva; University of Geneva,grid.8591.5; grid.8591.5,Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5199988,55569,Identification of human astrocytoma antigens: a necessary step for vaccine development,99201,1999-06-01,1999.0,2001-05-31,2001,University of Geneva,grid.8591.5,Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5199861,53927,Safety and immunogenicity of a recombinant attenuated salmonella live vaccine expressing H. Pylori urease,94392,1998-10-01,1998.0,2000-12-31,2000,University of Lausanne; University Hospital of Lausanne; University Hospital of Lausanne,grid.9851.5; grid.8515.9; grid.8515.9,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5199583,57969,Virus like particles and Salmonella-based Vaccines against Human Papillomavirus and Cervical Cancer,762005,2000-05-01,2000.0,2004-04-30,2004,University of Lausanne; University Hospital of Lausanne,grid.9851.5; grid.8515.9,Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,6,0,0
grant.5199241,57817,"Virulence gene probes for bacterial safety monitoring, medical diagnostics, vaccine development and quality control",73705,2000-05-01,2000.0,2002-12-31,2002,University of Bern; University of Bern; University of Bern,grid.5734.5; grid.5734.5; grid.5734.5,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,2,0,0
grant.5197260,43240,Development of a live vaccine against HELICOBACTER PYLORI based on the molecular understanding of gastritis,274848,1995-10-01,1995.0,1998-09-30,1998,University of Lausanne; University of Lausanne; University of Lausanne,grid.9851.5; grid.9851.5; grid.9851.5,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,1,0,0
grant.5196596,43475,Measles virus (MV) reverse genetics; rescued MV variants and chimera as vaccines and vectors,474793,1995-10-01,1995.0,2002-04-30,2002,University of Zurich,grid.7400.3,Switzerland,Swiss National Science Foundation,Switzerland,1,0,0
grant.5071186,LY12H19009,CD40L基因修饰单纯疱疹病毒治疗性DNA疫苗的实验研究,0,2012-01-01,2012.0,2016-12-31,2016,Zhejiang Academy of Medical Sciences,grid.469605.8,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5071090,Y3100084,迟缓爱德华菌菌蜕疫苗的研制及其免疫保护机制,0,2010-01-01,2010.0,2012-12-31,2012,Zhejiang Mariculture Research Institute,grid.469622.d,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5070666,LY12H19008,MCP1 /CCR2在呼吸道合胞病毒疫苗增强性疾病中的关键作用研究,0,2012-01-01,2012.0,2015-12-31,2015,Zhejiang University,grid.13402.34,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5070548,Y304338,利用油菜种子作畜禽口服疫苗生物反应器的研究,0,2004-01-01,2004.0,2008-12-31,2008,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5069978,Y3110544,IBDV丝素蛋白-壳聚糖DNA微球疫苗制备及免疫原性研究,0,2011-01-01,2011.0,2014-12-31,2014,ZheJiang Academy of Agricultural Sciences,grid.410744.2,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5069908,Y2100660,胃癌相关肿瘤抗原多表位疫苗的设计与免疫效应研究,0,2010-01-01,2010.0,2014-12-31,2014,Wenzhou Medical University,grid.268099.c,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5069646,Y2080761,纳米壳聚糖基因递送载体与新型单纯疱疹治疗性DNA疫苗的研究,0,2008-01-01,2008.0,2012-12-31,2012,Zhejiang University,grid.13402.34,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5068787,LY12H30002,基于多重靶向于树突状细胞的抗恶性黑色素瘤DNA疫苗纳米传递系统的研究,0,2012-01-01,2012.0,2015-12-31,2015,Zhejiang Pharmaceutical College,grid.469632.c,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5068391,Y205445,基于对DC细胞功能影响的HBs抗原多态性及新型乙肝DNA疫苗的研究,0,2005-01-01,2005.0,2009-12-31,2009,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5067627,Y2110768,CD40L基因修饰HBeAg多T细胞表位DNA疫苗的实验研究,0,2011-01-01,2011.0,2015-12-31,2015,Wenzhou Medical University,grid.268099.c,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5067554,Y3090487,用衣藻叶绿体高效表达禽流感饲用疫苗研究,0,2009-01-01,2009.0,2014-12-31,2014,Zhejiang Sci-Tech University,grid.413273.0,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5067428,Y2101423,沙眼衣原体MOMP抗原T-B联合表位鉴定及其MAP疫苗免疫保护性研究,0,2010-01-01,2010.0,2013-12-31,2013,Zhejiang Chinese Medical University,grid.268505.c,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5067287,Y207239,基于CTB的I型糖尿病蛋白疫苗设计及其功能研究,0,2007-01-01,2007.0,2011-12-31,2011,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5066859,Y307519,作为基因疫苗载体的海水鱼肠道乳酸杆菌系统构建,0,2007-01-01,2007.0,2010-12-31,2010,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5066823,Y2080298,HIV-1 B＇/C重组亚型gag-tat融合基因 DNA 疫苗的研制,0,2008-01-01,2008.0,2011-12-31,2011,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5066726,Y307582,兔瘟病毒抗原表位的鉴定及表位疫苗研究,0,2007-01-01,2007.0,2011-12-31,2011,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5066201,Y204307,I型糖尿病口服疫苗的设计和在家蚕中表达及其作用机理研究,0,2004-01-01,2004.0,2007-12-31,2007,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5065299,Y207643,4-1BBL重组质粒增强乙肝疫苗抗病毒免疫治疗的佐剂作用,0,2007-01-01,2007.0,2011-12-31,2011,,,,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5065243,Y3100701,手足口病主要病原EV71 VP1重组杆状病毒疫苗载体研究,0,2010-01-01,2010.0,2016-12-31,2016,Chinese Center For Disease Control and Prevention,grid.198530.6,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5064719,Y2090395,伤寒和副伤寒通用型糖肽结合疫苗构建及免疫保护性研究,0,2009-01-01,2009.0,2013-12-31,2013,Shaoxing University,grid.412551.6,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.5061893,DRT-S97-83,Development of Feline Vaccines Containing Antigens and Adjuvants Produced Entirely in Tobacco Plants,103806,1998-06-01,1998.0,2000-05-31,2000,"University of California, Davis",grid.27860.3b,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.5061411,DRT-bio05-10557,Alzheimer`s vaccine that avoids inflammatory side effects.,225085,2006-09-01,2006.0,2009-02-28,2009,"University of California, Irvine",grid.266093.8,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.5061178,DRT-bio03-10375,Alzheimer`s vaccine that avoids inflammatory side effects,105232,2004-01-21,2004.0,2006-06-30,2006,"University of California, Irvine",grid.266093.8,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.5060857,DRT-S96-46,Development of Live Attenuated FIV Vaccines Expressing Feline Cytokines,44984,1997-01-01,1997.0,1997-12-31,1997,"University of California, Davis",grid.27860.3b,United States,UC Discovery Grants (formerly IUCRP),United States,0,0,0
grant.4933887,30771994,首例慢病毒疫苗－马传染性贫血减毒疫苗免疫机理的研究,40870,2008-01-01,2008.0,2010-12-31,2010,Harbin Veterinary Research Institute,grid.38587.31,China,National Natural Science Foundation of China,China,4,0,0
grant.4847532,5023,Development of novel genetic cancer vaccines encoding dendritic cell activation receptors,180196,2006-01-01,2006.0,2009-12-31,2009,Migal - Galilee Technology Center; Migal - Galilee Technology Center; Migal - Galilee Technology Center,grid.425662.1; grid.425662.1; grid.425662.1,Israel; Israel; Israel,Israel Science Foundation,Israel,0,0,0
grant.4788607,5431239,Development of a multivalent therapeutic HPV-16 and HPV-18 -specific vaccine,0,2004-01-01,2004.0,2012-12-31,2012,FH Aachen,grid.434081.a,Germany,German Research Foundation,Germany,0,0,0
grant.4787773,5431245,Development of a multivalent therapeutic HPV-16 and HPV-18 -specific vaccine,0,2004-01-01,2004.0,2011-12-31,2011,Charité – University Medicine Berlin,grid.6363.0,Germany,German Research Foundation,Germany,0,0,0
grant.4767408,5349959,Entwicklung und klinische Erprobung eines Salmonellen-basierten Helicobacter-Impfstoffs,0,2001-01-01,2001.0,2010-12-31,2010,Robert Koch Institute; Robert Koch Institute; Robert Koch Institute; Robert Koch Institute,grid.13652.33; grid.13652.33; grid.13652.33; grid.13652.33,Germany; Germany; Germany; Germany,German Research Foundation,Germany,0,0,0
grant.4743415,5188066,Development of a DNA vaccine against Schistosoma japonicum              (A 4),0,1999-01-01,1999.0,2001-12-31,2001,Heidelberg University; Heidelberg University,grid.7700.0; grid.7700.0,Germany; Germany,German Research Foundation,Germany,0,0,0
grant.4712414,NN 310151837,Produkcyjna i środowiskowa weryfikacja stosowania szczepionek bakteryjnych i nawozu mikroelementowego.,58881,2009-10-28,2009.0,2012-12-31,2012,University of Agriculture in Krakow,grid.410701.3,Poland,National Science Center,Poland,0,0,0
grant.4699846,06377,Inkomsten op project 00627: Bereiding van vaccins tegen de ziekte van Aujeszky (deel Berns),2292,2004-09-13,2004.0,2011-05-17,2011,Antoni van Leeuwenhoek Hospital; Antoni van Leeuwenhoek Hospital,grid.430814.a; grid.430814.a,Netherlands; Netherlands,Netherlands Organisation for Scientific Research,Netherlands,0,0,0
grant.4698120,06376,Inkomsten op project 00627: Bereiding van vaccins tegen de ziekte van Aujeszky (deel Gielkens),3832,2004-09-13,2004.0,2011-11-04,2011,Wageningen University & Research; Wageningen University & Research,grid.4818.5; grid.4818.5,Netherlands; Netherlands,Netherlands Organisation for Scientific Research,Netherlands,0,0,0
grant.4698047,07992,Protein Misfolding in a New Spotlight - The design of new and safer vaccines,1335832,2008-09-01,2008.0,2012-11-26,2012,Utrecht University; Utrecht University; Utrecht University; Utrecht University; Utrecht University,grid.5477.1; grid.5477.1; grid.5477.1; grid.5477.1; grid.5477.1,Netherlands; Netherlands; Netherlands; Netherlands; Netherlands,Netherlands Organisation for Scientific Research,Netherlands,0,0,0
grant.4696218,1-2000-812,Targetting Plant-Based Vaccines for Prevention of Type I Diabetes,190944,2000-10-01,2000.0,2002-12-31,2002,Loma Linda University,grid.43582.38,United States,Juvenile Diabetes Research Foundation,United States,1,0,0
grant.4679884,146184,GAVI-oriented research at the Centre for International Health: Participation in a rotavirus vaccine trial.,109024,2001-01-01,2001.0,2005-12-31,2005,University of Bergen,grid.7914.b,Norway,The Research Council of Norway,Norway,1,0,0
grant.4679007,174227,Development of vaccines and diagnostic tools against a new bacterial fish pathogen,255214,2005-01-01,2005.0,2009-12-31,2009,MSD Animal Health (Norway),grid.458568.2,Norway,The Research Council of Norway,Norway,2,0,0
grant.4673673,29662,Sécurité de l'utilisation du vaccin vivant atténué contre l'influenza chez les enfants et adolescents avec fibrose kystique.,17503,2014-04-01,2014.0,2015-03-31,2015,McGill University,grid.14709.3b,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.4668582,26290,L'homme invisible: Facteurs influençant la connaissance et les intetions de recevoir le vaccine VPH,14889,2012-04-01,2012.0,2013-03-31,2013,Jewish General Hospital,grid.414980.0,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.4653188,111946,Centre de Recherche en Infectiologie Porcine (CRIP),310096,2006-04-01,2006.0,2010-03-31,2010,University of Montreal,grid.14848.31,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,9,0,0
grant.4642241,205961,Improved vaccines against intracellular pathogens by combining PHARMAQ and Isconova adjuvant technologies,16543,2010-01-01,2010.0,2010-12-31,2010,Pharmaq (Norway),grid.458841.4,Norway,The Research Council of Norway,Norway,0,0,0
grant.4640698,148535,"Poxviruses in Norway: Biodiversity, characteristics and recombinations between naturally occuring and genetically engineered vaccine viruses",281330,2002-01-01,2002.0,2006-12-31,2006,The Arctic University of Norway,grid.10919.30,Norway,The Research Council of Norway,Norway,2,0,0
grant.4639761,170576,"Internasjonalt seminar ""4th International Veterinary Vaccines and Diagnostics Conference, 25. - 30. june 2006""",15555,2005-01-01,2005.0,2006-12-31,2006,Norwegian Veterinary Institute,grid.410549.d,Norway,The Research Council of Norway,Norway,0,0,0
grant.4638064,192428,"Live, attenuatet vaccine against infectious pancreatic necrosis in Atlantic salmon fry",194992,2008-01-01,2008.0,2009-12-31,2009,,,,The Research Council of Norway,Norway,0,0,0
grant.4637482,V4-0481 (D),Rekombinantno cepivo proti aviarni influenci za peroralno uporabo (CRP),0,2008-01-09,2008.0,2010-08-31,2010,National Institute of Chemistry; National Institute of Chemistry; University of Ljubljana; University of Ljubljana; University of Ljubljana; University of Ljubljana; Ljubljana University Medical Centre; National Institute of Chemistry,grid.454324.0; grid.454324.0; grid.8954.0; grid.8954.0; grid.8954.0; grid.8954.0; grid.29524.38; grid.454324.0,Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia,Slovenian Research Agency,Slovenia,0,0,0
grant.4636020,L4-2404 (C),Cepiva nove generacije proti Helicobacter pylori (applied research project),0,2009-01-05,2009.0,2012-04-30,2012,National Institute of Chemistry; Blood Transfusion Centre of Slovenia; Blood Transfusion Centre of Slovenia; National Institute of Chemistry; Blood Transfusion Centre of Slovenia; National Institute of Chemistry; National Institute of Chemistry; Blood Transfusion Centre of Slovenia; National Institute of Chemistry; National Institute of Chemistry,grid.454324.0; grid.418408.1; grid.418408.1; grid.454324.0; grid.418408.1; grid.454324.0; grid.454324.0; grid.418408.1; grid.454324.0; grid.454324.0,Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia,Slovenian Research Agency,Slovenia,0,0,0
grant.4577354,060868/Z/00/Z,Recombinant baculovirus occlusion bodies as a novel vaccine delivery system.,128341,2001-05-01,2001.0,2003-06-30,2003,Imperial College London,grid.7445.2,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.4577044,062062/Z/00/Z,Development of a mucosally active ISCOMS based diphtheria toxoid vaccine.,153852,2001-04-23,2001.0,2003-04-22,2003,University of Glasgow,grid.8756.c,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.4501254,08/00261-0,Mucosal immunization with recombinant Lactobacillus casei: development of vaccines against Streptococcus pneumoniae diseases,0,2008-08-01,2008.0,2010-07-31,2010,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4451771,,"Development of a Prototype Multivalent, Oral Vaccine for Traveler's Diarrhea",100000,1998-10-01,1998.0,1999-09-30,1999,Johns Hopkins University,grid.21107.35,United States,United States Department of the Army,United States,0,0,0
grant.4449427,,Biodegradable Bioadherent Microcapsules for Orally Administered Sustained Release Vaccines,70000,1994-10-01,1994.0,1995-09-30,1995,Lynntech,grid.280661.b,United States,United States Department of the Army,United States,0,0,0
grant.4441774,,Delivery of Vaccines by Biodegradable Polymeric Microcapsules with Bioadhesion Properties,70000,1994-10-01,1994.0,1995-09-30,1995,Cambridge Scientific (United States),grid.423337.2,United States,United States Department of the Army,United States,0,0,0
grant.4411106,,SYNTHETIC VACCINES: TEST OF CONCEPTS AND APPLICATION TO RIFT VALLEY FEVER VIRUS,59777,1988-10-01,1988.0,1989-09-30,1989,Molecular Oncology (United States),grid.421533.2,United States,United States Department of the Army,United States,0,0,0
grant.4365216,4422,Biological and immunological properties of saccharidic antigens of pathogens -utilization for preparation of subcellular vaccines,30375,2007-01-01,2007.0,2009-12-01,2009,Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences,grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c,Slovakia; Slovakia; Slovakia; Slovakia; Slovakia; Slovakia; Slovakia; Slovakia; Slovakia,"Ministry of Education, Science, Research and Sport of the Slovak Republic",Slovakia,0,0,0
grant.4359918,4070,Efficasy of an experimental recombinant vaccine against herpes simplex virus in animal model(s),11729,2005-01-01,2005.0,2007-12-01,2007,Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences,grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c,Slovakia; Slovakia; Slovakia; Slovakia,"Ministry of Education, Science, Research and Sport of the Slovak Republic",Slovakia,0,0,0
grant.4169035,565604,Analytics on Blog and Tweet Reactions to Vaccine-related Incidents,4071,2014-04-01,2014.0,2015-03-31,2015,Concordia University,grid.410319.e,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.4169013,561560,Mechanism of action of a novel respiratory syncytial virus subunit vaccine formulation.,4071,2014-04-01,2014.0,2015-03-31,2015,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.4025012,FE-21670-87,History of the Introduction of the Salk Polio Vaccine as a Public Event,750,1987-06-01,1987.0,1988-02-29,1988,,,,National Endowment for the Humanities,United States,0,0,0
grant.4014669,FT-38411-93,Ethical Disputes in Experimental Medicine: The 1935 Polio Vaccine Controversy,4750,1993-05-01,1993.0,1993-09-30,1993,University of Illinois at Chicago; University of Illinois at Urbana Champaign,grid.185648.6; grid.35403.31,United States; United States,National Endowment for the Humanities,United States,0,0,0
grant.4009508,RH-21188-94,"Ethical Constraints in Medical Science: Clinical Testing of Vaccines, 1930-60",119000,1995-06-01,1995.0,1998-05-31,1998,University of Illinois at Chicago; University of Illinois at Urbana Champaign,grid.185648.6; grid.35403.31,United States; United States,National Endowment for the Humanities,United States,0,0,0
grant.4000021,FA-32567-94,"Colleague Control and Experimental Ethics: American Vaccine-Research Communities, 1920-60",30000,1994-09-01,1994.0,1995-05-31,1995,University of Illinois at Chicago; University of Illinois at Urbana Champaign,grid.185648.6; grid.35403.31,United States; United States,National Endowment for the Humanities,United States,0,0,0
grant.3983232,13/TIDA/B2691,BPVacc: Development of a vaccine against meliodosis with Burkholderia pseudomallei antigens,133517,2014-01-01,2014.0,2015-07-31,2015,Technological University Dublin,grid.497880.a,Ireland,Science Foundation Ireland,Ireland,1,0,0
grant.3983001,13/IA/1959,"Design, Synthesis, and Development of Carbohydrate–Based Vaccines, Therapeutics, Diagnostics, and Medical Devices.",2211404,2014-07-01,2014.0,2019-06-30,2019,University College Dublin,grid.7886.1,Ireland,Science Foundation Ireland,Ireland,17,0,0
grant.3937863,200700852,A Novel Vaccine for the Prevention and Cure of Type 1 Diabetes,1234210,2008-07-01,2008.0,2015-06-30,2015,University of Calgary,grid.22072.35,Canada,Alberta Innovates,Canada,0,0,0
grant.3936269,200700591,The AHFMR Interdisciplinary Team in Vaccine Design and Implementation,4798781,2008-04-01,2008.0,2014-03-31,2014,University of Calgary; University of Alberta; Alberta Health Services,grid.22072.35; grid.17089.37; grid.413574.0,Canada; Canada; Canada,Alberta Innovates,Canada,4,0,0
grant.3857719,H23IP000923,SYSTEM ENHANCEMENTS AND SUPPORT TO FULLY INTEGRATE ALERT IIS WITH VTRCKS AND VACCINE MANAGEMENT FUNCTIONS,700000,2014-09-30,2014.0,2016-09-29,2016,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857714,H23IP000917,ENHANCE AN IIS TO INTERFACE WITH CDCs VTRCKS VACCINE ORDERING AND MANAGEMENT SYSTEM,470729,2014-09-30,2014.0,2016-09-29,2016,Wisconsin Department of Health Services,grid.280246.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857709,H23IP000912,ENHANCING NEVADAS IMMUNIZATION INFORMATION SYSTEM (IIS) TO INTERFACE WITH CDCs VTRCKS VACCINE ORDERING & MGMT SYSTEM,284625,2014-09-30,2014.0,2016-09-29,2016,Nevada Division of Public and Behavioral Health,grid.422589.0,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3812833,0228804,"IMMUNOGENICITY, POTENCY, AND STABILITY OF ELECTRON BEAM-BASED SALMONELLA VACCINES",0,2012-03-26,2012.0,2016-09-30,2016,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3765676,QLK2-CT-2001-60005,"Training in vaccine development: combined glycoconjugate vaccine against meningococcus a,c, w135,y",176424,2001-10-10,2001.0,2003-10-09,2003,Novartis (Italy),grid.15585.3c,Italy,European Commission,Belgium,0,0,0
grant.3758497,HPMI-CT-1999-00081,Vaccines and the hypothetical risk of autoimmune reactions: development of evaluation methods.,94601,2000-03-01,2000.0,2004-02-29,2004,Sanofi (France),grid.417924.d,France,European Commission,Belgium,0,0,0
grant.3748458,IC20980302,"Novel mechanisms of live, bacterial vaccines in protection against salmonella and other food-borne zoonoses",0,1999-04-01,1999.0,2002-03-31,2002,Pirbright Institute; Veterinary Research Institute; Institute for Veterinary Medical Research,grid.63622.33; grid.426567.4; grid.417756.6,United Kingdom; Czechia; Hungary,European Commission,Belgium,0,0,0
grant.3744479,ICA4-CT-1999-50002,Workshops on the molecular biology and immunology of malaria vaccines,202402,2000-01-01,2000.0,2002-12-31,2002,State Serum Institute,grid.6203.7,Denmark,European Commission,Belgium,0,0,0
grant.3742708,QLK2-CT-1999-00609,Programme EVA (European Vaccine against Aids) centralised facility for Aids reagents,703596,2000-02-01,2000.0,2003-07-31,2003,Public Health England; Pasteur Institute; Tampere University; Public Health England; Academic Medical Center; St Savas Hospital; French National Centre for Scientific Research; Université Libre de Bruxelles; Helmholtz Zentrum München; Spanish National Research Council; University of Milan; Karolinska Institute; German Primate Center,grid.271308.f; grid.428999.7; grid.502801.e; grid.271308.f; grid.5650.6; grid.416564.4; grid.4444.0; grid.4989.c; grid.4567.0; grid.4711.3; grid.4708.b; grid.4714.6; grid.418215.b,United Kingdom; France; Finland; United Kingdom; Netherlands; Greece; France; Belgium; Germany; Spain; Italy; Sweden; Germany,European Commission,Belgium,81,0,0
grant.3741466,QLK2-CT-1999-01215,Siv/hiv vaccines : detecting efficacy and explaining inefficacy,1697952,2000-02-01,2000.0,2003-07-31,2003,Bernhard Nocht Institute for Tropical Medicine; Rockefeller University; University of Iceland; Free University of Berlin; University of Innsbruck; German Primate Center; Sapienza University of Rome; Ruhr University Bochum; University of Italian Switzerland,grid.424065.1; grid.134907.8; grid.14013.37; grid.14095.39; grid.5771.4; grid.418215.b; grid.7841.a; grid.5570.7; grid.29078.34,Germany; United States; Iceland; Germany; Austria; Germany; Italy; Germany; Switzerland,European Commission,Belgium,9,0,0
grant.3734650,IC15960917,Herpesvirus vector vaccines against helminth parasite infections in calves and sheep,0,1997-04-01,1997.0,2000-09-30,2000,Wageningen University & Research; Aberystwyth University; De Montfort University; University of Gdańsk; Institute of Virology,grid.4818.5; grid.8186.7; grid.48815.30; grid.8585.0; grid.426602.4,Netherlands; United Kingdom; United Kingdom; Poland; Slovakia,European Commission,Belgium,0,0,0
grant.3733935,IC18980383,Development of a clade C-based HIV-1 vaccine for China,0,1999-01-01,1999.0,2002-12-31,2002,University of Regensburg; Tsinghua University; Biomedical Primate Research Centre,grid.7727.5; grid.12527.33; grid.11184.3d,Germany; China; Netherlands,European Commission,Belgium,0,0,0
grant.3733798,IC18980358,Production and characterisation of mutant leishmania lacking proteinase genes as attenuated live vaccines,0,1998-10-01,1998.0,2003-09-30,2003,University of Glasgow; Centro Internacional de Entrenamiento e Investigaciones Medicas; Cayetano Heredia University; Institute of Health Carlos III,grid.8756.c; grid.418350.b; grid.11100.31; grid.413448.e,United Kingdom; Colombia; Peru; Spain,European Commission,Belgium,0,0,0
grant.3733451,FAIR973046,PRODUCTION OF RECOMBINANT IMMUNE COMPLEXES IN TRANSGENIC PLANTS FOR SYSTEMIC AND MUCOSAL VACCINES,805186,1997-10-01,1997.0,2000-09-30,2000,King's College London; Copenhagen University Hospital; Advanced Biotechnology Center,grid.13097.3c; grid.4973.9; grid.417674.7,United Kingdom; Denmark; Italy,European Commission,Belgium,4,0,0
grant.3732551,BIO4972164,"Safety, immunogenicity and field efficacy studies of a plasmodium falciparum malaria pre-erythrocytic stage vaccine.",0,1997-09-01,1997.0,2001-02-28,2001,GlaxoSmithKline (Belgium); London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene & Tropical Medicine,grid.425090.a; grid.8991.9; grid.4991.5; grid.8991.9,Belgium; United Kingdom; United Kingdom; United Kingdom,European Commission,Belgium,0,0,0
grant.3729405,CI1*900762,Genetic variation and attenuation of human respiratory syncytial virus : implications for vaccine development,0,1991-02-01,1991.0,1994-04-30,1994,University of Warwick,grid.7372.1,United Kingdom,European Commission,Belgium,0,0,0
grant.3728553,CI1*940023,Development of new safe and economical recombinant hepatitis virus vaccines and diagnostic materials,0,1995-02-01,1995.0,1998-07-31,1998,Max Planck Society; Chinese Academy of Sciences; Tsinghua University,grid.4372.2; grid.9227.e; grid.12527.33,Germany; China; China,European Commission,Belgium,0,0,0
grant.3728251,BIO4960374,Development of vaccine approaches for the control of infection and inflammatoryreactions in parasitic diseases,0,1996-10-01,1996.0,1999-12-31,1999,Pasteur Institute of Lille; University of York; University of Gothenburg; Catholic University of Louvain,grid.8970.6; grid.5685.e; grid.8761.8; grid.7942.8,France; United Kingdom; Sweden; Belgium,European Commission,Belgium,0,0,0
grant.3728156,IC18950013,Efficacy of rsh28gst as an antifecundity vaccine - Immune mechanisms in experimental models and in man,0,1996-01-01,1996.0,1997-12-31,1997,Pasteur Institute of Lille; University of York; Ghent University; Newcastle University; Ministère de la Santé Publique et Action Sociale,grid.8970.6; grid.5685.e; grid.5342.0; grid.1006.7; grid.426396.c,France; United Kingdom; Belgium; United Kingdom; Senegal,European Commission,Belgium,0,0,0
grant.3726362,IC18950022,The application of transfection technology to malaria vaccine devel opment,0,1996-01-01,1996.0,1998-12-31,1998,Leiden University; National Institute of Public Health of Mexico; International Centre for Genetic Engineering and Biotechnology; Imperial College London; Biomedical Primate Research Centre,grid.5132.5; grid.415771.1; grid.425195.e; grid.7445.2; grid.11184.3d,Netherlands; Mexico; India; United Kingdom; Netherlands,European Commission,Belgium,0,0,0
grant.3725647,CIPA940152,"Genetically engineered vaccines a single molecule comprising antigen, targeting-device and adjuvant activity",0,1995-01-01,1995.0,1997-12-31,1997,Utrecht University; National Center of Infectious and Parasitic Diseases; Eötvös Loránd University,grid.5477.1; grid.419273.a; grid.5591.8,Netherlands; Bulgaria; Hungary,European Commission,Belgium,0,0,0
grant.3724558,CI1*870120,Preparation and characterization of an experimental anti-diotype vaccine against Echinococcus Granulosus,0,1988-08-01,1988.0,1992-03-31,1992,University of the Republic,grid.11630.35,Uruguay,European Commission,Belgium,0,0,0
grant.3722730,CI1*930022,Basic studies on the development of a vaccine against Haemorrhagic fever with renal syndrome,0,1994-01-01,1994.0,1996-08-31,1996,University of Glasgow,grid.8756.c,United Kingdom,European Commission,Belgium,0,0,0
grant.3721317,BIO4960144,Combined multi antigen mucosal vaccines: optimization of local and systemic immunity,0,1996-10-01,1996.0,1999-12-31,1999,Imperial College London; Trinity College Dublin; French Institute of Health and Medical Research; Novartis (Italy); Max Planck Institute for Molecular Genetics,grid.7445.2; grid.8217.c; grid.7429.8; grid.15585.3c; grid.419538.2,United Kingdom; Ireland; France; Italy; Germany,European Commission,Belgium,0,0,0
grant.3721082,CIPA930187,Recombinant Viral Particulate Proteins as Tools for New Vaccines and Diagnostics,0,1994-02-01,1994.0,1997-01-31,1997,University of Giessen; Vilnius University; Humboldt University of Berlin; University of Latvia,grid.8664.c; grid.6441.7; grid.7468.d; grid.9845.0,Germany; Lithuania; Germany; Latvia,European Commission,Belgium,0,0,0
grant.3720248,TS3*920161,A network for malaria vaccine evaluation and testing in experimental primate models,0,1993-07-01,1993.0,1994-12-31,1994,Netherlands Organisation for Applied Scientific Research,grid.4858.1,Netherlands,European Commission,Belgium,0,0,0
grant.3720142,BIO4960422,European union network for evaluation of nucleic acid-based vaccines for induction of antiviral immunity,0,1996-12-01,1996.0,2000-03-31,2000,French Institute of Health and Medical Research; Pasteur Hellenic Institute; University of Bonn; University of Oxford; Fujirebio (Belgium),grid.7429.8; grid.418497.7; grid.10388.32; grid.4991.5; grid.420287.b,France; Greece; Germany; United Kingdom; Belgium,European Commission,Belgium,0,0,0
grant.3708816,TS1*0091,PESTE DES PETITS RUMINANTS DIAGNOSIS; EPIDEMIOLOGY AND CONTROL BY VACCINE,0,1984-04-01,1984.0,1987-09-30,1987,Pirbright Institute,grid.63622.33,United Kingdom,European Commission,Belgium,0,0,0
grant.3707102,GB1*0009,PRODUCTION OF A VACCINE FOR FOOT- AND-MOUTH DISEASE VIRUS USING RECOMBINANT DNA,0,1982-12-01,1982.0,1986-03-31,1986,Netherlands Organisation for Applied Scientific Research,grid.4858.1,Netherlands,European Commission,Belgium,0,0,0
grant.3704927,GB1*0053,PRODUCTION OF A FOOT-AND-MOUTH DISEASE VACCINE BY CHEMICAL S YNTHESIS,0,1984-04-01,1984.0,1986-03-31,1986,Wellcome Trust,grid.52788.30,United Kingdom,European Commission,Belgium,0,0,0
grant.3701541,GB1*0089,TOWARDS A GENETICALLY ENGINEERED VACCINE AGAINST PORCINE TRANSMISSIBLE GASTROENTERITIS VIRUS (TGEV),0,1984-04-01,1984.0,1986-03-31,1986,John Innes Centre,grid.14830.3e,United Kingdom,European Commission,Belgium,0,0,0
grant.3701540,GB1*0090,THE APPLICATION OF RECOMBINANT DNA TECHNOLOGY TO THE DEVELOPMENT OF PORCINE ROTAVIRUS VACCINES,0,1984-04-01,1984.0,1986-03-31,1986,University of Warwick,grid.7372.1,United Kingdom,European Commission,Belgium,0,0,0
grant.3700937,TS2*0214,EVALUATION OF ADULT SCHISTOSOMA MANSONI SURFACE MEMBRANE ANTIGENES AS VACCINE CONSTITUENTS AND IMMUNODIGNOSTIC REAGENTS,0,1989-06-01,1989.0,1992-08-31,1992,Medical Research Council,grid.14105.31,United Kingdom,European Commission,Belgium,0,0,0
grant.3700838,TS2*0311,DEVELOPMENT OF DIAGNOSTIC TECHNIQUES AND VACCINES FOR CRIMEAN CONGO HAEMORRHAGIC FEVER,0,1990-09-15,1990.0,1992-05-14,1992,Aristotle University of Thessaloniki; University of Ibadan; Natural Environment Research Council,grid.4793.9; grid.9582.6; grid.8682.4,Greece; Nigeria; United Kingdom,European Commission,Belgium,0,0,0
grant.3654213,532981,Monitoring and diagnosis of a vaccine manufacturing process using spectro-fluorescence,14558,2013-04-01,2013.0,2014-03-31,2014,University of Waterloo,grid.46078.3d,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.3648386,535476,Transmission dynamics of live coccidiosis vaccines: Does management have an impact?,33977,2013-04-01,2013.0,2014-03-31,2014,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.3635542,065188/Z/01/Z,"Orphan Vaccines - Bridging the Gaps conference, Queensland Australia, Aug 2001",11631,2001-08-01,2001.0,2001-08-31,2001,Monash University,grid.1002.3,Australia,Wellcome Trust,United Kingdom,0,0,0
grant.3627751,068028/Z/02/Z,Anti-Trichuris vaccines: larval antigens and cytokines.,190580,2002-07-01,2002.0,2005-12-31,2005,University of Manchester,grid.5379.8,United Kingdom,Wellcome Trust,United Kingdom,3,0,0
grant.3568934,DP130103991,Alphaherpesvirus recombination: safety implications for attenuated Herpesvirus vaccines,287882,2013-01-01,2013.0,2015-12-31,2015,University of Melbourne,grid.1008.9,Australia,Australian Research Council,Australia,4,0,0
grant.3568475,LP120100703,Exploiting the lymphatic system for next generation vaccine development,551253,2012-01-01,2012.0,2014-12-31,2014,Monash University,grid.1002.3,Australia,Australian Research Council,Australia,1,0,0
grant.3534703,134154,Molecular approaches to develop an insect cell production system for Hepatitis C vaccine candidate.,61059,2014-03-01,2014.0,2015-07-31,2015,Instituto de Biologia Experimental Tecnológica; Universidade Nova de Lisboa; Genethon (France),grid.7665.2; grid.10772.33; grid.419946.7,Portugal; Portugal; France,Foundation for Science and Technology,Portugal,0,0,0
grant.3534560,133382,Avian influenza hemagglutinin subunit DNA vaccines with targeting sequences in frame with DIVA strategy,62685,2014-03-01,2014.0,2015-05-31,2015,Instituto Nacional de Investigação Agrária e Veterinária; University of Lisbon; University of Lisbon; Instituto Nacional de Investigação Agrária e Veterinária; Instituto Nacional de Investigação Agrária e Veterinária; Instituto Nacional de Investigação Agrária e Veterinária; Instituto Nacional de Investigação Agrária e Veterinária; University of Lisbon; Instituto Nacional de Investigação Agrária e Veterinária; Instituto Nacional de Investigação Agrária e Veterinária,grid.420943.8; grid.9983.b; grid.9983.b; grid.420943.8; grid.420943.8; grid.420943.8; grid.420943.8; grid.9983.b; grid.420943.8; grid.420943.8,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3534398,131146,Immunogenicity of vaccine candidate antigens from Staphylococcus pseudintermedius in Canis canis,244027,2013-06-01,2013.0,2015-11-30,2015,University of Lisbon; Universidade Nova de Lisboa; University of Lisbon; Universidade Nova de Lisboa; University of Lisbon; University of Lisbon,grid.9983.b; grid.10772.33; grid.9983.b; grid.10772.33; grid.9983.b; grid.9983.b,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3532496,115290,Development and pre-clinical evaluation of a new HIV-1 vaccine concept,224199,2010-12-22,2010.0,2014-09-21,2014,Instituto Superior de Ciências da Saúde Egas Moniz; Universidade Nova de Lisboa; Instituto Superior de Ciências da Saúde Egas Moniz; Universidade Nova de Lisboa,grid.257640.2; grid.10772.33; grid.257640.2; grid.10772.33,Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3532197,102649,Retroviral like particles: improving potential as candidate vaccines for Hepatitis C,207917,2010-03-01,2010.0,2013-08-31,2013,Instituto de Biologia Experimental Tecnológica; Instituto de Biologia Experimental Tecnológica; Universidade Nova de Lisboa; Instituto de Biologia Experimental Tecnológica; Pitié-Salpêtrière Hospital,grid.7665.2; grid.7665.2; grid.10772.33; grid.7665.2; grid.411439.a,Portugal; Portugal; Portugal; Portugal; France,Foundation for Science and Technology,Portugal,0,0,0
grant.3530564,33421,"Bovine Viral Diarrhea Virus (BVDV): diagnosis, genotype characterization, vaccine efficacy and transmission studies",53609,2000-12-01,2000.0,2004-03-31,2004,,,,Foundation for Science and Technology,Portugal,0,0,0
grant.3529752,119389,TherMelVac- dendritic cell-targeted peptide vaccine against melanoma by ligand-modified nanoparticles,161223,2012-03-21,2012.0,2015-09-20,2015,University of Lisbon; University of Lisbon; University of Lisbon; University of Lisbon; Catholic University of Louvain; University of Lisbon; University College London; University of Lisbon,grid.9983.b; grid.9983.b; grid.9983.b; grid.9983.b; grid.7942.8; grid.9983.b; grid.83440.3b; grid.9983.b,Portugal; Portugal; Portugal; Portugal; Belgium; Portugal; United Kingdom; Portugal,Foundation for Science and Technology,Portugal,1,0,0
grant.3529532,47260,Development of experimental DNA vaccines against sheep Maedi-Visna virus,110065,2005-02-01,2005.0,2008-01-31,2008,,,,Foundation for Science and Technology,Portugal,2,0,0
grant.3528804,65492,"Synthesis, optimization and intensification of bioseparation processes for DNA vaccine manufacturing",225739,2007-10-01,2007.0,2010-12-31,2010,University of Lisbon; University of Lisbon; University of Beira Interior; University of Lisbon; University of Beira Interior; University of Lisbon; University of Beira Interior; University of Beira Interior; University of Lisbon,grid.9983.b; grid.9983.b; grid.7427.6; grid.9983.b; grid.7427.6; grid.9983.b; grid.7427.6; grid.7427.6; grid.9983.b,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,1,0,0
grant.3528569,123631,Development of a new Nab based strategy to produce a universal HIV vaccine,134336,2014-04-28,2014.0,2016-04-27,2016,Instituto Superior de Ciências da Saúde Egas Moniz; Universidade Nova de Lisboa; University of Lisbon; University of Lisbon,grid.257640.2; grid.10772.33; grid.9983.b; grid.9983.b,Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3526005,69242,Integrated methodologies for the development of bi and three-valent DNA-vaccines against Helycobacter pylori,246507,2007-09-01,2007.0,2012-03-31,2012,Catholic University of Portugal; Universidade Nova de Lisboa; Catholic University of Portugal; Catholic University of Portugal; University of Lisbon; University of Lisbon; University of Lisbon; Catholic University of Portugal; Catholic University of Portugal; Catholic University of Portugal; Hospital do Espírito Santo; University of Lisbon; Zeltia (Spain),grid.7831.d; grid.10772.33; grid.7831.d; grid.7831.d; grid.9983.b; grid.9983.b; grid.9983.b; grid.7831.d; grid.7831.d; grid.7831.d; grid.414648.b; grid.9983.b; grid.425446.5,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Spain,Foundation for Science and Technology,Portugal,16,0,0
grant.3525583,103359,BACULOME-Engineering cellular energetics for improvement of bioprocesses: metabolic modeling for enhanced vaccines production.,238736,2010-03-01,2010.0,2013-02-28,2013,Instituto de Biologia Experimental Tecnológica; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Instituto de Biologia Experimental Tecnológica; Universidade Nova de Lisboa; University of Murcia; Instituto de Biologia Experimental Tecnológica,grid.7665.2; grid.10772.33; grid.10772.33; grid.10772.33; grid.7665.2; grid.10772.33; grid.10586.3a; grid.7665.2,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Spain; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3525132,111387,Pre-clinical assays of a GAPDH-based vaccine against Group B Streptococcus infection,213304,2011-01-01,2011.0,2014-06-30,2014,University of Porto; University of Porto; University of Porto; University of Lisbon; Pasteur Institute; University of Porto,grid.5808.5; grid.5808.5; grid.5808.5; grid.9983.b; grid.428999.7; grid.5808.5,Portugal; Portugal; Portugal; Portugal; France; Portugal,Foundation for Science and Technology,Portugal,1,0,0
grant.3524741,38273,Studies to produce an exopolysaccharide-vaccine to protect cystic fibrosis patients against Burkholderia cepacia infections,93927,2003-01-01,2003.0,2006-07-01,2006,,,,Foundation for Science and Technology,Portugal,6,0,0
grant.3219565,7137607,DEVELOPMENT OF A RADIATION-AND/OR HEATATTENTUATED VACCINE FOR CONTROL OF CUTANEOUS LEISHMANIASIS,26000,1971-01-01,1971.0,1972-07-01,1972,SRI International,grid.98913.3a,United States,National Science Foundation,United States,0,0,0
grant.2988739,295684,NSERC/Bioniche Chairs in vaccines to reduce food and water contamination,190644,2005-04-01,2005.0,2006-03-31,2006,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2984732,135176,Development of a broad spectrum recombinant vaccine against respiratory pathogens of cattle,130306,1996-04-01,1996.0,1999-03-31,1999,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2983275,286542,NSERC/Bioniche Chairs in Vaccines to Reduce Food and Water Contamination,105367,2004-04-01,2004.0,2005-03-31,2005,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2983032,327060,NSERC/Bioniche Industrial Research Chair in Vaccines to Reduce Food and Water Contamination,156547,2006-04-01,2006.0,2007-03-31,2007,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2982550,93245,Controlled-release delivery of liposome-associated and micelle-associated glycoconjugate fish vaccines,5974,1991-04-01,1991.0,1992-03-31,1992,Memorial University of Newfoundland; Fisheries and Oceans Canada,grid.25055.37; grid.23618.3e,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2981934,5570,Développement d'un vaccin contre les infections dues à Streptococcus suis sérotype 2 chez l'espèce porcine,41373,1995-04-01,1995.0,1997-03-31,1997,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2981566,327059,NSERC/Bioniche Industrial Research Chair in Vaccines to Reduce Food and Water Contamination,197648,2006-04-01,2006.0,2007-03-31,2007,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2979837,427774,NSERC/Bioniche Industrial Research Chair in Vaccines to Reduce Food and Water Contamination,250751,2009-04-01,2009.0,2010-03-31,2010,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2974877,295690,NSERC/Bioniche Chairs in vaccines to reduce food and water contamination,129479,2005-04-01,2005.0,2006-03-31,2006,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2968154,85301,Control of the bovine respiratory disease complex: the development of novel vaccine alternatives,124344,1991-04-01,1991.0,1992-03-31,1992,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2965354,286908,NSERC/Bioniche Chairs in Vaccines to Reduce Food and Water Contamination,195552,2004-04-01,2004.0,2005-03-31,2005,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2963789,427773,NSERC/Bioniche Industrial Research Chair in Vaccines to Reduce Food and Water Contamination,410374,2009-04-01,2009.0,2010-03-31,2010,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2962827,213679,Enhancement of DNA vaccine efficacy by targeting antigen presenting cells,269851,2000-04-01,2000.0,2003-03-31,2003,University of Saskatchewan; Vétoquinol (Canada),grid.25152.31; grid.450582.e,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2957389,135135,Development of an oral vaccine in alfalfa against transmissible gastroenteritis virus in swine,221659,1996-04-01,1996.0,1999-03-31,1999,"University of Guelph; Ministry of Agriculture, Food and Rural Affairs",grid.34429.38; grid.419891.c,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2955810,296074,Canadian Network for Vaccines and Immunotherapeutics of Cancer and Chronic Viral Diseases (CANVAC),5801500,1999-04-01,1999.0,2006-03-31,2006,University of Montreal; Canadian Institutes of Health Research; Canadian Institutes of Health Research,grid.14848.31; grid.248883.d; grid.248883.d,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2955686,216071,"A proteomics approach to the development of a recombinant ""Aeromonas salmonicida"" vaccine",13676,2002-04-01,2002.0,2003-03-31,2003,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2950864,14472,Development of a live-attenuated oral E. coli vaccine for poultry,104370,1994-04-01,1994.0,1996-03-31,1996,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2949454,379653,the evalutation of antigens for a vaccine against aeromonas spp,4184,2007-04-01,2007.0,2008-03-31,2008,Novartis (Canada),grid.436665.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2949291,487820,Development of new alternative vaccine delivery approaches for the prevention of human disease,25052,2011-04-01,2011.0,2012-03-31,2012,GlaxoSmithKline (Canada),grid.420846.c,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2947979,96078,Clinical and commercial applications of an O-sialoglycoprotease in bone marrow transplantation and vaccine development,47372,1991-04-01,1991.0,1992-03-31,1992,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2943297,419188,Host: parasite interaction in bovine pneumonic pasteurellosis: the immunological basis for a novel vaccine strategies,231657,2005-04-01,2005.0,2010-03-31,2010,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2941820,275165,A new method to create conjugate vaccine with fine control of T-cell epitopes,13447,2004-04-01,2004.0,2005-03-31,2005,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2936514,405402,Development of a Prion vaccine using a unique PrP-Sc epitope,19690,2008-04-01,2008.0,2009-03-31,2009,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2934649,199156,Outer membrane proteins for iron uptake: candidate vaccine against Actinobacillus pleuropneumoniae,197992,1999-04-01,1999.0,2002-03-31,2002,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2933624,295896,Development of a Vaccine for Atlantic Salmon against Aeromonas sp.,24761,2005-04-01,2005.0,2006-03-31,2006,NovaLipids (Canada),grid.422887.3,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2930402,242133,Development of an Edible Vaccine for Shipping Fever Using Transgenic Forage Crops,7138,2003-04-01,2003.0,2004-03-31,2004,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2927950,504212,Development of new alternative vaccine delivery approaches for the prevention of human disease,483,2012-04-01,2012.0,2013-03-31,2013,GlaxoSmithKline (Canada),grid.420846.c,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2926979,442352,Development of novel depot-based vaccine formulations for therapeutic cancer and infectious diseases,8757,2009-04-01,2009.0,2010-03-31,2010,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2925616,327202,Development of a Vaccine for Atlantic Salmon against Aeromonas sp.,8812,2006-04-01,2006.0,2007-03-31,2007,NovaLipids (Canada),grid.422887.3,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2922486,369883,Design and evaluation of DNA vaccines using cell-targeting polymeric vectors,37236,2007-04-01,2007.0,2008-03-31,2008,Massachusetts Institute of Technology,grid.116068.8,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2920384,276014,Adjuvant activity of Complement component C3d in novel vaccine strategies for cattle,42383,2002-04-01,2002.0,2005-03-31,2005,University of Guelph; Canadian Cattlemen's Association; Canadian Cattlemen's Association; Canadian Cattlemen's Association,grid.34429.38; grid.450500.4; grid.450500.4; grid.450500.4,Canada; Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2919077,214523,Development of an enterophemorrhagic 0157:H7 E. coli pediatric vaccine,151008,2001-04-01,2001.0,2003-03-31,2003,University of British Columbia,grid.17091.3e,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2919001,141244,HPLC for purification of glycolipid and glycopeptide conjugates; novel molecules with vaccine potential,35614,1998-04-01,1998.0,1999-03-31,1999,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2912988,196937,"Facteurs de virulence des coronavirus hémagglutinants et, valeur vaccinale et diagnostique des protéines recombinantes",124232,1997-04-01,1997.0,2002-03-31,2002,National Institute of Scientific Research,grid.418084.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2911688,286846,Design of therapeutic vaccines for chronic hepatitis B virus infection,425964,2002-04-01,2002.0,2005-03-31,2005,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2911376,57309,Development of a vaccine for bovine pneumonic pasteurellosis using recombinant antigens of Pasteurella haemolytica Al,335043,1991-04-01,1991.0,1994-03-31,1994,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2910140,398131,Identification of novel mucosal adjuvants and immune biomarkers for neonatal respiratory syncytial virus vaccine development,18753,2008-04-01,2008.0,2009-03-31,2009,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2905508,295056,Development of an Edible Vaccine for Shipping Fever Using Transgenic Forage Crops,4124,2005-04-01,2005.0,2006-03-31,2006,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2904392,250651,Selection of the optimal CpG as an adjuvant for S. aureus Vaccine,40522,2002-04-01,2002.0,2004-03-31,2004,McGill University; Dairy Farmers Of Canada,grid.14709.3b; grid.410426.5,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2902965,340891,"Reverse vaccinology, a genomics approach to vaccine development for A. pleuropneumoniae",383574,2004-04-01,2004.0,2007-03-31,2007,McGill University; GlaxoSmithKline (Canada); GlaxoSmithKline (Canada),grid.14709.3b; grid.420846.c; grid.420846.c,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2900056,110198,Recombinant bovine viral diarrhea virus gp53 as subunit vaccine and diagnostic tool,149806,1995-04-01,1995.0,1998-03-31,1998,National Institute of Scientific Research,grid.418084.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2896764,53950,Development of bovine adenovirus vector and its use for the engineering of viral vaccines,61877,1991-04-01,1991.0,1994-03-31,1994,Brock University,grid.411793.9,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2895087,30750,Control of the bovine respiratory disease complex: The development of novel vaccine alternatives,249348,1992-04-01,1992.0,1995-03-31,1995,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2878108,485049,Development of novel depot-based vaccine formulations for therapeutic cancer and infectious diseases,20216,2011-04-01,2011.0,2012-03-31,2012,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2877530,299144,A new method to create conjugate vaccine with fine control of T-cell epitopes,14278,2005-04-01,2005.0,2006-03-31,2006,University of Alberta,grid.17089.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2875336,158799,"Development of a vaccine against Myxobolus cerebralis, the causative agent of whirling disease in fr",23560,1999-04-01,1999.0,2000-03-31,2000,"University of California, Davis",grid.27860.3b,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2874545,54112,Development of STb-fimbrial vaccine for enterotoxigenic Escherichia coli post-weaning diarrhea in pigs,211157,1991-04-01,1991.0,1994-03-31,1994,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2874092,438385,Testing the Efficacy of Novel Pandemic Influenza and Hepatitis B Vaccine Formulations,3939,2009-04-01,2009.0,2010-03-31,2010,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2871835,175486,Development of transgenic alfalfa expressing the P. haemolytica leukotoxin as an oral vaccine in cattle,223462,1998-04-01,1998.0,2001-03-31,2001,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2870999,441908,Developing vaccines using lambda phage particle display and dna technology,3939,2009-04-01,2009.0,2010-03-31,2010,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2870975,327881,Identification of novel mucosal adjuvants and immune biomarkers for neonatal respiratory syncytial virus vaccine development,17630,2006-04-01,2006.0,2007-03-31,2007,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2867924,370186,Identification of novel mucosal adjuvants and immune biomarkers for neonatal respiratory syncytial virus vaccine development,37236,2007-04-01,2007.0,2008-03-31,2008,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2867499,436406,Bioencapsulation of HIV gag secreting myoblasts in alginate microparticles as an HIV vaccine strategy,15328,2009-04-01,2009.0,2010-03-31,2010,Queen's University,grid.410356.5,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2866559,44474,Design of a viral vector for the development of ployvalent vaccines for cattle,43922,1994-04-01,1994.0,1995-03-31,1995,National Institute of Scientific Research,grid.418084.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2865004,187284,"A proteomics approach to the development of a recombinant ""Aeromonas salmonicida"" vaccine",12913,2001-04-01,2001.0,2002-03-31,2002,Zoetis (Canada),grid.436699.7,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2863719,5176,Engineering of recombinant bovine respiratory syncytial virus vaccine using bovine adenovirus vector,40000,1994-04-01,1994.0,1997-03-31,1997,Brock University,grid.411793.9,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2850068,485055,Evaluation of alternative vaccine delivery routes and assessment of their mode of action,20216,2011-04-01,2011.0,2012-03-31,2012,GlaxoSmithKline (Canada),grid.420846.c,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2846353,438383,Exploring the use of peptide-lipid conjugates in novel depot-based vaccine formulations.,3939,2009-04-01,2009.0,2010-03-31,2010,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2842052,276087,Development of a Vaccine for Atlantic Salmon against Aeromonas sp.,15368,2004-04-01,2004.0,2005-03-31,2005,NovaLipids (Canada),grid.422887.3,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2835764,335810,Structural characterization of new bacterial polysaccharides and their use in vaccine design,74256,2004-04-01,2004.0,2007-03-31,2007,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2829384,436407,Bioencapsulation of HIV gag secreting myoblasts in alginate microparticles as an HIV vaccine strategy,2042,2009-04-01,2009.0,2010-03-31,2010,Queen's University,grid.410356.5,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2825619,339823,Mathematical approaches for controlling emerging and re-emerging diseases using vaccines,11945,2005-04-01,2005.0,2007-03-31,2007,University of Manitoba,grid.21613.37,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2821847,501923,Monitoring and diagnosis of a vaccine manufacturing process using spectro-fluorescence,14997,2012-04-01,2012.0,2013-03-31,2013,University of Waterloo,grid.46078.3d,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2816881,442362,Evaluation of alternative vaccine delivery routes and assessment of their mode of action,8757,2009-04-01,2009.0,2010-03-31,2010,GlaxoSmithKline (Canada),grid.420846.c,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2813322,433707,Development of a Prion vaccine using a unique PrP-Sc epitope,18396,2009-04-01,2009.0,2010-03-31,2010,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2808920,408135,Développement de procédé pour la production d'un vaccin influenza en culture cellulaire,4216,2008-04-01,2008.0,2009-03-31,2009,Laval University,grid.23856.3a,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2799721,463518,Evaluation of alternative vaccine delivery routes and assessment of their mode of action,29109,2010-04-01,2010.0,2011-03-31,2011,GlaxoSmithKline (Canada),grid.420846.c,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2798408,463511,Development of novel depot-based vaccine formulations for therapeutic cancer and infectious diseases,29109,2010-04-01,2010.0,2011-03-31,2011,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2798291,179529,"Development of a vaccine against Myxobolus cerebralis, the causative agent of whirling disease in fr",23569,2000-04-01,2000.0,2001-03-31,2001,"University of California, Davis",grid.27860.3b,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2795798,272749,Development of an Edible Vaccine for Shipping Fever Using Transgenic Forage Crops,11525,2004-04-01,2004.0,2005-03-31,2005,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2792691,327529,Design and evaluation of DNA vaccines using cell-targeting polymeric vectors,35262,2006-04-01,2006.0,2007-03-31,2007,Massachusetts Institute of Technology,grid.116068.8,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2707018,Y2AI6114-3-0-1,Bio-Warfare Agent detection and development of a third-generation plague vaccine,312700,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706836,Y1NS8057-1-0-1,Support Vaccine Safety Task Force through HHS,5000,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Neurological Disorders and Stroke,United States,0,0,0
grant.2706240,Y1AI8374-1-0-1,"NIAID/MRMC Comprehensive HIV/AIDS Therapeutic and Non-Vaccine Prev Clin, Research",1240957,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706208,Y1AI6153-3-0-1,New Scientific Approaches to Facilitate Development of Vaccines,2796534,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,25,0,0
grant.2706196,Y1AI6110-3-0-1,Development of Live Oral Vaccine for Protection against Bacillus Anthracis,166666,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2706173,Y1AI4893-6-0-1,Assessing Safety of Cell Substrates and Vaccine Components,2254678,2008-01-01,2008.0,2008-12-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,15,0,0
grant.2702582,U66IP000451,THE IMMUNIZATION PROGRAM WAS CREATED TO REDUCE THE INCIDENCE OF VACCINE-PREVENTAB,1079999,2010-09-01,2010.0,2012-08-31,2012,Mississippi State Department of Health,grid.280409.7,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2698721,U51IP000833,INTRODUCING THE USE OF SEASONAL INFLUENZA VACCINE IN PUBLIC HEALTH,719883,2013-09-01,2013.0,2016-08-31,2016,Uganda Virus Research Institute,grid.415861.f,Uganda,Centers for Disease Control and Prevention,United States,0,0,0
grant.2698712,U51IP000819,Expanding the Use of Seasonal Influenza Vaccines in Public Health Programs in Chi,725000,2013-09-01,2013.0,2016-08-31,2016,Chinese Center For Disease Control and Prevention,grid.198530.6,China,Centers for Disease Control and Prevention,United States,6,0,0
grant.2698071,U50CI022279,EVALUATE THE LONG-TERM PROTECTION FROM HEPATITIS A AND B VACCINE AMONG,0,2002-09-30,2002.0,2008-09-29,2008,Alaska Native Tribal Health Consortium,grid.413552.4,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2597418,R21AI042687,A RATIONAL APPROACH TO DEVELOPING A KILLED HIV-1 VACCINE,189000,1999-09-30,1999.0,2002-09-29,2002,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2566869,R03AI051300,Statistical Center for Rotavirus Vaccine in India,77142,2001-07-01,2001.0,2003-06-30,2003,Stanford University,grid.168010.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2471645,R01CA060783,CLINICAL TRIAL OF MELANOMA VACCINE AND IL-2 IN LIPOSOME,0,1993-08-01,1993.0,1997-07-31,1997,New York University,grid.137628.9,United States,National Cancer Institute,United States,6,0,0
grant.2455014,R01AI047539,THERAPORE-HIV AS A VACCINE TO ELICIT T CELL RESPONSE,1371344,1999-09-05,1999.0,2003-08-31,2003,Harvard University,grid.38142.3c,United States,National Institute of Allergy and Infectious Diseases,United States,3,4,0
grant.2430609,N01HD033180,DEVELOPMENT OF A CONTRACEPTIVE VACCINE,0,1993-09-16,1993.0,2000-05-31,2000,Population Council,grid.250540.6,United States,National Institute of Child Health and Human Development,United States,2,0,0
grant.2425472,N01AI50007-7-0-1,"HIV Vaccine Design and Development, Part A-Preventative Vaccines",12988052,2005-08-31,2005.0,2013-12-31,2013,,,,National Institute of Allergy and Infectious Diseases,United States,3,2,0
grant.2424945,N01AI085333,PRODUCTION OF A RECOMBINANT H5 N1 VACCINE FOR PHASE 1,0,1997-12-19,1997.0,1998-12-18,1998,Protein Sciences (United States),grid.437366.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424533,N01AI030024,HLA TYPING AND EPITOPE MAPPING RELATIVE TO HIV VACCINE DESIGN-266030024,0,2003-01-01,2003.0,2005-01-01,2005,Massachusetts General Hospital,grid.32224.35,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2424530,N01AI030016,Development and Testing of a Modified Vaccinia Ankara /MVA/ Vaccine-266030016,0,2003-01-01,2003.0,2005-01-01,2005,,,,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2424521,N01AI025477,PHASE III PNEUMOCOCCAL CONJUGATE VACCINE STIDY IN THE GAMBIA-266025477,0,2003-01-01,2003.0,2005-01-01,2005,Medical Research Council,grid.14105.31,United Kingdom,National Institute of Allergy and Infectious Diseases,United States,11,0,0
grant.2424511,N01AI025455,Expanded Phase II and IV Vaccine Trials in Humans-26625455,0,2002-01-01,2002.0,2004-01-01,2004,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424510,N01AI025454,EXPANDED PHASE II AND IV VACCINE TRIALS IN HUMANS-266025454,0,2002-01-01,2002.0,2004-01-01,2004,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424509,N01AI025453,Expanded Phase II and IV Vaccine Trials in Humans-26625453,0,2002-01-01,2002.0,2004-01-01,2004,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424508,N01AI025452,Expanded Phase II and IV Vaccine Trials in Humans-26625452,0,2002-01-01,2002.0,2004-01-01,2004,Kaiser Permanente,grid.280062.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424475,N01AI015442,HLA TYPING AND EPITOPE MAPPING GUIDE TO HIV VACCINE DESIGN-266015442,0,2003-01-01,2003.0,2005-01-01,2005,Massachusetts General Hospital,grid.32224.35,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2424336,N01AI000072,PRODUCTION AND TESTING OF A MODIFIED VACCINIA ANKARA /MVA/ VACCINE.-266000072,0,2006-01-01,2006.0,2006-12-31,2006,,,,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2424335,N01AI000071,PRODUCTION OF TESTING OF A MODIFIED VACCINIA ANKARA /MVA/ VACCINE-266000071,0,2005-01-01,2005.0,2005-12-31,2005,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,1,0
grant.2424327,N01AI000034,DEVELOPMENT TESTING AND EVALUATION OF CANDIDATE VACCINES AGAINST PLAGU-266000034,0,2005-01-01,2005.0,2005-12-31,2005,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424317,N01AI000016,MALARIA VACCINES: CLINICAL RESEARCH AND TRIAL SITES IN ENDEMIC AREAS-2-266000016,0,2005-01-01,2005.0,2006-01-01,2006,Noguchi Memorial Institute for Medical Research,grid.462644.6,Ghana,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424315,N01AI000008,HIV VACCINES DESIGN AND DEVELOPMENT TEAMS PART A - PREVENTATIVE VACCIN-266000008,0,2005-01-01,2005.0,2005-12-31,2005,Children's Hospital of Philadelphia,grid.239552.a,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2393894,H23IP622547,TO SUPPORT IMMUNIZATIONS & THE VACCINES FOR CHILDREN PROG STATEWIDE IN NEW MEXICO,12912147,2003-01-01,2003.0,2012-12-31,2012,New Mexico Department of Health,grid.238456.e,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393834,H23IP000768,"CDC-RFA-IP13-1301, Virgin Islands Immunizations and Vaccines for Children Grants",4962999,2013-01-01,2013.0,2017-12-31,2017,United States Virgin Islands Department of Health,grid.280577.f,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393832,H23IP000766,PROVIDE FUNDING FOR OKLAHOMA STATE DOH TO PROVIDE VACCINE SERVICES TO THE STATE,12743213,2013-01-01,2013.0,2017-12-31,2017,Oklahoma State Department of Health,grid.238667.e,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393825,H23IP000759,"PREVENT DISEASE, DISABILITY & DEATH FROM VACCINE PREVENTABLE DISEASE IN CHILDREN.",23722558,2013-01-01,2013.0,2017-12-31,2017,NC Department of Health and Human Services,grid.410399.6,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393823,H23IP000757,"2013 COOPERATIVE AGREEMENT APPLICATION FOR THE IMMUNIZATION, VACCINE FOR CHILDREN",6081296,2013-01-01,2013.0,2017-12-31,2017,New Hampshire Department of Health and Human Services,grid.422654.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393818,H23IP000752,IMMUNIZATION VACCINES FOR CHILDREN GRANT FOR INFRASTRUCTURE TO STATE OF MICHIGAN,26740972,2013-01-01,2013.0,2017-12-31,2017,Michigan Department of Health and Human Services,grid.467944.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393815,H23IP000749,PROVIDE IMMUNIZATION SVCS FOR TO CONTROL VACCINE PREVENTABLE DISEASE TRANSMISSION,8376947,2013-01-01,2013.0,2017-12-31,2017,State of Maine Department of Health and Human Services,grid.280289.9,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393806,H23IP000739,PUERTO RICO'S IMMUNIZATION & VACCINES FOR CHILDREN 2013-2017 PROGRAM PLAN,11099589,2013-01-01,2013.0,2017-12-31,2017,Puerto Rico Department of Health,grid.280499.e,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393781,H23IP000714,"Improve Vaccine Management, Storage and Handling in the Republic of the Marshall",200000,2012-09-30,2012.0,2015-09-29,2015,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393765,H23IP000698,"Improve vaccine management, storage and handling at provider and grantee level",832647,2012-09-30,2012.0,2015-03-29,2015,Pennsylvania Department of Health,grid.280365.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393762,H23IP000695,"Nevada State Immunization Program: to improve vaccine management, storage and han",836253,2012-09-30,2012.0,2015-09-29,2015,Nevada Division of Public and Behavioral Health,grid.422589.0,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393757,H23IP000690,"Program Area 5 - Improve Vaccine management, storage and handling at provider",307405,2012-09-30,2012.0,2014-09-29,2014,New Hampshire Department of Health and Human Services,grid.422654.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2393745,H23IP000678,"Improve Vaccine Management, Storage and Handling at the Provider and Grantee",900000,2012-09-30,2012.0,2015-09-29,2015,Massachusetts Department of Public Health,grid.416511.6,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2346803,272200800063C-7-0-1,Development of Improved DNA Vaccines and Electroporation Delivery Devices for HIV,1312685,2013-09-30,2013.0,2014-09-29,2014,Inovio Pharmaceuticals (United States),grid.421774.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346802,272200800063C-6-0-1,Development of Improved DNA Vaccines and Electroporation Delivery Devices for HIV,2529017,2008-09-30,2008.0,2015-09-29,2015,Inovio Pharmaceuticals (United States),grid.421774.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346801,272200800063C-4-0-1,Development of Improved DNA Vaccines and Electroporation Delivery Devices for HIV,3342566,2008-09-30,2008.0,2013-03-31,2013,Inovio Pharmaceuticals (United States),grid.421774.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346800,272200800063C-2-0-1,Development of Improved DNA Vaccines and Electroporation Delivery Devices for HIV,5258144,2008-09-30,2008.0,2012-03-31,2012,Inovio Pharmaceuticals (United States),grid.421774.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346799,272200800063C-1-0-1,Development of Improved DNA Vaccines and Electroporation Delivery Devices for HIV,6573776,2008-09-30,2008.0,2015-09-29,2015,Inovio Pharmaceuticals (United States),grid.421774.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346798,272200800063C-0-0-1,Development of Improved DNA Vaccines and Electroporation Delivery Devices for HIV,4663588,2008-09-30,2008.0,2015-09-29,2015,Inovio Pharmaceuticals (United States),grid.421774.3,United States,National Institute of Allergy and Infectious Diseases,United States,15,2,0
grant.2346745,272200800055C-0-0-1,Development of Mutivalent Filovirus (Ebola and Marburg) Vaccines,5818745,2008-09-30,2008.0,2012-09-29,2012,Integrated BioTherapeutics (United States),grid.420253.2,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2346744,272200800051C-2-0-1,Development of an Anthrax Vaccine,11351920,2008-09-25,2008.0,2012-10-31,2012,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346742,272200800049C-0-0-1,Development of a Third Generation Anthrax Vaccine,10000000,2008-09-25,2008.0,2011-09-24,2011,PharmAthene (United States),grid.437146.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2343520,261200700064C-0-0-0,SBIR TOPIC 241 LIPID NANO-PARTICLE THERAPEUTIC CERVICAL CANCER VACCINE,149291,2007-09-28,2007.0,2008-03-27,2008,,,,National Cancer Institute,United States,0,0,0
grant.6125262,25461127,The development of hypertension vaccine toward clinical application.,46798,2013-04-01,2013.0,2016-03-31,2016,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.5946523,18380110,"Development of RNA vaccine with fish retrovirus, a substitution of DNA vaccine, for fish viral diseases",129672,2006-01-01,2006.0,2008-12-31,2008,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.4921725,30371426,基因重组酵母PSMA疫苗抗前列腺癌的实验研究,24545,2004-01-01,2004.0,2006-12-31,2006,Sun Yat-sen University,grid.12981.33,China,National Natural Science Foundation of China,China,1,0,0
grant.2711162,Z01BE003006,MOUSE SYSTEM FOR EVALUATION OF CHOLERA VACCINE,0,1990-01-01,1990.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.8144729,21332006,糖肽疫苗的设计、合成与性质研究,463753,2014-01-01,2014.0,2018-12-31,2018,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,18,0,0
grant.7172501,272201300004I-5-27200002-1,SVEU - Maintenance of NHPs,209612,2013-05-01,2013.0,2018-04-30,2018,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172492,272201300003I-6-27200002-1,SVEU - Maintenance of Nonhuman Primates,255699,2013-05-01,2013.0,2018-04-30,2018,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172476,272201300002I-6-27200002-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,307005,2013-05-01,2013.0,2018-04-30,2018,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172475,272201300002I-5-27200004-1,SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY,2265914,2013-05-01,2013.0,2018-04-30,2018,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172474,272201300002I-5-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,533784,2013-05-01,2013.0,2018-04-30,2018,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172464,272201300002I-0-27200016-1,Evaluation of Immune Responses to a Trimerically Stabilized gp120 Immunogen,368553,2017-08-15,2017.0,2019-02-14,2019,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172024,272201300003I-5-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,632260,2014-05-01,2014.0,2018-04-30,2018,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7170302,272201300004I-5-27200001-1,SVEU - Core Activities - Administrative and Technical Support,259942,2013-05-01,2013.0,2018-04-30,2018,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501678,272201300004I-4-27200002-1,SVEU - Maintenance of NHPs,204988,2013-05-01,2013.0,2017-04-30,2017,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501676,272201300002I-4-27200004-1,SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY,2166265,2013-05-01,2013.0,2017-04-30,2017,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501549,272201300002I-5-27200002-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,299702,2013-05-01,2013.0,2017-04-30,2017,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501534,272201300003I-4-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,611569,2014-05-01,2014.0,2017-04-30,2017,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501449,272201300002I-2-27200010-1,TIER 2 SHIV-C CHALLENAGE OF NONHUMAN PRIMATES PREVIOUSLY PROTECTED FROM TIER 1 SHIV-C CHALLENGE,127190,2014-09-05,2014.0,2016-10-14,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500868,272201300002I-4-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,518332,2013-05-01,2013.0,2017-04-30,2017,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500311,272201300002I-1-27200012-1,Conduct of Virus In Vivo Titration Study (P196): ?In Vivo SHIV Titration via Intrarectal Route in Indian-origin Rhesus Macaques?,129943,2015-09-01,2015.0,2017-01-31,2017,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499762,272201300004I-4-27200001-1,SVEU - Core Activities - Administrative and Technical Support,279086,2013-05-01,2013.0,2017-04-30,2017,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499609,272201300003I-5-27200002-1,SVEU - Maintenance of Nonhuman Primates,250136,2013-05-01,2013.0,2017-04-30,2017,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5578606,03454270,DEVELOPMENTS IN UPPER AIRWAY MUCOSAL INFLUENZA VIRUS VACCINES,47027,1991-01-01,1991.0,1993-12-31,1993,Tokai University,grid.265061.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5245887,272201300004I-3-27200002-1,SVEU - Maintenance of NHPs,200527,2013-05-01,2013.0,2016-04-30,2016,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245886,272201300004I-3-27200001-1,SVEU - Core Activities - Administrative and Technical Support,247522,2013-05-01,2013.0,2016-04-30,2016,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245881,272201300003I-3-27200002-1,SVEU - Maintenance of Nonhuman Primates,342398,2014-05-01,2014.0,2016-04-30,2016,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245880,272201300003I-3-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,590969,2014-05-01,2014.0,2016-04-30,2016,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245879,272201300003I-2-27200005-1,SVEU - IMMUNOGENICITY OF A NONINTEGRATING INTEGRASE-DEFECTIVE LENTIVIRAL VECTOR,61940,2013-06-21,2013.0,2015-12-31,2015,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245877,272201300003I-1-27200006-1,IN VIVO SHIV TITRATION VIA INTRATECTAL ROUTE IN INDIAN-ORIGIN RHESUS MACAQUES,39631,2013-11-01,2013.0,2014-10-31,2014,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245876,272201300003I-0-27200009-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,260807,2015-05-15,2015.0,2015-11-14,2015,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245875,272201300003I-0-27200008-1,Conduct Study P189,115753,2014-12-19,2014.0,2015-09-18,2015,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245873,272201300002I-4-27200007-1,"SVEU - Prime Boost Efficacy, Boosting Immunization, and Virus Challenge Studies",127065,2013-06-21,2013.0,2015-02-28,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245872,272201300002I-3-27200005-1,SVEU - CONDUCT OF STUDIES IN NONHUMAN PRIMATES: REIMMUNIZATION AND CHALLENG,332996,2013-05-01,2013.0,2015-06-30,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245871,272201300002I-3-27200004-1,SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY,2163717,2013-05-01,2013.0,2016-04-30,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245870,272201300002I-3-27200003-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,259157,2013-05-01,2013.0,2016-04-30,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245869,272201300002I-3-27200002-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,438924,2013-05-01,2013.0,2016-04-30,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245868,272201300002I-3-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,503347,2013-05-01,2013.0,2016-04-30,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245867,272201300002I-1-27200010-1,TIER 2 SHIV-C CHALLENAGE OF NONHUMAN PRIMATES PREVIOUSLY PROTECTED FROM TIER 1 SHIV-C CHALLENGE,110840,2014-09-05,2014.0,2016-10-14,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245866,272201300002I-1-27200009-1,PREPARATION OF SHIV VIRUS STOCK,93756,2015-07-01,2015.0,2016-06-30,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245864,272201300002I-0-27200012-1,Conduct of Virus In Vivo Titration Study (P196): ?In Vivo SHIV Titration via Intrarectal Route in Indian-origin Rhesus Macaques?,219135,2015-09-01,2015.0,2016-01-31,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.4940208,30500492,胰腺癌MUC4抗原多表位嵌合DNA疫苗的设计和免疫研究,33389,2006-01-01,2006.0,2008-12-31,2008,Nanjing Medical University,grid.89957.3a,China,National Natural Science Foundation of China,China,2,0,0
grant.3857027,272201300004I-2-27200002-1,SVEU - Maintenance of NHPs,196137,2013-05-01,2013.0,2015-04-30,2015,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857026,272201300004I-2-27200001-1,SVEU - Core Activities - Administrative and Technical Support,243744,2013-05-01,2013.0,2015-04-30,2015,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857022,272201300003I-2-27200004-1,SVEU - Evaluation of Prime-Boost Regimen Emplyoing Clade C Proteins,121834,2013-06-21,2013.0,2015-01-18,2015,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857021,272201300003I-2-27200002-1,SVEU - Maintenance of Nonhuman Primates,237885,2014-05-01,2014.0,2015-04-30,2015,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857020,272201300003I-2-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,570443,2014-05-01,2014.0,2015-04-30,2015,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857018,272201300003I-0-27200006-1,IN VIVO SHIV TITRATION VIA INTRATECTAL ROUTE IN INDIAN-ORIGIN RHESUS MACAQUES,154229,2013-11-01,2013.0,2014-10-31,2014,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857017,272201300002I-2-27200007-1,"SVEU - Prime Boost Efficacy, Boosting Immunization, and Virus Challenge Studies",352580,2013-06-21,2013.0,2014-11-07,2014,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857016,272201300002I-2-27200005-1,SVEU - CONDUCT OF STUDIES IN NONHUMAN PRIMATES: REIMMUNIZATION AND CHALLENG,438713,2013-05-01,2013.0,2015-04-30,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857015,272201300002I-2-27200004-1,SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY,2069231,2013-05-01,2013.0,2015-04-30,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857014,272201300002I-2-27200003-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,247531,2013-05-01,2013.0,2015-04-30,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857013,272201300002I-2-27200002-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,285645,2013-05-01,2013.0,2015-04-30,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857012,272201300002I-2-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,488790,2013-05-01,2013.0,2015-04-30,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857011,272201300002I-0-27200011-1,IN VIVO SHIV TITRATION VIS INTRARECTAL ROUTE IN INDIAN-ORIGIN REHESUS MACAQUES,242453,2014-09-18,2014.0,2015-09-17,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857010,272201300002I-0-27200010-1,TIER 2 SHIV-C CHALLENAGE OF NONHUMAN PRIMATES PREVIOUSLY PROTECTED FROM TIER 1 SHIV-C CHALLENGE,449958,2014-09-05,2014.0,2015-11-14,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857009,272201300002I-0-27200009-1,PREPARATION OF SHIV VIRUS STOCK,90032,2014-09-01,2014.0,2015-08-15,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3749682,QLK2-CT-1999-00871,European network for vaccine evaluation in primates: combined vector immunisations for aids vaccine development,2860561,2000-02-01,2000.0,2003-07-31,2003,German Primate Center; Biomedical Primate Research Centre; Head of The Unit of Foodborne Zoonoses and Veterinary Epidemiology; Public Health England; Paul Ehrlich Institut; Public Health Agency of Sweden; Atomic Energy and Alternative Energies Commission; Public Health England,grid.418215.b; grid.11184.3d; grid.30579.38; grid.271308.f; grid.425396.f; grid.419734.c; grid.5583.b; grid.271308.f,Germany; Netherlands; Italy; United Kingdom; Germany; Sweden; France; United Kingdom,European Commission,Belgium,5,0,0
grant.2347716,272201300004I-0-27200002-1,SVEU - Maintenance of NHPs,191821,2013-05-01,2013.0,2014-04-30,2014,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347715,272201300004I-0-27200001-1,SVEU - Core Activities - Administrative and Technical Support,239730,2013-05-01,2013.0,2014-04-30,2014,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347713,272201300003I-0-27200005-1,SVEU - IMMUNOGENICITY OF A NONINTEGRATING INTEGRASE-DEFECTIVE LENTIVIRAL VECTOR,276309,2013-06-21,2013.0,2015-08-20,2015,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2347712,272201300003I-0-27200004-1,SVEU - Evaluation of Prime-Boost Regimen Emplyoing Clade C Proteins,335623,2013-06-21,2013.0,2014-11-07,2014,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347711,272201300003I-0-27200003-1,SVEU - Reimmunization and Challenge Studies,1436214,2013-05-01,2013.0,2015-04-30,2015,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347710,272201300003I-0-27200002-1,SVEU - Maintenance of Nonhuman Primates,232415,2013-05-01,2013.0,2014-04-30,2014,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347709,272201300003I-0-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,549981,2013-05-01,2013.0,2014-04-30,2014,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347706,272201300002I-0-27200007-1,"SVEU - Prime Boost Efficacy, Boosting Immunization, and Virus Challenge Studies",625247,2013-06-21,2013.0,2014-11-07,2014,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347705,272201300002I-0-27200006-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,89448,2013-06-10,2013.0,2013-10-09,2013,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347704,272201300002I-0-27200005-1,SVEU - CONDUCT OF STUDIES IN NONHUMAN PRIMATES: REIMMUNIZATION AND CHALLENG,734103,2013-05-01,2013.0,2015-04-30,2015,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347703,272201300002I-0-27200004-1,SVEU - OPERATION OF A NONHUMAN PRIMATE BREEDING COLONY,2066824,2013-05-01,2013.0,2014-04-30,2014,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347702,272201300002I-0-27200003-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,269544,2013-05-01,2013.0,2014-04-30,2014,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347701,272201300002I-0-27200002-1,SVEU - MAINTENANCE OF NONHUMAN PRIMATES,278866,2013-05-01,2013.0,2014-04-30,2014,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347700,272201300002I-0-27200001-1,SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT,474656,2013-05-01,2013.0,2014-04-30,2014,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.8593316,a9565a62-fa09-4b74-bccf-ce52582b2add,Polymeric microparticulate vaccine formulations based on hydrogen bonding,0,2014-03-01,2014.0,2017-09-30,2017,Ghent University; Ghent University,grid.5342.0; grid.5342.0,Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8106367,UofG2011-1220,Enhancing the efficacy of poultry vaccines using innate immune adjuvants,0,2012-07-02,2012.0,2016-04-30,2016,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.7874837,1103367,How do cross-reactive memory B cells affect influenza vaccine titers?,600108,2016-01-01,2016.0,2019-01-01,2019,University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6783786,573138580,Understanding Bacille Calmette Guerin's immune-defenses to generate a truly protective TB vaccine.,0,2011-07-01,2011.0,2016-04-30,2016,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6723674,1074296,Dengue fever vaccine: Towards low cost production and delivery,467820,2014-01-01,2014.0,2017-12-31,2017,University of Queensland; University of Queensland; University of Queensland; University of Queensland,grid.1003.2; grid.1003.2; grid.1003.2; grid.1003.2,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6581736,OPP1109526,"To inform members of Congress that 1) U.S. investments in vaccine research and development are working, 2) that there are some exciting new directions in vaccine research that could lead to new or improved vaccines for many of the most intractable infectious diseases, for which we do not have vaccines or only partially effective vaccines, and 3) to provide an outline of the resources needed that could dramatically accelerate these advances",23165,2014-04-01,2014.0,2015-01-01,2015,Foundation for Vaccine Research,grid.475547.0,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6107935,25293336,Development of multi-peptide tumor vaccine for renal cell carcinoma,166811,2013-04-01,2013.0,2016-03-31,2016,Kindai University,grid.258622.9,Japan,Japan Society for the Promotion of Science,Japan,5,0,0
grant.4890245,489/L-4/2012,Jadalna szczepionka przeciwko wirusowi grypy dla drobiu (Oral vaccine against influenza virus for poultry).,331358,2013-12-01,2013.0,2017-11-30,2017,University of Gdańsk,grid.8585.0,Poland,National Centre for Research and Development,Poland,0,0,0
grant.3950330,2009-65119-05733,MANNHEIMIA HAEMOLYTICA CHIMERIC PROTEIN VACCINE FOR DELIVERY OF MULTIPLE OUTER MEMBRANE PROTEIN AND LEUKOTOXIN ANTIGENS,374989,2013-09-01,2013.0,2014-04-30,2014,Oklahoma State University; Oklahoma State University,grid.65519.3e; grid.65519.3e,United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3817924,0215819,"EVALUATION OF LIVE, ATTENUATED BRUCELLA VACCINE CANDIDATES",0,2014-10-21,2014.0,2019-08-28,2019,Tennessee State University,grid.280741.8,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3815156,0227849,"IMMUNOINFORMATICS DRIVEN, GENOME DERIVED FISH VACCINE AGAINST THE BACTERIAL PATHOGEN V. ANGUILLARUM",0,2011-10-01,2011.0,2012-09-30,2012,University of Rhode Island; University of Rhode Island; University of Rhode Island,grid.20431.34; grid.20431.34; grid.20431.34,United States; United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3654851,536632,Market assessment and feasibility study on fowl adenovirus (FAdV) vaccine in chicken,9705,2013-04-01,2013.0,2014-03-31,2014,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2769922,BBS/E/I/00001237,Dissection of protective responses to heterologous Campylobacter vaccines,591008,2006-06-30,2006.0,2009-06-29,2009,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.2718430,Z01HD002511,IMMUNOGENICITY OF ROUTINE CHILDHOOD VACCINES IN HIV POSITIVE CHILDREN,0,1994-01-01,1994.0,1994-12-31,1994,National Institute of Child Health and Human Development,grid.420089.7,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.2709168,Z01AI005003,Influenza Vaccine Development,2673357,2002-01-01,2002.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2425014,N01AI095379,HIV VACCINE PRODUCTION,110985,1999-06-30,1999.0,2006-06-29,2006,SRI International,grid.98913.3a,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425013,N01AI095378,HIV VACCINE PRODUCTION,78512,1999-07-07,1999.0,2006-07-06,2006,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425012,N01AI095377,HIV VACCINE PRODUCTION,0,1999-07-07,1999.0,2006-07-06,2006,Progenics Pharmaceuticals (United States),grid.280766.d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425011,N01AI095376,HIV VACCINE PRODUCTION,0,1999-07-09,1999.0,2006-07-08,2006,Vical (United States),grid.422245.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347755,272201300033C-10-0-1,"HIV Vaccine Design and Development Teams, Part A- Preventative Vaccines",2186845,2013-09-27,2013.0,2015-12-31,2015,Novartis (United States),grid.418424.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3811630,0219036,GENETICS OF BOVINE VACCINE RESPONSE,0,2009-07-01,2009.0,2014-09-30,2014,South Dakota State University,grid.263791.8,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.2724237,ZIABC011356,FLSC - Vaccine Branch HIV Vaccine Primate Study,9808478,2010-01-01,2010.0,2012-01-01,2012,,,,National Cancer Institute,United States,0,0,0
grant.2723417,ZIAAI005047,Biodefense/Emerging Infection Vaccine Studies,31219180,2009-01-01,2009.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,41,0,0
grant.7665986,,Understanding the publics' response to the H1N1 vaccine,94733,2010-03-01,2010.0,2011-02-28,2011,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.6720191,251563,Determinants of the clearance of HIV infected cells by successful AIDS vaccines,122302,2003-01-01,2003.0,2003-12-31,2003,University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6381020,1006533,DETECTION AND CONTROL OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND EMERGING VIRAL DISEASES OF SWINE,0,2015-07-01,2015.0,2019-09-30,2019,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.5596486,04454281,RESEARCHES ON IMPROVEMENT OF PERTUSSIS VACCINE,56901,1992-01-01,1992.0,1994-12-31,1994,Tokai University,grid.265061.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5501782,hrc_34e130fc,Chromatin nanofibre as a therapeutic cancer vaccine,105485,2016-01-01,2016.0,2018-01-01,2018,Massey University,grid.148374.d,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.7001888,31100658,创伤弧菌DNA疫苗免疫欧洲鳗鲡的研究,32164,2012-01-01,2012.0,2014-12-31,2014,,,,National Natural Science Foundation of China,China,0,0,0
grant.5932057,17390129,Novel Vaccines against Pseudomonas aeruginosa and Other Microorganisms,127290,2005-01-01,2005.0,2006-12-31,2006,Yokohama City University,grid.268441.d,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.2709799,Z01BA007028,REGIONAL SYSTEM FOR VACCINES,0,1992-01-01,1992.0,1992-12-31,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2687851,U01AI069481,Seattle Vaccine Trials Unit,3004113,2007-02-01,2007.0,2013-12-31,2013,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,National Institute of Allergy and Infectious Diseases,United States,29,0,0
grant.7560606,,"Estudo das possíveis interferências dos múltiplos componentes na avaliação da potência do antígeno da hepatite b, nas vacinas combinadas",0,2012-12-05,2012.0,2016-09-30,2016,Oswaldo Cruz Foundation,grid.418068.3,Brazil,National Council for Scientific and Technological Development,Brazil,0,0,0
grant.3634487,077343/Z/05/Z,"Contribution to the WHO Global Vaccine Research Forum to be held at Salvador da Bahia, Brazil on the 12 - 15 June 2005.",18180,2005-06-12,2005.0,2005-07-11,2005,World Health Organization,grid.3575.4,Switzerland,Wellcome Trust,United Kingdom,0,0,0
grant.8107232,25968,Immunogenicity and efficacy of vaccines for pneumonic pasteurelllosis in lambs,0,2003-05-01,2003.0,2005-04-30,2005,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8106298,UofG2012-1341,Better control of Bacterial Cold Water Disease in farmed rainbow trout by the development of an effective Flavobacterium psychrophilum vaccine,0,2013-06-01,2013.0,2016-12-31,2016,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.7877531,1126379,Developing a quadrivalent HCV vaccine,494472,2017-01-01,2017.0,2019-01-01,2019,University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7875034,1150999,Population-level vaccine safety monitoring: risk assessment and policy implications,63052,2018-01-01,2018.0,2019-01-01,2019,University of Sydney,grid.1013.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7644259,,Use of Streptococcus gordonii as a live oral vector to prevent infectious diseases,218826,2003-04-01,2003.0,2006-03-31,2006,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7644256,,Use of Streptococcus gordonii as a live oral vaccine vehicle,115696,2006-10-01,2006.0,2009-09-30,2009,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.6887620,GA312/95/0137,Využití klonovaného imunoregulačního IL-2 genu pro přípravu protinádorových vakcin,88299,1995-01-01,1995.0,1997-12-31,1997,Institute of Molecular Genetics; Institute of Haematology and Blood Transfusion,grid.418827.0; grid.419035.a,Czechia; Czechia,Czech Science Foundation,Czechia,1,0,0
grant.6734139,1016272,Immunisation practice and policy development in Australia: responding to urgent priorities in prevention of endemic and epidemic infectious diseases in children.,394665,2011-01-01,2011.0,2014-12-31,2014,University of Adelaide,grid.1010.0,Australia,National Health and Medical Research Council,Australia,20,0,0
grant.6732327,1036470,Innate immune effector recruiting potential of HIV-1 human vaccine induced antibodies,286490,2012-01-01,2012.0,2017-12-31,2017,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,5,0,0
grant.6714226,605810,Single versus combination pneumococcal conjugate vaccines (13PCV and PHiD-CV) for high-risk Aboriginal children (COMBO),2927343,2010-01-01,2010.0,2014-12-31,2014,Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research,grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6378493,1004893,ORAL VACCINATION OF DOMESTIC SHEEP AGAINST MANNHEIMIA HAEMOLYTICA LEUKOTOXIN UTILIZING A NOVEL RECOMBINANT BACTERIOPHAGE,0,2014-10-01,2014.0,2017-09-30,2017,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.6140485,26460511,A New nanoparticle glycogen for development of vaccine against malaria,44079,2014-04-01,2014.0,2017-03-31,2017,Kagoshima University,grid.258333.c,Japan,Japan Society for the Promotion of Science,Japan,9,0,0
grant.6092952,24591939,Spreading immune-reactions in esophageal cancer patients who were given cancer vaccine and whose tumors co-express additional antigens,55375,2012-04-01,2012.0,2015-03-31,2015,Mie University,grid.260026.0,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.5861265,15H04869,Lipid immunity in rhesus monkeys and development of a new anti-tuberculosis vaccine,156568,2015-04-01,2015.0,2018-03-31,2018,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.4936643,30571719,自制口服DNA疫苗的粘膜表达部位与诱导肠IEL效应机制的研究,36061,2006-01-01,2006.0,2008-12-31,2008,China Medical University,grid.412449.e,China,National Natural Science Foundation of China,China,2,0,0
grant.4914039,39960047,鼠透明带DNA免疫不育疫苗的研究,14488,2000-01-01,2000.0,2002-12-31,2002,Xinjiang University,grid.413254.5,China,National Natural Science Foundation of China,China,0,0,0
grant.4908668,30471621,HIV壳体蛋白疫苗的免疫原性研究,30306,2005-01-01,2005.0,2007-12-31,2007,Shandong Academy of Medical Science,grid.410587.f,China,National Natural Science Foundation of China,China,1,0,0
grant.4579636,104750/Z/14/Z,A multi-component high efficacy malaria vaccine.,2760093,2014-09-01,2014.0,2019-08-31,2019,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,38,0,0
grant.3743835,QLK2-CT-1999-00938,The development of vaccines to prevent shigella infections,1342449,2000-02-01,2000.0,2004-02-01,2004,Pasteur Institute; University of Oxford; Université Libre de Bruxelles; Sapienza University of Rome,grid.428999.7; grid.4991.5; grid.4989.c; grid.7841.a,France; United Kingdom; Belgium; Italy,European Commission,Belgium,4,0,0
grant.3576877,LP0883901,Enhancing immunogenicity of DNA vaccines by targeted delivery to antigen presenting cells,64655,2008-01-01,2008.0,2009-12-31,2009,University of Melbourne; Lipotek (Australia),grid.1008.9; grid.479404.a,Australia; Australia,Australian Research Council,Australia,0,0,0
grant.3572390,LP0218929,Novel vaccines and serotyping scheme for Haemophilus parasuis,111991,2002-01-01,2002.0,2004-12-31,2004,University of Queensland,grid.1003.2,Australia,Australian Research Council,Australia,3,0,0
grant.3030814,0222597,Exploratory Research On Engineering The Service Sector: Collaborative Research: Research on Designing Vaccine Formularies for Childhood Immunization,110477,2003-01-01,2003.0,2005-06-30,2005,University of Illinois at Urbana Champaign,grid.35403.31,United States,Directorate for Engineering,United States,3,0,0
grant.3030807,0222554,Exploratory Research On Engineering The Service Sector: Collaborative Research: Research on Designing Vaccine Formularies for Childhood Immunization,39522,2003-01-01,2003.0,2005-06-30,2005,Southern Illinois University Edwardsville,grid.263857.d,United States,Directorate for Engineering,United States,2,0,0
grant.2726463,ZICAI005124,Immunology Core,6394689,2013-01-01,2013.0,2016-01-01,2016,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,17,0,0
grant.2723432,ZIAAI005082,Ebola Vaccine Immune Correlates and Mechanism of Protection,10050972,2009-01-01,2009.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,14,0,0
grant.2723219,ZIAAI001003,Malaria Vaccine:  BSAM,5305432,2009-01-01,2009.0,2012-01-01,2012,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,15,0,0
grant.2709263,Z01AI005973,Testing of Blood Samples for Immune Response and Vaccine,0,2006-01-01,2006.0,2006-12-31,2006,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2709246,Z01AI005082,Ebola Vaccine Immune Correlates and Mechanism of Protection,1149705,2005-01-01,2005.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2709237,Z01AI005073,Testing of Blood Samples for Immune Response and Vaccine Research,2627641,2004-01-01,2004.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,18,0,0
grant.2709213,Z01AI005048,Vaccine Studies in HIV-infected Subjects,723267,2003-01-01,2003.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5147109,NIHRDH-HTA/09/94/01,Head-to-head comparison of two H1N1 swine influenza vaccines in children aged 6 months to 12 years,957312,2009-09-26,2009.0,2010-03-25,2010,Public Health England,grid.271308.f,United Kingdom,NIHR Evaluation Trials and Studies Coordinating Centre,United Kingdom,1,0,0
grant.3774990,44115,Efficacious vaccine formulation system for prophylactic control of influenza pandemics,4626733,2007-01-01,2007.0,2011-06-30,2011,Federal Department of Economic Affairs Education and Research; Sciprom (Switzerland); Helmholtz Centre for Infection Research; Retroscreen Virology (United Kingdom); University of Bergen; Public Health England; National Institute of Health,grid.18068.37; grid.437903.a; grid.7490.a; grid.425987.5; grid.7914.b; grid.271308.f; grid.416651.1,Switzerland; Switzerland; Germany; United Kingdom; Norway; United Kingdom; Italy,European Commission,Belgium,14,0,0
grant.2726425,ZIBAI005118,ARRA: Process Development and Manufacture of Universal Influenza Vaccine,13400000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2459886,R01AI105170,VLP Vaccine Technology,3743620,2013-01-15,2013.0,2018-12-31,2018,Georgia State University,grid.256304.6,United States,National Institute of Allergy and Infectious Diseases,United States,84,1,0
grant.7172484,272201300003I-0-27200013-1,Immunogenicity and Efficacy of a Bivalent Clade B gp120 Protein Boost for aDNA/MVA Vaccine,746628,2017-08-01,2017.0,2019-05-31,2019,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499752,272201300004I-2-27200003-1,EFFICACY OF DNA AND PROTEIN CO-IMMUNIZATION PROTOCOL TO PROTECT MACAQUES FORM SHIV INFECTION,1347763,2014-09-05,2014.0,2018-08-31,2018,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5880876,16017324,重症急性呼吸器症候群(SARS)ウイルスに対するワクチン開発と免疫防御機構の研究,115466,2004-01-01,2004.0,2005-12-31,2005,National Kinki Chuo Hospital for Chest Disease,grid.415611.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5245884,272201300004I-1-27200003-1,EFFICACY OF DNA AND PROTEIN CO-IMMUNIZATION PROTOCOL TO PROTECT MACAQUES FORM SHIV INFECTION,609583,2014-09-05,2014.0,2016-09-04,2016,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857024,272201300004I-0-27200003-1,EFFICACY OF DNA AND PROTEIN CO-IMMUNIZATION PROTOCOL TO PROTECT MACAQUES FORM SHIV INFECTION,1879802,2014-09-05,2014.0,2016-09-04,2016,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3732274,BMH4960984,An evaluation of HIB vaccination and description of risk factors for HIB vaccine failure in Europe,0,1996-04-01,1996.0,1999-03-31,1999,Public Health England,grid.271308.f,United Kingdom,European Commission,Belgium,1,0,0
grant.3638486,100157/Z/12/Z,Advancing human and veterinary vaccinology.,2101817,2013-07-01,2013.0,2017-03-31,2017,University of Oxford; University of Oxford; University of Oxford,grid.4991.5; grid.4991.5; grid.4991.5,United Kingdom; United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,2,0,0
grant.3630621,079126/Z/06/Z,Pneumococcal vaccine escape: genome-wide characterisation of recombinants arising after vaccine implementation.,486798,2006-10-01,2006.0,2010-03-31,2010,University of Oxford; University of Oxford; University of Oxford; University of Oxford,grid.4991.5; grid.4991.5; grid.4991.5; grid.4991.5,United Kingdom; United Kingdom; United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,1,0,0
grant.2709212,Z01AI005047,Biodefense/Emerging Infection Vaccine Studies,2543724,2003-01-01,2003.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2424468,N01AI015129,VACCINE PRODUCTION FACILITY,0,1991-09-30,1991.0,1997-12-31,1997,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.8595279,26_3992,Development of mass spectrometry methods for the quantification and characterization of antigens during the vaccine development process,0,2014-10-01,2014.0,2016-11-30,2016,University of Liège,grid.4861.b,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8594208,e9c88ce1-f6bf-42f3-8274-6ac467718b24,Vaccine and diagnostics development against swine dysentery,0,2016-04-01,2016.0,2018-01-31,2018,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8591102,00585ebc-00fb-4678-84a4-eb9c17e83946,Development of a vaccine against reproductive failure in pigs,0,2015-04-15,2015.0,2017-08-09,2017,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8446493,2010-02158,Development and comparative evaluation of three new generation BRSV DIVA vaccines and a corresponding DIVA test,424610,2010-01-01,2010.0,2010-12-31,2010,Swedish University of Agricultural Sciences,grid.6341.0,Sweden,Swedish Research Council for Environment Agricultural Sciences and Spatial Planning,Sweden,0,0,0
grant.8218376,39870100,精子表面蛋白DNA 疫苗生物控制害鼠的研究,13284,1999-01-01,1999.0,2001-12-31,2001,Institute of Zoology,grid.458458.0,China,National Natural Science Foundation of China,China,0,0,0
grant.8041818,13N11738,Verbundprojekt: Development of a hepatitis C vaccine by targeted delivery of nanogel RNA-replicon constructs (HCVAX) - Teilvorhaben: Immunologische funktionelle Assays für die in vitro Analyse eines Nanogel-basierten Hepatitis C Impfstoffes,457876,2011-07-01,2011.0,2014-06-30,2014,Myriad Genetics (Germany),grid.473925.e,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8036880,13GW0127A,"CI3: Realisierung von Software, Planungs- und Steuerungsmodulen für die beschleunigte automatisierte Herstellung individualisierter MUTANOM-Vakzine (IVAC IT) - Teilvorhaben: Einsatz von innovativen Softwarelösungen als Grundlage zur iterativen Verbesserung von IVAC MUTANOME Impfstoffen",1051770,2015-08-01,2015.0,2017-03-31,2017,BioNTech (Germany),grid.434484.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8025091,03ZZ0820D,"Zwanzig20 - InfectControl 2020 - Verbundvorhaben: Molekulare Serologie zur schnellen Bestimmung der Impftiter gegen impf-präventable Infektionskrankheiten (STIKO-Liste) bei Migranten und anderen Patientengruppen, Teilvorhaben: STIKO-Serologie - TV4",214536,2016-10-01,2016.0,2019-09-30,2019,Jena University Hospital,grid.275559.9,Germany,Federal Ministry of Education and Research,Germany,3,0,0
grant.8025090,03ZZ0820C,"Zwanzig20 - InfectControl 2020 - Verbundvorhaben: Molekulare Serologie zur schnellen Bestimmung der Impftiter gegen impf-präventable Infektionskrankheiten (STIKO-Liste) bei Migranten und anderen Patientengruppen, Teilvorhaben: STIKO-Serologie - TV3",251869,2016-10-01,2016.0,2019-09-30,2019,Institut Virion\Serion,grid.482452.d,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8025089,03ZZ0820B,"Zwanzig20 - InfectControl 2020 - Verbundvorhaben: Molekulare Serologie zur schnellen Bestimmung der Impftiter gegen impf-präventable Infektionskrankheiten (STIKO-Liste) bei Migranten und anderen Patientengruppen, Teilvorhaben: STIKO-Serologie - TV 2 'Mikroarrays'",281392,2016-10-01,2016.0,2019-09-30,2019,Alere (Germany),grid.472845.8,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8025088,03ZZ0820A,"Zwanzig20 - InfectControl 2020 - Verbundvorhaben: Molekulare Serologie zur schnellen Bestimmung der Impftiter gegen impf-präventable Infektionskrankheiten (STIKO-Liste) bei Migranten und anderen Patientengruppen, Teilvorhaben: STIKO-Serologie - TV1",364448,2016-10-01,2016.0,2019-09-30,2019,Friedrich Schiller University Jena,grid.9613.d,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7986569,0310616B/0,Entwicklung von in vitro Methoden als Ersatz für Letalchaellengeversuche an Fischen zur Beurteilung von Vakzinen - Phase II - Teilprojekt 2: Optimierung und Standardisierung eines ELISA-Systems für Furunkulose-Vakzine,375122,1997-04-01,1997.0,2000-03-31,2000,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7652306,,Development of Molecular Adjuvants for HIV-1 Canarypox  Vaccines,61388,2005-03-01,2005.0,2006-02-28,2006,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7608126,SERB_70292a3cc6,Construction and studies on vaccine potential of chimeric protein molecules comprising immunodominant regions of outer membrane proteins of enterobacteriacease for application as broad spectrum vaccine against salmonella shigella E Coil and proteus,49831,2016-04-01,2016.0,2017-03-31,2017,,,,Science and Engineering Research Board,India,0,0,0
grant.7560596,,Associação entre antígenos tumorais ao vírus vacinal da febre amarela yf 17d como vetor vacinal contra o câncer,0,2014-11-18,2014.0,2017-11-30,2017,Oswaldo Cruz Foundation,grid.418068.3,Brazil,National Council for Scientific and Technological Development,Brazil,0,0,0
grant.7559701,,Associação entre antígenos tumorais ao vírus vacinal da febre amarela yf 17d como vetor vacinal contra o câncer,0,2014-11-18,2014.0,2017-11-30,2017,Oswaldo Cruz Foundation,grid.418068.3,Brazil,National Council for Scientific and Technological Development,Brazil,0,0,0
grant.7400758,Pbmn121,Immunogenność szczepienia przypominającego przeciw krztuścowi przy użyciu szczepionki typu dTap u dzieci z nowotworami i po transplantacji komórek hematopoetycznych.,7603,2013-01-01,2013.0,2016-12-31,2016,Wrocław Medical University,grid.4495.c,Poland,Ministry of Science and Higher Education,Poland,0,0,0
grant.7390106,OPP1181682,To better track vaccines and improve supply chains in developing countries by using radio-frequency identification tags (RFID) on vaccine packages that can be detected by near field communication (NFC) found on most smartphones,100000,2017-10-01,2017.0,2019-05-01,2019,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7389561,OPP1182320,To ensure quality vaccines are available when needed by developing an application along with blockchain technology to monitor the supply chains delivering vaccines from producers to health workers,100000,2017-10-01,2017.0,2019-05-01,2019,Jomo Kenyatta University of Agriculture and Technology,grid.411943.a,Kenya,Bill & Melinda Gates Foundation,United States,1,0,0
grant.7211661,201600518,"Cytomegalovirus (CMV) vaccine development: A study of viral tropism, genomic diversity and neutralizing epitopes in CMV positive clinical samples",209056,2017-03-01,2017.0,2018-09-30,2018,University of Alberta; University of Alberta; University of Alberta; University of Alberta,grid.17089.37; grid.17089.37; grid.17089.37; grid.17089.37,Canada; Canada; Canada; Canada,Alberta Innovates,Canada,0,0,0
grant.7170506,275201500006I-1-27500002-1,IGF::OT::IGF:THE SCRIPPS RESEARCH INSTITUTE. TASK ORDER 2 (HHSN275201500006I/HHSN27500002).PRODUCTION AND DISTRIBUTION OF INVESTIGATIONAL GHRELIN VACCINES--GHRELIN VACCINE AGAINST RAT HORMONE. 09/21/,24333,2016-09-21,2016.0,2017-09-20,2017,Scripps Research Institute,grid.214007.0,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.7170505,275201500006I-0-27500003-1,IGF::OT::IGF:The Scripps Research Institute. Task Order 3 (HHSN275201500006I/HHSN27500003).Production and Distribution of Investigational Ghrelin Vaccines--Ghrelin Vaccine Against Rat Hormone. 09/21/,122391,2017-09-21,2017.0,2018-09-20,2018,Scripps Research Institute,grid.214007.0,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.7170202,APC16011001-1-0-1,CPCRN Special Project on HPV Vaccine Uptake,61006,2017-01-01,2017.0,2017-12-31,2017,National Cancer Institute,grid.48336.3a,United States,National Cancer Institute,United States,0,0,0
grant.7131991,W81XWH-06-1-0348,"Cancer Vaccine (for Continued Development of Molecular Switching Vaccines Using Genetically Modified Listeria for Cancer, Infectious Disease and Bio-Defense)",4927000,2004-10-01,2004.0,2005-09-01,2005,Cerus (United States),grid.418416.e,United States,Congressionally Directed Medical Research Programs,United States,6,0,0
grant.6897600,OC 848.002,Odvození a charakterizace oslabené linie Eimeria flavescens a vývoj vakcíny proti kokcidióze králíků.,417016,2001-01-01,2001.0,2005-12-31,2005,BioPharma (Czechia),grid.448012.b,Czechia,Ministry of Education Youth and Sports,Czechia,0,0,0
grant.6735776,1055321,Optimizing a vaccine for HPV immunotherapy,187878,2013-01-01,2013.0,2015-12-31,2015,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6734643,1041802,Developing drugs and vaccines for malaria by undertaking experimental studies in humans,330375,2013-01-01,2013.0,2017-12-31,2017,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,5,0,0
grant.6733494,1012425,RV3 Rotavirus Vaccine: A human neonatal rotavirus vaccine for the Asia-Pacific region,2288617,2011-01-01,2011.0,2013-12-31,2013,Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute,grid.1058.c; grid.1058.c; grid.1058.c,Australia; Australia; Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6586489,OPP1125745,To improve understanding of how conjugate vaccines impact pneumococcal ecology and to inform how vaccines of higher valences can be most effectively used to reduce the burden of pneumococcal illness,131330,2015-03-01,2015.0,2016-09-01,2016,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6586167,OPP1131826,To support the implementation of phase IV clinical trials in adults to evaluate the safety and reactogenicity of monovalent type 2 and trivalent Oral Polio Vaccine for future comparisons with data on new Oral Polio Vaccines,3095548,2015-10-01,2015.0,2019-05-01,2019,University of Antwerp,grid.5284.b,Belgium,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585950,OPP48901,"To design, produce and test in preclinical and clinical studies new material forms of drugs and vaccines for improved drug and vaccine delivery to patients in developing countries",8322236,2007-11-01,2007.0,2010-11-01,2010,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585864,OPP1016829,To identify biomarkers of correlates of protection against pre-erythrocytic (PE) malaria infection that will enable down selection of vaccine antigens and predict outcomes of trials for anti-infection vaccines against Plasmodium falciparum,6671738,2011-03-01,2011.0,2014-06-01,2014,Center for Infectious Disease Research,grid.53964.3d,United States,Bill & Melinda Gates Foundation,United States,8,0,0
grant.6585745,OPP1044260,"To study the pattern and severity of childhood pneumonia before and after pneumococcal vaccination, evaluate the vaccine status of children with severe illnesses, and analyze the cost effectiveness of the pneumococcal vaccine in Malawi",2164081,2011-10-01,2011.0,2014-10-01,2014,University College London,grid.83440.3b,United Kingdom,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6585214,OPPGH5333,"To generate information on the impact of a Japanese encephalitis vaccination program, using a safe, affordable Japanese encephalitis vaccine produced by a developing country manufacturer, and to support expanded use of the vaccine",3266919,2009-11-01,2009.0,2019-04-01,2019,Centers for Disease Control and Prevention,grid.416738.f,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584814,OPP1007931,"To test the efficacy of administering two approved vaccines directly under the tongue, which could help improve vaccine delivery, compliance, and enhance immunity against a variety of pathogens.",100000,2009-11-01,2009.0,2012-05-01,2012,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584759,OPP1156378,To assess delivery strategies for tetanus vaccine during pregnancy and to understand how antenatal care and maternal immunization can be strengthened to optimally deliver current and future vaccines to pregnant women,2155957,2016-10-01,2016.0,2019-10-01,2019,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584546,OPP1149211,To build imaging capacity (PET-CT scanning) of the Tulane National Primate Research Center for TB vaccine studies as a part of a service component of the Collaboration for TB Vaccine Discovery (CTVD),1999982,2016-05-01,2016.0,2019-06-01,2019,Tulane University,grid.265219.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584455,OPP1068073,To further optimize the immune response to a combined placental malaria and cervical cancer vaccine and investigate the scalability and efficient production of such a vaccine for the developing world.,813050,2012-10-01,2012.0,2015-01-01,2015,University of Copenhagen,grid.5254.6,Denmark,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584450,OPP1045760,"To use a new vaccine technology to produce non-infectious poliovirus-like particles that can be used in one highly effective, low-cost polio vaccine capable of inducing protective immunity against all circulating serotypes.",100000,2011-09-01,2011.0,2013-11-01,2013,Biological Mimetics (United States),grid.465136.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584406,OPP1136714,"To accelerate the development of therapeutics and vaccines by formalizing an experimental medicine model of Cryptosporidium hominis, the most prevalent cause of human cryptosporidiosis, that can be used to test candidate therapeutics and vaccines",3283816,2015-11-01,2015.0,2019-03-01,2019,University of Vermont,grid.59062.38,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584404,OPP53213,To develop a novel vaccine for TB based on existing BCG vaccines modifi ed to express a gene that is specifi c to latent TB in order to generate a robust immune response to a latent infection.,100000,2009-05-01,2009.0,2010-11-01,2010,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584109,OPP1127318,To reduce cholera burden globally and make the case for rational use of oral cholera vaccines by evaluating strategies to most effectively deploy Oral Cholera Vaccines across multiple settings,662094,2015-05-01,2015.0,2017-06-01,2017,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,4,0,0
grant.6584024,OPPGH5265,"To develop a blueprint for strengthening global vaccine safety and coordination between different agencies working on vaccine safety issues, identifying core capacities at various levels, and how these activities can be can be funded and sustained",1091584,2009-09-01,2009.0,2011-12-01,2011,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583631,OPP1048143,"To evaluate the safety of oral polio vaccine (OPV) by monitoring the incidence of vaccine-associated paralytic poliomyelitis (VAPP) in China, and to provide useful genomic & bio-feature information for developing a safer OPV",1068783,2012-10-01,2012.0,2014-08-01,2014,Chinese Center For Disease Control and Prevention,grid.198530.6,China,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583583,OPP1131997,To develop and update an assessment framework for the long-term viability of vaccine manufacturers for the traditional Expanded Program on Immunization vaccines and insights into factors that influence their success,405750,2015-07-01,2015.0,2017-07-01,2017,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6583497,OPP1041149,"To catalyze TB vaccine research and development in China and promote collaboration between international and Chinese researchers with the common goal of developing new, more effective TB vaccines",50000,2011-08-01,2011.0,2011-12-01,2011,Aeras,grid.432518.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583423,OPP1139845,"To enable development of the Vaccine Development and Introduction Platforms, which will position PATH to evaluate and progress a robust pipeline of global health vaccine projects from product concept to impact with industry-standard quality, speed, and effectiveness",10928780,2015-11-01,2015.0,2019-04-01,2019,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583264,OPP1095702,To examine the etiology of cases of diarrhea at one rotavirus vaccine clinical trial site in India in order to gather data that will help establish priorities for future enteric vaccine development,77256,2013-11-01,2013.0,2014-07-01,2014,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583173,OPP1015309,To test the theory that providing children with antihelminthic and anti-giardiasis drugs prior to administration of an oral typhoid vaccine ill produce a robust immune response to the vaccine.,100000,2010-05-01,2010.0,2011-11-01,2011,International Centre for Diarrhoeal Disease Research,grid.414142.6,Bangladesh,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583098,OPP1123814,"To identify, evaluate, and apply platform vaccine formulation and stabilization technologies to accelerate the development and introduction of safe, efficacious, and programmatically suitable vaccines in low- to middle-income countries",600000,2015-04-01,2015.0,2019-04-01,2019,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583000,OPP1141998,"To translate the History of Vaccines website into Hindi, Urdu and Arabic and increase the reach of the site to audiences that currently have little access to reliable information about vaccines in their native languages",249261,2015-10-01,2015.0,2017-06-01,2017,College of Physicians of Philadelphia,grid.418804.1,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582999,OPP1151018,"To improve a malaria vaccine by combining it with a monoclonal antibody to increase competition for the vaccine antigen by antibody-producing immune cells, and with a molecule to prolong the survival of those immune cells",100000,2016-04-01,2016.0,2018-05-01,2018,Australian National University,grid.1001.0,Australia,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6582987,OPP1133631,To build imaging capacity (PET-CT scanning) of the University of Pittsburgh for TB vaccine studies as a part of a service component of the Collaboration for TB Vaccine Discovery (CTVD),1600000,2015-11-01,2015.0,2019-03-01,2019,University of Pittsburgh,grid.21925.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582771,OPP1160830,To maximize impact and accelerate development of new TB vaccines by creating and applying novel mathematical models to estimate the main target product profiles drivers for epidemiological impact of new TB vaccines,129913,2016-10-01,2016.0,2018-03-01,2018,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,Bill & Melinda Gates Foundation,United States,10,0,0
grant.6582742,OPP1141288,"To provide capacity building support for International Vaccine Institute to execute its 2015 strategic plan in support of its mission to discover, develop and deliver safe, effective, and affordable vaccines for global health",4982891,2015-10-01,2015.0,2018-11-01,2018,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582706,OPP1156831,"To assess safety and tolerability of different vaccine regimens with Ad26.Mos4.HIV, Ad26.Mos.HIV and Clade C gp140 and immunogenicity between the different vaccine regimens with Ad26.Mos4.HIV, Ad26.Mos.HIV and Clade C gp140",4472467,2016-10-01,2016.0,2019-06-01,2019,Janssen (Netherlands),grid.497529.4,Netherlands,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582244,OPP51828,To establish a program to link new vaccine discoveries with vaccine manufacturers in developing countries while simultaneously evaluating ways to help these manufacturers purchase rights to these innovative candidates.,99991,2008-10-01,2008.0,2010-03-01,2010,University of Michigan,grid.214458.e,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582226,OPPGH5375,"To develop an effective, stable intranasal nanoemulsion adjuvanted respiratory syncytial virus (RSV) vaccine for the developing world without the hyper-reactivity observed with prior RSV vaccines in clinical trials",5930094,2010-11-01,2010.0,2013-10-01,2013,NanoBio (United States),grid.479371.f,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6582137,OPP1115326,To accelerate the successful uptake of human papillomavirus vaccine in Gavi eligible countries and other low-resource settings by providing key information for national decision-making and planning on human papillomavirus vaccine introduction,1326233,2014-11-01,2014.0,2018-01-01,2018,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,Bill & Melinda Gates Foundation,United States,5,0,0
grant.6581980,OPP1117728,To determine if live attenuated influenza vaccine (LAIV) or trivalent influenza vaccine (TIV) affects the density and / or duration of pneumococcal colonization in healthy adults using the EHPC (Experimental Human Pneumococcal Carriage) model,2597817,2014-11-01,2014.0,2019-01-01,2019,Liverpool School of Tropical Medicine,grid.48004.38,United Kingdom,Bill & Melinda Gates Foundation,United States,10,0,0
grant.6581846,OPP1024631,"To integrate characteristics of heat shock proteins from thermophilic organisms, which live at relatively high temperatures, into attenuated bacterial vaccines to enhance viability and immunogenicity these vaccines during the freeze-drying process",100000,2010-11-01,2010.0,2012-05-01,2012,"University of Maryland, Baltimore",grid.411024.2,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581809,OPP1119033,"To identify malaria vaccine targets for the liver-stage of infection using novel, parasite cultivation strategies. These newly identified antigens may be used to supplement the existing RTS,S vaccine, improving levels of protection from malaria",455878,2015-11-01,2015.0,2018-01-01,2018,Naval Medical Research Center,grid.415913.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581790,OPP1045651,"To assess the capacity of six China National Biotec Group institutes to meet World Health Organization requirements for priority vaccines, to improve their potential to provide safe, effective, and affordable vaccines",1782978,2011-12-01,2011.0,2015-01-01,2015,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581425,OPP1053432,"To reduce the burden of dengue in developing countries by accelerating the introduction of safe and broadly protective dengue vaccines into public sector programs, especially for children, and support the development of dengue vaccine candidates",10044535,2013-03-01,2013.0,2018-01-01,2018,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6581394,OPP1117653,"To generate evidence and a prediction model to inform vaccine scheduling and the design of alternative Pneumococcal conjugate vaccine regimens focused on reducing carriage, person-to-person transmission and optimizing herd protection from disease",2047398,2014-10-01,2014.0,2019-09-01,2019,Liverpool School of Tropical Medicine,grid.48004.38,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581259,OPP1113642,To sustain and increase political support and financing for HIV vaccine research and development from European Union institutions and key Member States to help accelerate product development by ensuring a robust pipeline of vaccine candidates,1199081,2014-11-01,2014.0,2018-04-01,2018,International AIDS Vaccine Initiative,grid.420368.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581039,OPP51694,To design a mosquito that can produce and secrete a malaria vaccine protein into a host’s skin. The hope is that such mosquitoes could deliver protective vaccines against other infectious diseases as well.,100000,2008-10-01,2008.0,2009-10-01,2009,Jichi Medical University,grid.410804.9,Japan,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580990,OPP52797,To reduce the burden of cholera in endemic and epidemic settings with the use of a single dose regimen of the cholera vaccine developed by International Vaccine Institute (IVI) and recently licensed in India by Shantha Biotechnics,13430939,2009-10-01,2009.0,2018-01-01,2018,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6580975,OPP1061359,To develop a new vaccine technology that accumulates a high number of antigen-specific cells in the lymph nodes at the time of immunization to improve vaccine effectiveness,100000,2012-04-01,2012.0,2014-05-01,2014,National Institute of Health,grid.416651.1,Italy,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580961,OPP1142017,"To explore the value proposition and technical feasibility of blow-fill-seal for oral and injectable vaccines (IPV, Penta, HPV, PCV, Rota and Cholera), including other pipeline vaccines in development",715789,2016-03-01,2016.0,2019-01-01,2019,Rommelag (Switzerland),grid.479494.3,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580430,OPP631,"To develop a vaccine for leishmaniasis by focusing on the scientific and practical issues leading to the development of effective vaccines and therapies, initially in Brazil and India",15000000,2000-04-01,2000.0,2005-06-01,2005,Infectious Disease Research Institute,grid.53959.33,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580190,OPP1032144,"To facilitate the discovery of a safe, effective and practical HIV-1 vaccine by using valid laboratory criteria and Good Clinical Laboratory Practices to monitor antibody responses in the systemic and mucosal compartment in vaccine testing",31925352,2011-06-01,2011.0,2017-04-01,2017,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,28,0,0
grant.6500971,275201500006I-0-27500002-1,IGF::OT::IGF:THE SCRIPPS RESEARCH INSTITUTE. TASK ORDER 2 (HHSN275201500006I/HHSN27500002).PRODUCTION AND DISTRIBUTION OF INVESTIGATIONAL GHRELIN VACCINES--GHRELIN VACCINE AGAINST RAT HORMONE. 09/21/,93963,2016-09-21,2016.0,2017-09-20,2017,Scripps Research Institute,grid.214007.0,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.6500600,272201200003I-1-27200014-1,Task X14:  Evaluation of Ebola Vaccines,157455,2015-09-10,2015.0,2018-07-31,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500029,272201600032C-0-0-1,DEVELOPMENT OF A WEST NILE VIRUS VACCINE,440933,2016-08-30,2016.0,2018-08-29,2018,Molecular GPS Technologies (United States),grid.281192.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499437,272201300010C-5-0-1,Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a,2737556,2013-07-01,2013.0,2017-06-30,2017,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6015965,21380187,Basic study on novel vaccine strategy for avian influenza,218199,2009-04-01,2009.0,2014-03-31,2014,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,12,0,0
grant.5900519,16H03822,B細胞表層での分子認識制御によるユニバーサルナノワクチンの創製,176607,2016-04-01,2016.0,2019-03-31,2019,Nippon Institute of Technology,grid.444271.0,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5869803,15K15390,Development of novel pertussis vaccine,32060,2015-04-01,2015.0,2017-03-31,2017,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5246526,N01AI40071-12-0-1,PRODUCTION AND TESTING OF A MODIFIED VACCINIA ANKARA (MVA) VACCINE,1421912,2004-09-30,2004.0,2015-02-06,2015,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245891,272201300010C-3-0-1,Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a,2969205,2013-07-01,2013.0,2016-06-30,2016,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245785,272201200003I-0-27200014-1,Task X14:  Evaluation of Ebola Vaccines,8942639,2015-09-10,2015.0,2018-07-31,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5144861,NIHRDH-IS-HPU-1112-10096,NIHR Health Protection Research Unit in Immunisation,5837308,2014-04-01,2014.0,2019-03-31,2019,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,National Institute for Health Research,United Kingdom,0,0,0
grant.4893018,W81XWH-15-C-0175,NanoVector Vaccine Potentiation,100000,2014-10-01,2014.0,2015-09-30,2015,Oceanit (United States),grid.423002.7,United States,United States Department of the Army,United States,0,0,0
grant.4702691,2014/13/B/NZ6/00245,Konstrukcja szczepionek odpornościowych opartych na żywych szczepach Salmonella enterica Typhimurium zawierających rekombinowane fagi nitkowate,129485,2015-02-09,2015.0,2018-02-08,2018,University of Warsaw,grid.12847.38,Poland,National Science Center,Poland,1,0,0
grant.4694137,BB/N012682/1,Improving the duration of immunity for FMD vaccines,270289,2016-05-13,2016.0,2017-09-11,2017,Pirbright Institute; Pirbright Institute; Pirbright Institute; Pirbright Institute; Jenner Institute; Department of Biotechnology; Indian Immunologicals (India); Department of Biotechnology,grid.63622.33; grid.63622.33; grid.63622.33; grid.63622.33; grid.418731.8; grid.454774.1; grid.496635.b; grid.454774.1,United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; India; India; India,Biotechnology and Biological Sciences Research Council,United Kingdom,3,0,0
grant.4551429,00/11994-7,Novas estratégias vacinas para patógenos entéricos: vacinas contra diarréia baseadas no fator de colonização I (CFA/I) de Escherichia coli enterotoxigênica (ETEC),0,2001-05-01,2001.0,2004-03-31,2004,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4540717,03/07447-9,Desenvolvimento de vacina celular anti-pneumocócica: utilização de cepa não capsulada de Streptococcus pneumoniae,0,2005-04-01,2005.0,2007-09-30,2007,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,1,0,0
grant.4161796,553994,Transmission dynamics of live coccidiosis vaccines: Does management have an impact?,31693,2014-04-01,2014.0,2015-03-31,2015,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.4045940,NA03NMF4270150,Ultrasound mediated delivery of vaccines for aquaculture,150079,2003-05-01,2003.0,2005-10-31,2005,University System of Maryland,grid.410443.6,United States,National Oceanic and Atmospheric Administration,United States,0,0,0
grant.4040616,NA03NMF4270132,"Development of a Reverse Genetics System to Produce Live, Attenuated Infectious Salmon Anemia Virus (ISAV) Vaccine Candidates",252834,2003-07-01,2003.0,2005-12-31,2005,,,,National Oceanic and Atmospheric Administration,United States,0,0,0
grant.3984324,08/IN.1/B1845,Surface proteins of Staphylococcus aureus involved in nasal colonization biofilm formation and immune evasion. Potential for vaccine development,1884051,2008-10-01,2008.0,2013-03-31,2013,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,8,0,0
grant.3983030,03/IN3/B364,Construction & Development of a New Prototype Measles-Mumps-Rubella Vaccine Based on Recombinant RNA,964737,2004-01-01,2004.0,2008-06-08,2008,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.3857103,272201400031C-0-0-1,A NUTRITIVE VACCINE ADJUVANT AGAINST INFLUENZA,224981,2014-09-15,2014.0,2015-09-14,2015,EpitoGenesis (United States),grid.428901.6,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.3857090,272201400016C-0-0-1,CHLAMYDIA TRACHOMATIS VACCINE SAFETY AND EFFICACY EVALUATION IN NONHUMAN PRIMATES,1113776,2014-05-31,2014.0,2015-02-28,2015,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.3857030,272201300010C-1-0-1,Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a,3183629,2013-07-01,2013.0,2015-06-30,2015,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856249,261201200013I-0-26100009-1,Multi-Antigen Vaccine for Lung Cancer PreventionPOP: 09/18/2014-09/17/2016,884531,2014-09-18,2014.0,2016-09-17,2016,,,,National Cancer Institute,United States,1,0,0
grant.3771580,37435,New preventative and therapeutic Hepatits C vaccines: from pre-clinical to phase I,12112367,2007-02-01,2007.0,2012-07-31,2012,University of Naples Federico II; Novartis (Italy); Ghent University; University of Oxford; Vacsera (Egypt); Goethe University Frankfurt; University of Gdańsk; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Erasmus University Medical Center; IRBM Science Park; University of Birmingham; Saarland University; ALTA (Italy); University of Pisa,grid.4691.a; grid.15585.3c; grid.5342.0; grid.4991.5; grid.463319.a; grid.7839.5; grid.8585.0; grid.414818.0; grid.5645.2; grid.425285.c; grid.6572.6; grid.11749.3a; grid.424010.3; grid.5395.a,Italy; Italy; Belgium; United Kingdom; Egypt; Germany; Poland; Italy; Netherlands; Italy; United Kingdom; Germany; Italy; Italy,European Commission,Belgium,2,0,0
grant.3759147,QLK2-CT-2002-01197,The second phase of a european malaria vaccine development consortium,4392553,2002-09-01,2002.0,2006-05-31,2006,University of Edinburgh; London School of Hygiene & Tropical Medicine; Radboud University Nijmegen; Biomedical Primate Research Centre; Pasteur Institute; University of Copenhagen; Public Health Agency of Sweden; Covance (United Kingdom); Albemarle (Belgium); Bernhard Nocht Institute for Tropical Medicine; The Francis Crick Institute,grid.4305.2; grid.8991.9; grid.5590.9; grid.11184.3d; grid.428999.7; grid.5254.6; grid.419734.c; grid.417605.1; grid.434767.5; grid.424065.1; grid.451388.3,United Kingdom; United Kingdom; Netherlands; Netherlands; France; Denmark; Sweden; United Kingdom; Belgium; Germany; United Kingdom,European Commission,Belgium,28,0,0
grant.3726131,TS3*930168,An international Primate Vaccine Evaluation Network (PVEN) for the optimal use of a variety of primate species for the evaluation of vaccines and other tools against the major infectious diseases in developing countries,0,1994-05-01,1994.0,1995-04-30,1995,Netherlands Organisation for Applied Scientific Research; Centre International de Recherches Médicales de Franceville; National Museums of Kenya; University of Valle,grid.4858.1; grid.418115.8; grid.425505.3; grid.8271.c,Netherlands; Gabon; Kenya; Colombia,European Commission,Belgium,0,0,0
grant.3627196,081122/Z/06/Z,"Evaluation of the safety and immunogenicity of a new tuberculosis vaccine, MVA85A, as a booster vaccine for BCG, in a series of Phase II clinical trials in South Africa.",2951225,2006-10-01,2006.0,2008-09-30,2008,University of Oxford; University of Oxford,grid.4991.5; grid.4991.5,United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,5,0,0
grant.3624371,N01AI40071-10-0-1,PRODUCTION AND TESTING OF A MODIFIED VACCINIA ANKARA (MVA) VACCINE,6072797,2004-09-30,2004.0,2015-02-06,2015,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3568375,LP120200244,A single vaccine for influenza and pneumonia,252019,2012-01-01,2012.0,2015-12-31,2015,University of Adelaide,grid.1010.0,Australia,Australian Research Council,Australia,0,0,0
grant.2757767,BBS/E/I/00001489,Improving the quality of FMD vaccines by understanding the correlation of vaccine-induced protection with immune responses in cattle,687443,2011-05-16,2011.0,2014-05-15,2014,Pirbright Institute; Pirbright Institute; Pirbright Institute; Pirbright Institute,grid.63622.33; grid.63622.33; grid.63622.33; grid.63622.33,United Kingdom; United Kingdom; United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.2726424,ZIBAI005116,ARRA: H1N1 and Other ARRA Equipment,3314695,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2712019,Z01BR004009,The Determination of Phosphorus in Vaccines,0,1999-01-01,1999.0,2001-01-01,2001,,,,United States Food and Drug Administration,United States,0,0,0
grant.2706262,Y1AI9459-2-0-5,Development of oral vaccine tech for multivalent protection against Shigella,115000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706261,Y1AI9459-2-0-4,Development of technology for a combination anthrax-plague live oral vaccine,85000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706257,Y1AI9459-1-0-5,Development of oral vaccine tech for multivalent protection against Shigella,115000,2009-01-01,2009.0,2009-12-31,2009,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706256,Y1AI9459-1-0-4,Development of technology for a combination anthrax-plague live oral vaccine,85000,2009-01-01,2009.0,2009-12-31,2009,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706135,Y1AI0665-2-0-1,Development of Anti-Ebola MHC Tetramers to Evaluate Vaccines,200000,2011-01-01,2011.0,2011-12-31,2011,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706134,Y1AI0665-1-0-1,Development of Anti-Ebola MHC Tetramers to Evaluate Vaccines,250000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706123,Y1AI0647-2-0-1,Guinea Pig Model for Shigellosis Vaccine Development,106000,2011-01-01,2011.0,2011-12-31,2011,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706119,Y1AI0631-2-0-1,Characterization of the Mechanism of Action of Vaccine Adjuvants,162000,2011-01-01,2011.0,2011-12-31,2011,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706118,Y1AI0631-1-0-1,Characterization of the Mechanism of Action of Vaccine Adjuvants,114000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706115,Y1AI0608-1-0-1,Development of New Tools for Influenza Vaccines,165000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706114,Y1AI0607-1-0-1,Development of Assays and Pre-clinical Evaluation of Francisella Vaccines,76000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706113,Y1AI0606-1-0-1,Assays for Characterization and Efficacy Evaluation of Anthrax Vaccines,85000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2658141,R44AI092916,"Robust, defined, animal-free cell culture medium for the production of vaccines",1516871,2012-06-01,2012.0,2015-05-31,2015,Ventria Bioscience (United States),grid.422159.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2449044,R01AG043419,Effectiveness of the Influenza Vaccine in the Aging Population,953844,2013-07-01,2013.0,2017-06-30,2017,Vanderbilt University Medical Center,grid.412807.8,United States,National Institute on Aging,United States,6,0,0
grant.2425380,N01AI40071-8-0-1,Production/Testing of a MVA Vaccine,243579,2004-09-30,2004.0,2009-01-30,2009,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425071,N01AI15425-6-0-1,"HIV Vaccine Production, PreClinical Testing, FDA Submissions",89573,2001-02-15,2001.0,2008-07-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347720,272201300010C-0-0-1,Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a,2564723,2013-07-01,2013.0,2014-06-30,2014,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2344566,261201200013I-0-26100006-1,Use of TERT Vaccine in Prevention of Lung Cancer in Animal Models,443988,2013-09-19,2013.0,2015-09-18,2015,,,,National Cancer Institute,United States,0,0,0
grant.2438487,P20RR020735,Exploratory Center for Vaccinology Research (RMI),1799453,2004-09-28,2004.0,2007-07-31,2007,Emory University,grid.189967.8,United States,National Center for Advancing Translational Sciences,United States,7,0,0
grant.8592540,7017d233-cc88-4177-aa1b-8ca7c077da17,RNA synthetic biology for genetic engineering of a programmable one-shot smart RNA vaccine,0,2016-10-01,2016.0,2018-09-30,2018,Ghent University; Ghent University,grid.5342.0; grid.5342.0,Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8591411,194e3253-0b4a-4d60-a756-05b467aa8c1d,An integrated strategy for preclinical development of improved vaccines against dendritrische cell lung cancer,0,2009-10-01,2009.0,2019-09-30,2019,Ghent University; Ghent University,grid.5342.0; grid.5342.0,Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8574771,18251_1,Developing a novel cancer vaccine using IDO2-silenced DCs for breast cancer,0,2010-01-01,2010.0,2010-12-31,2010,London Health Sciences Centre,grid.412745.1,Canada,Breast Cancer Society of Canada,Canada,0,0,0
grant.8565074,BT/PR20795/MED/29/1103/2016,VACCINATION AND PROTECTION STUDIES FOR A TARGETED NANOPARTICULATE ORAL VACCINE AGAINST SHIGELLOSIS,46163,2018-01-10,2018.0,2019-07-10,2019,National Institute of Cholera and Enteric Diseases; Indian Institute of Technology Kanpur,grid.419566.9; grid.417965.8,India; India,Department of Biotechnology,India,0,0,0
grant.8564502,BT/PR14351/PFN/20/1118/2015,Development of Molecular Diagnostics and Immunotherapeutic Vaccines for Prawn and Brinjal Allergy,70075,2016-08-05,2016.0,2019-08-05,2019,Bose Institute,grid.418423.8,India,Department of Biotechnology,India,0,0,0
grant.8564392,BT/PR15722/NER/95/24/2015,Development of Nanoparticle or Microparticle Adjuvanted Subunit Oral Vaccine against Poultry Salmonellosis,118059,2016-08-22,2016.0,2019-08-22,2019,Assam Agricultural University; Institute of Advanced Study in Science and Technology; National Institute of Cholera and Enteric Diseases,grid.411459.c; grid.467306.0; grid.419566.9,India; India; India,Department of Biotechnology,India,0,0,0
grant.8564076,BT/PR9711/ADV/90/158/2013,"Development of a novel ""broad-spectrum"" subunit vaccine for Bluetongue disease in animals",65794,2016-08-26,2016.0,2019-08-26,2019,P.V. Narsimha Rao Telangana Veterinary University,grid.506065.0,India,Department of Biotechnology,India,0,0,0
grant.8563355,BT/PR8624/MED/29/798/2013,Programming protective humoral responses with novel vaccine formulations against Dengue Virus.,106699,2014-03-31,2014.0,2017-03-31,2017,University of Hyderabad,grid.18048.35,India,Department of Biotechnology,India,0,0,0
grant.8562762,BT/MB/Indo-US/HIPC/04/2013,Innate Predictors of Adaptive BCG and HBV Vaccine-induce Responses in Bangalore Adolescents,255862,2013-10-18,2013.0,2015-10-18,2015,Indian Institute of Science Bangalore; Rajiv Gandhi University of Health Sciences,grid.34980.36; grid.418280.7,India; India,Department of Biotechnology,India,0,0,0
grant.8561092,BT/PR13900/ADV/57/44/2010,Development of prophylactic as well as therapeutic DNA vaccine for canine mammary cancer,85433,2012-01-24,2012.0,2015-01-24,2015,Indian Veterinary Research Institute,grid.417990.2,India,Department of Biotechnology,India,0,0,0
grant.8560406,BT/PR12849/MED/15/35/2009,Evaulation of novel adjuvants for mucosal priming following cutaneous delivery of vaccine,132827,2010-03-25,2010.0,2013-03-25,2013,Tata Institute of Fundamental Research; Translational Health Science and Technology Institute,grid.22401.35; grid.464764.3,India; India,Department of Biotechnology,India,0,0,0
grant.8560404,BT/PR13738/MED/15/37/2010,Development of envelope domain III-based Dengue Virus-like particle (VLP) Vaccine candidates,779042,2010-03-29,2010.0,2015-03-29,2015,International Centre for Genetic Engineering and Biotechnology,grid.425195.e,India,Department of Biotechnology,India,0,0,0
grant.8560168,BT/PR15284/MED/29/291/2011,Targeted nanoparticulate oral vaccine against shigellosis: mimicking shigell's strqategy of infection,80696,2011-03-09,2011.0,2014-03-09,2014,Indian Institute of Technology Kanpur,grid.417965.8,India,Department of Biotechnology,India,0,0,0
grant.8559075,BT/PR9415/AAQ/03/344/2007,Development of DNA vaccine to combat Edwardsiella tarda infection in commercially important food fishes.,133985,2009-08-12,2009.0,2012-08-12,2012,Centre for Cellular and Molecular Biology; Tata Institute of Fundamental Research,grid.417634.3; grid.22401.35,India; India,Department of Biotechnology,India,0,0,0
grant.8559057,BT/PR9094/AAQ/01/327/2007,Immuno-prophylactic evaluation of potential vaccine candidates against Fasciola gigantica in domestic animals.,81001,2007-09-06,2007.0,2010-09-06,2010,Indian Veterinary Research Institute,grid.417990.2,India,Department of Biotechnology,India,0,0,0
grant.8559047,BT/PR8373/AAQ/01/322/2006,Development of Calcium Phosphate Nanoparticle based DNA vaccine against FMD(Foot and Mouth Disease),56670,2008-03-24,2008.0,2011-03-24,2011,Indian Veterinary Research Institute,grid.417990.2,India,Department of Biotechnology,India,0,0,0
grant.8514300,G022902N,Karakterisatie en evaluatie van kandidaat vaccin antigenen tegenover de lebmaag-nematode Ostertagia ostertagi bij het rund.,0,2002-01-01,2002.0,2005-12-31,2005,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8513722,G007211N,Onderzoek naar het gebruik van mRNA moleculen als alternatief voor een Chlamydophila psittaci DNA vaccin,0,2011-01-01,2011.0,2014-12-31,2014,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8512105,1S07716N,"Development of an mRNA-based vaccine to treat HPV-positive oropharyngeal squamous cell carcinoma: immunogenicity, therapeutic efficacy and safety.",0,2016-01-01,2016.0,2017-12-31,2017,Vrije Universiteit Brussel,grid.8767.e,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8509618,1147204N,Ontwikkeling van een cellular HIV vaccin gebaseerd op dendritische cellen ge- transfecteerd met mRNA coderend voor HIV antigenen.,0,2003-10-01,2003.0,2005-09-30,2005,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8509617,1147202N,Ontwikkeling van een cellulair HIV vaccin gebaseerd op dendritische cellen getransfecteerd met mRNA coderend voor HIV antigenen.,0,2001-10-01,2001.0,2003-09-30,2003,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8507925,G010797N,Inductie van een cellulaire immuunrespons tegen idiotype determinanten. Lymfoma vaccinatie : vaccin productie en evaluatie van de immuunrespons.,0,1996-12-01,1996.0,2000-12-31,2000,Vrije Universiteit Brussel,grid.8767.e,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8505547,1521909N,De ontwikkeling van RSV vaccins op basis van virus like partikels die korte fragmenten van RSV oppervlakte-eiwitten presenteren.,0,2009-01-01,2009.0,2009-12-31,2009,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8505546,1217313N,Onderzoek naar de structurele en mechanistische eigenschappen van een nieuwe RSV therapie en een nieuw RSV vaccin.,0,2012-10-01,2012.0,2015-09-30,2015,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8494481,12B0211N,Ophelderen van het mechanisme van verbeterde protectie door een M. bovis BCG mutant als een vaccin tegen Mycobacterium tuberculosis infectie,0,2010-10-01,2010.0,2014-09-30,2014,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8488885,G032595N,"Immunobiologie van gastheer-trypanosoom interacties : identificatie van immunopathologische trypanosoom componenten en ontwikkeling van anti-""ziekte"" vaccins.",0,1995-01-01,1995.0,1998-12-31,1998,Vrije Universiteit Brussel,grid.8767.e,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8486017,1542487N,Zuivering en studie van adenylaat cyclase van Bordetella pertussis : met het oogop een eventuele toepassing ervan in een verbeterd acellulair kinkhoest vaccin.,0,1986-10-01,1986.0,1987-09-30,1987,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8485222,G021812N,T cel immunogeniciteit van RHAMM en BMI-1: ontwikkeling van een multi-antigenisch dendritisch celvaccin voor hematologische maligniteiten,0,2012-01-01,2012.0,2015-12-31,2015,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8215714,39580004,新一代HPV16E7核酸疫苗构建及抗癌的细胞与分子生物学,12048,1996-01-01,1996.0,1998-12-31,1998,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8107229,25691,DNA Immunization Against Rhodococcus equi pneumonia of Foals using an Attenuated Salmonella Vaccine Vector,0,2003-05-01,2003.0,2004-04-30,2004,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8070874,2817600912,Verbundprojekt: Entwicklung innovativer bestandsspezifischer Impfstoffe für Geflügel zur vereinfachten Applikation (innoVAK4DART) - Teilprojekt: 5,513128,2014-05-01,2014.0,2017-10-31,2017,,,,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8070873,2817600812,Verbundprojekt: Entwicklung innovativer bestandsspezifischer Impfstoffe für Geflügel zur vereinfachten Applikation (innoVAK4DART) - Teilprojekt: 4,268146,2014-05-01,2014.0,2017-10-31,2017,,,,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8070872,2817600712,Verbundprojekt: Entwicklung innovativer bestandsspezifischer Impfstoffe für Geflügel zur vereinfachten Applikation (innoVAK4DART) - Teilprojekt 3,203123,2014-05-01,2014.0,2017-10-31,2017,University of Potsdam,grid.11348.3f,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8070871,2817600612,Verbundprojekt: Entwicklung innovativer bestandsspezifischer Impfstoffe für Geflügel zur vereinfachten Applikation (innoVAK4DART) - Teilprojekt 2,261659,2014-05-01,2014.0,2017-10-31,2017,University of Veterinary Medicine Hanover,grid.412970.9,Germany,Federal Ministry of Food and Agriculture,Germany,1,0,0
grant.8070870,2817600512,Verbundprojekt: Entwicklung innovativer bestandsspezifischer Impfstoffe für Geflügel zur vereinfachten Applikation (innoVAK4DART) - Teilprojekt 1,552013,2014-05-01,2014.0,2017-10-31,2017,,,,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8068997,2813200706,Verbundprojekt: Neuartiger Ansatz zur Entwicklung eines heterosubtypischen Marker-Impfstoffs gegen die aviäre Influenza in Geflügel - Teilprojekt 2,836661,2007-03-01,2007.0,2010-11-30,2010,,,,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8068992,2813200106,Verbundprojekt: Neuartiger Ansatz zur Entwicklung eines heterosubtypischen Marker-Impfstoffs gegen die aviäre Influenza in Geflügel - Teilprojekt 1,635484,2006-11-01,2006.0,2008-04-30,2008,,,,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8068981,2813100606,Entwicklung einer Subunit- und inaktivierten Vollvirus-Vakzine zur Immunisierung von Katzen gegen eine Influenza H5N1-Infektion,252680,2006-11-01,2006.0,2007-10-31,2007,Friedrich Loeffler Institute,grid.417834.d,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8048327,13N9197,Verbundprojekt: Topische Vakzinierung mit funktionalen Nanopartikeln - Teilvorhaben: Hautpenetration und immunologische Validierung von funktionalen Nanopartikelvakzinen,1272513,2007-04-01,2007.0,2010-09-30,2010,Charité – University Medicine Berlin,grid.6363.0,Germany,Federal Ministry of Education and Research,Germany,7,0,0
grant.7999613,03 8662 /7,EUREKA-Projekt: Malaria-Impfstoff (EU 101) - Teilvorhaben 1 (Zur Anwendung in Entwicklungsländern),2241990,1985-07-01,1985.0,1988-06-30,1988,Sanofi (Germany),grid.420214.1,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7999604,03 8652 /9,Entwicklung eines Malaria-Impfstoffes: Teilvorhaben 2 und 3 - zur Anwendung in Entwicklungsländern,659051,1985-07-01,1985.0,1989-12-31,1989,Max Planck Institute of Biochemistry,grid.418615.f,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7999573,03 8606 /1,"Herstellung eines synthetischen, veterinärmedizinisch Verwendbaren Peptid-Impfstoffes Gegen Virusleukaemie mit dem Ziel der Entwicklung Humanmedizinischer Pharmaka",1214576,1984-09-01,1984.0,1988-03-31,1988,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7999438,03 8398 /5,"Verbundprojekt: Entwicklung eines Impfstoffs Gegen Herpes Simplex-Virus, Gewonnen mit Hilfe eines Bakteriellen Systems",1049542,1982-01-01,1982.0,1984-12-31,1984,Sanofi (Germany),grid.420214.1,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992719,031A061A,KMU-innovativ-8: VakMech - Wirkmechanismus von mRNA-Vakzinen als Basis der nächsten Technologiegeneration,402705,2012-09-01,2012.0,2014-08-31,2014,CureVac (Germany),grid.476259.b,Germany,Federal Ministry of Education and Research,Germany,3,0,0
grant.7992663,0319922A/0,Neues Prinzip einer Vermehrungsfähigen Totvakzine am Modell der infektiösen Bovinen Rhinotracheitits (Ibr),76164,1991-01-01,1991.0,1991-12-31,1991,Friedrich Loeffler Institute,grid.417834.d,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992247,0319273B/4,Verbundprojekt: Ein Flexibles System zur gezielten Antigen-Variation bei Humanen Influenza-Viren für die Herstellung von Vakzinen,174288,1989-01-01,1989.0,1992-12-31,1992,University of Giessen,grid.8664.c,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992176,0319143A/0,Verbundprojekt: Molekulargenetische Entwicklung eines Impfstoffes Gegen Herpesviren zum Einsatz in der Tiermedizin,877427,1988-05-01,1988.0,1992-07-31,1992,Bayer (Germany),grid.420044.6,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992114,0318994C/9,"Verbundprojekt: Gentechnologische Bearbeitung des menschenpathogenen Hanta-Virus mit dem Ziel, einen Impfstoff zu entwickeln",455829,1992-03-01,1992.0,1995-02-28,1995,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992113,0318994B/6,"Verbundprojekt: Gentechnologische Bearbeitung des menschenpathogenen Hanta-Virus mit dem Ziel, einen Impfstoff zu entwickeln",254784,1990-01-01,1990.0,1991-10-31,1991,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992093,0318973C/1,"Verbundprojekt: Gentechnologische Bearbeitung des menschenpathogenen Hanta-Virus mit dem Ziel, einen Impfstoff zu entwickeln",549424,1992-03-01,1992.0,1995-04-30,1995,Heidelberg University,grid.7700.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992092,0318973B/9,"Verbundprojekt: Gentechnologische Bearbeitung des menschenpathogenen Hanta-Virus mit dem Ziel, einen Impfstoff zu entwickeln",348852,1990-01-01,1990.0,1991-10-31,1991,Heidelberg University,grid.7700.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7991943,0318768A/8,Entwicklung von Verfahren zur effizienten Herstellung von Antikörpern und synthetischen Vakzinen mittels neuartiger Antigen-Lipopeptid-Konjugate,718672,1987-01-01,1987.0,1989-09-30,1989,University of Tübingen,grid.10392.39,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7990361,0315640D,"Verbundprojekt: Optimierung der industriellen zellbasierten Herstellung von Influenzavakzine (saisonal und pandemisch), TP 4",271024,2013-07-01,2013.0,2016-12-31,2016,,,,Federal Ministry of Education and Research,Germany,3,0,0
grant.7990359,0315640B,"Verbundprojekt: Optimierung der industriellen zellkulturbasierten Herstellung von Influenza Vakzinen (saisonal und pandemisch), TP 2",677935,2013-07-01,2013.0,2016-12-31,2016,Karlsruhe Institute of Technology,grid.7892.4,Germany,Federal Ministry of Education and Research,Germany,8,0,0
grant.7990055,0315479,ERA Net EuroTransBio-3: Entwicklung einer anti-CETP Vakzine für die Vorbeugung und Behandlung der Arteriosklerose,108627,2009-03-01,2009.0,2012-09-30,2012,EMC microcollections (Germany),grid.424419.e,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989716,0315281B,ERA Net EuroTransBio-2: Entwicklung von Crossbetas Adjuvanz Technologie. Eine neue Technologie zur Verbesserung von Impfstoffeigenschaften,104249,2008-04-01,2008.0,2010-03-31,2010,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989660,0315253,KMU-innovativ-1: CSC - Entwicklung eines tumorstammzell-spezifischen therapeutischen Impfstoffs zur Behandlung von Tumoren,881036,2008-04-01,2008.0,2009-12-31,2009,Immatics Biotechnologies (Germany),grid.434836.e,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7989511,0315151,BioChancePLUS-4: Entwicklung eines effizienten mRNA basierten Impfstoffes gegen schwer konventionell therapierbare Infektionskrankheiten am Beispiel von CMV,436313,2007-09-01,2007.0,2009-08-31,2009,CureVac (Germany),grid.476259.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989508,0315145,BioChancePLUS-4: 'IgE-AAV' Partikel als Vakzine zur Behandlung von Asthma und anderen allergischen Erkrankungen,836093,2007-08-01,2007.0,2009-07-31,2009,Medigene (Germany),grid.487265.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7988963,0313809,BioProfile Stuttgart/Neckar-Alb: Verfahren zur Entwicklung eines therapeutischen Impfstoffs zur Anwendung von Pankreaskarzinomen,680681,2006-08-01,2006.0,2008-01-31,2008,Immatics Biotechnologies (Germany),grid.434836.e,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7988826,0313697A,BioChancePLUS-2: Verbundprojekt: Therapeutische Tumorimpfstoffe auf der Basis von universellen Tumorantigenen und des Polyoma-Trägersystems,282847,2005-12-01,2005.0,2007-11-30,2007,,,,Federal Ministry of Education and Research,Germany,1,0,0
grant.7988307,0313071,"BioProfile Braunschweig/Göttingen/Hannover: Entwicklung einer rekombinanten Vakzine gegen Dictycaulus viviparus, den Lungenwurm der Rinder",426764,2004-04-01,2004.0,2005-09-30,2005,University of Veterinary Medicine Hanover,grid.412970.9,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7988084,0312744,Genom-basierte Untersuchungen zur Expression und Produktion von Impfstoffen gegen virale Erkrankungen von Tieren in transgenen Pflanzen.,888499,2001-11-01,2001.0,2005-03-31,2005,University of Rostock,grid.10493.3f,Germany,Federal Ministry of Education and Research,Germany,4,0,0
grant.7987789,0312267 /2,Modellregion München: Die Entwicklung von Impfstoffen auf molekularbiologischem Wege gegen Erreger menschlicher Infektionskrankheiten,1852226,1999-08-01,1999.0,2002-12-31,2002,,,,Federal Ministry of Education and Research,Germany,1,0,0
grant.7987708,0312178,Modellregion München: Entwicklung neuartiger Impfstoffe zur prophylaktischen Bekämpfung bakterieller Infektionen und deren chronischen Folgeerkrankungen,625588,2000-05-01,2000.0,2001-09-30,2001,,,,Federal Ministry of Education and Research,Germany,3,0,0
grant.7968467,01VW016 /,Entwicklung einer Chicken Factor freien Hühnerherde für wissenschaftlich experimentelle und diagnostische Zwecke sowie zur Impfstoffherstellung,93269,1977-01-01,1977.0,1977-12-31,1977,University of Giessen,grid.8664.c,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7936517,01EK1411,Phase I/II-Studie zur Verminderung von Rückfällen beim Melanom mit einem Vakzin gegen mutierte Tumorantigene.,66346,2014-07-01,2014.0,2014-12-31,2014,University of Erlangen-Nuremberg,grid.5330.5,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7936234,01ED1501A,JPND Verbundprojekt CrossSeeds: Charakterisierung modifizierter Amyloidpeptide zur Ableitung von Impfstoff-Strategien und spezifischen Nachweismethoden,464221,2015-05-01,2015.0,2018-07-31,2018,,,,Federal Ministry of Education and Research,Germany,1,0,0
grant.7934392,01DN12042,Pilot Studie zur therapeutischen Impfung von Patienten mit einer chronischen HBV Infektion mittels eines neuen Impfstoff aus Kuba,10536,2012-01-01,2012.0,2012-12-31,2012,Hannover Medical School,grid.10423.34,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7911448,,Major Cell Culture Improvements Needed for a Live Attenuated RSV Vaccine to be Economically Feasible,0,2019-02-01,2019.0,2019-06-01,2019,Nationwide Children's Hospital; Universidad del Norte,grid.240344.5; grid.412188.6,United States; Colombia,Council for International Exchange of Scholars,United States,0,0,0
grant.7894792,0328720A/3,Verbundprojekt: Thermoelektrischer Solarkühlschrank zur Aufbewahrung von Impfseren in Entlegenen Krankenstationen der Entwicklungsländer,765044,1987-01-01,1987.0,1990-12-31,1990,Technical University of Berlin,grid.6734.6,Germany,Federal Ministry for Economic Affairs and Energy,Germany,0,0,0
grant.7878400,1113269,Investigating the altered landscape of enteric viruses causing severe gastroenteritis in Australian children following rotavirus vaccine introduction,236595,2016-01-01,2016.0,2019-01-01,2019,Murdoch Childrens Research Institute; Murdoch Childrens Research Institute,grid.1058.c; grid.1058.c,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7874354,1129099,Mechanisms of B cell immunodominance to influenza virus,467142,2017-01-01,2017.0,2019-01-01,2019,University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7851738,SERB_034c81a395,Generation of a genetically-stable live vaccine candidate against infectious bursal disease virus (IBDV) through mutagen- driven lethal mutagenesis,68713,2017-04-01,2017.0,2018-03-31,2018,University of Kashmir,grid.412997.0,India,Science and Engineering Research Board,India,0,0,0
grant.7850972,SERB_08d2823081,“Plasmodium SCOT1 Mutant As Experimental Malaria Vaccine: Implications For Inducing Pre-Erythrocytic And Cross-Stage Immunity’’.,103111,2017-04-01,2017.0,2018-03-31,2018,Central Drug Research Institute,grid.418363.b,India,Science and Engineering Research Board,India,0,0,0
grant.7850587,SERB_aad640500c,Enhancement Of The Immunogenicity And Protective Efficacy Of Lipopeptide Vaccine Against Mycobacterium Tuberculosis Using Peptidomimetics And Conjugation With Isoniazid,66379,2017-04-01,2017.0,2018-03-31,2018,Panjab University,grid.261674.0,India,Science and Engineering Research Board,India,0,0,0
grant.7850585,SERB_8520330bc0,Enhancement Of The Immunogenicity And Protective Efficacy Of Lipopeptide Vaccine Against Mycobacterium Tuberculosis Using Peptidomimetics And Conjugation With Isoniazid,27064,2017-04-01,2017.0,2018-03-31,2018,Institute of Microbial Technology,grid.417641.1,India,Science and Engineering Research Board,India,0,0,0
grant.7832860,BSP2009jnew1,Transplastomic chloroplasts as bioreactors for the synthesis of antigen-based vaccines and enzymes for bomass degradation,19300,2009-05-15,2009.0,2010-08-15,2010,University of Central Florida,grid.170430.1,United States,Arnold and Mabel Beckman Foundation,United States,0,0,0
grant.7827744,,Development of a Curative Therapeutic Vaccine for the Treatment of Large Established Tumors in Mice,0,2018-10-01,2018.0,2019-07-01,2019,National Cancer Institute,grid.48336.3a,United States,Council for International Exchange of Scholars,United States,0,0,0
grant.7736617,DST/INT/Spain/P-27/2011,Evaluation of Plasmodium falciparum erythrocyte binding antigens as malaria vaccine candidates,79197,2011-04-01,2011.0,2014-04-01,2014,,,,Department of Science and Technology,India,9,0,0
grant.7735618,DST_074468b7ed,Probiotic lactic acid bacteria as anticholera oral edible vaccine to be used as a functional food,12004,2006-04-01,2006.0,2009-04-01,2009,,,,Department of Science and Technology,India,0,0,0
grant.7700954,,Attenuation and Characterisation of Eimeria spp for Development and Increasing Live Vaccine Product Quality of Avian Coccidiosis,0,2013-09-01,2013.0,2013-12-01,2013,United States Department of Agriculture; Airlangga University,grid.417548.b; grid.440745.6,United States; Indonesia,Council for International Exchange of Scholars,United States,0,0,0
grant.7697237,,Simulation of the Dynamics of Viral Evolution Aiming at Engineering Effective Vaccines: A Computer-Aided Study on HIV,0,2015-11-01,2015.0,2016-03-01,2016,Massachusetts Institute of Technology; National Technical University of Athens,grid.116068.8; grid.4241.3,United States; Greece,Council for International Exchange of Scholars,United States,0,0,0
grant.7696953,,Evaluation and Development of Some Potent and Safe Plant-Derived Immunostimulants as Adjuvants for Sub-Unit Vaccines,0,2012-11-01,2012.0,2013-08-01,2013,"University of Pittsburgh; University of Nigeria, Nsukka",grid.21925.3d; grid.10757.34,United States; Nigeria,Council for International Exchange of Scholars,United States,0,0,0
grant.7696886,,Screening for Critical Genes from Plasmodium Falciparum as Potential Drug Targets/Vaccine Candidates Against Malaria,0,2013-10-01,2013.0,2014-06-01,2014,University of Notre Dame; University of Buea,grid.131063.6; grid.29273.3d,United States; Cameroon,Council for International Exchange of Scholars,United States,0,0,0
grant.7696299,,Development of Vaccine Using Recombinant Protein and Attenuated Mutant Technologies for the Prevention of Mycobacterial and Leptospiral Infection,0,2016-01-01,2016.0,2016-07-01,2016,Cornell University; Department of Agriculture,grid.5386.8; grid.501571.7,United States; Philippines,Council for International Exchange of Scholars,United States,0,0,0
grant.7687242,,"The Network of Digestive Gut Enzymes in Ticks: Isolation, Characterization and Their Promise as Molecular Vaccines",0,2009-01-01,2009.0,2009-09-01,2009,"University of California, San Francisco; University of California, San Francisco; Institute of Parasitology",grid.266102.1; grid.266102.1; grid.448361.c,United States; United States; Czechia,Council for International Exchange of Scholars,United States,0,0,0
grant.7684163,,Development and Use of Attenuated Salmonella as a Vaccine Vector for Expression of Antigen From an Unrelated Organism,0,2012-02-01,2012.0,2012-06-30,2012,Arizona State University; Arizona State University; Arizona State University; Arizona State University; Indian Veterinary Research Institute; Indian Veterinary Research Institute; Indian Veterinary Research Institute,grid.215654.1; grid.215654.1; grid.215654.1; grid.215654.1; grid.417990.2; grid.417990.2; grid.417990.2,United States; United States; United States; United States; India; India; India,Council for International Exchange of Scholars,United States,0,0,0
grant.7670754,13/TIDA/B2691 TIDA Training 2014,BPVacc: Development of a vaccine against meliodosis with Burkholderia pseudomallei antigens,3870,2015-04-01,2015.0,2016-12-31,2016,Technological University Dublin,grid.497880.a,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7670286,03/IN2/B364s1,Industrial Supplement - Construction & Development of a new prototype measles-mumps-rubella vaccine based on recombinant RNA,261289,2005-09-01,2005.0,2008-08-16,2008,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7669326,13/SIRG/2136,Targeting microRNA to drive a successful host response to Mycobacterium tuberculosis – engineering a better vaccine,593483,2014-09-01,2014.0,2018-08-31,2018,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,3,0,0
grant.7669027,03/IN3/B364/STAR 06,Construction and development of a new prototype measles-mumps-rubella vaccine based on recombinant RNA,17119,2006-06-15,2006.0,2006-08-14,2006,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7667098,,Development of native and recombinant mumps virus subunit nasal vaccines using proteosome technology,16338,2007-09-01,2007.0,2008-08-31,2008,McGill University Health Centre,grid.63984.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7662845,,Effects of Lipid Virulence Factors (PDIM/PGLs) on Virulence and Immunogenicity of BCG Vaccine Strains,15957,2008-09-01,2008.0,2009-08-31,2009,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7651615,,The relationship between socio-political forces and bioethics with respect to future access to HIV vaccines,29214,2001-07-01,2001.0,2003-08-31,2003,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7638223,,"Science, Controversy, and Genetically Modified Plants: Participant Observation of the Creation of New Genetic Knowledge and Edible Vaccines.",3836,2003-04-01,2003.0,2003-09-30,2003,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7622450,,Understanding the communication between gene-modified cells and the immune system:  Development of new gene therapies and vaccines,135408,2001-07-01,2001.0,2006-06-30,2006,McMaster University,grid.25073.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7619028,,"Travel support to attend the AIDS Vaccine 2008 Parternship Development Forum in Cape Town, South Africa",8908,2008-10-01,2008.0,2008-12-31,2008,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7606382,SERB_41fa99e2cd,Development of glycoprotein E1/E2-immunoglobulin (Ig) chaimeric subunit vaccine candidates against chikungunya viru in E.Coil,51561,2016-04-01,2016.0,2017-03-31,2017,,,,Science and Engineering Research Board,India,0,0,0
grant.7550482,0248,Application of DNA vaccines to the clinic: a phase II study of idiotypic vaccination for follicle centre lymphoma,50804,2003-02-02,2003.0,2004-02-01,2004,University of Southampton,grid.5491.9,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.7502649,2015R1D1A1A01058902,IL-12 유도성 새로운 면역활성제로서 원충 유래 프로필린의 면역 증강 및 자가암 백신 효과 규명,0,2015-01-01,2015.0,2016-01-01,2016,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7499459,2015H1D3A1066317,신변종 바이러스의 분자진화 연구 및 단백질 나노입자 기반 차세대 복합백신 개발,0,2015-01-01,2015.0,2016-01-01,2016,Chung-Ang University,grid.254224.7,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7499218,2015H1C1A1035921,감염성 가축질병 제어를 위한 모니터링 기법 개발 및 효모 디스플레이 기반의 차세대 백신 응용,0,2015-01-01,2015.0,2016-01-01,2016,Chungbuk National University,grid.254229.a,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7499047,2015H1C1A1035949,화학적 유도 박테리아고스트(BG)를 이용한 그람음성균 및 그람양성균 백신 및 면역증강제 개발,0,2015-01-01,2015.0,2016-01-01,2016,Pai Chai University,grid.412439.9,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7486134,2012R1A2A2A01009887,TM4SF5 펩타이드-CpG-DNA-리포좀 복합체 백신에 의한 대장암 억제 기전 규명,0,2012-01-01,2012.0,2013-01-01,2013,Chungbuk National University,grid.254229.a,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7479088,2013R1A1A2065600,살모넬라 및 브루셀라 생균백신의 면역반응 향상 및 면역반응 기간 장기화를 위한 나노캡슐화기술 응용,0,2013-01-01,2013.0,2014-01-01,2014,Kangwon National University,grid.412010.6,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7478175,2012R1A1A2042924,GSK-3β 의존적인 IDO 발현조절기작을 통한 수지상세포 기반의 암 백신 개발,0,2012-01-01,2012.0,2013-01-01,2013,,,,National Research Foundation of Korea,South Korea,3,0,0
grant.7465104,355-2010-1-C00052,나노 수송체를 이용하여 여러 유전자를 동시에 전달하는 자궁경부암 다가 백신 시스템 연구,0,2010-01-01,2010.0,2011-01-01,2011,Konkuk University,grid.258676.8,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7459155,327-2009-1-B00143,실물옵션과 SIS/SIR 모형을 이용한 백신의 최적비축 관리에 대한 연구,0,2009-01-01,2009.0,2010-01-01,2010,Korea University,grid.222754.4,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7457000,2011-0016401,High-throughput immunomics 방법을 이용한 새로운 삼일열말라리아 백신  항원의 발굴 및 작용 기전 규명,0,2011-01-01,2011.0,2012-01-01,2012,Kangwon National University,grid.412010.6,South Korea,National Research Foundation of Korea,South Korea,11,0,0
grant.7451639,2010-0002273,Bomb bacteria-type 재조합 Live Edwardsiella tarda 제작 및 이를 이용한 복합백신 개발,0,2010-01-01,2010.0,2011-01-01,2011,Pukyong National University,grid.412576.3,South Korea,National Research Foundation of Korea,South Korea,5,0,0
grant.7450913,2010-0023377,연쇄상구균 (Streptococcus iniae)의 표면 단백질을 발현하는 넙치자생 유산균을 이용한 급여형 어류백신 개발,0,2010-01-01,2010.0,2011-01-01,2011,Handong Global University,grid.411957.f,South Korea,National Research Foundation of Korea,South Korea,3,0,0
grant.7449704,2010-0022066,의대생 코호트에서 A형 간염 백신 1회 접종의 효과 평가,0,2010-01-01,2010.0,2011-01-01,2011,Eulji University,grid.255588.7,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7447431,2009-0076972,신규 종양인자 SCP3의 Jab1의존적 항암면역내성 및 암전이 기전 연구 및 SCP3 암백신 개발,0,2009-01-01,2009.0,2010-01-01,2010,Korea University,grid.222754.4,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7446594,2011-0028135,오믹스 기반 삼일열원충 유성생식기 특이 단백질 대단위 발굴을 통한전파 차단 백신 후보물질 도출 연구,0,2011-01-01,2011.0,2012-01-01,2012,Inha University,grid.202119.9,South Korea,National Research Foundation of Korea,South Korea,8,0,0
grant.7445541,2009-0091639,"예방 백신, 진단법, 치료법, 예후 판정법 개발을 위한 MRSA와 수퍼박테리아의 타겟 발굴",0,2009-01-01,2009.0,2010-01-01,2010,University of Ulsan,grid.267370.7,South Korea,National Research Foundation of Korea,South Korea,4,0,0
grant.7433140,448306,Identification of Viral Peptide Candidates for the Development of Second Generation Cervical Cancer Vaccines Tailored for Chinese Women,53609,2006-04-01,2006.0,2008-06-30,2008,Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong,grid.10784.3a; grid.10784.3a; grid.10784.3a; grid.10784.3a,China; China; China; China,University Grants Committee,China,0,0,0
grant.7407196,NR13 0046 06,Nowy uniwersalny wektor i jego zastosowanie do konstrukcji szczepionki nowej generacji,618330,2009-10-01,2009.0,2013-09-30,2013,University of Warsaw,grid.12847.38,Poland,National Centre for Research and Development,Poland,0,0,0
grant.7390001,OPP1178956,"To develop an inexpensive, broadly protective (universal) influenza A virus vaccine in pre-clinical animal studies",2700800,2017-11-01,2017.0,2019-10-01,2019,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7172641,272201300018I-3-27200004-1,Vaccine and Treatment Evaluation Unit: Respiratory Syncytial Virus Diagnostic and Vaccine Assays,284831,2014-09-08,2014.0,2019-09-30,2019,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7170046,272201700077C-0-0-1,Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever,6964520,2017-09-01,2017.0,2018-08-14,2018,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.7155115,660817,A pilot study to determine the appropriate design for a trial of acellular pertussis vaccine given at birth,97911,2004-07-01,2004.0,2006-06-30,2006,National Centre for Immunisation Research & Surveillance,grid.493834.1,Australia,Financial Markets Foundation for Children,Australia,0,0,0
grant.7149455,,Magnetic resonance imaging-assisted design of a thermostable and self-administrable tuberculosis vaccine for inhalation,682841,2015-01-01,2015.0,2015-12-31,2015,University of Copenhagen,grid.5254.6,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7132410,W81XWH-11-1-0686,Development of a Staphylococcus aureus Candida sp. Vaccine,5594000,2009-10-01,2009.0,2010-09-01,2010,NovaDigm Therapeutics (United States),grid.422883.7,United States,Congressionally Directed Medical Research Programs,United States,4,0,0
grant.7132355,W81XWH-10-2-0035,Development of a Staphylococcus aureus Candida sp. Vaccine,3502000,2008-10-01,2008.0,2009-09-01,2009,NovaDigm Therapeutics (United States),grid.422883.7,United States,Congressionally Directed Medical Research Programs,United States,3,1,0
grant.7132231,W81XWH-10-2-0082,Plant-Based Expression Systems for New Vaccines and Therapeutics,3634039,2008-10-01,2008.0,2009-09-01,2009,Owensboro Health,grid.477687.d,United States,Congressionally Directed Medical Research Programs,United States,5,5,0
grant.7132151,W81XWH-09-2-0022,Development of Novel Vaccines and Therapeutics Using Plant-Based Expression Systems,1698000,2007-10-01,2007.0,2008-09-01,2008,,,,Congressionally Directed Medical Research Programs,United States,0,2,0
grant.7132082,W81XWH-08-1-0151,Development of a Staphylococcus aureus Candida sp. Vaccine,2540478,2006-10-01,2006.0,2007-09-01,2007,NovaDigm Therapeutics (United States),grid.422883.7,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7119583,2009-08212,Development of rice plants for the delivery of oral vaccines,35233,2010-01-01,2010.0,2012-12-31,2012,Stockholm University,grid.10548.38,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7109539,2008-07934,SYSTEMS BIOLOGY IN HOST-PATHOGEN INTERACTIONS – IMPLICATIONS FOR VACCINE TARGET DISCOVERY,257058,2009-01-01,2009.0,2012-12-31,2012,Lund University,grid.4514.4,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7082427,2-PAR-2016-139-Q-R,Development of an antidiabetogenic enterovirus vaccine for prevention of type 1 diabetes,175648,2015-09-23,2015.0,2016-09-23,2016,Tampere University,grid.502801.e,Finland,Juvenile Diabetes Research Foundation,United States,0,0,0
grant.7050128,1009665,DETECTION AND CONTROL OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND EMERGING VIRAL DISEASES OF SWINE,0,2016-07-01,2016.0,2019-09-30,2019,Virginia Tech,grid.438526.e,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.7043747,VM0121,Development of in vitro assay to replace the hamster potency test used for evaluating commercial L.hardjo vaccines,109560,1996-12-01,1996.0,1998-05-31,1998,Queen's University Belfast,grid.4777.3,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043738,VM0112,Development & evaluation of standard preparations for assessing QC methods for cat and dog vaccines [was VM0101],97254,1995-04-01,1995.0,1996-03-31,1996,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043141,SE3250,Field trial to assess the safety and efficacy of BCG vaccine admininster parenterally (part of project CB0115),882018,2008-04-01,2008.0,2009-03-31,2009,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043098,SE3202,The development of animal models to test candidate vaccines for M. bovis infection in badgers (continuation of SE0130),333436,1998-04-01,1998.0,1999-03-31,1999,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042329,SE0122,Development of vaccines to protect badgers against M. bovis: development of surrogate assays [was part SE0110],598339,1995-04-01,1995.0,1997-03-31,1997,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042317,SE0110,The development of vaccines for the protection of badgers against infection with Mycobacterium bovis [became SE0122/3],334652,1994-04-01,1994.0,1995-03-31,1995,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7040554,OD1716,The rational selection of candidate antigens for inclusion in vaccines against bovine mastitis caused by S.uberis,564519,2006-01-01,2006.0,2007-06-30,2007,University of Oxford,grid.4991.5,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7040497,OD0709,Genetic and immune basis of protection against infectious bursal disease virus (IBDV) by defined molecular vaccines,304563,1997-04-01,1997.0,2000-03-31,2000,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.6946051,971521,Multi-valent Hantvirus-Vaccine (MVA SEO-HTN: Vacc) and a ferret model of disease,612888,2017-04-30,2017.0,2018-04-29,2018,Public Health England,grid.271308.f,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.6897580,OC 820.20,Vakcína proti kokcidióze koz,4927,1999-01-01,1999.0,2000-12-31,2000,Institute of Parasitology,grid.448361.c,Czechia,Ministry of Education Youth and Sports,Czechia,0,0,0
grant.6896534,FR-TI3/059,*Vývoj univerzální vakcíny proti chřipce prasat respektující aktuální epizootologickou situaci v České republice a ve světě.,2434208,2011-01-01,2011.0,2014-12-31,2014,Bioveta (Czechia),grid.448017.e,Czechia,Ministry of Industry and Trade,Czechia,0,0,0
grant.6838452,17K13030,機能性ペプチドの構造活性相関に基づく最適設計と新規がんワクチンへの応用,37232,2017-04-01,2017.0,2018-03-31,2018,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6808619,,Application of Protein Capsular Matrix Vaccine Technology to the Development of a Novel Form of Killed Whole Cell Vaccines,120593,2014-08-01,2014.0,2017-07-31,2017,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.6784314,3013fdb9-7acb-4941-83a4-b69f9a7420fe,Glycopolymer-based vaccine nanocarriers,0,2014-01-01,2014.0,2018-10-31,2018,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6730239,987038,Bacterial DNA and DNA vaccines as regulators of macrophage function and as a therapeutic approach to Leishmani,157549,1998-01-01,1998.0,2003-12-31,2003,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6727681,1069915,Development of a self-adjuvanting mucosal vaccine candidate against Group A Streptococcus using lipid core technology,238071,2014-01-01,2014.0,2018-12-31,2018,Griffith University,grid.1022.1,Australia,National Health and Medical Research Council,Australia,2,0,0
grant.6725541,402737,Identifying determinants of mycobacterial pathogenesis and understanding host immunity for devel. of novel anti-TB vaccine,392357,2006-01-01,2006.0,2010-12-31,2010,University of Sydney,grid.1013.3,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6725469,433632,Understanding the mechanisms of action and optimising the ISCOMATRIX� adjuvant for the development of human vaccines,194218,2007-01-01,2007.0,2009-12-31,2009,,,,National Health and Medical Research Council,Australia,0,0,0
grant.6723851,241952,The development of a group A streptococcal vaccine and understanding the immunopathogenesis of rheumatic heart disease,325419,2003-01-01,2003.0,2007-12-31,2007,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6723630,224273,Defining the T cell epitopes of vaccinia and ectromelia viruses: exploring immunodominance in recombinant vaccines and r,144001,2003-01-01,2003.0,2005-12-31,2005,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6723325,193322,"The impact of a conjugate pneumococcal vaccine on pneumococcal carriage, antibiotic resistance, & otitis media in Aborig",68282,2002-01-01,2002.0,2005-12-31,2005,Flinders University,grid.1014.4,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6722622,404159,"Efficacy and mode of action of a pro-apoptotic, TLR7-specific ligand adjuvant in anti-tumour vaccine immune responses.",61486,2006-01-01,2006.0,2009-12-31,2009,University of Western Australia,grid.1012.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6721150,569869,Studying the function and mechanism of histone ADP-ribosylation; (ii) Lipo-peptide--protein vaccine development,469297,2009-01-01,2009.0,2013-12-31,2013,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,15,0,0
grant.6716567,630779,H1N1 Optimal use of vaccine to mitigate a second wave of H1N1 2009 influenza in Australia,72436,2009-01-01,2009.0,2011-12-31,2011,UNSW Sydney; UNSW Sydney; UNSW Sydney,grid.1005.4; grid.1005.4; grid.1005.4,Australia; Australia; Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6715624,991146,"Development of hybrid HPV/HIV VLPs, a novel vaccine to prevent both HIV and HPV infection",106387,1999-01-01,1999.0,2001-12-31,2001,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6713982,604925,H1N1 Estimating the protective effect of seasonal influenza vaccine against medically attended ILI due to novel influenz,135190,2009-01-01,2009.0,2010-12-31,2010,Melbourne Health; Melbourne Health; Melbourne Health; Melbourne Health; Melbourne Health,grid.429299.d; grid.429299.d; grid.429299.d; grid.429299.d; grid.429299.d,Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,2,0,0
grant.6663534,OPP1168067,To convene a group of experts to discuss the value of vaccines in reducing the impact of antimicrobial resistance,136700,2017-01-01,2017.0,2017-11-01,2017,Chatham House,grid.426490.d,United Kingdom,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6586329,OPP37736_01,To create a favorable social environment for accelerated ethical research and global delivery of HIV/AIDS vaccines,19323722,2007-07-01,2007.0,2014-03-01,2014,AIDS Vaccine Advocacy Coalition,grid.475060.0,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586246,OPP37736,To create a favorable social environment for accelerated ethical research and global delivery of HIV/AIDS vaccines,701129,2005-07-01,2005.0,2008-07-01,2008,AIDS Vaccine Advocacy Coalition,grid.475060.0,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586174,OPPGH5231,To build additional evidence to understand where typhoid vaccine is needed in Africa and accelerate its delivery where needed,11203452,2009-11-01,2009.0,2017-06-01,2017,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,13,0,0
grant.6586069,OPP1057975,"To develop and field test solar powered, battery-free icepack freezers to cool vaccines during transport and immunization sessions.",100000,2012-04-01,2012.0,2013-11-01,2013,Solar Electric Light Fund,grid.479590.6,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585995,OPP1007840,To convene an international symposium to review the potential contribution of new vaccines to improving global health,89000,2010-06-01,2010.0,2010-12-01,2010,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585899,OPP43543,To support clinic renovations in support of the Center for HIV/AIDS Vaccine Immunology clinical trials in Africa,134282,2006-09-01,2006.0,2007-09-01,2007,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585892,OPPGH5234,To identify actions necessary to accelerate introduction and uptake of cholera vaccines in high burden endemic regions in India,1093389,2009-11-01,2009.0,2013-04-01,2013,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6585854,OPP49764,"To develop and deploy genetic tests useful for monitoring drug resistance, vaccine responses, and disease severity",603646,2008-10-01,2008.0,2011-10-01,2011,Massachusetts Institute of Technology,grid.116068.8,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6585784,OPP38144,To provide financial support for participants from developing countries to attend an international conference on AIDS vaccine,305325,2005-08-01,2005.0,2005-11-01,2005,University of Montreal,grid.14848.31,Canada,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585750,OPP1031406,To develop and license a low cost booster vaccine to develop immunity against all serotypes of polio virus,757785,2011-03-01,2011.0,2016-09-01,2016,University of Pennsylvania,grid.25879.31,United States,Bill & Melinda Gates Foundation,United States,15,0,0
grant.6585632,OPP1061405,To develop a new vaccine for rotavirus that uses low-technology engineering methods suitable for the developing world.,100000,2012-04-01,2012.0,2013-11-01,2013,University of Queensland,grid.1003.2,Australia,Bill & Melinda Gates Foundation,United States,4,0,0
grant.6585333,OPP1159137,To assess pneumococcal carriage in children 4 -5 years after introduction of PCV10 (Pneumococcal conjugate vaccine) in Kenya,778266,2016-10-01,2016.0,2019-04-01,2019,HJF Medical Research International,grid.475284.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585297,OPP1007246,To create a novel DNA vaccine delivery system that targets dendritic cells in GI mucosal tissues.,100000,2009-10-01,2009.0,2011-05-01,2011,Chulalongkorn University,grid.7922.e,Thailand,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6585194,OPP1061509,"To develop an inexpensive, safe, and effective oral vaccine against invasive Salmonella disease using gas-filled bacterial vesicles.",100000,2012-04-01,2012.0,2014-05-01,2014,"University of Maryland, Baltimore",grid.411024.2,United States,Bill & Melinda Gates Foundation,United States,9,0,0
grant.6585174,OPP1008439,"To develop a broad-range vaccine, using your knowledge of bioinformatics, biochemistry, and immunology in an interdisciplinary approach",100000,2009-11-01,2009.0,2010-11-01,2010,Max Planck Society,grid.4372.2,Germany,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585001,OPP1084500,To reduce HIV infections by supporting research addressing the role of mucosal immunology in HIV protection for vaccine development.,2902288,2013-11-01,2013.0,2019-05-01,2019,Canadian Institutes of Health Research,grid.248883.d,Canada,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584798,OPP1162209,To develop a randomized control trial to assess the non-specific effects of oral poliovirus vaccine in Bangladesh,100561,2016-10-01,2016.0,2017-08-01,2017,International Centre for Diarrhoeal Disease Research,grid.414142.6,Bangladesh,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584784,OPP1032960,To develop protein chips that encapsulate poliovirus-like particles (PLP) for use as a safe and effective polio vaccine.,100000,2011-04-01,2011.0,2012-11-01,2012,Kyoto Institute of Technology,grid.419025.b,Japan,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584730,OPP32800,To assess the advantage of plant-derived vaccines as an inexpensive technique compared to traditional production methods,48391,2004-12-01,2004.0,2005-09-01,2005,Arizona State University,grid.215654.1,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584586,OPP1049425,To explore alternative cost-effective delivery methods for inactivated poliovirus vaccine based on the Sabin strains (Sabin-IPV),1299811,2012-04-01,2012.0,2017-04-01,2017,China Academy of Chinese Medical Sciences,grid.410318.f,China,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584577,OPP1041024,To develop an IPV vaccine adjuvanted with CAF01 that is able to enhance mucosal immunity and promote dose-sparing,326293,2011-11-01,2011.0,2013-07-01,2013,State Serum Institute,grid.6203.7,Denmark,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584372,OPP1065133,To develop and license a quadrivalent HPV vaccine available to the masses at an affordable cost,1892006,2012-11-01,2012.0,2016-03-01,2016,Serum Institute of India (India),grid.475452.5,India,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584276,OPP1160685,To convene global stakeholders to develop consensus with respect to preferred product characteristics for a TB vaccine,340202,2016-11-01,2016.0,2018-06-01,2018,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6584258,OPP1109905,To provide preliminary evidence in order to determine the most effective vaccine strategy for Hepatitis E virus (HEV),169739,2014-06-01,2014.0,2016-07-01,2016,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6584081,OPP1007027,To develop receptor blocking malaria vaccines based on a combination of a novel RBL family of Plasmodium merozoite proteins,100000,2009-11-01,2009.0,2011-05-01,2011,International Centre for Genetic Engineering and Biotechnology,grid.425195.e,India,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6583962,OPP1025490,To test three components from the mosquito’s innate signaling pathways for possible use in a malaria vaccine,100000,2010-11-01,2010.0,2012-05-01,2012,Jenner Institute,grid.418731.8,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583804,OPP1151840,To identify unique immune responses in individuals who resist tuberculosis infection to guide future vaccine design,2984509,2016-11-01,2016.0,2019-09-01,2019,Massachusetts General Hospital,grid.32224.35,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6583532,OPP1040705,"To develop improved vaccines against HIV/AIDS for use throughout the world, in particular in high disease burden countries",8029763,2012-09-01,2012.0,2018-09-01,2018,University Hospital of Lausanne,grid.8515.9,Switzerland,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6583522,OPP1087778,For the analysis of samples and data from Scientific Advisory Board-approved vaccine trials and natural history studies,2387938,2013-10-01,2013.0,2017-01-01,2017,Stanford University,grid.168010.e,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583118,OPP1119893,To test a large scale deployment of 75 passive vaccine storage devices in different rural settings across Ethiopia,868090,2015-06-01,2015.0,2019-04-01,2019,United Nations Children's Fund,grid.420318.c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583065,OPP1112842,To maximize immunization coverage for children across the developing world by reliably providing vaccines at the point-of-care,2047166,2014-10-01,2014.0,2017-05-01,2017,Logistimo (India),grid.479443.9,India,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582905,OPP52282,To conduct a Phase I HIV vaccine study that will compare the immunogenicity of different centralized gene (env) constructs,7473711,2009-11-01,2009.0,2018-04-01,2018,Duke University,grid.26009.3d,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6582843,OPP41351,To develop a vaccine in both developing and developed nations that prevents the transmission of HIV,15000000,2007-07-01,2007.0,2013-10-01,2013,"University of Maryland, Baltimore",grid.411024.2,United States,Bill & Melinda Gates Foundation,United States,4,0,0
grant.6582827,OPP29860,To bring together worldwide researchers to discuss the latest findings and trends associated with TB vaccines,10000,2003-08-01,2003.0,2004-08-01,2004,Aeras,grid.432518.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582644,OPP1061315,To design and test self-assembling peptide vaccine materials that are stable in the face of significant temperature fluctuations.,100000,2012-04-01,2012.0,2013-11-01,2013,University of Chicago,grid.170205.1,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6582624,OPP1032522,To develop the optimal techniques for cryopreservation of human mucosal tissues for use in assessing HIV vaccines and microbicides.,1469628,2013-11-01,2013.0,2016-12-01,2016,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,4,0,0
grant.6582595,OPP1126431,To evaluate the immunogenicity and impact of a reduced 13 valent pneumococcal conjugate vaccine (PCV13) dosing schedule,1197569,2015-03-01,2015.0,2019-01-01,2019,University College London,grid.83440.3b,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582570,OPP1059735,To test the ability of a low-cost plant-based synthetic biology method to produce an RNA malaria vaccine.,100000,2012-03-01,2012.0,2013-11-01,2013,Touro University California,grid.265117.6,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582231,OPP51833,To change characteristics in gram-negative bacteria to test an innovative approach for new vaccine generation,100000,2008-10-01,2008.0,2010-04-01,2010,Novartis (Italy),grid.15585.3c,Italy,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582229,OPP1091355,To identify novel immune targets and studies on mechanisms of protective immunity in order to accelerate rational vaccine development,2050341,2013-10-01,2013.0,2019-01-01,2019,Radboud University Nijmegen,grid.5590.9,Netherlands,Bill & Melinda Gates Foundation,United States,4,0,0
grant.6582223,OPP1134361,To better understand if clearance of malaria will improve T cell function and improve immune responses to vaccines,353295,2015-11-01,2015.0,2018-07-01,2018,National Institutes of Health,grid.94365.3d,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6582172,OPP1066663,To develop and characterize a naturally infected Guinea Pig model that can be used for vaccine evaluation.,1745409,2012-11-01,2012.0,2015-07-01,2015,Brigham and Women's Hospital,grid.62560.37,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582074,OPP1024654,To understand the impact of pneumococcal conjugate vaccine (PCV) to nasopharynx microbiome in Africa and Southeast countries,3550000,2011-10-01,2011.0,2017-01-01,2017,Jackson Laboratory,grid.249880.f,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582065,OPP1006884,To discover new mucosal immunity targets for the design of cheap vaccines effective against all serotypes of pneumococci,100000,2009-11-01,2009.0,2011-11-01,2011,University of Southampton,grid.5491.9,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581842,OPP37039,To accelerate the development of a global pediatric HIV/AIDS vaccine through basic research and Phase I clinical trials,2697613,2007-04-01,2007.0,2013-04-01,2013,Elizabeth Glaser Pediatric AIDS Foundation,grid.420931.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581686,OPP1070036,To develop a new vaccine for tuberculosis that uses an arabinomannan-protein conjugate to elicit strong antibody-mediated immunity.,100000,2012-10-01,2012.0,2014-05-01,2014,Yeshiva University,grid.268433.8,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6581626,OPP51796,To test whether changes in the bacteria that naturally reside in human bowels affect vaccine responsiveness.,99550,2008-10-01,2008.0,2010-03-01,2010,Yale University,grid.47100.32,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581582,OPP1036165,To design recombinant viruses that can generate self-assembling poliovirus-like particles for use in a poliovirus vaccine.,100000,2011-05-01,2011.0,2012-11-01,2012,Sentinext Therapeutics (Malaysia),grid.479547.c,Malaysia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581454,OPP1060854,To develop and test a device for rapid detection of freeze-damage in widely used adjuvant-type vaccines.,100000,2012-03-01,2012.0,2013-10-01,2013,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581388,OPP1061417,To develop Unmanned Aerial Vehicles (UAVs) that can be deployed via cell phones to transport vaccines to rural locations,93882,2012-04-01,2012.0,2014-11-01,2014,Massachusetts Institute of Technology,grid.116068.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581057,OPP1117815,To fund epidemiological and clinical endpoint definition studies in support of adjuvanted purified and inactivated vaccine development,6000000,2014-11-01,2014.0,2017-05-01,2017,GlaxoSmithKline (United States),grid.418019.5,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580952,OPP31844,To provide solutions to the problem of HIV and host genetic diversity to HIV vaccine development,9792730,2004-12-01,2004.0,2010-03-01,2010,Murdoch University,grid.1025.6,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580853,OPP31801,"To support the development of an attenuated Plasmodium falciparum sporozoite vaccine to reduce malaria infection, morbidity, and mortality",1429611,2004-04-01,2004.0,2005-04-01,2005,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580838,OPP1034606,To provide technical assistance to develop a research plan for the impact evaluation of pneumococcal conjugate vaccine in India,906539,2012-11-01,2012.0,2015-04-01,2015,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580808,OPP1007041,To develop a novel method to validate new potential drug and vaccine gene targets in the malaria parasite,100000,2009-10-01,2009.0,2011-05-01,2011,National Center for Genetic Engineering and Biotechnology,grid.419250.b,Thailand,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580797,OPP38648,To develop a vaccine that elicits durable cellular and humoral immunity to HIV-1 by targeting dendritic cells,23034708,2006-07-01,2006.0,2012-07-01,2012,Aaron Diamond AIDS Research Center,grid.280587.0,United States,Bill & Melinda Gates Foundation,United States,11,0,0
grant.6580650,OPPGH5233,To understand the burden of disease for cholera in Africa and build evidence to support cholera vaccine adoption there,9184036,2009-11-01,2009.0,2016-10-01,2016,Agence de Médecine Préventive,grid.417713.7,France,Bill & Melinda Gates Foundation,United States,5,0,0
grant.6580563,OPP1116967,To support the development of typhoid conjugate vaccine cost-effectiveness models to inform optimal delivery strategy,609150,2014-11-01,2014.0,2019-11-01,2019,Yale University,grid.47100.32,United States,Bill & Melinda Gates Foundation,United States,12,0,0
grant.6580385,OPP1095741,To develop and clinically test economically donor-friendly adjuvanted trivalent Inactivated Polio virus (IPV) vaccines with reduced IPV doses,34717072,2013-10-01,2013.0,2019-10-01,2019,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580374,OPP1036038,To develop a non-infectious poliovirus vaccine using encapsidated replicons or mature empty capsids that retain full immunogenicity.,100000,2011-04-01,2011.0,2012-11-01,2012,University of Florida,grid.15276.37,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580283,OPP1128644,"To provide research, develop and improve technologies and manufacture vaccines to improve health in developing countries",2503510,2015-07-01,2015.0,2017-06-01,2017,Batavia Biosciences (Netherlands),grid.474933.e,Netherlands,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6500883,272201000036C-8-0-1,Development of Technologies to Facilitate the use and Response of Vaccines,593314,2010-08-31,2010.0,2016-10-30,2016,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6383528,200601367,Influence of Parental Concern about Vaccine Safety on Incomplete Immunization of Alberta Pre-School Children,60820,2008-01-01,2008.0,2011-08-31,2011,University of Alberta,grid.17089.37,Canada,Alberta Innovates,Canada,0,0,0
grant.6346669,X40120-----71100,鶏胎児細胞の浮遊培養による日本脳炎ワクチンの製造(継2年),3106,1965-01-01,1965.0,1965-12-31,1965,Yokohama City University,grid.268441.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6344144,X40120-----72157,"ジフテリア(D), 百日咳(D), 破傷風(T), 麻疹(M), 混合ワクチンの実用化に関する研究",4349,1965-01-01,1965.0,1965-12-31,1965,Kanazawa University,grid.9707.9,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6320450,X00160----504164,インフルエンザの常在する東南アジアの調査と予防効果の高いワクチン製造の研究,34536,1980-01-01,1980.0,1980-12-31,1980,Nippon Medical School,grid.410821.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6318196,X00120----187041,"緑膿菌感染症のワクチン, 治療用γグロブリン及び診断液の臨床応用",14780,1976-01-01,1976.0,1976-12-31,1976,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6315037,X00120----287049,緑膿菌三種混合ワクチン及びその抗γ-グロブリンの臨床応用に関する研究,17957,1977-01-01,1977.0,1977-12-31,1977,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6313398,X00120----587055,遺伝子組み換えによるインフルエンザウイルスの温度感受性生ワクチン親株の作製,33842,1980-01-01,1980.0,1981-12-31,1981,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6312268,X00120----387005,"緑膿菌3種混合ワクチン及び抗菌体成分(OEP), 菌体外酵素抗体の臨床応用",33153,1978-01-01,1978.0,1978-12-31,1978,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6311355,X00120----587003,組織培養狂犬病ワクチンの人体接種効果及び最適接種法の研究,27626,1980-01-01,1980.0,1981-12-31,1981,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6310840,X00120----286040,魚群を対照とする浸漬ワクチン処理方法に関する研究,22792,1977-01-01,1977.0,1977-12-31,1977,University of Miyazaki,grid.410849.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6268587,97F00144,伝染性気管支炎ウイルススパイク蛋白を発現するマレック病ウイルス血清2型のリコンビナント生ワクチンの開発,9169,1998-01-01,1998.0,1998-12-31,1998,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6263047,97F00473,抗腫瘍免疫のモデルとしてのマレック病生ワクチンの作用機序に関する研究,8403,1998-01-01,1998.0,1998-12-31,1998,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6261734,97J08271,潜伏HIV-1活性化機序の解明およびAIDS発症予防ワクチンの開発,6876,1998-01-01,1998.0,1998-12-31,1998,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6261713,63771964,単クローン抗体による病原レプトスピラ感染防御抗原の構造解析と成分ワクチンの開発,5524,1988-01-01,1988.0,1988-12-31,1988,University of Shizuoka,grid.469280.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6219378,60770312,Trypanosoma cruzi 種特異抗原の診断とワクチンへの応用に関する研究,4833,1985-01-01,1985.0,1985-12-31,1985,Tokai University,grid.265061.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6219113,61041064,タイ国北部における日本脳炎伝播要因の生態学的研究と予防ワクチンの効果判定,60091,1986-01-01,1986.0,1986-12-31,1986,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6206358,58770354,水痘ウィルスゲノムの構造解析および水痘ウィルスワクチン株の分子マーカーの同定,4833,1983-01-01,1983.0,1983-12-31,1983,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6184545,57770342,ハシカウイルスの野生株からワクチン株への馴化現象の分子生物学的解析,5523,1982-01-01,1982.0,1982-12-31,1982,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6159196,56043057,インフルエンザの常在する東南アジアの調査と予防効果の高いワクチン製造の研究,11050,1981-01-01,1981.0,1981-12-31,1981,Nippon Medical School,grid.410821.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6156843,26861105,ペプチドワクチン療法における免疫抑制解除と免疫賦活の分子機構の解明,34512,2014-04-01,2014.0,2015-03-31,2015,Kurume University,grid.410781.b,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6121147,25460817,Parents' preferences for vaccination for their children in Japan,46798,2013-04-01,2013.0,2016-03-31,2016,Meiji Pharmaceutical University,grid.411763.6,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.6112342,25290055,革新的人工ロングペプチド癌ワクチン、H/K-HELPの抗腫瘍免疫活性化機序の解明,61401,2013-04-01,2013.0,2014-03-31,2014,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6072994,23659078,Development of transcutaneous vaccine with efficacy and safety for the overcoming infectious diseases,47262,2011-01-01,2011.0,2012-12-31,2012,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6036749,22390305,Development of tailor made peptide vaccines for renal cell carcinoma,232270,2010-01-01,2010.0,2012-12-31,2012,Kindai University,grid.258622.9,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.6036094,21790567,ファージディスプレイ法を用いた抗体様素子の開発とペプチドワクチンへの応用,18055,2009-01-01,2009.0,2009-12-31,2009,National Institute of Advanced Industrial Science and Technology,grid.208504.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6028416,21780262,Characterization of abortion related factor of intracellular protozoan parasite Neospora caninum and its application for vaccine development,50211,2009-01-01,2009.0,2010-12-31,2010,Obihiro University of Agriculture and Veterinary Medicine,grid.412310.5,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6000794,20591201,Novel oral vaccine using genetically engineering bifidobacterium displaying antigen on its cell-surface,49504,2008-01-01,2008.0,2010-12-31,2010,Kobe University,grid.31432.37,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5994958,19790063,Development of Novel Oral Vaccine Delivery System for Mucosal Immunization in Gut-Associated Lymphoid Tissue,34312,2007-01-01,2007.0,2008-12-31,2008,Kumamoto University,grid.274841.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5987989,19791181,頭頚部悪性腫瘍に対するFAKとEphA2を標的としたペプチドワクチン療法の開発,14430,2007-01-01,2007.0,2007-12-31,2007,Asahikawa Medical University,grid.252427.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5975123,19390424,Development of a prophylactic vaccine effective against a broader spectrum of HPVs associated with cervical cancer and basic research on therapeutic HPV vaccine for cervical cancer,177460,2007-01-01,2007.0,2009-12-31,2009,University of Tsukuba,grid.20515.33,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5921930,16K15367,Attitudes Towards and Acceptance of HPV Vaccine in Japanese Mothers of Adolescents living in the UK and Australia,32960,2016-04-01,2016.0,2019-03-31,2019,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5900336,16H05033,Development of subunit cocktail vaccine against bovine babesiosis,156594,2016-04-01,2016.0,2019-03-31,2019,Obihiro University of Agriculture and Veterinary Medicine,grid.412310.5,Japan,Japan Society for the Promotion of Science,Japan,13,0,0
grant.5883958,15K19096,Development of the toxoid vaccines and neutralizing monoclonal antibodies against Shiga toxins,35497,2015-04-01,2015.0,2017-03-31,2017,University of the Ryukyus,grid.267625.2,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5874094,15K08767,サイトメガロウイルスによる眼疾患の新規治療法とゲノム編集技術によるワクチン作成,43742,2015-04-01,2015.0,2018-03-31,2018,Gunma University,grid.256642.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5868586,15K10331,WT1ペプチドワクチンを中心とした悪性神経膠腫幹細胞標的療法の探索,42879,2015-04-01,2015.0,2019-03-31,2019,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,10,0,0
grant.5831528,14760059,ダニアレルゲン蛋白質の高次構造に焦点をあてたIgEエピトープ解析及びワクチン設計,31559,2002-01-01,2002.0,2003-12-31,2003,Juntendo University,grid.258269.2,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5568161,02770573,B型肝炎ワクチンによる抗体獲得例のうちHB_s抗体が陰性化した例の免疫学的検討,6213,1990-01-01,1990.0,1990-12-31,1990,Wakayama Medical University,grid.412857.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5562717,01771984,病原レプトスピラ感染防御凝集抗原を用いた成分ワクチン及び迅速診断法の開発,6213,1989-01-01,1989.0,1989-12-31,1989,University of Shizuoka,grid.469280.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5552615,00J06827,"新しい遺伝子操作技術を用いた""半生""ウイルスワクチンの開発と応用",17502,2000-01-01,2000.0,2001-12-31,2001,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5523176,201400473,Engineering Peptide-MHC/co-stimulator-based Nanoparticle Vaccines for the Treatment of Metastatic Cancer,126489,2015-09-01,2015.0,2018-08-31,2018,University of Calgary,grid.22072.35,Canada,Alberta Innovates,Canada,0,0,0
grant.5392972,06-04-08026,Изучение свойств рекомбинантных стрептококковых полипептидов  в качестве  компонентов вакцины против стрептококков группы В,0,2006-01-01,2006.0,2006-12-31,2006,,,,Russian Foundation for Basic Research,Russia,0,0,0
grant.5245678,272201000036C-7-0-1,Development of Technologies to Facilitate the use and Response of Vaccines,698949,2010-08-31,2010.0,2016-10-30,2016,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245677,272201000035C-13-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,700000,2015-03-20,2015.0,2015-07-31,2015,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5217877,117176,Persistence of protection against invasive bacterial disease-Memory B cell responses in infants after meningococcal vaccines,0,2007-02-01,2007.0,2008-01-31,2008,University of Oxford,grid.4991.5,United Kingdom,Swiss National Science Foundation,Switzerland,0,0,0
grant.5205699,45720,Prophylactic vaccine against Human papillomavirus 16: Mucosal immunity in the genital tract elicited by Salmonella recombinant strains,143595,1996-05-01,1996.0,1998-07-31,1998,University of Lausanne; University Hospital of Lausanne; Agroscope,grid.9851.5; grid.8515.9; grid.417771.3,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5185722,8832,Inaktivierte Vakzinen gegen das Afrikanische Schweinepest- virus (ASPV) : Molekulare Basis der immunogenen Proteine.,76035,1987-04-01,1987.0,1991-12-31,1991,University of Zurich,grid.7400.3,Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5184334,10778,Verminderung der zur Kontrolle von Tollwutimpfstoffen benö- tigten Anzahl Mäuse in der Human- und Veterinärmedizin,57822,1984-10-01,1984.0,1987-09-30,1987,,,,Swiss National Science Foundation,Switzerland,0,0,0
grant.5127911,LP160100138,Developing a chlamydial vaccine for koalas,254924,2016-01-01,2016.0,2018-12-31,2018,University of the Sunshine Coast; University of Tasmania; Australia Zoo,grid.1034.6; grid.1009.8; grid.474001.6,Australia; Australia; Australia,Australian Research Council,Australia,1,0,0
grant.5068881,Y4090024,基于CTL表位和Tn抗原的治疗性拟肽肿瘤疫苗的设计、合成及构效关系,0,2009-01-01,2009.0,2012-12-31,2012,Zhejiang University,grid.13402.34,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.4900549,,The basis of the irradiated sporozoite vaccine: identification of Plasmodium genes essential for development to liver stages,0,2002-05-01,2002.0,2005-04-30,2005,Pasteur Institute,grid.428999.7,France,International Human Frontier Science Program Organization,France,0,0,0
grant.4853338,86528,Generating regional rotavirus vaccine strains through reverse genetics to alleviate viral diarrhoea in Africa (extension: Dr. Hester O'Neill),0,2012-04-18,2012.0,2014-04-18,2014,Bernhard Nocht Institute for Tropical Medicine; Bernhard Nocht Institute for Tropical Medicine; Bernhard Nocht Institute for Tropical Medicine,grid.424065.1; grid.424065.1; grid.424065.1,Germany; Germany; Germany,Volkswagen Foundation,Germany,0,0,0
grant.4759025,5268688,Kombinierte CpG-Oligodeoxynukleotid/Lipopeptid Liposomen als neuer immunmodulatorischer Impfstoff gegen Hepatitis C Virus Infektion,0,2000-01-01,2000.0,2003-12-31,2003,Heinrich-Pette-Institute,grid.418481.0,Germany,German Research Foundation,Germany,0,0,0
grant.4716904,0115/B/P01/2009/36,Terapia czerniaka u myszy przy pomocy szczepionki zawierającej komórki dendrytyczne JAWSII.,48474,2009-04-22,2009.0,2012-04-21,2012,Medical University of Warsaw,grid.13339.3b,Poland,National Science Center,Poland,0,0,0
grant.4682361,139674,Impact of a novel vaccine candidate against Group B Streptococcus-induced neonatal diseases on commensal microbiota,0,2015-10-01,2015.0,2018-09-30,2018,National Laboratory for Civil Engineering,grid.16326.30,Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.4673194,20045,Etudes cliniques en vaccinologie visant en particulier à évaluer l impact épidémiologique de différents vaccins et à améliorer leur impact populationnel,8990,2009-04-01,2009.0,2010-03-31,2010,Université de Sherbrooke,grid.86715.3d,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.4671755,114080,Statistical Methods for Identifying Correlates of Risk and Surrogate Endpoints in Vaccine Trials,6065,2006-04-01,2006.0,2010-03-31,2010,University of Washington,grid.34477.33,United States,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4671560,16221,Etudes cliniques en vaccinologie visant en particulier à évaluer l impact épidémiologique de différents vaccins et à améliorer leur impact populationnel,40481,2009-04-01,2009.0,2010-03-31,2010,Université de Sherbrooke,grid.86715.3d,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.4670969,22068,Développement d'indicateurs novateurs de performance de la couverture vaccinale au Burkina Faso et dans les pays à revenu faible et intermédiaire,6741,2009-04-01,2009.0,2010-03-31,2010,Centre Hospitalier de l’Université de Montréal,grid.410559.c,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.4665556,159155,Development of phase I vaccine against Staphylococcus epidermis infections resulting from implant associated surgery - Avslutning dr.grad,172901,2003-01-01,2003.0,2005-12-31,2005,,,,The Research Council of Norway,Norway,0,0,0
grant.4652669,178621,Génération de nanoparticules dans le but de développer un vaccin universel contre la grippe,4962,2012-04-01,2012.0,2013-03-31,2013,Laval University,grid.23856.3a,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4652646,178622,Génération de nanoparticules dans le but de développer un vaccin universel contre la grippe,4962,2012-04-01,2012.0,2013-03-31,2013,Laval University,grid.23856.3a,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4649874,170993,Centre de Recherche en Infectiologie Porcine (CRIP),5762,2011-04-01,2011.0,2013-03-31,2013,University of Montreal,grid.14848.31,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4646557,141255,"New cancer vaccines based on Troy-bodies, telomerase as tumor-specific antigen, and CD40-activated B cells as APC",394683,2001-01-01,2001.0,2004-12-31,2004,University of Oslo,grid.5510.1,Norway,The Research Council of Norway,Norway,0,0,0
grant.4578598,060820/Z/00/Z,Elucidating the potential of baculovirions as an effective and safe 'DNA vaccine' delivery system.,92200,2000-11-01,2000.0,2002-07-31,2002,Animal Health Trust,grid.412911.e,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.4569274,94/03069-9,Vacina brasileira contra a meningite meningocócica b e c,0,1994-11-01,1994.0,1996-10-31,1996,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4489548,09/00728-9,RNA interference and recombinant protein prodution for identification of antigens to develop an anti-tick vaccine,0,2009-05-01,2009.0,2011-04-30,2011,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4455107,U38IP000879,ENHANCING AN IMMUNIZATION INFORMATION SYSTEM (IIS) TO INTERFACE WITH CDCs VTRACKS VACCINE ORDERING AND MANAGEMENT SYSTEM,962494,2015-09-30,2015.0,2016-09-29,2016,Arizona Department of Health Services,grid.413872.b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.4411536,,BACULOVIRUS RECOMBINANTS THAT EXPRESS HEPATITIS B VIRUS SURFACE AN TIGEN: DEMONSTRATION FOR PRODUCTION OF SUBUNIT VACCINES,92550,1984-10-01,1984.0,1985-09-30,1985,,,,United States Department of the Army,United States,0,0,0
grant.4360865,9621,Development of diagnostic techniques for detection of pathogens transmitted by ticks and procedures for preparation of vaccines against ticks,1254206,2010-11-01,2010.0,2013-10-31,2013,Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences,grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c,Slovakia; Slovakia; Slovakia; Slovakia,"Ministry of Education, Science, Research and Sport of the Slovak Republic",Slovakia,0,0,0
grant.4360740,4543,Molecular-biological characterisation of selected tick saliva proteins as potential antigens for development of anti-tick vaccine,17542,2007-01-01,2007.0,2009-12-01,2009,Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences; Slovak Academy of Sciences,grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c; grid.419303.c,Slovakia; Slovakia; Slovakia; Slovakia; Slovakia,"Ministry of Education, Science, Research and Sport of the Slovak Republic",Slovakia,0,0,0
grant.4358725,6843,Protractive activity of anti-rabies vaccines for rabies-like lyssavirus infections; possibility of influencing it by using adjuvant substances.,27041,2007-01-01,2007.0,2009-12-31,2009,University of Veterinary Medicine in Košice; University of Veterinary Medicine in Košice; University of Veterinary Medicine in Košice; University of Veterinary Medicine in Košice; University of Veterinary Medicine in Košice,grid.412971.8; grid.412971.8; grid.412971.8; grid.412971.8; grid.412971.8,Slovakia; Slovakia; Slovakia; Slovakia; Slovakia,"Ministry of Education, Science, Research and Sport of the Slovak Republic",Slovakia,0,0,0
grant.4113804,10412,New technology to improve vaccines for immunotherapy of cancer: antibody-mediated targeting of synthetic peptide constructs,1653087,2009-03-01,2009.0,2017-05-31,2017,Leiden University; Leiden University; Leiden University; Leiden University; Leiden University; Leiden University; Leiden University; Leiden University; Leiden University; Leiden University,grid.5132.5; grid.5132.5; grid.5132.5; grid.5132.5; grid.5132.5; grid.5132.5; grid.5132.5; grid.5132.5; grid.5132.5; grid.5132.5,Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands,Netherlands Organisation for Scientific Research,Netherlands,1,0,0
grant.3936854,200600438,Immune Responses and Regulation in Hepatitis C Virus (HCV) Infection: Implications for Vaccine/Immunotheraphy,1083754,2007-07-01,2007.0,2014-06-30,2014,University of Alberta,grid.17089.37,Canada,Alberta Innovates,Canada,0,0,0
grant.3936613,201100527,Influence of Parental Concern about Vaccine Safety on Incomplete Immunization of Alberta Pre-School Children,32352,2011-09-01,2011.0,2011-12-05,2011,University of Alberta,grid.17089.37,Canada,Alberta Innovates,Canada,0,0,0
grant.3936324,201100384,Small Molecule Agonists of RIG-I as Adjuvants for Hepatitis C and other Viral Vaccines,158210,2012-01-01,2012.0,2014-12-31,2014,University of Alberta,grid.17089.37,Canada,Alberta Innovates,Canada,0,0,0
grant.3882865,54944,"Chair in Social Justice, Equity and Diversity",478014,2007-04-01,2007.0,2013-03-31,2013,University of Toronto,grid.17063.33,Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.3857726,H23IP000930,PPHF 2014: IMMUNIZTAION: ENHANCE AN IMMUNIZATION INFORMATIONSYSTEM (IIS) TO INTERFACE WITH CDCs VTRCKS VACCINE ORDERING AND MANAGEMENT SYSTEM,495914,2014-09-30,2014.0,2016-09-29,2016,Wyoming State Department of Health,grid.280415.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857725,H23IP000929,PPHF 2014: IMMUNIZATION ENHANCE AN IMMUNIZATION INFORMATION SYSTEM (IIS) TO INTERFACE WITH CDCs VTRCKS VACCINE ORDERING & MGMT SYSTEM,700000,2014-09-30,2014.0,2016-09-29,2016,Massachusetts Department of Public Health,grid.416511.6,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857724,H23IP000928,TO ENHANCE THE STATEWIDE IMMUNIZATION REGISTRY (IRIS) TO INTERFACE WITH CDCs NATIONAL VACCINE ORDERING AND INVENTORY MGMT SYSTEM (VTRCKS),700000,2014-09-30,2014.0,2016-09-29,2016,Iowa Department of Public Health,grid.280302.b,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857722,H23IP000926,PPHF 2014: IMMUNIZATION-ENHANCE AN IMMUNIZATION INFORMATION SYSTEM (IIS) TO INTERFACE WITH CDCs VTRCKS VACCINE ORDERING AND MANAGEMENT SYSTEM,693022,2014-09-30,2014.0,2016-09-29,2016,Colorado Department of Public Health and Environment,grid.410375.4,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857718,H23IP000922,PPHF 2014: IMMUNIZATION ENHANCE AN IMMUNIZATION INFORMATION SYSTEM (IIS) TO INTERFACE WITH CDCs VTRCKS VACCINE ORDERING & MANAGEMENT SYSTEM,700000,2014-09-30,2014.0,2016-09-29,2016,Washington State Department of Health,grid.1658.a,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857717,H23IP000921,IMMUNIZATION ENHANEMENTS OF OUR IMMUNIZATION INFORMATION SYSTEM (IIS) TO INTERFACE WITH CDCs VTRCKS VACCINE ORDERING & MGMT SYSTEM,530337,2014-09-30,2014.0,2016-09-29,2016,Rhode Island Department of Health,grid.280336.c,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857712,H23IP000915,"BUILDING ON THE EXISTING NYSIIS VTRCKS INTERFACE TO ENHANCE VACCINE INVENTORY , ACCOUNTABILITY AND USABILITY OF THE NYSIIS SYSTEM",675415,2014-09-30,2014.0,2016-09-29,2016,New York State Department of Health,grid.238491.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857711,H23IP000914,ENHANCING IDAHOS IIS IN ELECTRONICALLY COLLECTING FROM PROVIDERS INFORMATION ON WASTED AND RETURNED VACCINES FOR EXPORT TO VTRCKS,668888,2014-09-30,2014.0,2016-09-29,2016,Idaho Department of Health and Welfare,grid.280384.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857707,H23IP000910,NORTH CAROLINA IMMUNIZATION REGISTRY WHICH IS THE STATE IMMUNIZATION INFORMATION SYSTEM WILL IMPROVE INTERFACE CAPACITY WITH CDCs VACCINE ORDERING,250000,2014-09-30,2014.0,2016-09-29,2016,NC Department of Health and Human Services,grid.410399.6,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857704,H23IP000907,PPHF 2014: IMMUNIZATION: ENHANCE AN IMMUNIZATION INFO SYSTEM (IIS) TO INTERFACE WITH CDCs VTRCKS VACCINE ORDERING & MGMT SYSTEM,698272,2014-09-30,2014.0,2016-09-29,2016,Minnesota Department of Health,grid.280248.4,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3856851,272201000036C-6-0-1,Development of Technologies to Facilitate the use and Response of Vaccines,651370,2010-08-31,2010.0,2019-07-21,2019,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3823776,0212452,PRESERVING A TENUOUS RESOURCE: MAINTENANCE OF A PROMISING VACCINE STRAIN OF TOXOPLASMA GONDII,0,2007-10-01,2007.0,2008-09-30,2008,University of Illinois at Urbana Champaign,grid.35403.31,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3810813,2012-33610-19517,NOVEL VACCINES FOR JOHNE'S DISEASE,99682,2011-09-01,2011.0,2012-04-30,2012,Pan Genome Systems (United States),grid.427099.1,United States,National Institute of Food and Agriculture,United States,0,4,0
grant.3776489,228403,European Network of Vaccine Development and Research,13227582,2009-10-01,2009.0,2013-09-30,2013,Helmholtz Centre for Infection Research; Wageningen University & Research; University of Oxford; University of Regensburg; University of Lausanne; Biomedical Primate Research Centre; Lionex (Germany); Department of Health and Social Care; Max Planck Society; Department of Health and Social Care; Wageningen University & Research; TuBerculosis Vaccine Initiative; London School of Hygiene & Tropical Medicine,grid.7490.a; grid.4818.5; grid.4991.5; grid.7727.5; grid.9851.5; grid.11184.3d; grid.425267.0; grid.57981.32; grid.4372.2; grid.57981.32; grid.4818.5; grid.425962.e; grid.8991.9,Germany; Netherlands; United Kingdom; Germany; Switzerland; Netherlands; Germany; United Kingdom; Germany; United Kingdom; Netherlands; Netherlands; United Kingdom,European Commission,Belgium,19,0,0
grant.3745760,IC15980307,"Recombinant vaccines against tuberculosis challenge in normal as we ll as transgenic, HLADR-expressing, IA-deficient mice",0,1998-11-01,1998.0,2001-10-31,2001,Department of Medical Sciences; Imperial College London; Leiden University,grid.466123.4; grid.7445.2; grid.5132.5,Russia; United Kingdom; Netherlands,European Commission,Belgium,0,0,0
grant.3728264,CI1*930026,Construction of potential rotavirus vaccines and evaluation of their capacity for inducing both humoral and cellular immunity,0,1994-01-01,1994.0,1995-12-31,1995,University of Bristol; National Autonomous University of Mexico,grid.5337.2; grid.9486.3,United Kingdom; Mexico,European Commission,Belgium,0,0,0
grant.3708037,TS2*0223,IMMUNOLOGICAL PROTECTION MECHANISM AND ASSESSMENT OF CANDIDA TE VACCINE PREPARATIONS IN A NONHUMAN PRIMATE MODEL FOR SCHI STOSOMIASIS,0,1989-05-01,1989.0,1991-08-31,1991,Institute of Primate Research,grid.418948.8,Kenya,European Commission,Belgium,0,0,0
grant.3707096,GB1*0011,THE PRODUCTION OF A NOVEL VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS (IBV) BY THE USE OF GENETIC ENGINEERING TECHNIQUES,0,1982-12-01,1982.0,1986-03-31,1986,Pirbright Institute,grid.63622.33,United Kingdom,European Commission,Belgium,0,0,0
grant.3700062,TS2*0071,DEVELOPMENT OF DIAGNOSTICS FOR T. EVANSI IN CAMELS AND WATER BUFFALOES. PERSPECTIVES IN VACCINE DEVELOPMENT,0,1988-10-01,1988.0,1992-09-30,1992,Vrije Universiteit Brussel,grid.8767.e,Belgium,European Commission,Belgium,0,0,0
grant.3641531,085485/Z/08/B,Development of an oral adenovirus-based vaccine against influenza for pandemic protection.,3108448,2010-03-31,2010.0,2011-12-30,2011,PaxVax (United States),grid.437314.6,United States,Wellcome Trust,United Kingdom,0,0,0
grant.3641529,085485/Z/08/Z,Development of an oral adenovirus-based vaccine against influenza for pandemic protection.,8005393,2008-06-25,2008.0,2012-12-24,2012,PaxVax (United States),grid.437314.6,United States,Wellcome Trust,United Kingdom,0,0,0
grant.3634752,067592/Z/02/Z,Out of Africa: British trypanosomes as vaccine vehicles against important cattle pathogens.,220394,2003-02-01,2003.0,2005-11-30,2005,University of Manchester; University of Manchester,grid.5379.8; grid.5379.8,United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,1,0,0
grant.3633304,060147/Z/00/Z,Analysis of candidate pre-erythrocytic vaccines against malaria in semi-immune Africans.,393024,2001-03-01,2001.0,2003-12-31,2003,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3631322,066020/Z/01/Z,Investigation of pre-erythrocytic malaria vaccines in a mouse model using transgenic parasites.,183912,2001-10-01,2001.0,2004-09-30,2004,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3630183,062710/Z/00/Z,Expression of recombinant antigen-antibody fusion complexes for developing new vaccines.,358668,2001-05-01,2001.0,2005-03-31,2005,"St George's, University of London",grid.264200.2,United Kingdom,Wellcome Trust,United Kingdom,2,0,0
grant.3626707,082924/Z/07/Z,WHO MALVAC 2007 Meeting,10004,2007-05-01,2007.0,2007-05-31,2007,World Health Organization,grid.3575.4,Switzerland,Wellcome Trust,United Kingdom,0,0,0
grant.3624593,272201000035C-9-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,10928292,2012-12-21,2012.0,2015-03-31,2015,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3579359,LP0883815,Characterisation and development of adjuvants for new generation veterinary and human vaccines,276317,2008-01-01,2008.0,2011-12-31,2011,Monash University; Pfizer (Australia),grid.1002.3; grid.467540.4,Australia; Australia,Australian Research Council,Australia,1,0,0
grant.3534575,134566,Establishment of a flexible insect cell platform for fast production of pseudo-typed VLPs for drug and vaccine development,61237,2014-04-01,2014.0,2015-08-31,2015,Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa,grid.10772.33; grid.10772.33; grid.10772.33; grid.10772.33; grid.10772.33,Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3534289,135843,A combination of two gp41 peptides for a new prophylactic vaccine both neutralizing HIV-1 and inhibiting CD4 depletion,149116,2014-01-20,2014.0,2016-01-19,2016,Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Portuguese Oncology Institute; Hospital de Santa Maria,grid.10772.33; grid.10772.33; grid.10772.33; grid.418711.a; grid.411265.5,Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3533959,115044,Development of a mucosal hepatitis B vaccine: Design and mechanistic studies of a prototypic multi-component polymeric delivery system.,162809,2011-01-01,2011.0,2014-03-31,2014,University of Coimbra; University of Coimbra; University of Geneva; University of Coimbra,grid.8051.c; grid.8051.c; grid.8591.5; grid.8051.c,Portugal; Portugal; Switzerland; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3529219,114118,ER_TRANSPROT -“Ehrlichia ruminantium proteome analysis: a complementary approach to transcriptomics towards increased knowledge on heartwater pathogenesis and vaccine development,207485,2011-03-01,2011.0,2014-07-31,2014,Instituto de Biologia Experimental Tecnológica; Instituto de Investigação Científica Tropical,grid.7665.2; grid.420930.c,Portugal; Portugal,Foundation for Science and Technology,Portugal,9,0,0
grant.3526706,109366,Development of ultra-sensitive detection methods and plant nano-vaccines for the fungi Fusarium spp. using nanotechnological devices.,162328,2009-09-01,2009.0,2012-03-31,2012,Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade Nova de Lisboa; Biocant,grid.10772.33; grid.10772.33; grid.10772.33; grid.10772.33; grid.423312.5,Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3526045,116470,"Helicobacter pylori diversity in pathogenesis, antibiotic resistance, and evasion from natural and vaccine-induced immune responses (HELDIVPAT)",133010,2011-03-01,2011.0,2014-10-31,2014,University of Porto; University of Porto; University of Porto; University of Porto,grid.5808.5; grid.5808.5; grid.5808.5; grid.5808.5,Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3525527,65047,The Leishmania TDR1 family-related gene: functional studies and evaluation of TDR1 recombinant protein and knockout vaccines against leishmaniasis.,234142,2007-11-01,2007.0,2010-12-31,2010,University of Porto; University of Porto; University of Montpellier; University of Porto; University of Porto; University of Porto; University of Coimbra; University of Porto; University of Porto,grid.5808.5; grid.5808.5; grid.121334.6; grid.5808.5; grid.5808.5; grid.5808.5; grid.8051.c; grid.5808.5; grid.5808.5,Portugal; Portugal; France; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,4,0,0
grant.2960566,153526,Développement d'un vaccin recombinant contre l'infection par le virus du syndrome reproducteur et respiratoire des porcs (SRRP),174671,1997-04-01,1997.0,2000-03-31,2000,National Institute of Scientific Research,grid.418084.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2958077,137409,Développement dun vaccin recombinant contre linfection par le virus du syndrome reproducteur et respiratoire des porcs (SRRP),87628,1998-04-01,1998.0,1999-03-31,1999,National Institute of Scientific Research,grid.418084.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2955084,62495,Development of caulobacters as a vaccine presentation system for the passive immunization of hatchery salmonids against IHNV virus,12016,1992-04-01,1992.0,1994-03-31,1994,University of British Columbia; Fisheries and Oceans Canada,grid.17091.3e; grid.23618.3e,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2935828,282028,Peptide epitopes for the HIV -1 neutralizing antibodies 2F5 and 2G12 as anti HIV-1 vaccine candidates,26896,2004-04-01,2004.0,2005-03-31,2005,Simon Fraser University,grid.61971.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2934662,38752,Plant molecular pharming: application for the development of an experimental recombinant subunit vaccine against human respiratory syncytial virus,112209,1992-04-01,1992.0,1995-03-31,1995,National Institute of Scientific Research,grid.418084.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2932892,110200,Construction and testing of vaccine proteins against pseudomonas infections using the Caulobacter crescentus S-Layer presentation,258754,1995-04-01,1995.0,1998-03-31,1998,University of British Columbia,grid.17091.3e,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2922759,213638,Vaccins sous-unitaires induisant une immunité mucosale effectrice contre l'infection par le virus du syndrome reproducteur et respiratoire porcin,297553,2000-04-01,2000.0,2003-03-31,2003,National Institute of Scientific Research; Vétoquinol (Canada); Vétoquinol (Canada); Vétoquinol (Canada); Vétoquinol (Canada); Vétoquinol (Canada); Vétoquinol (Canada),grid.418084.1; grid.450582.e; grid.450582.e; grid.450582.e; grid.450582.e; grid.450582.e; grid.450582.e,Canada; Canada; Canada; Canada; Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2919468,153538,The Hu-SCID mouse: An experimental model for the development and testing of candidate TB vaccines,170948,1997-04-01,1997.0,2000-03-31,2000,University of Toronto; Sanofi (Canada),grid.17063.33; grid.418933.4,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2906395,394911,In ovo and mucosal delivery of CpG-ODN in chickens as an immunostimulant and vaccine adjuvant,136977,2004-04-01,2004.0,2009-03-31,2009,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2892234,3031,Immunologie des protéines structurales du virus du syndrome reproducteur et respiratoire du porc (SRRP) et valeur vaccinale des protéines recombinantes,233654,1994-04-01,1994.0,1997-03-31,1997,National Institute of Scientific Research,grid.418084.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2889085,327422,Canadian Network for Vaccines and Immunotherapeutics of Cancer and Chronic Viral Diseases (CANVAC)                    (2006 Renewal Competition),3525888,2006-04-01,2006.0,2007-03-31,2007,University of Montreal; Canadian Institutes of Health Research; Canadian Institutes of Health Research,grid.14848.31; grid.248883.d; grid.248883.d,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2888595,237352,Peptide epitopes for the HIV -1 neutralizing antibodies 2F5 and 2G12 as anti HIV-1 vaccine candidates,24988,2003-04-01,2003.0,2004-03-31,2004,Simon Fraser University,grid.61971.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2840073,293427,Discovering the optimal signals for T cell proliferation and differentiation: the key to effective vaccines and immunotherapy,14442,2005-04-01,2005.0,2006-03-31,2006,University of Victoria,grid.143640.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2829016,369746,Canadian plaform for a cell culture based influenza vaccine production network (IVPN)  ( Funding request for full application preparation.),23272,2007-04-01,2007.0,2008-03-31,2008,Laval University,grid.23856.3a,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2803549,112465,Developing vaccine and immunotherapeutic strategies for the prevention and treatment of cancer and viral diseases (CANVAC),18051,1997-04-01,1997.0,1998-03-31,1998,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2711624,Z01BK005012,"Safety of live vaccines that establish life-long, persis",0,1999-01-01,1999.0,2002-01-01,2002,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709220,Z01AI005055,SARS DNA Recombinant Adenoviral Vaccine,0,2003-01-01,2003.0,2005-01-01,2005,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2709217,Z01AI005052,Develop /Production Of A SARS DNA Plasmid Vaccine,0,2003-01-01,2003.0,2005-01-01,2005,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2709216,Z01AI005051,West Nile Virus DNA Plasmid Vaccine,0,2003-01-01,2003.0,2005-01-01,2005,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2654337,R43IP000011,High Speed Automated Influenza Vaccine Harvester,0,2001-09-30,2001.0,2002-03-31,2002,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2640565,R43AI044579,LIPOSOMAL VACCINE ADJUVANT FOR INFLUENZA IMMUNIZATION,0,1999-03-15,1999.0,2000-09-14,2000,Molecular GPS Technologies (United States),grid.281192.1,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2640533,R43AI043807,LIPOSOME-BASED VACCINE ADJUVANT SYSTEM FOR HIV,0,1998-08-15,1998.0,2000-08-31,2000,Molecular GPS Technologies (United States),grid.281192.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2640045,R43AI032272,FUNGAL EXPRESSION OF DENGUE PROTEINS FOR VACCINES,0,1992-02-01,1992.0,1992-09-30,1992,Hawaii Biotech (United States),grid.420613.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2430556,N01HD023337,PHASE 2 STUDY IF E COLI O157-REPA CONJUGATE VACCINE IN 2-5 YEAR OLD CH-275023337,0,2002-01-01,2002.0,2003-01-01,2003,Carolinas Medical Center,grid.239494.1,United States,National Institute of Child Health and Human Development,United States,8,0,0
grant.2425177,N01AI30037-7-0-1,SARS Vaccine Development,245150,2003-09-30,2003.0,2009-12-30,2009,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425009,N01AI095374,HIV VACCINE PRODUCTION,158846,1999-07-09,1999.0,2006-07-08,2006,Vical (United States),grid.422245.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425008,N01AI095373,HIV VACCINE PRODUCTION,0,1999-07-09,1999.0,2000-07-08,2000,Diadexus (United States),grid.438929.d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425007,N01AI095372,HIV VACCINE PRODUCTION,0,1999-07-09,1999.0,2000-06-29,2000,University of Michigan,grid.214458.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425006,N01AI095371,HIV VACCINE PRODUCTION,0,1999-07-07,1999.0,2001-07-31,2001,,,,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2425005,N01AI095370,HIV VACCINE PRODUCTION,277934,1999-07-07,1999.0,2006-07-06,2006,Protein Sciences (United States),grid.437366.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425004,N01AI095369,HIV VACCINE PRODUCTION,541959,1999-07-07,1999.0,2006-07-06,2006,Progenics Pharmaceuticals (United States),grid.280766.d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425003,N01AI095368,]HIV VACCINE PRODUCTION,0,1999-07-07,1999.0,2006-07-06,2006,Immune Response BioPharma (United States),grid.420121.4,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425002,N01AI095367,HIV VACCINE PRODUCTION,514485,1999-07-09,1999.0,2006-07-09,2006,Novartis (United States),grid.418424.f,United States,National Institute of Allergy and Infectious Diseases,United States,14,0,0
grant.2425001,N01AI095366,HIV VACCINE PRODUCTION,0,1999-07-01,1999.0,2006-06-30,2006,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2424565,N01AI035156,VACCINE EFFECTS IN PREGNANT MODEL &OFFSPRING,145000,1993-02-15,1993.0,2001-07-31,2001,Texas Biomedical Research Institute,grid.250889.e,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2347296,272201000036C-4-0-1,Development of Technologies to Facilitate the use and Response of Vaccines,10792404,2010-08-31,2010.0,2015-08-30,2015,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347290,272201000035C-5-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,2045144,2012-12-21,2012.0,2014-08-29,2014,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2344594,261201200021I-0-26100002-1,Efficacy of a Multi-Antigen Vaccine in the Prevention of Methylnitrosourea,669243,2012-09-21,2012.0,2014-09-20,2014,University of Alabama at Birmingham,grid.265892.2,United States,National Cancer Institute,United States,0,0,0
grant.100071392,PSDA-2008-King,Promoting Tolerogenic Dendritic Cell Migration In Vivo As A Potential For Autoimmune Vaccine Therapy,150000,2008-07-01,2008.0,2011-06-30,2011,University of California Los Angeles,grid.19006.3e,United States,Rheumatology Research Foundation,United States,0,0,0
grant.8571244,19552_1,Evaluation of immune responses engendered in CEA transgenic mice by a vaccine formulation composed of a recombinant CEA N domain antigen and GSK AS15 adjuvant,0,2014-03-24,2014.0,2015-03-23,2015,Sunnybrook Health Science Centre,grid.413104.3,Canada,Ontario Institute for Cancer Research,Canada,0,0,0
grant.8182708,31402347,适用于鲤的“自杀性”DNA疫苗载体清除机制、清除效果及免疫研究,35187,2015-01-01,2015.0,2017-12-31,2017,Guangdong Academy of Agricultural Sciences,grid.135769.f,China,National Natural Science Foundation of China,China,1,0,0
grant.8108623,11490,Live avirulent vaccine against E. coli infections in broilers.,0,1995-05-01,1995.0,1998-04-30,1998,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.7876865,1147654,OptiMalVax: Optimizing a deployable high efficacy malaria vaccine,369799,2017-01-01,2017.0,2019-01-01,2019,James Cook University,grid.1011.1,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7667275,,Novel Vaccines for Measles,85975,2008-10-01,2008.0,2010-09-30,2010,University of Saskatchewan,grid.25152.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7573170,281386,Gave fra Stiftelsen Kristian Gerhard Jebsen til K.G. Jebsen-senter for forskning på influensavaksiner,151024,2017-01-01,2017.0,2017-12-31,2017,University of Oslo,grid.5510.1,Norway,The Research Council of Norway,Norway,0,0,0
grant.7172465,272201300002I-0-27200017-1,Evaluation of the Immunogenicity and Efficacy of a DNA Prime/Protein Boost Vaccine,715267,2017-09-01,2017.0,2018-08-15,2018,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172057,272201300004I-0-27200006-1,Identifying correlates of protection afforded by (Delta)GY SIVmac239 attenuated virus vaccine,1593039,2016-12-07,2016.0,2018-02-06,2018,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7035746,FC1143,Development of vaccines & strategy for their use to control ulcer disease in coldwater ornamental fish.,163368,2001-01-01,2001.0,2004-01-31,2004,Heriot-Watt University,grid.9531.e,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,1,0,0
grant.7020002,31170871,人工合成新型腺病毒及其作为疫苗载体的研究,104502,2012-01-01,2012.0,2015-12-31,2015,,,,National Natural Science Foundation of China,China,16,0,0
grant.6958979,addf2a1949f8e19de38230b2da6716ae93be,Oral Amyloid AAV Vaccine for Alzheimer's Disease,130794,2008-10-01,2008.0,2009-09-30,2009,University of Alabama at Birmingham,grid.265892.2,United States,Alzheimer's Drug Discovery Foundation,United States,0,0,0
grant.6782476,2578045900,Bench top flow cytometer,0,2012-06-15,2012.0,2014-06-04,2014,Ghent University; Ghent University; Ghent University,grid.5342.0; grid.5342.0; grid.5342.0,Belgium; Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6779368,30857,Building Vaccinology Expertise in South-East Asia.,0,2014-05-28,2014.0,2014-12-31,2014,University of Antwerp; University of Antwerp,grid.5284.b; grid.5284.b,Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6718669,1000761,A Novel Vaccine Platform for Trimeric Envelope Proteins: HIV-1 envelope,127719,2010-01-01,2010.0,2010-12-31,2010,Burnet Institute; Burnet Institute; Burnet Institute,grid.1056.2; grid.1056.2; grid.1056.2,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6585082,OPP1127207,"To enable participation by vaccine experts from developing countries in a workshop to be held on the MIT campus to improve technology transfer and improve local vaccine development and manufacturing so that vaccines can be provided at an affordable price, which will, in turn, lead to local employment",30000,2015-02-01,2015.0,2015-10-01,2015,Massachusetts Institute of Technology,grid.116068.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581567,OPP1070827,To develop an economically donor-friendly IPV vaccine with a reduced IPV dose of at least 5 fold. This vaccine will despite the lower dose of IPV show an immunogenicity which equals or surpasses the current full dose IPV vaccine.,551049,2012-11-01,2012.0,2014-07-01,2014,State Serum Institute,grid.6203.7,Denmark,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6500531,N01AI60007-13-0-1,Simian Vaccine Evaluation Units,23204,2006-06-22,2006.0,2013-06-21,2013,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499878,272201300003I-2-27200007-1,Efficacy of Conserved Element SIV Gag Vaccine in Control of SIVmac239 Viremia,53067,2014-09-01,2014.0,2016-10-31,2016,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6083410,24500527,The application  to cancer vaccine of SSF that mimics pulmonary surfactant,54024,2012-04-01,2012.0,2015-03-31,2015,Musashino University,grid.411867.d,Japan,Japan Society for the Promotion of Science,Japan,8,0,0
grant.6067495,23659504,Killer T cell inducing peptide vaccine against malaria infection,45632,2011-01-01,2011.0,2012-12-31,2012,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6039996,22592247,Establishment of dendritic cell-based vaccine in combination with chemotherapy for oral cancer patients,53717,2010-01-01,2010.0,2012-12-31,2012,Keio University,grid.26091.3c,Japan,Japan Society for the Promotion of Science,Japan,8,0,0
grant.5979969,19590888,Development of dendritic cell vaccine modified with a ligand of NKT cells against tuberculosis,40126,2007-01-01,2007.0,2008-12-31,2008,Hamamatsu University School of Medicine,grid.505613.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5693464,08672565,Synthesis of Tn and Sialyl Tn Antigen-Lipid A Analog Conjugate for Synthetic Vaccines,16583,1996-01-01,1996.0,1997-12-31,1997,University of Shizuoka,grid.469280.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5534219,586424,Optimizing Vaccine Formulations for Veterinary Vaccines,3264,2015-04-01,2015.0,2016-03-31,2016,University of Calgary,grid.22072.35,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5246649,N01AI60005-14-0-1,Simian Vaccine Evaluation Unit (SVEU),182163,2006-06-22,2006.0,2013-06-22,2013,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5150921,CSO-AUKCAR/14/03,Seasonal influenza vaccine effectiveness in Asthma,159934,2015-02-01,2015.0,2018-01-31,2018,University of Edinburgh,grid.4305.2,United Kingdom,Scottish Government Health and Social Care Directorates,United Kingdom,2,0,0
grant.5003535,31072245,减毒迟缓爱德华氏菌作为疫苗载体呈递异源抗原的研究,60106,2011-01-01,2011.0,2013-12-31,2013,Chinese Academy of Fishery Sciences,grid.43308.3c,China,National Natural Science Foundation of China,China,5,0,0
grant.4987483,30872392,诱导和增强肠道粘膜抗HIV感染免疫反应的疫苗免疫实验研究,44874,2009-01-01,2009.0,2011-12-31,2011,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,0,0,0
grant.4980963,30801046,TLR配体逆转CD4+CD25+调节性T细胞对日本血吸虫表位疫苗效应抑制的分子机制,29916,2009-01-01,2009.0,2011-12-31,2011,Anhui University of Science and Technology,grid.440648.a,China,National Natural Science Foundation of China,China,3,0,0
grant.4968317,30901375,载体骨架CpG化修饰对新型复制子DNA疫苗免疫调节作用研究,30715,2010-01-01,2010.0,2012-12-31,2012,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,7,0,0
grant.4566767,97/08182-6,Vacinas de polissacarídeos,0,1997-11-01,1997.0,2001-01-31,2001,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4566381,95/02497-0,Desenvolvimento de vacinas para uso humano: da bancada para a produção,0,1996-01-01,1996.0,1998-12-31,1998,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4122515,017.005.011,Immunological memory induced by attenuated malaria parasites,0,2008-10-01,2008.0,2013-02-28,2013,Radboud University Nijmegen; Radboud University Nijmegen,grid.5590.9; grid.5590.9,Netherlands; Netherlands,Netherlands Organisation for Scientific Research,Netherlands,4,0,0
grant.3928388,228382,Mobile Computer-Assisted Survey Research Laboratory for HIV Vaccine Implementation Science,28151,2013-02-08,2013.0,2018-02-07,2018,University of Toronto,grid.17063.33,Canada,"Ministry of Research, Innovation and Science",Canada,0,0,0
grant.3921156,63627,Towards a science of community engagement in international HIV vaccine research:  an embedded multinational case study of the social impact of a failed HIV vaccine trial,69179,2008-04-01,2008.0,2009-03-31,2009,University of Toronto; University of Toronto; University of Toronto; University of Toronto,grid.17063.33; grid.17063.33; grid.17063.33; grid.17063.33,Canada; Canada; Canada; Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.3843484,130873,Feasibility of applying an innovative bioprocessing methodology in a novel vaccine approach,39572,2012-07-31,2012.0,2012-11-30,2012,,,,Innovate UK,United Kingdom,0,0,0
grant.3830612,0212514,IMMUNOSUPPRESSION BY TICK SALIVA AND VACCINE DEVELOPMENT,0,2007-10-01,2007.0,2012-09-30,2012,University of Massachusetts Amherst; University of Massachusetts Amherst; University of Massachusetts Amherst; University of Massachusetts Amherst; University of Massachusetts Amherst,grid.266683.f; grid.266683.f; grid.266683.f; grid.266683.f; grid.266683.f,United States; United States; United States; United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3829753,0212140,PREVENTION OF THE IPNV CARRIER STATE WITH DNA AND SUBUNIT VACCINES,0,2007-10-01,2007.0,2010-09-30,2010,University of Maine,grid.21106.34,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3578378,LP0454160,Development and Assessment of Chimaeric Feline Caliciviruses as Vaccines,53005,2004-01-01,2004.0,2006-12-31,2006,University of Melbourne; CSL (Australia),grid.1008.9; grid.1135.6,Australia; Australia,Australian Research Council,Australia,0,0,0
grant.3575849,LP0454047,Proteomics and vaccine development in swine dysentery,225064,2004-01-01,2004.0,2006-12-31,2006,Monash University,grid.1002.3,Australia,Australian Research Council,Australia,0,0,0
grant.3570522,DP110104165,Designing effective Gram negative bacterial vaccines,242564,2011-01-01,2011.0,2013-12-31,2013,Monash University,grid.1002.3,Australia,Australian Research Council,Australia,3,0,0
grant.3569846,DP110101019,Multifunctional biodegradable nanoparticles for enhanced DNA vaccine delivery,444710,2011-01-01,2011.0,2013-12-31,2013,Monash University; Burnet Institute; Sichuan University,grid.1002.3; grid.1056.2; grid.13291.38,Australia; Australia; China,Australian Research Council,Australia,0,0,0
grant.3566220,DP120102824,Designing new generation adjuvants for allergy and parasite vaccines,304637,2012-01-01,2012.0,2014-12-31,2014,Monash University,grid.1002.3,Australia,Australian Research Council,Australia,0,0,0
grant.3562866,LP120100226,Understanding heat shock protein complex vaccines,246609,2012-01-01,2012.0,2014-12-31,2014,University of Melbourne,grid.1008.9,Australia,Australian Research Council,Australia,3,0,0
grant.2709696,Z01BA001024,EVALUATION OF ADVERSE ALLERGIC REACTIONS TO VACCINES,0,1992-01-01,1992.0,1992-12-31,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709222,Z01AI005057,West Nile Virus Vaccine Development,0,2003-01-01,2003.0,2006-01-01,2006,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2709221,Z01AI005056,SARS Coronavirus Vaccine Development,0,2003-01-01,2003.0,2005-01-01,2005,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2709169,Z01AI005004,Ebola Vaccine Development,0,2002-01-01,2002.0,2006-01-01,2006,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,16,0,0
grant.2707079,Y2AI9460-1-0-2,Characterization of Y. pestis antigens for the development of a novel vaccine,99508,2009-01-01,2009.0,2009-12-31,2009,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425673,N01AI95379-3-0-1,HIV Vaccine Production,3691,1999-06-30,1999.0,2009-05-31,2009,SRI International,grid.98913.3a,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425671,N01AI95366-6-0-1,HIV Vaccine Production,1029,1999-06-30,1999.0,2006-09-30,2006,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425670,N01AI95366-5-0-1,HIV Vaccine Production,16181,1999-06-30,1999.0,2006-09-30,2006,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425597,N01AI60024-7-0-1,Evaluation of NIAID's HIV Vaccine Research Education Initiative,60000,2011-07-29,2011.0,2012-09-29,2012,Nova Research Company (United States),grid.281579.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425596,N01AI60024-6-0-1,Evaluation of NIAID's HIV Vaccine Research Education Initiative,321632,2006-09-30,2006.0,2012-09-29,2012,Nova Research Company (United States),grid.281579.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425595,N01AI60024-4-0-1,Evaluation of NIAID's HIV Vaccine Research Education Initiative,1310836,2006-09-30,2006.0,2010-12-15,2010,Nova Research Company (United States),grid.281579.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425593,N01AI60023-7-0-1,Evaluation of NIAID's HIV Vaccine Research Education Initiative,2993798,2010-09-29,2010.0,2011-09-30,2011,Academy for Educational Development,grid.420327.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425559,N01AI60007-11-0-1,Simian Vaccine Evaluation Units,2435221,2006-06-22,2006.0,2013-06-21,2013,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425557,N01AI60006-8-0-1,Simian Vaccine Evaluation Unit (SVEU),1413590,2006-06-22,2006.0,2013-05-31,2013,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425556,N01AI60006-7-0-1,Simian Vaccine Evaluation Unit (SVEU),3283375,2006-06-22,2006.0,2013-05-31,2013,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425551,N01AI60005-11-0-1,Simian Vaccine Evaluation Unit (SVEU),6297694,2006-06-22,2006.0,2013-06-22,2013,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425475,N01AI50009-6-0-1,HIV Vaccine Design and Dev. Teams for Preventation and Treatment,1793396,2005-06-30,2005.0,2010-06-29,2010,United Biomedical (United States),grid.421974.d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425433,N01AI40091-9-0-1,Tuberculosis Research Materials and Vaccine Testing,1000000,2004-09-24,2004.0,2011-09-23,2011,Colorado State University,grid.47894.36,United States,National Institute of Allergy and Infectious Diseases,United States,67,0,0
grant.2425432,N01AI40091-11-0-2,TB VACCINE TESTING,426223,2004-09-24,2004.0,2012-09-23,2012,Colorado State University,grid.47894.36,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425431,N01AI40091-11-0-1,Tuberculosis Research Materials and Vaccine Testing,3836004,2004-09-24,2004.0,2012-09-23,2012,Colorado State University,grid.47894.36,United States,National Institute of Allergy and Infectious Diseases,United States,11,0,0
grant.2350080,AAI12034001-1-0-1,Development of BSL-2 Neutralization Assays to Evaluate Filovirus Vaccines,257740,2013-01-01,2013.0,2013-12-31,2013,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2350059,AAI12010001-1-0-1,HIV/AIDS Therapeutic and Non-vaccine Prevention Clinical Research,821096,2013-01-01,2013.0,2013-12-31,2013,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346793,272200800061C-4-0-1,HVDDT: HIV-1 Vaccine Candidates Delivered by VSV Vectors,242736,2008-09-01,2008.0,2014-06-30,2014,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346792,272200800061C-2-0-1,HIV-1 VACCINE CANDIDATES DELIVERED BY VSV VECTORS,2740852,2008-09-01,2008.0,2012-12-31,2012,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346791,272200800061C-1-0-1,HIV-1 VACCINE CANDIDATES DELIVERED BY VSV VECTORS,1792234,2008-09-01,2008.0,2012-12-31,2012,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2346750,272200800056C-6-0-1,Advanced Development of Multivalent Filovirus Vaccines,4000000,2008-09-30,2008.0,2015-09-29,2015,Janssen (Netherlands),grid.497529.4,Netherlands,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657943,R44AI055212,DNA Vaccine Delivery System for Biodefense with dengue,4326403,2003-04-15,2003.0,2009-07-31,2009,Cellectis (United States),grid.433243.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,1,0
grant.2451354,R01AI025850,EIAV Envelope Variation and Vaccine Efficacy,7055360,1987-09-30,1987.0,2015-03-31,2015,University of Pittsburgh,grid.21925.3d,United States,National Institute of Allergy and Infectious Diseases,United States,48,0,0
grant.7667819,,Comparison and basis of efficacy in commercial conventional vaccines against the H5N1 influenza virus.,1320390,2008-04-01,2008.0,2011-03-31,2011,Canadian Science Centre for Human and Animal Health,grid.413309.c,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.5678539,08457144,Examination of Side Effects occured after Vaccination,58478,1996-01-01,1996.0,1997-12-31,1997,Osaka Prefectural Institute of Public Health,grid.416993.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.3791018,316940,Vaccine Design and Immune Responses,1443106,2012-10-01,2012.0,2016-09-30,2016,University of Birmingham; University of Birmingham; GlaxoSmithKline (Italy),grid.6572.6; grid.6572.6; grid.425088.3,United Kingdom; United Kingdom; Italy,European Commission,Belgium,4,0,0
grant.2711561,Z01BK002008,"Vaccine Safety:  Neurotoxicity safety test development,",0,1996-01-01,1996.0,2002-01-01,2002,,,,United States Food and Drug Administration,United States,0,0,0
grant.2695872,U19AI089987,Systems Analysis Vaccine Responses in Healthy and Hyporesponsive Humans,17002768,2010-07-12,2010.0,2017-06-30,2017,Baylor Scott & White Health,grid.486749.0,United States,National Institute of Allergy and Infectious Diseases,United States,66,3,0
grant.2458954,R01AI088729,Influence of maternal antibodies on a Sendai virus-vectored RSV vaccine,2964667,2010-04-01,2010.0,2016-03-31,2016,St. Jude Children's Research Hospital,grid.240871.8,United States,National Institute of Allergy and Infectious Diseases,United States,33,4,0
grant.2424817,N01AI065293,MAO/DETECTION OF ANTIBODIES AND PROTEINS,0,1996-09-30,1996.0,2000-09-29,2000,SRA International (United States),grid.421489.2,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2424751,N01AI055273,MAO/DETECTION OF ANTIBODIES &PROTEINS--ISOLATION OF VIR,0,1995-09-30,1995.0,1998-12-31,1998,SeraCare Life Sciences (United States),grid.422121.6,United States,National Institute of Allergy and Infectious Diseases,United States,29,0,0
grant.2424750,N01AI055271,MAO/DETECTION OF ANTIBODIES &PROTEINS--ISOLATION OF VIR,0,1995-09-30,1995.0,1999-09-30,1999,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.4896895,14-15-00034,DESIGNING LIVE INFLUENZA UNIVERSAL VACCINE BASED ON NEW GENE–ENGINEERING AND IMMUNOGENETICS APPROACHES,0,2014-01-01,2014.0,2016-12-31,2016,Institute of Experimental Medicine,grid.465311.4,Russia,Russian Science Foundation,Russia,15,0,0
grant.8218859,39870703,结核病B7/hsp嵌合DNA 疫苗研究,12074,1999-01-01,1999.0,2001-12-31,2001,,,,National Natural Science Foundation of China,China,0,0,0
grant.8218788,39870605,双重组病毒疫苗中白细胞介素—2 免疫佐剂活性的研究,14488,1999-01-01,1999.0,2001-12-31,2001,Harbin Veterinary Research Institute,grid.38587.31,China,National Natural Science Foundation of China,China,0,0,0
grant.8171714,30371316,I型糖尿病反义DNA疫苗的研究,20863,2004-01-01,2004.0,2006-12-31,2006,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8170951,30271416,靶向融合防龋DNA疫苗的研制和粘膜免疫防龋的作用机制,24240,2003-01-01,2003.0,2005-12-31,2005,Wuhan University,grid.49470.3e,China,National Natural Science Foundation of China,China,1,0,0
grant.8170771,30271192,基因枪介导单纯疱疹病毒gD2DNA疫苗免疫的研究,9664,2003-01-01,2003.0,2003-12-31,2003,General Hospital of Guangzhou Military Command,grid.413435.4,China,National Natural Science Foundation of China,China,0,0,0
grant.8169338,30200239,细粒棘球绦虫重组BCG-Eg95疫苗构建及其免疫机制研究,24240,2003-01-01,2003.0,2005-12-31,2005,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,0,0,0
grant.8107149,26197,Bovine pneumonic pasteurellosis: a model for development of novel vaccine platforms,0,2004-05-01,2004.0,2007-04-30,2007,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.7878050,1067703,The STARSS e-Health system for post-marketing safety surveillance of drugs and vaccines.,341368,2014-01-01,2014.0,2017-12-31,2017,University of Adelaide; University of Adelaide; University of Adelaide; University of Adelaide; University of Adelaide; University of Adelaide; University of Adelaide; University of Adelaide,grid.1010.0; grid.1010.0; grid.1010.0; grid.1010.0; grid.1010.0; grid.1010.0; grid.1010.0; grid.1010.0,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7877498,1125822,Novel HIV-1 glycoprotein vaccines with enhanced presentation of broad neutralization epitopes,562499,2017-01-01,2017.0,2019-01-01,2019,Burnet Institute; Burnet Institute; Burnet Institute,grid.1056.2; grid.1056.2; grid.1056.2,Australia; Australia; Australia,National Health and Medical Research Council,Australia,1,0,0
grant.7874725,1093311,"Formulation of a pan-species, multi-stage vaccine for the malaria eradication agenda",567934,2015-01-01,2015.0,2018-12-31,2018,Walter and Eliza Hall Institute of Medical Research,grid.1042.7,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7764034,2018-03109,Next generation of targeted dendritic cell vaccines for cancer treatment,56751,2018-10-01,2018.0,2019-03-31,2019,3H Biomedical (Sweden),grid.431857.c,Sweden,VINNOVA,Sweden,0,0,0
grant.7646394,,"Safety and uptake of the Measles, Mumps, Rubella and Varicella (MMR-V) vaccine",91578,2014-06-01,2014.0,2016-05-31,2016,University of Calgary,grid.22072.35,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7155174,2012-057,Developing more accurate measures of immune response and vaccine efficacy of standard and novel schedules of two new pneumococcal conjugate vaccines (Prevenar13 or Synflorix) in indigenous infants,154242,2012-07-01,2012.0,2014-06-30,2014,Menzies School of Health Research,grid.271089.5,Australia,Financial Markets Foundation for Children,Australia,0,0,0
grant.7035732,FC1120,Use of polylactidecoglycolide microparticles as an oral vaccine delivery system for farmed fish (LINKSAL17),62303,1999-02-01,1999.0,2001-01-31,2001,Marine Scotland,grid.438570.d,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.6896550,FR-TI1/161,"*Průmyslový výzkum nejkomplexnější (v 1 vakcinační dávce 11 antigenů) vakcíny Biocan Max DHPPi+L5CR, chránící celosvětově psy proti závažným infekčním onemocněním, kterou může veterinární lékař použít kdekoliv na světě bez ohledu na lokální výzkyt kmenů.",2827097,2009-03-01,2009.0,2012-12-31,2012,Bioveta (Czechia),grid.448017.e,Czechia,Ministry of Industry and Trade,Czechia,0,0,0
grant.6736064,1036229,Applying active hospital-based case ascertainment to assess vaccine effectiveness and safety,227450,2012-01-01,2012.0,2016-12-31,2016,University of Western Australia,grid.1012.2,Australia,National Health and Medical Research Council,Australia,2,0,0
grant.6734893,1045235,"Vaccine discovery for human mucosal pathogens: identifying novel vaccine antigens that are stably expressed during host interactions, using analysis of cell-contact and phasevarion mediated expression profiles",345343,2013-01-01,2013.0,2017-12-31,2017,Griffith University,grid.1022.1,Australia,National Health and Medical Research Council,Australia,15,0,0
grant.6733474,1012178,The influence of HIV on T cell function and application to vaccine design.,420770,2011-01-01,2011.0,2014-12-31,2014,Murdoch University; Murdoch University; Murdoch University; Murdoch University,grid.1025.6; grid.1025.6; grid.1025.6; grid.1025.6,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6723455,1056401,"Boosting effectiveness of new vaccines for dengue ,HFMD and influenza by targeting vaccine antigens to Clec9A on dendritic cells.",345750,2013-01-01,2013.0,2015-12-31,2015,Walter and Eliza Hall Institute of Medical Research; Walter and Eliza Hall Institute of Medical Research; Walter and Eliza Hall Institute of Medical Research; Walter and Eliza Hall Institute of Medical Research,grid.1042.7; grid.1042.7; grid.1042.7; grid.1042.7,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6718920,491239,RV3 rotavirus vaccine: Phase I and II clinical trials of a human neonatal rotavirus vaccine for the global community,979747,2008-01-01,2008.0,2011-12-31,2011,Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute,grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c,Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6716490,512269,Regulation of pulmonary immune responses to subunit vaccines against tuberculosis,430039,2008-01-01,2008.0,2010-12-31,2010,University of Sydney; University of Sydney; University of Sydney,grid.1013.3; grid.1013.3; grid.1013.3,Australia; Australia; Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6665071,104750/Z/14/A,Prime-Target Vaccination in Malaria,264513,2016-06-01,2016.0,2017-11-30,2017,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.6146427,26670220,Construction of novel platforms for herpes simplex virus attenuated vaccines,32478,2014-04-01,2014.0,2017-03-31,2017,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.6030319,22300332,Use of long overlapping peptides for cancer vaccine and Treg control for potentiating immune response,158006,2010-01-01,2010.0,2012-12-31,2012,Kawasaki University of Medical Welfare,grid.412082.d,Japan,Japan Society for the Promotion of Science,Japan,18,0,0
grant.6009389,20780238,Study on the anti-allergic DNA vaccines with nanoparticle in gut mucosal immune system,43646,2008-01-01,2008.0,2009-12-31,2009,Shinshu University,grid.263518.b,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5991944,20390131,Analysis of efficacy of a vaccine inducing confined avirulent virus replication against immunodeficiency virus infection,210414,2008-01-01,2008.0,2010-12-31,2010,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5954535,18390289,Development of a new class of lipid-based vaccines against tuberculosis,157856,2006-01-01,2006.0,2008-12-31,2008,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5923641,16K18792,Development of a novel vaccine platform based on Adeno associated virus.,37595,2016-04-01,2016.0,2018-03-31,2018,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5863354,15H04589,Identification of Neospora virulence factor and its application for the vaccine development,149659,2015-04-01,2015.0,2018-03-31,2018,Obihiro University of Agriculture and Veterinary Medicine,grid.412310.5,Japan,Japan Society for the Promotion of Science,Japan,12,0,0
grant.5128942,FT140101287,"Alphaherpesvirus vaccination, recombination and latency",603515,2014-01-01,2014.0,2018-12-31,2018,University of Melbourne; University of Georgia,grid.1008.9; grid.213876.9,Australia; United States,Australian Research Council,Australia,10,0,0
grant.4982560,30400385,HBcAg-DNA复合疫苗免疫效应研究,26517,2005-01-01,2005.0,2007-12-31,2007,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,5,0,0
grant.4975021,30471519,可预防婴幼儿呼吸道合胞病毒感染的口服DNA疫苗,26517,2005-01-01,2005.0,2007-12-31,2007,Anhui Medical University,grid.186775.a,China,National Natural Science Foundation of China,China,2,0,0
grant.4938417,30400375,trpD基因敲除耦联靶向递送GLS/IL-12的重组BCG治疗性活疫苗的实验研究,25253,2005-01-01,2005.0,2007-12-31,2007,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,1,0,0
grant.4035064,1662,Developing an RSV vaccine: Investigating possible adjuvants,83088,2009-01-01,2009.0,2010-12-31,2010,University of Saskatchewan; University of Saskatchewan,grid.25152.31; grid.25152.31,Canada; Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.3811194,2012-67016-19507,DETERMINING VIRUS-LIKE PARTICLE (VLP) FEASIBILITY FOR NEW PORCINE REPRODUCTIVE RESPIRATORY SYNDROME VIRUS (PRRSV) VACCINES,150000,2011-02-01,2011.0,2014-01-31,2014,South Dakota State University,grid.263791.8,United States,National Institute of Food and Agriculture,United States,2,0,0
grant.3751805,ICC1-CT-2002-50001,European malaria vaccine initiative,830704,2002-07-01,2002.0,2006-12-31,2006,University of Bergen,grid.7914.b,Norway,European Commission,Belgium,0,0,0
grant.3574802,LP0455598,Immunological mechanisms underlying the protective immune responses induced by botulinum oil adjuvanted vaccine,58004,2004-01-01,2004.0,2007-12-31,2007,University of Wollongong,grid.1007.6,Australia,Australian Research Council,Australia,0,0,0
grant.2726419,ZIBAI005092,Production of Alternate Adenovector Filovirus Vaccines,14695725,2009-01-01,2009.0,2016-01-01,2016,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2726418,ZIBAI005087,"Development/production of seasonal, pandemic and universa influenza DNA vaccines",6031409,2009-01-01,2009.0,2012-01-01,2012,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2712047,Z01BS002006,TIME COURSE OF LOT UTILIZATION,0,1995-01-01,1995.0,1995-12-31,1995,Center for Biologics Evaluation and Research,grid.290496.0,United States,United States Food and Drug Administration,United States,0,0,0
grant.2709255,Z01AI005092,Production of Alternate Adenovector Filovirus Vaccines,3710279,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2709251,Z01AI005087,Development/production of H3/H1 influenza DNA plasmid vaccine,5300620,2006-01-01,2006.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2709249,Z01AI005085,Development/production of a Marburg rAd Vaccine,5300619,2006-01-01,2006.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2709204,Z01AI005039,Production/Testing Of A Recombinant Modified Vaccine Ank,0,2002-01-01,2002.0,2004-01-01,2004,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2692209,U01IP000104,"Understanding &Estimating Costs of Vaccine Development,Production and Pricing",0,2006-09-15,2006.0,2009-09-14,2009,University of Michigan,grid.214458.e,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2687951,U01AI074515,Nanoemulsions as novel adjuvents for influenza virus vaccines,2985700,2007-09-15,2007.0,2013-08-31,2013,University of Wisconsin–Madison,grid.14003.36,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2644200,R43CA086650,ENGINEERED OPSONINS FOR WHOLE CELL TUMOR VACCINES,204019,2000-03-01,2000.0,2001-10-31,2001,,,,National Cancer Institute,United States,0,0,0
grant.2451110,R01AI024557,VACCINATION AGAINST S MANSONI WITH STPI AND SM23,774884,1988-07-01,1988.0,2002-06-30,2002,Harvard University,grid.38142.3c,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.8605530,71151,Establishing the Human Vaccines Project as a paradigm for accelerating vaccine development against major global diseases,377815,2013-11-01,2013.0,2015-09-30,2015,International AIDS Vaccine Initiative,grid.420368.b,United States,Robert Wood Johnson Foundation,United States,0,0,0
grant.8505272,G043515N,Bescherming tegen influenza A en modulering van antigenpresentatie door matrix eiwit 2 ectodomein-specifieke antistoffen,0,2015-01-01,2015.0,2018-12-31,2018,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8255921,51403159,基于MHC-I短肽的还原响应型小分子水凝胶亚单位疫苗的制备及其诱导细胞免疫反应的实验研究,38248,2015-01-01,2015.0,2017-12-31,2017,Wenzhou Medical University,grid.268099.c,China,National Natural Science Foundation of China,China,4,0,0
grant.7646359,,Varicella zoster virus as an HIV vaccine vector: Immunogenicity and protective efficacy in the SIV macaque model,236905,2005-10-01,2005.0,2007-09-30,2007,Sinai Health System,grid.492573.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7433662,472113,"Dose-ranging study of safety, reactogenicity and immunogenicity of a human papillomavirus vaccine administered intradermally and intramuscularly to adults aged 20 to 26 years",66995,2013-04-01,2013.0,2015-01-08,2015,Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong,grid.10784.3a; grid.10784.3a; grid.10784.3a; grid.10784.3a; grid.10784.3a,China; China; China; China; China,University Grants Committee,China,0,0,0
grant.6443851,R43CK000494,MagaVax vaccine for Ebola,225000,2016-09-30,2016.0,2017-08-31,2017,Multimeric Biotherapeutics (United States),grid.436661.0,United States,National Center for Emerging and Zoonotic Infectious Diseases,United States,0,0,0
grant.6379228,1004086,MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF INFECTIOUS BURSAL DISEASE VIRUSES,0,2014-10-01,2014.0,2019-09-30,2019,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.5799261,13670595,Development of DC-vaccine against tuberclulosis,26753,2001-01-01,2001.0,2002-12-31,2002,Hamamatsu University School of Medicine,grid.505613.4,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.5245878,272201300003I-1-27200007-1,EFFIVAVY OF CONSERVED ELEMENT SIV GAG VACCINCE IN CONTROL OF SIVmac239 VIREMIA,77788,2014-09-01,2014.0,2016-10-31,2016,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5002002,81071845,基于hTERT T细胞表位的多抗原肽(MAP)疫苗设计及其抗肿瘤效应研究,52197,2011-01-01,2011.0,2013-12-31,2013,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,2,0,0
grant.4995055,81071346,新甲型H1N1流感病毒基因工程亚单位疫苗对抗病毒感染的研究,50616,2011-01-01,2011.0,2013-12-31,2013,Hunan Normal University,grid.411427.5,China,National Natural Science Foundation of China,China,13,0,0
grant.4985797,30972803,免疫主导效应在疫苗载体中的作用及消除,11815,2010-01-01,2010.0,2010-12-31,2010,Nankai University,grid.216938.7,China,National Natural Science Foundation of China,China,1,0,0
grant.4959800,30901349,慢病毒疫苗诱导的免疫应答与免疫保护关系研究,35324,2010-01-01,2010.0,2012-12-31,2012,Harbin Veterinary Research Institute,grid.38587.31,China,National Natural Science Foundation of China,China,7,0,0
grant.4959052,30872395,以细菌鬼影为载体的双重靶向DNA疫苗的研究策略,44874,2009-01-01,2009.0,2011-12-31,2011,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,1,0,0
grant.4902945,20906094,多聚亚基疫苗层析介质的设计及性能研究,30715,2010-01-01,2010.0,2012-12-31,2012,Institute of Process Engineering,grid.458442.b,China,National Natural Science Foundation of China,China,5,0,0
grant.4664479,187959,Novel vaccines (vaccibodies) against avian influenza and prostate cancer.,703494,2008-01-01,2008.0,2011-12-31,2011,Oslotech (Norway),grid.457886.0,Norway,The Research Council of Norway,Norway,0,0,0
grant.4578801,102464/Z/13/A,"Predictors of rotavirus vaccine virus replication, immune response and clinical protection following oral rotavirus vaccination in Malawian children.",532417,2014-09-01,2014.0,2017-08-31,2017,University of Liverpool,grid.10025.36,United Kingdom,Wellcome Trust,United Kingdom,2,0,0
grant.4404204,W911NF-09-C-0072,Improved Venezuelan equine encephalitis virus vaccines,749999,2008-10-01,2008.0,2009-09-30,2009,NewLink Genetics (United States),grid.426927.c,United States,United States Department of Defense,United States,0,0,0
grant.3857019,272201300003I-0-27200007-1,EFFIVAVY OF CONSERVED ELEMENT SIV GAG VACCINCE IN CONTROL OF SIVmac239 VIREMIA,610218,2014-09-01,2014.0,2016-10-31,2016,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3810632,2009-34397-20133,"BRUCELLOSIS VACCINE, MT",284348,2008-08-15,2008.0,2011-08-14,2011,Montana State University,grid.41891.35,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3740989,FAIR984003,DNA vaccines for aquaculture: Development and testing of plasmid vectors for vaccination against bacterial and viral fish pathogens.,922365,1999-01-01,1999.0,2001-12-31,2001,Qiagen (Germany); National Institute for Agricultural and Food Research and Technology; Norwegian Institute of Marine Research; Umeå University; Plymouth University; University of Aberdeen,grid.420167.6; grid.419190.4; grid.10917.3e; grid.12650.30; grid.11201.33; grid.7107.1,Germany; Spain; Norway; Sweden; United Kingdom; United Kingdom,European Commission,Belgium,3,0,0
grant.3640066,091909/B/10/Z,"New childhood vaccines for Malawi: Impact of a national pneumococcal and rotavirus vaccine roll-out on child mortality and disease burden, in a region of sub-optimal strain coverage.",1306122,2010-08-01,2010.0,2015-12-31,2015,London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,grid.8991.9; grid.8991.9; grid.8991.9; grid.8991.9; grid.8991.9,United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3637315,091909/Z/10/Z,"New childhood vaccines for Malawi: Impact of a national pneumococcal and rotavirus vaccine roll-out on child mortality and disease burden, in a region of sub-optimal strain coverage.",2273034,2011-02-01,2011.0,2017-01-31,2017,University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool,grid.10025.36; grid.10025.36; grid.10025.36; grid.10025.36; grid.10025.36,United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,16,0,0
grant.2726420,ZIBAI005094,Development And Production Of Filovirus DNA Plasmid Vaccines,5931410,2009-01-01,2009.0,2012-01-01,2012,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2718448,Z01HD002529,FIELD TRIAL OF KILLED ORAL CHOLERA VACCINES IN VIETNAM,0,1996-01-01,1996.0,2000-01-01,2000,National Institute of Child Health and Human Development,grid.420089.7,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.2711159,Z01BE003003,DEVELOPMENT OF AN SRID POTENCY TEST FOR RABIES VACCINE,0,1990-01-01,1990.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709791,Z01BA007020,CONTROL TESTING OF WHOLE CELL AND ACELLULAR PERTUSSIS VACCINES,0,1990-01-01,1990.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709257,Z01AI005094,Development And Production Of Filovirus DNA Plasmid Vaccines,3725819,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2658405,R44CA044246,MONOCLONAL ANTIBODY ANTI-IDIOTYPE TUMOR VACCINES,0,1988-08-01,1988.0,1990-07-31,1990,Biogen (United States),grid.417832.b,United States,National Cancer Institute,United States,1,0,0
grant.2641845,R43AI092916,"Robust, animal-free cell culture medium for the production of vaccines",158820,2011-07-08,2011.0,2012-02-29,2012,Ventria Bioscience (United States),grid.422159.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2639272,R43AG013803,OPTIVAX ADJUVANT--IMPROVE INFLUENZA VIRUS VACCINE,0,1997-07-01,1997.0,1998-06-30,1998,Vaxcel (United States),grid.438928.c,United States,National Institute on Aging,United States,0,0,0
grant.2455328,R01AI049153,Rabies Virus-Based Vectors as an HIV-1 Vaccine,3075652,2001-03-15,2001.0,2010-02-28,2010,Thomas Jefferson University,grid.265008.9,United States,National Institute of Allergy and Infectious Diseases,United States,20,0,0
grant.2453659,R01AI040846,DESIGN AND ANALYSIS OF HIV VACCINE TRIALS,0,1997-04-01,1997.0,2001-03-31,2001,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.8336713,81401368,发热伴血小板减少综合征病毒新型疫苗的研制,35187,2015-01-01,2015.0,2017-12-31,2017,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,7,0,0
grant.8329109,81020108030,免疫保护机制的系统疫苗学研究及其在HIV疫苗研究中的应用,318635,2011-01-01,2011.0,2014-12-31,2014,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,15,0,0
grant.8169853,30240035,太空诱变肿瘤细胞制备瘤苗的实验研究,12080,2003-01-01,2003.0,2003-12-31,2003,China-Japan Friendship Hospital,grid.415954.8,China,National Natural Science Foundation of China,China,0,0,0
grant.7654331,,"Pan-Provincial Vaccine Enterprise (PREVENT), Saskatoon",8439847,2008-03-01,2008.0,2017-03-31,2017,Pan-Provincial Vaccine Enterprise,grid.440055.0,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7646360,,CIHR/CHVI Team in HIV Vaccine Design Based on Novel Strategies to Induce Protective Mucosal Cellular and Humoral Immunity,1198845,2010-08-01,2010.0,2015-07-31,2015,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7630520,,Transcutaneous microsphere vaccine technology,265892,2013-04-01,2013.0,2016-03-31,2016,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.6895933,TA01011165,Multiepitopová syntetická vakcína proti borelióze pro veterinární aplikace,1577020,2011-01-01,2011.0,2014-12-31,2014,Institute of Physics; Institute of Organic Chemistry and Biochemistry; Bioveta (Czechia); Veterinary Research Institute,grid.424881.3; grid.418892.e; grid.448017.e; grid.426567.4,Czechia; Czechia; Czechia; Czechia,Technology Agency of the Czech Republic,Czechia,8,0,0
grant.6848880,DISC2-10188,Immunization strategies to prevent Zika viral congenital eye and brain disease,2355304,2016-07-21,2016.0,2016-12-31,2016,University of California Los Angeles,grid.19006.3e,United States,California Institute for Regenerative Medicine,United States,1,0,0
grant.6716817,375199,The use of inulin-based adjuvants to enhance the effectiveness and population coverage of influenza vaccination,199021,2006-01-01,2006.0,2007-12-31,2007,Flinders University; Flinders University,grid.1014.4; grid.1014.4,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6716223,400580,Self Adjuvanting CTL-Based Influenza Vaccines for Human Use,170763,2006-01-01,2006.0,2007-12-31,2007,University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.5863289,15H04803,Translational research of therapeutic vaccine to improve the quality of anti-hypertensive therapy,156568,2015-04-01,2015.0,2018-03-31,2018,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.5128696,LP160100442,Optimisation of a novel hybrid vaccine for liver fluke disease in cattle,291775,2016-01-01,2016.0,2018-12-31,2018,La Trobe University,grid.1018.8,Australia,Australian Research Council,Australia,1,0,0
grant.4985692,30371329,“模拟病毒”型疫苗的优化设计及其免疫机制研究,24545,2004-01-01,2004.0,2006-12-31,2006,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,2,0,0
grant.4920061,30371631,血吸虫病合成多肽疫苗的研究,24545,2004-01-01,2004.0,2006-12-31,2006,Peking University,grid.11135.37,China,National Natural Science Foundation of China,China,1,0,0
grant.4905273,30360062,草原兔尾鼠透明带3基因疫苗免疫不育的研究,22090,2004-01-01,2004.0,2006-12-31,2006,Xinjiang University,grid.413254.5,China,National Natural Science Foundation of China,China,2,0,0
grant.4898035,R44AI094863,Novel DNA-Launched Attenuated Vaccine for VEE Virus SBIR Phase II,1624180,2011-06-01,2011.0,2019-01-31,2019,Medigen (United States),grid.421237.1,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.4541353,03/01516-9,Avaliação sorológica de vacina experimental contra a enterotoxemia causada pela toxina épsilon do Clostridium perfringens tipo d em caprinos,0,2003-12-01,2003.0,2005-11-30,2005,Sao Paulo State University,grid.410543.7,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.3846417,101360,Development of a Universal Meningococcal Vaccine,776428,2012-12-01,2012.0,2014-05-30,2014,ImmBio (United Kingdom),grid.434859.7,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.3846351,130871,Method for manufacture of biodegradable microsphere as matrices for control and stabilisation of aluminium containing vaccine adjuvants,39572,2012-07-31,2012.0,2012-11-30,2012,,,,Innovate UK,United Kingdom,0,0,0
grant.3836293,0229459,OPTIMIZING THE IMMUNE RESPONSE TO ALUMINUM-CONTAINING VACCINES,0,2012-10-01,2012.0,2017-09-30,2017,Purdue University West Lafayette,grid.169077.e,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3825471,2010-65119-20547,IMPROVING THE SAFETY AND EFFICACY OF MAREK`S DISEASE VIRUS VACCINE CANDIDATES EXPRESSING THE MEQ PROTEIN FROM CVI988 VACCINE STRAIN,375000,2009-09-01,2009.0,2010-08-31,2010,Texas A&M University; Texas A&M University,grid.264756.4; grid.264756.4,United States; United States,National Institute of Food and Agriculture,United States,5,0,0
grant.3764201,18685,Development of a Dendritic Cell-targeted Vaccine against AIDS,4625863,2006-01-01,2006.0,2010-12-31,2010,Ruhr University Bochum; German Primate Center; Bernhard Nocht Institute for Tropical Medicine; Innsbruck Medical University; University of Italian Switzerland; Université des Montagnes; Charité – University Medicine Berlin; Public Health Agency of Sweden; Thermo Fisher Scientific (Germany),grid.5570.7; grid.418215.b; grid.424065.1; grid.5361.1; grid.29078.34; grid.449595.0; grid.6363.0; grid.419734.c; grid.424957.9,Germany; Germany; Germany; Austria; Switzerland; Cameroon; Germany; Sweden; Germany,European Commission,Belgium,3,0,0
grant.3753923,ICA4-CT-2002-10036,"Study of immunogenicity of DNA HIV-1 env, gag and pol plasmid vaccines boosted with MVA in Tanzania; HIV vaccine immunogenicity study",1340958,2002-12-01,2002.0,2006-12-31,2006,Karolinska Institute; Ludwig Maximilian University of Munich; University of Cape Town; Muhimbili University of Health and Allied Sciences,grid.4714.6; grid.5252.0; grid.7836.a; grid.25867.3e,Sweden; Germany; South Africa; Tanzania,European Commission,Belgium,1,0,0
grant.3750984,QLK2-CT-2002-01034,Novel vaccination strategies and vaccine formulations for epidemic and pandemic influenza control,1976817,2002-10-01,2002.0,2005-09-30,2005,Erasmus University Rotterdam; University of Cambridge; Paul Ehrlich Institut; Pasteur Institute; Solvay (Netherlands),grid.6906.9; grid.5335.0; grid.425396.f; grid.428999.7; grid.433899.c,Netherlands; United Kingdom; Germany; France; Netherlands,European Commission,Belgium,6,0,0
grant.3743638,QLK1-CT-1999-00122,Food safety screening: synthetic glucocorticoids,904115,2000-02-01,2000.0,2003-01-31,2003,Ghent University; Queen's University Belfast; Netherlands Organisation for Applied Scientific Research; Euro Diagnostica (Netherlands); Institute of Health Carlos III; National Food Administration; Queen's University Belfast; University of Zurich; Ghent University; University of Zurich,grid.5342.0; grid.4777.3; grid.4858.1; grid.443894.6; grid.413448.e; grid.419359.3; grid.4777.3; grid.7400.3; grid.5342.0; grid.7400.3,Belgium; United Kingdom; Netherlands; Netherlands; Spain; Sweden; United Kingdom; Switzerland; Belgium; Switzerland,European Commission,Belgium,4,0,0
grant.3657208,554457,Transcutaneous microsphere vaccine technology,278198,2013-04-01,2013.0,2015-03-31,2015,University of British Columbia,grid.17091.3e,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.3637796,085206/Z/08/Z,Predicting Vaccine escape: Improving strategic vaccine design.,551080,2008-08-01,2008.0,2011-05-31,2011,University of Cambridge,grid.5335.0,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.2773787,MC_U190088485,Interaction between live and killed vaccines: effect of DTP combined vaccine on T cell memory after measles vaccination,5968686,2007-03-31,2007.0,2011-03-30,2011,Medical Research Council The Gambia Unit; Monash University; State Serum Institute; Royal Children's Hospital; Bandim Health Project,grid.415063.5; grid.1002.3; grid.6203.7; grid.416107.5; grid.418811.5,Gambia; Australia; Denmark; Australia; Guinea-Bissau,Medical Research Council,United Kingdom,5,0,0
grant.2709256,Z01AI005093,Production of New Adenovector Constructs with Fiber-Shaft Modifications,2733246,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,72,0,0
grant.2709228,Z01AI005063,Establishment of a Vaccine Pilot Plant,65974672,2004-01-01,2004.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2640301,R43AI038803,IN VIVO MODELS FOR SUPERANTIGEN VACCINES,0,1997-09-30,1997.0,1999-03-29,1999,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7666252,,Generating Antigen-Specific Immune Memory,144262,2009-09-01,2009.0,2012-08-31,2012,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665836,,"Herpes viruses as re-activating Vaccine Vectors: Protective Efficacy of a Varicella Zoster-HIV Vaccine in the SIV Macaque model""",7067,2008-10-01,2008.0,2008-12-31,2008,Sinai Health System,grid.492573.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7201078,31302066,马传染性贫血病毒弱毒疫苗株和亲本强毒株的体内进化及其与免疫应答关系研究,34737,2014-01-01,2014.0,2016-12-31,2016,Harbin Veterinary Research Institute,grid.38587.31,China,National Natural Science Foundation of China,China,7,0,0
grant.5737923,10670481,Role of dendritic cells during vaccine therapy in hepatitis B virus carriers.,24644,1998-01-01,1998.0,1999-12-31,1999,Ehime University,grid.255464.4,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5733477,10044308,Study on the DNA immunization against microbial infection,22179,1998-01-01,1998.0,1999-12-31,1999,Yokohama City University,grid.268441.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.4675373,179360,Development and validation of  delivery technology for  gene based prophylactic vaccines,28879,2006-01-01,2006.0,2008-12-31,2008,,,,The Research Council of Norway,Norway,0,0,0
grant.4643905,192477,Development of an outer membrane vesicle vaccine for Africa against serogroup A and W-135 meningococcal disease,1145452,2008-01-01,2008.0,2013-12-31,2013,Norwegian Institute of Public Health,grid.418193.6,Norway,The Research Council of Norway,Norway,6,0,0
grant.4457723,8109,Protein thermal stability using amorphous silica,132039,2015-10-01,2015.0,2019-03-01,2019,University of Bath,grid.7340.0,United Kingdom,Royal Society,United Kingdom,0,0,0
grant.4457698,8109-1,"New flexible frameworks for catalysis, energy materials and nanotechnology",870706,2011-01-01,2011.0,2015-09-01,2015,University of Bath,grid.7340.0,United Kingdom,Royal Society,United Kingdom,0,0,0
grant.3641781,092734/Z/10/Z,Development of A549 cells as a cell substrate for vaccine production,3122237,2010-03-01,2010.0,2012-12-31,2012,PaxVax (United States),grid.437314.6,United States,Wellcome Trust,United Kingdom,0,0,0
grant.3629515,078289/Z/05/Z,AIDS Vaccine 2005 International Conference.,9091,2005-09-01,2005.0,2005-09-30,2005,University of Montreal,grid.14848.31,Canada,Wellcome Trust,United Kingdom,0,0,0
grant.2709733,Z01BA003005,THE EFFECTS OF DPT VACCINE ON HEPATIC DRUG METABOLISM,0,1990-01-01,1990.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2704615,UC1AI062531,Vitrification-stabilized Multivalent Botulinum Vaccines,5388306,2004-09-01,2004.0,2009-08-31,2009,Computer Sciences Corporation (United States),grid.420789.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687501,U01AI047985,HIV VACCINE CLINICAL TRIALS UNIT,12074176,2000-06-01,2000.0,2007-12-31,2007,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2640816,R43AI050326,Development of a non-living subunit rotavirus vaccine,117500,2001-08-15,2001.0,2002-01-31,2002,Emerging Concepts (United States),grid.450786.8,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2640477,R43AI043112,EVALUATION OF LIPOSOME BASED HERPES VACCINES,0,1998-06-15,1998.0,1999-06-30,1999,Molecular GPS Technologies (United States),grid.281192.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2602795,R21CA078659,PEPTIDE SPECIFIC CD8 T CELLS AS MARKER OF VACCINE ACTION,0,1998-07-10,1998.0,2000-06-30,2000,New York University,grid.137628.9,United States,National Cancer Institute,United States,2,0,0
grant.2486616,R01DA025305,Adenovirus-based Nanoparticle Vaccines,1871266,2009-08-01,2009.0,2014-05-31,2014,Cornell University,grid.5386.8,United States,National Institute on Drug Abuse,United States,9,6,0
grant.2458301,R01AI078420,Mechanisms of Mycobacterial Antigen Processing,2158469,2009-07-01,2009.0,2015-12-31,2015,The University of Texas Health Science Center at Houston,grid.267308.8,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2456583,R01AI058727,Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV,2022231,2004-02-01,2004.0,2010-01-31,2010,Beth Israel Deaconess Medical Center,grid.239395.7,United States,National Institute of Allergy and Infectious Diseases,United States,19,6,0
grant.2452630,R01AI033560,SAPONIN ADJUVANT ENHANCED PNEUMOCOCCAL VACCINE,0,1992-09-30,1992.0,1995-08-31,1995,Agenus (United States),grid.420152.0,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.3739224,IC18950020,A concerted european approach towards the development of amalaria vaccine,0,1996-01-01,1996.0,1998-06-30,1998,State Serum Institute; University of Valle; International Centre for Genetic Engineering and Biotechnology; Pasteur Institute; Pasteur Institute; Radboud University Nijmegen; The Francis Crick Institute; National Institute for Medical Research; Biomedical Primate Research Centre; Sapienza University of Rome,grid.6203.7; grid.8271.c; grid.425195.e; grid.428999.7; grid.428999.7; grid.5590.9; grid.451388.3; grid.416716.3; grid.11184.3d; grid.7841.a,Denmark; Colombia; India; France; France; Netherlands; United Kingdom; Tanzania; Netherlands; Italy,European Commission,Belgium,0,0,0
grant.2762017,G0600846,Prime-boost vaccination using influenza A H5N1 vaccines,1806275,2008-06-30,2008.0,2013-12-31,2013,University of Leicester,grid.9918.9,United Kingdom,Medical Research Council,United Kingdom,0,0,0
grant.2550560,R01MH069087,"Post-trial HIV Vaccines: Receptivity, Risk &Disparities",1970145,2004-09-29,2004.0,2009-03-31,2009,University of California Los Angeles,grid.19006.3e,United States,National Institute of Mental Health,United States,20,0,0
grant.2454639,R01AI045725,DEVELOP AND EVALUATE NEW LEPROSY AND TB VACCINES,461348,2000-07-01,2000.0,2005-06-30,2005,,,,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.7145585,W81XWH-10-1-0232,Attenuated West Nile Virus Live Vaccine for Human Use,3686016,2008-10-01,2008.0,2009-09-01,2009,Southern Research Institute,grid.454225.0,United States,Congressionally Directed Medical Research Programs,United States,2,0,0
grant.2458524,R01AI081062,Ontology-based Information Network to Support Vaccine Research,1068034,2009-09-22,2009.0,2014-02-28,2014,University of Michigan,grid.214458.e,United States,National Institute of Allergy and Infectious Diseases,United States,61,0,0
grant.6714841,400590,Enhancing Australia's pandemic influenza vaccine output by increasing the yeild of vaccine from eggs,199915,2006-01-01,2006.0,2007-12-31,2007,University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.4316876,UH2DA041146,Immunopharmacotherapy for Mitigating Opioid Addiction,1589558,2015-09-15,2015.0,2017-07-31,2017,Scripps Research Institute,grid.214007.0,United States,National Institute on Drug Abuse,United States,3,1,0
grant.2666760,R56AI101189,Pre-Exposure Prophylaxis Against Francisella tularensis,709102,2012-08-01,2012.0,2013-05-31,2013,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2658057,R44AI074216,Enhanced Oral Vaccine Delivery Vehicle,2779602,2007-04-01,2007.0,2013-05-31,2013,Vaxart (United States),grid.438926.2,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2641453,R43AI072925,Topical Adjuvants to Enhance the Efficacy of Influenza Vaccines,587238,2007-06-15,2007.0,2010-05-31,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2567129,R03AI065774,Anthrax DNA vaccine for non-invasive immunization on skin,144811,2007-08-01,2007.0,2010-07-31,2010,Oregon State University,grid.4391.f,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2459697,R01AI101189,Pre-Exposure Prophylaxis Against Francisella tularensis,2666650,2013-06-01,2013.0,2018-05-31,2018,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,5,1,0
grant.2457459,R01AI068109,Prophylactic Vaccines for Schistosomiasis,2028150,2007-04-01,2007.0,2014-03-31,2014,University of Georgia,grid.213876.9,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2452884,R01AI035149,MEASLES VACCINES--IMMUNE RESPONSES AND ATYPICAL MEASLES,719493,1993-09-30,1993.0,2002-06-30,2002,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,17,1,0
grant.8574610,1499,Engineering the Lymph Node Environment with Therapeutic Vaccine Depots to Combat Neuroblastoma,0,2013-12-30,2013.0,2016-12-29,2016,"University of Maryland, College Park",grid.164295.d,United States,Alex's Lemonade Stand Foundation,United States,0,0,0
grant.8462567,,Development and evaluation of a knowledge translation strategy to improve influenza immunization rates among pregnant women,104363,2011-09-01,2011.0,2014-08-31,2014,Sinai Health System,grid.492573.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8456193,,Studies on the Development of an Effective Vaccine Against Hepatitis C Virus,132940,2013-09-01,2013.0,2016-08-31,2016,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8345233,81501429,基于霍乱毒素AB5结构的个体化自组装抗癌疫苗的研究,26974,2016-01-01,2016.0,2018-12-31,2018,Guangdong University of Technology,grid.411851.8,China,National Natural Science Foundation of China,China,1,0,0
grant.8345230,81501426,汉滩病毒嵌合疫苗（VLP/DNA）的制备及其免疫学特性的研究,26974,2016-01-01,2016.0,2018-12-31,2018,,,,National Natural Science Foundation of China,China,1,0,0
grant.8329560,81072346,甲肝减毒活疫苗的抗体持久性与免疫记忆研究,50616,2011-01-01,2011.0,2013-12-31,2013,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,2,0,0
grant.8216494,39670558,马立克氏病Ⅱ、Ⅲ型病毒(Z4+FC126)免疫协同机理研究,24142,1997-01-01,1997.0,1999-12-31,1999,Yangzhou University,grid.268415.c,China,National Natural Science Foundation of China,China,0,0,0
grant.8205069,38670211,内蒙锡盟中部草原生态系统结构功能生产力提高途径研究,5166,1987-01-01,1987.0,1991-10-01,1991,Institute of Botany,grid.435133.3,China,National Natural Science Foundation of China,China,0,0,0
grant.8184628,31470890,汉滩病毒新型疫苗--免疫增强型VLPs疫苗的构建、免疫学特性和免疫保护作用的研究,129661,2015-01-01,2015.0,2018-12-31,2018,,,,National Natural Science Foundation of China,China,4,0,0
grant.8174468,30772514,中国高危型人乳头瘤病毒16/58/18嵌合病毒样颗粒疫苗的实验研究,42327,2008-01-01,2008.0,2010-12-31,2010,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,2,0,0
grant.7742845,,idMALVAC: Establishing immunological correlates of protection against malaria vaccine candidates using functional bioassays and proteomic deciphering of host-parasite interactions,1119651,2013-01-01,2013.0,2017-01-01,2017,,,,Danish Ministry of Higher Education and Science,Denmark,0,0,0
grant.7666219,,Development and evaluation of a recombinant porcine adenovirus vaccine for post-exposure protection against Ebolavirus,104345,2010-05-01,2010.0,2013-04-30,2013,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7638735,,Immunogenicity of pneumococcal vaccine in liver transplant recipients,292514,2006-04-01,2006.0,2009-03-31,2009,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7206349,81270331,高效诱导2型免疫应答的降压疫苗呈递系统CpG ODN-VLP研究,111158,2013-01-01,2013.0,2016-12-31,2016,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,2,0,0
grant.7172498,272201300004I-0-27200007-1,Elicitation of ?4?7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen,303353,2017-09-01,2017.0,2018-11-30,2018,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172487,272201300003I-1-27200010-1,"Study to investigate the immunogenicity and efficacy of a rVSV-HIVenv Prime, HIV envelope protein boost vaccination regimen and DNA-HIV Prime, rVSV-HIVenv boost vaccination regimen",465058,2016-04-15,2016.0,2018-07-14,2018,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172485,272201300003I-0-27200014-1,In Vivo SHIV/SIV Titration via Mucosal Route in Indian-origin Rhesus Macaques,149505,2017-09-01,2017.0,2018-08-31,2018,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172432,272201300002I-3-27200013-1,Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates,129321,2015-09-18,2015.0,2018-07-14,2018,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7022403,81171446,基于智能化多糖纳米凝胶的肿瘤疫苗及抗肿瘤作用研究,93247,2012-01-01,2012.0,2015-12-31,2015,Shenzhen Institutes of Advanced Technology,grid.458489.c,China,National Natural Science Foundation of China,China,30,0,0
grant.7016017,81172166,CEA联合4-1BBL基因疫苗抗大肠癌的实验研究,88425,2012-01-01,2012.0,2015-12-31,2015,Soochow University,grid.263761.7,China,National Natural Science Foundation of China,China,3,0,0
grant.7014356,31100657,布氏菌减毒疫苗株M5-90的bp26蛋白表位分子修饰与初步免疫评价,36990,2012-01-01,2012.0,2014-12-31,2014,Southern Medical University,grid.284723.8,China,National Natural Science Foundation of China,China,4,0,0
grant.7004808,81101708,双抗原双靶向乳腺癌DNA疫苗的研究策略,35383,2012-01-01,2012.0,2014-12-31,2014,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,0,0,0
grant.7003466,81100546,基于Bin1b的雄性免疫节育DNA疫苗构建及其效应研究,36990,2012-01-01,2012.0,2014-12-31,2014,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,0,0,0
grant.6988267,31100652,以细菌菌影为载体的新型淋病奈瑟菌靶向黏膜疫苗的实验研究,36990,2012-01-01,2012.0,2014-12-31,2014,Yangzhou University,grid.268415.c,China,National Natural Science Foundation of China,China,4,0,0
grant.6944901,971519,Preclinical Crimean Congo Haemorraghic Fever Vaccine Development,451559,2017-03-31,2017.0,2018-03-30,2018,University of Oxford,grid.4991.5,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.6501119,272201300002I-1-27200013-1,Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates,445044,2015-09-18,2015.0,2017-11-14,2017,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6379290,1003626,DISCOVERY OF PROTECTIVE ANTIGENS FOR NOVEL JOHNE'S DISEASES VACCINES,0,2014-10-01,2014.0,2017-09-30,2017,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.6146605,26670488,Development of novel Norovirus vaccines using virus vector,32113,2014-04-01,2014.0,2016-03-31,2016,Suzuka University of Medical Science,grid.412879.1,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5604349,04557026,Development of adjuvant-combined nasal influenza vaccine,175162,1992-01-01,1992.0,1994-12-31,1994,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5245865,272201300002I-0-27200013-1,Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates,867569,2015-09-18,2015.0,2017-08-17,2017,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5220334,119828,Manipulation of particulate vaccine delivery vehicles to target dendritic cells,211084,2008-09-01,2008.0,2012-06-30,2012,Swiss Federal Institute of Technology in Zurich; Federal Department of Home Affairs; Federal Department of Home Affairs; Federal Department of Home Affairs,grid.5801.c; grid.424284.c; grid.424284.c; grid.424284.c,Switzerland; Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5071867,30760136,草原兔尾鼠卵透明带3DNA疫苗粘膜免疫及饵料释放效果的研究,27730,2008-01-01,2008.0,2010-12-31,2010,Xinjiang University,grid.413254.5,China,National Natural Science Foundation of China,China,3,0,0
grant.4997073,31000368,L-rhamnose修饰对肿瘤相关糖抗原疫苗效应的影响,31631,2011-01-01,2011.0,2013-12-31,2013,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,2,0,0
grant.4979100,30871862,转基因球虫激发鸡抗禽流感的保护性粘膜免疫应答机制,59836,2009-01-01,2009.0,2011-12-31,2011,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,8,0,0
grant.4955222,30471547,乙脑病毒基因组多区段构建DNA疫苗增强效应主要环节研究,26517,2005-01-01,2005.0,2007-12-31,2007,China Medical University,grid.412449.e,China,National Natural Science Foundation of China,China,2,0,0
grant.4948991,30801054,幽门螺杆菌益生菌型口服疫苗的研制,29916,2009-01-01,2009.0,2011-12-31,2011,Guangzhou Medical University,grid.410737.6,China,National Natural Science Foundation of China,China,3,0,0
grant.4938318,30772010,葎草花粉主要变应原核酸疫苗的研究,37948,2008-01-01,2008.0,2010-12-31,2010,Xi'an Jiaotong University,grid.43169.39,China,National Natural Science Foundation of China,China,0,0,0
grant.4929868,30700994,肠道M细胞靶向口服肿瘤纳米乳剂疫苗的研究,24809,2008-01-01,2008.0,2010-12-31,2010,,,,National Natural Science Foundation of China,China,2,0,0
grant.4918970,30901679,联合应用单磷酸酰脂质（MPL）的WapA防龋DNA疫苗增强粘膜免疫反应的效应及其机制研究,32252,2010-01-01,2010.0,2012-12-31,2012,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,2,0,0
grant.4539488,04/00559-9,Vacinas de DNA contra Streptococcus pneumoniae: avaliação do antígeno pneumolisina e de interleucinas,0,2004-12-01,2004.0,2007-11-30,2007,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4406518,W81XWH-10-C-0003,GeMI-Vax as a multi-life stage  malaria vaccine,119607,2008-10-01,2008.0,2009-09-30,2009,Vital Probes (United States),grid.505454.5,United States,United States Department of the Army,United States,0,0,0
grant.3935679,R03AI100707,Optimized second-generation recombinant mycobacteria vaccine vectors against HIV,193700,2015-04-15,2015.0,2017-03-31,2017,Harvard University,grid.38142.3c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3841651,700197,Market viability of ImmBioVax vaccines against H. Pylori and C. Difficile,38301,2013-03-01,2013.0,2013-09-29,2013,ImmBio (United Kingdom),grid.434859.7,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.3818017,0225045,DNA VACCINES FOR BRUCELLA,0,2009-10-01,2009.0,2014-09-30,2014,Montana State University,grid.41891.35,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3817834,2010-34397-21391,"BRUCELLOSIS VACCINE, MT",283854,2009-02-01,2009.0,2013-01-31,2013,Montana State University,grid.41891.35,United States,National Institute of Food and Agriculture,United States,2,0,0
grant.3813009,2008-34397-19471,"''BRUCELLOSIS VACCINE, MT''",302799,2011-10-01,2011.0,2013-09-30,2013,Montana State University,grid.41891.35,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3806983,R01AI107721,Methods for Safety Evaluation of Vaccination Schedules,1558344,2014-08-04,2014.0,2019-07-31,2019,Brigham and Women's Hospital,grid.62560.37,United States,National Institute of Allergy and Infectious Diseases,United States,10,0,0
grant.3775566,44512,Immunogenicity and protective efficacy of intranasal delNS1(H5N1) influenza vaccine,3741548,2007-01-01,2007.0,2010-06-30,2010,Institute of Bioorganic Chemistry; Retroscreen Virology (United Kingdom); MediTox (Czechia); Medical University of Vienna; University Hospital Frankfurt,grid.418853.3; grid.425987.5; grid.424217.6; grid.22937.3d; grid.411088.4,Russia; United Kingdom; Czechia; Austria; Germany,European Commission,Belgium,6,0,0
grant.3641057,099813/Z/12/A,Developing a novel single dose prime-boost vaccine against malaria,81007,2013-10-01,2013.0,2017-04-30,2017,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3638768,099813/Z/12/Z,Developing a novel single dose prime-boost vaccine against malaria,240389,2012-10-01,2012.0,2017-04-30,2017,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3636813,102464/Z/13/Z,"Wellcome Trust Clinical PhD Programme, University of Liverpool 'Health Priorities in the Developing World'",123199,2013-09-01,2013.0,2014-08-31,2014,University of Liverpool,grid.10025.36,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3067850,0610716,SBIR Phase I: A New Vaccine Development Method,99937,2006-07-01,2006.0,2006-12-31,2006,NovaSterilis (United States),grid.422916.a,United States,Directorate for Engineering,United States,0,0,0
grant.2726422,ZIBAI005109,Development/production of universal influenza vaccines,87090464,2010-01-01,2010.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2726416,ZIBAI005063,Establishment and operation of a Vaccine Pilot Plant,191620736,2009-01-01,2009.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2723430,ZIAAI005080,Marburg Vaccine Development,6816766,2009-01-01,2009.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,10,0,0
grant.2712030,Z01BR005005,MOLECULAR TEST FOR REVERTANT MUTATIONS IN LIVE VIRUS VAC,0,1996-01-01,1996.0,1999-01-01,1999,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711999,Z01BR001003,DEVELOPMENT OF AN SURID POTENCY TEST FOR RABIES VACCINE,0,1993-01-01,1993.0,1993-12-31,1993,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709790,Z01BA007019,DEVELOPMENT OF TESTS FOR ACELLULAR PERTUSSIS VACCINES,0,1990-01-01,1990.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709244,Z01AI005080,Marburg Vaccine Development,1149705,2005-01-01,2005.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2709091,Z01AI001006,Malaria Vaccine:  AMA1-rEPA,1594234,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2709090,Z01AI001005,Malaria Vaccine:  AMA1-C1/ISA 720,1691450,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2709088,Z01AI001003,Malaria Vaccine:  BSAM,4571373,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2709086,Z01AI001001,Malaria Vaccine: AMA1-C1,4388414,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,10,0,0
grant.2704634,UC1AI067129,Smallpox subunit vaccine in the C-PERL expression system,4118394,2005-09-01,2005.0,2008-08-31,2008,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2704628,UC1AI062632,Alphavirus Replicon Vaccines against Influenza,6490848,2005-04-15,2005.0,2009-10-14,2009,AlphaVax (United States),grid.422340.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2704604,UC1AI049517,Chimeric yellow fever 17D/Dengue vaccines,1827779,2000-09-30,2000.0,2004-03-31,2004,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2687150,U01AI026463,IMMUNE AND BIOLOGICAL STRATEGIES FOR AIDS VACCINES,0,1988-03-01,1988.0,1998-04-30,1998,Massachusetts Institute of Technology,grid.116068.8,United States,National Institute of Allergy and Infectious Diseases,United States,21,3,0
grant.2657831,R44AI046168,Generation of bPIV3-vectored PIV and RSV Vaccines,750000,1999-08-04,1999.0,2003-08-31,2003,AstraZeneca (United States),grid.418152.b,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2641718,R43AI084263,"Development of a VEEV, WEEV, EEEV DNA Vaccine Delivered by Electroporation",299495,2009-09-10,2009.0,2011-08-31,2011,Ichor Medical Systems (United States),grid.282549.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640564,R43AI044578,NEW CONJUGATE VACCINE FOR GRAM NEGATIVE SEPSIS,0,1999-04-01,1999.0,1999-09-30,1999,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2636410,R41AI060257,Vaccine enhancement through antigen targeting,104000,2004-06-15,2004.0,2007-05-31,2007,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2558965,R01NS038213,T-Cell Vaccine-A Clinical Trail for Progressive MS,3977843,1999-08-01,1999.0,2006-07-31,2006,University of Southern California,grid.42505.36,United States,National Institute of Neurological Disorders and Stroke,United States,1,0,0
grant.2451050,R01AI024292,SYSTEMATIC APPROACH TO VACCINES FOR RETROVIRAL DISEASES,0,1986-09-01,1986.0,1990-08-31,1990,"University of California, Davis",grid.27860.3b,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.8331301,81360481,壳聚糖-枸杞多糖微粒幽门螺旋杆菌疫苗Hp-WAE的治疗作用及机制研究,73047,2014-01-01,2014.0,2017-12-31,2017,Ningxia Medical University,grid.412194.b,China,National Natural Science Foundation of China,China,4,0,0
grant.7665046,,The next generation of vaccines: characterization of virus-like particle (VLP) vaccines made in plants.,297212,2010-04-01,2010.0,2012-03-31,2012,McGill University Health Centre,grid.63984.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7631957,,Improvement of a cattle vaccine against Escherichia coli serotype O157:H7,69741,2008-07-01,2008.0,2011-10-31,2011,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.5810873,14026043,悪性黒色腫に対するcalreticulin/TRP-2DNAワクチンの開発,41531,2002-01-01,2002.0,2002-12-31,2002,Sapporo Medical University,grid.263171.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5737049,10670252,GENE GUN-MEDIATED INOCULATION OF ORIENTED DNA VACCINES AGAINST AN INTRACELLULAR PATHOGEN,25464,1998-01-01,1998.0,1999-12-31,1999,Hamamatsu University School of Medicine,grid.505613.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5565937,02453151,Molecular Assembly and Stability of Human Hepatitis B Virus Surface Antigen Vaccine,21507,1990-01-01,1990.0,1991-12-31,1991,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.4909556,30600518,囊尾蚴病多期复合基因疫苗的研究,0,2007-01-01,2007.0,2009-12-31,2009,Bengbu Medical College,grid.252957.e,China,National Natural Science Foundation of China,China,1,0,0
grant.4729728,R21AI117706,Adjuvants and Glucan Particle Vaccines,460625,2015-12-16,2015.0,2018-11-30,2018,University of Massachusetts Medical School,grid.168645.8,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.4480704,14/15297-1,"Study of Monophosphoril lipid A, from Bordetella pertussis LPS, mechanisms as Influenza vaccine adjuvant",0,2014-11-01,2014.0,2017-10-31,2017,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.3791043,618334,Identification of vaccine candidates using reverse vaccinology,116147,2014-03-01,2014.0,2018-02-28,2018,University of Southampton; University of Southampton,grid.5491.9; grid.5491.9,United Kingdom; United Kingdom,European Commission,Belgium,0,0,0
grant.3778860,44211,Improved vaccines for Bluetongue Disease,1168526,2007-01-01,2007.0,2010-09-30,2010,"London School of Hygiene & Tropical Medicine; French Agency for Food, Environmental and Occupational Health & Safety; Boehringer Ingelheim (France); Complutense University of Madrid; Aristotle University of Thessaloniki",grid.8991.9; grid.15540.35; grid.484445.d; grid.4795.f; grid.4793.9,United Kingdom; France; France; Spain; Greece,European Commission,Belgium,0,0,0
grant.3776536,37506,The European malaria vaccine development association,18602506,2006-12-01,2006.0,2012-05-31,2012,University Hospital Heidelberg; Stockholm University; University of Oxford; Janssen (Netherlands); Etna Biotech (Italy); State Serum Institute; Biomedical Primate Research Centre; University of Tübingen; Swiss Tropical and Public Health Institute; University of Edinburgh; Medical Research Council; Radboud University Nijmegen; African Malaria Network Trust; University Hospital of Lausanne; Heidelberg University,grid.5253.1; grid.10548.38; grid.4991.5; grid.497529.4; grid.434329.b; grid.6203.7; grid.11184.3d; grid.10392.39; grid.416786.a; grid.4305.2; grid.14105.31; grid.5590.9; grid.432645.2; grid.8515.9; grid.7700.0,Germany; Sweden; United Kingdom; Netherlands; Italy; Denmark; Netherlands; Germany; Switzerland; United Kingdom; United Kingdom; Netherlands; Tanzania; Switzerland; Germany,European Commission,Belgium,3,0,0
grant.3766949,5246,Ration design and standardized evaluation of novel genetic vaccines.,11072727,2005-01-01,2005.0,2009-06-30,2009,French National Centre for Scientific Research; Poznań University of Technology; University of Zurich; Sorbonne University; Ludwig Maximilian University of Munich; French Institute of Health and Medical Research; Kuros Biosciences (Switzerland); Karolinska Institute; Claude Bernard University Lyon 1; University Hospital Ulm; Erasmus University Medical Center; Vilnius University; University of Cape Town; Pasteur Institute; University of Geneva,grid.4444.0; grid.6963.a; grid.7400.3; grid.462844.8; grid.5252.0; grid.7429.8; grid.476272.2; grid.4714.6; grid.7849.2; grid.410712.1; grid.5645.2; grid.6441.7; grid.7836.a; grid.428999.7; grid.8591.5,France; Poland; Switzerland; France; Germany; France; Switzerland; Sweden; France; Germany; Netherlands; Lithuania; South Africa; France; Switzerland,European Commission,Belgium,0,0,0
grant.3765327,17749,Novel antigen-adjuvant vehicle as an effective influenza vaccine,1472178,2005-06-01,2005.0,2007-05-31,2007,Swedish Orphan Biovitrum (Sweden); University of Gothenburg; Pepscan (Netherlands); Eurogentec (Belgium); Flanders Institute for Biotechnology,grid.420059.a; grid.8761.8; grid.425414.2; grid.424726.1; grid.11486.3a,Sweden; Sweden; Netherlands; Belgium; Belgium,European Commission,Belgium,0,0,0
grant.3135709,1161458,A Game Theoretic Approach to Pediatric Vaccine Pricing,368000,2012-08-01,2012.0,2017-07-31,2017,University of Illinois at Urbana Champaign; University of Illinois at Urbana Champaign,grid.35403.31; grid.35403.31,United States; United States,Directorate for Engineering,United States,1,0,0
grant.2726767,ZIGAI005117,ARRA: Animal Model Support of Universal Influenza Vaccine,3600000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2692186,U01IP000022,Enhanced Surveillance: New Vaccine Preventable Diseases,1101809,2004-09-30,2004.0,2011-09-29,2011,Vanderbilt University,grid.152326.1,United States,Centers for Disease Control and Prevention,United States,27,0,0
grant.2687918,U01AI070443,Preclinical development of a chimeric tetravalent dengue vaccine,2873420,2006-09-26,2006.0,2010-08-31,2010,Takeda (United States),grid.419849.9,United States,National Institute of Allergy and Infectious Diseases,United States,3,11,0
grant.2666472,R56AI087782,Novel nanotechnology based oral influenza vaccines,421237,2011-07-15,2011.0,2013-06-30,2013,Georgia State University,grid.256304.6,United States,National Institute of Allergy and Infectious Diseases,United States,22,1,0
grant.2666264,R56AI076506,Vaccine-induced CD8+ T cell memory,308000,2008-09-26,2008.0,2010-08-31,2010,Oregon Health & Science University,grid.5288.7,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2640832,R43AI051025,Innovative Single-Dose Hepatitis B Vaccine Formulation,96565,2002-08-01,2002.0,2004-01-31,2004,BioTek (United States),grid.288134.4,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2638358,R42AI073064,A novel vaccine: botulinum neurotoxin subunit on a viral carrier.,2509160,2012-06-21,2012.0,2016-05-31,2016,Molecular Targeting Technologies (United States),grid.421557.0,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2604855,R21CA130293,Immunotherapy after ASCT for MM Using hTERT Vaccination + Vaccine-primed T cells,709842,2007-08-14,2007.0,2010-07-31,2010,"University of Maryland, Baltimore",grid.411024.2,United States,National Cancer Institute,United States,3,0,0
grant.2601369,R21AI105605,Universal T cell targeted influenza vaccine,412500,2013-04-15,2013.0,2016-03-31,2016,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2582899,R13CA057170,SPECIFIC IMMUNOTHERPY OF CANCER WITH VACCINES,0,1992-09-30,1992.0,1993-09-29,1993,New York Academy of Sciences,grid.281219.1,United States,National Cancer Institute,United States,0,0,0
grant.2459468,R01AI097368,Developing a Novel Mumps Virus Vaccine,1833975,2012-05-10,2012.0,2017-04-30,2017,University of Georgia,grid.213876.9,United States,National Institute of Allergy and Infectious Diseases,United States,10,0,0
grant.2458019,R01AI074946,Improved Vaccines for Rift Valley Fever Virus,1403333,2008-04-01,2008.0,2012-03-31,2012,University of North Carolina at Chapel Hill,grid.10698.36,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2453751,R01AI041365,HIV and SIV Vaccines and Mucosal Immunity,3875811,1997-07-01,1997.0,2007-05-31,2007,Boston Children's Hospital,grid.2515.3,United States,National Institute of Allergy and Infectious Diseases,United States,6,2,0
grant.2424809,N01AI062637,MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MOD,0,1996-09-30,1996.0,2000-04-30,2000,Southern Research Institute,grid.454225.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424762,N01AI055293,MAO/EVALUATION OF AIDS VACCINES,0,1995-09-30,1995.0,1998-07-31,1998,Southern Research Institute,grid.454225.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424753,N01AI055276,MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE,0,1995-09-30,1995.0,2000-03-31,2000,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424739,N01AI055259,EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE MODELS,0,1995-02-03,1995.0,1999-12-31,1999,Nationwide Children's Hospital,grid.240344.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424715,N01AI052633,MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE,0,1995-06-30,1995.0,1999-06-30,1999,Southern Research Institute,grid.454225.0,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2424714,N01AI052632,MAO/EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE,40000,1995-05-24,1995.0,2000-03-31,2000,Bioqual,grid.282501.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424713,N01AI052631,EVALUATION OF RECOMBINANT BCG/SIV VACCINES,0,1995-09-30,1995.0,1998-03-29,1998,"University of Puerto Rico, Medical Sciences Campus",grid.267034.4,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424711,N01AI052629,EVALUATION OF AIDS VACCINES IN NON-HUMAN PRIMATE,0,1995-06-13,1995.0,1998-09-15,1998,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7674238,W81XWH-17-1-0604,Multitarget-Display Viruslike Particle-Based Vaccine to Combat Lyme Disease,385631,2015-10-01,2015.0,2016-09-01,2016,Center for Molecular Biotechnology,grid.418018.4,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7145476,W81XWH-06-2-0008,Conjugate Vaccines to Prevent Shigellosis,1003866,2004-10-01,2004.0,2005-09-01,2005,,,,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.8330424,81273330,基于cDNA表达库梯级组分免疫高通量筛选抗内脏利什曼病疫苗候选分子,25828,2013-01-01,2013.0,2013-12-31,2013,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,0,0,0
grant.8195513,31661143017,鸡球虫树突状细胞刺激性抗原的确定及其应用,372089,2016-11-01,2016.0,2019-10-31,2019,Nanjing Agricultural University,grid.27871.3b,China,National Natural Science Foundation of China,China,3,0,0
grant.7145367,DAMD17-01-1-0678,Enhancing the Immunogenicity of a Dengue-2 DNA Vaccine with Adjuvants and Anti-FC and RI Antibodies,439850,1999-10-01,1999.0,2000-09-01,2000,Naval Medical Research Center,grid.415913.b,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7143322,W81XWH-06-1-0184,Androgen Deprivation as an Immunomodulatory Therapy in Combination with DNA Vaccines for the Treatment of Prostate Cancer,545616,2004-10-01,2004.0,2005-09-01,2005,University of Wisconsin–Madison,grid.14003.36,United States,Congressionally Directed Medical Research Programs,United States,3,0,0
grant.6381570,2016-67015-24924,DEVELOPING A PARAINFLUENZA VIRUS 5 (PIV5)-BASED PRRSV VACCINE,450000,2016-02-15,2016.0,2019-02-14,2019,University of Georgia; University of Georgia,grid.213876.9; grid.213876.9,United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.6381112,972226,Emerging Viral Vaccine Antigen Insert Consortium (EVAC),673197,2016-08-31,2016.0,2017-10-31,2017,University of Cambridge,grid.5335.0,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.4119569,12383,"The use of CpG adjuvants, bio-degradable microparticles, and microneedle technology for the design of novel single-dose vaccines",113556,2011-09-01,2011.0,2014-08-31,2014,University of British Columbia,grid.17091.3e,Canada,Michael Smith Foundation for Health Research,Canada,0,0,0
grant.3623486,R43AI109924,Ultra-low dose Influenza vaccines,399808,2014-06-01,2014.0,2017-05-31,2017,Codagenix (United States),grid.450645.6,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2718419,Z01HD002500,Etec Epidemiology And Vaccine Research In Lower Egypt,0,1993-01-01,1993.0,2002-01-01,2002,National Institute of Child Health and Human Development,grid.420089.7,United States,National Institute of Child Health and Human Development,United States,4,0,0
grant.2688054,U01AI082069,Assessment of the Immunogenicity and Protective Efficacy of a Multiagent DNA Vacc,1406421,2009-09-28,2009.0,2013-08-31,2013,Geneva Foundation,grid.417469.9,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2668272,RC1AI048895,THERAPEUTIC TB VACCINE,26000,2000-05-05,2000.0,2000-08-31,2000,Sequella (United States),grid.281326.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641837,R43AI091546,Ad4 vectored HIV-Env vaccines with improved immunogenicity,300000,2010-06-15,2010.0,2012-05-31,2012,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2641738,R43AI084350,Development of Multivalent Vaccines Against Yellow Fever and Arena Viruses,599895,2010-04-06,2010.0,2013-03-31,2013,NewLink Genetics (United States),grid.426927.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641270,R43AI063728,Adjuvants for Agile Vaccine Development,886845,2005-07-01,2005.0,2008-06-30,2008,Antigen Discovery (United States),grid.420905.a,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2581359,R13AI044471,MOLECULAR APPROACHES TO HUMAN VIRAL VACCINES,0,1999-03-01,1999.0,2000-02-29,2000,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2575565,R03HD072796,Vaccine-induced HIV antibody responses in infants,152997,2012-07-01,2012.0,2015-06-30,2015,Duke University,grid.26009.3d,United States,National Institute of Child Health and Human Development,United States,5,0,0
grant.2475260,R01CA089270,POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA,1048913,2001-09-12,2001.0,2004-10-31,2004,New York University,grid.137628.9,United States,National Cancer Institute,United States,3,0,0
grant.2474639,R01CA084232,Cell-based tumor vaccines targeting CD4+ T lymphocytes,2595114,2000-04-01,2000.0,2014-01-31,2014,"University of Maryland, Baltimore County",grid.266673.0,United States,National Cancer Institute,United States,65,10,0
grant.2459890,R01AI105204,Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine,5020398,2013-02-01,2013.0,2019-01-31,2019,Thomas Jefferson University,grid.265008.9,United States,National Institute of Allergy and Infectious Diseases,United States,16,0,0
grant.2458998,R01AI089779,Boosting Flu Vaccination without Adjuvant Injection,2759672,2011-06-01,2011.0,2018-05-31,2018,Massachusetts General Hospital,grid.32224.35,United States,National Institute of Allergy and Infectious Diseases,United States,24,1,0
grant.2454989,R01AI047393,DEVELOPMENT OF ROTAVIRUS DNA VACCINES,995610,2001-01-01,2001.0,2004-12-31,2004,Tufts University,grid.429997.8,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2454038,R01AI042588,Genetic Vaccines Against HIV Mutants,1368221,1998-03-01,1998.0,2006-04-30,2006,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2444968,R01AG004884,CLINICAL EFFICACY OF PNEUMOCOCCAL VACCINE IN THE ELDERLY,0,1984-09-01,1984.0,1990-12-31,1990,Yale University,grid.47100.32,United States,National Institute on Aging,United States,2,0,0
grant.8574909,466_1,Interaction between conventional cancer therapy and gene-based cancer vaccines,0,2005-04-25,2005.0,2008-04-24,2008,McMaster University,grid.25073.33,Canada,Ontario Institute for Cancer Research,Canada,0,0,0
grant.8451257,W81XWH-18-C-0075,Passively Regulated Cryogenic (PaRC) Vial System for Vaccine Distribution and Administration,999997,2017-10-01,2017.0,2018-09-30,2018,Mainstream Engineering Corporation (United States),grid.426847.b,United States,United States Department of Defense,United States,0,0,0
grant.8342308,81472347,新型胶质瘤复合抗原DC疫苗抗肿瘤免疫的功能研究,106780,2015-01-01,2015.0,2018-12-31,2018,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,1,0,0
grant.8335660,81400314,ATRQβ-001疫苗通过AT1R/APJ异二聚化抗血管重构机制的研究,35187,2015-01-01,2015.0,2017-12-31,2017,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,3,0,0
grant.8215501,39570663,乙型肝炎病毒表面抗原基因免疫的研究,9640,1996-01-01,1996.0,1998-12-31,1998,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8171485,30340037,增强HIV疫苗诱导免疫应答策略的探讨,12079,2003-09-01,2003.0,2004-08-01,2004,Sun Yat-sen University,grid.12981.33,China,National Natural Science Foundation of China,China,0,0,0
grant.7749356,W81XWH-18-2-0054,Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Versus Unexposed Adults Ages 51 to 65,2750059,2016-10-01,2016.0,2017-09-01,2017,United States Army Medical Research and Materiel Command,grid.420210.5,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7658431,,Prophylactic HIV Vaccines for Social Networks of Injection Drug Users,8759,2009-12-01,2009.0,2010-03-31,2010,Simon Fraser University,grid.61971.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7178376,81270731,靶向DC的FSHR非病理表位的新型避孕疫苗的设计及效应研究,111158,2013-01-01,2013.0,2016-12-31,2016,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,1,0,0
grant.7175809,31270983,O157多糖蛋白疫苗的糖链数目及长度最佳配比研究,127034,2013-01-01,2013.0,2016-12-31,2016,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,11,0,0
grant.7155172,2011-019,Can a pneumococcal H. influenzae protein D conjugate vaccine (PHiD-CV) reduce the frequency of NTHi infection in the lower airway (defined by >10E4 cfu/ml bronchoalveolar lavage) and upper airway (nasopharynx) colonisation of children with chronic suppurative lung disease?,160625,2010-07-01,2010.0,2012-06-30,2012,Menzies School of Health Research,grid.271089.5,Australia,Financial Markets Foundation for Children,Australia,1,0,0
grant.7145974,W81XWH-16-2-0057,Using VacSIM Delivery to Enhance Malaria Vaccine Efficacy,729996,2014-10-01,2014.0,2015-09-01,2015,Geneva Foundation,grid.417469.9,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7145973,W81XWH-16-2-0056,Using VacSIM Delivery to Enhance Malaria Vaccine Efficacy,1017724,2014-10-01,2014.0,2015-09-01,2015,University of Georgia,grid.213876.9,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.6898658,TH01010837,Vývoj unikátních vakcín proti závažným onemocněním zvířat,948927,2015-01-01,2015.0,2016-12-31,2016,Institute of Biotechnology; Institute of Biotechnology; Dyntec (Czechia),grid.448014.d; grid.448014.d; grid.485251.f,Czechia; Czechia; Czechia,Technology Agency of the Czech Republic,Czechia,0,0,0
grant.6665260,109744/Z/15/Z,Vaccine microencapsulation for single dose delayed release delivery.,130504,2016-04-01,2016.0,2017-09-30,2017,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.6434353,,Desenvolvimento nacional de vacina para a prevenção de doença reumática cardíaca,0,2014-12-03,2014.0,2017-12-31,2017,University of Sao Paulo,grid.11899.38,Brazil,National Council for Scientific and Technological Development,Brazil,0,0,0
grant.6192914,I 222,In vivo induced Bacterial Ghosts from live attenuated bacter,0,2009-02-01,2009.0,2012-08-31,2012,University of Vienna,grid.10420.37,Austria,FWF Austrian Science Fund,Austria,0,0,0
grant.6151353,26670267,Evaluation of hypertension vaccine using pig model,34512,2014-04-01,2014.0,2015-03-31,2015,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6144228,26293034,Development of the novel technique intended to the prophylaxis and treatment of neglected tropical diseases,149649,2014-04-01,2014.0,2017-03-31,2017,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,7,0,0
grant.6137871,26430176,Development of next generation transdermal vaccine for cancer treatment,45237,2014-04-01,2014.0,2017-03-31,2017,Kurume University,grid.410781.b,Japan,Japan Society for the Promotion of Science,Japan,22,0,0
grant.6126425,25850194,Development of a novel vaccine to control virulent strains of Marek's disease virus: enhancement of vaccine efficacy by modulating the host immunosuppression pathway,41188,2013-04-01,2013.0,2015-03-31,2015,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,18,0,0
grant.6126244,25670462,Basic study for development of a novel anti-tuberculosis vaccine using magnetite nanoparticles,36196,2013-04-01,2013.0,2015-03-31,2015,Tohoku University,grid.69566.3a,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6091507,24590198,Development of safety vaccine using spleen- and dendritice cells-targeted nano device,56727,2012-04-01,2012.0,2015-03-31,2015,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6089432,24500603,Comparative study on differences between  polio and vaccine-derived polio,46273,2012-04-01,2012.0,2018-03-31,2018,Wakayama Medical University,grid.412857.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6083982,24390041,Development of the transcutaneous influenza vaccine formulation using an self-dissolving microneedle patch,190456,2012-04-01,2012.0,2015-03-31,2015,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,9,0,0
grant.6081969,24390255,Development of a new type of anti-tuberculosis vaccines by the use of lipid immunity,186402,2012-04-01,2012.0,2015-03-31,2015,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.6005234,20592166,Basic research of the antigen delivery system that it aimed at the optimization of the DNA vaccine for cancer prevention,48130,2008-01-01,2008.0,2010-12-31,2010,Aichi Gakuin University,grid.411253.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5982630,19590889,Superantigen pulsed DCs supports the induction of tumor immunity,41305,2007-01-01,2007.0,2008-12-31,2008,Hamamatsu University School of Medicine,grid.505613.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5954904,18390138,The study of the mechanism of therapeutic efficacy of novel vaccines on Tuberculosis-infection and the induction of cytotoxic T cells by the vaccines,163227,2006-01-01,2006.0,2009-12-31,2009,National Kinki Chuo Hospital for Chest Disease,grid.415611.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5952636,18406016,Dynamics of circulating rotavirus strains after vaccine introduction in Brazil.,137114,2006-01-01,2006.0,2009-12-31,2009,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5501860,hrc_3c67d1ab,Targeting cancer vaccines to human dendritic cells via CD301,832820,2016-01-01,2016.0,2019-01-01,2019,University of Auckland,grid.9654.e,New Zealand,Health Research Council of New Zealand,New Zealand,0,0,0
grant.5128726,LP160101044,Development of a live vaccine for gut health in poultry,338400,2016-01-01,2016.0,2018-12-31,2018,RMIT University,grid.1017.7,Australia,Australian Research Council,Australia,0,0,0
grant.4995647,31001121,评价鳗弧菌减毒活疫苗体内免疫效力的新方法,30049,2011-01-01,2011.0,2013-12-31,2013,East China University of Science and Technology,grid.28056.39,China,National Natural Science Foundation of China,China,8,0,0
grant.4988160,30371347,间日疟原虫传播阻断疫苗候选蛋白Pvs25和Pvs28疫苗效果的研究,22090,2004-01-01,2004.0,2006-12-31,2006,China Medical University,grid.412449.e,China,National Natural Science Foundation of China,China,0,0,0
grant.4957740,30170710,犬抗细粒棘球绦虫感染的基因工程疫苗研究,18118,2002-01-01,2002.0,2004-12-31,2004,Shantou University,grid.263451.7,China,National Natural Science Foundation of China,China,0,0,0
grant.4930861,30400476,光动力学肿瘤疫苗治疗和预防上皮性卵巢癌的实验研究,25253,2005-01-01,2005.0,2007-12-31,2007,Capital Medical University,grid.24696.3f,China,National Natural Science Foundation of China,China,0,0,0
grant.4929762,30430600,日本血吸虫病疫苗发展策略研究：辐照致弱尾蚴诱导高保护性效应机理的分子免疫学评价,200748,2005-01-01,2005.0,2009-12-31,2009,Nanjing Medical University,grid.89957.3a,China,National Natural Science Foundation of China,China,6,0,0
grant.4903563,30460052,壳聚糖纳米粒装载HP BabA2/UreI基因双价黏膜DNA疫苗的研究,25253,2005-01-01,2005.0,2007-12-31,2007,Nanchang University,grid.260463.5,China,National Natural Science Foundation of China,China,2,0,0
grant.4898322,R21HD083770,Use of a Novel Parent-Report Measure to Improve Childhood Vaccine Uptake,453725,2016-03-01,2016.0,2019-02-28,2019,Seattle Children's Hospital,grid.240741.4,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.4785156,5439125,Entwicklung eines Impfstoffs gegen Tuberkulose basierend auf Kohlenhydraten,0,2004-01-01,2004.0,2006-12-31,2006,TU Dortmund University; TU Dortmund University,grid.5675.1; grid.5675.1,Germany; Germany,German Research Foundation,Germany,0,0,0
grant.4639323,189686,Development of novel vaccine candidates to prevent primary or reactivated tuberculosis,13205,2008-01-01,2008.0,2010-12-31,2010,University of Bergen,grid.7914.b,Norway,The Research Council of Norway,Norway,0,0,0
grant.4639129,192480,Development of novel vaccine candidates to prevent primary or reactivated tuberculosis,1041432,2009-01-01,2009.0,2012-12-31,2012,University of Bergen,grid.7914.b,Norway,The Research Council of Norway,Norway,1,0,0
grant.4498646,06/06735-9,Conjugated vaccines: from the laboratory to pilot scale 3,0,2007-05-01,2007.0,2009-10-31,2009,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4491503,11/14079-2,Use of nanoparticles in vaccines against bacterial meningitis,0,2012-02-01,2012.0,2014-01-31,2014,State University of Campinas,grid.411087.b,Brazil,São Paulo Research Foundation,Brazil,2,0,0
grant.4404905,W81XWH-10-C-0005,Malarial Vaccines Utilizing Antigen/Adjuvant Display on Viral-Like Particles,120000,2008-10-01,2008.0,2009-09-30,2009,Agave BioSystems (United States),grid.422143.2,United States,United States Department of the Army,United States,0,0,0
grant.4295482,102089,Development of autogenous vaccines for the control of amoebic gill disease in farmed salmon,484301,2015-04-30,2015.0,2019-07-30,2019,Marine Harvest (United Kingdom); University of Stirling,grid.499401.1; grid.11918.30,United Kingdom; United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.4124086,10099,Development of a defective live virus vaccine against porcine reproductive and respiratory syndrome.,886827,2009-01-01,2009.0,2014-01-09,2014,Utrecht University; Utrecht University; Utrecht University; Utrecht University; Utrecht University,grid.5477.1; grid.5477.1; grid.5477.1; grid.5477.1; grid.5477.1,Netherlands; Netherlands; Netherlands; Netherlands; Netherlands,Netherlands Organisation for Scientific Research,Netherlands,1,0,0
grant.4035582,1779,Investigations of polyphosphazenes as adjuvants for mucosal vaccines,82030,2007-11-01,2007.0,2009-10-31,2009,University of Saskatchewan; University of Saskatchewan,grid.25152.31; grid.25152.31,Canada; Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.3949435,1002533,EVALUATING EFFICACY OF A NOVEL BVDV MULTI-ANTIGEN VACCINE,0,2014-02-26,2014.0,2016-09-30,2016,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3928563,ER07-03-251,HIV Vaccine Trial Preparedness: Socio-behavioural Challenges of HIV Vaccine Development,133254,2007-06-26,2007.0,2012-06-25,2012,University of Toronto,grid.17063.33,Canada,"Ministry of Research, Innovation and Science",Canada,0,0,0
grant.3865901,131619,Tablet Vaccines,235362,2014-08-31,2014.0,2015-08-30,2015,,,,Innovate UK,United Kingdom,0,0,0
grant.3844884,131044,"Low cost, broadly efficacious Pneumococcal vaccine",229805,2013-03-31,2013.0,2014-03-30,2014,ImmBio (United Kingdom),grid.434859.7,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.3818388,0215991,RECOMBINANT VACCINES FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME,0,2012-10-01,2012.0,2017-09-30,2017,Purdue University West Lafayette; Purdue University West Lafayette; Purdue University West Lafayette; Purdue University West Lafayette,grid.169077.e; grid.169077.e; grid.169077.e; grid.169077.e,United States; United States; United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3714886,AQ .1.260,"Vaccination against the viral haemorrhagic septicaemia: comparison between a live attenuated virus, a preparation of killed virus and a genetically engineered subunit vaccine",0,1989-01-01,1989.0,1993-01-01,1993,"Eurogentec (Belgium); French Agency for Food, Environmental and Occupational Health & Safety; Research Center at Jouy-en-Josas; Istituto Zooprofilattico Sperimentale del Piemonte Liguria e Valle d'Aosta",grid.424726.1; grid.15540.35; grid.417961.c; grid.425427.2,Belgium; France; France; Italy,European Commission,Belgium,0,0,0
grant.3630766,081865/Z/06/Z,Flu vaccine for heterosubtypic protection.,952830,2007-05-01,2007.0,2010-04-30,2010,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,1,0,0
grant.2763714,BB/J019070/1,Exploiting plant synthetic biology for the production of glycoproteins in plant chloroplasts.,189866,2012-03-01,2012.0,2013-02-28,2013,University of Manchester; University of Manchester,grid.5379.8; grid.5379.8,United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,1,0,0
grant.2723221,ZIAAI001005,Malaria Vaccine:  AMA1-C1/ISA 720,1637386,2009-01-01,2009.0,2011-01-01,2011,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2715650,Z01DE000437,PEPTIDE POLYMERS AS VACCINE CANDIDATES,0,1988-01-01,1988.0,1991-01-01,1991,National Institute of Dental and Craniofacial Research,grid.419633.a,United States,National Institute of Dental and Craniofacial Research,United States,0,0,0
grant.2687858,U01AI069496,San Francisco Vaccine and Prevention Unit,7333610,2007-03-02,2007.0,2013-12-31,2013,Public Health Foundation Enterprises,grid.280537.b,United States,National Institute of Allergy and Infectious Diseases,United States,41,0,0
grant.2640246,R43AI037414,LIVE VIBRIO CHOLERA AS AN ORAL SIV VACCINE VECTOR,0,1995-02-01,1995.0,1995-07-31,1995,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2636361,R41AI047629,MUCOSAL VACCINE DELIVERY SYSTEMS,99938,2000-05-10,2000.0,2002-04-30,2002,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2435122,P01AI056354,Novel Prophylactic HIV Vaccines Based on rAAV Vectors,2203357,2003-09-29,2003.0,2007-08-31,2007,Children's Hospital of Philadelphia,grid.239552.a,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2424828,N01AI065305,CENTRAL IMMUNOLOGY LAB FOR AIDS VACCINE CLINICAL TRIALS,0,1996-04-17,1996.0,2003-04-16,2003,Duke University,grid.26009.3d,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2424679,N01AI052564,DEVELOP LIVE ATTENUATED COLD-ADAPTED INFLUENZA VACCINE,0,1984-10-25,1984.0,1989-10-24,1989,University of Michigan,grid.214458.e,United States,National Institute of Allergy and Infectious Diseases,United States,10,2,0
grant.8591204,0927286a-86ad-4668-9ccb-8505fcb368d7,PARAGONE: vaccines for animal parasites,0,2015-04-01,2015.0,2019-03-31,2019,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8460363,,Developing a Novel Modular Nanoparticle Vaccine Strategy to Induce Durable Systemic and Mucosal HIV Envelope Specific Antibodies,192572,2017-06-01,2017.0,2018-11-30,2018,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8322418,71503196,基于计划行为理论的HPV疫苗支付意愿与需求预测研究,25476,2016-01-01,2016.0,2018-12-31,2018,Xi'an Jiaotong University,grid.43169.39,China,National Natural Science Foundation of China,China,3,0,0
grant.8170828,30271258,CART基因疫苗在吗啡依赖和复吸中的作用及其神经机制,23024,2003-01-01,2003.0,2005-12-31,2005,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8106986,26321,Isolation of unique coccidial antigens for coccidial vaccine development,0,2005-05-01,2005.0,2007-04-30,2007,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.7878549,1111596,Evaluation and optimisation of paediatric vaccination programs in Australia and the region,220641,2016-01-01,2016.0,2019-01-01,2019,University of Western Australia; University of Western Australia,grid.1012.2; grid.1012.2,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7877701,1125788,Enhancing the immune response to disordered malaria antigens,486905,2017-01-01,2017.0,2019-01-01,2019,Monash University; Monash University; Monash University,grid.1002.3; grid.1002.3; grid.1002.3,Australia; Australia; Australia,National Health and Medical Research Council,Australia,1,0,0
grant.7876441,1136351,Mucosal human immunodeficiency virus vaccine late pre-clinical evaluation,429523,2018-01-01,2018.0,2019-01-01,2019,Australian National University; Australian National University; Australian National University; Australian National University; Australian National University,grid.1001.0; grid.1001.0; grid.1001.0; grid.1001.0; grid.1001.0,Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7876107,1107008,Quantifying the effectiveness of pertussis vaccine in older adults,338615,2016-01-01,2016.0,2018-01-01,2018,UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney,grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4,Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7875969,1108066,Understanding immune memory diversity,315205,2016-01-01,2016.0,2019-01-01,2019,Walter and Eliza Hall Institute of Medical Research,grid.1042.7,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7875387,1041897,Viral entry and the development of vaccines.,540720,2013-01-01,2013.0,2018-12-31,2018,Burnet Institute,grid.1056.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7874648,1099183,Group A streptococcal human challenge study: accelerating vaccine development,1518048,2016-01-01,2016.0,2019-01-01,2019,Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute,grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,2,0,0
grant.7874420,1129672,Improving Therapeutic Delivery by Understanding Nanoparticle Interactions with Cells,418384,2017-01-01,2017.0,2019-01-01,2019,Monash University; Monash University; Monash University,grid.1002.3; grid.1002.3; grid.1002.3,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7874167,1134095,Strategies to reduce the burden of gastroenteritis in Aboriginal children.,94296,2017-01-01,2017.0,2019-01-01,2019,University of Western Australia; University of Western Australia,grid.1012.2; grid.1012.2,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7667097,,Virus-like-particles for vaccines produced in plants:  immunologic and structural characterization,100005,2009-05-01,2009.0,2012-04-30,2012,McGill University Health Centre,grid.63984.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7666870,,Long-term preservation of a whole parasite malaria vaccine for storage and delivery in the tropics,125204,2015-04-01,2015.0,2016-03-31,2016,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665052,,Needle-free vaccines for respiratory viruses,646101,2004-10-01,2004.0,2007-09-30,2007,McGill University Health Centre,grid.63984.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7665044,,Understanding the unusual effectiveness of Virus-Like Particle (VLP) vaccines made in plants,503006,2013-10-01,2013.0,2016-09-30,2016,McGill University Health Centre,grid.63984.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7656556,,"Parents, Daughters, and the HPV Vaccine: Factors Affecting Parental Decision-Making in a Universal Immunization Program",87612,2009-01-01,2009.0,2009-12-31,2009,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.7652308,,Discovery of new B cell immunogens for HIV vaccines,86956,2009-10-01,2009.0,2010-09-30,2010,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7651334,,Community Engagement in HIV Vaccine Research: Advancing HIV Vaccine Trial Preparedness among Men who have Sex with Men in India,231230,2010-04-01,2010.0,2013-03-31,2013,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7629111,,Evaluation of viral sensitizer technology in improving egg-based influenza vaccine manufacturing processes,258005,2014-10-01,2014.0,2015-09-30,2015,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7441200,355317,Randomized phase II study of adjuvant WT-1 analog peptide vaccine in patients with malignant pleural mesothelioma after completion of combined modality therapy.,100000,2012-02-16,2012.0,2016-12-31,2016,Memorial Sloan Kettering Cancer Center,grid.51462.34,United States,Mesothelioma Applied Research Foundation,United States,0,0,0
grant.7171754,272200800002C-28-0-3,Vaccine and Treatment Evaluation Units,5590,2007-11-01,2007.0,2017-12-31,2017,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7171753,272200800002C-28-0-2,Vaccine Treatment and Evaluation Unit,82586,2007-11-01,2007.0,2017-12-31,2017,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7170694,261201500039I-2-26100003-1,IGF::OT::IGF TESTING OF COMBINATION IMMUNO AND CHEMOPREVENTION STRATEGIES FOR LYNCH SYNDROME GASTROINTESTINAL CANCER,151260,2015-09-24,2015.0,2017-09-23,2017,Cornell University,grid.5386.8,United States,National Cancer Institute,United States,0,0,0
grant.7170367,261201200042I-0-26100013-1,IGF::OT::IGF A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER,390096,2017-09-01,2017.0,2018-08-31,2018,Mayo Clinic,grid.66875.3a,United States,National Cancer Institute,United States,0,0,0
grant.7170051,272201700082C-0-0-1,Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever,2639002,2017-08-31,2017.0,2017-12-31,2017,Thomas Jefferson University,grid.265008.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7169931,272201600045C-1-0-1,VACCINE TECHNOLOGIES TO ADVANCE NEXT GENERATION ANTHRAX VACCINES,6412369,2012-09-27,2012.0,2017-12-31,2017,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7169712,272201300029C-7-0-1,"Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)",763534,2013-09-30,2013.0,2018-09-29,2018,Science Applications International Corporation (United States),grid.419669.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7169682,272201300023C-3-0-1,"Novel Innate Immune Adjuvant for Avian Influenza. West Nile Virus, and ZIKA Vaccines",3307969,2017-09-30,2017.0,2018-09-29,2018,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7169663,272201300022C-4-0-1,Development of Adjuvant with Vaccines for Tuberculosis and Shigellosis,1546239,2017-09-30,2017.0,2018-09-29,2018,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7043105,SE3210,Development of badger vaccines,560648,1999-04-01,1999.0,2002-03-31,2002,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.6944652,971510,Novel multivalent vaccines against haemorrhagic fevers,622353,2017-03-31,2017.0,2018-05-30,2018,University of Oxford,grid.4991.5,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.6918355,,Viral attenuation and pathogenesis,0,2016-07-04,2016.0,2018-07-04,2018,Pasteur Institute,grid.428999.7,France,European Molecular Biology Organization,Germany,0,0,0
grant.6896523,FR-TI3/156,*Vývoj vakcíny k zabránění přenosu klíšťaty přenášených nákaz na bázi Ferritinu-2 pro veterinární a humánní použití.,3237783,2011-01-01,2011.0,2014-12-31,2014,Biology Centre; Bioveta (Czechia),grid.418338.5; grid.448017.e,Czechia; Czechia,Ministry of Industry and Trade,Czechia,0,0,0
grant.6894372,NR9075,Imunoterapie chronické myeloidní leukemie: vývoj a testování experimentálních vakcím v myším systému a imunologická studie pacientů,1018196,2006-01-01,2006.0,2008-12-31,2008,Institute of Microbiology; General University hospital; Institute of Haematology and Blood Transfusion,grid.418800.5; grid.411798.2; grid.419035.a,Czechia; Czechia; Czechia,Ministry of Health,Czechia,0,0,0
grant.6892045,IZ3431,Kombinované vakcíny s imunomodulačními účinky v prevenci a léčbě infekcí a imunodeficiencí,50712,1996-01-01,1996.0,1998-12-31,1998,Poliklinika Budějovická; Masaryk University; Masaryk University,grid.486007.d; grid.10267.32; grid.10267.32,Czechia; Czechia; Czechia,Ministry of Health,Czechia,0,0,0
grant.6890299,QF3115,"Vývoj vektorů, nosičů a adjuvans pro konstrukci DNA vakcín",460354,2003-01-01,2003.0,2007-12-01,2007,"Palacký University, Olomouc; University of Veterinary and Pharmaceutical Sciences; Institute of Organic Chemistry and Biochemistry; Veterinary Research Institute",grid.10979.36; grid.412968.0; grid.418892.e; grid.426567.4,Czechia; Czechia; Czechia; Czechia,Ministry of Agriculture,Czechia,4,0,0
grant.6842704,17K17282,ナチュラルペプチドの網羅的解析による口腔がん幹細胞特異的再発予防ワクチンの開発,36362,2017-04-01,2017.0,2019-03-31,2019,Sapporo Medical University,grid.263171.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6782853,3537216580,Formulation of ultrasmall vaccine nanoparticles,0,2012-10-01,2012.0,2014-09-30,2014,Ghent University; Ghent University,grid.5342.0; grid.5342.0,Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6781706,1011590620,Evaluation of highly immunogenic tumor cell vaccines in combination with regulatory T-cell depletion,0,2011-10-01,2011.0,2013-09-30,2013,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6779573,31328,"A phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine.",0,2014-11-14,2014.0,2015-09-30,2015,University of Antwerp,grid.5284.b,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6736731,1025201,Molecular characterisation of the dendritic cell receptor Clec9a and its ligand interactions,630350,2012-01-01,2012.0,2014-12-31,2014,Burnet Institute; Burnet Institute; Burnet Institute,grid.1056.2; grid.1056.2; grid.1056.2,Australia; Australia; Australia,National Health and Medical Research Council,Australia,4,0,0
grant.6735856,1056219,Assessing vaccine effectiveness of publicly funded vaccination programs in Queensland,87126,2013-01-01,2013.0,2015-12-31,2015,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6735120,1074899,Developing a safe vaccine against group A streptococci,601061,2014-01-01,2014.0,2016-12-31,2016,University of Queensland; University of Queensland; University of Queensland; University of Queensland; University of Queensland; University of Queensland,grid.1003.2; grid.1003.2; grid.1003.2; grid.1003.2; grid.1003.2; grid.1003.2,Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,2,0,0
grant.6734755,1042634,Antibody-Dependent Cellular Cytotoxicity based immunity to Influenza,591421,2013-01-01,2013.0,2015-12-31,2015,University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia,National Health and Medical Research Council,Australia,2,0,0
grant.6734733,1042520,Generating an effective vaccine response against the intrinsically unstructured malaria antigen Merozoite Surface Protein 2,592147,2013-01-01,2013.0,2015-12-31,2015,Monash University; Monash University; Monash University,grid.1002.3; grid.1002.3; grid.1002.3,Australia; Australia; Australia,National Health and Medical Research Council,Australia,8,0,0
grant.6734493,1026488,Development of Carbohydrate Based Self-adjuvanting Vaccine Delivery System,284575,2012-01-01,2012.0,2015-12-31,2015,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,5,0,0
grant.6733436,1011578,Nanoparticle Vaccines for HIV,376035,2011-01-01,2011.0,2015-12-31,2015,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,6,0,0
grant.6729651,1000512,Preclinical studies of group A streptococcal vaccine candidates,529757,2010-01-01,2010.0,2012-12-31,2012,University of Queensland; University of Queensland; University of Queensland,grid.1003.2; grid.1003.2; grid.1003.2,Australia; Australia; Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6729464,510448,HIV and HCV Vaccines and Immunopathogenesis.,17733272,2009-01-01,2009.0,2013-12-31,2013,UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney,grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,61,0,0
grant.6727555,210112,Optimising immunity towards cancers by vaccination.,135800,2002-01-01,2002.0,2004-12-31,2004,University of Queensland,grid.1003.2,Australia,National Health and Medical Research Council,Australia,2,0,0
grant.6719701,1093532,Pre-clinica evaluation of a novel HIV-1 vaccine statrgy,385879,2015-01-01,2015.0,2017-12-31,2017,Australian National University; Australian National University; Australian National University; Australian National University,grid.1001.0; grid.1001.0; grid.1001.0; grid.1001.0,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,6,0,0
grant.6718063,628331,Comparative effectiveness of vaccine-induced SIV-specific CD8 T cells,604672,2010-01-01,2010.0,2012-12-31,2012,University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9,Australia; Australia,National Health and Medical Research Council,Australia,5,0,0
grant.6717351,1003885,Prophylactic vaccine to prevent cytomegalovirus disease,441027,2011-01-01,2011.0,2013-12-31,2013,QIMR Berghofer Medical Research Institute,grid.1049.c,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6717315,1003546,Immunological Prevention of Cysticercosis and Hydatid Disease,752052,2011-01-01,2011.0,2015-12-31,2015,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,6,0,0
grant.6716641,488221,Population genomics of Plasmodium falciparum surface antigen genes,325412,2008-01-01,2008.0,2010-12-31,2010,Burnet Institute; Burnet Institute,grid.1056.2; grid.1056.2,Australia; Australia,National Health and Medical Research Council,Australia,4,0,0
grant.6715616,251648,A study to investigate alternative regimens for pneumococcal vaccination of infants in a developing country,1160801,2003-01-01,2003.0,2005-12-31,2005,University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,4,0,0
grant.6663756,172381,Entrapment and deletion of melanoma-specific T cells at vaccination sites,300000,2010-06-01,2010.0,2013-05-31,2013,The University of Texas MD Anderson Cancer Center,grid.240145.6,United States,Melanoma Research Alliance,United States,0,0,0
grant.6501588,272201300023I-1-27200004-1,VTEU: Phase I Influenza Vaccine Clinical Trial,4825191,2015-11-15,2015.0,2018-09-30,2018,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501538,272201300022I-2-27200007-1,VTEU: Phase I Malaria Vaccine Clinical Trial,845285,2015-04-10,2015.0,2017-05-30,2017,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501493,272201300022C-1-0-1,Development of Adjuvant with Vaccines for Tuberculosis and Shigellosis,2814783,2013-09-30,2013.0,2017-09-29,2017,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501452,272201300023C-1-0-1,Novel Innate Immune Adjuvant for Avian Influenza and West Nile Virus Vaccines,2901850,2013-09-30,2013.0,2017-09-29,2017,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501422,272200800006C-23-0-9,VTEU: Shigella Vaccine Trial,75154,2007-11-01,2007.0,2017-07-31,2017,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501274,272201300019I-3-27200005-1,VTEU: Phase I Malaria Vaccine Study,138132,2015-09-04,2015.0,2016-12-31,2016,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501039,272201300021I-1-27200006-1,Assay Work for Malaria Vaccines - VTEU,48753,2015-09-15,2015.0,2018-03-29,2018,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500835,272201300021I-1-27200008-1,VTEU: Assay Work for Influenza Vaccines,30442,2015-09-20,2015.0,2016-10-31,2016,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500039,272201300018I-1-27200009-1,VTEU: Assay Work for Yellow Fever Vaccines,38524,2015-09-15,2015.0,2017-05-14,2017,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499682,272201300029C-5-0-1,"Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)",1933277,2013-09-30,2013.0,2017-09-29,2017,Science Applications International Corporation (United States),grid.419669.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6378521,1005043,DEVELOPMENT OF AD-VECTORED VACCINES INDUCING BROAD IMMUNITY TO SWINE INFLUENZA,0,2014-10-08,2014.0,2015-09-30,2015,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.6163461,26893206,Development of cancer peptide vaccine that can induce tumor-specific CTLs and Th cells.,23645,2014-08-29,2014.0,2016-03-31,2016,Kumamoto University,grid.274841.c,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6154182,26670514,Development of Nasal Vaccine agaisnt RS virus based on neonatal innate immunity,32478,2014-04-01,2014.0,2017-03-31,2017,Osaka City University,grid.261445.0,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.6104573,24790902,Identification of the antibody induced by the new vaccine against Alzheimer's diseasese induces,45791,2012-04-01,2012.0,2014-03-31,2014,Tokyo Metropolitan Institute of Medical Science,grid.272456.0,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6052241,22890255,Development of novel vaccine against tuberculosis using recombinant BCG expressing SOCS1 antagonist,36084,2010-01-01,2010.0,2011-12-31,2011,"National Institute of Biomedical Innovation, Health and Nutrition",grid.482562.f,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6051363,22791645,Development of macrophage migration inhibitory factor DNA vaccine against inflammatory ocular disease,48978,2010-01-01,2010.0,2012-12-31,2012,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6036546,22590723,Development of immunotherapy for hepatocellular carcinoma by peptide vaccine,53717,2010-01-01,2010.0,2012-12-31,2012,Kanazawa University,grid.9707.9,Japan,Japan Society for the Promotion of Science,Japan,7,0,0
grant.6030160,21792013,Development of a tailor-made type of cancer vaccine treatment,49025,2009-01-01,2009.0,2012-12-31,2012,Kyushu University,grid.177174.3,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6025747,21689044,Search for immunopotentiating adjuvants in cancer vaccine therapy for gynecologic malignancies,294118,2009-01-01,2009.0,2010-12-31,2010,Waseda University,grid.5290.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6014906,21390046,The creation and safety assessment of cytokine adjuvant and nano-carrier for mucosal vaccine,214523,2009-01-01,2009.0,2012-12-31,2012,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6003007,20590439,Establishment of a novel vaccine against Mycobacterium tuberculosis employing carbohydrate-coated liposomes,50880,2008-01-01,2008.0,2010-12-31,2010,Hamamatsu University School of Medicine,grid.505613.4,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6002508,20590033,Construction of influenza virosome and its development to preparation of vaccine,50880,2008-01-01,2008.0,2010-12-31,2010,University of Toyama,grid.267346.2,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5958855,18592022,The study of DNA vaccine potency against hamster oral papillomavirus-associated oral cancer,32374,2006-01-01,2006.0,2007-12-31,2007,Aichi Gakuin University,grid.411253.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5924448,16K19132,クロストリジウム・ディフィシル感染症に対するDNAワクチンの開発と応用,36496,2016-04-01,2016.0,2019-03-31,2019,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5906334,16K08415,経鼻投与型リポソームワクチンを用いた新規非侵襲性子宮頸がんワクチンの開発,44737,2016-04-01,2016.0,2019-03-31,2019,Tokyo University of Pharmacy and Life Sciences,grid.410785.f,Japan,Japan Society for the Promotion of Science,Japan,5,0,0
grant.5877614,15K19116,Induction of vaccine-elicited T cell responses by non-natural amino acids,35497,2015-04-01,2015.0,2017-03-31,2017,Kyushu University,grid.177174.3,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5876809,16017244,経口ワクチンによる粘膜免疫誘導可能なprime/boostワクチンの開発,93473,2004-01-01,2004.0,2005-12-31,2005,Mie University,grid.260026.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5872498,15K11031,Fundamental study on delivery system of DNA vaccine-embedded CPH nanoparticles for cancer prevention using oral mucosa,42591,2015-04-01,2015.0,2018-03-31,2018,Aichi Gakuin University,grid.411253.0,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.5869872,15K10470,The prophylactic effect of IL-17A DNA vaccine on arthritis,43742,2015-04-01,2015.0,2018-03-31,2018,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5836707,15390145,Developmental research of new generation DNA vaccine against microorganism using synthesized DNA,137604,2003-01-01,2003.0,2004-12-31,2004,Yokohama City University,grid.268441.d,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5828744,15019081,西ナイルウイルスのワクチン試作とその評価,23284,2003-01-01,2003.0,2003-12-31,2003,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5824909,14370095,Development of mucosal vaccines for prevention of prevention of respiratory infectious diseases,44847,2002-01-01,2002.0,2003-12-31,2003,Nagoya City University,grid.260433.0,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5815366,14021086,免疫調節遺伝子とのフュージョンDNAワクチンによる細胞内寄生原虫感染制御の新戦略,51914,2002-01-01,2002.0,2002-12-31,2002,Kyushu University,grid.177174.3,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5648738,06J00100,二本鎖RNAを用いたアジュバント併用経鼻不活化インフルエンザワクチンの開発,16227,2006-01-01,2006.0,2007-12-31,2007,Tokyo University of Science,grid.143643.7,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5597699,04304033,Immunopotentiation by immunoadjuvants of human viral vaccines,151152,1992-01-01,1992.0,1994-12-31,1994,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5245953,272201300029C-3-0-1,"Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)",2823243,2013-09-30,2013.0,2016-09-29,2016,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245950,272201300023I-0-27200008-1,Assay Work for Influenza Vaccines - VTEU,236233,2015-09-15,2015.0,2016-09-14,2016,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245948,272201300023I-0-27200006-1,Vaccine and Treatment Evaluation Unit,280264,2015-07-13,2015.0,2018-10-31,2018,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245945,272201300022I-1-27200003-1,Phase 1 Malaria Vaccine Trial  - VTEU,1555265,2014-03-23,2014.0,2017-12-31,2017,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245944,272201300022I-0-27200012-1,Assay Work for Yellow Fever Vaccines - VTEU,2767600,2015-09-01,2015.0,2018-02-28,2018,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245943,272201300022I-0-27200011-1,Vaccine and Treatment Evaluation Unit,363918,2015-07-13,2015.0,2018-10-31,2018,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245939,272201300022I-0-27200007-1,Phase I Malaria Vaccine Clinical Trial - VTEU,90057,2015-04-10,2015.0,2017-05-30,2017,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245937,272201300021I-0-27200010-1,Assay Work for Plague Vaccines - VTEU,299974,2015-09-20,2015.0,2017-03-31,2017,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245936,272201300021I-0-27200009-1,Assay Work for Herpes Vaccines - VTEU,274978,2015-09-20,2015.0,2017-04-30,2017,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245935,272201300021I-0-27200008-1,Assay Work for Influenza Vaccines - VTEU,52261,2015-09-20,2015.0,2016-07-15,2016,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245934,272201300021I-0-27200007-1,Assay Work for TB Vaccines - VTEU,89053,2013-09-20,2013.0,2016-07-15,2016,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245933,272201300021I-0-27200006-1,Assay Work for Malaria Vaccines - VTEU,1056336,2015-09-15,2015.0,2016-09-14,2016,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245932,272201300021I-0-27200005-1,Vaccine and Treatment Evaluation Unit,277593,2015-07-13,2015.0,2018-10-31,2018,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245928,272201300020I-2-27200002-1,Phase I Trial of Tuberculosis Vaccine - VTEU,954161,2014-08-20,2014.0,2017-12-31,2017,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245927,272201300020I-0-27200005-1,Vaccine and Treatment Evaluation Unit,323706,2015-07-13,2015.0,2018-10-31,2018,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245925,272201300019I-0-27200005-1,Phase I Malaria Vaccine Study - VTEU,137248,2015-09-04,2015.0,2016-04-30,2016,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245924,272201300019I-0-27200004-1,Vaccine and Treatment Evaluation Unit,375778,2015-07-13,2015.0,2018-10-31,2018,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245922,272201300018I-1-27200004-1,Respiratory Syncytial Virus: Diagnostic and Vaccine Assays  - VTEU,1022794,2014-09-08,2014.0,2018-12-31,2018,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245921,272201300018I-0-27200009-1,Assay Work for Yellow Fever Vaccines - VTEU,1213064,2015-09-15,2015.0,2016-09-14,2016,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245920,272201300018I-0-27200008-1,Vaccine and Treatment Evaluation Unit,277215,2015-07-13,2015.0,2018-10-31,2018,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245918,272201300018I-0-27200006-1,Phase I Trial of Filovirus Vaccine  - VTEU,4098006,2015-07-01,2015.0,2018-10-31,2018,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245914,272201300017I-0-27200010-1,Assay Work for Malaria Vaccines - VTEU,2549706,2015-09-01,2015.0,2017-04-30,2017,Duke University,grid.26009.3d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245907,272201300016I-0-27200005-1,Vaccine and Treatment Evaluation Unit,336281,2015-07-13,2015.0,2018-10-31,2018,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245903,272201300015I-0-27200003-1,Vaccine and Treatment Evaluation Unit,307228,2015-07-13,2015.0,2018-10-31,2018,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245624,272200800057C-21-0-3,VACCINE AND TREATMENT EVALUATION UNITS,343826,2007-11-01,2007.0,2016-10-31,2016,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245623,272200800057C-21-0-2,Vaccine and Treatment Evaluation Units,171226,2007-11-01,2007.0,2016-10-31,2016,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245622,272200800057C-21-0-1,Vaccine and Treatment Evaluation Units,84504,2007-11-01,2007.0,2016-10-31,2016,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245617,272200800007C-24-0-2,Vaccine and Treatment Evaluation Units,251317,2007-11-01,2007.0,2016-07-31,2016,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245616,272200800006C-21-0-9,VACCINE AND TREATMENT EVALUATION UNITS,501265,2007-11-01,2007.0,2017-07-31,2017,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245615,272200800006C-21-0-3,VACCINE AND TREATMENT EVALUATION UNITS,315741,2007-11-01,2007.0,2017-07-31,2017,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245614,272200800006C-21-0-2,Vaccine and Treatment Evaluation Units,36669,2007-11-01,2007.0,2017-07-31,2017,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245613,272200800005C-21-0-6,VACCINE AND EVALUTION TREATMENT UNITS,649581,2007-11-01,2007.0,2017-06-30,2017,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245612,272200800004C-18-0-1,Vaccine and Treatment Evaluation Units,104980,2007-11-01,2007.0,2016-10-31,2016,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245610,272200800003C-23-0-5,VACCINE AND EVALUATION TREATMENT UNITS,867107,2007-11-01,2007.0,2019-09-30,2019,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245609,272200800002C-22-0-4,Vaccine and Treatment Evaluation Units,743576,2007-11-01,2007.0,2017-01-31,2017,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245608,272200800002C-22-0-2,Vaccine Treatment and Evaluation Unit,3506,2007-11-01,2007.0,2017-01-31,2017,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245607,272200800002C-22-0-1,Vaccine and Treatment Evaluation Unit,305211,2007-11-01,2007.0,2017-01-31,2017,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245208,261201500039I-0-26100003-1,IGF::OT::IGF TESTING OF COMBINATION IMMUNO AND CHEMOPREVENTION STRATEGIES FOR LYNCH SYNDROME GASTROINTESTINAL CANCER,679964,2015-09-24,2015.0,2017-09-23,2017,Cornell University,grid.5386.8,United States,National Cancer Institute,United States,0,0,0
grant.5073020,MC_PC_15104,Zika: a safe recombinant vaccine with proof of efficacy in rodents,74555,2016-03-30,2016.0,2017-09-30,2017,University of Manchester; University of Manchester,grid.5379.8; grid.5379.8,United Kingdom; United Kingdom,Medical Research Council,United Kingdom,0,0,0
grant.4944049,30572272,抗动脉粥样硬化DNA疫苗/壳聚糖纳米粒鼻腔给药的研究,26709,2006-01-01,2006.0,2008-12-31,2008,China Pharmaceutical University,grid.254147.1,China,National Natural Science Foundation of China,China,8,0,0
grant.4924046,30700703,汉坦病毒灭活疫苗经呼吸道粘膜免疫的研究,27730,2008-01-01,2008.0,2010-12-31,2010,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,1,0,0
grant.4904457,30170836,纳米粒子作为血吸虫病疫苗佐剂的应用研究,25364,2002-01-01,2002.0,2004-12-31,2004,Nanjing Medical University,grid.89957.3a,China,National Natural Science Foundation of China,China,0,0,0
grant.4561045,96/10049-0,Yuji Sato | National Institutes of Health - Japão,0,1997-02-04,1997.0,1997-02-25,1997,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4555134,00/12957-8,Produção de vacina de DNA recombinante para o vírus dengue-3,0,2001-05-01,2001.0,2005-03-31,2005,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,1,0,0
grant.4546340,03/11861-5,Vacinas conjugadas: da bancada para escala piloto - 2,0,2004-02-01,2004.0,2007-08-31,2007,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,2,0,0
grant.4522499,ANR-12-EMMA-0032,Development of an innovative sub-unit vaccine against toxoplasmosis,343114,2012-11-01,2012.0,2014-10-31,2014,University of Lille,grid.503422.2,France,National Agency for Research,France,0,0,0
grant.3857112,272201400042C-0-0-1,STAGED VACCINE DEVELOPMENT: IMMUNOPROPHYLAXIS BY GENE TRANSFER,223056,2014-09-17,2014.0,2016-08-31,2016,Children's Hospital of Philadelphia,grid.239552.a,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.3857104,272201400032C-0-0-1,Development of Inulin Acetate-Based Adjuvant,225000,2014-09-15,2014.0,2015-09-14,2015,Medgene Labs (United States),grid.470383.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857065,272201300029C-2-0-1,"Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)",3529059,2013-09-30,2013.0,2015-09-29,2015,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857064,272201300023I-0-27200003-1,Vaccine and Treatment Evaluation Units,335005,2014-09-16,2014.0,2015-09-15,2015,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857063,272201300023I-0-27200002-1,Respiratory Syncytial Virus: Diagnostic and Vaccine Assays  - VTEU,57339,2014-09-08,2014.0,2015-03-08,2015,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857062,272201300022I-0-27200005-1,Vaccine and Treatment Evaluation Units,344492,2014-09-16,2014.0,2015-09-15,2015,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857060,272201300022I-0-27200003-1,Phase 1 Malaria Vaccine Trial  - VTEU,67121,2014-08-05,2014.0,2015-08-04,2015,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857058,272201300021I-0-27200002-1,Vaccine and Treatment Evaluation Units,344940,2014-09-16,2014.0,2015-09-15,2015,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857056,272201300020I-0-27200003-1,Vaccine and Treatment Evaluation Units,339191,2014-09-16,2014.0,2015-09-16,2015,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857055,272201300020I-0-27200002-1,Phase I Trial of Tuberculosis Vaccine - VTEU,35983,2014-08-20,2014.0,2015-02-20,2015,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857054,272201300019I-0-27200003-1,Vaccine and Treatment Evaluation Units,411019,2014-09-16,2014.0,2015-09-15,2015,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857052,272201300018I-0-27200005-1,Vaccine and Treatment Evaluation Units,290933,2014-09-16,2014.0,2015-09-15,2015,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857051,272201300018I-0-27200004-1,Respiratory Syncytial Virus: Diagnostic and Vaccine Assays  - VTEU,59634,2014-09-08,2014.0,2015-03-08,2015,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857049,272201300018I-0-27200002-1,Phase IIb Pneumococcal Conjugate Vaccine Trial - VTEU,356164,2014-07-10,2014.0,2016-10-31,2016,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857048,272201300017I-0-27200005-1,Vaccine and Treatment Evaluation Units,285964,2014-09-16,2014.0,2015-09-15,2015,Duke University,grid.26009.3d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857044,272201300016I-0-27200004-1,Vaccine and Treatment Evaluation Units,363731,2014-09-16,2014.0,2015-09-15,2015,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857043,272201300016I-0-27200003-1,Safety and Immunogenicity of Shigella Vaccines - VTEU,600083,2014-08-18,2014.0,2015-10-31,2015,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3857041,272201300015I-0-27200002-1,Vaccine and Treatment Evaluation Units,333338,2014-09-16,2014.0,2015-09-15,2015,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856792,272200800057C-17-0-3,VACCINE AND TREATMENT EVALUATION UNITS,301498,2013-03-19,2013.0,2015-07-09,2015,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856791,272200800057C-17-0-2,Vaccine and Treatment Evaluation Units,4402,2013-03-19,2013.0,2015-07-09,2015,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856790,272200800057C-17-0-1,Vaccine and Treatment Evaluation Units,300000,2013-03-19,2013.0,2015-07-09,2015,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856772,272200800008C-18-0-2,Vaccine and Treatment Evaluation Units,374688,2007-11-01,2007.0,2015-09-10,2015,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856771,272200800008C-18-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2015-09-10,2015,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856769,272200800007C-19-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2015-09-18,2015,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856768,272200800006C-18-0-8,VACCINE AND TREATMENT EVALUATION UNITS,1681983,2007-11-01,2007.0,2015-08-26,2015,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856767,272200800006C-18-0-2,Vaccine and Treatment Evaluation Units,123745,2007-11-01,2007.0,2015-08-26,2015,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856766,272200800006C-18-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2015-08-26,2015,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856765,272200800005C-18-0-4,VACCINE AND EVALUTION TREATMENT UNITS,230381,2007-11-01,2007.0,2015-08-26,2015,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856764,272200800005C-18-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2015-08-26,2015,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856763,272200800004C-13-0-4,VACCINE AND TREATMENT EVALUATION UNITS,379243,2007-11-01,2007.0,2015-08-26,2015,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856762,272200800004C-13-0-3,VACCINE AND TREATMENT EVALUATION UNITS,52453,2007-11-01,2007.0,2015-08-26,2015,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856761,272200800004C-13-0-2,Vaccine and Treatment Evaluation Units,383846,2007-11-01,2007.0,2015-08-26,2015,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856760,272200800004C-13-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2015-08-26,2015,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856759,272200800003C-18-0-4,VACCINE AND EVALUATION TREATMENT UNITS,275912,2007-11-01,2007.0,2015-08-26,2015,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856758,272200800003C-18-0-3,VACCINE AND EVALUATION TREATMENT UNITS,76157,2007-11-01,2007.0,2015-08-26,2015,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856757,272200800003C-18-0-2,Vaccine and Treatment Evaluation Units,90157,2007-11-01,2007.0,2015-08-26,2015,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856756,272200800003C-18-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2015-08-26,2015,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856755,272200800002C-18-0-2,Vaccine and Treatment Evaluation Units,176652,2007-11-01,2007.0,2015-08-27,2015,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856754,272200800002C-18-0-1,Vaccine and Treatment Evaluation Unit,300000,2007-11-01,2007.0,2015-08-27,2015,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3824163,0219672,PROSTAGLANDIN PRODUCTION DURING ORTHOPOXVIRUS INFECTIONS,0,2009-10-01,2009.0,2013-07-01,2013,North Carolina State University,grid.40803.3f,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3823145,0185790,DEVELOPMENT OF IMPROVED VACCINES AGAINST AVIAN PATHOGENS AND POULTRY BORNE FOOD SAFETY TARGETS,0,2012-09-04,2012.0,2017-09-03,2017,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3778836,223064,"Establishment, Strategy and Initial activities of the TuBerculosis Vaccine Initiative : Coordination of European efforts with global research initiatives",603289,2008-05-01,2008.0,2010-04-30,2010,Wageningen University & Research; Wageningen University & Research; TuBerculosis Vaccine Initiative; TuBerculosis Vaccine Initiative; State Serum Institute; Max Planck Society; London School of Hygiene & Tropical Medicine,grid.4818.5; grid.4818.5; grid.425962.e; grid.425962.e; grid.6203.7; grid.4372.2; grid.8991.9,Netherlands; Netherlands; Netherlands; Netherlands; Denmark; Germany; United Kingdom,European Commission,Belgium,0,0,0
grant.3764850,503367,"An Integrated project for the design and testing of vaccine candidates against tuberculosis: Identification, development and clinical studies",22562190,2004-01-01,2004.0,2009-12-31,2009,Wageningen University & Research; French National Centre for Scientific Research; Leiden University Medical Center; GlaxoSmithKline (Belgium); Max Planck Society; University of Birmingham; Aston University; University of Manchester; University of Oxford; French Institute of Health and Medical Research; Université Libre de Bruxelles; Armauer Hansen Research Institute; Pasteur Institute; Public Health England; State Serum Institute; University of Lübeck; Technical University Munich; Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani; University of Palermo; Cheikh Anta Diop University; University of Zaragoza; University of Italian Switzerland; University of Geneva; University Hospital of Basel; Biomedical Primate Research Centre; Medical Research Council; Imperial College London; London School of Hygiene & Tropical Medicine; University of Cape Town; University Hospital Ulm; University of Erlangen-Nuremberg,grid.4818.5; grid.4444.0; grid.10419.3d; grid.425090.a; grid.4372.2; grid.6572.6; grid.7273.1; grid.5379.8; grid.4991.5; grid.7429.8; grid.4989.c; grid.418720.8; grid.428999.7; grid.271308.f; grid.6203.7; grid.4562.5; grid.6936.a; grid.419423.9; grid.10776.37; grid.8191.1; grid.11205.37; grid.29078.34; grid.8591.5; grid.410567.1; grid.11184.3d; grid.14105.31; grid.7445.2; grid.8991.9; grid.7836.a; grid.410712.1; grid.5330.5,Netherlands; France; Netherlands; Belgium; Germany; United Kingdom; United Kingdom; United Kingdom; United Kingdom; France; Belgium; Ethiopia; France; United Kingdom; Denmark; Germany; Germany; Italy; Italy; Senegal; Spain; Switzerland; Switzerland; Switzerland; Netherlands; United Kingdom; United Kingdom; United Kingdom; South Africa; Germany; Germany,European Commission,Belgium,3,0,0
grant.3749525,QLK2-CT-1999-01293,A european malaria vaccine development consortium: euromalvac 1,3294831,2000-02-01,2000.0,2003-05-01,2003,University of Edinburgh; University of Copenhagen; Radboud University Nijmegen; The Francis Crick Institute; London School of Hygiene & Tropical Medicine; King's College London; Karolinska Institute; University of Tübingen; Biomedical Primate Research Centre; Pasteur Institute,grid.4305.2; grid.5254.6; grid.5590.9; grid.451388.3; grid.8991.9; grid.13097.3c; grid.4714.6; grid.10392.39; grid.11184.3d; grid.428999.7,United Kingdom; Denmark; Netherlands; United Kingdom; United Kingdom; United Kingdom; Sweden; Germany; Netherlands; France,European Commission,Belgium,29,0,0
grant.3737709,BMH4972515,European Vaccine against AIDS: Centralised facility,0,1997-05-01,1997.0,2000-04-30,2000,National Institute for Biological Standards and Control,grid.70909.37,United Kingdom,European Commission,Belgium,0,0,0
grant.3568675,DP120100194,New methods for the chemical synthesis of a library of glycopeptide-based tri-component cancer vaccines,406185,2012-01-01,2012.0,2014-12-31,2014,University of Sydney,grid.1013.3,Australia,Australian Research Council,Australia,6,0,0
grant.3535570,R01AI111851,Targeting neutralizing epitopes in the MPER of HIV Env,2551532,2014-05-06,2014.0,2019-04-30,2019,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2715730,Z01DE000518,DEVELOPMENT OF DETOXIFIED PERTUSSIS TOXIN FOR ACELLULAR WHOOPING COUGH VACCINE,0,1990-01-01,1990.0,1997-01-01,1997,National Institute of Dental and Craniofacial Research,grid.419633.a,United States,National Institute of Dental and Craniofacial Research,United States,0,0,0
grant.2711573,Z01BK002021,Vaccinia-based Smallpox Vaccine Safety,0,2002-01-01,2002.0,2002-12-31,2002,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709087,Z01AI001002,Malaria Vaccine:  AMA1-C2,3010820,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2706161,Y1AI2642-16-0-1,HIV Vaccine Research and Development,17222880,2011-01-01,2011.0,2011-12-31,2011,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706160,Y1AI2642-15-0-1,HIV Vaccine Research and Development,52000000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2692261,U01IP000461,Enhanced Surveillance for New Vaccine Preventable Disease,2710474,2011-09-30,2011.0,2017-09-29,2017,Texas Children's Hospital,grid.416975.8,United States,Centers for Disease Control and Prevention,United States,1,0,0
grant.2692183,U01IP000017,Enhanced Surveillance-Newly Vaccine Preventable Diseases,1341560,2004-09-30,2004.0,2011-09-29,2011,University of Rochester,grid.16416.34,United States,Centers for Disease Control and Prevention,United States,17,0,0
grant.2687964,U01AI074579,Self-administered microneedle patches for influenza vaccines,7662077,2007-05-15,2007.0,2013-04-30,2013,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,40,0,0
grant.2687955,U01AI074527,Pandemic influenza DNA vaccine Development,5613677,2007-06-15,2007.0,2011-05-31,2011,Vical (United States),grid.422245.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687666,U01AI057853,Comparative Study of Influenza Vaccines in Adults,4311175,2004-08-15,2004.0,2008-07-31,2008,University of Michigan,grid.214458.e,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2641946,R43AI098253,A Novel Cassette System for the Assembly of VLP Vaccines,296731,2012-06-01,2012.0,2014-05-31,2014,Shifa Biomedical (United States),grid.422162.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2608115,R21DE016323,An Adenoviral-Based Mucosal Vaccine for AIDS,586500,2004-04-01,2004.0,2007-03-31,2007,La Jolla Institute For Molecular Medicine,grid.281320.a,United States,National Institute of Dental and Craniofacial Research,United States,0,0,0
grant.2598780,R21AI063982,Combined TNFSF and TLR stimulation of HIV vaccines,428110,2005-04-01,2005.0,2007-09-30,2007,Veterans Medical Research Foundation of San Diego,grid.44214.37,United States,National Institute of Allergy and Infectious Diseases,United States,5,4,0
grant.2456829,R01AI061123,Efficacy of soybean-based vaccines using a model antigen,806160,2005-07-15,2005.0,2010-06-30,2010,University of North Carolina at Charlotte,grid.266859.6,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2455959,R01AI052373,Animal models to design &evaluate improved VZV vaccines,1492314,2003-02-01,2003.0,2010-01-31,2010,University of Arkansas for Medical Sciences,grid.241054.6,United States,National Institute of Allergy and Infectious Diseases,United States,15,0,0
grant.2435046,P01AI046007,NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES,6670070,1999-09-01,1999.0,2005-06-30,2005,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,21,4,0
grant.2425260,N01AI30063-66-0-10,Task 13/C26: Influenza Challenge Models and Assays for Influenza Vaccines,845992,2003-09-30,2003.0,2012-12-31,2012,Southern Research Institute,grid.454225.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425119,N01AI25459-10-0-1,Vaccine and Treatment Evaluation Units (VTEUs),154474,2002-06-01,2002.0,2010-08-31,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2354950,DP1DA033502,Human methamphetamine vaccine:  Translational Avante Garde Award,4033446,2011-09-30,2011.0,2017-08-31,2017,Baylor College of Medicine,grid.39382.33,United States,National Institute on Drug Abuse,United States,15,0,0
grant.2350072,AAI12025001-1-0-1,Assessing Safety of Cell Substrates and Vaccine Components,696600,2014-01-01,2014.0,2014-12-31,2014,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2350065,AAI12016001-1-0-1,Evaluation of Anti-Poliovirus Drugs and Vaccines,99992,2013-01-01,2013.0,2013-12-31,2013,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347753,272201300029C-0-0-1,"Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)",2244621,2013-09-30,2013.0,2014-09-29,2014,Science Applications International Corporation (United States),grid.419669.5,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2347752,272201300028C-0-0-1,Development of a Nanoemulsion Adjuvant with a Vaccine for Pandemic Influenza,5516166,2013-09-30,2013.0,2016-09-29,2016,NanoBio (United States),grid.479371.f,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2347747,272201300023I-0-27200001-1,VACCINE AND TREATMENT EVALUATION UNITS (VTEUS),328127,2013-09-16,2013.0,2014-09-15,2014,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347746,272201300023C-0-0-1,Novel Innate Immune Adjuvant for Avian Influenza and West Nile Virus Vaccines,6770054,2013-09-30,2013.0,2016-09-29,2016,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2347745,272201300022I-0-27200001-1,VACCINE AND TREATMENT EVALUATION UNITS (VTEUS),371344,2013-09-16,2013.0,2014-09-15,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347744,272201300022C-0-0-1,Development of Adjuvant with Vaccines for Tuberculosis and Shigellosis,5490179,2013-09-30,2013.0,2016-09-29,2016,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2347743,272201300021I-0-27200001-1,VACCINE AND TREATMENT EVALUATION UNITS (VTEU),466955,2013-09-16,2013.0,2014-09-15,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347741,272201300020I-0-27200001-1,VACCINE TREATMENT AND EVALUATION UNITS (VTEU),332887,2013-09-16,2013.0,2014-09-15,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347740,272201300019I-0-27200001-1,VACCINE AND TREATMENT EVALUATION UNITS (VTEU),348579,2013-09-16,2013.0,2014-09-15,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347738,272201300018I-0-27200001-1,Vaccine and Treatment Evaluation Units (VTEUs),349613,2013-09-16,2013.0,2014-09-15,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347736,272201300017I-0-27200001-1,Vaccine and Treatment Evaluation Units (VTEUs),297960,2013-09-16,2013.0,2014-09-15,2014,Duke University,grid.26009.3d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347734,272201300016I-0-27200001-1,VACCINE AND TREATMENT EVALUATION UNITS (VTEU),328061,2013-09-16,2013.0,2014-09-15,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347732,272201300015I-0-27200001-1,VACCINE TREATMENT EVALUATION UNITS (VTEUS),390743,2013-09-16,2013.0,2014-09-15,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347295,272201000036C-3-0-1,Development of Technologies to Facilitate the use and Response of Vaccines,1651037,2010-08-31,2010.0,2015-08-30,2015,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347294,272201000036C-1-0-1,Development of Technologies to Facilitate the use and Response of Vaccines,1869229,2010-08-31,2010.0,2015-08-30,2015,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347293,272201000036C-0-0-1,Development of Technologies to Facilitate the use and Response of Vaccines,3804245,2010-08-31,2010.0,2015-08-30,2015,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347289,272201000035C-4-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,14455413,2010-08-31,2010.0,2014-08-29,2014,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347288,272201000035C-0-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,9113435,2010-08-31,2010.0,2014-08-05,2014,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2347286,272201000034C-6-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,3183629,2011-06-30,2011.0,2016-06-29,2016,Takeda (United States),grid.419849.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347285,272201000034C-5-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,4654902,2011-06-30,2011.0,2014-08-05,2014,Takeda (United States),grid.419849.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347284,272201000034C-3-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,1358731,2011-06-30,2011.0,2012-12-31,2012,Takeda (United States),grid.419849.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347283,272201000034C-0-0-1,Development of Technologies to Facilitate the Use of and Response to Vaccines,1833080,2010-08-31,2010.0,2015-08-30,2015,Takeda (United States),grid.419849.9,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2346797,272200800062C-4-0-1,THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOP,25800,2008-09-01,2008.0,2013-12-31,2013,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346796,272200800062C-3-0-1,THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOP,1306067,2008-09-01,2008.0,2013-12-31,2013,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346795,272200800062C-2-0-1,THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOP,292954,2008-09-01,2008.0,2013-12-31,2013,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346794,272200800062C-1-0-1,THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOP,12110276,2008-09-01,2008.0,2013-12-31,2013,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2346772,272200800057C-6-0-7,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2014-10-31,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346771,272200800057C-6-0-6,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2014-10-31,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346770,272200800057C-6-0-5,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2014-10-31,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346769,272200800057C-6-0-4,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2014-10-31,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346768,272200800057C-6-0-3,VACCINE AND TREATMENT EVALUATION UNITS,1100000,2007-11-01,2007.0,2014-10-31,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346762,272200800057C-13-0-4,VACCINE AND TREATMENT EVALUATION UNITS,165729,2012-11-01,2012.0,2013-10-31,2013,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346761,272200800057C-13-0-3,VACCINE AND TREATMENT EVALUATION UNITS,50000,2012-11-01,2012.0,2013-10-31,2013,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346760,272200800057C-13-0-2,Vaccine and Treatment Evaluation Units,135867,2012-11-01,2012.0,2013-10-31,2013,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346759,272200800057C-13-0-1,Vaccine and Treatment Evaluation Units,300025,2012-11-01,2012.0,2013-10-31,2013,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346758,272200800057C-12-0-6,VACCINE AND TREATMENT EVALUATION UNITS,500000,2012-09-13,2012.0,2014-09-18,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346757,272200800057C-12-0-5,VACCINE AND TREATMENT EVALUATION UNITS,50000,2012-09-13,2012.0,2014-09-18,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346756,272200800057C-12-0-4,VACCINE AND TREATMENT EVALUATION UNITS,794044,2012-09-13,2012.0,2014-09-18,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346755,272200800057C-12-0-3,VACCINE AND TREATMENT EVALUATION UNITS,500000,2012-09-13,2012.0,2014-09-18,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346754,272200800057C-12-0-2,Vaccine and Treatment Evaluation Units,548024,2012-09-13,2012.0,2014-09-18,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346753,272200800057C-12-0-1,Vaccine and Treatment Evaluation Units,300000,2012-09-13,2012.0,2014-09-18,2014,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346640,272200800008C-8-0-9,VACCINE AND TREATMENT EVALUATION UNITS,600000,2007-11-01,2007.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346639,272200800008C-8-0-8,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346638,272200800008C-8-0-7,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346637,272200800008C-8-0-6,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346636,272200800008C-8-0-5,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346635,272200800008C-8-0-4,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346634,272200800008C-8-0-3,VACCINE AND TREATMENT EVALUATION UNITS,2000000,2007-11-01,2007.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346632,272200800008C-8-0-10,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346627,272200800008C-13-0-7,VACCINE AND TREATMENT EVALUATION UNITS,650000,2012-11-01,2012.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346626,272200800008C-13-0-3,VACCINE AND TREATMENT EVALUATION UNITS,1414886,2012-11-01,2012.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346625,272200800008C-13-0-2,Vaccine and Treatment Evaluation Units,1914885,2012-11-01,2012.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346624,272200800008C-13-0-1,Vaccine and Treatment Evaluation Units,300000,2012-11-01,2012.0,2013-10-31,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346623,272200800008C-12-0-7,VACCINE AND TREATMENT EVALUATION UNITS,50000,2012-09-13,2012.0,2014-09-18,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346622,272200800008C-12-0-6,VACCINE AND TREATMENT EVALUATION UNITS,500000,2012-09-13,2012.0,2014-09-18,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346621,272200800008C-12-0-5,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2012-09-13,2012.0,2014-09-18,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346620,272200800008C-12-0-4,VACCINE AND TREATMENT EVALUATION UNITS,600000,2012-09-13,2012.0,2014-09-18,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346619,272200800008C-12-0-3,VACCINE AND TREATMENT EVALUATION UNITS,1100000,2012-09-13,2012.0,2014-09-18,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346618,272200800008C-12-0-2,Vaccine and Treatment Evaluation Units,500000,2012-09-13,2012.0,2014-09-18,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346617,272200800008C-12-0-10,VACCINE AND TREATMENT EVALUATION UNITS,500000,2012-09-13,2012.0,2014-09-18,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346616,272200800008C-12-0-1,Vaccine and Treatment Evaluation Units,300000,2012-09-13,2012.0,2014-09-18,2014,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346615,272200800007C-6-0-8,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346614,272200800007C-6-0-7,VACCINE AND TREATMENT EVALUATION UNITS,1200000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346613,272200800007C-6-0-6,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346612,272200800007C-6-0-5,VACCINE AND TREATMENT EVALUATION UNITS,1500000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346611,272200800007C-6-0-4,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346610,272200800007C-6-0-3,VACCINE AND TREATMENT EVALUATION UNITS,1018554,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346606,272200800007C-12-0-8,Vaccine and Treatment Evaluation Units,500000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346605,272200800007C-12-0-7,Vaccine and Treatment Evaluation Units,600000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346603,272200800007C-12-0-5,VACCINE AND TREATMENT EVALUATION UNITS,600000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346602,272200800007C-12-0-3,VACCINE AND TREATMENT EVALUATION UNITS,1721918,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346601,272200800007C-12-0-2,Vaccine and Treatment Evaluation Units,650000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346600,272200800007C-12-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2013-10-31,2013,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346599,272200800007C-11-0-5,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2014-09-18,2014,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346598,272200800007C-11-0-3,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2014-09-18,2014,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346597,272200800007C-11-0-2,Vaccine and Treatment Evaluation Units,50000,2007-11-01,2007.0,2014-09-18,2014,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346596,272200800007C-11-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2014-09-18,2014,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346593,272200800006C-8-0-9,VACCINE AND TREATMENT EVALUATION UNITS,476679,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346592,272200800006C-8-0-8,VACCINE AND TREATMENT EVALUATION UNITS,600000,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346591,272200800006C-8-0-7,VACCINE AND TREATMENT EVALUATION UNITS,1100000,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346590,272200800006C-8-0-6,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346589,272200800006C-8-0-5,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346588,272200800006C-8-0-4,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346587,272200800006C-8-0-3,VACCINE AND TREATMENT EVALUATION UNITS,1500000,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346585,272200800006C-8-0-11,VACCINE AND TREATMENT EVALUATION UNITS,500014,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346584,272200800006C-8-0-10,VACCINE AND TREATMENT EVALUATION UNITS,250000,2007-11-01,2007.0,2013-10-31,2013,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346580,272200800006C-12-0-9,VACCINE AND TREATMENT EVALUATION UNITS,1363051,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346579,272200800006C-12-0-8,VACCINE AND TREATMENT EVALUATION UNITS,600000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346578,272200800006C-12-0-6,VACCINE AND TREATMENT EVALUATION UNITS,462625,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346577,272200800006C-12-0-4,VACCINE AND TREATMENT EVALUATION UNITS,50000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346576,272200800006C-12-0-2,Vaccine and Treatment Evaluation Units,1701238,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346575,272200800006C-12-0-1,Vaccine and Treatment Evaluation Units,300000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346574,272200800006C-11-0-9,VACCINE AND TREATMENT EVALUATION UNITS,600000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346573,272200800006C-11-0-8,VACCINE AND TREATMENT EVALUATION UNITS,500000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346572,272200800006C-11-0-6,VACCINE AND TREATMENT EVALUATION UNITS,600000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346571,272200800006C-11-0-4,VACCINE AND TREATMENT EVALUATION UNITS,500000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346570,272200800006C-11-0-3,VACCINE AND TREATMENT EVALUATION UNITS,1100000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346569,272200800006C-11-0-2,Vaccine and Treatment Evaluation Units,1002259,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346568,272200800006C-11-0-1,Vaccine and Treatment Evaluation Units,300000,2012-09-17,2012.0,2014-09-11,2014,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346566,272200800005C-9-0-8,VACCINE AND EVALUTION TREATMENT UNITS,256667,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346565,272200800005C-9-0-7,VACCINE AND EVALUTION TREATMENT UNITS,600000,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346564,272200800005C-9-0-6,VACCINE AND EVALUTION TREATMENT UNITS,500000,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346563,272200800005C-9-0-5,VACCINE AND EVALUTION TREATMENT UNITS,1100000,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346562,272200800005C-9-0-4,VACCINE AND EVALUTION TREATMENT UNITS,500000,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346561,272200800005C-9-0-3,VACCINE AND EVALUTION TREATMENT UNITS,500000,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346560,272200800005C-9-0-2,Vaccine and Treatment Evaluation Units,629614,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346559,272200800005C-9-0-10,VACCINE AND EVALUTION TREATMENT UNITS,500000,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346558,272200800005C-9-0-1,Vaccine and Treatment Evaluation Units,300000,2012-09-14,2012.0,2014-09-18,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346557,272200800005C-6-0-8,VACCINE AND EVALUTION TREATMENT UNITS,250000,2007-11-01,2007.0,2013-06-15,2013,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346556,272200800005C-6-0-7,VACCINE AND EVALUTION TREATMENT UNITS,600000,2007-11-01,2007.0,2013-06-15,2013,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346555,272200800005C-6-0-6,VACCINE AND EVALUTION TREATMENT UNITS,1000000,2007-11-01,2007.0,2013-06-15,2013,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346554,272200800005C-6-0-5,VACCINE AND EVALUTION TREATMENT UNITS,500000,2007-11-01,2007.0,2013-06-15,2013,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346553,272200800005C-6-0-4,VACCINE AND EVALUTION TREATMENT UNITS,1000000,2007-11-01,2007.0,2013-06-15,2013,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346552,272200800005C-6-0-3,VACCINE AND EVALUTION TREATMENT UNITS,1000000,2007-11-01,2007.0,2013-06-15,2013,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346545,272200800005C-10-0-8,VACCINE AND EVALUTION TREATMENT UNITS,475886,2012-09-14,2012.0,2014-10-31,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346543,272200800005C-10-0-4,VACCINE AND EVALUTION TREATMENT UNITS,1225886,2012-09-14,2012.0,2014-10-31,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346542,272200800005C-10-0-2,Vaccine and Treatment Evaluation Units,540544,2012-09-14,2012.0,2014-10-31,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346541,272200800005C-10-0-10,VACCINE AND EVALUTION TREATMENT UNITS,50000,2012-09-14,2012.0,2014-10-31,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346540,272200800005C-10-0-1,Vaccine and Treatment Evaluation Units,300000,2012-09-14,2012.0,2014-10-31,2014,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346539,272200800004C-9-0-4,VACCINE AND TREATMENT EVALUATION UNITS,500000,2012-09-17,2012.0,2014-09-18,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346538,272200800004C-9-0-3,VACCINE AND TREATMENT EVALUATION UNITS,600000,2012-09-17,2012.0,2014-09-18,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346537,272200800004C-9-0-2,Vaccine and Treatment Evaluation Units,500000,2012-09-17,2012.0,2014-09-18,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346536,272200800004C-9-0-1,Vaccine and Treatment Evaluation Units,300000,2012-09-17,2012.0,2014-09-18,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346535,272200800004C-6-0-7,VACCINE AND TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2013-06-15,2013,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346534,272200800004C-6-0-6,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2013-06-15,2013,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346533,272200800004C-6-0-5,VACCINE AND TREATMENT EVALUATION UNITS,712157,2007-11-01,2007.0,2013-06-15,2013,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346532,272200800004C-6-0-4,VACCINE AND TREATMENT EVALUATION UNITS,2000000,2007-11-01,2007.0,2013-06-15,2013,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346531,272200800004C-6-0-3,VACCINE AND TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2013-06-15,2013,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346525,272200800004C-10-0-3,VACCINE AND TREATMENT EVALUATION UNITS,50000,2012-09-17,2012.0,2014-09-18,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346524,272200800004C-10-0-2,Vaccine and Treatment Evaluation Units,744662,2012-09-17,2012.0,2014-09-18,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346523,272200800004C-10-0-1,Vaccine and Treatment Evaluation Units,300000,2012-09-17,2012.0,2014-09-18,2014,Group Health Cooperative,grid.280243.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346522,272200800003C-8-0-9,VACCINE AND EVALUATION TREATMENT UNITS,573540,2007-11-01,2007.0,2013-06-15,2013,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346521,272200800003C-8-0-8,VACCINE AND EVALUATION TREATMENT UNITS,100000,2007-11-01,2007.0,2013-06-15,2013,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346520,272200800003C-8-0-7,VACCINE AND EVALUATION TREATMENT UNITS,600000,2007-11-01,2007.0,2013-06-15,2013,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346519,272200800003C-8-0-6,VACCINE AND EVALUATION TREATMENT UNITS,500000,2007-11-01,2007.0,2013-06-15,2013,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346518,272200800003C-8-0-5,VACCINE AND EVALUATION TREATMENT UNITS,1200000,2007-11-01,2007.0,2013-06-15,2013,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346517,272200800003C-8-0-4,VACCINE AND EVALUATION TREATMENT UNITS,1000000,2007-11-01,2007.0,2013-06-15,2013,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346516,272200800003C-8-0-3,VACCINE AND EVALUATION TREATMENT UNITS,55000,2007-11-01,2007.0,2013-06-15,2013,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346514,272200800003C-8-0-10,VACCINE AND EVALUATION TREATMENT UNITS,1000000,2007-11-01,2007.0,2013-06-15,2013,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346509,272200800003C-13-0-6,VACCINE AND EVALUATION TREATMENT UNITS,577778,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346508,272200800003C-13-0-5,VACCINE AND EVALUATION TREATMENT UNITS,250000,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346507,272200800003C-13-0-4,VACCINE AND EVALUATION TREATMENT UNITS,100000,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346506,272200800003C-13-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346505,272200800003C-12-0-6,VACCINE AND EVALUATION TREATMENT UNITS,600000,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346504,272200800003C-12-0-5,VACCINE AND EVALUATION TREATMENT UNITS,600000,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346503,272200800003C-12-0-4,VACCINE AND EVALUATION TREATMENT UNITS,500000,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346502,272200800003C-12-0-3,VACCINE AND EVALUATION TREATMENT UNITS,500000,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346501,272200800003C-12-0-2,Vaccine and Treatment Evaluation Units,229626,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346500,272200800003C-12-0-1,Vaccine and Treatment Evaluation Units,300000,2007-11-01,2007.0,2014-09-13,2014,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346499,272200800002C-8-0-4,VACCINE TREATMENT EVALUATION UNITS,1000000,2007-11-01,2007.0,2012-10-31,2012,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346498,272200800002C-8-0-3,VACCINE TREATMENT EVALUATION UNITS,500000,2007-11-01,2007.0,2012-10-31,2012,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346495,272200800002C-14-0-5,Vaccine and Treatment Evaluation Units,1650000,2012-11-01,2012.0,2013-10-31,2013,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346494,272200800002C-14-0-4,Vaccine and Treatment Evaluation Units,500000,2012-11-01,2012.0,2013-10-31,2013,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346493,272200800002C-14-0-2,Vaccine and Treatment Evaluation Units,333309,2012-11-01,2012.0,2013-10-31,2013,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346492,272200800002C-14-0-1,Vaccine and Treatment Evaluation Unit,300000,2012-11-01,2012.0,2013-10-31,2013,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346491,272200800002C-13-0-6,Vaccine and Treatment Evaluation Units,500000,2007-11-01,2007.0,2014-09-18,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346490,272200800002C-13-0-5,Vaccine and Treatment Evaluation Units,50000,2007-11-01,2007.0,2014-09-18,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346489,272200800002C-13-0-4,Vaccine and Treatment Evaluation Units,600000,2007-11-01,2007.0,2014-09-18,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346488,272200800002C-13-0-3,Vaccine and Treatment Evaluation Units,668081,2007-11-01,2007.0,2014-09-18,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346487,272200800002C-13-0-2,Vaccine and Treatment Evaluation Units,500000,2007-11-01,2007.0,2014-09-18,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346486,272200800002C-13-0-1,Vaccine and Treatment Evaluation Unit,300000,2007-11-01,2007.0,2014-09-18,2014,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2344491,261201100088C-0-0-1,"SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER",1483094,2011-09-29,2011.0,2013-09-28,2013,Medigen (United States),grid.421237.1,United States,National Cancer Institute,United States,1,0,0
grant.8610139,63199,Colloquium on protecting public trust in immunization -- 2007,50000,2007-09-15,2007.0,2008-12-14,2008,Sabin Vaccine Institute,grid.452766.4,United States,Robert Wood Johnson Foundation,United States,0,0,0
grant.8579320,W81XWH-19-C-0051,"Development of a Flexible, Live Tetravalent Dengue Vaccine",451256,2018-10-01,2018.0,2019-09-30,2019,Codagenix (United States),grid.450645.6,United States,United States Department of the Army,United States,0,0,0
grant.8572899,18486_1E,Imaging Immunotherapy Development of MRI Probes for In Vivo Tracking of Cell-based Therapies,0,2012-04-01,2012.0,2013-06-30,2013,Western University,grid.39381.30,Canada,Ontario Institute for Cancer Research,Canada,0,0,0
grant.8569729,5536_1,Molecular Epidemiology and Surveillance Network For Human Papillomavirus in Manitoba Women - a Pilot Study,0,2006-07-01,2006.0,2007-06-30,2007,CancerCare Manitoba,grid.419404.c,Canada,CancerCare Manitoba,Canada,0,0,0
grant.8565507,BT/IACBGF/05/08/2018,"Development of novel recombinant BCG expressing ESAT-6 that activatesNLRP3, to increase vaccine efficacy against pulmonary andlatent TB infection",18235,2018-05-09,2018.0,2018-12-09,2018,Central India Institute of Medical Sciences,grid.413751.5,India,Department of Biotechnology,India,0,0,0
grant.8564388,BT/PR16025/NER/95/52/2015,Development and evaluation of DIVA-based vaccine utilizing an Indian isolate of classical swine fever virus.,105670,2016-08-22,2016.0,2019-08-22,2019,Indian Veterinary Research Institute,grid.417990.2,India,Department of Biotechnology,India,0,0,0
grant.8564082,BT/PR13554/ADV/90/186/2015,Sub viral particle based Infectious bursal disease vaccine: a way forward towards translation from lab to land,26242,2016-04-29,2016.0,2017-09-29,2017,Suguna Holdings (India); Indian Veterinary Research Institute,grid.505977.9; grid.417990.2,India; India,Department of Biotechnology,India,0,0,0
grant.8563871,BT/IN/Indo-UK/FADH/50/GDR/2013,Understanding the immune mechanism of host disease and development of marker vaccines and DIVA test for Peste des Petits ruminants,333837,2015-07-24,2015.0,2018-07-24,2018,Indian Veterinary Research Institute; Department of Biotechnology; Tamil Nadu Veterinary and Animal Sciences University,grid.417990.2; grid.454774.1; grid.412908.6,India; India; India,Department of Biotechnology,India,0,0,0
grant.8563305,BT/IN/Indo-UK/FADH/53/SK/2013,Development of recombinant BCG vaccine and complimentary diagnostics for TB control in cattle,785613,2014-09-22,2014.0,2017-09-22,2017,BAIF Development Research Foundation; Centre for Cellular and Molecular Biology,grid.464825.9; grid.417634.3,India; India,Department of Biotechnology,India,0,0,0
grant.8563040,BT/PR7593/ADV/90/144/2013,Development of recombinant antigen based diagnostics and chimeric plant virus-like particle based vaccine for infectious bursal disease virus,81055,2014-06-24,2014.0,2017-06-24,2017,Tamil Nadu Veterinary and Animal Sciences University; Tamil Nadu Veterinary and Animal Sciences University; Sri Venkateswara University,grid.412908.6; grid.412908.6; grid.412313.6,India; India; India,Department of Biotechnology,India,0,0,0
grant.8562784,BT/PR6686/NNT/28/626/2012,Development of novel nanoparticle based hepatitis B (HBV) vaccine with enhanced antigen presentation and prolonged immunity,181553,2013-04-09,2013.0,2018-04-09,2018,All India Institute of Medical Sciences,grid.413618.9,India,Department of Biotechnology,India,0,0,0
grant.8562757,BT/PR7236/MED/15/94/2013,Development of virus-like particle (VLP) of Japanese encephalitis virus as a potential vaccine candidate,59295,2013-10-28,2013.0,2016-10-28,2016,Guru Angad Dev Veterinary and Animal Sciences University,grid.411890.5,India,Department of Biotechnology,India,0,0,0
grant.8562431,BT/Bio-CARe/04/439/2011-12,Development of recombinant sheep pox vectored Peste des petits ruminants (PPR) vaccine for small ruminants,80687,2013-10-17,2013.0,2017-04-17,2017,Indian Veterinary Research Institute,grid.417990.2,India,Department of Biotechnology,India,0,0,0
grant.8562366,BT/PR7937/ADV/90/152/2013,Proof of concept studies on FMDV genetics vaccines targeted to antigen presenting cells in guinea pigs,29689,2013-10-30,2013.0,2014-10-30,2014,Indian Institute of Chemical Technology; Indian Institute of Chemical Technology,grid.417636.1; grid.417636.1,India; India,Department of Biotechnology,India,0,0,0
grant.8562365,BT/PR7198/ADV/90/139/2012,Genetic characterisation of variability in immune responses of sheep and goat for PPR and ET vaccine elicited immune response,85043,2013-09-04,2013.0,2016-09-04,2016,Central Sheep and Wool Research Institute,grid.464535.5,India,Department of Biotechnology,India,0,0,0
grant.8562156,BT/PR5158/MED/15/79/2012,Develop a receptor blocking malaria vaccine against Plasmodium falciparum based on a novel combination of three blood stage antigens (PfAARP + PfRH2 + PfF2),543790,2012-06-05,2012.0,2017-06-05,2017,International Centre for Genetic Engineering and Biotechnology,grid.425195.e,India,Department of Biotechnology,India,0,0,0
grant.8561994,BT/IN/Denmark/13/SS/2013,"""Establishing immunological correlates of protection against malaria vaccine candidate using functional bio-assays and Proteomic deciphering of Host-Parasite Interactions""",855517,2013-03-19,2013.0,2017-03-19,2017,Indian Institute of Integrative Medicine; Indian Institute of Science Bangalore; International Centre for Genetic Engineering and Biotechnology; National Institute of Malaria Research; National Institute of Malaria Research,grid.418225.8; grid.34980.36; grid.425195.e; grid.419641.f; grid.419641.f,India; India; India; India; India,Department of Biotechnology,India,0,0,0
grant.8561785,BT/PR4410/AAQ/3/579/2011,"Development of nanodelivery system of DNA based RNAi vaccine against WSSV in tiger shrimp, Peneaus monodon",108416,2012-08-13,2012.0,2015-11-13,2015,Central Institute of Fisheries Education,grid.444582.b,India,Department of Biotechnology,India,0,0,0
grant.8561598,BT/PR2573/NNT/28/534/2011,DEVELOPMENT OF SMALL PEPTIDE BASED NANOSTRUCTURES AS VEHICLES FOR TUMOR SPECIFIC DRUG AND THERAPEUTIC VACCINE DELIVERY,347282,2011-09-27,2011.0,2014-09-27,2014,National Centre for Cell Science; International Centre for Genetic Engineering and Biotechnology,grid.419235.8; grid.425195.e,India; India,Department of Biotechnology,India,0,0,0
grant.8561575,BT/PR5207/MED/15/81/2012,Development of Contraceptive Vaccine and Novel Delivery Strategies for Wildlife with Special Reference to Street Dog Population Management,190183,2012-03-28,2012.0,2015-09-28,2015,National Institute of Immunology; National Institute of Immunology,grid.19100.39; grid.19100.39,India; India,Department of Biotechnology,India,0,0,0
grant.8561572,BT/PR5062/MED/15/78/2012,Development and pre-clinical studies on safety and immunogenicity of novel candidate vaccines against Salmonella enterica serovar Typhi and Paratyphi,102142,2012-03-22,2012.0,2015-11-22,2015,National Institute of Cholera and Enteric Diseases,grid.419566.9,India,Department of Biotechnology,India,0,0,0
grant.8561569,BT/PR5037/MED/15/77/2012,Chemoenzymatic assembly of defined protein dendrimers for vaccine use: Immunogenicity and protective efficacy of multivalent PspA constructs from Streptococcus pneumoniae,133431,2012-03-28,2012.0,2015-03-28,2015,National Institute of Immunology; National Institute of Immunology,grid.19100.39; grid.19100.39,India; India,Department of Biotechnology,India,0,0,0
grant.8561568,BT/PR5267/MED/15/87/2012,Characterization of Plasmodium falciparum merozoite surface complex for the development of a multicomponent subunit vaccine,218645,2012-03-23,2012.0,2016-03-23,2016,International Centre for Genetic Engineering and Biotechnology,grid.425195.e,India,Department of Biotechnology,India,0,0,0
grant.8561567,BT/PR2000/MED/15/73/2011,"""Mapping of the Resource Requirements for Basic Science and Biomedical Research for Development of Drugs, Diagnostics, Vaccines, Implants and Devices""",62225,2012-01-09,2012.0,2013-01-09,2013,National Institute of Immunology,grid.19100.39,India,Department of Biotechnology,India,0,0,0
grant.8561494,BT/PR2109/MED/30/628/2011,Experimental studies on therapy of cancers expressing hCG / hCGß with a recombinant highly immunogenic vaccine against hCG,84499,2012-02-16,2012.0,2014-02-16,2014,Rajiv Gandhi Centre for Biotechnology; National Institute of Immunology,grid.418917.2; grid.19100.39,India; India,Department of Biotechnology,India,0,0,0
grant.8561094,BT/PR15373/AAQ/57/116/2011,Generation of an improved Newcastle disease virus vaccine candidate using a novel reverse genetics technology,132923,2011-09-22,2011.0,2014-09-22,2014,Indian Veterinary Research Institute,grid.417990.2,India,Department of Biotechnology,India,0,0,0
grant.8560863,BT/PR12883/AGR/36/618/2009,Functional Characterization of genes in Leishmania Parasites by RNAi Technology for Drug Discovery and Vaccine Development.,122643,2010-06-09,2010.0,2014-03-09,2014,Institute of Molecular Medicine,grid.464859.2,India,Department of Biotechnology,India,0,0,0
grant.8560702,BT/PR13376/GBD/27/260/2009,"Functional characterization of the role of the Plasmodium falciparum reticulocyte homology proteins, in erythrocyte invasion and their evaluation as potential vaccine candidates",53181,2010-01-21,2010.0,2013-01-21,2013,,,,Department of Biotechnology,India,0,0,0
grant.8560674,BT/PR13257/GBD/27/241/2009,Development of Standardization and field evaluation of thermostable newcastlle disease vaccine strains for use in village chicken.,28412,2010-05-18,2010.0,2013-05-18,2013,Sri Venkateswara Veterinary University,grid.459994.c,India,Department of Biotechnology,India,0,0,0
grant.8560493,BT/PR10842/NNT/28/122/2008,Multiple antigen peptide approach (MAP) incorporating B-T constructs of F1 and V antigens of Y. pestis in nanoparticles for plague vaccine.,87972,2008-09-10,2008.0,2012-03-10,2012,All India Institute of Medical Sciences,grid.413618.9,India,Department of Biotechnology,India,0,0,0
grant.8560411,BT/PR14723/MED/15/44/2010,Vitamin D supplementation to improve immune responses to vaccines administered in early infancy- The NutriVac - D Trial,291644,2011-02-03,2011.0,2015-02-03,2015,Translational Health Science and Technology Institute,grid.464764.3,India,Department of Biotechnology,India,0,0,0
grant.8560410,BT/PR14139/MED/15/41/2010,Recovery of infectious chandipura Virus Entirely from cDNA clones and its application in vaccine development,40482,2010-07-30,2010.0,2013-07-30,2013,National Institute of Virology,grid.419672.f,India,Department of Biotechnology,India,0,0,0
grant.8560408,BT/PR12795/MED/15/38/2009,Isolation and characterization of animal adenoviruses for development of a novel viral vector for vaccine delivery,191060,2010-05-11,2010.0,2013-05-11,2013,National Institute of Immunology; Tata Institute of Fundamental Research,grid.19100.39; grid.22401.35,India; India,Department of Biotechnology,India,0,0,0
grant.8560305,BT/PR12837/MED/30/223/2009,"rBCG85C- a candidate TB vaccine: Removal of antibiotic resistance marker, modifications for stabilization of antigen expression and efficacy studies",387537,2010-03-23,2010.0,2012-09-23,2012,University of Delhi,grid.8195.5,India,Department of Biotechnology,India,0,0,0
grant.8560215,BT/PR8475/MED/14/1255/2006,Development and characterization of Autologous NKT cell based dendritic cell Vaccine for Active Specific Immunotherapy of oral squamous cell carcinoma,51163,2007-09-24,2007.0,2012-03-24,2012,All India Institute of Medical Sciences,grid.413618.9,India,Department of Biotechnology,India,0,0,0
grant.8560171,BT/PR10004/MED/15/21/2007,A Randomise control Trail of recombinant live oral Cholera Vaccine in Estern Kolkata using cGMP grade material,2095674,2007-09-25,2007.0,2012-09-25,2012,Tata Institute of Fundamental Research; Sanofi (India),grid.22401.35; grid.497468.0,India; India,Department of Biotechnology,India,0,0,0
grant.8560114,BT/MED-II/VAP/01/2008,Design and testing of a CD40 ligand adjuvanted HIV virus-like particle (VLP) as a candidate vaccine against HIV/AIDS,168072,2010-05-21,2010.0,2013-05-21,2013,International Centre for Genetic Engineering and Biotechnology,grid.425195.e,India,Department of Biotechnology,India,0,0,0
grant.8560031,BT/PR13502/MED/15/36/2010,Construction of genomic library of Leptospira interrogans serovar Autumnalis for the identification of immunogenic proteins and development DNA Vaccine,84115,2010-10-29,2010.0,2013-10-29,2013,Tata Institute of Fundamental Research,grid.22401.35,India,Department of Biotechnology,India,0,0,0
grant.8559996,BT/PR7708/Med/14/1068/2006,Development of liposome-encapsulated recombinant DNA/protein vaccine(s) for H5N1 and other Influenza viruses,206470,2007-09-18,2007.0,2010-09-18,2010,Tata Institute of Fundamental Research,grid.22401.35,India,Department of Biotechnology,India,0,0,0
grant.8559990,BT/PR12853/MED/29/141/2009,Construction and Characterization of Genetically Engineered Chimeric HIV-1 Envelope Protein Modulating Virus Neutralization: Implication and Relevance in Vaccine development.,105876,2010-03-04,2010.0,2013-03-04,2013,National AIDS Research Institute,grid.419119.5,India,Department of Biotechnology,India,0,0,0
grant.8559937,BT/IN/Finland/AP/2006,Improved immunogenecity of enterovirus antigen by use of microparticles carriers- a proof principle study for development of multivalent enterovirus vaccine.,109695,2006-07-14,2006.0,2010-07-14,2010,National Institute of Immunology,grid.19100.39,India,Department of Biotechnology,India,0,0,0
grant.8559873,BT/Indo-Aus/04/06/2009,Rational Development of an effective Vaccine for the prevention of Staphylococcal Mastitis in bovines using mouse mastitis as a model system,209795,2010-07-16,2010.0,2013-07-16,2013,Karnataka Veterinary Animal and Fisheries Sciences University; Department of Biotechnology,grid.418768.4; grid.454774.1,India; India,Department of Biotechnology,India,0,0,0
grant.8559861,BT/PR12677/ICD/55/14/2009,Development of blood-stage vaccines for Plasmodium falciparum malaria based on the EBA and PfRH proteins,137705,2009-07-06,2009.0,2012-07-06,2012,International Centre for Genetic Engineering and Biotechnology,grid.425195.e,India,Department of Biotechnology,India,0,0,0
grant.8559049,BT/PR10989/ADV/57/17/2008,Development of oral vaccine against Clostridium perfringens employing translation fusion of immunodominant epitopes of beta toxin with heat table labile enterotoxin B,162423,2010-02-22,2010.0,2014-02-22,2014,National Institute of Immunology,grid.19100.39,India,Department of Biotechnology,India,0,0,0
grant.8559046,BT/PR11847/ADV/57/25/2009,Development of a novel marker vaccine for Bovine Herpesvirus-I(BHV-1) and companion diagnostic test.,79855,2009-12-08,2009.0,2012-12-08,2012,Guru Angad Dev Veterinary and Animal Sciences University,grid.411890.5,India,Department of Biotechnology,India,0,0,0
grant.8559045,BT/PR7943/AAQ/01/302/2006,Designing heat stable lasota vaccine using vacuum foam drying for efficient treatment of new castle disease.,69033,2007-10-24,2007.0,2010-10-24,2010,Bharati Vidyapeeth Deemed University,grid.411681.b,India,Department of Biotechnology,India,0,0,0
grant.8515281,1S24517N,Maximalisatie van het anti-tumoraal potentieel van next-generation dendritische celvaccins door combinatie van interleukine-15 en in situ neutralisatie van geprogrammeerde celdoodliganden,0,2017-01-01,2017.0,2018-12-31,2018,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8505548,1522112N,"Onderzoek naar het werkingsmechanisme van een nieuw vaccin tegen het respiratoir syncytieel virus op basis van het ectodomein van het ""small hydrophobic protein"".",0,2012-01-01,2012.0,2012-12-31,2012,Ghent University,grid.5342.0,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8497451,G026600N,Optimalisering van tuberculose DNA vaccins koderend voor een trehalosemycolyl-transferase (Ag85A) en voor een fosfaat transport receptor (PstS-3) van Mycobacterium tuberculosis.,0,2000-01-01,2000.0,2003-12-31,2003,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8497448,1514404N,Analyse van de immunogeniciteit en het protektief vermogen van DNA vaccins tegen M. ulcerans infectie (Buruli Ulcer) in muizen en cavia's.,0,2004-01-01,2004.0,2006-12-31,2006,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8492684,1S00616N,Towards a “negative” cellular vaccine for the treatment of multiple sclerosis: counter-acting epitope spreading for long-lasting tolerance induction using mRNA-electroporated tolerogenic dendritic cells.,0,2016-01-01,2016.0,2017-12-31,2017,,,,Research Foundation - Flanders,Belgium,0,0,0
grant.8485877,12B0111N,Verbetering van de T cel stimulatoire capaciteit van immature dendritische cellen met als doel de ontwikkeling van een potent anti-tumor vaccin: de TriMix methodologie.,0,2010-10-01,2010.0,2014-03-24,2014,Vrije Universiteit Brussel,grid.8767.e,Belgium,Research Foundation - Flanders,Belgium,0,0,0
grant.8456354,,Respiratory mucosal immunization with a novel simian adenovirus-based vaccine against tuberculosis: Overcoming pre-existing anti-human adenovirus type 5 immunity,15845,2014-09-01,2014.0,2015-08-31,2015,McMaster University,grid.25073.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8450872,W81XWH-16-C-0107,Layer-by-Layer Multiple Antigen Nano-delivery Platform for Malaria Vaccine,149998,2015-10-01,2015.0,2016-09-30,2016,Luna Innovations (United States),grid.281080.3,United States,United States Department of the Army,United States,0,0,0
grant.8385722,OPP1209661,To fund participants from LMIC's to attend a three-day workshop that will explore the critical issues at each stage of vaccine development,35000,2019-02-01,2019.0,2019-10-01,2019,Massachusetts Institute of Technology,grid.116068.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.8218824,39870663,新型基因工程疫苗对结核病预防作用的实验研究,12074,1999-01-01,1999.0,2001-12-31,2001,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,0,0,0
grant.8211545,39200048,痘苗病毒瘤苗免疫有效抗原成分的抗肿瘤免疫效应研究,5282,1993-01-01,1993.0,1996-12-31,1996,Dalian Medical University,grid.411971.b,China,National Natural Science Foundation of China,China,0,0,0
grant.8186853,31500746,减毒沙门氏菌传递的基于微基因与AIDA-1自转运蛋白的新型肿瘤疫苗,35966,2016-01-01,2016.0,2018-12-31,2018,Soochow University,grid.263761.7,China,National Natural Science Foundation of China,China,3,0,0
grant.8183858,31461163007,鱼类虹彩病毒新型疫苗研发和机制探讨,229517,2015-01-01,2015.0,2017-12-31,2017,South China Sea Institute Of Oceanology,grid.458498.c,China,National Natural Science Foundation of China,China,16,0,0
grant.8181157,31400790,进一步研究抗流感病毒TH DDV免疫策略的广谱性和保护机制,38248,2015-01-01,2015.0,2017-12-31,2017,,,,National Natural Science Foundation of China,China,2,0,0
grant.8173944,30711120567,利用干扰素敏感疫苗病毒重组系统对A型流感病毒H5N1 NS1蛋白在逃避天然和获得性免疫中作用机制的研究,65685,2008-01-01,2008.0,2010-12-31,2010,Institute of Microbiology,grid.458488.d,China,National Natural Science Foundation of China,China,0,0,0
grant.8173186,30571371,传染性法氏囊病多表位疫苗分子设计及其免疫效应的研究,32055,2006-01-01,2006.0,2008-12-31,2008,Nanjing General Hospital of Nanjing Military Command,grid.440259.e,China,National Natural Science Foundation of China,China,3,0,0
grant.8170800,30271226,以纳米粒子为佐剂的屋尘螨疫苗免疫治疗的实验研究,21815,2003-01-01,2003.0,2005-12-31,2005,Shenzhen University,grid.263488.3,China,National Natural Science Foundation of China,China,4,0,0
grant.8170752,30271167,核酸疫苗pcDNA3-γanxB1诱导猪囊尾蚴细胞凋亡的机理,21815,2003-01-01,2003.0,2005-12-31,2005,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,5,0,0
grant.8170018,30270066,流感病毒血凝素和神经氨酸酶基因抗流感关键序列解析,21815,2003-01-01,2003.0,2005-12-31,2005,Hunan Normal University,grid.411427.5,China,National Natural Science Foundation of China,China,0,0,0
grant.8169351,30200258,重组核小体通用性Th细胞表位诱导SLE口服耐受的研究,24240,2003-01-01,2003.0,2005-12-31,2005,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,0,0,0
grant.8167514,30070783,应用新型肿瘤活疫苗治疗大鼠诱发性卵巢癌实验研究,21744,2001-01-01,2001.0,2003-12-31,2003,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,1,0,0
grant.8107157,26242,Vaccination against Rhodococcus equi pneumonia of foals.,0,2004-02-01,2004.0,2005-09-30,2005,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8106662,27240,Ear Tip Necrosis in Swine,0,2009-12-01,2009.0,2011-06-30,2011,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8106079,UofG2014-2110,Enhacning immunity to avian influenza viruses,0,2015-11-02,2015.0,2018-11-01,2018,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8081142,BCT0359 /8,Kooperation mit Brasilien - Entwicklung einer T.Cruzi-Vaccine und deren Prüfung auf Wirksamkeit in Tiermodellen unter besonderer Berücksichtigung sicherheitspharmakologischer Bestimmungen,231609,1982-07-01,1982.0,1985-03-31,1985,Sanofi (Germany),grid.420214.1,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8070298,2815HS011,Entwicklung neuer und Verbesserung bestehender Diagnostik-Methoden zum Nachweis des Koi-Herpesvirus (KHV) sowie Entwicklung und Etablierung eines wirksamen Impfstoffes,371817,2015-10-01,2015.0,2019-09-30,2019,,,,Federal Ministry of Food and Agriculture,Germany,1,0,0
grant.8070297,2815HS010,Entwicklung neuer und Verbesserung bestehender Diagnostik-Methoden zum Nachweis des Koi-Herpesvirus (KHV) sowie Entwicklung und Etablierung eines wirksamen Impfstoffes,451992,2015-10-01,2015.0,2019-09-30,2019,University of Erlangen-Nuremberg,grid.5330.5,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8070293,2815HS005,Entwicklung neuer und Verbesserung bestehender Diagnostik-Methoden zum Nachweis des Koi-Herpesvirus (KHV) sowie Entwicklung und Etablierung eines wirksamen Impfstoffes,336879,2015-10-01,2015.0,2019-09-30,2019,University of Veterinary Medicine Hanover,grid.412970.9,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8069684,2814ERA01D,Untersuchungen zum mukosalen Immunsystem beim Huhn und seine Reaktion auf Koinfektionen als Basis zur Entwicklung neuer Impfstoffstrategien,258716,2015-09-01,2015.0,2018-12-31,2018,Ludwig Maximilian University of Munich,grid.5252.0,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8068998,2813200806,Verbundprojekt: Neuartiger Ansatz zur Entwicklung eines heterosubtypischen Marker-Impfstoffs gegen die aviäre Influenza in Geflügel - Teilprojekt 1 (Anschlussprojekt),886943,2008-11-10,2008.0,2010-11-09,2010,,,,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8068993,2813200306,Entwicklung eines diagnostischen Systems zur Entdeckung von West-Nile-Virus(WNV)- Infektionen und Entwicklung eines gentechnischen Impfstoffes gegen diese Infektion,1806623,2007-01-01,2007.0,2009-12-31,2009,Fraunhofer Institute for Cell Therapy and Immunology,grid.418008.5,Germany,Federal Ministry of Food and Agriculture,Germany,0,0,0
grant.8054102,16IN0172,"Verbundprojekt: Integriertes, patientennahes Verfahren zur Herstellung einer therapeutischen zellulären Vakzine im geschlossenen System, Teilvorhaben: Gewinnung Kultivierung und Charaktisierung von DC",364829,2003-07-01,2003.0,2006-06-30,2006,,,,Federal Ministry for Economic Affairs and Energy,Germany,0,0,0
grant.8041593,13N11318,Verbundprojekt: Nadelfreie Injektion von flüssigen oder pulverförmigen biomolekularen Arzneimitteln (Bio-Injekt) - Teilvorhaben: Pharmazeutische Technologie und Charakterisierung pulverförmiger Vakzine,570102,2010-12-01,2010.0,2014-08-31,2014,Ludwig Maximilian University of Munich,grid.5252.0,Germany,Federal Ministry of Education and Research,Germany,3,0,0
grant.8036881,13GW0127B,"CI3: Realisierung von Software, Planungs- und Steuerungsmodulen für die beschleunigte automatisierte Herstellung individualisierter MUTANOM-Vakzine (IVAC IT) - Teilvorhaben: Software und Steuerungsmodule für die GMP Produktion",155119,2015-08-01,2015.0,2017-03-31,2017,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.8036722,13GW0076A,CI3: Entwicklung individualisierter MUTANOM-Vakzine - From Proof of Concept to Proof of Market (IVAC MUTANOM 2.0) - Teilvorhaben: Individualisierte Immundiagnostik und Leitstruktur,2210362,2014-12-01,2014.0,2017-03-31,2017,BioNTech (Germany),grid.434484.b,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8034479,131A016A,"CI3: Herstellung und präklinische Validierung eines auf chimären virus-like particles (VLPs) basierenden Impfstoffes zur Tumorvakzinierung, Projektteil Tulip",1774396,2012-10-01,2012.0,2017-03-31,2017,,,,Federal Ministry of Education and Research,Germany,1,0,0
grant.8023963,03ZIK011,"Analyse der Lokalisation, Orientierung und Interaktion von Proteinen durch Mikroskopie, Toponomics und Bioinformatics zur Identifikation von Wirts-Pathogen-Interaktionen, Resistenztransportern in Trophoblasten und Vakzinkandidaten",4990726,2005-06-01,2005.0,2010-05-31,2010,University of Greifswald,grid.5603.0,Germany,Federal Ministry of Education and Research,Germany,11,0,0
grant.8019041,03VP01200,"Entwicklung eines Biomolekül-Kopierers zur Erzeugung neuartiger Next Generation Mikroarrays - erste Anwendungen für 10.000 Wirkstoffe, Enzyme und Impfstoffe - BioKopierer",1924083,2016-08-01,2016.0,2019-07-31,2019,University of Freiburg,grid.5963.9,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8003914,03F0056F/7,Deutsch-israelische Zusammenarbeit auf dem Gebiet der Aquakultur - Teilprojekt ISR-Aq3: Orale Vakzinierung von Nutzfischen: Verbesserung verschiedener Vakzinen und neue Anwendungsmethoden,150244,1992-03-01,1992.0,1996-09-15,1996,Federal Institute for Risk Assessment,grid.417830.9,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.8001077,03EFU2BW12,EXIST-Forschungstransfer: Entwicklung eines Subunit-Impfstoffes (Totimpfstoff) gegen Malaria basierend auf neu identifizierten Parasitenantigenen aus den Leberstadien der Erreger,198548,2011-06-15,2011.0,2012-12-14,2012,,,,Federal Ministry for Economic Affairs and Energy,Germany,0,0,0
grant.7999276,03 8064 /5,Entwicklung einer Chicken Factor freien Hühnerherde für wissenschaftlich experimentelle und diagnostische Zwecke sowie zur Impfstoffherstellung,170442,1978-01-01,1978.0,1979-12-31,1979,University of Giessen,grid.8664.c,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7993550,031A505B,ERA Net EuroTransBio-8: Plurivax: Ausbau und Weiterentwicklung der Enten-Hepatitis VLP(virus like particle) Plattformtechnologie zur Herstellung von Vakzinen für den Veterinärbereich.,389872,2014-06-01,2014.0,2017-11-30,2017,Artes Biotechnology (Germany),grid.432181.d,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992772,031A087,KMU-innovativ-9: Entwicklung eines EliSpot-Testsystems zur Impfüberwachung von HPV und Ableitung neuer Impfstoff- und Therapieansätze' ('HPV-EliSpot'),552029,2012-07-01,2012.0,2016-03-31,2016,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992112,0318994A/3,"Verbundprojekt: Gentechnologische Bearbeitung des menschenpathogenen Hanta-Virus mit dem Ziel, einen Impfstoff zu entwickeln - Teilvorhaben 2",192626,1988-01-01,1988.0,1989-08-31,1989,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7992091,0318973A/6,"Verbundprojekt: Gentechnologische Bearbeitung des menschenpathogenen Hanta-Virus mit dem Ziel, einen Impfstoff zu entwickeln - Teilvorhaben 1",731315,1987-08-01,1987.0,1989-12-31,1989,Heidelberg University,grid.7700.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7991654,0317423A/2,Entwicklung eines Produktionsverfahrens für S- und S/L-Partikel für die Herstellung eines verbesserten Impfstoffs und Empfindlicher Diagnostikverfahren für Hepatitis B,342510,1991-08-01,1991.0,1993-07-31,1993,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7990743,0315905D,"ERA-NET PathoGenoMics 3: Diversität von Helicobacter pylori: Rolle in Pathogenese, Antibiotikaresistenz und der Umgehung natürlicher und impfstoffinduzierter Immunreaktionen (HELDIVPAT), Teilprojekt Magdeburg",281403,2011-03-01,2011.0,2014-10-31,2014,Otto-von-Guericke University Magdeburg,grid.5807.a,Germany,Federal Ministry of Education and Research,Germany,10,0,0
grant.7990742,0315905C,"ERA-NET PathoGenoMics 3: Diversität von Helicobacter pylori: Rolle in Pathogenese, Antibiotikaresistenz und der Umgehung natürlicher und impfstoffinduzierter Immunreaktionen (HELDIVPAT), Teilprojekt München",326450,2011-03-01,2011.0,2014-02-28,2014,Ludwig Maximilian University of Munich,grid.5252.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7990741,0315905B,"ERA-NET PathoGenoMics 3: Diversität von Helicobacter pylori: Rolle in Pathogenese, Antibiotikaresistenz und der Umgehung natürlicher und impfstoffinduzierter Immunreaktionen (HELDIVPAT), Teilprojekt Hannover, Josenhans",280075,2011-03-01,2011.0,2014-10-31,2014,Hannover Medical School,grid.10423.34,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7990740,0315905A,"ERA-NET PathoGenoMics 3: Diversität von Helicobacter pylori: Rolle in Pathogenese, Antibiotikaresistenz und der Umgehung natürlicher und impfstoffinduzierter Immunreaktionen (HELDIVPAT), Teilprojekt Hannover, Suerbaum",310364,2011-03-01,2011.0,2014-10-31,2014,Hannover Medical School,grid.10423.34,Germany,Federal Ministry of Education and Research,Germany,2,0,0
grant.7990244,0315562,GO-Bio 3: DENOVO - Entwicklung einer Plattformtechnologie für das Targeting genetischer Vakzine auf der Basis eines natürlichen Opsonins,2218550,2010-04-01,2010.0,2015-02-28,2015,,,,Federal Ministry of Education and Research,Germany,5,0,0
grant.7989781,0315336C,"Aufreinigungstechnologie-Verbundprojekt: Einsatz synthetischer Liganden zur Aufreinigung sialinsäurehaltiger, rekombinanter humaner Proteine und Impfstoff-Antigene, TP 3",169987,2008-10-01,2008.0,2012-03-31,2012,IDT Biologika (Germany),grid.498615.7,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989780,0315336B,"Aufreinigungstechnologie-Verbundprojekt: Einsatz synthetischer Liganden zur Aufreinigung sialinsäurehaltiger, rekombinanter humaner Proteine und Impfstoff-Antigene, TP 2",364405,2008-10-01,2008.0,2012-03-31,2012,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7989779,0315336A,"Aufreinigungstechnologie-Verbundprojekt: Einsatz synthetischer Liganden zur Aufreinigung sialinsäurehaltiger, rekombinanter humaner Proteine und Impfstoff-Antigene, TP 1",941022,2008-10-01,2008.0,2012-03-31,2012,Otto-von-Guericke University Magdeburg,grid.5807.a,Germany,Federal Ministry of Education and Research,Germany,2,0,0
grant.7988709,0313607,"BioProfile Stuttgart/Neckar-Alb: Identifizierung, Selektion und Validierung von Tumor-assoziierten Peptiden von Magenkarzinomen zur Definition eines therapeutischen Impfstoffs auf Basis immunogener Peptid-Epitope",526467,2005-08-01,2005.0,2007-01-31,2007,Immatics Biotechnologies (Germany),grid.434836.e,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7988460,0313167,"BioChancePLUS: DNAShield, ein leicht adaptierbarer Vakzin-Prototyp mit schnellem Wirkeintritt auf der Grundlage von Antigen-exprimierenden (MIDGE-TH1P) und Antigen-gekoppelten (DNABarrier) DNA-Konstrukten",330858,2004-04-01,2004.0,2006-09-30,2006,Mologen (Germany),grid.476508.8,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7987175,0311438 /7,Verbundprojekt: Entwicklung von Methoden zur Herstellung und Anwendung einer Vakzine zur Behandlung von Humanpapillomvirus-assoziiertem Zervixkarzinom,918448,1997-05-01,1997.0,1999-10-31,1999,Medigene (Germany),grid.487265.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7987167,0311427 /8,Entwicklung von Alternativmethoden zur Prüfung von Clostridiumimpfstoffen - Teilprojekt 2: Ablösung von Tierversuchen bei der Chargenprüfung (DAB 10),248687,1997-07-01,1997.0,2000-09-30,2000,,,,Federal Ministry of Education and Research,Germany,1,0,0
grant.7986679,0310762 /1,Verbundprojekt: Ersatz des Neurovirulenztests an Säugetieren zur Sicherheitsprüfung von Polioimpfviruschargen. Teilprojekt 2: Etablierung nichtradioaktiver Detektionsmethoden.,166655,1995-04-01,1995.0,1999-06-30,1999,Novartis (Germany),grid.467675.1,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7986571,0310623 /2,Ersatz von Tierversuchen bei der Wirksamkeitsprüfung von Clostridien-Immunpräparaten - Teilprojekt 3: Ersatzmethoden zur Prüfung von Rauschbrand-Impfstoffen,471743,1993-12-01,1993.0,1997-06-30,1997,University of Göttingen,grid.7450.6,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7986568,0310616A/7,Entwicklung von in vitro-Methoden als Ersatz für Letalchallengeversuche an Fischen zur Beurteilung von Vakzinen - Teilprojekt 2: Epitopspezifischer Enzymimmunoassay,396818,1993-07-01,1993.0,1996-12-31,1996,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7986566,0310614A/5,Entwicklung von in vitro-Methoden als Ersatz für Letalchallengeversuche an Fischen zur Beurteilung von Vakzinen - Teilprojekt 1: Lymphozytenproliferationstest,425601,1993-07-01,1993.0,1996-09-30,1996,Federal Institute for Risk Assessment,grid.417830.9,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7963522,01QE1657B,"Verbundprojekt: Entwicklung einer neuartigen Behandlungsstrategie von Allergien: zielgerichtete Glycan-Allergen Immuntherapie, Teilprojekt: Impfstoff-Charakterisierung und bioanalytische Methodenentwicklung",4476,2016-11-01,2016.0,2017-02-10,2017,,,,Federal Ministry of Education and Research,Germany,0,0,0
grant.7963422,01QE1547B,"Verbundprojekt: Entwicklung eines kosteneffizienten Impfstoffs gegen Zervixkarzinome - ein prophylaktischer Ansatz, Teilprojekt: Entwicklung von gereinigten Antigenen und Evaluierung der Immunogenität",169357,2015-12-01,2015.0,2018-11-30,2018,German Cancer Research Center,grid.7497.d,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7953453,01KX9613/6,"Lebend-Impfstoffe für Schleimhautimmunität: Vergleichsstudien mit Shigella, Salmonella und Streptokokken als Trägerstämme für rekombinante Antigene aus Krankheitserregern.",242139,1996-11-01,1996.0,1997-02-28,1997,Helmholtz Centre for Infection Research,grid.7490.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7953163,01KV9912/5,Entwicklung und Erprobung eines konditionalen Immortalisationssystems primärer humaner Tumorzellen zur Konstruktion gentechnisch modifizierter Tumorzellvakzine,225358,1999-09-01,1999.0,2002-08-31,2002,Max Delbrück Center for Molecular Medicine,grid.419491.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7953114,01KV9543/8,Entwicklung eines konditionalen Immortalisationssystems primärer humaner Tumorzellen zur Konstruktion gentechnisch modifizierter autologer Tumorzellvakzine,223823,1996-06-01,1996.0,1999-08-31,1999,Max Delbrück Center for Molecular Medicine,grid.419491.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7953112,01KV9541/2,Verbund: Immuntherapie mit genetisch veränderten Zellen: Einführung von kostimulatorischen Molekülen in frisch isolierte autologe Tumorzellvakzine mittels rekombinanter bifunktioneller Konjugate und Gentransfer,411901,1996-05-01,1996.0,1999-07-31,1999,German Cancer Research Center,grid.7497.d,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7952527,01KI9607/5,Komplikationen der Organtransplantationen durch Herpesviren: Cytomegalovirus Latenz in der Lunge und Entwicklung einer Vakzine mit rekombinanten inkompletten Viruspartikeln,374966,1997-03-01,1997.0,2000-04-30,2000,University Medical Center of the Johannes Gutenberg University Mainz,grid.410607.4,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7952494,01KI9481/0,"AIDS-Verbund Göttingen: Austestung Chimaerer, nicht infektiöser Hiv-1 Virus-ähnlicher Partikel als Vakzinekandidat im S-Hiv Makakenmodell",395762,1995-01-01,1995.0,1998-02-28,1998,University of Regensburg,grid.7727.5,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7952387,01KI8832/3,Pseudomembranoese Colitis durch Clostridium Difficile Toxine: Isolierung und Charakterisierung von Liganden- und Wirtsstruktur zur Entwicklung einer Vakzine,287568,1989-06-01,1989.0,1993-01-31,1993,University Medical Center of the Johannes Gutenberg University Mainz,grid.410607.4,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7952277,01KI1306,Verbundprojekt HIVERA VIHDUAVAX: Entwicklung eines neuen HIV-1 Impfstoffs mit bivalenten Eigenschaften durch Kombination von zwei gp41 Epitopen: Neutralisation von HIV-1 und CD4 Zell-Depletion,169854,2014-02-01,2014.0,2016-01-31,2016,Georg Speyer Haus,grid.418483.2,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7951285,01KA1202,EDCTP HIV-Vakzine:TaMoVac II - Evaluierung der Sicherheit und der Immunantwort nach HIV-Impfung mit einem DNA-Prime/MVA/gp140-Boost-Ansatz in Mbeya Tansania,946302,2012-06-01,2012.0,2017-02-28,2017,Ludwig Maximilian University of Munich,grid.5252.0,Germany,Federal Ministry of Education and Research,Germany,1,0,0
grant.7939768,01GE9629/5,Verbundprojekt: Entwicklung und klinische Anwendung von genetisch hergestellten Vakzinen basierend auf dem Tumorartigen Muzin zur Behandlung von Patienten mit Pankreas- oder Mammakarzinomen,701792,1997-04-01,1997.0,2001-12-31,2001,Max Delbrück Center for Molecular Medicine,grid.419491.0,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7934122,01DK17039,"Verbundprojekt: Kirgisisch-Deutsche Hepatitis B Initiative - Bildung einer nachhaltigen binationalen Infrastruktur für epidemiologische und impfungsbezogene Forschung, Teilvorhaben: Twincore",173865,2017-09-01,2017.0,2019-08-31,2019,Center for Experimental and Clinical Infection Research,grid.452370.7,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7878743,1120353,"Otitis media, hearing loss and school readiness of Indigenous children followed from birth in two randomised controlled trials of novel pneumococcal conjugate vaccine schedules (VOICES. Vaccines to prevent Otitis media In Children Entering School)",1009125,2017-01-01,2017.0,2018-01-01,2018,Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research,grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7878387,1112870,Low-Cost Portable Inhalation Therapy Platform for Needle-Free DNA-Based Influenza Vaccination,389948,2016-01-01,2016.0,2017-01-01,2017,RMIT University; RMIT University; RMIT University; RMIT University,grid.1017.7; grid.1017.7; grid.1017.7; grid.1017.7,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7878132,1060436,Hepatitis C vaccine,361225,2014-01-01,2014.0,2017-12-31,2017,University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7877873,1122897,The role of capsid protein nucleolar localisation in chikungunya virus: implications for vaccine development,393705,2017-01-01,2017.0,2019-01-01,2019,Griffith University,grid.1022.1,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7877641,1125164,Sytemic and mucosal functional antibodies in protection against HIV,423186,2017-01-01,2017.0,2019-01-01,2019,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7876543,1087200,"Comparing pneumococcal vaccines in a high risk population: a randomised controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea",759019,2015-01-01,2015.0,2018-12-31,2018,University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia,grid.1012.2; grid.1012.2; grid.1012.2; grid.1012.2; grid.1012.2,Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7875422,1055999,Development of a safe live genetically attenuated blood stage malaria vaccine,667743,2013-01-01,2013.0,2018-12-31,2018,Walter and Eliza Hall Institute of Medical Research; Walter and Eliza Hall Institute of Medical Research; Walter and Eliza Hall Institute of Medical Research; Walter and Eliza Hall Institute of Medical Research,grid.1042.7; grid.1042.7; grid.1042.7; grid.1042.7,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7874578,1102597,Multistage vaccines for the prevention of tuberculosis,664963,2016-01-01,2016.0,2019-01-01,2019,University of Sydney; University of Sydney; University of Sydney; University of Sydney,grid.1013.3; grid.1013.3; grid.1013.3; grid.1013.3,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7874365,1129234,Artificial synthesis of the type III secretion system translocon. A new approach to vaccine design,505814,2017-01-01,2017.0,2019-01-01,2019,UNSW Sydney; UNSW Sydney; UNSW Sydney; UNSW Sydney,grid.1005.4; grid.1005.4; grid.1005.4; grid.1005.4,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7874342,1128968,Monitoring the gap between evidence and vaccination behaviour by sampling the location-specific consumption of health information from news and social media,360521,2017-01-01,2017.0,2019-01-01,2019,Macquarie University; Macquarie University; Macquarie University,grid.1004.5; grid.1004.5; grid.1004.5,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.7854022,104514,"For research on teens' knowledge of & sources for information about abstinence, contraception & STDs & for an article identifying challenges to HPV vaccine rollout, public education & acceptability",275000,2007-06-01,2007.0,2009-05-31,2009,Guttmacher Institute,grid.417837.e,United States,Ford Foundation,United States,0,0,0
grant.7851210,SERB_25e6e86969,Modulation of T effector memory (TEM) vs T Central Memory (TCM) ratio for the immunotherapy and vaccine strategy for Tuberculosis.,38426,2017-04-01,2017.0,2018-03-31,2018,,,,Science and Engineering Research Board,India,0,0,0
grant.7825840,HU0001151TS06,HPV Knowledge & HPV Vaccine Update Among US Navy Personnel 18-26 Years Old,14708,2015-04-01,2015.0,2016-10-31,2016,University of San Diego,grid.267102.0,United States,Uniformed Services University of the Health Sciences,United States,0,0,0
grant.7821010,BCTR9827,Characterization of the GRP 170 Peptide Binding Protein in Murine and Patients' Tumors and Its Use in the Development of New Breast Cancer Vaccines,200000,1998-05-01,1998.0,2001-04-30,2001,,,,Susan G. Komen Breast Cancer Foundation,United States,0,0,0
grant.7764353,W81XWH-18-C-0073,Layer by Layer Multiple Antigen Nano-delivery Platform for Malaria Vaccine,499999,2017-10-01,2017.0,2018-09-30,2018,Luna Innovations (United States),grid.281080.3,United States,United States Department of the Army,United States,0,0,0
grant.7736401,INT/TUN/P1(5),Antigen and genome characterization of viral nervous necrosis virus (VNNV) of fish for development of diagnostics and vaccine,4976,2009-04-01,2009.0,2012-04-01,2012,,,,Department of Science and Technology,India,0,0,0
grant.7697897,,Development of a Novel Anthrax-Subunit Vaccine Based on Protective Antigens of Bacillus Anthracis and the Innate Immunity Agonist FliC Flagellin of Salmonella,0,2013-09-01,2013.0,2014-08-01,2014,University of Pennsylvania; Gautam Buddha University,grid.25879.31; grid.448827.5,United States; India,Council for International Exchange of Scholars,United States,0,0,0
grant.7694260,,Evaluating the Current Immune Status of Subjects Against Lymphatic Filariasis Infection in India and Assessing the Need for a Prophylactic Vaccine,0,2014-08-01,2014.0,2015-01-01,2015,Mahatma Gandhi Institute; University of Illinois at Chicago,grid.501921.e; grid.185648.6,Mauritius; United States,Council for International Exchange of Scholars,United States,0,0,0
grant.7681939,,"A Novel Policy to Improve Vaccine Coverage of Health Care Workers in New South Wales, Australia: Process and Impact Evaluation",0,2009-01-01,2009.0,2009-07-01,2009,University of Sydney; University of Iowa,grid.1013.3; grid.214572.7,Australia; United States,Council for International Exchange of Scholars,United States,0,0,0
grant.7670327,03/IN3/B364STAR,Sequencing of commercially available MMR vaccine virus strains and attenuation of cloned virus genes by site directed mutagenesis.,13916,2004-05-01,2004.0,2004-06-30,2004,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7669734,15/IACA/3407,H2020 Catalyst Award: Profiling ‘immune signatures’ predictive of outcome in Staphylococcus aureus infection: Advancing next generation vaccine design,27895,2015-12-01,2015.0,2017-11-30,2017,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,0,0,0
grant.7667461,,"Detailed analysis of the ""helper"" and ""effector: function by CD4+ T cells in antitumor immunity: relevance to the design of therapeutic vaccines for cancer",5349,2005-07-01,2005.0,2006-06-30,2006,McMaster University,grid.25073.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7664944,,Dendritic cell targeting of antigens for enhanced immune responses: developing a universal adjuvant vector for theraputics and vaccines.,20132,2006-07-01,2006.0,2008-06-30,2008,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7660038,,The impact of publicly funded human papillomavirus (HPV) vaccination on cervical dysplasia: The Ontario Grade 8 HPV vaccine cohort study,2409,2013-04-15,2013.0,2013-07-14,2013,McGill University,grid.14709.3b,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7658043,,Can a modified vaccine reduce the rate of large local reactions to the pre-school booster with DTPa-IPV?,231386,2002-04-01,2002.0,2003-03-31,2003,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7657790,,Cancer vaccines targeting the ganglioside tumor-marker GD2,157625,2012-10-01,2012.0,2013-09-30,2013,Jewish General Hospital,grid.414980.0,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7646362,,Herpes viruses as Re-activating Vaccine Vectors: Protective Efficacy of a Varicella Zoster-HIV Vaccine in the SIV Macaque model,428361,2008-10-01,2008.0,2011-09-30,2011,Sinai Health System,grid.492573.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7643463,,Defining innovating cancer vaccine based on virus-like particles by targeting multiple antigens,92324,2009-10-01,2009.0,2010-09-30,2010,Centre Hospitalier de l’Université de Montréal,grid.410559.c,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7643219,,Development of an Implementation Guide for Long Term Care Homes Planning to Use the Ottawa Influenza Vaccine Decision Aid,15957,2008-09-01,2008.0,2009-08-31,2009,University of Ottawa,grid.28046.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7640347,,Structural characterization of the HIV-1 Env trimer as a guide for the development of a vaccine immunogen.,149074,2010-08-01,2010.0,2013-07-31,2013,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.7630516,,Novel transdermal vaccine delivery,87338,2009-10-01,2009.0,2010-09-30,2010,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7626822,,Optimizing H1N1 Vaccination Uptake among Health Care Workers,93285,2010-03-01,2010.0,2011-02-28,2011,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7617634,,Viral modulators of inflammation and vascular perturbation,651400,2006-04-01,2006.0,2011-03-31,2011,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7610021,SERB_2cfd90acd0,Vaccine adjuvant Co-delivery with food allergen via intestinal mucosa as a novel allergen- specific immunotherpy approach to food allergy,59290,2016-04-01,2016.0,2017-03-31,2017,Institute for Stem Cell Biology and Regenerative Medicine,grid.475408.a,India,Science and Engineering Research Board,India,0,0,0
grant.7609730,SERB_b3a85902db,Comrehending the role of mucosal-associated immunity during host pathogen following avibacterium paragallinarum infection in poultry (chicken and japanese quail) for development a futristic mucosal vaccine,59784,2015-04-01,2015.0,2016-03-31,2016,Guru Angad Dev Veterinary and Animal Sciences University,grid.411890.5,India,Science and Engineering Research Board,India,0,0,0
grant.7608227,SERB_b559fd8963,Investigation and characterization of protective immune responses generated against novel vaccine candidates isolated from non- albicans Candida species in murine systemic candidiasis.,66530,2016-04-01,2016.0,2017-03-31,2017,,,,Science and Engineering Research Board,India,0,0,0
grant.7550388,0125,Application of DNA vaccines to the clinic: a phase II study of idiotypic vaccination for follicle centre lymphoma. Pilot studies in myeloma and CLL,95752,2002-03-18,2002.0,2004-03-17,2004,University of Southampton,grid.5491.9,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.7550184,9854,APPLICATION OF DNA VACCINES TO THE CLINIC: A PHASE II STUDY OF IDIOTYPIC VACCINATION FOR FOLLICLE CENTRE LYMPHOMA. PRE-PROTOCOL STUDIES IN MYLEOMA AND CLL,70103,1999-06-01,1999.0,2002-05-31,2002,University of Southampton,grid.5491.9,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.7502771,2015R1D1A1A01057153,"Disialyl Neu5Acɑ2-3Galβ1-3[Neu5Acɑ2-6]GalNAc-R의 암항원, 암진단 및 암백신 당사슬화합물 개발을 위한 융합과학연구",0,2015-01-01,2015.0,2016-01-01,2016,Sungkyunkwan University,grid.264381.a,South Korea,National Research Foundation of Korea,South Korea,9,0,0
grant.7495652,2015R1A2A2A01005548,체내 암세포 유도를 통해 실시간 암특이항원의 생성이 가능한 3차원 스캐폴드 기반 All-in-One 암백신 개발,0,2015-01-01,2015.0,2016-01-01,2016,Sungkyunkwan University,grid.264381.a,South Korea,National Research Foundation of Korea,South Korea,12,0,0
grant.7486795,2012R1A2A4A01002318,신개념 delivery system과 Secretory 발현 vector를 이용한 살모넬라균증 및 병원성 대장균증 예방의 동시다가예방백신 개발,0,2012-01-01,2012.0,2013-01-01,2013,Chonbuk National University,grid.411545.0,South Korea,National Research Foundation of Korea,South Korea,8,0,0
grant.7478477,2012R1A1A2007017,여드름 치료제 개발과 관련하여 여드름 전 임상 마우스 모델 개발 및 마우스에서 P. acnes 기반 불활성화 백신 효과에 관한 연구,0,2012-01-01,2012.0,2013-01-01,2013,Kyungpook National University,grid.258803.4,South Korea,National Research Foundation of Korea,South Korea,9,0,0
grant.7476327,2014R1A2A1A11052922,원예채소기반 항원 융합백신단백질 거대분자 구조개선 및 발현시스템 구축을 통한 전립선 암 예방 및 치료 효과 극대화 기술개발,0,2014-01-01,2014.0,2015-01-01,2015,Chung-Ang University,grid.254224.7,South Korea,National Research Foundation of Korea,South Korea,7,0,0
grant.7473054,2013R1A6A3A03022769,뎅기 면역복합체의 고발현 식물체 확보 및 동물실험을 통한 4가 뎅기백신 후보물질의 방어능력 검정,0,2013-01-01,2013.0,2014-01-01,2014,Chonbuk National University,grid.411545.0,South Korea,National Research Foundation of Korea,South Korea,3,0,0
grant.7466278,220-2008-1-E00018,만성 C형 간염에 대한 HCV DNA vaccine과 sPD-1-Fc의 치료 효능 및 그 작용 기작에 관한 연구,0,2009-01-01,2009.0,2010-01-01,2010,Pohang University of Science and Technology,grid.49100.3c,South Korea,National Research Foundation of Korea,South Korea,0,0,0
grant.7453344,2009-0088860,Metabolomics profiling을 이용한 어류 면역반응 표지인자 개발 및 해산식물유래로부터  넙치 불활화 백신의 ajuvant 개발에 관한 연구,0,2009-01-01,2009.0,2010-01-01,2010,Soonchunhyang University,grid.412674.2,South Korea,National Research Foundation of Korea,South Korea,1,0,0
grant.7446466,2011-0029416,가축 수인성 질병 예방을 위한 다기능성 고분자 미립자 및 유산균체를 이용한 복합 경구백신 전달 시스템의 개발 및 평가,0,2011-01-01,2011.0,2012-01-01,2012,Seoul National University,grid.31501.36,South Korea,National Research Foundation of Korea,South Korea,9,0,0
grant.7437175,763707,A comparison study of humoral and cellular immune responses in very young infants after intradermal versus intramuscular injection of influenza vaccine,86160,2007-04-01,2007.0,2009-06-30,2009,University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong,grid.194645.b; grid.194645.b; grid.194645.b; grid.194645.b,China; China; China; China,University Grants Committee,China,2,0,0
grant.7433396,460708,Efficacy of recombinant Epstein-Barr virus (EBV) vaccine in patients with nasopharyngeal cancer who had residual EBV DNA load after conventional therapy,122599,2008-04-01,2008.0,2011-12-31,2011,Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong,grid.10784.3a; grid.10784.3a; grid.10784.3a; grid.10784.3a; grid.10784.3a; grid.10784.3a,China; China; China; China; China; China,University Grants Committee,China,0,0,0
grant.7428097,14111514,EFFECTIVENESS OF ROTAVIRUS VACCINE IN HONG KONG CHILDREN,66982,2014-04-01,2014.0,2016-03-31,2016,Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong,grid.10784.3a; grid.10784.3a; grid.10784.3a; grid.10784.3a; grid.10784.3a,China; China; China; China; China,University Grants Committee,China,0,0,0
grant.7407419,2015/19/N/NZ6/02908,Ocena aktywności przeciwnowotworowej chemioimmunoterapii z udziałem nanokoniugatów metotreksatu oraz szczepionek na bazie komórek dendrytycznych z wyciszoną ekspresją receptora IL-10,40062,2016-06-17,2016.0,2019-06-16,2019,Ludwik Hirszfeld Institute of Immunology and Experimental Therapy,grid.418769.5,Poland,National Science Center,Poland,0,0,0
grant.7389944,OPP1176780,To use mathematical modelling to evaluate the added-value of a schistosomiasis vaccine to current Mass Drug Administration approaches and identify optimal delivery systems,337459,2017-09-01,2017.0,2019-04-01,2019,University of Warwick,grid.7372.1,United Kingdom,Bill & Melinda Gates Foundation,United States,2,0,0
grant.7389680,OPP1188170,To support the 2018 Sabin Gold Medal Award which recognizes individuals who have helped to reduce needless human suffering from vaccine-preventable and neglected tropical diseases,40000,2017-11-01,2017.0,2018-06-01,2018,Sabin Vaccine Institute,grid.452766.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7389650,OPP1184831,To evaluate nasopharyngeal carriage in children with pneumonia 4 years post introduction of pneumococcal conjugate vaccine vaccination to determine herd impact on unimmunized,496438,2017-11-01,2017.0,2019-05-01,2019,Murdoch Childrens Research Institute,grid.1058.c,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7389647,OPP1184796,"To convene an international conference to discuss and share broadly the latest HIV vaccine, microbicide, and ARV-based prevention research",749999,2017-10-01,2017.0,2019-02-01,2019,Global HIV Vaccine Enterprise,grid.420432.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.7204754,81300369,新型幽门螺杆菌多肽纳米疫苗的构建及其免疫保护效应的实验研究,36318,2014-01-01,2014.0,2016-12-31,2016,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,3,0,0
grant.7183855,81270071,哮喘疫苗重组BCG与肠道黏膜细胞相互作用的信号传导,87335,2013-01-01,2013.0,2016-12-31,2016,,,,National Natural Science Foundation of China,China,0,0,0
grant.7172652,272201300019I-6-27200005-1,Vaccine and Treatment Evaluation Unit: Phase I Malaria Vaccine Study,3218382,2015-09-04,2015.0,2017-09-01,2017,Kaiser Foundation Health Plan,grid.414864.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172642,272201300018I-3-27200006-1,Vaccine and Treatment Evaluation Unit: Phase I Trial of Filovirus Vaccine,327462,2015-07-01,2015.0,2019-07-01,2019,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172177,272201300018I-2-27200009-1,Vaccine and Treatment Evaluation Unit: Assay Work for Yellow Fever Vaccines,1360130,2015-09-15,2015.0,2017-09-05,2017,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7171780,272200800005C-25-0-6,VACCINE AND EVALUTION TREATMENT UNITS:PHASE I CLINICAL TRIAL OF A HPV VACCINE CANDIDATE,3039,2007-11-01,2007.0,2017-06-30,2017,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7171779,272200800005C-25-0-5,VACCINE AND EVALUTION TREATMENT UNITS:PHASE I CLINICAL TRIAL OF A NOROVIRUS VACCINE CANDIDATE,194950,2007-11-01,2007.0,2017-06-30,2017,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7171361,272200800006C-24-0-8,VACCINE AND TREATMENT EVALUATION UNITS: Phase I Clinical Trial to Evaluate an E. Coli Vaccine,312232,2007-11-01,2007.0,2017-09-30,2017,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7169661,272201300021I-4-27200004-1,Vaccine and Treatment Evaluation Unit: Phase I Trial of a Yellow Fever Virus Vaccine,485555,2015-07-01,2015.0,2018-05-31,2018,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7169658,272201300021I-2-27200006-1,Vaccine and Treatment Evaluation Unit: Malaria Vaccine Development,767273,2015-09-15,2015.0,2018-10-14,2018,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7169636,272201300020I-4-27200004-1,Vaccine and Treatment Evaluation Unit: Phase I Trial of a Yellow Fever Virus Vaccine,311677,2015-07-01,2015.0,2018-07-16,2018,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7167652,AF/247/95,Development of Infectious Bursal Disease Virus (IBDV) Vaccines for the Poultry Industries in Hong Kong and Southern China,125479,1995-01-01,1995.0,1998-01-30,1998,University of Hong Kong,grid.194645.b,China,Innovation and Technology Commission,China,0,0,0
grant.7166385,GHX/001/07,"Development of Robust, Scaleable and Cost Effective Technologies for the Large-scale Production of Plasmid DNA for Therapy or Vaccine",257434,2008-01-15,2008.0,2010-01-14,2010,Hong Kong Institute of Biotechnology; Hong Kong Institute of Biotechnology,grid.493670.f; grid.493670.f,China; China,Innovation and Technology Commission,China,0,0,0
grant.7166056,InP/123/09,"Development of Robust, Scaleable and Cost Effective Technologies for the Large-scale Production of Plasmid DNA for Therapy or Vaccine",16249,2009-01-15,2009.0,2010-01-14,2010,Hong Kong Institute of Biotechnology,grid.493670.f,China,Innovation and Technology Commission,China,0,0,0
grant.7166054,InP/124/09,"Development of Robust, Scaleable and Cost Effective Technologies for the Large-scale Production of Plasmid DNA for Therapy or Vaccine",16249,2009-01-15,2009.0,2010-01-14,2010,Hong Kong Institute of Biotechnology,grid.493670.f,China,Innovation and Technology Commission,China,0,0,0
grant.7150051,,The use of the ex vivo placental perfusion model to study placental malaria vaccine efficacy and the biology of parasite sequestration,19861,2014-01-01,2014.0,2014-12-31,2014,University of Copenhagen,grid.5254.6,Denmark,Danish Agency for Science and Higher Education,Denmark,0,0,0
grant.7140909,W81XWH-13-2-0099,Secreted HSP Vaccine for Malaria Prophylaxis,295138,2011-10-01,2011.0,2012-09-01,2012,Naval Medical Research Center,grid.415913.b,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7140908,W81XWH-13-2-0098,Secreted HSP Vaccine for Malaria Prophylaxis,573749,2011-10-01,2011.0,2012-09-01,2012,University of Miami,grid.26790.3a,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7132079,W81XWH-09-2-0164,Malaria Vaccine Development-Rapid T Cell Antigen Discovery Using Human T Cell Screens of a P. falciparum Proteomic Library,2725993,2007-10-01,2007.0,2008-09-01,2008,Genocea (United States),grid.475330.6,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7121561,2011-01318,"Eurostarsproject, New-Vac, 5934, Isconova AB, New vaccines against intracellular pathogens in salmom",404888,2011-01-01,2011.0,2013-12-31,2013,Novavax (Sweden),grid.425310.1,Sweden,VINNOVA,Sweden,0,0,0
grant.7121461,2012-02703,Dry formulation of vaccine,75383,2012-11-15,2012.0,2013-11-30,2013,,,,VINNOVA,Sweden,0,0,0
grant.7049077,1009825,RECOMBINANT SUBUNIT VACCINE AGAINST PISCINE FRANCISELLOSIS,0,2016-06-07,2016.0,2017-06-30,2017,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.7043750,VM0126,The development of an in vitro inactivation test for Rabies vaccine using reverse transcriptase polymerase chain,199259,2000-01-01,2000.0,2001-12-31,2001,,,,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7043094,SE3135,Social science study to accompany the Badger Vaccine Deployment,65464,2014-02-01,2014.0,2015-03-31,2015,University of Gloucestershire,grid.21027.36,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,3,0,0
grant.7042337,SE0130,The development of animal models to test candidate vaccines for M. bovis infection in badgers,286567,1997-04-01,1997.0,1998-03-31,1998,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042336,SE0129,Development of vaccine candidates for protection of badgers against infection with Mycobacterium bovis,239079,1997-04-01,1997.0,1998-03-31,1998,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,1,0,0
grant.7027773,R21AI129844,Preclinical development of candidate Zika virus vaccines using mouse models,433250,2017-09-01,2017.0,2019-08-31,2019,The University of Texas System,grid.55460.32,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.7025507,17H06487,インフルエンザワクチンの接種政策変更に伴う医療経済学的効果の解明,24704,2017-08-25,2017.0,2019-03-31,2019,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.7022667,31170877,李斯特菌载体在增强丙型肝炎病毒重组多表位树突细胞疫苗中的作用,96462,2012-01-01,2012.0,2015-12-31,2015,,,,National Natural Science Foundation of China,China,3,0,0
grant.7018877,81171981,基于重组MS2噬菌体样颗粒的肿瘤RNA疫苗的研究,96462,2012-01-01,2012.0,2015-12-31,2015,,,,National Natural Science Foundation of China,China,2,0,0
grant.7009269,81102288,VP22增强铜绿假单胞菌DNA疫苗免疫效力的评价,40207,2012-01-01,2012.0,2014-12-31,2014,North Sichuan Medical University,grid.449525.b,China,National Natural Science Foundation of China,China,4,0,0
grant.7002205,31101936,石斑鱼特异性CpG ODN的筛选及其作为SGIV疫苗佐剂的研究,36990,2012-01-01,2012.0,2014-12-31,2014,South China Sea Institute Of Oceanology,grid.458498.c,China,National Natural Science Foundation of China,China,8,0,0
grant.6989342,31100655,慢性乙肝新型可复制型DNA疫苗的免疫增效策略研究,36990,2012-01-01,2012.0,2014-12-31,2014,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,2,0,0
grant.6949912,J001917F,Characterisation of the Group A Streptococcus M-like proteins and their potential as vaccine antigens,0,2017-01-01,2017.0,2018-12-31,2018,Université Libre de Bruxelles,grid.4989.c,Belgium,Fund for Scientific Research,Belgium,4,0,0
grant.6944544,971524,PRECLINICAL PoC OF MULTIVALENT VACCINE AGENTS & TECHNOLOGY PLATFORM,577937,2017-04-30,2017.0,2018-04-29,2018,,,,Innovate UK,United Kingdom,0,0,0
grant.6896091,1P05OE187,Mykorhizní technologie pro trvale udržitelnou zemědělskou produkci ovocných plodin (MYCOTAGRIF),326819,2005-01-01,2005.0,2007-12-31,2007,Institute of Botany; Symbiom (Czechia),grid.424923.a; grid.448144.9,Czechia; Czechia,Ministry of Education Youth and Sports,Czechia,0,0,0
grant.6895027,NT12372,Prevalence HPV infekcí ve vakcinované populaci žen ČR,155737,2011-06-01,2011.0,2014-12-31,2014,Institute of Haematology and Blood Transfusion,grid.419035.a,Czechia,Ministry of Health,Czechia,1,0,0
grant.6860321,OPP1166044,To develop a measles and rubella vaccine microarray patch that meets the preferred product characteristics and contributes to global measles and rubella elimination,2313835,2017-06-01,2017.0,2019-07-01,2019,Micron Biomedical (United States),grid.479335.f,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6860231,OPP1169602,To develop monoclonal antibodies to all pneumococcal serotypes and have a repository so that these can be used in future vaccine development,1662279,2017-06-01,2017.0,2019-08-01,2019,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6857517,2005068289,LA VACCINAZIONE ANTINFLUENZALE IN ETAâ   PEDIATRICA COPERTURA VACCINALE NEI BAMBINI CON MALATTIA CRONICA E IN QUELLI SANI ED EFFICACIA DEL VACCINO DURANTE IL PERIODO EPIDEMICO,64636,2005-01-01,2005.0,2007-01-01,2007,University of Bari Aldo Moro; University of Bari Aldo Moro; University of Bari Aldo Moro,grid.7644.1; grid.7644.1; grid.7644.1,Italy; Italy; Italy,"Ministry of Education, Universities and Research",Italy,0,0,0
grant.6792174,LY14H160015,新肿瘤抗原人工表位肽Survivin序列的发现及其纳米疫苗联合IFN-γ靶向脑肿瘤干细胞治疗研究,0,2014-01-01,2014.0,2017-12-31,2017,Huzhou University,grid.411440.4,China,Science and Technology Department of Zhejiang Province,China,0,0,0
grant.6785800,9444289180,"Development of customizable attenuated and vector vaccines to protect against porcine reproductive and respiratory syndrome (PRRS), essential for a successful treatment",0,2012-01-01,2012.0,2015-12-31,2015,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6784292,6850782940,BIOVACSAFE ? Biomarkers for enhanced vaccine safety,0,2012-03-01,2012.0,2017-02-28,2017,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6775789,3E130363,Selection of Mycoplasma mycoides subsp. mycoides candidate vaccine molecules through identification of monoclonal antibodies that inhibit pathogen-host cell adhesion,0,2012-10-01,2012.0,2016-10-01,2016,KU Leuven,grid.5596.f,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6736385,1046999,Pneumococcal conjugate vaccine (PCV) schedules for the Northern Territory (NT): randomised controlled trial of booster vaccines to broaden and strengthen protection from invasive and mucosal infections.,1715612,2013-01-01,2013.0,2017-12-31,2017,Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research,grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6735254,613616,A dual antigen synthetic peptide subunit vaccine approach to prevent streptococcal associated cardiovascular disease,596372,2010-01-01,2010.0,2013-12-31,2013,QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute,grid.1049.c; grid.1049.c,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6734608,1044343,Improving subunit vaccines against tuberculosis for pulmonary delivery,554242,2013-01-01,2013.0,2015-12-31,2015,University of Sydney; University of Sydney; University of Sydney; University of Sydney,grid.1013.3; grid.1013.3; grid.1013.3; grid.1013.3,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6734606,1044332,Mucosal vaccine for Hendra virus,174934,2012-01-01,2012.0,2015-12-31,2015,Burnet Institute,grid.1056.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6734536,1043519,"New candidate vaccines to prevent tuberculosis: preclinical assessment of efficacy, safety and mechanism of protection",499073,2013-01-01,2013.0,2016-12-31,2016,University of Sydney; University of Sydney,grid.1013.3; grid.1013.3,Australia; Australia,National Health and Medical Research Council,Australia,8,0,0
grant.6734309,1027819,A multi-protein vaccine targeting the oral pathogens associated with chronic periodontitis,694093,2012-01-01,2012.0,2014-12-31,2014,University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6732590,546496,RV3 rotavirus vaccine: developing a neonatal rotavirus vaccine formulation for the global community,105455,2009-01-01,2009.0,2009-12-31,2009,Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute,grid.1058.c; grid.1058.c; grid.1058.c,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6731983,1060811,A novel Hepatitis B virus genotype in Indigenous Australians: impact on vaccine efficacy and clinical outcomes,842370,2014-01-01,2014.0,2017-12-31,2017,Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research; Menzies School of Health Research,grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5; grid.271089.5,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6728300,1064408,A novel paradigm for immunity and vaccine development against group A streptococcus,380529,2014-01-01,2014.0,2016-12-31,2016,Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute,grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c,Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,4,0,0
grant.6728257,630542,Research Fellowship,633567,2010-01-01,2010.0,2014-12-31,2014,UNSW Sydney,grid.1005.4,Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6728176,637303,Research Fellowship - Grant ID:637303,769096,2010-01-01,2010.0,2014-12-31,2014,Walter and Eliza Hall Institute of Medical Research,grid.1042.7,Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6727551,613668,Apical membrane proteins as targets for a schistosomiasis vaccine,477988,2010-01-01,2010.0,2012-12-31,2012,James Cook University; James Cook University,grid.1011.1; grid.1011.1,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6721784,1078987,A new approach to the design and evaluation of T cell vaccines for cancer and infectious disease.,287893,2015-01-01,2015.0,2017-12-31,2017,University of Queensland; University of Queensland; University of Queensland; University of Queensland,grid.1003.2; grid.1003.2; grid.1003.2; grid.1003.2,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,6,0,0
grant.6716522,543325,Novel vaccine formulation for immunotherapy of adenocarcinomas,139279,2009-01-01,2009.0,2009-12-31,2009,Burnet Institute,grid.1056.2,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6716069,496600,Immunity and pathogenesis in Tropical and Infectious Diseases: Implications for Vaccines and,14651668,2008-01-01,2008.0,2013-12-31,2013,QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute,grid.1049.c; grid.1049.c; grid.1049.c; grid.1049.c; grid.1049.c; grid.1049.c; grid.1049.c; grid.1049.c; grid.1049.c,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,72,0,0
grant.6714938,552423,Application of Protein Microarrays to Develop a Cross-Species Malaria Vaccine,425320,2009-01-01,2009.0,2012-12-31,2012,QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute,grid.1049.c; grid.1049.c,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6714625,509299,Heterosubtypic T cell-inducing vaccines for influenza in humans,297529,2008-01-01,2008.0,2010-12-31,2010,University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6713836,543143,Multiple vector vaccine for hepatitis C virus.,467887,2009-01-01,2009.0,2012-12-31,2012,University of Adelaide; University of Adelaide,grid.1010.0; grid.1010.0,Australia; Australia,National Health and Medical Research Council,Australia,9,0,0
grant.6713438,628980,H1N1 Ability of H1N1-09 and seasonal influenza vaccines to reduce symptoms and halt spread of H1N1-09 infection in ferre,251556,2009-01-01,2009.0,2010-12-31,2010,University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6710344,OPP1171001,To generate data to inform country- and global-level decision-making related to fractional dose inactivated poliovirus vaccine (fIPV) introduction,942923,2017-03-01,2017.0,2019-04-01,2019,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6665669,201293/Z/16/Z,The impact of the intestinal environment on the immunogenicity of oral vaccines in Zimbabwean infants,503022,2016-09-05,2016.0,2019-09-05,2019,Queen Mary University of London,grid.4868.2,United Kingdom,Wellcome Trust,United Kingdom,4,0,0
grant.6620139,132678,Evaluation of the technical & commercial viability of developing an accelerated MERS vaccine,217169,2017-02-01,2017.0,2018-01-31,2018,University of Reading,grid.9435.b,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.6586245,OPP1060886,To develop compostable vaccine packaging to diminish the environmental impact of mass vaccination campaigns in developing countries lacking adequate disposal infrastructure.,100000,2012-04-01,2012.0,2014-11-01,2014,University of California Los Angeles,grid.19006.3e,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586158,OPP43526,"To create a centralized, comprehensive, integrated and publicly accessible bioinformatics platform that will enable TB drug and vaccine discovery missions",8280212,2006-11-01,2006.0,2014-09-01,2014,Stanford University,grid.168010.e,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586118,OPP1053556,To insure that populations at risk of cholera will benefit from receiving oral cholera vaccine (OCV) in an appropriate and effective manner.,4995354,2012-11-01,2012.0,2016-11-01,2016,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,9,0,0
grant.6586057,OPP1153675,"To foster the exploration and innovation needed to identify, develop and deliver the right TB vaccines to those most in need",1500000,2016-06-01,2016.0,2018-06-01,2018,Aeras,grid.432518.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586048,OPP39452,To create awareness about the need for and challenges facing the research and development of HIV/AIDS vaccines for Africa,44078,2005-09-01,2005.0,2005-12-01,2005,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6586014,OPP1136441,"To develop a broad-spectrum ‘universal’ vaccine effective against infective sporozoites, disease-causing blood-stages and transmissible sexual stages of most species of human malaria",1758440,2015-11-01,2015.0,2018-12-01,2018,James Cook University,grid.1011.1,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585997,OPP1111654,"To conduct initial primate studies that can significantly accelerate the clinical development of a safe, effective AIDS vaccine with activity across clades",1854359,2014-10-01,2014.0,2017-04-01,2017,Texas Biomedical Research Institute,grid.250889.e,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585976,OPP1091720,To discover biomarkers in blood that can be used to identify individuals at risk of developing active tuberculosis (TB) for priority enrollment into TB vaccine trials,430153,2014-02-01,2014.0,2018-01-01,2018,SomaLogic (United States),grid.437866.8,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6585956,OPP53047,To design and evaluate so-called “infinite-epitope” vaccines for their potential to provide simultaneous and broad protective immunity to the many variant forms of HIV.,100000,2009-05-01,2009.0,2010-11-01,2010,Royal Holloway University of London,grid.4970.a,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585946,OPP1127967,"To examine a new mechanism that may influence rotavirus vaccine take, and improve our understanding of immunological correlates of protection",265696,2015-07-01,2015.0,2017-08-01,2017,Murdoch Childrens Research Institute,grid.1058.c,Australia,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6585942,OPP1129543,To support for the 2015 Sabin Gold Medal Award which recognizes individuals who have helped to reduce needless human suffering from vaccine-preventable and neglected tropical diseases,20000,2015-03-01,2015.0,2015-05-01,2015,Sabin Vaccine Institute,grid.452766.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585914,OPPGH5157,To develop a novel vector for HIV vaccines based on non-integrating lentivirus vectors that directly target the specialized cells that present antigens to the immune system,1954441,2009-09-01,2009.0,2011-08-01,2011,California Institute of Technology,grid.20861.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585634,OPP52109,"To develop an oral HIV vaccine based on Clostridium perfringens to deliver large amounts of antigens to gut-associated lymphoid tissue, a major site of HIV activity",100000,2008-10-01,2008.0,2010-04-01,2010,University of Pittsburgh,grid.21925.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585612,OPP1131495,To develop high quality master seed viruses and cell lines that are relevant for foot-and-mouth disease virus vaccine production for East Africa,1494536,2015-10-01,2015.0,2018-04-01,2018,Pirbright Institute,grid.63622.33,United Kingdom,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6585589,OPP1069964,To identify malaria peptide antigens that present themselves on the surface of infected liver cells for use in the development of new malaria vaccines.,100000,2012-10-01,2012.0,2014-05-01,2014,Naval Medical Research Center,grid.415913.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585586,OPP1008274,"To target T-cells against these ERV antigens. If true, new host-directed vaccines could be developed to eliminate HIV infected cells.",100000,2009-11-01,2009.0,2011-11-01,2011,Oregon Health & Science University,grid.5288.7,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585423,OPP1043475,"To develop and test a low-cost cellular architecture that can track an individual’s immunization status, disseminate vaccine-related information, and track at-risk populations.",98455,2011-10-01,2011.0,2013-11-01,2013,"University of California, Santa Barbara",grid.133342.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585351,OPP32470,"To introduce and monitor the effects of Haemophilus influenzae type b (Hib) conjugate vaccine in high-risk infant populations in Mali, West Africa",4222128,2004-12-01,2004.0,2009-09-01,2009,"University of Maryland, Baltimore",grid.411024.2,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585328,OPP1162987,To convene global experts to consider the issues around the design and delivery of effectiveness studies for typhoid conjugate vaccines.,132130,2016-09-01,2016.0,2017-01-01,2017,University of Oxford,grid.4991.5,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585277,OPP1069119,To develop a software-based modeling tool that allows vaccine program managers to analyze all clinical and logistical factors that determine the cost per dose administered.,100000,2012-10-01,2012.0,2014-05-01,2014,Logistics Management Institute (United States),grid.426687.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585251,OPP1061381,To apply a new liquid stabilizing technology to create thermostable vaccines that can withstand extremes of temperature and eliminate the need for a cold chain.,100000,2012-04-01,2012.0,2013-11-01,2013,University College London,grid.83440.3b,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585136,OPP1015745,To develop a microchip to assess the functioning of single T cells to evaluate HIV-specific T cell response in future HIV vaccine trials,100000,2010-05-01,2010.0,2012-05-01,2012,Yale University,grid.47100.32,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585027,OPP1025588,"To construct and test a vaccine platform that utilizes low-cost, stable surfactant vesicles to deliver antigens for a sustained immune response",100000,2010-11-01,2010.0,2012-05-01,2012,"University of Maryland, College Park",grid.164295.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584993,OPP1069721,To develop and field test a simple inexpensive micro-hydroturbine that can drive a generator to power vaccine refrigerators and other health care facility equipment.,100000,2012-11-01,2012.0,2015-11-01,2015,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584850,OPP42316,"To engineer, produce, and assess target antigens for developing a potent and cost-effective vaccine to control and prevent influenza infections",2663930,2006-10-01,2006.0,2009-10-01,2009,Fraunhofer USA,grid.426697.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584848,OPP1060394,To study if a bacterial protease inhibitor from Brucella is a new molecular pattern that could be useful for improving mucosal (oral) delivery of anti-infectious vaccines,100000,2012-04-01,2012.0,2014-05-01,2014,National Scientific and Technical Research Council,grid.423606.5,Argentina,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6584845,OPP1036107,To test the theory that poor immunity generated by the oral poliovirus vaccine (OPV) may be responsible for persistence of the disease.,100000,2011-05-01,2011.0,2014-05-01,2014,Christian Medical College & Hospital,grid.11586.3b,India,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584829,OPP1115940,To define a shared strategy and related action plan as well as Monitoring and Evaluation framework to enhance sustainable access to vaccines in Middle Income countries (MICs),497671,2014-11-01,2014.0,2017-02-01,2017,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584806,OPP1043666,"To further research the production and immune stimulating effects of multi-antigen and adjuvant formulations that could be used in a low-cost, long-lasting malaria vaccine.",826426,2012-06-01,2012.0,2015-07-01,2015,TetraGenetics (United States),grid.479566.f,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584800,OPP1033211,To evaluate the population effectiveness of rotavirus vaccine introduction in the context of a comprehensive diarrhoea control pilot in Zambia’s Lusaka Province,2530317,2011-11-01,2011.0,2013-10-01,2013,Centre for Infectious Disease Research in Zambia,grid.418015.9,Zambia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584797,OPP1036175,To develop a non-live polio vaccine using liposomes to entrap and deliver defined poliovirus antigens effectively to the immune system,84554,2011-05-01,2011.0,2014-01-01,2014,Xenetic Biosciences (United States),grid.475720.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584777,OPP1156795,To identify the potential causal role of antibodies in MTB control in vivo in an effort to guide future vaccine design,3239928,2016-11-01,2016.0,2019-11-01,2019,Massachusetts General Hospital,grid.32224.35,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584720,OPP1069046,"To develop a printable label for vaccine vials to indicate when they have been exposed to temperatures below a set threshold, which would compromise activity.",100000,2012-10-01,2012.0,2014-05-01,2014,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584666,OPP1040768,To evaluate the ability of nanoparticle based vaccines to induce Env-specific protective antibody responses against HIV infection in non human primates,7810252,2012-08-01,2012.0,2018-08-01,2018,Emory University,grid.189967.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584493,OPP1162810,To make the first description of specific histo-blood group antigens (HBGAs) in Zambian children and to assess their influence on immunogenicity of rotavirus vaccines.,78522,2016-12-01,2016.0,2018-07-01,2018,Centre for Infectious Disease Research in Zambia,grid.418015.9,Zambia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584467,OPP1022521,"To convene experts to discuss new information about vibrios in the environment particularly in relation to diarrhea/enteric diseases, diagnostics, and vaccines",30459,2010-09-01,2010.0,2011-02-01,2011,University of Southern Mississippi,grid.267193.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584441,OPP1043886,To engineer a highly immunogenic virus to express replication-restricted poliovirus proteins for use in a new nasal spray polio vaccine.,99115,2011-10-01,2011.0,2014-05-01,2014,Yale University,grid.47100.32,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584432,OPP1024664,"To develop a bio-compatible, biodegradable polymer device that can be placed under the skin to introduce vaccines and antigens to the immune system",98427,2010-11-01,2010.0,2012-10-01,2012,University of North Carolina at Chapel Hill,grid.10698.36,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584336,OPP1056753,"To test an innovative single vial system (SVS) technology that allows for easier transport, reconstitution, and storage of vaccines with lyophilized components",99996,2012-04-01,2012.0,2014-01-01,2014,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584308,OPP53271,"To develop high-throughput glycan microarrays to identify glycan antigens, determine their chemical structure, and design glycan-peptide vaccines for future testing.",100000,2009-05-01,2009.0,2010-05-01,2010,Emory University,grid.189967.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584301,OPP1058944,"To generate chimeric Plasmodium falciparum that expresses the antigens of another malaria parasite, P. vivax, allowing them to be evaluated as vaccine candidates.",100000,2012-03-01,2012.0,2013-11-01,2013,Burnet Institute,grid.1056.2,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584273,OPP1139763,"To develop novel vaccines for African trypanosomiasis, a neglected disease of animals and humans in sub-Saharan Africa that is transmitted by an infected tsetse fly bite",880000,2016-02-01,2016.0,2019-09-01,2019,Yale University,grid.47100.32,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584214,OPP1058454,"To develop an effective, low cost, oral, human neonatal rotavirus vaccine aimed at prevention of rotavirus gastroenteritis from birth, for infants and children worldwide",3902497,2012-07-01,2012.0,2015-08-01,2015,Murdoch Childrens Research Institute,grid.1058.c,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584206,OPP1129479,To apply highly sensitive quantitative molecular diagnostics for pathogens to understand the etiology of severe diarrhea in post-rotavirus vaccine communities,2475646,2015-07-01,2015.0,2019-04-01,2019,University of Virginia,grid.27755.32,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584151,OPP1100708,"To enhance the impact of immunization on childhood mortality by defining the potential heterologous effects of vaccines, and adjusting immunization policies if deemed appropriate",1117685,2013-10-01,2013.0,2018-01-01,2018,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584136,OPP43648,"To provide information on the potential cost-effectiveness of additional investments in several ongoing, vaccine-improvement initiatives aimed at reducing the global disease burden of measles",550470,2007-06-01,2007.0,2008-03-01,2008,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584098,OPP1030707,"To develop the knowledge which is needed to develop vaccines and drugs for global infectious diseases including malaria, tuberculosis, HIV/AIDS, and emerging and neglected diseases",3559859,2010-11-01,2010.0,2014-04-01,2014,Center for Infectious Disease Research,grid.53964.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584086,OPP1131823,To support the planning of a phase I clinical trial in Belgium for the Oral Polio Vaccines being developed by a consortium of researchers,105417,2015-06-01,2015.0,2015-11-01,2015,University of Antwerp,grid.5284.b,Belgium,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584073,OPP1016416,To develop and test a vaccine delivery system that uses Norovirus virus-like particles (VLPs) to deliver desired antigens directly to the gut mucosa,100000,2010-04-01,2010.0,2011-04-01,2011,Arizona State University,grid.215654.1,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584067,OPP1067511,To develop a vaccine for Salmonella that uses a serotype-independent Salmonella antigen combined with an adjuvant to deliver immunity against all serotypes of the bacteria.,100000,2012-10-01,2012.0,2014-05-01,2014,Oklahoma State University,grid.65519.3e,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584061,OPP1152430,To support pre-clinical and early clinical development of a novel TB vaccine for use in high burden countries in the developing world,1303692,2016-06-01,2016.0,2019-07-01,2019,Oregon Health & Science University,grid.5288.7,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6584059,OPP1099507,To optimize and augment methods to identify mucosal immune factors that may contribute to HIV prevention and vaccine-induced protection.,2840871,2013-11-01,2013.0,2016-10-01,2016,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6584047,OPP1088039,"To increase capacity to conduct HIV vaccine clinical trials, including licensure trials, in highly impacted populations in clade C region of southern Africa.",6938504,2013-11-01,2013.0,2018-10-01,2018,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584038,OPP1130833,To provide technical assistance for the Institute of Medical Biology’s pursuit of World Health Organization prequalification for their Sabin Inactivated Poliovirus vaccine (sIPV),1038645,2015-11-01,2015.0,2019-01-01,2019,China Academy of Chinese Medical Sciences,grid.410318.f,China,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583914,OPP51947,To work to develop a single dose vaccine that can be given as close to birth as possible to protect against multiple diseases.,100000,2008-10-01,2008.0,2011-10-01,2011,Roswell Park Cancer Institute,grid.240614.5,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6583847,OPP50314,To develop a vaccine imunogen capable of eliciting broadly neutralizing antibodies to prevent infection with the HIV strains most common in Africa,3969624,2008-09-01,2008.0,2014-05-01,2014,Dana-Farber Cancer Institute,grid.65499.37,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583842,OPP52070,To study the complex sugar coating that surrounds and protects HIV to see if parts of this shield can serve as targets for a vaccine,99972,2008-10-01,2008.0,2010-03-01,2010,Augusta University,grid.410427.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583825,OPP53285,To develop a novel vaccine approach that is based on blocking mosquito transmission of these disease agents rather than inducing pathogen-specific immunity.,100000,2009-05-01,2009.0,2010-11-01,2010,University of Queensland,grid.1003.2,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583815,OPP48621,"To establish a program to search for new innovative, potentially high risk, ideas/technologies that may offer promise to the HIV vaccine research and development field",5000000,2007-08-01,2007.0,2012-09-01,2012,International AIDS Vaccine Initiative,grid.420368.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583742,OPP1099494,To leverage recent discoveries involving the immunobiology of TLR11 to develop a tractable small animal model for preclinical testing of ETEC vaccine candidates.,317693,2013-10-01,2013.0,2015-05-01,2015,Washington University in St. Louis,grid.4367.6,United States,Bill & Melinda Gates Foundation,United States,5,0,0
grant.6583725,OPP1070613,To develop an IPV vaccine adjuvanted with CAF01 that is able to promote significant dose-sparing and enhance mucosal immunity.,158739,2012-10-01,2012.0,2015-02-01,2015,State Serum Institute,grid.6203.7,Denmark,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6583645,OPP1089243,"To support cholera modeling activities using data from endemic and epidemic settings, in order to better understand how to target vaccine use for highest impact",471557,2013-06-01,2013.0,2015-11-01,2015,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,11,0,0
grant.6583627,OPP51992,"To incorporate engineered frameshifting gene cassettes into vaccine vectors in hopes of eliciting broader T helper and cytotoxic T cell response, leading to better protection against disease.",100000,2008-10-01,2008.0,2010-04-01,2010,Centre Hospitalier Universitaire Sainte-Justine,grid.411418.9,Canada,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583621,OPP51988,To develop a novel vaccine against salivary proteins of sand fl ies with the aim to induce a strong immune response against the parasite,100000,2009-05-01,2009.0,2010-05-01,2010,National Institutes of Health,grid.94365.3d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583587,OPP52090,To develop a mutable vaccine in which the gene coding for the antigen mutates a million times more frequently than a typical gene to trigger immune response,100000,2008-10-01,2008.0,2010-04-01,2010,University of Michigan,grid.214458.e,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6583580,OPP1008310,"To produce a multi-stage malaria vaccine using transgenic sporozoites, generating protective immunity against early stages of infection and antibodies to block transmission via mosquitoes",100000,2009-11-01,2009.0,2011-05-01,2011,Leiden University Medical Center,grid.10419.3d,Netherlands,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583473,OPP1036194,"To develop a low-cost, single-dose, oral polio vaccine using a live, safe adenovirus containing protein-encoding genes from poliovirus.",100000,2011-05-01,2011.0,2012-11-01,2012,PaxVax (United States),grid.437314.6,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583461,OPP1120377,To develop an evidence base for the determinants of maternal vaccine acceptance to inform future maternal vaccination demand creation strategies in low- and middle-income countries,998300,2015-09-01,2015.0,2018-06-01,2018,Emory University,grid.189967.8,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6583407,OPP1055850,To develop novel pulsed antigen-releasing single-injection vaccine delivery systems to facilitate pediatric immunizations in Developing World circumstances where repeated patient access can be problematic.,300000,2012-06-01,2012.0,2014-07-01,2014,Massachusetts Institute of Technology,grid.116068.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583342,OPP1148601,To provide a low cost pneumococcal vaccine to reduce morbidity and mortality from pneumococcal diseases of infants and children in developing countries,1530000,2016-11-01,2016.0,2019-06-01,2019,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583302,OPP1043555,"To target T-cells against ERV antigens. If true, new host-directed vaccines could be developed to eliminate HIV infected cells.",999998,2012-04-01,2012.0,2016-04-01,2016,Oregon Health & Science University,grid.5288.7,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583288,OPP1047314,To convene a meeting of experts in meningococcal disease to determine how to monitor the long-term impact of meningococcal vaccines in Africa,229861,2011-09-01,2011.0,2016-01-01,2016,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583263,OPP1148779,To develop a standardized analytical commutability protocol that Developing Country Vaccine Manufacturers may use for evaluating Vi-conjugate ELISA assays and reference standards to support product registration,50025,2016-03-01,2016.0,2017-03-01,2017,CDC Foundation,grid.474959.2,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6583217,OPP1155863,To better monitor viral infections and vaccine efficacy in populations throughout the world in order to enhance our ability to improve human health and detect emerging epidemics,2020533,2016-10-01,2016.0,2019-10-01,2019,Brigham and Women's Hospital,grid.62560.37,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6583127,OPP30358,To disseminate the most up-to-date information on gastric cancer and the development of possible vaccines; and to encourage research and collaboration on gastric cancer worldwide,15000,2003-08-01,2003.0,2004-08-01,2004,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583035,OPP51760,To test whether a prototype malaria vaccine which targets a newly identifi ed dendritic cell molecule will produce a strong antibody response without the use of adjuvants.,100000,2008-10-01,2008.0,2009-10-01,2009,Walter and Eliza Hall Institute of Medical Research,grid.1042.7,Australia,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582996,OPP1069993,"To produce libraries of DNA fragments encoding thousands of peptides from malaria parasite proteins, for use in production and testing of malaria vaccine formulations",100000,2012-10-01,2012.0,2014-11-01,2014,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6582961,OPPGH5284,"To test novel technologies for developing more effective neonatal vaccines to improve infant health and survival, particularly in low income countries and the world's poorest communities",2511087,2010-04-01,2010.0,2014-09-01,2014,Boston Children's Hospital,grid.2515.3,United States,Bill & Melinda Gates Foundation,United States,24,0,0
grant.6582958,OPP1136638,To develop a single-injection delayed-release T-solium (swine tapeworm) vaccine that would require a one-time access to facilitate control programs in the Developing World,970344,2015-11-01,2015.0,2018-05-01,2018,Massachusetts Institute of Technology,grid.116068.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582848,OPP1017093,"To identify why oral poliovirus and rotavirus vaccines are less effective in the developing world, in order to develop new approaches to protect children from enteric diseases",16207773,2010-11-01,2010.0,2018-06-01,2018,University of Virginia,grid.27755.32,United States,Bill & Melinda Gates Foundation,United States,25,0,0
grant.6582822,OPP1005560,To reduce the burden of cholera through the deployment of the killed whole cell oral cholera vaccine in endemic and epidemic settings,3553004,2010-11-01,2010.0,2014-06-01,2014,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582719,OPP1135510,To enhance IDRI’s capabilities to provide industry quality adjuvants and formulations for the development of vaccines for diseases in the developing world,4349073,2015-10-01,2015.0,2019-11-01,2019,Infectious Disease Research Institute,grid.53959.33,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582668,OPP47732,"To analyze paired mother infant sera from HIV positive mothers to determine the effectiveness of trans-placental antibody transfer for vaccine preventable diseases (flu, pneumo, and tetanus)",103985,2007-10-01,2007.0,2009-03-01,2009,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582628,OPP48640,To enhance global awareness and visibility of AIDS vaccine research and development in developing countries among the general public and decisionmakers,73750,2007-09-01,2007.0,2008-09-01,2008,International AIDS Vaccine Initiative,grid.420368.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582557,OPP51961,To explore whether green fluorescent protein is endowed with unique immunological properties which could be used to develop a universal fl u vaccine.,100000,2008-10-01,2008.0,2010-04-01,2010,International Vaccine Institute,grid.30311.30,South Korea,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582548,OPP1058489,To develop an oral vaccine for tuberculosis that uses rice seeds that express proteins that will induce immunity in the gastrointestinal tract and in the respiratory mucosa.,100000,2012-04-01,2012.0,2013-11-01,2013,International Centre for Diarrhoeal Disease Research,grid.414142.6,Bangladesh,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6582542,OPP1069577,"To reduce disability and deaths due to cholera in epidemic and outbreak settings through the introduction of an additional control tool, oral cholera vaccines",544773,2012-09-01,2012.0,2013-12-01,2013,United Nations Children's Fund,grid.420318.c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582500,OPP1113581,"To develop a comprehensive framework and tools for a systematic and coordinated approach to rotavirus vaccine implementation evaluation at country, regional, and global levels",878292,2014-09-01,2014.0,2018-01-01,2018,World Health Organization,grid.3575.4,Switzerland,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582340,OPP1151962,To support for the 2016 Sabin Gold Medal Award which recognizes individuals who have helped to reduce needless human suffering from vaccine-preventable and neglected tropical diseases,20000,2016-03-01,2016.0,2016-06-01,2016,Sabin Vaccine Institute,grid.452766.4,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582339,OPP1068382,To develop live bacterial-based contraceptive vaccines that deliver testis- and sperm-specific antigens to sterilize rodent populations that destroy food crops.,100000,2012-10-01,2012.0,2014-05-01,2014,Arizona State University,grid.215654.1,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582310,OPP1033109,To define the relationship between anti-HIV-1 Env antibody specificity and Fc-mediated effector function to guide HIV-1 vaccine development,6965308,2011-09-01,2011.0,2017-01-01,2017,"University of Maryland, Baltimore",grid.411024.2,United States,Bill & Melinda Gates Foundation,United States,20,0,0
grant.6582295,OPP51762,To develop a library of media compounds needed to optimize in vitro production of infective malaria sporozites needed for use in an effective vaccine,100000,2008-10-01,2008.0,2010-04-01,2010,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582178,OPP37902,To define the qualities of an HIV vaccine that will make it sufficiently immunogenic to elicit protective responses in humans,9990782,2006-06-01,2006.0,2011-12-01,2011,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6582119,OPP1023440,To enable and drive the development of improved and appropriate vaccines against invasive pneumococcal disease for use in high burden low income countries,1499862,2010-11-01,2010.0,2015-04-01,2015,University of Liverpool,grid.10025.36,United Kingdom,Bill & Melinda Gates Foundation,United States,8,0,0
grant.6582060,OPP50805,To use a genetic approach to identify cellular targets that mediate adjuvant effects to accelerate the design of vaccines against globally persistent pathogens,7502819,2008-09-01,2008.0,2014-01-01,2014,The University of Texas Southwestern Medical Center,grid.267313.2,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582051,OPP1015136,To develop a versatile pollen mimetic transcutaneous vaccination platform with built-in adjuvant properties for needle-free transdermal delivery of vaccine antigens via hair follicles,100000,2010-05-01,2010.0,2011-11-01,2011,Helmholtz Centre for Infection Research,grid.7490.a,Germany,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6581990,OPPGD1129,To develop an Animal Health Services Franchising Business for the delivery of vaccines and pharmaceuticals to smallholder farmers in Kenya,5188438,2010-11-01,2010.0,2015-05-01,2015,Farm Africa,grid.475145.6,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581941,OPP39527,To convene experts in HIV virology and vaccinology to examine role of acute and early infections in HIV vaccine development.,40000,2005-08-01,2005.0,2006-02-01,2006,Harvard University,grid.38142.3c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581793,OPP1106054,To prevent deaths from vaccine-preventable diseases (VPD) by developing an accurate and field-friendly method to assess effective vaccination coverage in young children,1732980,2014-04-01,2014.0,2018-10-01,2018,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581714,OPP1036117,To try to improve the immune response to oral poliovirus vaccine among children in India by treating enteric infections before vaccination.,100000,2011-04-01,2011.0,2013-11-01,2013,Imperial College London,grid.7445.2,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581702,OPP1117483,"To provide critical evidence about the population impact of a highly promising pneumococcal conjugate vaccine, PCV10, on radiologically and ultrasound confirmed pneumonia in rural Bangladesh",2381694,2014-10-01,2014.0,2019-01-01,2019,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,4,0,0
grant.6581700,OPP38874,To guide development of broadly effective vaccines against enteric infections by measuring etiology and burden of severe diarrhea among young children in developing countries,30319836,2006-05-01,2006.0,2012-01-01,2012,"University of Maryland, Baltimore",grid.411024.2,United States,Bill & Melinda Gates Foundation,United States,29,0,0
grant.6581601,OPP1070001,To test the hypothesis that immunizing newborns with soluble rather than particulate antigens will overcome maternal-mediated suppression of infant immune responses to vaccines.,100000,2012-10-01,2012.0,2014-11-01,2014,Emory University,grid.189967.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581595,OPP1070028,To develop a tuberculosis vaccine that uses polyester biobeads produced in mycobacteria that carry a large repertoire of known and undiscovered antigens on their surface.,100000,2012-10-01,2012.0,2014-05-01,2014,AgResearch (New Zealand),grid.417738.e,New Zealand,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6581503,OPP1118840,To test computational design and experimental approaches that could lead to significantly improved next generation vaccine candidates for human immunodeficiency virus/simian immunodeficiency virus (HIV/SIV),2358606,2014-11-01,2014.0,2018-08-01,2018,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6581421,OPP1069064,To develop a printable label that can be used on vaccines to indicate when contents have surpassed a set temperature threshold or exceeded a cumulative temperature limit.,100000,2012-10-01,2012.0,2014-05-01,2014,,,,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581364,OPP1111923,To test the Nearest Neighbor immunogen hypothesis and could lead to significantly improved next generation HIV-1 Env vaccine candidates,7416108,2014-11-01,2014.0,2019-06-01,2019,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,6,0,0
grant.6581325,OPP1146617,"To convene an international conference to discuss and share broadly the latest HIV vaccine, microbicide, and ARV-based prevention research",749216,2016-02-01,2016.0,2017-06-01,2017,Global HIV Vaccine Enterprise,grid.420432.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581316,OPP1127586,To explore the technical and regulatory feasibility of Micropellet technology for the development of cost-effective novel combination vaccines that are thermal stable,1795242,2015-10-01,2015.0,2018-09-01,2018,Sanofi (United States),grid.417555.7,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6581313,OPP44083,"To support development of an attenuated Plasmodium falciparum sporozoite vaccine to reduce malaria infection, morbidity, and mortality in infants and children in Africa",8339709,2006-10-01,2006.0,2010-10-01,2010,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581280,OPP1004851,"To evaluate the capacity of a new intradermal vaccine using polypropylene sulfide nanoparticles to induce immunity against HIV, Tuberculosis, and Cytomegalovirus infections",848000,2010-06-01,2010.0,2015-02-01,2015,Cardiff University,grid.5600.3,United Kingdom,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581271,OPP1031734,To develop the concept that a vaccine can prevent HIV transmission by the trapping of virus-antibody complexes in cervical and cervical/vaginal mucus,6886056,2011-07-01,2011.0,2015-07-01,2015,Northwestern University,grid.16753.36,United States,Bill & Melinda Gates Foundation,United States,7,0,0
grant.6581221,OPP1152837,"To fund the activities of the ACO which support the Alliance in their work on developing a safe, effective and globally accessible HIV vaccine",100137,2016-06-01,2016.0,2017-06-01,2017,International Centre for Infectious Diseases,grid.423578.f,Canada,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581206,OPP1068988,To develop children’s ankle bands with electrochemical indicators that change color at specified intervals to remind mothers of their childrens’ vaccine due dates.,98047,2012-10-01,2012.0,2015-10-01,2015,Trust for Vaccines & Immunization,grid.475702.3,Pakistan,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581196,OPP1069110,"To develop and test an aluminum wicking medium that can be used in an evaporative, passive-cooling refrigeration system for vaccine storage and delivery in dry climates.",100000,2012-10-01,2012.0,2014-05-01,2014,The University of Texas at Dallas,grid.267323.1,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6581169,OPP1152198,"To plan for clinical and environmental surveillance of enteric fever in India, and to identify sites of vaccine evaluation with or without complementary sanitary interventions",236785,2016-06-01,2016.0,2018-01-01,2018,Christian Medical College & Hospital,grid.11586.3b,India,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581131,OPP1006946,"To engineer Salmonella and Shigella vaccine vectors to overproduce an essential antigen to stimulate gamma delta T cells, to boost mucosal immune response against these enteric pathogens",100000,2009-11-01,2009.0,2011-05-01,2011,University of Iowa,grid.214572.7,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6581126,OPP1033102,"To develop novel vaccines against HIV, with an approach to modify HIV envelope protein to enhance its immunogenic potency for clinical development",7699399,2011-11-01,2011.0,2016-11-01,2016,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,20,0,0
grant.6581123,OPP1044181,To develop a new oral poliovirus type 2 vaccine (OPV-2) to greatly improve the chances of success of the global eradication of all three poliovirus serotypes,1325223,2011-10-01,2011.0,2016-09-01,2016,Stony Brook University,grid.36425.36,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581115,OPP38608,"To develop a safe, effective and affordable vaccine for the prevention and control of HIV-AIDS, especially in developing countries",5761970,2006-06-01,2006.0,2009-06-01,2009,King's College London,grid.13097.3c,United Kingdom,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6581020,OPP1060817,To create requirements and engineering specifications to develop new “net zero energy” warehouse and distribution systems for vaccines and drugs in developing countries.,100000,2012-04-01,2012.0,2014-05-01,2014,Georgia Institute of Technology,grid.213917.f,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580908,OPP42359,"To conduct the Global Health Series of conferences on HIV/AIDS, tuberculosis, malaria, parasitic diseases, and common infectious disease challenges, such as vaccine development",3745079,2006-09-01,2006.0,2010-11-01,2010,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580890,OPP1138859,"To evaluate the infant response to pneumococcal vaccination in a Belgian cohort of infants whose mothers were previously vaccinated with tetanus, diphtheria, acellular pertussis vaccine (Tdap)",63258,2015-11-01,2015.0,2017-01-01,2017,University of Antwerp,grid.5284.b,Belgium,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580836,OPP1061366,To develop microcapsules that allow vaccines to be released only after bypassing the acidic stomach environment and arriving at the mucosal tissues of the lower gastrointestinal tract,100000,2012-04-01,2012.0,2014-11-01,2014,University of Alberta,grid.17089.37,Canada,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6580835,OPP1151836,To discover novel pathways of host defense against Mtb that will impact development of vaccines and host-directed therapies for tuberculosis,2000000,2016-11-01,2016.0,2019-10-01,2019,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580803,OPP1125279,"To understand host factors associated with infection of tuberculosis in order to develop new diagnostic tools, host-directed therapeutics or vaccines",998090,2015-04-01,2015.0,2018-01-01,2018,Liverpool School of Tropical Medicine,grid.48004.38,United Kingdom,Bill & Melinda Gates Foundation,United States,5,0,0
grant.6580786,OPP1061430,"To test a mobile phone short message service (SMS) system that provides texts to parents to improve timely immunizations, increase vaccine acceptance, and report of side effects.",100000,2012-04-01,2012.0,2014-05-01,2014,University of Colorado Anschutz Medical Campus,grid.430503.1,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6580745,OPP1017334,"To develop evidence for improving the performance of live, attenuated, orally delivered rotavirus vaccines in infants in the developing world",9588867,2010-11-01,2010.0,2016-07-01,2016,Program for Appropriate Technology in Health,grid.415269.d,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580649,OPP1070505,To develop an efficacious vaccine against malaria using novel nanoparticle-based technologies termed Interbilayer-Crosslinked Multilamellar Vesicles (ICMVs) and malarial antigens,1588114,2012-10-01,2012.0,2017-04-01,2017,Vedantra Pharmaceuticals (United States),grid.479591.7,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580576,OPP1066865,To improve infant vaccine responses and early childhood development by identifying the mechanisms of and solutions to the detrimental impact of maternal parasitic infection.,2000134,2012-11-01,2012.0,2016-11-01,2016,Case Western Reserve University,grid.67105.35,United States,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580564,OPP53278,To determine whether novel synthetic molecules (imidazoquinolines) are able to activate newborns white blood cells as candidate vaccine adjuvants to dramatically enhance immunization of infants.,100000,2009-05-01,2009.0,2011-11-01,2011,Boston Children's Hospital,grid.2515.3,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580559,OPP1060901,To develop a customizable Geographical Information System web application platform that integrates existing data in a particular region to maximize delivery of vaccines to target populations.,100000,2012-04-01,2012.0,2013-11-01,2013,Vsolvit (United States),grid.479625.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580484,OPP1084301,"To reduce disability and deaths due to cholera in epidemic settings through the introduction of oral cholera vaccines, an additional control tool",2680283,2013-10-01,2013.0,2017-01-01,2017,United Nations Children's Fund,grid.420318.c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580403,OPP1060845,To develop a mobile-phone based “bulletin-board” for capturing and broadcasting availability and demand information for vaccines and medicines.,100000,2012-04-01,2012.0,2013-11-01,2013,Logistimo (India),grid.479443.9,India,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6580386,OPP1139130,To support the development of novel vaccine approaches that aim to decrease transmission of the Malaria parasite from mosquito to human,839483,2015-11-01,2015.0,2019-05-01,2019,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6580304,OPP1060862,"To establish an internet-based global monitoring and rapid alert system for finding, analyzing, and counteracting misinformation communication campaigns regarding vaccines to support global immunization efforts.",100000,2012-04-01,2012.0,2013-11-01,2013,University of Connecticut,grid.63054.34,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580266,OPP1130379,To provide foundation grantees with novel and innovative industry quality adjuvants and formulations to enhance the success of pre-clinical and clinical vaccine development,1376376,2015-10-01,2015.0,2019-07-01,2019,Infectious Disease Research Institute,grid.53959.33,United States,Bill & Melinda Gates Foundation,United States,10,0,0
grant.6580261,OPP40581,"To support a project to develop a public haplotype resource for monitoring drug resistance, vaccine responses, and markers of disease severity in malaria",2831215,2006-04-01,2006.0,2008-08-01,2008,Massachusetts Institute of Technology,grid.116068.8,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580223,OPP1084271,To expand efforts to identify populations and build capacity in India where future pivotal TB vaccine trials can be conducted,68696,2013-09-01,2013.0,2015-01-01,2015,CRDF Global,grid.428357.f,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580182,OPP1043517,To futher develop “homing factors” as vaccine adjuvants that induce the development of memory T cells and generate site-specific immunity against pathogens in the gut.,990225,2012-08-01,2012.0,2016-09-01,2016,Queen Mary University of London,grid.4868.2,United Kingdom,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6580179,OPP26748,To evaluate the effect of high levels of maternal antibody on the infant's response to pneumococcal conjugate vaccine given in the routine infant schedule,349159,2003-10-01,2003.0,2008-12-01,2008,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6501370,272201600011C-0-0-1,IGF::OT::IGF STAGED VACCINE DEVELOPMENT,199797,2016-05-15,2016.0,2017-05-14,2017,University of Massachusetts Medical School,grid.168645.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501028,272201600020C-0-0-1,IGF::OT::IGF STAGE VACCINE DEVELOPMENT,199442,2016-08-01,2016.0,2017-07-31,2017,GeoVax (United States),grid.434905.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6500987,272201600010C-0-0-1,IGF::OT::IGF PRODUCTION OF PDNA VACCINE EXPRESSING FLSC,75289,2016-05-15,2016.0,2017-05-14,2017,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499448,272201200003I-2-27200010-1,Task X10: Ebola Vaccine Immunogenicity and Efficacy Testing,344576,2014-08-21,2014.0,2018-08-20,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499443,272201400043C-1-0-1,STAGED VACCINE DEVELOPMENT OF ADENIVIRUS-4 VECTORED VACCINE FOR HUMAN IMMUNODEFICIENCY VIRUS,3239039,2016-09-15,2016.0,2018-04-05,2018,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6369955,X46120-----70031,"デング熱, 出血熱ウイルスの免疫学的性状の検討ならびにそれに基くワクチン試作の研究",7597,1971-01-01,1971.0,1971-12-31,1971,Kobe University,grid.31432.37,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6347725,X41120-----72188,ジフテリア(D)百日咳(P)破傷風(T)麻疹(M)混合ワクチンの実用化に関する研究(継2年),5732,1966-01-01,1966.0,1966-12-31,1966,Kanazawa University,grid.9707.9,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6344179,X40430----992326,細菌感染症の新しい姿の把握及び菌交代症の予防治療に関する基礎的研究(ワクチン療法),3106,1965-01-01,1965.0,1965-12-31,1965,Iwate Medical University,grid.411790.a,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6316491,X00095----367090,百日咳薗の産生する赤血球凝集素の簡易迅速な分離精製と改良百日咳ワクチンへの応用,3038,1978-01-01,1978.0,1978-12-31,1978,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6311022,X00120----287051,毒素フラグメントを応用した現行のものにかわる破傷風ワクチンと抗毒素標準化法の作成,15885,1977-01-01,1977.0,1977-12-31,1977,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6289275,X00090----456194,NDV不活化ワクチンに対する抗体産生能の異なるウズラの育種と選抜系の免疫学的特性,12430,1979-01-01,1979.0,1979-12-31,1979,Tohoku University,grid.69566.3a,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6260168,63770243,マラリアワクチン開発の基礎的研究:マラリア原虫強毒株と弱毒株との遺伝子発現の比較,6214,1988-01-01,1988.0,1988-12-31,1988,Gunma University,grid.256642.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6243074,62770266,マラリアワクチン開発の基礎的研究:マラリア原虫強毒株と弱毒株との遺伝子発現の比較,6213,1987-01-01,1987.0,1987-12-31,1987,Gunma University,grid.256642.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6233945,61770265,マラリアワクチン開発の基礎的研究:マラリア原虫強毒株と弱毒株との遺伝子発現の比較,6907,1986-01-01,1986.0,1986-12-31,1986,Gunma University,grid.256642.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6193744,J 2122,Structural characterization of major timothy grass pollen allergens: Basis for the rational development of vaccines against grass pollen allergy,0,2001-09-01,2001.0,2002-08-31,2002,Yeshiva University,grid.268433.8,United States,FWF Austrian Science Fund,Austria,1,0,0
grant.6192027,J 1835,"Structural characterization of the major timothy grass pollen allergen, Phl p: Basis for the rationale development of vaccines against grass pollen allergy",0,2000-09-01,2000.0,2001-08-31,2001,Yeshiva University,grid.268433.8,United States,FWF Austrian Science Fund,Austria,1,0,0
grant.6190734,J 1376,A Phase I Study of a Bcr-abl peptide based Vaccine with GM-CSF as an Adjuvant in Patients with Chronic Myleogenous Leikemia,0,1997-04-01,1997.0,1998-04-30,1998,Medical University of Vienna,grid.22937.3d,Austria,FWF Austrian Science Fund,Austria,0,0,0
grant.6189018,J 1628,A Phase I Study of a Bcr-abl peptide based Vaccine with GM-CSF as an Adjuvant in Patients with Chronic Myleogenous Leukemia,0,1998-05-01,1998.0,1998-06-30,1998,University of Washington,grid.34477.33,United States,FWF Austrian Science Fund,Austria,0,0,0
grant.6187641,J 1784,Rescue of Infectious Newcastle Disease Virus (NDV) from Cloned cDNA for the development of a Novel Vaccine against AIDS,0,2000-06-15,2000.0,2001-06-15,2001,Icahn School of Medicine at Mount Sinai,grid.59734.3c,United States,FWF Austrian Science Fund,Austria,0,0,0
grant.6154969,26670588,IL-27により分化誘導したDC前駆細胞を用いた新しい癌DCワクチン療法の開発,32132,2014-04-01,2014.0,2015-03-31,2015,Tokyo Medical University,grid.410793.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6128334,25861570,NKT細胞と樹状細胞による上気道粘膜免疫応答の解析と経鼻ワクチンへの展開,35272,2013-04-01,2013.0,2014-03-31,2014,Oita University,grid.412334.3,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6124081,25460835,Dynamics of Pneumococcal carriage and emergence of high virulence clone after introduction of vaccine in Japan,45598,2013-04-01,2013.0,2016-03-31,2016,Osaka Prefectural Institute of Public Health,grid.416993.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6120738,25450421,Development of vaccines against leishmaniasis using polyvalent CDV vaccine and cytokine adjuvant.,47999,2013-04-01,2013.0,2016-03-31,2016,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.6096975,24790404,DNA macromolecule as a vaccine antigen scaffold for organization of the antigens into repetitively ordered arrays,48654,2012-04-01,2012.0,2014-03-31,2014,Kagoshima University,grid.258333.c,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.6059097,23590490,Malaria vaccine platform technology,61221,2011-01-01,2011.0,2013-12-31,2013,University of the Ryukyus,grid.267625.2,Japan,Japan Society for the Promotion of Science,Japan,5,0,0
grant.6010588,20890301,Development of an oral delivery vehicle for HIV-1 DNA vaccines to stimulate mucosal immune responses,28038,2008-01-01,2008.0,2009-12-31,2009,"National Institute of Biomedical Innovation, Health and Nutrition",grid.482562.f,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5996145,19790497,Vaccine development against hepatitis virus by transcutaneous peptide immunization with TLR7 ligand.,32954,2007-01-01,2007.0,2008-12-31,2008,Tokyo Medical University,grid.410793.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5924715,16K15440,Development of vaccine therapy for pulmonary arterial hypertension,30544,2016-04-01,2016.0,2018-03-31,2018,Mie University,grid.260026.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5919672,16K19131,百日咳菌の感染成立機構の解明とワクチン開発への応用,37673,2016-04-01,2016.0,2019-03-31,2019,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,8,0,0
grant.5909934,16K08024,M13ファージワクチンによるB細胞活性化機構の解明とワクチン効果の検討,43558,2016-04-01,2016.0,2019-03-31,2019,Kagoshima University,grid.258333.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5878597,15K15605,Development of the noninvasive nasal spray vaccine for prevention of cervical cancer using the next generation type virus vector.,32060,2015-04-01,2015.0,2017-03-31,2017,Mie University,grid.260026.0,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5875292,15K11085,Analysis of mechanisms related to the induction of mucosal immunity in Peyer's patches against oral vaccine,41440,2015-04-01,2015.0,2018-03-31,2018,Nihon University,grid.260969.2,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5872775,15K09658,"Basic research for ""RSV pregnant women vaccine"" by clinical isolates aimed at overcoming RSV infection",41440,2015-04-01,2015.0,2018-03-31,2018,Fukushima Medical University,grid.411582.b,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5866656,15K08461,抗結核ワクチン効果の増強を目指した結核菌/BCGによる防御免疫制御機序の解明,41954,2015-04-01,2015.0,2016-03-31,2016,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5864910,15J10381,遺伝子組換えニワトリを用いたインフルエンザワクチン製造の効率化に向けた研究,14998,2015-04-24,2015.0,2017-03-31,2017,Nagoya University,grid.27476.30,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5861645,15J05949,ヘパトゾーンに対する免疫応答に関与する抗原蛋白の同定とワクチンへの応用,7941,2015-04-24,2015.0,2017-03-31,2017,Kagoshima University,grid.258333.c,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5856674,15H05052,Vaccines against periodontitis using DNA ORIGAMI and imidazoquinolines,153114,2015-04-01,2015.0,2018-03-31,2018,Niigata University,grid.260975.f,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5847585,15F15117,下痢症ウイルスの分子疫学、構造の特徴、進化とワクチン設計,17828,2015-07-29,2015.0,2017-03-31,2017,Nihon University,grid.260969.2,Japan,Japan Society for the Promotion of Science,Japan,8,0,0
grant.5847284,15F15716,Development of a new influenza vaccine of global standard.,20711,2015-11-09,2015.0,2018-03-31,2018,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5829932,14J00656,心筋梗塞に対するアンジオテンシン２ワクチンを用いた新規治療法の開発,17601,2014-04-25,2014.0,2016-03-31,2016,Tokyo Medical and Dental University,grid.265073.5,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5826474,14J06317,オリゴＤＮＡカプセルをアジュバントとする乳酸菌経口ワクチンの創製,28513,2014-04-25,2014.0,2017-03-31,2017,Shinshu University,grid.263518.b,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.5815012,13J05302,組換えワクシニアウイルスを用いた抗ＨＴＬＶ－１ワクチンの開発,39874,2013-04-01,2013.0,2016-03-31,2016,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.5814353,13J01263,狂犬病ウイルスの伝播ダイナミクス及びワクチン戦略研究,27692,2013-04-01,2013.0,2016-03-31,2016,Tohoku University,grid.69566.3a,Japan,Japan Society for the Promotion of Science,Japan,8,0,0
grant.5814043,13F03775,ヘリコバクターピロリの病原性因子とワクチンに関する研究,21226,2013-04-01,2013.0,2016-03-31,2016,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5812232,13F03329,糖鎖抗原の化学合成と複合型合成ワクチンへの展開,21226,2013-04-01,2013.0,2016-03-31,2016,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5809744,13J06054,ワクチンハザードの克服を目指した新規経皮ナノキャリアの設計,17281,2013-04-01,2013.0,2015-03-31,2015,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5749055,11470070,Enhancement of protection against various microbial infection by the modification of dominance of Thl or Th2 immune responses,134092,1999-01-01,1999.0,2001-12-31,2001,Yokohama City University,grid.268441.d,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5452530,96-04-58591,"научной конференции-14 встpеча Евpопейского общества по технологии клеток животных ""Технология клеток животных: от вакцин до медицинской генетики",0,1996-01-01,1996.0,1996-12-31,1996,,,,Russian Foundation for Basic Research,Russia,0,0,0
grant.5451369,96-04-58611,международной конференции под эгидой European Society for Animal Cell Technology 14th ESACT Meeting Animal Cell Technology: from Vaccines to Genetic Medicine,0,1996-01-01,1996.0,1996-12-31,1996,,,,Russian Foundation for Basic Research,Russia,0,0,0
grant.5325910,ASTHMA99/045,"A double-blind placebo-controlled trial of an HLA-restricted, allergen-derived T cell peptide vaccine in cat-allergic asthma",173800,1999-07-01,1999.0,2001-06-30,2001,McMaster University,grid.25073.33,Canada,Asthma UK,United Kingdom,0,0,0
grant.5245909,272201300016I-0-27200007-1,Vaccine and Treatment Evaluation Unit - Assay Work for CMV Vaccines,200000,2015-09-20,2015.0,2017-04-14,2017,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245786,272201200003I-1-27200009-1,Task X9: Development of Standardized Filovirus Immune Assays and Reagents,1222829,2014-08-20,2014.0,2017-08-19,2017,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5218024,69279,Dendritic-cell (DC) based vaccines; influence of DC maturational stage and maturational stimuli on their efficacy to induce a specific anti-tumor T cell response.,0,2002-07-01,2002.0,2003-10-31,2003,,,,Swiss National Science Foundation,Switzerland,0,0,0
grant.5207502,65231,"Feline leukemia virus infection: Factors that influence the sus- ceptibility of the host, the pathogenesis of the infection, and the efficacy of vaccines",147331,2002-05-01,2002.0,2005-04-30,2005,University of Zurich; University of Zurich,grid.7400.3; grid.7400.3,Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,9,0,0
grant.5203540,66308,Development of a specific immunotherapy in pollen related food allergy: low IgE binding carrot allergens as potential vaccines. (MHV-Beitrag),49994,2002-08-01,2002.0,2003-07-31,2003,University of Zurich,grid.7400.3,Switzerland,Swiss National Science Foundation,Switzerland,1,0,0
grant.5202775,67022,A fine characterization of the T cell response induced by active immunization in melanoma patients: a pivotal step for vaccine development.,132123,2002-04-01,2002.0,2005-09-30,2005,University of Lausanne; University of Geneva; University of Lausanne,grid.9851.5; grid.8591.5; grid.9851.5,Switzerland; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5197165,44451,Analysis of particular features of the immune responses to vaccine antigens during the neonatal period: importance of antigen presentation systems. (S C O R E A),477171,1996-01-01,1996.0,2000-03-31,2000,University of Geneva,grid.8591.5,Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5196035,40779,Analysis of particular features of the immune responses to vaccine antigens during the neonatal period: importance of anti- gen presentation systems,588647,1994-10-01,1994.0,1999-09-30,1999,University of Geneva; University of Geneva,grid.8591.5; grid.8591.5,Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5181420,8944,Studies of the cross-protective antibodies elicited after immunization with E.coli J5 vaccine for the prevention of gram-negative shock and death,5388,1986-10-01,1986.0,1989-03-31,1989,University of Lausanne; University Hospital of Lausanne,grid.9851.5; grid.8515.9,Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.5140527,CRUK-A5897,A randomised Feasability adjuvant autologous renal carcinoma vaccine (ARCV) comparing ARCV to ARCV/interleukin-2 to control (the ART trial),0,2005-06-01,2005.0,2010-05-31,2010,University of Leeds,grid.9909.9,United Kingdom,Cancer Research UK,United Kingdom,0,0,0
grant.5139795,BW-12017,Understanding success or failure: evaluating DNA vaccine-induced human CD8+ T-cell responses as a function of peptide-MHC stability,0,2012-08-01,2012.0,2015-08-01,2015,University of Southampton,grid.5491.9,United Kingdom,Bloodwise,United Kingdom,0,0,0
grant.5041907,CRN-01-200222,Enhanced dendritic cell recruitment and anti-tumor efficacy in a breast cancer DNA vaccine that includes IRES driven expression of cytokine biological adjuvants,50000,2001-07-01,2001.0,2002-06-30,2002,"University of California, Irvine",grid.266093.8,United States,University of California - Cancer Research Coordinating Committee,United States,0,0,0
grant.5014857,81071033,可折叠四价Aβ15基因工程疫苗的免疫特异性及安全性研究,63269,2011-01-01,2011.0,2013-12-31,2013,Sun Yat-sen University,grid.12981.33,China,National Natural Science Foundation of China,China,3,0,0
grant.5006764,81000917,新型DC靶向性MUC1-VNTRn纳米核酸疫苗的优化构建及抗胰腺癌的实验研究,31631,2011-01-01,2011.0,2013-12-31,2013,Sun Yat-sen University,grid.12981.33,China,National Natural Science Foundation of China,China,11,0,0
grant.5005894,81071401,含HSV-2 gD基因重组腺病毒修饰的抗II型单纯疱疹病毒树突状细胞疫苗的构建及其免疫效应研究,52197,2011-01-01,2011.0,2013-12-31,2013,General Hospital of Guangzhou Military Command,grid.413435.4,China,National Natural Science Foundation of China,China,1,0,0
grant.5004249,81001345,乳酸乳球菌递呈的嗜肺军团菌新型FlaA/MompS疫苗的构建和免疫效应研究,36375,2011-01-01,2011.0,2013-12-31,2013,Chengdu Medical College,grid.413856.d,China,National Natural Science Foundation of China,China,4,0,0
grant.4991934,30873013,新型双功能靶向治疗性融合蛋白疫苗及其抑瘤作用研究,44874,2009-01-01,2009.0,2011-12-31,2011,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,2,0,0
grant.4973345,30973453,抗肿瘤血管生成新型佐剂疫苗Hydrolipid-bFGF抗肿瘤作用及其免疫机制,11815,2010-01-01,2010.0,2010-12-31,2010,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,2,0,0
grant.4971252,30771915,有效活化粘膜免疫反应的艾滋病疫苗策略研究,43790,2008-01-01,2008.0,2010-12-31,2010,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,1,0,0
grant.4966996,30973280,以壳聚糖为载体的屋尘螨低变应原性DNA黏膜疫苗的构建及鼻腔免疫效果研究,49152,2010-01-01,2010.0,2012-12-31,2012,Wuhan University,grid.49470.3e,China,National Natural Science Foundation of China,China,2,0,0
grant.4962853,30901371,人高致病性禽流感H5N1病毒通用型疫苗基础研究,27644,2010-01-01,2010.0,2012-12-31,2012,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,4,0,0
grant.4960564,30872419,艾滋病自然感染与疫苗诱导产生抗体的鉴别研究,44874,2009-01-01,2009.0,2011-12-31,2011,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,1,0,0
grant.4957450,30500453,以发夹RNA表达盒作为佐剂的新型DNA疫苗载体研究,10031,2006-01-01,2006.0,2006-12-31,2006,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,1,0,0
grant.4952980,30801055,结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究,28418,2009-01-01,2009.0,2011-12-31,2011,,,,National Natural Science Foundation of China,China,1,0,0
grant.4951199,30472087,hCGbeta-CTP多聚体和C3d片段嵌合肽的生物合成及其在肿瘤治疗中的应用,26517,2005-01-01,2005.0,2007-12-31,2007,Shanghai Institute of Planned Parenthood Research,grid.419100.d,China,National Natural Science Foundation of China,China,0,0,0
grant.4950725,30300305,噬菌体活载体HPV16、18联合多价预防性疫苗的研究,24545,2004-01-01,2004.0,2006-12-31,2006,Xi'an Jiaotong University,grid.43169.39,China,National Natural Science Foundation of China,China,1,0,0
grant.4943778,30801357,双分子修饰的抗原递呈细胞靶向肿瘤纳米疫苗的研究,29916,2009-01-01,2009.0,2011-12-31,2011,,,,National Natural Science Foundation of China,China,0,0,0
grant.4941775,30570683,卵透明带DNA避孕疫苗诱发生殖道粘膜免疫反应的研究,34725,2006-01-01,2006.0,2008-12-31,2008,,,,National Natural Science Foundation of China,China,0,0,0
grant.4938724,30500605,通用型DC靶向脂质体疫苗的抗肿瘤作用机理研究,33389,2006-01-01,2006.0,2008-12-31,2008,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.4937991,30500458,疫苗多肽纳米载药新分子的研究,34725,2006-01-01,2006.0,2008-12-31,2008,China Pharmaceutical University,grid.254147.1,China,National Natural Science Foundation of China,China,19,0,0
grant.4932812,30500639,派伊尔集合淋巴结定位口服疫苗纳米粒给药系统的研究,28046,2006-01-01,2006.0,2008-12-31,2008,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,1,0,0
grant.4924967,30971341,基于肝素酶CTL表位多抗原肽(MAP)疫苗的设计及其抗肿瘤免疫效应研究,49152,2010-01-01,2010.0,2012-12-31,2012,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,1,0,0
grant.4924180,30700902,PB转座子介导的自杀基因对自体肿瘤活疫苗的靶向杀伤作用,27730,2008-01-01,2008.0,2010-12-31,2010,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,3,0,0
grant.4918569,30271164,间日疟多表位疫苗的实验室研究,21815,2003-01-01,2003.0,2005-12-31,2005,Southern Medical University,grid.284723.8,China,National Natural Science Foundation of China,China,0,0,0
grant.4914216,39960079,人乳头瘤病毒16型E7核酸疫苗的制备研究,12074,2000-01-01,2000.0,2002-12-31,2002,Xinjiang University,grid.413254.5,China,National Natural Science Foundation of China,China,0,0,0
grant.4912945,30271284,PSCA颗粒-DNA复合疫苗抗胰腺癌效应的研究,23024,2003-01-01,2003.0,2005-12-31,2005,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,2,0,0
grant.4903965,30973650,甘露糖化壳聚糖介导的抗动脉粥样硬化DNA疫苗经粘膜免疫,46080,2010-01-01,2010.0,2012-12-31,2012,China Pharmaceutical University,grid.254147.1,China,National Natural Science Foundation of China,China,5,0,0
grant.4892909,W81XWH-15-C-0178,Next Generation of Multivalent Adenovirus Vaccines Based on Novel Virus-Like Particle (VLP) Technology,100000,2014-10-01,2014.0,2015-09-30,2015,TechnoVax (United States),grid.438336.9,United States,United States Department of the Army,United States,0,0,0
grant.4853334,84015,Generating regional rotavirus vaccine strains through reverse genetics to alleviate viral diarrhoea in Africa (Senior Fellowship for Dr. Hester Gertruida O'Neill),0,2008-11-24,2008.0,2011-11-24,2011,Bernhard Nocht Institute for Tropical Medicine; Bernhard Nocht Institute for Tropical Medicine; Bernhard Nocht Institute for Tropical Medicine,grid.424065.1; grid.424065.1; grid.424065.1,Germany; Germany; Germany,Volkswagen Foundation,Germany,0,0,0
grant.4799742,22321033,Entwicklung RNS basierter Impfstoffe zur Induktion integrierter T und B-Zellimmunantworten gegen molekular definierte Tumorantigene              (A15),0,2006-01-01,2006.0,2008-12-31,2008,Johannes Gutenberg University of Mainz,grid.5802.f,Germany,German Research Foundation,Germany,0,0,0
grant.4774701,5404514,Evaluierung der Effektivität der Vakzinebehandlung des Prostatakarzinoms in Kombination mit nicht-myeloablativer Knochenmarktransplantation im Tiermodell,0,2003-01-01,2003.0,2006-12-31,2006,,,,German Research Foundation,Germany,0,0,0
grant.4762047,5364102,"Bestimmung der antigen-Spezifität der T-Zellantwort gegen eine genmodifizierte, polyvalente Vakzine bei der chronischen lymphatischen Leukämie (CLL)              (C 4)",0,2002-01-01,2002.0,2004-12-31,2004,Ludwig Maximilian University of Munich; Ludwig Maximilian University of Munich; Ludwig Maximilian University of Munich,grid.5252.0; grid.5252.0; grid.5252.0,Germany; Germany; Germany,German Research Foundation,Germany,0,0,0
grant.4760941,5268966,Native display of Borrelia antigens on the surface of hepatitis B virus capsids: Improved prophylactic and potential therapeutic vaccines against Lyme disease,0,2000-01-01,2000.0,2010-12-31,2010,Max Planck Institute of Immunobiology and Epigenetics,grid.429509.3,Germany,German Research Foundation,Germany,0,0,0
grant.4760813,5268080,Identification of low-molecular mass ligands for targeting of subunit vaccines to Peyer`s patch M cells,0,2000-01-01,2000.0,2003-12-31,2003,Research Center Borstel - Leibniz-Center for Medicine and Biosciences,grid.418187.3,Germany,German Research Foundation,Germany,0,0,0
grant.4744457,5188008,"Das Merozoitenoberflächenprotein 1 (MSP-1), ein Kandidat für einen Impfstoff gegen P.falciparum-Infektionen: Untersuchungen zur zellulären Immunantwort des Menschen              (A01)",0,1999-01-01,1999.0,2006-12-31,2006,Heidelberg University,grid.7700.0,Germany,German Research Foundation,Germany,0,0,0
grant.4704204,2013/11/B/NZ4/04468,Doustna szczepionka przeciwko endoglinie skojarzona z terapią genową IL-12 polaryzuje mikrośrodowisko nowotworowe z proangiogennego i immunosupresyjnego na środowisko antyangiogenne i immunostymulujące.,161521,2014-07-11,2014.0,2017-07-10,2017,Centrum Onkologii Instytut,grid.418165.f,Poland,National Science Center,Poland,0,0,0
grant.4703174,2013/09/B/NZ6/03526,Badania nad wielofunkcyjną szczepionką przeciwko C.albicans wykorzystującą kierowanie do komórek dendrytycznych i aktywację receptora dektynowego.,254516,2014-03-19,2014.0,2018-03-18,2018,Ludwik Hirszfeld Institute of Immunology and Experimental Therapy,grid.418769.5,Poland,National Science Center,Poland,0,0,0
grant.4700536,0771/B/P01/2011/40,Ocena odpowiedzi humoralnej poszczepieniu trzynastowalentną skoniugowaną szczepionką pneumokokową u dzieci i młodzieży z nieswoistymi zapeleniami jeltit.,64829,2011-05-17,2011.0,2014-05-16,2014,Medical University of Warsaw,grid.13339.3b,Poland,National Science Center,Poland,0,0,0
grant.4669594,123628,A multi-pronged approach to find endogenous agRNAs,27538,2007-04-01,2007.0,2010-03-31,2010,The University of Texas at Dallas,grid.267323.1,United States,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4667828,197912,Development of a proposal on Norwegian engagement and collaborative projects in a phase III trial of oral rotavirus vaccine ORV 116E in Indi,189461,2009-01-01,2009.0,2010-12-31,2010,Norwegian Institute of Public Health,grid.418193.6,Norway,The Research Council of Norway,Norway,0,0,0
grant.4659338,189682,Development of an improved vaccine towards meningococcal disease in sub-Saharan Africa,35442,2008-01-01,2008.0,2008-12-31,2008,Norwegian Institute of Public Health,grid.418193.6,Norway,The Research Council of Norway,Norway,0,0,0
grant.4649510,16702,Étude de l immunodominance de type T CD8+ dans un contexte d infection par le Virus de l Immunodéficience Humaine : implications dans l élaboration d un nouveau vaccin.,40469,2009-04-01,2009.0,2010-03-31,2010,John Radcliffe Hospital,grid.8348.7,United Kingdom,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.4649346,148465,Développement de formulations pour vaccins conventionnels suite à l'étude du comportement des particules injectées avec l'injecteur sans aiguille du LOCUS,13440,2011-04-01,2011.0,2012-03-31,2012,Université de Sherbrooke,grid.86715.3d,Canada,Fonds de Recherche du Québec – Nature et technologies,Canada,0,0,0
grant.4647673,182479,Development of vaccine concepts that protect farmed fish throughout the entire production cycle,25594,2007-01-01,2007.0,2007-12-31,2007,The Arctic University of Norway,grid.10919.30,Norway,The Research Council of Norway,Norway,0,0,0
grant.4578575,061948/Z/00/Z,Investigation into the immunological basis for enhancing immunity to Marek's disease by using re-vaccination with Marek's disease vaccines.,122341,2001-10-01,2001.0,2004-03-31,2004,Pirbright Institute,grid.63622.33,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.4578365,058700/Z/99/Z,The regulation of HIV-1 specific T-cell immune responses: influence of highly active antiretroviral drugs cytokines and vaccines.,634779,2000-07-01,2000.0,2004-06-30,2004,Imperial College London,grid.7445.2,United Kingdom,Wellcome Trust,United Kingdom,15,0,0
grant.4577798,050988/Z/97/A,For additional refurbishment costs associated with Phase II of the Vaccine Unit of the Division of Infectious Diseases.,131301,2000-10-01,2000.0,2001-09-30,2001,"St George's, University of London",grid.264200.2,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.4520509,ANR-11-EMMA-0026,Development of a bivalent vaccine against hepatitis B and C viruses,366806,2012-01-01,2012.0,2013-12-31,2013,François Rabelais University,grid.12366.30,France,National Agency for Research,France,0,0,0
grant.4491575,08/11418-8,"Nisin obtention in milk whey medium, evaluation of antimicrobial application in food biopreservation, pharmaceutics products; and vaccines adjuvant",0,2009-06-01,2009.0,2011-05-31,2011,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4472561,152411051,Recombinant BCG expressing Pasteurella antigens,133320,2015-01-01,2015.0,2016-12-31,2016,,,,The Icelandic Centre for Research,Iceland,0,0,0
grant.4455522,H23IP001003,"To enhance the IIS for AFIX assessment functionality so the IIS, IRIS, will serve as a single reference source to ensure consistent vaccine coverage reporting statewide.",450000,2015-09-30,2015.0,2017-09-29,2017,Iowa Department of Public Health,grid.280302.b,United States,Centers for Disease Control and Prevention,United States,6,0,0
grant.4439726,W81XWH-11-C-0042,Testing of a Novel Skin Electroporation Procedure for Multivalent Alphavirus DNA Vaccine Delivery,69997,2010-10-01,2010.0,2011-09-30,2011,Ichor Medical Systems (United States),grid.282549.0,United States,United States Department of the Army,United States,0,0,0
grant.4414245,N00014-05-M-0133,Marine Mammal Vaccines,100000,2004-10-01,2004.0,2005-09-30,2005,TetraGenetics (United States),grid.479566.f,United States,United States Department of the Navy,United States,5,0,0
grant.4388528,W81XWH-04-C-0025,Innovative Manufacturing Techniques for Polysaccharide-Protein Conjugate Vaccines,1825370,2003-10-01,2003.0,2004-09-30,2004,,,,United States Department of the Army,United States,0,0,0
grant.4172834,564601,Genomic-guided discovery of new interventions against neglected parasitic diseases.,20372,2014-04-01,2014.0,2015-03-31,2015,University of Melbourne,grid.1008.9,Australia,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.4035481,2200,A combined early and late HIV-1 protein-specific exosome-targeted T cell vaccine capable of counteracting immune suppressions and stimulating CD8+ CTL responses in absence of,116907,2009-04-01,2009.0,2011-03-31,2011,University of Saskatchewan,grid.25152.31,Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.4035270,1435,Development of mucosal vaccines against Bordetella pertussis,63810,2003-07-01,2003.0,2005-06-30,2005,University of Saskatchewan; University of Saskatchewan; University of Saskatchewan,grid.25152.31; grid.25152.31; grid.25152.31,Canada; Canada; Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.3983436,11/RFP.1/BMT/3307,The role of bacterial outer membrane proteins in the pathogenesis of chronic lung infection: Potential vaccine candidates or novel drug targets,240432,2011-09-01,2011.0,2015-12-31,2015,Technological University Dublin,grid.497880.a,Ireland,Science Foundation Ireland,Ireland,3,0,0
grant.3983037,08/IN.1/B2067,Chemical Biology on Carbohydrates - Approaches Towards Potential Drugs and Vaccines against Infectious Diseases and Cancer,2037317,2009-07-01,2009.0,2016-01-31,2016,University College Dublin,grid.7886.1,Ireland,Science Foundation Ireland,Ireland,13,0,0
grant.3958702,131831,Breaking the cold chain for oral recombinant vaccines,163802,2015-03-31,2015.0,2016-06-29,2016,Biopharma Technology (United Kingdom),grid.432043.2,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.3951980,1002624,CROSS-PROTECTION EFFICACY AND CUSTOMIZATION OF THE EBEAM SALMONELLA VACCINE FOR THE POULTRY INDUSTRY,0,2014-03-18,2014.0,2014-09-30,2014,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3951949,2014-33610-21906,NEXT GENERATION VACCINE FOR INFECTIOUS BOVINE KERATOCONJUCTIVITIS,99333,2014-01-01,2014.0,2016-12-31,2016,Harrisvaccines (United States); Harrisvaccines (United States),grid.426879.6; grid.426879.6,United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3936592,201201140,Development of a Vaccine against the Hepatitis C Virus (HCV) and Demonstration of Efficacy in Intravenous Drug Users,4134427,2013-04-01,2013.0,2018-03-31,2018,University of Alberta; University of Alberta,grid.17089.37; grid.17089.37,Canada; Canada,Alberta Innovates,Canada,1,0,0
grant.3936423,201201082,"Do Current Immunization Delivery and Surveillance Systems Adequately Promote and Measure Uptake of the Measles, Mumps, Rubella and Varicella (MMR-V) Vaccine?",195389,2013-04-01,2013.0,2016-03-31,2016,University of Calgary,grid.22072.35,Canada,Alberta Innovates,Canada,0,0,0
grant.3898960,53233,"Inuit women's understanding of human papillomavirus:  implications for health education and prevention in Nunavik, Québec",37092,2007-04-01,2007.0,2009-03-31,2009,McGill University; McGill University; McGill University,grid.14709.3b; grid.14709.3b; grid.14709.3b,Canada; Canada; Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.3873602,128860,Love alone won't protect your daughter:  HPV vaccine and the moral negotiations of Ontario parents,36596,2013-04-01,2013.0,2015-03-31,2015,University of Toronto,grid.17063.33,Canada,Social Sciences and Humanities Research Council,Canada,0,0,0
grant.3866316,131595,Development of novel attenuated PRRS vaccine and disease model.,291264,2014-04-30,2014.0,2016-04-29,2016,,,,Innovate UK,United Kingdom,0,0,0
grant.3864778,BBS/E/I/00001744,IAH Jenner Influenza Fellowship,27882,2012-08-31,2012.0,2013-06-29,2013,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.3857720,H23IP000924,"THE PURPOSE OF THE PROPOSED PROJECT IS TO ENHANCE THE VERMONT IMMUNIZATION REGISTRY BY RESEARCHING, EVALUATING AND IMPLEMENTING A VACCINE",489169,2014-09-30,2014.0,2016-09-29,2016,Vermont Agency of Human Services,grid.422198.4,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857710,H23IP000913,ENHANCING ALASKAS VACCINE ORDERING & MGMT TOOLS IN THE IMMUNIZATION INFORMATION SYSTEMS (IIS) TO IMPROVE THE INTERFACE WITH CDCs VTRCKS SYSTEM,614072,2014-09-30,2014.0,2016-09-29,2016,Alaska Department of Health and Social Services,grid.413533.3,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.3857113,272201400043C-0-0-1,STAGED VACCINE DEVELOPMENT OF ADENIVIRUS-4 VECTORED VACCINE FOR HUMAN IMMUNODEFICIENCY VIRUS,195082,2014-09-05,2014.0,2016-09-14,2016,PaxVax (United States),grid.437314.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856956,272201200003I-0-27200009-1,Task X9: Development of Standardized Filovirus Immune Assays and Reagents,1761782,2014-08-20,2014.0,2017-08-19,2017,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3852689,1448195,SBIR Phase I: Silk: A New Approach to Developing a Heat-stable Rotavirus Vaccine,150000,2015-01-01,2015.0,2015-12-31,2015,Vaxess Technologies (United States),grid.505450.1,United States,Directorate for Engineering,United States,0,0,0
grant.3831853,2013-67015-21187,''BRUCELLOSIS VACCINES FOR LIVESTOCK'',500000,2012-06-01,2012.0,2014-05-31,2014,University of Florida,grid.15276.37,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3826462,0228327,EVALUATION OF THE ROLE OF CELL-MEDIATED IMMUNITY IN EFFICACY OF EXPERIMENTAL ALTERNATIVE SCHEDULE OF LIVE ATTENUATED RB51 VACCINE AGAINST BRUCELLOSIS IN CATTLE,0,2012-01-01,2012.0,2014-09-30,2014,University of Wyoming; University of Wyoming; University of Wyoming; University of Wyoming,grid.135963.b; grid.135963.b; grid.135963.b; grid.135963.b,United States; United States; United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3823830,0229573,EVALUATION OF A SEROTYPE 1 MAREKS DISEASE VIRUS (MDV) AS VECTOR VACCINE TO CONTROL INFECTIOUS BURSAL DISEASE (IBD) IN CHICKENS,0,2012-05-25,2012.0,2016-09-30,2016,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3818730,2008-33610-18923,DEVELOPMENT OF HIGHLY EFFECTIVE VACCINE TO PREVENT FISH TUBERCULOSIS FOR AQUACULTURE,80000,2010-10-01,2010.0,2012-09-30,2012,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.3814830,2008-35204-04603,LIVE-ATTENUATED INFLUENZA VIRUSES (LAIV) VACCINES FOR THE PREVENTION AND CONTROL OF SWINE INFLUENZA,375000,2011-10-01,2011.0,2013-09-30,2013,"University of Maryland, College Park; University of Maryland, College Park",grid.164295.d; grid.164295.d,United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3804783,R44AI102318,TITER ON CHIP: ALTERNATIVE TO SRID FOR INFLUENZA VACCINE POTENCY DETERMINATION,3321832,2012-05-15,2012.0,2018-07-31,2018,InDevR (United States),grid.420960.9,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.3803020,R56DK103651,Design Molecular Vaccines for Type 1 Diabetes,475752,2014-09-10,2014.0,2016-08-31,2016,Wayne State University,grid.254444.7,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,3,0,0
grant.3767650,ICC2-CT-1999-04011,"Support for the organisation of a study entitled ""update of the cost/std database on european vaccine research"" held in bergen/norway in 1999",56834,1999-12-20,1999.0,2000-04-19,2000,University of Bergen,grid.7914.b,Norway,European Commission,Belgium,0,0,0
grant.3763985,IPS-2000-8153,"Novel ""non live"" vaccine for animal healthcare enabling southern Europe to overcome a serious isue in sheep/cattle farming",1687336,2001-06-01,2001.0,2006-05-31,2006,Boehringer Ingelheim (France); Mannesmann (Germany),grid.484445.d; grid.480263.b,France; Germany,European Commission,Belgium,0,0,0
grant.3759847,ICB1-CT-2000-80005,Integrated diagnostic and recombinant vaccinedevelopment for cowdriosis and anaplasmosis,12553,2001-11-01,2001.0,2002-01-31,2002,Utrecht University; Centro Nacional de Sanidad Agropecuaria,grid.5477.1; grid.423908.4,Netherlands; Cuba,European Commission,Belgium,0,0,0
grant.3728055,TS3*940275,"A network for the development, evaluation and testing of anti-paras ite vaccines in experimental non-human primate models",0,1995-02-01,1995.0,1997-12-31,1997,Biomedical Primate Research Centre; Radboud University Nijmegen; Leiden University,grid.11184.3d; grid.5590.9; grid.5132.5,Netherlands; Netherlands; Netherlands,European Commission,Belgium,0,0,0
grant.3724885,CI1*880251,IDENTIFICATION OF IMMUNOREACTIVE POLYPEPTIDES INVOLVED IN THE IMMUNE RESPONS AGAINST HIV & T-CRUZI AS A BASIS FOR DIAGNOSTIC AND VACCINE DEVELOPMENT,0,1988-07-01,1988.0,1991-06-30,1991,Fujirebio (Belgium),grid.420287.b,Belgium,European Commission,Belgium,0,0,0
grant.3723073,CI1*930012,"Mapping of T & B cell epitopes on the major surface antigen 1 of plasmodium vivax, a candidate for vaccine development",0,1994-01-01,1994.0,1997-06-30,1997,Pasteur Institute; Mahidol University,grid.428999.7; grid.10223.32,France; Thailand,European Commission,Belgium,0,0,0
grant.3722905,TS3*940313,Development of an improved vaccine against Mycobacterum Tubercolosis,0,1995-02-01,1995.0,1998-04-30,1998,State Serum Institute; Armauer Hansen Research Institute; Norwegian Institute of Public Health; University of Oslo; University of Porto,grid.6203.7; grid.418720.8; grid.418193.6; grid.5510.1; grid.5808.5,Denmark; Ethiopia; Norway; Norway; Portugal,European Commission,Belgium,2,0,0
grant.3707655,TS2*0260,A STUDY OF THE EPIDEMIOLOGY OF TROPICAL BOVINE THEILERIOSIS IN TUNISIA WITH RELEVANCE TO THE DEVELOPMENT OF A VACCINE,0,1990-02-01,1990.0,1994-06-30,1994,University of Leicester; Manouba University,grid.9918.9; grid.424444.6,United Kingdom; Tunisia,European Commission,Belgium,0,0,0
grant.3706322,GB1*0085,PRODUCTION OF A VACCINE TO BOVINE LEUKEMIA VIRUS ; A MODEL SYSTEM OF PREVENTION AGAINST A WORLDWIDE SPREAD RETROVIRUS-INDUCED NEOPLASM,0,1984-04-01,1984.0,1986-03-31,1986,Université Libre de Bruxelles,grid.4989.c,Belgium,European Commission,Belgium,0,0,0
grant.3704851,TS2*0057,CHARACTERIZATION OF SOLUBLE PLASMODIUM FALCIPARUM ANTIGENS BY MEANS OF DNA-RECOMBINANT TECHNIQUE AND IMMUNOCHEMICAL METHODS WITH THE PURPOSE OF DEVELOPING A MALARIA VACCINE,0,1989-01-01,1989.0,1991-12-31,1991,State Serum Institute,grid.6203.7,Denmark,European Commission,Belgium,0,0,0
grant.3701397,TS1*0148,THE DEVELOPMENT OF SEXUAL STAGE VACCINES OF PLASMODIUM FALCIPARUM FOR SUPPLEMENTARY CONTROL OF MALARIA TRANSMISSION A MOLECULAR BIOLOGICAL APPROACH,0,1985-06-01,1985.0,1987-06-30,1987,Radboud University Nijmegen,grid.5590.9,Netherlands,European Commission,Belgium,0,0,0
grant.3700414,TS2*0050,LABORATORY AND FIELD EVALUATION OF DEFINED ANTIGEN VACCINES AGAINST SCHISTOSOMA BOVIS AND S. JAPONICUM IN ANIMALS AND OF DEFINED ANTIGENS FOR THE IMMUNODIAGNOSIS OF HUMANS,0,1989-01-01,1989.0,1992-02-28,1992,London School of Hygiene & Tropical Medicine,grid.8991.9,United Kingdom,European Commission,Belgium,0,0,0
grant.3643227,089102/Z/09/Z,Development and Early Clinical Evaluation of a conjugate vaccine that protects against typhoid fever caused by the Salmonella enterica serovars typhi and paratyphi,7170458,2009-07-01,2009.0,2018-09-30,2018,GlaxoSmithKline (Italy); GlaxoSmithKline (Italy); GlaxoSmithKline (Italy); GlaxoSmithKline (Italy),grid.425088.3; grid.425088.3; grid.425088.3; grid.425088.3,Italy; Italy; Italy; Italy,Wellcome Trust,United Kingdom,3,0,0
grant.3637822,100527/Z/12/Z,Development of a multivalent Shigella bioconjugate vaccine to prevent deadly diarrhea in children,3146567,2013-12-01,2013.0,2016-12-31,2016,,,,Wellcome Trust,United Kingdom,0,0,0
grant.3637682,100527/B/12/Z,Development of a multivalent Shigella bioconjugate vaccine to prevent deadly diarrhea in children,2037393,2013-12-01,2013.0,2016-11-30,2016,,,,Wellcome Trust,United Kingdom,2,0,0
grant.3634826,055863/Z/98/A,Investigation of novel vaccines against Japanese encephalitis virus infection by virus-like particle or genetic vaccination approach.,3473,2001-03-01,2001.0,2002-02-28,2002,Imperial College London,grid.7445.2,United Kingdom,Wellcome Trust,United Kingdom,1,0,0
grant.3633305,065947/Z/01/Z,"A randomised comparative study of the immunogenicity of modified, multisite, intradermal post-exposure rabies vaccine regimens.",203834,2002-04-01,2002.0,2003-09-30,2003,University of Oxford; University of Oxford,grid.4991.5; grid.4991.5,United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,1,0,0
grant.3632595,067781/Z/02/Z,The development of recombiant modified vaccinia virus Ankara vaccine delivery systems of increased immunogenicity by manipulation of immunomodulatory genes.,309556,2002-10-01,2002.0,2005-09-30,2005,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3628432,062057/Z/00/Z,Carriage of hypervirulent meningococci before and after the introduction of serogroup C conjugate polysaccharide vaccine in the UK.,1250019,2000-10-01,2000.0,2005-09-30,2005,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,5,0,0
grant.3628313,065400/Z/01/Z,Schistosoma mansoni proteases involved in haemoglobin digestion: efficacy as vaccine molecules and elucidation of immunological parameters required for protection.,366958,2001-10-01,2001.0,2005-03-31,2005,Dublin City University; Dublin City University,grid.15596.3e; grid.15596.3e,Ireland; Ireland,Wellcome Trust,United Kingdom,0,0,0
grant.3577639,LP0347058,Development of novel vaccine delivery systems for induction of mucosal immunity in a large animal model,279064,2003-01-01,2003.0,2005-12-31,2005,University of Melbourne; CSL (Australia),grid.1008.9; grid.1135.6,Australia; Australia,Australian Research Council,Australia,3,0,0
grant.3576834,LP0211396,Characterisation and Stability of ISCOM Vaccines,131974,2002-01-01,2002.0,2004-12-31,2004,University of Melbourne; CSL (Australia),grid.1008.9; grid.1135.6,Australia; Australia,Australian Research Council,Australia,0,0,0
grant.3573998,LP0349352,Development of an Attenuated Infectious Laryngotracheitis Virus Vaccine,152218,2003-01-01,2003.0,2006-12-31,2006,University of Melbourne,grid.1008.9,Australia,Australian Research Council,Australia,0,0,0
grant.3572850,LP0990147,Development of an anti-Chlamydia vaccine for the koala,272985,2009-01-01,2009.0,2012-12-31,2012,Queensland University of Technology; Australia Zoo; Gold Coast City Council,grid.1024.7; grid.474001.6; grid.473973.d,Australia; Australia; Australia,Australian Research Council,Australia,10,0,0
grant.3571261,LP0455698,Novel lipid-based adjuvants for induction of mucosal immunity,77692,2004-01-01,2004.0,2007-12-31,2007,University of Newcastle Australia,grid.266842.c,Australia,Australian Research Council,Australia,0,0,0
grant.3570402,FT0991982,Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin,843112,2009-01-01,2009.0,2013-12-31,2013,University of Queensland,grid.1003.2,Australia,Australian Research Council,Australia,3,0,0
grant.3531001,83065,Implications for therapy and disease presentation of the changes triggered by the use of the pneumococcal 7-valent conjugate vaccine,242438,2009-02-01,2009.0,2012-12-31,2012,University of Lisbon; Hospital de Dona Estefânia; University of Lisbon; University of Lisbon; University of Lisbon; University of Lisbon; University of Lisbon,grid.9983.b; grid.414034.6; grid.9983.b; grid.9983.b; grid.9983.b; grid.9983.b; grid.9983.b,Portugal; Portugal; Portugal; Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3530308,59840,The Leishmania SIR2 family-related gene: functional studies and evaluation of SIR2 recombinant DNA and knockout vaccine to protect against Leishmnaniasis,119761,2005-07-01,2005.0,2008-06-30,2008,University of Porto; University of Porto; University of Porto; University of Porto,grid.5808.5; grid.5808.5; grid.5808.5; grid.5808.5,Portugal; Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,6,0,0
grant.3527792,59147,"New approach on the development of an efficient vaccine against streptococcal infection by modulating the conditions of expression, production, purification and formulation",33466,2005-01-01,2005.0,2006-12-31,2006,University of Lisbon; University of Lisbon; Universidade Nova de Lisboa,grid.9983.b; grid.9983.b; grid.10772.33,Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,6,0,0
grant.3525856,82449,"New approach on the development of an efficient vaccine against streptococcal infection by modulating the conditions of expression, production, purification and formulation",18368,2007-01-01,2007.0,2008-04-30,2008,University of Lisbon; University of Lisbon; Universidade Nova de Lisboa,grid.9983.b; grid.9983.b; grid.10772.33,Portugal; Portugal; Portugal,Foundation for Science and Technology,Portugal,0,0,0
grant.3104434,0924479,Integration of Spatial and Social Network Analysis in Vaccine Trials,301183,2009-09-01,2009.0,2013-09-30,2013,University of North Carolina at Chapel Hill,grid.10698.36,United States,"Directorate for Social, Behavioral & Economic Sciences",United States,6,0,0
grant.2975118,135180,Development of DNA-based vaccines for bovine viral diarrhoea virus. Développement des vaccins à base dADN le virus de diarrhée bovine.,81237,1998-04-01,1998.0,1999-03-31,1999,Université de Sherbrooke,grid.86715.3d,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2923517,485534,Generation of murine tumor cell lines that express human HLA-A2 and over-express genes of interest for pre-clinical evaluation and novel cancer vaccine development,20216,2011-04-01,2011.0,2012-03-31,2012,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2907618,309378,Development of a vaccine for sterile immunity to infectious salmon anaemia (ISA) virus and diagnostic kits for ISA virus and antibodies,562956,2002-04-01,2002.0,2006-03-31,2006,University of Prince Edward Island,grid.139596.1,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2897984,9237,Development of fowl adenovirus as a vaccine for Newcastle disease and as a gene delivery system to improve feed utilization in poultry,133838,1994-04-01,1994.0,1997-03-31,1997,University of Guelph,grid.34429.38,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2897604,286123,Developing MUC-1 cancer vaccines with the caulobacter S-layer:  use of whole cells as a platform for cancer therapy,211520,2002-04-01,2002.0,2005-03-31,2005,University of British Columbia; Oncothyreon (Canada),grid.17091.3e; grid.418358.3,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2890649,463978,Generation of murine tumor cell lines that express human HLA-A2 and over-express genes of interest for pre-clinical evaluation and novel cancer vaccine development,29109,2010-04-01,2010.0,2011-03-31,2011,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2868164,76409,"Development of a sea lice vaccine for farmed salmon; collaborative research at the Dept. of Agriculture and Fisheries, Marine Laboratory, Aberdeen, Scotland, U.K.",4300,1992-04-01,1992.0,1993-03-31,1993,University of New Brunswick,grid.266820.8,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2846662,442640,Generation of murine tumor cell lines that express human HLA-A2 and over-express genes of interest for pre-clinical evaluation and novel cancer vaccine development,8757,2009-04-01,2009.0,2010-03-31,2010,Immunovaccine (Canada),grid.420938.4,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2845972,501105,Development of Immunomodulators and Vaccines to Reduce Fish Infections of the Intracellular Parasite Microsporidia Using In vivo and In vitro Research Techniques,17498,2012-04-01,2012.0,2013-03-31,2013,Western University,grid.39381.30,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2842611,501913,Using reverse vaccinology to identify novel antigens for vaccine development against Mannheimia haemolytica as a model for bacterial agents associated with bovine respiratory disease,14997,2012-04-01,2012.0,2013-03-31,2013,University of Saskatchewan,grid.25152.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2839616,370805,"Towards a carbohydrate vaccine for HIV-1: Exploring the Immunogenicity and Antigenicity of the Glycan Shield on the HIV-1 Envelope Glycoprotein, gp120",19546,2007-04-01,2007.0,2008-03-31,2008,Scripps Research Institute,grid.214007.0,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2803801,329040,"Towards a carbohydrate vaccine for HIV-1: Exploring the Immunogenicity and Antigenicity of the Glycan Shield on the HIV-1 Envelope Glycoprotein, gp120",18511,2006-04-01,2006.0,2007-03-31,2007,Scripps Research Institute,grid.214007.0,United States,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2786005,BB/I007768/1,Understanding and manipulating chemokines and their receptors in the context of adjuvants,676283,2011-10-02,2011.0,2014-10-01,2014,University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; UCB Pharma (Belgium); GSI Helmholtz Centre for Heavy Ion Research; Scripps Research Institute,grid.8756.c; grid.8756.c; grid.8756.c; grid.8756.c; grid.421932.f; grid.159791.2; grid.214007.0,United Kingdom; United Kingdom; United Kingdom; United Kingdom; Belgium; Germany; United States,Biotechnology and Biological Sciences Research Council,United Kingdom,3,0,0
grant.2785892,G0600509,Molecular Genetics of Influenza haemagglutinin production: Developing a rational basis for optimising vaccine yield,1112489,2006-09-17,2006.0,2009-09-16,2009,National Institute for Biological Standards and Control; National Institute for Biological Standards and Control; National Institute for Biological Standards and Control; National Institute of Allergy and Infectious Diseases,grid.70909.37; grid.70909.37; grid.70909.37; grid.419681.3,United Kingdom; United Kingdom; United Kingdom; United States,Medical Research Council,United Kingdom,7,0,0
grant.2783837,BB/G019177/1,A multivalent vaccine and single platform diagnostic for bacterial respiratory diseases of pigs,932571,2010-04-30,2010.0,2015-10-31,2015,London School of Hygiene & Tropical Medicine; Defence Science and Technology Laboratory,grid.8991.9; grid.417845.b,United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,24,0,0
grant.2769709,BBS/E/I/00001494,Structurally modified master seed viruses to enhance conventional foot-and-mouth disease virus vaccine protection,54193,2010-03-31,2010.0,2013-03-31,2013,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,10,0,0
grant.2754059,BB/G020744/1,A multivalent vaccine and single platform diagnostic for bacterial respiratory diseases of pigs,1793362,2010-06-13,2010.0,2017-03-13,2017,Royal Veterinary College; United States Department of Agriculture; University of Technology Sydney,grid.20931.39; grid.417548.b; grid.117476.2,United Kingdom; United States; Australia,Biotechnology and Biological Sciences Research Council,United Kingdom,30,0,0
grant.2726564,ZICDK070011,"Production , purification and preparation of various candidiate vaccines",1934424,2010-01-01,2010.0,2016-01-01,2016,National Institute of Diabetes and Digestive and Kidney Diseases,grid.419635.c,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,11,0,0
grant.2726423,ZIBAI005110,Development and Production of alphavirus vaccines,11022684,2009-01-01,2009.0,2016-01-01,2016,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2726421,ZIBAI005108,HIV LCMV vaccines,5822186,2009-01-01,2009.0,2012-01-01,2012,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2726417,ZIBAI005074,Development/Production-Alternative Serotype HIV Recombinant Adenoviral Vaccine,27046474,2009-01-01,2009.0,2016-01-01,2016,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2726415,ZIBAI005041,Development Of A Multicomponent HIV-1 Recombinant Adenoviral Vector Vaccine,8736822,2009-01-01,2009.0,2012-01-01,2012,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2723429,ZIAAI005079,Ebola Vaccine Development,17873060,2009-01-01,2009.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,15,0,0
grant.2723071,ZIAAI000672,Chlamydial Immunity and Vaccine Development,6777742,2009-01-01,2009.0,2016-01-01,2016,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,38,0,0
grant.2712715,Z01CL000183,PHASE I-II TRIAL OF A GENETIC VACCINE FOR HIV INFECTION,0,1996-01-01,1996.0,2000-01-01,2000,National Institutes of Health Clinical Center,grid.410305.3,United States,National Institutes of Health Clinical Center,United States,0,0,0
grant.2712046,Z01BS002005,COMPARISON OF LEDERLE DTPH AND DTP VACCINES,0,1995-01-01,1995.0,1995-12-31,1995,Center for Biologics Evaluation and Research,grid.290496.0,United States,United States Food and Drug Administration,United States,0,0,0
grant.2711205,Z01BF003015,"POTENCY TEST FOR JAPANESE ENCEPHALITIS VIRUS VACCINE, INACTIVATED, LYOPHILIZED",0,1991-01-01,1991.0,1991-12-31,1991,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711169,Z01BF001005,VIROLOGICAL STUDIES OF RECIPIENTS OF HIV-1 VACCINES,0,1990-01-01,1990.0,1991-01-01,1991,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709250,Z01AI005086,Development/production of H5 influenza DNA plasmid vaccine,5400619,2006-01-01,2006.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2709243,Z01AI005079,Ebola Vaccine Development,1149705,2005-01-01,2005.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2709238,Z01AI005074,Development/Production-Alternative Serotype HIV Recombinant Adenoviral Vaccine,7322441,2005-01-01,2005.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2709208,Z01AI005043,Multiclade HIV-1 DNA Plasmid Vaccine With Plasmid Cytoki,0,2002-01-01,2002.0,2005-01-01,2005,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2709206,Z01AI005041,Development Of A Multicomponent HIV-1 Recombinant Adenoviral Vector Vaccine,6232846,2002-01-01,2002.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2709167,Z01AI005002,HIV/AIDS Vaccine Development,3530037,2002-01-01,2002.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,31,0,0
grant.2708553,Z01AI000446,TESTING OF ROTAVIRUS VACCINE CANDIDATES IN VENEZUELA AND PERU,0,1985-01-01,1985.0,1992-01-01,1992,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2708458,Z01AI000312,CLINICAL AND EXPERIMENTAL STUDIES OF HEPATITIS B VACCINES,0,1985-01-01,1985.0,1987-01-01,1987,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706122,Y1AI0647-1-0-1,Guinea Pig Model for Shigellosis,70000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706116,Y1AI0609-1-0-1,Storage of serum samples from a smallpox vaccine-associated myocarditis study,13680,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2688037,U01AI078205,Mucosal Vector with TLR3 agonist for protection against VEE,1246796,2009-09-12,2009.0,2012-05-31,2012,Vaxart (United States),grid.438926.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687949,U01AI074509,DNA Vaccine for Seasonal &Pandemic Influenza,5771762,2007-08-15,2007.0,2013-07-31,2013,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,8,1,0
grant.2687703,U01AI061242,A single-dose prophylactic Japanese Encephalitis vaccine,6505821,2005-06-01,2005.0,2010-05-31,2010,Valneva (Austria),grid.420366.5,Austria,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687484,U01AI046747,HIV VACCINE TRAILS NETWORK LEADERSHIP GROUP,124686256,1999-09-30,1999.0,2008-05-31,2008,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,National Institute of Allergy and Infectious Diseases,United States,27,0,0
grant.2669265,RC2CA148982,Evaluation of a CCR5 Vaccine for HIV infection in the SIV/Macaque Model,1000000,2009-09-30,2009.0,2012-08-31,2012,University of New Mexico,grid.266832.b,United States,National Cancer Institute,United States,3,0,0
grant.2668278,RC1AI048906,PRODUCTION OF NON-EGG GROWN INFLUENZA VACCINES,26000,2000-05-05,2000.0,2000-08-31,2000,Novavax (United States),grid.436677.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2644101,R43CA084449,WHOLE CELL TUMOR VACCINES BASED ON GPI LINKED MOLECULE,0,1999-07-01,1999.0,2000-06-30,2000,,,,National Cancer Institute,United States,0,0,0
grant.2643860,R43CA079246,CHIMERIC CELL-SURFACE CYTOKINE FOR TUMOR VACCINES,0,1998-09-21,1998.0,1999-09-20,1999,,,,National Cancer Institute,United States,0,0,0
grant.2641629,R43AI080434,A Novel Immune Modulator/ Adjuvant for HIV Vaccines,599314,2008-07-15,2008.0,2010-06-30,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641339,R43AI066616,Development of a Recombinant Subunit Ebola Vaccine,951338,2007-06-15,2007.0,2009-11-30,2009,PanThera Biopharma,grid.423387.9,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2641242,R43AI062176,Novel Adenovirus Vectors for Biodefense Vaccines,433476,2006-08-15,2006.0,2009-01-31,2009,GenVec,grid.281217.f,United States,National Institute of Allergy and Infectious Diseases,United States,1,1,0
grant.2641097,R43AI056847,Evaluation of rotavirus vaccines in a primate model,298422,2003-09-01,2003.0,2006-11-30,2006,P2D Bioscience (United States),grid.281093.1,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2640968,R43AI052985,DNA Vaccines for Anthrax: Targeting Afferent Immunity,148163,2003-04-15,2003.0,2005-02-14,2005,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640965,R43AI052969,Rational Anthrax Vaccine with Structural Epitopes on VLP,98000,2002-09-01,2002.0,2003-08-30,2003,,,,National Institute of Allergy and Infectious Diseases,United States,0,1,0
grant.2640907,R43AI052567,Membrane-Stabilized Lymphotoxin As a Vaccine Adjuvant,95872,2003-06-01,2003.0,2003-11-30,2003,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640880,R43AI051903,A Unique AIDS Vaccine Candidate For Multiple HIV Strains,497617,2002-06-01,2002.0,2005-05-31,2005,ProSci Incorporated (United States),grid.423421.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,1,0
grant.2640182,R43AI035452,LIVE ORAL BACTERIAL VACCINE EVALUATION,0,1994-07-01,1994.0,1994-12-31,1994,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2601232,R21AI103466,Rational Approach to Optimize Immune Potency of DNA Vaccines,393210,2013-06-15,2013.0,2017-05-31,2017,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2600952,R21AI099431,Mucoadhesive Polymers for Sublingual Vaccine Delivery,413875,2012-04-01,2012.0,2015-03-31,2015,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2599022,R21AI068433,Novel DNA/VLP Vaccines Against Influenza,415204,2006-07-15,2006.0,2009-06-30,2009,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2544527,R01HS007286,DIFFUSION AND ADOPTION OF CHILDREN'S VACCINE GUIDELINES,0,1992-07-01,1992.0,1996-06-30,1996,University of North Carolina at Chapel Hill,grid.10698.36,United States,Agency for Healthcare Research and Quality,United States,5,0,0
grant.2506017,R01EY009392,THERAPEUTIC VACCINES TO REDUCE OCULAR HSV RECURRENCE,1542675,1992-01-01,1992.0,2005-03-31,2005,"University of California, Irvine",grid.266093.8,United States,National Eye Institute,United States,8,0,0
grant.2485747,R01DA017482,HIV Vaccine Trials in Women,1653241,2003-09-30,2003.0,2007-06-30,2007,New York Blood Center,grid.250415.7,United States,National Institute on Drug Abuse,United States,5,0,1
grant.2459206,R01AI093491,Novel Vaccine Technology for Chikungunya,3167056,2011-08-01,2011.0,2016-07-31,2016,The University of Texas System,grid.55460.32,United States,National Institute of Allergy and Infectious Diseases,United States,21,3,0
grant.2458313,R01AI078787,Effect of Helminth Infection on HIV-1 Vaccines,1885691,2008-02-15,2008.0,2014-01-31,2014,University of Georgia,grid.213876.9,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2435112,P01AI055944,An Adjuvanted Therapeutic DNA Vaccine for AIDS,2869421,2003-07-01,2003.0,2007-12-31,2007,University of Pittsburgh,grid.21925.3d,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2435103,P01AI054955,Preclinical-Clinical Paramyxovirus Vaccine Development,3691362,2004-06-01,2004.0,2010-05-31,2010,St. Jude Children's Research Hospital,grid.240871.8,United States,National Institute of Allergy and Infectious Diseases,United States,19,4,0
grant.2425590,N01AI60019-8-0-1,Therapeutics/Vaccine Teams,6027830,2006-09-30,2006.0,2013-05-31,2013,Argos Therapeutics (United States),grid.428047.d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425589,N01AI60019-6-0-1,Therapeutics/Vaccine Teams,15067360,2006-09-30,2006.0,2013-05-31,2013,Argos Therapeutics (United States),grid.428047.d,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2425446,N01AI40095-44-0-13,Task 09 (C21): Development of a Murine Model for Plague Vaccines,358137,2010-09-27,2010.0,2012-09-30,2012,Lovelace Respiratory Research Institute,grid.280401.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425142,N01AI30018-10-0-1,Reagent Research Support,3164485,2003-04-14,2003.0,2011-04-13,2011,Quality Biological,grid.283674.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424838,N01AI065315,VACCINE PRODUCTION FACILITY,1025578,1996-09-30,1996.0,2001-09-29,2001,University of Massachusetts Medical School,grid.168645.8,United States,National Institute of Allergy and Infectious Diseases,United States,6,1,0
grant.2424825,N01AI065302,SIMIAN VACCINE EVALUATION UNITS,0,1996-04-01,1996.0,2001-03-31,2001,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2424824,N01AI065301,SIMIAN VACCINE EVALUATION UNITS,715315,1996-04-01,1996.0,2001-03-31,2001,Henry M. Jackson Foundation,grid.201075.1,United States,National Institute of Allergy and Infectious Diseases,United States,18,0,0
grant.2424823,N01AI065300,SIMIAN VACCINE EVALUATION UNITS,0,1996-04-01,1996.0,2001-03-31,2001,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2417267,K22AI068489,CD40L and GITRL adjuvants for adenoviral vaccines against HIV,270000,2008-05-01,2008.0,2010-04-30,2010,University of Miami,grid.26790.3a,United States,National Institute of Allergy and Infectious Diseases,United States,9,4,0
grant.2369962,F32AI009659,STATISTICAL METHODS FOR ANALYSES OF HIV VACCINE TRIALS,0,1997-02-28,1997.0,1998-01-01,1998,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347135,272201000009I-0-27200003-2,Task A12: SMALL ANIMAL MODELS FOR MYCOBACTERIA  VACCINE TESTING,1219723,2013-01-01,2013.0,2013-12-31,2013,Colorado State University,grid.47894.36,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2459198,R01AI093406,A dual vaccine strategy against filovirus infection,5135559,2011-05-01,2011.0,2018-04-30,2018,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.4294554,MR/N006259/1,"Impact of maternally derived antibodies and infant microbiota on the immunogenicity of rotavirus vaccines in African, Indian and European infants.",1307957,2015-07-12,2015.0,2018-12-31,2018,University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; Medical Research Council; Kenya Medical Research Institute; University of Leeds; Imperial College London,grid.10025.36; grid.10025.36; grid.10025.36; grid.10025.36; grid.14105.31; grid.33058.3d; grid.9909.9; grid.7445.2,United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; Kenya; United Kingdom; United Kingdom,Medical Research Council,United Kingdom,7,0,0
grant.7673939,W81XWH-18-2-0011,Evaluation of Protein Capsule Matrix Vaccines Against Campylobacter jejuni,225284,2016-10-01,2016.0,2017-09-01,2017,Henry M. Jackson Foundation,grid.201075.1,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7146038,W81XWH-17-2-0074,Clinical Evaluation of an Improved Adenovirus Vaccine,6507730,2015-10-01,2015.0,2016-09-01,2016,PaxVax (United States),grid.437314.6,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.6382318,972224,A Dengue/Zika Vaccine That Avoids Antibody-Dependent Enhancement,675386,2016-08-31,2016.0,2017-08-30,2017,Excivion (United Kingdom),grid.498296.8,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.3859869,R43AI112264,Development of a Universal Influenza B Vaccine,600000,2015-01-15,2015.0,2017-12-31,2017,Altravax (United States),grid.422379.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2692222,U01IP000147,Enhanced Surveillance for New Vaccine Preventable Diseases,1067820,2007-08-31,2007.0,2011-08-30,2011,Cincinnati Children's Hospital Medical Center,grid.239573.9,United States,Centers for Disease Control and Prevention,United States,13,0,0
grant.2666434,R56AI084908,Development of a tularemia vaccine that is safer and more potent than LVS,670197,2010-07-06,2010.0,2012-06-30,2012,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2458298,R01AI078357,HA Surface Presented Yeast Flu Vaccine and Its Enhancement by CD154 Codisplay,1323632,2009-07-07,2009.0,2015-06-30,2015,Binghamton University,grid.264260.4,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.7430482,17122915,Role of PD1-Based Vaccine-Elicited CD8+ T Lymphocytes in Modulating MDSC-associated Immunosuppression,125500,2015-04-01,2015.0,2018-12-31,2018,University of Hong Kong; University of Hong Kong; University of Hong Kong,grid.194645.b; grid.194645.b; grid.194645.b,China; China; China,University Grants Committee,China,3,0,0
grant.6952757,R03CA219715,Antibodies to melanoma vaccine peptides,161250,2017-07-01,2017.0,2019-06-30,2019,University of Virginia,grid.27755.32,United States,National Cancer Institute,United States,0,0,0
grant.6380452,2015-33610-23672,A NEW CLASS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) AUTOGENOUS VACCINE PRODUCED IN A NOVEL PORCINE MACROPHAGE CELL LINE,99948,2015-07-15,2015.0,2016-03-14,2016,Aptimmune Biologics (United States); Aptimmune Biologics (United States),grid.486867.3; grid.486867.3,United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.5503451,R41AI126940,Stabilization of Influenza Vaccine by Silica-Coating,224993,2016-08-15,2016.0,2018-07-31,2018,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.4295315,BB/M028224/1,Development of autogenous vaccines for the control of amoebic gill disease in farmed Atlantic salmon,260785,2015-04-30,2015.0,2018-04-29,2018,University of Stirling; University of Stirling,grid.11918.30; grid.11918.30,United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,2,0,0
grant.4103659,R21CA194831,Increasing HPV Vaccine Coverage among Young Adult Gay and Bisexual Men,382920,2015-07-01,2015.0,2018-06-30,2018,The Ohio State University,grid.261331.4,United States,National Cancer Institute,United States,3,0,1
grant.3867852,R21AI113407,Next Generation sequencing of yellow fever 17D vaccine virus,426250,2015-02-01,2015.0,2018-01-31,2018,The University of Texas System,grid.55460.32,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.3733061,FAIR961502,NEW MOLECULAR APPROACHES FOR IMPROVED VACCINES TO POULTRY DISEASES,1205314,1997-02-01,1997.0,2000-06-30,2000,Pirbright Institute; Pirbright Institute; Aarhus University; University of Copenhagen; Loire Valley Centre; University of Turku; University of Innsbruck,grid.63622.33; grid.63622.33; grid.7048.b; grid.5254.6; grid.418065.e; grid.1374.1; grid.5771.4,United Kingdom; United Kingdom; Denmark; Denmark; France; Finland; Austria,European Commission,Belgium,0,0,0
grant.3625269,R43AI107999,An immunomodulatory yeast-derived beta glucan as a component of a conjugate,149450,2014-06-15,2014.0,2016-12-31,2016,Biothera (United States),grid.427510.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3535533,F31DA037709,Chemical Strategies for Developing Improved Vaccines against Phenethylamines,59796,2014-04-15,2014.0,2016-04-14,2016,Scripps Research Institute,grid.214007.0,United States,National Institute on Drug Abuse,United States,5,0,0
grant.2754548,BB/I017216/1,Development and comparative evaluation of three new generation BRSV DIVA vaccines and a corresponding DIVA test,639632,2011-01-03,2011.0,2015-01-02,2015,Pirbright Institute; Swedish University of Agricultural Sciences; French National Institute for Agricultural Research,grid.63622.33; grid.6341.0; grid.414548.8,United Kingdom; Sweden; France,Biotechnology and Biological Sciences Research Council,United Kingdom,7,0,0
grant.2692257,U01IP000457,Enhanced Surveillance for New Vaccine Preventable Disease,3294116,2011-08-01,2011.0,2017-07-31,2017,Seattle Children's Hospital,grid.240741.4,United States,Centers for Disease Control and Prevention,United States,4,0,0
grant.2692202,U01IP000074,PiiiTCH Study,0,2006-09-15,2006.0,2008-09-14,2008,Duke University,grid.26009.3d,United States,Centers for Disease Control and Prevention,United States,2,0,1
grant.2688086,U01AI082210,Development of stable and rapidly acting adjuvanted vaccines for biodefense,9054372,2009-09-24,2009.0,2014-12-31,2014,Soligenix (United States),grid.422346.5,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2688014,U01AI077910,Bivalent Recombinant LHn Botulinum Vaccine (Serotypes A and B),1805738,2008-06-25,2008.0,2012-05-31,2012,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687686,U01AI060603,Development of a Global GBS Vaccine,2606237,2004-07-15,2004.0,2008-06-30,2008,Brigham and Women's Hospital,grid.62560.37,United States,National Institute of Allergy and Infectious Diseases,United States,11,0,0
grant.2658051,R44AI072925,Topical adjuvants to enhance the efficacy of influenza vaccines,1287837,2007-06-15,2007.0,2013-02-28,2013,,,,National Institute of Allergy and Infectious Diseases,United States,0,2,0
grant.2657928,R44AI053060,Prophylactic Anthrax Toxin Vaccine,5819399,2002-07-01,2002.0,2007-06-30,2007,Vical (United States),grid.422245.7,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2645385,R43CA139663,Development of a Novel Her2/neu Expressing Adenovirus for Treatment,123567,2009-04-01,2009.0,2010-06-30,2010,Etubics (United States),grid.421196.9,United States,National Cancer Institute,United States,1,6,0
grant.2641871,R43AI094700,Trivalent Arenaviral Vaccine Based on Virus-Like Particle Vectors (VLPVs),222146,2011-07-15,2011.0,2013-06-30,2013,Medigen (United States),grid.421237.1,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2612876,R21HD062929,School Mandates for Human Papillomavirus Vaccination: Use of an Agent-Based Model,375910,2010-08-11,2010.0,2013-07-31,2013,University of Michigan,grid.214458.e,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.2601484,R21AI107678,Laser-based powder vaccine delivery for improved newborn immunization,432439,2013-06-01,2013.0,2017-05-31,2017,University of Rhode Island,grid.20431.34,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2600266,R21AI087382,Addressing Intra-/Inter-Clade Diversity in HIV Vaccine Design by Immune Focusing,448015,2010-04-12,2010.0,2013-03-31,2013,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2599911,R21AI081071,Development of live attenuated influenza virus vaccine,423500,2009-05-22,2009.0,2012-04-30,2012,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2599769,R21AI079521,Targeted Gene Expression from NL63 Vaccine Vectors,489914,2008-07-01,2008.0,2011-06-30,2011,University of North Carolina at Chapel Hill,grid.10698.36,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2581895,R13AI094946,Vaccine Renaissance Conference at the Institute for Immunology and Informatics,61000,2011-03-01,2011.0,2019-06-30,2019,University of Rhode Island,grid.20431.34,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2567250,R03AI076748,Integration of Spatial and Social Network Analysis in Vaccine Trials,147260,2009-09-04,2009.0,2012-08-31,2012,University of North Carolina at Chapel Hill,grid.10698.36,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2458818,R01AI084952,Oral Vaccine Platform for Yersinia pestis,1233215,2010-05-01,2010.0,2013-04-30,2013,Icahn School of Medicine at Mount Sinai,grid.59734.3c,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2456916,R01AI062518,Passive-Active Immunization Strategies Against Pediatric AIDS,1818457,2006-03-01,2006.0,2010-02-28,2010,"University of California, Davis",grid.27860.3b,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2456421,R01AI057029,Poxvirus Immunity and DNA/MVA HIV Vaccines,2064580,2003-07-01,2003.0,2008-10-31,2008,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,15,4,0
grant.2355138,DP2AI112194,Directing the Immune System via Polymeric Combinations of Molecular Signals,2254727,2013-09-24,2013.0,2018-08-31,2018,"University of California, Irvine",grid.266093.8,United States,National Institute of Allergy and Infectious Diseases,United States,14,0,0
grant.8579772,,Understanding the issues surrounding parents'decisions to accept new vaccines for their children: A psychological theory-based approach.,16980,2010-09-01,2010.0,2011-05-06,2011,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8459443,,Identification of biomarkers indicative of Respiratory Syncytial Virus (RSV) vaccine-induced immune responses,13692,2015-05-01,2015.0,2016-04-30,2016,University of Ottawa,grid.28046.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8339888,81460541,基于DDA/TDB阳离子脂质体为佐剂的新型流感疫苗构建及经鼻粘膜免疫效应与机制研究,68640,2015-01-01,2015.0,2018-12-31,2018,Ningxia Medical University,grid.412194.b,China,National Natural Science Foundation of China,China,2,0,0
grant.8181151,31400784,表达鸡传染性支气管炎病毒S1和N蛋白重组新城疫病毒的构建及免疫保护评价,38248,2015-01-01,2015.0,2017-12-31,2017,Southwest University,grid.263906.8,China,National Natural Science Foundation of China,China,0,0,0
grant.7749383,CDMRPL-13-0-PR130236,Use of the Dual Platform Immunization (DuPI) Approach to Develop a Tetravalent Dengue Vaccine,812000,2012-10-01,2012.0,2013-09-01,2013,Naval Medical Research Center,grid.415913.b,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7673878,W81XWH-18-2-0037,Controlled Release of Inactivated Chikungunya Virus Vaccine Candidate: A Single Vaccination Approach for Long-Term Immunity,267964,2016-10-01,2016.0,2017-09-01,2017,Henry M. Jackson Foundation,grid.201075.1,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7665291,,"Development of a Single Shot, Neonatal Pertussis Vaccine",16980,2010-09-01,2010.0,2011-08-31,2011,British Columbia Children's Hospital,grid.414137.4,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7651902,,Public deliberation on vaccine hesitancy,75443,2016-07-01,2016.0,2017-06-30,2017,University of Guelph,grid.34429.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7641966,,In vivo evaluation of conventional and experimental avian influenza A (H5N1) virus vaccines,137729,2007-02-01,2007.0,2009-01-31,2009,Public Health Agency of Canada,grid.415368.d,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7616855,,Novel cross-protective (universal) vaccine for influenza infections,160015,2012-10-01,2012.0,2013-09-30,2013,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7566317,C10X0307,Novel tuberculosis vaccine for cattle,1605046,2003-07-01,2003.0,2008-09-30,2008,AgResearch (New Zealand),grid.417738.e,New Zealand,"Ministry of Business, Innovation and Employment",New Zealand,0,0,0
grant.7124299,2015-02686,ImmuneTrack - for optimisation of vaccine stock management in Uganda,33628,2015-08-01,2015.0,2016-04-30,2016,,,,VINNOVA,Sweden,0,0,0
grant.7109721,2016-00748,Development of a therapeutic vaccine against genital herpes simplex virus 2 infection,58417,2016-06-01,2016.0,2018-01-31,2018,University of Gothenburg,grid.8761.8,Sweden,VINNOVA,Sweden,0,0,0
grant.7029068,R21AI134495,A Novel Vaccine Platform for Preventing Zika Virus Infection,449875,2017-07-25,2017.0,2019-06-30,2019,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6715541,257536,Pre-clinical development of a chemically synthetic anti-toxic vaccine against malaria,118061,2003-01-01,2003.0,2005-12-31,2005,Walter and Eliza Hall Institute of Medical Research,grid.1042.7,Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6713972,350375,Improving efficacy of vaccination against the gut pathogen Helicobacter pylori,395117,2005-01-01,2005.0,2007-12-31,2007,University of Melbourne,grid.1008.9,Australia,National Health and Medical Research Council,Australia,4,0,0
grant.6663822,274053,Next Generation Vaccines to Augment Anti-PD-1 Immunotherapy for Melanoma,270000,2013-07-01,2013.0,2016-06-30,2016,Johns Hopkins University,grid.21107.35,United States,Melanoma Research Alliance,United States,0,0,0
grant.6501302,ZIAAI005128,Rapid Development of Vaccines for Emerging Viruses,41801392,2016-01-01,2016.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.6049130,22659033,経皮免疫製剤の利便性・汎用性向上に適うアジュバントの同定と構造改変抗原分子の創製,33025,2010-01-01,2010.0,2010-12-31,2010,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5829752,15019075,ユビキチンプロテアソーム系の応用による細胞内寄生原虫に対するDNAワクチンの開発,44843,2003-01-01,2003.0,2003-12-31,2003,Kyushu University,grid.177174.3,Japan,Japan Society for the Promotion of Science,Japan,6,0,0
grant.5823968,14370694,Development of effective immunization by DNA vaccine against iron-acquisition protein of periodontopathic bacteria,108801,2002-01-01,2002.0,2003-12-31,2003,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.5721408,09770180,牛のボツリヌスC型、D型中毒の両方に効果のあるリコンビナントワクチンの作製,14311,1997-01-01,1997.0,1998-12-31,1998,Okayama University,grid.261356.5,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5664360,07507001,Deparment of vaccine for new type of Vibrio cholerae O139 Bengal,493431,1995-01-01,1995.0,1997-12-31,1997,National Center For Global Health and Medicine,grid.45203.30,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5475778,R21AI119733,Ultra-dense peptide array analysis of naturally acquired and vaccine-induced P. falciparum immunity,360695,2016-07-07,2016.0,2019-06-30,2019,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.5223759,133373,11th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology / DC2010: Forum on Vaccine Science,19803,2010-09-01,2010.0,2011-04-30,2011,University Hospital of Zurich; Institute for Research in Biomedicine; Swiss Federal Institute of Technology in Zurich; University of Italian Switzerland,grid.412004.3; grid.7722.0; grid.5801.c; grid.29078.34,Switzerland; Spain; Switzerland; Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.4899209,ID06-VMRF-231,CD40L and GITRL adjuvants for anti-HIV Ad5 vector vaccines,100000,2006-09-01,2006.0,2007-12-31,2007,Veterans Medical Research Foundation of San Diego,grid.44214.37,United States,California HIV/AIDS Research Program,United States,0,0,0
grant.4660769,235356,Development of photochemical internalisation for enhancement of therapeutic and prophylactic vaccination,1637114,2014-01-01,2014.0,2017-12-31,2017,PCI Biotech (Norway),grid.458787.1,Norway,The Research Council of Norway,Norway,1,0,0
grant.4640178,185441,The Immunogenicity and Protective Efficacy of Plant-Derived Influenza H5N1 Vaccine in Preclinical Models.,851858,2008-01-01,2008.0,2012-12-31,2012,University of Bergen,grid.7914.b,Norway,The Research Council of Norway,Norway,2,0,0
grant.4633981,J3-7878 (D),Razvoj avtolognih tumorskih vakcin (basic research project),0,1996-01-01,1996.0,2001-06-30,2001,University of Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; Institute of Oncology Ljubljana; University of Ljubljana,grid.8954.0; grid.418872.0; grid.418872.0; grid.418872.0; grid.418872.0; grid.8954.0,Slovenia; Slovenia; Slovenia; Slovenia; Slovenia; Slovenia,Slovenian Research Agency,Slovenia,0,0,0
grant.4485915,11/06583-2,Vaccine against Streptococcus pneumoniae based on choline-binding proteins,0,2011-10-01,2011.0,2013-09-30,2013,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4415436,W81XWH-06-C-0033,Needleless Intradermal Vaccine Delivery System Using Ultrasound,69540,2004-10-01,2004.0,2005-09-30,2005,,,,United States Department of the Army,United States,2,0,0
grant.4390182,N00014-03-M-0098,Boost-Phase Sub-Unit Vaccine Development for Binary Vaccines Against Infectious Diseases and Biological Warfare Agents,69997,2002-10-01,2002.0,2003-09-30,2003,Vaxin (United States),grid.422117.3,United States,United States Department of the Navy,United States,0,0,0
grant.3940618,646122,MAnufacturing process for Cold-chain Independent VIrosome-based VAccines,6036395,2015-05-04,2015.0,2018-11-03,2018,Bachem (Switzerland); Bachem (Switzerland),grid.483224.b; grid.483224.b,Switzerland; Switzerland,European Commission,Belgium,0,0,0
grant.3784451,241745,Discovery and preclinical development of new generation tuberculosis vaccines,15978946,2010-01-01,2010.0,2014-02-28,2014,TuBerculosis Vaccine Initiative; GlaxoSmithKline (Belgium); Leiden University Medical Center; Yonsei University; International Vaccine Institute; Scientific Institute of Public Health; University of Zaragoza; University of Geneva; State Serum Institute; Biomedical Primate Research Centre; University of Ulm; Institut Pasteur Korea; National Institute of Health; Department of Health and Social Care; Max Planck Society; Ministry of Health Welfare and Sport; GlaxoSmithKline (Belgium); University of Palermo; University of Padua; Université Libre de Bruxelles; Department of Health and Social Care; Health Sciences Research Institute of the “Germans Trias i Pujol” Foundation; University of Zurich; London School of Hygiene & Tropical Medicine; Pasteur Institute; Pasteur Institute of Lille; University of Oxford; University of Tübingen; University of Italian Switzerland; University Hospital Erlangen; French National Centre for Scientific Research; University Hospital of Basel; Wageningen University & Research; Aston University; Aguettant (France),grid.425962.e; grid.425090.a; grid.10419.3d; grid.15444.30; grid.30311.30; grid.418170.b; grid.11205.37; grid.8591.5; grid.6203.7; grid.11184.3d; grid.6582.9; grid.418549.5; grid.416651.1; grid.57981.32; grid.4372.2; grid.425719.c; grid.425090.a; grid.10776.37; grid.5608.b; grid.4989.c; grid.57981.32; grid.429186.0; grid.7400.3; grid.8991.9; grid.428999.7; grid.8970.6; grid.4991.5; grid.10392.39; grid.29078.34; grid.411668.c; grid.4444.0; grid.410567.1; grid.4818.5; grid.7273.1; grid.451249.f,Netherlands; Belgium; Netherlands; South Korea; South Korea; Belgium; Spain; Switzerland; Denmark; Netherlands; Germany; South Korea; Italy; United Kingdom; Germany; Netherlands; Belgium; Italy; Italy; Belgium; United Kingdom; Spain; Switzerland; United Kingdom; France; France; United Kingdom; Germany; Switzerland; Germany; France; Switzerland; Netherlands; United Kingdom; France,European Commission,Belgium,49,0,0
grant.3784425,245145,Improvement of current and development of new vaccines for theileriosis and babesios of small ruminants,3994998,2010-04-01,2010.0,2014-09-30,2014,Research Center Borstel - Leibniz-Center for Medicine and Biosciences; French Institute of Health and Medical Research; Adnan Menderes University; Royal Veterinary College; Ministry of Agriculture and Rural Development; MSD (Netherlands); University of Bern; National Agricultural Technology Institute; Adnan Menderes University; Parco Tecnologico Padano; University of Glasgow; Bernhard Nocht Institute for Tropical Medicine; Oniris; University of Edinburgh; Instituto de Biologia Experimental Tecnológica; Lanzhou Institute of Veterinary Research,grid.418187.3; grid.7429.8; grid.34517.34; grid.20931.39; grid.425807.c; grid.420097.8; grid.5734.5; grid.419231.c; grid.34517.34; grid.425375.2; grid.8756.c; grid.424065.1; grid.418682.1; grid.4305.2; grid.7665.2; grid.454892.6,Germany; France; Turkey; United Kingdom; Israel; Netherlands; Switzerland; Argentina; Turkey; Italy; United Kingdom; Germany; France; United Kingdom; Portugal; China,European Commission,Belgium,42,0,0
grant.3772404,223126,Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation,1360148,2009-04-01,2009.0,2012-03-31,2012,University of Oxford; University of Edinburgh; World Health Organization; Stockholm University; Barcelona Institute for Global Health; United States Department of Health and Human Services; Barcelona Institute for Global Health; State Serum Institute; Radboud University Nijmegen; Biomedical Primate Research Centre; Department of Health and Social Care; Pasteur Institute; United States Department of Health and Human Services,grid.4991.5; grid.4305.2; grid.3575.4; grid.10548.38; grid.434607.2; grid.27235.31; grid.434607.2; grid.6203.7; grid.5590.9; grid.11184.3d; grid.57981.32; grid.428999.7; grid.27235.31,United Kingdom; United Kingdom; Switzerland; Sweden; Spain; United States; Spain; Denmark; Netherlands; Netherlands; United Kingdom; France; United States,European Commission,Belgium,0,0,0
grant.3129185,1131172,Markov Decision Process Models for Optimizing Vaccine Administration,336957,2011-09-01,2011.0,2015-08-31,2015,University of Pittsburgh; University of Pittsburgh; University of Pittsburgh; University of Pittsburgh,grid.21925.3d; grid.21925.3d; grid.21925.3d; grid.21925.3d,United States; United States; United States; United States,Directorate for Engineering,United States,1,0,0
grant.3081070,0724616,Parental Decision Making in the Context of New Medical Technologies: The HPV Vaccine and its Potential Challenges,8234,2007-12-01,2007.0,2008-11-30,2008,Johns Hopkins University; Johns Hopkins University,grid.21107.35; grid.21107.35,United States; United States,"Directorate for Social, Behavioral & Economic Sciences",United States,1,0,0
grant.2960431,397320,Engineered porcine adenovirus type 3 as a vaccine vector,58580,2008-04-01,2008.0,2009-03-31,2009,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2918611,362670,Engineered porcine adenovirus type 3 as a vaccine vector,243993,2005-04-01,2005.0,2008-03-31,2008,University of Saskatchewan; Telesta Therapeutics (Canada),grid.25152.31; grid.450586.a,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2711784,Z01BN003001,IMMUNOPATHOGENESIS OF RUBELLA VIRUS ASSOCIATED AUTOIMMUN,0,1993-01-01,1993.0,1998-01-01,1998,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709010,Z01AI000923,Immune Responses to Vaccinia Virus Vaccination,863263,2003-01-01,2003.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2704625,UC1AI062582,Development of Alphavirus Replicon Vaccine Against SARS,4839367,2004-09-01,2004.0,2009-08-31,2009,AlphaVax (United States),grid.422340.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2704605,UC1AI049519,DNA Based Generation of Avian Influenza virus Vaccines,1400000,2000-09-30,2000.0,2005-09-29,2005,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2687787,U01AI068614,Leadership Group for a Global HIV Vaccine Clinical Trials Network,181539904,2006-06-29,2006.0,2013-05-31,2013,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,National Institute of Allergy and Infectious Diseases,United States,64,0,2
grant.2687506,U01AI048001,COALITION FOR HIV VACCINE DEVELOPMENT,10254597,2000-06-01,2000.0,2007-01-31,2007,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2668265,RC1AI048872,DNA BASED GENERATION OF AVIAN INFLUENZA VIRUS VACCINES,26000,2000-05-05,2000.0,2000-08-31,2000,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2668260,RC1AI048861,CHIMERIC YELLOW FEVER 17D/DENGUE AND WEST NILE VACCINES,26000,2000-05-03,2000.0,2000-08-31,2000,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657974,R44AI058535,Development of an anti-malaria toxin vaccine candidate,3320986,2004-03-01,2004.0,2010-02-28,2010,Corden Pharma (United States),grid.432520.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657783,R44AI043107,HETEROCONJUGATE VACCINES AGAINST HERPES SIMPLEX VIRUS,764116,1998-06-01,1998.0,2004-08-31,2004,Cel-Sci (United States),grid.420516.4,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2641688,R43AI082834,Development of a plant-grown subunit vaccine against respiratory syncytial virus,581068,2010-03-15,2010.0,2015-02-28,2015,Virogenomics BioDevelopment (United States),grid.281425.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641619,R43AI080029,Improved influenza A virus vaccines using alpha-Gal epitope modification,578784,2008-09-17,2008.0,2011-08-31,2011,NewLink Genetics (United States),grid.426927.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641309,R43AI065021,An improved targeted vaccine strategy against anthrax,408908,2005-05-15,2005.0,2006-04-30,2006,Bristol-Myers Squibb (United States),grid.419971.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641121,R43AI058326,"A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE",831922,2004-09-15,2004.0,2007-08-31,2007,EpiVax (United States),grid.421087.8,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2641056,R43AI055271,Development of a Plant-based Vaccine aganist HIV,144408,2003-05-01,2003.0,2004-04-30,2004,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640855,R43AI051135,DNA Tolerizing Vaccine Therapy for Multiple Sclerosis,100000,2002-09-15,2002.0,2003-03-14,2003,,,,National Institute of Allergy and Infectious Diseases,United States,0,1,0
grant.2640759,R43AI048985,A CMV vaccine with modified immuno-modulatory properties,99999,2001-09-15,2001.0,2002-03-14,2002,ChemoCentryx (United States),grid.452218.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2604455,R21CA121832,Multifunctional nanoparticles for targeted DNA vaccine delivery,408485,2006-06-01,2006.0,2009-05-31,2009,University of Minnesota,grid.17635.36,United States,National Cancer Institute,United States,2,0,0
grant.2598688,R21AI062518,Passive-Active Vaccine Strategies Against Pediatric AIDS,209719,2004-09-30,2004.0,2006-02-28,2006,"University of California, Davis",grid.27860.3b,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2598334,R21AI056974,Recombinant Sendai Virus as a Novel HIV Vaccine Vector,450000,2003-08-01,2003.0,2005-07-31,2005,St. Jude Children's Research Hospital,grid.240871.8,United States,National Institute of Allergy and Infectious Diseases,United States,14,2,0
grant.2597967,R21AI052761,AIDS Prevention: Mucosally-Targeted Plant Based Vaccines,446025,2004-09-30,2004.0,2006-08-31,2006,Arizona State University,grid.215654.1,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2597799,R21AI049153,Rabies Virus-Based Vectors as an HIV -1 Vaccine,378503,2001-03-15,2001.0,2005-05-31,2005,Thomas Jefferson University,grid.265008.9,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2583453,R13CA094576,Conference on Gene-Based Vaccines,8000,2002-04-01,2002.0,2003-03-31,2003,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Cancer Institute,United States,0,0,0
grant.2581808,R13AI087261,HIV Vaccines,15000,2010-03-01,2010.0,2011-02-28,2011,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2576351,R03HS010021,EFFECT OF COMMUNITY PHARMACISTS ON ADULT IMMUNIZATION,0,1998-09-30,1998.0,2000-09-29,2000,University of North Carolina at Chapel Hill,grid.10698.36,United States,Agency for Healthcare Research and Quality,United States,3,0,0
grant.2566915,R03AI053598,Multi-component and easily administrated anthrax vaccine,157500,2002-09-15,2002.0,2005-09-30,2005,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2566904,R03AI053214,Geographical Analysis in Vaccine Efficacy Trials,116212,2002-09-30,2002.0,2005-08-31,2005,Portland State University,grid.262075.4,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2526101,R01HD038416,Vaccines for Prevention of Experimental Congenital CMV,2198212,2000-04-01,2000.0,2013-02-28,2013,University of Minnesota,grid.17635.36,United States,National Institute of Child Health and Human Development,United States,57,2,0
grant.2468650,R01CA040714,IMMUNOPREVENTION OF HTLV INFECTION,0,1985-09-30,1985.0,1992-11-30,1992,The Ohio State University,grid.261331.4,United States,National Cancer Institute,United States,9,0,0
grant.2457755,R01AI071883,The Effect of Helminth Infection on HIV-1 Vaccines,743208,2009-06-19,2009.0,2011-05-30,2011,University of Georgia,grid.213876.9,United States,National Institute of Allergy and Infectious Diseases,United States,5,6,0
grant.2457231,R01AI065697,TB Vaccine Development in Nonhuman Primate Model,3327766,2005-09-30,2005.0,2012-03-31,2012,Texas Biomedical Research Institute,grid.250889.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2457183,R01AI065276,HIV/FIV-cat model: a model to identify vaccine epitopes,1087229,2006-07-01,2006.0,2010-06-30,2010,University of Florida,grid.15276.37,United States,National Institute of Allergy and Infectious Diseases,United States,10,4,0
grant.2453301,R01AI038383,Acquisition and Natural History of Genital HPV Infection,5970977,1995-05-15,1995.0,2012-02-28,2012,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,28,0,0
grant.2392441,G13LM007898,Childhood Vaccine Policy in the U.S. Since 1955,215235,2003-07-01,2003.0,2007-06-30,2007,Duke University,grid.26009.3d,United States,United States National Library of Medicine,United States,1,0,0
grant.2350946,C06RR021833,Center for Research in Emerging Infections and Vaccines,4000000,2005-09-30,2005.0,2010-06-30,2010,Saint Louis University,grid.262962.b,United States,National Center for Advancing Translational Sciences,United States,0,0,0
grant.100072047,T2014-013,Lymph Node-Targeted Cancer Vaccines,600000,2014-11-01,2014.0,2018-10-31,2018,Massachusetts Institute of Technology,grid.116068.8,United States,V Foundation for Cancer Research,United States,0,0,0
grant.2769275,BB/H009175/1,Improving the quality of FMD vaccines by understanding the correlation of vaccine-induced protection with humoral and cellular immune responses,1399240,2011-05-16,2011.0,2015-05-15,2015,"Pirbright Institute; Pirbright Institute; Pirbright Institute; Pirbright Institute; University of Oxford; Ministry of Agriculture, Animal Industry and Fisheries; Onderstepoort Veterinary Institute; University of Glasgow; Indian Immunologicals (India); Indian Immunologicals (India)",grid.63622.33; grid.63622.33; grid.63622.33; grid.63622.33; grid.4991.5; grid.463498.4; grid.452772.1; grid.8756.c; grid.496635.b; grid.496635.b,United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; Uganda; South Africa; United Kingdom; India; India,Biotechnology and Biological Sciences Research Council,United Kingdom,20,0,0
grant.7143297,W81XWH-05-1-0404,A Phase I Study of a DNA-Based Vaccine Targeting Prostatic Acid Phosphatase (PAP) in Patients with Stage D0 Prostate Cancer,736307,2004-10-01,2004.0,2005-09-01,2005,University of Wisconsin–Madison,grid.14003.36,United States,Congressionally Directed Medical Research Programs,United States,8,0,0
grant.4731287,ANR-15-CE36-0008,"Risks, Controversies & Vaccinations",396651,2015-10-01,2015.0,2018-09-30,2018,"Economic & Social Sciences, Health Systems & Medical Informatics",grid.464064.4,France,National Agency for Research,France,0,0,0
grant.3859527,R21AI115383,Newcastle Disease Virus Vectored Vaccine against Poliomyelitis,418000,2014-12-01,2014.0,2017-11-30,2017,"University of Maryland, College Park",grid.164295.d,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.3728056,TS3*940327,Development and Testing of an Oral B Subunit-Whole Cell Cholera Vaccine Protecting Against Both O1 and O139 Cholera,0,1995-02-01,1995.0,1998-06-30,1998,University of Gothenburg; National Institute for Health and Welfare; International Centre for Diarrhoeal Disease Research; Ludwig Maximilian University of Munich; French Institute of Health and Medical Research,grid.8761.8; grid.14758.3f; grid.414142.6; grid.5252.0; grid.7429.8,Sweden; Finland; Bangladesh; Germany; France,European Commission,Belgium,0,0,0
grant.2642043,R43AI106422,Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine,566331,2013-08-01,2013.0,2015-07-31,2015,GeoVax (United States),grid.434905.f,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2709072,Z01AI000987,"Clinical Trials of  Biodefense Vaccines (Dengue, West Nile Virus, TBEV)",2041400,2007-01-01,2007.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.8593212,a296e3a3-0cb9-46f2-ad16-2b40acbf28a2,Evolution of the influenza A virus quasispecies in naive and immune hosts,0,2012-01-01,2012.0,2017-12-31,2017,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8593181,a10b1afd-9ef5-4278-af24-1c5676ccdd35,Development of equine herpesvirus 1 vaccine based on new insights into the pathogenesis of foeto- and neuro virulent equine herpesvirus 1 strains,0,2015-01-01,2015.0,2018-12-31,2018,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8592576,72c7f3d6-7385-4edf-abb9-6c284f3f03e2,Development and use of new genetic engineering and testing for BCG-based anti-tuberculosis vaccines,0,2015-01-01,2015.0,2018-12-31,2018,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8591458,1cc05338-b837-4650-b4a3-1c9cad5176ee,Modulation of NK cells by alpha herpes viruses with the aim of optimizing vaccines and virotherapy,0,2015-01-01,2015.0,2018-12-31,2018,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8591433,1acfc500-6a48-4b82-bdc9-8fa1794f0129,Development of Salmonella live attenuated vaccine strains for various serotypes in layers+ broilers,0,2015-01-15,2015.0,2017-01-14,2017,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8573271,523,Clinical Development of RNA Nanoparticle Vaccines Targeting Recurrent Pediatric Brain Cancers,0,2011-06-15,2011.0,2013-06-15,2013,Duke University,grid.26009.3d,United States,Alex's Lemonade Stand Foundation,United States,0,0,0
grant.8573193,10407_1,In vivo MR Imaging to assess delivery and efficacy of dendritic cell vaccines,0,2007-04-01,2007.0,2010-03-31,2010,Western University,grid.39381.30,Canada,Ontario Institute for Cancer Research,Canada,0,0,0
grant.8568312,TayBandz_02,Immunology vaccine,0,2011-01-01,2011.0,2011-12-31,2011,,,,The Taylor Matthews Foundation,United States,0,0,0
grant.8519075,,Étudiante-chercheuse étoile June 2013,0,2013-04-01,2013.0,2014-03-31,2014,Laval University,grid.23856.3a,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.8461487,,Influence of pre-existing HIV cross-reactive CD4 T cells on vaccine responses to new Env immunogens,192569,2017-06-01,2017.0,2018-11-30,2018,Centre Hospitalier de l’Université de Montréal,grid.410559.c,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8459735,,Immunogenic characterization of plant-specific glyco-epitopes present on influenza virus-like particle vaccines produced in Nicotiana benthamiana,13692,2015-05-01,2015.0,2016-04-30,2016,McGill University,grid.14709.3b,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8329544,81072145,新型多价口服HPV预防性疫苗的研制,47452,2011-01-01,2011.0,2013-12-31,2013,Xi'an Jiaotong University,grid.43169.39,China,National Natural Science Foundation of China,China,1,0,0
grant.8328985,81000724,基于DC的TLR及其信号转导通路在新型乙肝DNA疫苗弹性纳米粒经皮免疫中的作用及其机制研究,31631,2011-01-01,2011.0,2013-12-31,2013,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8216461,39670519,利用转基因植物生产鸡马立克氏病疫苗,12673,1997-01-01,1997.0,1999-12-31,1999,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,0,0,0
grant.8198250,31681260582,2016年度海峡两岸水生生物资源领域项目中期学术交流研讨会,7225,2016-11-20,2016.0,2016-12-31,2016,South China Sea Institute Of Oceanology,grid.458498.c,China,National Natural Science Foundation of China,China,0,0,0
grant.8181152,31400785,仿生硅矿化提高疫苗热稳定性的研究,38248,2015-01-01,2015.0,2017-12-31,2017,Zhejiang University,grid.13402.34,China,National Natural Science Foundation of China,China,4,0,0
grant.8178839,31370931,VLP颗粒抗原降压疫苗免疫应答机制的研究,124340,2014-01-01,2014.0,2017-12-31,2017,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,3,0,0
grant.8176925,31270978,含有GM-CSF或CD40L的汉滩病毒嵌合VLPs疫苗的构建及其免疫学特性研究,24213,2013-01-01,2013.0,2013-12-31,2013,,,,National Natural Science Foundation of China,China,2,0,0
grant.8173632,30670097,痘苗病毒载体重组AIDS疫苗与粘膜上皮细胞的相互作用,42166,2007-01-01,2007.0,2009-12-31,2009,Wuhan University,grid.49470.3e,China,National Natural Science Foundation of China,China,1,0,0
grant.8107190,25938,"Avian adenoviruses; molecular bilogy, vaccine, diagnostics",0,2003-05-01,2003.0,2007-04-30,2007,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8107088,26168,Characterization of and challenge studies with infectious bronchitis virus isolates of Ontario,0,2004-05-01,2004.0,2006-04-30,2006,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8106827,SF6062,Control of Salmonella in Market Hogs Using Immunizations,0,2008-02-20,2008.0,2009-02-19,2009,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8106823,SF6066,Controlling Salmonellosis in Broiler Chickens Using a Multivalent Attenuated Vaccine That Also Controls Necrotic Enteritis,0,2008-03-25,2008.0,2010-03-24,2010,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8041819,13N11739,Verbundprojekt: Development of a hepatitis C vaccine by targeted delivery of nanogel RNA-replicon constructs (HCVAX) - Teilvorhaben: Identifizierung und Generierung synthetischer Adjuvantien für die Verwendung mit Nanogel-verpackten RNA-Replicon Impfstoffen und deren in vitro und in vivo Validierung,676455,2011-07-01,2011.0,2014-06-30,2014,Helmholtz Centre for Infection Research,grid.7490.a,Germany,Federal Ministry of Education and Research,Germany,0,0,0
grant.7749605,W81XWH-18-1-0076,A Novel Influenza Vaccine with Enhanced Immunogenic Hemagglutinin Stalk Domain,259621,2016-10-01,2016.0,2017-09-01,2017,"University of California, Riverside",grid.266097.c,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7632107,,A sub-unit based vaccine for Salmonella,151332,2011-04-01,2011.0,2012-03-31,2012,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7630521,,Topical enhancement of vaccination,23274,2007-03-01,2007.0,2008-02-29,2008,British Columbia Children's Hospital,grid.414137.4,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7617679,,Canadian Immunization Research Network,5588065,2014-06-01,2014.0,2017-05-31,2017,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7615531,AAI18012001-1-0-1,Use of the Baboon Model of Pertussis to Evaluate Strategies for Next Generation Pertussis Vaccines,280000,2018-01-01,2018.0,2018-12-31,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7441243,368531,WT-1 analog peptide vaccine in patients with malignant mesothelioma,100000,2007-01-01,2007.0,2008-12-31,2008,Memorial Sloan Kettering Cancer Center,grid.51462.34,United States,Mesothelioma Applied Research Foundation,United States,0,0,0
grant.7413138,N N302 640740,Prototypy szczepionek przeciwko Neisseria gonorrhoeae oparte o żywe szczepy bakterii zawierając białka lub aktywne fagi nitkowate z Neisseria gonorrhoeae,112638,2011-05-06,2011.0,2014-05-05,2014,University of Warsaw,grid.12847.38,Poland,Ministry of Science and Higher Education,Poland,2,0,0
grant.7210090,31270972,口服Ag85A DNA疫苗肠黏膜细胞内传感器及传导途径与适应性免疫应答诱导,127034,2013-01-01,2013.0,2016-12-31,2016,China Medical University,grid.412449.e,China,National Natural Science Foundation of China,China,4,0,0
grant.7201259,31300824,功能化氧化石墨烯作为新型纳米佐剂在肿瘤DNA疫苗中的研究,39477,2014-01-01,2014.0,2016-12-31,2016,Soochow University,grid.263761.7,China,National Natural Science Foundation of China,China,15,0,0
grant.7198956,81301961,针对肿瘤微环境髓系抑制细胞的新型ImC疫苗抗肿瘤作用及免疫机制研究,36318,2014-01-01,2014.0,2016-12-31,2016,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,2,0,0
grant.7195059,31470134,产生免疫保护性的灭活迟缓爱德华氏菌的作用机制,46658,2015-01-01,2015.0,2016-12-31,2016,Chinese Academy of Fishery Sciences,grid.43308.3c,China,National Natural Science Foundation of China,China,1,0,0
grant.7188506,81271839,JEV疫苗交叉保护登革病毒感染的机理研究,125449,2013-01-01,2013.0,2016-12-31,2016,Capital Medical University,grid.24696.3f,China,National Natural Science Foundation of China,China,14,0,0
grant.7172307,272201100023C-13-0-1,Reagent Resource Support Program for AIDS Vaccine Development,1871237,2017-04-08,2017.0,2018-04-07,2018,Quality Biological,grid.283674.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7172128,272201300010C-6-0-1,Nonhuman Primate Core Functional Genomics Laboratory for AIDS Vaccines Research a,2796093,2013-07-01,2013.0,2018-06-30,2018,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7170344,261201200033I-0-26100012-1,"IGF::OT::IGF  A Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a candidate broadly protective vaccine for the prevention of HPV-associated cancer",95414,2017-09-15,2017.0,2018-09-14,2018,University of Wisconsin–Madison,grid.14003.36,United States,National Cancer Institute,United States,0,0,0
grant.7170037,272201700066C-0-0-1,Determining the Impact of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 on Influenza Vaccine Immunogenicity and Stability,223002,2017-08-01,2017.0,2018-07-31,2018,Adjuvance (United States),grid.504059.d,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7145281,W81XWH-07-1-0345,Second-Generation Therapeutic DNA Lymphoma Vaccines,962500,2005-10-01,2005.0,2006-09-01,2006,The University of Texas MD Anderson Cancer Center,grid.240145.6,United States,Congressionally Directed Medical Research Programs,United States,3,0,0
grant.7126490,2012-03465,"CHOLERA, MUCOSAL VACCINES AND IMMUNOMODULATION",689385,2013-01-01,2013.0,2015-12-31,2015,University of Gothenburg,grid.8761.8,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7111444,2015-01864,Immunological and histochemical assessment of an Alzheimer´s vaccine,59100,2015-06-01,2015.0,2016-02-29,2016,Mivac Development (Sweden),grid.451585.8,Sweden,VINNOVA,Sweden,0,0,0
grant.7110393,2012-03318,Alphavirus replicon vectors as vaccines,376024,2013-01-01,2013.0,2015-12-31,2015,Karolinska Institute,grid.4714.6,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7107704,2011-00585,Simplexia - development of a vaccine against HSV-2 infection,301904,2011-05-01,2011.0,2013-06-30,2013,Chalmersinvest,grid.451683.d,Sweden,VINNOVA,Sweden,0,0,0
grant.7102560,2013-06587,Do host genetic factors restrict natural rotavirus infection and vaccine performance in Nicaragua?,392169,2014-01-01,2014.0,2016-12-31,2016,Linköping University,grid.5640.7,Sweden,Swedish Research Council,Sweden,5,0,0
grant.7094056,2012-00789,Therapeutic vaccines for the treatment of severe atopic dermatitis and asthma,179873,2012-05-01,2012.0,2014-06-30,2014,,,,VINNOVA,Sweden,0,0,0
grant.7093414,2013-06727,Tools to study the effects of rotavirus vaccination in Burkina Faso,84223,2014-01-01,2014.0,2016-12-31,2016,Linköping University,grid.5640.7,Sweden,Swedish Research Council,Sweden,1,0,0
grant.7054358,16/06942-6,Immunogenicity and safety of HPV vaccine in immunosuppressed women due to solid organ transplant and rheumatologic disease. Study 1: Evaluation of primary imune response to vaccination,0,2017-05-01,2017.0,2019-07-31,2019,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.7052734,30_23913,Development of statistical tools for the analysis of complex data: application to associations between reactogenicity and innate/adaptive answer immune related to the adjuvded vaccines for man.,0,2015-11-01,2015.0,2017-10-31,2017,Catholic University of Louvain,grid.7942.8,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.7035750,FC1147,PKD Control  studies on the immune response in fish and vaccine development.,80476,2000-10-01,2000.0,2001-09-30,2001,University of Stirling,grid.11918.30,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7035728,FC1116,Development of vaccination methods for the control of bacterial kidney disease (BKD) in salmonids (LINKSAL10),589441,1998-04-01,1998.0,2001-04-30,2001,University of Stirling,grid.11918.30,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7027530,AAI17022001-1-0-1,Baboon Model of Pertussis to Evaluate Strategies for Next Generation Vaccines,350000,2017-01-01,2017.0,2017-12-31,2017,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7017474,81172443,MUC1模拟表位多肽疫苗设计及其抗肿瘤效应研究,91641,2012-01-01,2012.0,2015-12-31,2015,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,6,0,0
grant.7009470,31100133,人3型、7型腺病毒双价减毒重组疫苗候选株的构建及免疫原性研究,33773,2012-01-01,2012.0,2014-12-31,2014,Southern Medical University,grid.284723.8,China,National Natural Science Foundation of China,China,3,0,0
grant.7007594,31101793,猪瘟病毒糖蛋白E2高变区对疫苗C株获得性免疫应答影响的研究,35383,2012-01-01,2012.0,2014-12-31,2014,Zhejiang University,grid.13402.34,China,National Natural Science Foundation of China,China,1,0,0
grant.6989562,81172148,以Her2/neu为靶点的新型VLP疫苗免疫应答研究,88425,2012-01-01,2012.0,2015-12-31,2015,,,,National Natural Science Foundation of China,China,2,0,0
grant.6985802,81160378,细粒棘球蚴G1Y162抗原优势表位的筛选及其免疫特性的研究,73955,2012-01-01,2012.0,2015-12-31,2015,Xinjiang Medical University,grid.13394.3c,China,National Natural Science Foundation of China,China,13,0,0
grant.6984632,31160030,以番茄果实为受体表达结核分枝杆菌Ag85B-ESAT-6-WbbL融合蛋白及免疫效应研究,88425,2012-01-01,2012.0,2015-12-31,2015,Hainan Medical University,grid.443397.e,China,National Natural Science Foundation of China,China,2,0,0
grant.6956996,17K19642,Development of a novel fungal vaccine with glycolipid antigens,57569,2017-06-30,2017.0,2019-03-31,2019,Tohoku University,grid.69566.3a,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6898601,TA04011004,Optimalizace vakcinačního schématu oslabené vakcíny Salmonella Enteritidis vedoucí k dlouhodobé ochraně drůbeže před infekcí salmonelami,880111,2014-07-01,2014.0,2017-12-31,2017,Veterinary Research Institute; Veterinary Research Institute; Bioveta (Czechia),grid.426567.4; grid.426567.4; grid.448017.e,Czechia; Czechia; Czechia,Technology Agency of the Czech Republic,Czechia,1,0,0
grant.6898238,QJ1210115,Možnosti vakcinace prasat inaktivovanou vakcínou pro tlumení výskytu salmonel v chovech prasat,456077,2012-04-01,2012.0,2016-12-31,2016,Bioveta (Czechia); Veterinary Research Institute; Veterinary Research Institute,grid.448017.e; grid.426567.4; grid.426567.4,Czechia; Czechia; Czechia,Ministry of Agriculture,Czechia,1,0,0
grant.6897461,LF12016,Výzkum a vývoj vakcíny proti onemocnění dolních cest dýchacích v ozdravených chovech prasat,743184,2012-03-01,2012.0,2015-12-31,2015,Sevaron (Czechia),grid.486207.f,Czechia,Ministry of Education Youth and Sports,Czechia,0,0,0
grant.6895869,PZ-Z2/18,Biodegradabilní systémy s prolongovanou liberací vakcín,626037,1997-01-01,1997.0,2001-12-31,2001,Spolchemie (Czechia),grid.438360.a,Czechia,Ministry of Industry and Trade,Czechia,0,0,0
grant.6894818,NS9871,Využití dendritických buněk naložených univerzálními nádorovými antigeny pro přípravu protinádorových vakcín,445348,2008-07-01,2008.0,2011-12-31,2011,University Hospital Brno,grid.412554.3,Czechia,Ministry of Health,Czechia,0,0,0
grant.6893995,NR8004,Kombinovaná imunoterapie nádorů vyvolaných lidským papillomavirem,542256,2004-01-01,2004.0,2006-12-31,2006,Institute of Molecular Genetics; Institute of Haematology and Blood Transfusion,grid.418827.0; grid.419035.a,Czechia; Czechia,Ministry of Health,Czechia,0,0,0
grant.6893013,NC5526,Kombinovaná léčba zbytkové nádorové choroby pomocí IL-2 a GM-CSF využívající rekombinantních cytokinů a geneticky modifikovaných vakcin.,77128,1999-01-01,1999.0,2001-12-31,2001,Institute of Molecular Genetics,grid.418827.0,Czechia,Ministry of Health,Czechia,0,0,0
grant.6892489,IZ4414,Vývoj rekombinantních virů vakcinie s geny pro cytokiny pro léčbu nádorů.,220158,1997-01-01,1997.0,1999-12-31,1999,Institute of Haematology and Blood Transfusion,grid.419035.a,Czechia,Ministry of Health,Czechia,0,0,0
grant.6892046,IZ3449,Prevence IDDM BCG vakcínou : Lidský model přirozené vnímavosti /rezistence na infekci Mycobacterium bovis BCG.,265480,1996-01-01,1996.0,1998-12-31,1998,University Hospital Olomouc,grid.412730.3,Czechia,Ministry of Health,Czechia,0,0,0
grant.6891741,IAA5052203,Protinádorové vakciny připravené fúzí nádorových a dendritických buněk,104407,2002-01-01,2002.0,2004-12-31,2004,Institute of Molecular Genetics,grid.418827.0,Czechia,Academy of Sciences of the Czech Republic,Czechia,0,0,0
grant.6890237,OVUOFVZ200808,FRANCIS - Vývoj nových profylaktických prostředků proti infekci Francisella tularensis,507379,2008-11-01,2008.0,2011-12-31,2011,Institute of Molecular Genetics; Ministry of Defence,grid.418827.0; grid.447755.0,Czechia; Czechia,Ministry of Defence,Czechia,3,0,0
grant.6889913,IZ2629,KANVAKOL - vakcína k léčbě vleklých kvasinkových zánětů pochvy.,43739,1995-01-01,1995.0,1997-12-31,1997,"Palacký University, Olomouc; University Hospital Olomouc; Palacký University, Olomouc",grid.10979.36; grid.412730.3; grid.10979.36,Czechia; Czechia; Czechia,Ministry of Health,Czechia,0,0,0
grant.6889759,ME 167,Studium mechanismu působení bakteriálních toxinů,155930,1998-01-01,1998.0,2002-12-31,2002,Institute of Microbiology,grid.418800.5,Czechia,Ministry of Education Youth and Sports,Czechia,7,0,0
grant.6887770,GA521/09/1525,Biologicky bezpečný expresní systém založený na rostlinných virech pro transientní expresi papillomavirových onkoproteinů a vývoj terapeutické vakcíny,257888,2009-01-01,2009.0,2011-12-31,2011,Institute of Haematology and Blood Transfusion; Institute of Experimental Botany,grid.419035.a; grid.419008.4,Czechia; Czechia,Czech Science Foundation,Czechia,4,0,0
grant.6885923,FD-K3/100,*Biotechnologie výroby antigenů Borrelia burgdorferi sensu lato pro přípravu prototypu vakcíny proti Lymeské borelióze.,1233845,2003-01-01,2003.0,2005-12-31,2005,"Bioveta (Czechia); Palacký University, Olomouc",grid.448017.e; grid.10979.36,Czechia; Czechia,Ministry of Industry and Trade,Czechia,0,0,0
grant.6789856,3500000000020414,Assessment of vaccine efficacy for Malaria and Tuberculosis in a co-infection setting relevant for disease endemic sub-Saharan African regions.,0,2010-11-01,2010.0,2013-10-31,2013,Vrije Universiteit Brussel,grid.8767.e,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6782698,308562580,Analysis of vaccine induced immunity in cattle against the gastrointestinal namatode Ostertagia ostertagi,0,2011-01-01,2011.0,2015-10-31,2015,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6782088,1756041340,Evolution of the influenza A virus quasispecies in naive and immune hosts,0,2012-01-01,2012.0,2015-12-31,2015,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6779627,31484,"A ""negative"" dendritic-cell based vaccine for the treatment of multiple sclerosis: a first-in-man multicenter trial.",0,2015-01-15,2015.0,2019-01-14,2019,University of Antwerp,grid.5284.b,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6779163,30227,"A Randomized, Double-Blinded, Controlled with GARDASIL® Phase 3 Clinical Trial.",0,2014-03-11,2014.0,2015-04-30,2015,University of Antwerp,grid.5284.b,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6778182,27965,Preclinical development of an optimised dendritic cell-based vaccine against acute myeloid leukemia.,0,2012-10-01,2012.0,2013-09-30,2013,University of Antwerp,grid.5284.b,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6736604,1023636,Research Fellowship,701047,2012-01-01,2012.0,2017-12-31,2017,James Cook University,grid.1011.1,Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6734404,1031287,A polyvalent group A streptococcal vaccine,580953,2012-01-01,2012.0,2015-12-31,2015,University of the Sunshine Coast; University of the Sunshine Coast; University of the Sunshine Coast; University of the Sunshine Coast; University of the Sunshine Coast,grid.1034.6; grid.1034.6; grid.1034.6; grid.1034.6; grid.1034.6,Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6718161,226920,Attenuated and recombinant mycobacterial strains as novel vaccines to control tuberculosis,265112,2003-01-01,2003.0,2005-12-31,2005,University of Sydney; University of Sydney,grid.1013.3; grid.1013.3,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6715102,264429,Study of HPV 6 L1 virus like paticles as Therapeutic vaccine for genital warts and recurrent respiratory papillomatosis.,483026,2004-01-01,2004.0,2008-12-31,2008,University of Queensland; University of Queensland; University of Queensland,grid.1003.2; grid.1003.2; grid.1003.2,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6714516,302112,Molecular approaches to developing subunit vaccines with improved efficacy against tuberculosis,360670,2004-01-01,2004.0,2006-12-31,2006,University of Sydney; University of Sydney; University of Sydney,grid.1013.3; grid.1013.3; grid.1013.3,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6710383,OPP1169439,"To support the 5th Global Forum on TB Vaccines, which brings together stakeholders from around the world and across all areas of research to facilitate dialogue and to promote partnership and collaboration with the goal of accelerating TB vaccine R&D",150000,2017-04-01,2017.0,2018-03-01,2018,Aeras,grid.432518.9,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6665051,103367/Z/13/Z,"Pre-clinical development of an affordable, safe and efficacious four-in-one dengue vaccine candidate",1023577,2014-04-01,2014.0,2016-05-01,2016,,,,Wellcome Trust,United Kingdom,0,0,0
grant.6585701,OPP1043696,"To test the theory that a measured dose of vitamin A (retinoic acid) given with an oral vaccine will enhance immunoglobulin secretions in the gut, thus boosting the mucosal immune response. If successful, vitamin A could be used as an effective adjuvant for oral vaccines that target diarrhea, a leading cause of death among children worldwide.",988742,2012-05-01,2012.0,2014-10-01,2014,Queen Mary University of London,grid.4868.2,United Kingdom,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6585522,OPP1135369,"To expand CanSino’s capability to conduct clinical trials in Africa so that, in the future, CanSino will be able to provide low cost and high quality vaccines to African countries and to help prevent common diseases for poor, low-income or otherwise underserved communities that otherwise would lack access to such vaccines at an affordable price",150000,2015-10-01,2015.0,2016-07-01,2016,CanSino (China),grid.479603.f,China,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6585009,OPP1088553,To evaluate the ability of the BEN-1 vaccine to act as a highly effective and safe Contagious Bovine Pleuropneumonia (CBPP) vaccine that meets target product profile and that is a pivotal enabler for the control and then possibly elimination of the disease in Africa,1521491,2013-11-01,2013.0,2017-07-01,2017,Harbin Veterinary Research Institute,grid.38587.31,China,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6584480,OPP1097899,"To develop and deploy a low-cost, easy-to-use remote temperature monitoring system for cold chain monitoring which sends SMS alerts to reduce vaccine spoilage and integrates with existing electronic logistics management systems to improve distribution and management of vaccines at different levels of the supply chain",999550,2013-10-01,2013.0,2016-07-01,2016,Nexleaf Analytics,grid.479530.c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6583202,OPP1114833,"To develop and deploy a low-cost, easy-to-use remote temperature monitoring (RTM) system for cold chain monitoring, which sends SMS alerts to reduce vaccine spoilage and integrates with existing electronic logistics management systems to improve distribution and management of vaccines at different levels of the supply chain",732257,2014-10-01,2014.0,2016-07-01,2016,Nexleaf Analytics,grid.479530.c,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582837,OPP1090120,"To assess the safety, reactogenicity, immunogenicity and impact on intestinal shedding of 1 dose of a monovalent type 2 high dose inactivated poliovirus vaccine compared to a licensed trivalent inactivated poliovirus vaccine when given concomitantly with bOPV to infants early in life",1475832,2013-10-01,2013.0,2016-01-01,2016,Vax Trials,grid.479584.3,Panama,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582602,OPP1113323,To assess the feasibility of a project to establish poliovirus surveillance in Cap Verde following a switch from oral polio vaccine (OPV) to inactivated polio vaccine (IPV) to monitor ongoing viral circulation and to use a challenge study to understand the sensitivity of environmental surveillance and to develop a project protocol based on this feasibility study,88669,2014-10-01,2014.0,2015-06-01,2015,Agence de Médecine Préventive,grid.417713.7,France,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582377,OPP1135968,"To convene an international gathering of professionals from developing countries working in research, development, manufacturing and supply of vaccines, towards the common goal of protecting people against known and emerging viral and bacterial infectious diseases by increasing the availability of high-quality vaccines",60375,2015-07-01,2015.0,2015-12-01,2015,Developing Countries Vaccine Manufactures Network,grid.479199.b,Switzerland,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6582318,OPP53103,"To develop a vaccine vector based on a prototype vaccine for herpes simplex virus 2 (HSV-2) that encodes multiple CD8 T cell epitopes from HIV proteins, and test its ability to stimulate a robust CD8 T cell response against HIV",100000,2009-05-01,2009.0,2010-05-01,2010,Saint Louis University,grid.262962.b,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582277,OPP1134931,"To build consensus among the world’s immunization costing experts on how best to systematically improve immunization service delivery costs for by donors, national governments, and multilateral agencies to advance vaccine development and health policies and programs aimed at reducing vaccine preventable diseases among children, adolescents and adult populations",39742,2015-08-01,2015.0,2015-12-01,2015,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6582039,OPP1108188,"To boost the effect of vaccines against rotavirus infection, which causes diarrhea, by developing a pig model to mimic the gut conditions of children in developing countries who do not respond to vaccines, which can be used to test interventions.",99772,2014-04-01,2014.0,2015-10-01,2015,Virginia Tech,grid.438526.e,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6581667,OPP1097005,"To convene an international gathering of professionals working in research, development, manufacturing and supply of vaccines, towards the common goal of protecting people against known and emerging viral and bacterial infectious diseases by increasing the availability of high-quality vaccines produced in developing countries",34721,2013-10-01,2013.0,2013-11-01,2013,Developing Countries Vaccine Manufactures Network,grid.479199.b,Switzerland,Bill & Melinda Gates Foundation,United States,2,0,0
grant.6581629,OPP1105229,"To help inform evidence-based dialogue and public health policy related to vaccines in India, working closely with the Indian Ministry of Health, local experts, and local partners on including vaccines within comprehensive approaches to protect children from life-threatening diseases - namely diarrhea, pneumonia, and meningitis",9786362,2014-04-01,2014.0,2017-08-01,2017,Johns Hopkins University,grid.21107.35,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6581606,OPP1124110,To support the 4th Global Forum on Tuberculosis (TB) Vaccines intended to build on the success of the prior three conferences in bringing together researchers from all sectors for an in depth review and discussion of progress and gaps in TB vaccine research and development,35000,2015-01-01,2015.0,2015-11-01,2015,Aeras,grid.432518.9,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580667,OPP1120319,"To design, produce, characterize and assess the immunogenicity of nanoparticles of multiple, specific symmetries that present the prefusion forms of human respiratory syncytial virus (hRSV) F and human metapneumonia virus (hMPV) F, to potentially generate novel vaccine design concepts for hRSV/hMPV vaccines suitable for maternal immunization",2697432,2014-11-01,2014.0,2018-08-01,2018,University of Washington,grid.34477.33,United States,Bill & Melinda Gates Foundation,United States,3,0,0
grant.6580592,OPP1112700,"To develop a microneedle patch that can be used for safe, efficacious and cost-effective delivery of inactivated poliovirus vaccine (IPV) as part of the polio Eradication and Endgame strategic plan to stop the use of oral polio vaccine (OPV) worldwide by the end of 2019",1124690,2014-12-01,2014.0,2019-01-01,2019,Georgia Institute of Technology,grid.213917.f,United States,Bill & Melinda Gates Foundation,United States,1,0,0
grant.6580348,OPP1113319,"To develop a microneedle patch that can be used for safe, efficacious and cost-effective delivery of inactivated poliovirus vaccine (IPV) as part of the polio Eradication and Endgame strategic plan to stop the use of oral polio vaccine (OPV) worldwide by the end of 2019",1696952,2014-11-01,2014.0,2019-10-01,2019,Micron Biomedical (United States),grid.479335.f,United States,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6580253,OPP1118489,"To cover the expenses for the initial activities which are necessary in order to prepare Intravacc to be ready to start to produce, test and document new Oral Polio Vaccine type 2 (nOPV2) poliovirus Master- and Working seed lots (for two concepts) to ensure future production of live polio vaccines as soon as possible after the Product Development",99921,2014-08-01,2014.0,2014-12-01,2014,Intravacc (Netherlands),grid.452495.b,Netherlands,Bill & Melinda Gates Foundation,United States,0,0,0
grant.6501410,272201200005I-2-27200009-1,Task X9:  Agilvax Phage Display for Multiple Vaccine Candidates,29589,2014-11-06,2014.0,2016-05-19,2016,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6501086,272201100023C-11-0-1,Reagent Resource Support Program for AIDS Vaccine Development,2646088,2016-04-08,2016.0,2017-04-07,2017,Quality Biological,grid.283674.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6499761,272201000033I-0-27200005-1,Task A91: Development of a Murine Model of Subcutaneous (SC) Melioidosis for Use in Vaccine Evaluation,134680,2016-05-26,2016.0,2018-05-25,2018,University of Louisville,grid.266623.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6445309,102728,"Newton Fund - Development of an oral, thermostable enteric fever vaccine: saving lives and supporting tourism in Mexico",505635,2016-11-01,2016.0,2019-03-31,2019,,,,Innovate UK,United Kingdom,0,0,0
grant.6151642,26461583,Development new immunotherapy for pediatric cancer using human iPSCs,45237,2014-04-01,2014.0,2017-03-31,2017,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6098547,24791487,Development of the Novel Therapeutic Strategy for Cerebral Infarction; The Efficacy of  Angiotensin II DNA Vaccine in Rat Model of Cerebral Infarction.,44571,2012-04-01,2012.0,2015-03-31,2015,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6091957,24592409,Development of immunomodulatory  p53-targeted vaccine for mouse model of prostate cancer,55375,2012-04-01,2012.0,2015-03-31,2015,Kitasato University,grid.410786.c,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.6071280,23659086,Basic Study of orally-delivered vaccine development using a new innate immunity inducer,47262,2011-01-01,2011.0,2012-12-31,2012,Showa Pharmaceutical University,grid.412579.c,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6070744,23658157,Development of DNA vaccine against intracellular microbial pathogens by using artificially synthesized genes,48889,2011-01-01,2011.0,2012-12-31,2012,Tokyo University of Marine Science and Technology,grid.412785.d,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6042157,22390136,"Immunogenicity, effectiveness and safety of 2009 A (H1N1) pandemicinfluenza vaccine in high risk population.",240173,2010-01-01,2010.0,2012-12-31,2012,Osaka City University,grid.261445.0,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.6024774,21592127,Development of novel oncofetal antigen targeting immunotherapy for refractory ovarian carcinoma,52496,2009-01-01,2009.0,2011-12-31,2011,Nagoya University,grid.27476.30,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6012718,20790384,Persistent infection of Hepatitis C Virus,42324,2008-01-01,2008.0,2009-12-31,2009,Tokyo Institute of Psychiatry,grid.417113.1,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6012401,20790360,Reverse genetics for rotavirus and its applications,44970,2008-01-01,2008.0,2009-12-31,2009,Fujita Health University,grid.256115.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5992262,19791178,The development of the polysomal RNA vaccine to the ovarian cancer,39214,2007-01-01,2007.0,2010-12-31,2010,Kurume University,grid.410781.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5938062,17659120,難治性原虫感染症に対する細胞性免疫誘導型ワクチンシステムの評価,30050,2005-01-01,2005.0,2006-12-31,2006,Obihiro University of Agriculture and Veterinary Medicine,grid.412310.5,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5931400,17390554,Inhibition of S.mutans colonization by the DNA vaccine targeted on GTFC and It's anti-cariogenic effects,124637,2005-01-01,2005.0,2006-12-31,2006,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5920808,16K18798,Reconstitution of a novel recombinant Marek's disease virus as a vector vaccine against poultry red mites,37595,2016-04-01,2016.0,2018-03-31,2018,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,16,0,0
grant.5911040,16K09514,レニンアンジオテンシン系を標的としたワクチンの開発,43558,2016-04-01,2016.0,2019-03-31,2019,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5900028,16H05112,Preclinical and clinical study of influenza microneedle vaccine and analysis of immunity induction mechanism,161300,2016-04-01,2016.0,2019-03-31,2019,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5869490,15K08746,Ｂ型肝炎ワクチンに対する初期および記憶免疫応答に関する研究,44034,2015-04-01,2015.0,2019-03-31,2019,Iwate Medical University,grid.411790.a,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5861515,15H06366,Virus Like Nano-Particle as the delivery tool of vaccine adjuvant,26755,2015-08-28,2015.0,2017-03-31,2017,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5799529,13670285,Analysis of adjuvant action Escherichia coli enterotoxin,25131,2001-01-01,2001.0,2002-12-31,2002,Fujita Health University,grid.256115.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5501390,12961,Parasite digestive enzymes: targets for new drugs and vaccines,81205,2013-08-01,2013.0,2018-07-01,2018,Queen's University Belfast,grid.4777.3,United Kingdom,Royal Society,United Kingdom,0,0,0
grant.5495378,707128,Making a yeast-based candidate vaccine against Porcine Epidemic Diarrhea Virus  (PEDV),209730,2016-06-13,2016.0,2018-06-12,2018,Pasteur Institute,grid.428999.7,France,European Commission,Belgium,0,0,0
grant.5245789,272201200003I-2-27200007-3,Task X7: Preparedness for Testing NIAID Priority Vaccines for Infectious Diseases,737737,2013-09-23,2013.0,2018-09-22,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245788,272201200003I-2-27200007-2,Task X7: Preparedness for Testing NIAID Priority Vaccines for Infectious Diseases,29014,2013-09-23,2013.0,2018-09-22,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245787,272201200003I-2-27200007-1,Task X7: Preparedness for Testing NIAID Priority Vaccines for Infectious Diseases,550747,2013-09-23,2013.0,2018-09-22,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245784,272201200003I-0-27200013-1,TO X13: Evaluation of an E. coli Vaccine Candidate - Immunogenicity Testing,255693,2015-08-10,2015.0,2016-08-09,2016,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245782,272201200003I-0-27200011-1,Task X11:Evaluation of Clinical Samples from a Dengue Vaccine Clinical Trial,700445,2015-03-18,2015.0,2017-03-17,2017,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5245762,272201100023C-9-0-1,Reagent Resource Support Program for AIDS Vaccine Development,2585724,2015-04-08,2015.0,2016-04-07,2016,Quality Biological,grid.283674.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5244950,261200800001E-77-0-139,Expansion of Product Development Capacity,4568697,2008-09-26,2008.0,2018-09-25,2018,Leidos (United States),grid.419407.f,United States,National Cancer Institute,United States,0,0,0
grant.5151711,NIHRDH-RDA/03/07/014,Modelling the impact of vaccination targeted against serogroup B meningococcal disease.,399600,2007-10-01,2007.0,2010-09-30,2010,University of Bristol,grid.5337.2,United Kingdom,NIHR Trainees Coordinating Centre,United Kingdom,2,0,0
grant.5072711,132207,A novel prophylactic vaccine and delivery platform to prevent Clostridium difficile infections,140426,2016-04-30,2016.0,2017-10-31,2017,Absynth Biologics (United Kingdom),grid.432017.3,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.5014322,31072119,新城疫DNA疫苗三甲基壳聚糖纳米粒黏膜免疫传递系统的构建及其免疫作用机制研究,52197,2011-01-01,2011.0,2013-12-31,2013,Heilongjiang University,grid.412067.6,China,National Natural Science Foundation of China,China,8,0,0
grant.5006402,81072499,IL-28B和CD25抗体抑制调节性T细胞增强结核亚单位疫苗免疫活性实验研究,47452,2011-01-01,2011.0,2013-12-31,2013,Lanzhou University,grid.32566.34,China,National Natural Science Foundation of China,China,6,0,0
grant.5000845,31070824,PglB介导的一步合成多糖－蛋白缀合物疫苗平台构建,55361,2011-01-01,2011.0,2013-12-31,2013,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,7,0,0
grant.4996505,31072120,奶牛乳房炎金黄色葡萄球菌多亚单位嵌合蛋白抗原表达及免疫原性研究,55361,2011-01-01,2011.0,2013-12-31,2013,,,,National Natural Science Foundation of China,China,5,0,0
grant.4980908,30800977,嵌合RSV抗原表位的重组流感减毒疫苗构建及免疫保护,29885,2009-01-01,2009.0,2011-12-01,2011,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,6,0,0
grant.4980502,30800919,婴儿乙肝疫苗应答的母源性细胞假说及其验证,29916,2009-01-01,2009.0,2011-12-31,2011,,,,National Natural Science Foundation of China,China,4,0,0
grant.4977004,30471550,脂多糖表位模拟肽疫苗诱导再次免疫应答的研究,26517,2005-01-01,2005.0,2007-12-31,2007,Southern Medical University,grid.284723.8,China,National Natural Science Foundation of China,China,1,0,0
grant.4967684,30901735,MAGE多表位肽肿瘤纳米疫苗的研究,30715,2010-01-01,2010.0,2012-12-31,2012,,,,National Natural Science Foundation of China,China,0,0,0
grant.4965799,30771645,弧菌外膜蛋白在酵母菌细胞表面上的展示和作为多价活疫苗的潜在应用,51088,2008-01-01,2008.0,2010-12-31,2010,Ocean University of China,grid.4422.0,China,National Natural Science Foundation of China,China,18,0,0
grant.4965440,30772673,基于微针给药系统的DNA聚阳离子纳米复合物皮内免疫效应及其机理的研究,42327,2008-01-01,2008.0,2010-12-31,2010,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.4964345,30901372,基于抗体的针对登革病毒多肽疫苗的构建,32252,2010-01-01,2010.0,2012-12-31,2012,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,0,0,0
grant.4959645,31140038,纳米层状双氢氧化物/二氧化硅作为DNA疫苗递送系统的研究,15842,2012-01-01,2012.0,2012-12-31,2012,Tongji University,grid.24516.34,China,National Natural Science Foundation of China,China,10,0,0
grant.4953588,30901084,减毒沙门氏菌递呈的TGEV S/N双基因疫苗的构建与免疫诱导规律研究,30715,2010-01-01,2010.0,2012-12-31,2012,Sichuan Agricultural University,grid.80510.3c,China,National Natural Science Foundation of China,China,1,0,0
grant.4949617,30801104,新型MUC1 DNA疫苗的优化构建及治疗胰腺癌的实验研究,26920,2009-01-01,2009.0,2011-12-31,2011,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,1,0,0
grant.4944670,30801248,共表达gB及靶向BAK SiRNA的新型疫苗在动物模型上抗CMV胎仔感染的研究,29916,2009-01-01,2009.0,2011-12-31,2011,Tianjin Central Hospital for Gynecology and Obstetrics,grid.410626.7,China,National Natural Science Foundation of China,China,1,0,0
grant.4944517,30800520,基于肝素酶不同CTL表位混合多肽疫苗抗肿瘤效应的实验研究,31409,2009-01-01,2009.0,2011-12-31,2011,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,4,0,0
grant.4943857,81141091,OK-432肿瘤疫苗抗肿瘤作用的信号传导机制,15842,2012-01-01,2012.0,2012-12-31,2012,Shanxi Medical University,grid.263452.4,China,National Natural Science Foundation of China,China,0,0,0
grant.4942414,30300150,TRAG-3抗原为靶标的新型肿瘤疫苗治疗肺癌的实验研究,25772,2004-01-01,2004.0,2006-12-31,2006,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,1,0,0
grant.4938676,30772002,恶性肿瘤新型治疗性疫苗的应用基础研究,43790,2008-01-01,2008.0,2010-12-31,2010,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,3,0,0
grant.4938143,30771931,粘膜佐剂LTB优化淋病纳米核酸疫苗的实验研究,0,2008-01-01,2008.0,2010-12-31,2010,University of South China,grid.412017.1,China,National Natural Science Foundation of China,China,0,0,0
grant.4936988,30771602,免疫共刺激因子4-1BBL增强DNA疫苗细胞免疫反应的机理研究,43790,2008-01-01,2008.0,2010-12-31,2010,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,3,0,0
grant.4936799,30471285,副结核分枝杆菌非变态反应性免疫保护基因的研究,25253,2005-01-01,2005.0,2007-12-31,2007,Jilin Agricultural University,grid.464353.3,China,National Natural Science Foundation of China,China,1,0,0
grant.4931966,30371319,马传染性贫血病毒减毒疫苗的免疫保护机制的研究,29455,2004-01-01,2004.0,2006-12-31,2006,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,3,0,0
grant.4931866,30700295,L型钙通道治疗性降压疫苗的研究,23353,2008-01-01,2008.0,2010-12-31,2010,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,2,0,0
grant.4930008,30700756,靶向牙周炎DNA疫苗的研制和免疫机制研究,21892,2008-01-01,2008.0,2010-12-31,2010,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,2,0,0
grant.4929469,30700371,IDO基因修饰的T细胞表位疫苗诱导抗-GBM肾炎免疫耐受的效应机制研究,24809,2008-01-01,2008.0,2010-12-31,2010,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,0,0,0
grant.4666876,196394,Novel vaccine candidates against meningococcal disease,694349,2010-01-01,2010.0,2013-12-31,2013,Oslo University Hospital,grid.55325.34,Norway,The Research Council of Norway,Norway,1,0,0
grant.4661763,196363,Development of a food-grade Lactobacillus-based oral vaccine delivery system,532177,2009-01-01,2009.0,2013-12-31,2013,Norwegian University of Life Sciences,grid.19477.3c,Norway,The Research Council of Norway,Norway,3,0,0
grant.4645568,228339,Joining forces to produce next-generation vaccines against enterotoxigenic Escherichia coli,51032,2013-01-01,2013.0,2013-12-31,2013,University of Bergen,grid.7914.b,Norway,The Research Council of Norway,Norway,0,0,0
grant.4642003,216154,Protection against intracellular pathogens - T-cell based immunity and vaccines,590797,2012-01-01,2012.0,2017-12-31,2017,Norwegian Veterinary Institute,grid.410549.d,Norway,The Research Council of Norway,Norway,0,0,0
grant.4579186,106158/B/14/Z,A strategic vision to drive the control of enteric fever through vaccination,586530,2015-04-01,2015.0,2019-03-31,2019,Wellcome Sanger Institute,grid.10306.34,United Kingdom,Wellcome Trust,United Kingdom,5,0,0
grant.4533901,07/50966-8,Desenvolvimento de uma nova estratégia vacinal com propriedades profiláticas e terapêuticas contra a síndrome hemolítica urêmica (SHU) associada a Linhagens de Escherichia coli enterohemorrágica (EHEC) produtorass da toxina Shiga-like (Stx),0,2007-07-01,2007.0,2009-06-30,2009,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4511421,96/04340-3,Yuji Sato | National Institute of Health - Japão,0,1996-08-11,1996.0,1996-08-28,1996,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4457248,6759,Parasite digestive enzymes: targets for new drugs and vaccines,81205,2013-08-01,2013.0,2018-07-01,2018,Queen's University Belfast,grid.4777.3,United Kingdom,Royal Society,United Kingdom,0,0,0
grant.4446312,W81XWH-10-C-0003,GeMI-Vax as a multi-life stage  malaria vaccine,627143,2009-10-01,2009.0,2010-09-30,2010,Vital Probes (United States),grid.505454.5,United States,United States Department of the Army,United States,0,0,0
grant.4444178,,Orally Administered Bioadherent Sustained Release Microencapsulated Vaccines,100000,1994-10-01,1994.0,1995-09-30,1995,Lynntech,grid.280661.b,United States,United States Department of the Army,United States,0,0,0
grant.4419560,W81XWH-11-C-0512,Nanoparticle Technology for Minimally-invasive Delivery of DNA Vaccines,99999,2010-10-01,2010.0,2011-09-30,2011,Texas A&M University System,grid.264763.2,United States,United States Department of the Army,United States,0,0,0
grant.4385415,,Biodegradable Bioadherent Microcapsules for Orally Administered Sustained Release Vaccines,597630,1995-10-01,1995.0,1996-09-30,1996,Lynntech,grid.280661.b,United States,United States Department of the Army,United States,0,0,0
grant.4383163,,Absorbable Gels for Modulated Bioavailability of Vaccines,69828,1995-10-01,1995.0,1996-09-30,1996,Poly Med (United States),grid.423208.f,United States,United States Department of the Army,United States,0,0,0
grant.4294354,BBS/E/I/00001751,Selection versus mutation: reducing the risk of vaccine reversion,12604,2014-03-01,2014.0,2017-02-28,2017,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.4293335,0225046,DEVELOPMENT OF IMMUNOPROPHYLAXIS FOR RESPIRATORY DISEASE,0,2013-10-01,2013.0,2018-09-30,2018,Montana State University,grid.41891.35,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.4128821,714.013.001,Chemical Immunology to modulate cross-presentation for improved vaccines,0,2013-07-01,2013.0,2017-07-01,2017,Antoni van Leeuwenhoek Hospital; Antoni van Leeuwenhoek Hospital; Antoni van Leeuwenhoek Hospital,grid.430814.a; grid.430814.a; grid.430814.a,Netherlands; Netherlands; Netherlands,Netherlands Organisation for Scientific Research,Netherlands,0,0,0
grant.4102510,R21AI114706,VLP-based Vaccines for Targeting Staphylococcus aureus Secreted Virulence Factors,415875,2015-07-01,2015.0,2018-06-30,2018,University of New Mexico,grid.266832.b,United States,National Institute of Allergy and Infectious Diseases,United States,2,1,0
grant.4045744,NA03NMF4270163,Novel Oral Vaccine for Infectious Salmon Anemia,190400,2003-07-01,2003.0,2006-12-31,2006,,,,National Oceanic and Atmospheric Administration,United States,2,0,0
grant.4045136,NA03NMF4270119,Whole Killed ISA Virus Vaccine,157591,2003-07-01,2003.0,2005-12-31,2005,BioTek (United States),grid.288134.4,United States,National Oceanic and Atmospheric Administration,United States,0,0,0
grant.3955540,1002724,IMPROVED HERPESVIRUS OF TURKEY (HVT) VECTOR VACCINE TO CONTROL INFECTIOUS BURSAL DISEASE (IBD) IN CHICKENS,0,2014-03-18,2014.0,2016-09-30,2016,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3930806,LP130100882,"Investigating a novel, physical adjuvant for improving immune responses of vaccines",500382,2013-01-01,2013.0,2016-12-31,2016,University of Queensland; Vaxxas (Australia),grid.1003.2; grid.479585.2,Australia; Australia,Australian Research Council,Australia,6,0,0
grant.3930761,LP130100943,Development of a novel vaccine targeting parasite tegument proteins for liver fluke disease in livestock,219185,2013-01-01,2013.0,2016-12-31,2016,La Trobe University,grid.1018.8,Australia,Australian Research Council,Australia,4,0,0
grant.3928619,8675,"Establishment of a national GLP Core Facility to Monitor Immune Responses in Humans to Prophylactic and or Therapeutic Vaccines Against Infectious Diseases, Cancer and Autoimmunity",101097,2004-12-16,2004.0,2009-12-15,2009,University of Toronto,grid.17063.33,Canada,"Ministry of Research, Innovation and Science",Canada,0,0,0
grant.3865714,BB/L004240/1,Enhancing potency and efficacy of herpesvirus of turkeys-based multivalent vaccines against avian influenza viruses,208696,2014-03-30,2014.0,2015-07-29,2015,Pirbright Institute; Pirbright Institute; Pakistan Agricultural Research Council; University of Veterinary and Animal Sciences; Imperial College London; Suez Canal University; University of Oxford; University of Tokyo; Zagazig University; The Francis Crick Institute; University of Edinburgh; Royal Veterinary College,grid.63622.33; grid.63622.33; grid.419165.e; grid.412967.f; grid.7445.2; grid.33003.33; grid.4991.5; grid.26999.3d; grid.31451.32; grid.451388.3; grid.4305.2; grid.20931.39,United Kingdom; United Kingdom; Pakistan; Pakistan; United Kingdom; Egypt; United Kingdom; Japan; Egypt; United Kingdom; United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,32,0,0
grant.3856962,272201200003I-1-27200007-3,Task X7: Preparedness for Testing NIAID Priority Vaccines for Infectious Diseases,13706,2013-09-23,2013.0,2018-09-22,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856961,272201200003I-1-27200007-2,Task X7: Preparedness for Testing NIAID Priority Vaccines for Infectious Diseases,302399,2013-09-23,2013.0,2018-09-22,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856960,272201200003I-1-27200007-1,Task X7: Preparedness for Testing NIAID Priority Vaccines for Infectious Diseases,380129,2013-09-23,2013.0,2018-09-22,2018,Battelle,grid.27873.39,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856941,272201100023C-7-0-1,Reagent Resource Support Program for AIDS Vaccine Development,2530213,2014-04-08,2014.0,2015-04-07,2015,Quality Biological,grid.283674.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3856253,261201200018I-0-26100006-1,"IGF::OT::IGF  Base Contract Title:  Preclinical In Vitro and In Vivo Agent Development Assays, Task Order Title:  A Polyvalent Vaccine Against Fusion Proteins Observed in Solid Tumors, Period of Perfo",458635,2014-08-29,2014.0,2016-08-28,2016,Cornell University,grid.5386.8,United States,National Cancer Institute,United States,0,0,0
grant.3843674,710296,Optimisation of bacteriophage M13-based DNA and chimeric (DNA/ protein) vaccines,148517,2013-02-01,2013.0,2014-01-31,2014,,,,Innovate UK,United Kingdom,0,0,0
grant.3832512,ARS-0409116,VACCINOLOGY AND IMMUNITY OF AQUATIC ANIMALS,0,2004-12-14,2004.0,2009-12-13,2009,Aquatic Animal Health Research,grid.413853.8,United States,Agricultural Research Service,United States,0,0,0
grant.3826010,2009-65119-05671,LIVE ATTENUATED EDWARDSIELLA ICTALURI VACCINES FOR PREVENTION OF ENTERIC SEPTICEMIA OF CATFISH,374770,2009-08-15,2009.0,2011-08-14,2011,Mississippi State University; Mississippi State University,grid.260120.7; grid.260120.7,United States; United States,National Institute of Food and Agriculture,United States,3,2,0
grant.3820381,2011-67016-30175,INTEGRATIVE APPROACHES FOR ILTV VACCINES,234125,2010-02-01,2010.0,2011-01-31,2011,University of Delaware; University of Delaware,grid.33489.35; grid.33489.35,United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3820195,2009-65119-05703,BATH/ORAL LIVE RECOMBINANT EDWARDSIELLA VACCINE FOR THE AQUACULTURE INDUSTRY,372000,2009-08-15,2009.0,2012-08-14,2012,Arizona State University,grid.215654.1,United States,National Institute of Food and Agriculture,United States,0,2,0
grant.3810125,0227031,IDENTIFICATION OF COMMON ANTIGENS TO CREATE A UNIVERSAL PORCINE ETEC VACCINE,0,2011-10-01,2011.0,2016-09-30,2016,South Dakota State University,grid.263791.8,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3804353,AAI14017001-1-0-1,Baboon Model of Pertussis to Evaluate Strategies for Next Generation Vaccines,370000,2016-01-01,2016.0,2016-12-31,2016,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3769133,QLK2-CT-1999-51332,Generation of recombinant yellow fever virus (strain 17d) vaccine vectors to deliver heterologous antigens,197169,2000-09-06,2000.0,2004-09-05,2004,Pierre Fabre (France),grid.417944.b,France,European Commission,Belgium,0,0,0
grant.3765856,QLK2-CT-2000-60049,Generation of mumps virus vaccine vectors for heterologous antigens.,224182,2002-05-13,2002.0,2006-05-12,2006,Pierre Fabre (France),grid.417944.b,France,European Commission,Belgium,0,0,0
grant.3761112,QLK2-CT-2001-50970,Identification of new bradyzoite surface antigens for use in toxoplasma gondii vaccines and diagnostics,149561,2002-01-01,2002.0,2003-12-31,2003,State Serum Institute,grid.6203.7,Denmark,European Commission,Belgium,0,0,0
grant.3760628,QLK2-CT-1999-51115,"Artificial chimeric proteins as diagnostic, vaccine, and gene therapy carriers",196143,2001-06-06,2001.0,2005-06-05,2005,University of Latvia,grid.9845.0,Latvia,European Commission,Belgium,2,0,0
grant.3753632,HPMI-CT-2002-00184,High throughput vaccine evaluation,132939,2002-10-01,2002.0,2006-09-30,2006,Pepscan (Netherlands),grid.425414.2,Netherlands,European Commission,Belgium,5,0,0
grant.3751931,QLK2-CT-2002-30523,Fourth advanced vaccinology course (ADVAC-4),53353,2002-09-01,2002.0,2003-08-31,2003,,,,European Commission,Belgium,0,0,0
grant.3750111,QLK2-CT-2001-30013,Third advanced vaccinology course (ADVAC-3),92845,2002-01-01,2002.0,2002-12-31,2002,,,,European Commission,Belgium,0,0,0
grant.3641111,095540/Z/11/Z,T Cell Inducing Vaccines.,2190696,2011-09-01,2011.0,2014-10-31,2014,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,62,0,0
grant.3635581,076943/Z/05/Z,Clinical evaluation of innovative tuberculosis vaccination strategies.,2499219,2006-07-01,2006.0,2011-12-31,2011,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,43,0,0
grant.3632484,061230/Z/00/E,"Pneumococcal Conjugate Vaccine Trian in Adults: Blantyre, Malawi.",34320,2008-05-01,2008.0,2008-12-31,2008,Liverpool School of Tropical Medicine,grid.48004.38,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3576905,LP0989620,Development of an attenuated vaccine to control the emerging bovine respiratory pathogen Mycoplasma bovis,382193,2009-01-01,2009.0,2011-12-31,2011,University of Melbourne,grid.1008.9,Australia,Australian Research Council,Australia,2,0,0
grant.3576794,LP0562626,Vaccine against leptospirosis,406424,2005-01-01,2005.0,2008-12-31,2008,Monash University; Pfizer (Australia),grid.1002.3; grid.467540.4,Australia; Australia,Australian Research Council,Australia,0,0,0
grant.3570931,LP110200125,Development of dense gas technology platforms for the formulation of oral vaccines,324494,2011-01-01,2011.0,2014-12-31,2014,UNSW Sydney; University of Queensland,grid.1005.4; grid.1003.2,Australia; Australia,Australian Research Council,Australia,0,0,0
grant.3568449,LP120200051,Development of a safe and immunogenic anti-chlamydia vaccine for the koala,424619,2012-01-01,2012.0,2015-12-31,2015,Queensland University of Technology; Gold Coast City Council; Department of Transport and Main Roads,grid.1024.7; grid.473973.d; grid.474139.c,Australia; Australia; Australia,Australian Research Council,Australia,6,0,0
grant.3563226,DE120101113,Mathematical modelling of breast cancer immunity: guiding the development of preventative breast cancer vaccines,362663,2012-01-01,2012.0,2014-12-31,2014,University of Sydney,grid.1013.3,Australia,Australian Research Council,Australia,7,0,0
grant.3562443,DP130100595,Mathematical modelling can provide vital information on the effectiveness and practical implementation of microbicides and vaccines against HIV,248622,2013-01-01,2013.0,2015-12-31,2015,UNSW Sydney; University of Southern Queensland,grid.1005.4; grid.1048.d,Australia; Australia,Australian Research Council,Australia,5,0,0
grant.3492809,R01AI106005,Dissecting virus neutralizing determinants to guide HCV vaccine development,1532436,2014-03-01,2014.0,2018-05-31,2018,Scripps Research Institute,grid.214007.0,United States,National Institute of Allergy and Infectious Diseases,United States,30,0,0
grant.2801262,443681,Development of novel immune stimulators for poultry,21900,2009-04-01,2009.0,2010-03-31,2010,University of Saskatchewan; Maple Leaf Foods,grid.25152.31; grid.292466.d,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2776175,BBS/E/I/00001632,Pre-clinical development of a simian adenovirus vectored respiratory syncytial virus (RSV) vaccine,116150,2012-07-31,2012.0,2015-07-30,2015,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,2,0,0
grant.2770636,G0802507,Pre-clinical Development of an Adenovirus Vectored Universal Influenza Vaccine,1041867,2010-01-01,2010.0,2012-05-30,2012,University of Oxford,grid.4991.5,United Kingdom,Medical Research Council,United Kingdom,1,0,0
grant.2762266,G9025730,The characterisation of vaccine protection: models of AIDS vaccine development,17597300,1991-01-01,1991.0,2006-06-29,2006,National Institute for Biological Standards and Control; National Institute for Biological Standards and Control; National Institute for Biological Standards and Control; Imperial College London; Academic Medical Center; Pasteur Institute; University of Oxford,grid.70909.37; grid.70909.37; grid.70909.37; grid.7445.2; grid.5650.6; grid.428999.7; grid.4991.5,United Kingdom; United Kingdom; United Kingdom; United Kingdom; Netherlands; France; United Kingdom,Medical Research Council,United Kingdom,34,0,0
grant.2761525,MR/K012053/1,Development and testing of novel recombinant pnemococcal glyconjugate vaccines,882908,2013-03-31,2013.0,2016-06-29,2016,London School of Hygiene & Tropical Medicine; Defence Science and Technology Laboratory,grid.8991.9; grid.417845.b,United Kingdom; United Kingdom,Medical Research Council,United Kingdom,6,0,0
grant.2756358,BBS/E/I/00001703,Differentiation of Infection in Vaccinated Animals for PPR and FMD,680854,2012-03-31,2012.0,2017-03-30,2017,Pirbright Institute; Pirbright Institute; Tamil Nadu Veterinary and Animal Sciences University; Friedrich Loeffler Institute; French Agricultural Research Centre for International Development; Indian Immunologicals (India); Onderstepoort Veterinary Institute; University of Glasgow; Indian Veterinary Research Institute,grid.63622.33; grid.63622.33; grid.412908.6; grid.417834.d; grid.8183.2; grid.496635.b; grid.452772.1; grid.8756.c; grid.417990.2,United Kingdom; United Kingdom; India; Germany; France; India; South Africa; United Kingdom; India,Biotechnology and Biological Sciences Research Council,United Kingdom,19,0,0
grant.2723441,ZIAAI005119,ARRA: Development of Universal Influenza Assays,851102,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2722129,Z01RR010488,DEVELOPMENT OF FIV RECOMBINANT VACCINE,0,1996-01-01,1996.0,1996-12-31,1996,,,,National Center for Advancing Translational Sciences,United States,0,0,0
grant.2712045,Z01BS002004,LOT SPECIFIC CLUSTERING OF SIDS,0,1995-01-01,1995.0,1995-12-31,1995,Center for Biologics Evaluation and Research,grid.290496.0,United States,United States Food and Drug Administration,United States,0,0,0
grant.2712003,Z01BR003001,STABILITY OF TETANUS AND DIPHTHERIA TOXINS,0,1993-01-01,1993.0,1999-01-01,1999,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711997,Z01BR001001,RABIES IMMUNIZATION ANTIBODY DETECTION IN AT RISK PERSON,0,1993-01-01,1993.0,1998-01-01,1998,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711203,Z01BF003013,REACTIONS FOLLOWING IMMUNIZATION WITH JAPANESE ENCEPHALITIS VIRUS VACCINE,0,1991-01-01,1991.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711160,Z01BE003004,DEVELOPMENT OF AN ELISA FOR RABIES VACCINE POTENCY,0,1990-01-01,1990.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711158,Z01BE003002,RABIES IMMUNIZATION ANTIBODY DETECTION IN AT-RISK PERSONNEL,0,1990-01-01,1990.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709708,Z01BA002011,QUANTITATION OF POLYSACCHARIDE (PS) CONTENT IN HIB CONJUGATE VACCINES BY HPLC,0,1990-01-01,1990.0,1992-01-01,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709209,Z01AI005044,The T Cell Response to Hepatitis B Vaccine in Healthy Ad,0,2003-01-01,2003.0,2003-12-31,2003,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2708936,Z01AI000836,Novel Therapies For Herpes Simplex Virus Infections,0,1998-01-01,1998.0,2005-01-01,2005,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2708932,Z01AI000832,DEVELOPMENT OF NOVEL MUCOSAL VACCINE STRATEGIES,0,1998-01-01,1998.0,1999-01-01,1999,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2708555,Z01AI000448,"ROTAVIRUS VACCINE TRIAL IN UMEA, SWEDEN",0,1985-01-01,1985.0,1985-12-31,1985,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706445,Y1DA0121-1-0-1,Development of a Combination HIV-1 and Heroin Vaccine for NIDA,320000,2010-01-01,2010.0,2010-12-31,2010,National Institute on Drug Abuse,grid.420090.f,United States,National Institute on Drug Abuse,United States,0,0,0
grant.2706209,Y1AI6153-4-0-1,New Scientific Approaches to Facilitate Development of Vaccines,1406814,2009-01-01,2009.0,2009-12-31,2009,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2706207,Y1AI6132-4-0-1,In Vitro and Animal Models for Emerging Infectious Diseases and Biodefense,193426,2009-01-01,2009.0,2009-12-31,2009,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706205,Y1AI6131-5-0-1,In Vitro and Animal Models for Emerging Infectious Diseases and Biodefense,420061,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706204,Y1AI6131-4-0-1,In Vitro and Animal Models for Emerging Infectious Diseases and Biodefense,204023,2009-01-01,2009.0,2009-12-31,2009,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706150,Y1AI1722-1-0-1,Development of clinical correlates of efficacy for vaccines against Francisella,172000,2011-01-01,2011.0,2011-12-31,2011,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706130,Y1AI0658-1-0-1,Development of Assays to Assess Novel Cell Substrates,217000,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2688061,U01AI082105,Capsule conjugate vaccines against Campylobacter jejuni,1632408,2009-04-03,2009.0,2013-03-31,2013,Henry M. Jackson Foundation,grid.201075.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2668279,RC1AI048908,LIVE ATTENUATED VACCINES FOR PANDEMIC PREPAREDNESS,26000,2000-05-03,2000.0,2000-08-31,2000,AstraZeneca (United States),grid.418152.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2668269,RC1AI048890,NOVEL TECHNOLOGIES APPLIED TO A DENQUE DNA VACCINE,26000,2000-05-03,2000.0,2000-08-31,2000,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2666814,R56AI106005,Dissecting virus neutralizing determinants to guide HCV vaccine development,792744,2013-09-05,2013.0,2014-02-28,2014,Scripps Research Institute,grid.214007.0,United States,National Institute of Allergy and Infectious Diseases,United States,29,0,0
grant.2658005,R44AI063830,Development of Influenza Virus-Like Particle (VLP) Vaccines,2947514,2005-05-01,2005.0,2013-06-30,2013,TechnoVax (United States),grid.438336.9,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657883,R44AI049651,Vaccination Against Ixodes scapularis Tick Bites,748024,2001-09-15,2001.0,2004-08-31,2004,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657708,R44AI037352,BIODEGRADABLE MINERAL MICROSPHERE ADJUVANTS FOR VACCINES,0,1996-09-01,1996.0,2001-11-30,2001,BioTek (United States),grid.288134.4,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657702,R44AI036798,JAPANESE ENCEPHALITIS VACCINE FROM MUTATED CDNA CLONE,0,1994-08-01,1994.0,1998-05-31,1998,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2657621,R44AI030577,VACCINE DELIVERY SYSTEM FOR LIVE ROTAVIRUS VACCINES,0,1991-03-01,1991.0,1993-11-30,1993,CytRx (United States),grid.422976.c,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2651130,R43HD021872,RECOMBINANT CONTRACEPTIVE VACCINES,0,1986-03-01,1986.0,1986-08-31,1986,,,,National Institute of Child Health and Human Development,United States,0,0,0
grant.2640676,R43AI047510,DEVELOPMENT OF A REPLICATION-DEFECTIVE HSV-2 VACCINE,218442,2000-08-01,2000.0,2002-07-31,2002,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2640147,R43AI034675,ATTENUATED LIVE VIBRIO CHOLERAE-VECTORED ETEC VACCINE,0,1993-09-30,1993.0,1994-09-30,1994,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2639812,R43AI025237,SYNTHETIC PEPTIDES AS CARRIERS FOR CONJUGATE VACCINES,0,1988-07-01,1988.0,1988-12-31,1988,Pfizer (United States),grid.410513.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2636318,R41AI040716,PRODUCTION AND PRESERVATION OF AN ORAL CHOLERA VACCINE,0,1997-09-30,1997.0,1998-09-29,1998,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2602712,R21CA066669,CLINICAL TRIAL OF AN IMPROVED MELANOMA VACCINE,0,1996-03-01,1996.0,1999-02-28,1999,New York University,grid.137628.9,United States,National Cancer Institute,United States,0,0,0
grant.2600054,R21AI083133,"Development of needle-free, vectorless, RNA-based vaccines for HIV",470025,2009-07-20,2009.0,2012-06-30,2012,Massachusetts General Hospital,grid.32224.35,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2597874,R21AI050491,Lactobacilli: A Vaccine Delivery Vehicle for Women,467610,2001-09-01,2001.0,2004-08-31,2004,University of Illinois at Chicago,grid.185648.6,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2487387,R01DA035554,Rational design and targeted selection of DNA-scaffolded nicotine vaccines,3328489,2013-04-15,2013.0,2018-02-28,2018,Arizona State University,grid.215654.1,United States,National Institute on Drug Abuse,United States,1,4,0
grant.2468799,R01CA041636,IDIOTYPE VACCINES FOR CANCER PATIENTS,0,1986-04-01,1986.0,1990-02-28,1990,Sanford Burnham Prebys Medical Discovery Institute,grid.479509.6,United States,National Cancer Institute,United States,2,0,0
grant.2456215,R01AI055018,Oral Vaccine to Inhalation Rabies,1063222,2004-07-15,2004.0,2008-12-31,2008,The Wistar Institute,grid.251075.4,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2456201,R01AI054952,Vaccine-enhanced respiratory syncytial virus disease,1740596,2005-03-15,2005.0,2010-02-28,2010,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,17,0,0
grant.2455147,R01AI048297,"LIVE, ATTENUATED, RECOMBINANT VACCINE - WEST NILE VIRUS",2951659,2000-08-01,2000.0,2003-03-31,2003,Sanofi (United States),grid.417555.7,United States,National Institute of Allergy and Infectious Diseases,United States,5,1,0
grant.2454397,R01AI044373,Human T Cell Antigens of Mycobacterium tuberculosis,3700771,1999-09-30,1999.0,2012-01-31,2012,Infectious Disease Research Institute,grid.53959.33,United States,National Institute of Allergy and Infectious Diseases,United States,37,0,0
grant.2453038,R01AI036197,ENHANCED SAFETY &EFFICACY OF AIDS VACCINES BY IFN DELTA,0,1997-04-15,1997.0,2000-03-31,2000,"University of California, Davis",grid.27860.3b,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2452253,R01AI031580,HAEMOPHILUS INFLUENZAE B CONJUGATE VACCINE EFFICACY,0,1991-07-01,1991.0,1995-06-30,1995,,,,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2435222,P01AI094420,"Yellow Fever, rDNA (EP+IL-12) and rAd35 as Vectors for AIDS Vaccine Development",11354158,2012-07-01,2012.0,2018-06-30,2018,University of Miami,grid.26790.3a,United States,National Institute of Allergy and Infectious Diseases,United States,11,0,0
grant.2434259,N44AI082679,RECOMBINANT DNA-DERIVED PERTUSSIS SUBUNIT VACCINE   13.,0,1988-01-15,1988.0,1989-01-01,1989,Amgen (United States),grid.417886.4,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2430874,N01HD092905,IMMUNOGENICITY OF PERTUSSIS TOXOID,0,1989-09-30,1989.0,1995-03-31,1995,University of Gothenburg,grid.8761.8,Sweden,National Institute of Child Health and Human Development,United States,1,0,0
grant.2430828,N01HD073266,EPIDEMIOLOGY OF SHIGELLA INFECTION IN CHILDREN,0,1997-05-15,1997.0,1997-12-31,1997,National Institute Of Hygiene And Epidemiology,grid.419597.7,Vietnam,National Institute of Child Health and Human Development,United States,0,0,0
grant.2425461,N01AI40100-6-0-1,ASSESSING THE SAFETY OF CELL SUBSTRATES AND VACCINE COMPONENTS,500000,2004-09-24,2004.0,2010-05-31,2010,Ionis Pharmaceuticals (United States),grid.282569.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425460,N01AI40100-5-0-1,ASSESSING THE SAFETY OF CELL SUBSTRATES AND VACCINE COMPONENTS,621848,2004-09-24,2004.0,2010-05-31,2010,Ionis Pharmaceuticals (United States),grid.282569.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,8,0
grant.2425358,N01AI40045-13-0-1,MASTER CONTRACT FOR PRECLINICAL DEVELOPMENT AIDS RESEARCH (BASIC),1886200,2004-08-30,2004.0,2012-08-29,2012,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2425357,N01AI40045-11-0-1,MASTER CONTRACT FOR PRECLINICAL DEVELOPMENT AIDS RESEARCH (BASIC),13830000,2004-08-30,2004.0,2011-08-29,2011,Advanced Bioscience Laboratories (United States),grid.281126.e,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424781,N01AI062527,AN EFFICACY TRIAL OF TWO ACELLULAR PERTUSSIS VACCINES,0,1986-02-01,1986.0,1988-09-30,1988,Public Health Agency of Sweden,grid.419734.c,Sweden,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424621,N01AI045196,PNEUMOCOCCAL REFERENCE LABORATORY,0,1994-03-01,1994.0,1998-03-31,1998,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2424563,N01AI035154,OPERATION OF &EXPERIMENTAL VIRUS VACCINE PRODUCTION LAB,0,1992-11-30,1992.0,1998-11-30,1998,,,,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2424464,N01AI015125,PERTUSSIS CLINICAL TRIAL (PART 2),0,1991-09-25,1991.0,2003-09-30,2003,Public Health Agency of Sweden,grid.419734.c,Sweden,National Institute of Allergy and Infectious Diseases,United States,14,0,0
grant.2409638,K08AI001248,RECOMBINANT SALMONELLA AS AN ORAL HIV VACCINE,0,1994-09-01,1994.0,1998-08-31,1998,University of Colorado Anschutz Medical Campus,grid.430503.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2370535,F32AI071770,Propagation Enhancement of Chimeric Lentiviral Vaccines,145200,2006-08-01,2006.0,2009-07-31,2009,Global Vaccines (United States),grid.420435.4,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2350078,AAI12032001-1-0-1,Development of clinical correlates of efficacy for vaccines against Francisella,100000,2012-01-01,2012.0,2012-12-31,2012,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347550,272201100023C-5-0-1,Reagent Resource Support Program for AIDS Vaccine Development,2474435,2013-04-08,2013.0,2014-04-07,2014,Quality Biological,grid.283674.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347549,272201100023C-4-0-1,Reagent Resource Support Program for AIDS Vaccine Development,2420050,2012-04-08,2012.0,2013-04-07,2013,Quality Biological,grid.283674.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2347548,272201100023C-1-0-1,Reagent Resource Support Program for AIDS Vaccine Development,2368328,2011-04-08,2011.0,2012-04-07,2012,Quality Biological,grid.283674.c,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2347179,272201000017I-2-27200004-1,Task C11 NHP Model for Filovirus Vaccine: Efficacy and Immunogenecity Testing,1769568,2011-11-18,2011.0,2013-11-30,2013,Lovelace Respiratory Research Institute,grid.280401.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2346749,272200800056C-2-0-1,Advanced Development of Multivalent Filovirus Vaccines,20885824,2008-09-30,2008.0,2013-09-29,2013,Janssen (Netherlands),grid.497529.4,Netherlands,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2344565,261201200013I-0-26100005-1,Development of Muc1 Vaccine for the Prevention of Pancreatic Cancer,398919,2013-01-01,2013.0,2013-12-31,2013,,,,National Cancer Institute,United States,0,0,0
grant.100073101,BYI2009dmasopust,Testing The True Potential of CD8 T cells to Protect against Immunodefinciency Virus Infection via Novel Vaccination,300000,2009-08-01,2009.0,2012-07-31,2012,University of Minnesota System,grid.437349.e,United States,Arnold and Mabel Beckman Foundation,United States,0,0,0
grant.100071919,T2016-015,Development of Salmonella-based MYCN vaccine for immunotherapy of neuroblastoma,600000,2016-11-01,2016.0,2019-10-31,2019,Texas Children's Hospital,grid.416975.8,United States,V Foundation for Cancer Research,United States,0,0,0
grant.100070343,6003-07,Genetic Vaccines Eliciting Lymphoma-specific T-cell Immunity,600000,2006-10-01,2006.0,2009-09-30,2009,The University of Texas Health Science Center at Houston,grid.267308.8,United States,Leukemia and Lymphoma Society,United States,0,0,0
grant.7924078,MC_EX_G0700930,The study of efficacy and immune correlates to an inactivated H5N1 vaccine in non-human primates,932246,2008-02-01,2008.0,2012-07-30,2012,MRC Human Immunology Unit; Chinese Academy of Agricultural Sciences,grid.173746.0; grid.410727.7,United Kingdom; China,Medical Research Council,United Kingdom,4,0,0
grant.7083241,971511,"Trivalent Lassa, Ebola and Marburg viral vaccine (Tri-LEMvac)",895497,2017-03-31,2017.0,2018-05-30,2018,University of Cambridge,grid.5335.0,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.7025940,R56AI119397,Engineering an intranasal universal influenza vaccine,584330,2017-08-09,2017.0,2019-07-31,2019,Texas Tech University,grid.264784.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6709532,17-15-00071,DESIGNING LIVE INFLUENZA UNIVERSAL VACCINE BASED ON NEW GENE–ENGINEERING AND IMMUNOGENETICS APPROACHES,0,2017-01-01,2017.0,2018-12-31,2018,Institute of Experimental Medicine,grid.465311.4,Russia,Russian Science Foundation,Russia,0,0,0
grant.6617953,R43AI127053,"Development of an Innovative, Effective RNA-based Vaccine for Chikungunya Virus",224998,2017-03-15,2017.0,2018-11-30,2018,PAI Life Sciences (United States),grid.423437.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6376359,R56DE026321,"The Interplay of Oral Vaccines, Oral Immunity and the Oral Microbiome in Infants",400001,2016-09-01,2016.0,2018-08-31,2018,University of North Carolina at Chapel Hill,grid.10698.36,United States,National Institute of Dental and Craniofacial Research,United States,0,0,0
grant.5831961,14770111,マラリア伝搬阻止粘膜ワクチンの開発に関する研究,27577,2002-01-01,2002.0,2004-12-31,2004,University of the Ryukyus,grid.267625.2,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5796747,13770155,LIMPII、ユビキチン融合インフルエンザDNAワクチンによる免疫応答と感染防御,17021,2001-01-01,2001.0,2002-12-31,2002,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5792510,13226094,免疫調節遺伝子とのフュージョンDNAワクチンによる細胞内寄生原虫感染制御の新戦略,0,2001-01-01,2001.0,2001-12-31,2001,Kyushu University,grid.177174.3,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5222977,134275,"Phase II Double-blind, randomized, Placebo-controlled Study to evaluate the Safety and Immunogenicity of H1, an adjuvanted TB subunit vaccine (AG85B-ESAT-6 plus IC31), in HIV-infected, BCG vaccinated Adults with CD4 Lymphocyte Counts greater than 350",271609,2010-11-01,2010.0,2013-10-31,2013,University of Basel,grid.6612.3,Switzerland,Swiss National Science Foundation,Switzerland,0,0,0
grant.4294792,MC_UP_1204/7,HIV EPIDEMIOLOGY AND PREVENTION / International AIDS Vaccine Initiative,4407307,2013-03-31,2013.0,2018-01-31,2018,Uganda Virus Research Institute,grid.415861.f,Uganda,Medical Research Council,United Kingdom,0,0,0
grant.3952092,2011-67015-30136,IMPROVED INFECTIOUS LARYNGOTRACHEITIS VIRUS VACCINES AGAINST NEWCASTLE DISEASE VIRUS WORKSHOP,503000,2014-06-01,2014.0,2017-05-31,2017,"University of Maryland, College Park; University of Maryland, College Park; University of Maryland, College Park; University of Maryland, College Park",grid.164295.d; grid.164295.d; grid.164295.d; grid.164295.d,United States; United States; United States; United States,National Institute of Food and Agriculture,United States,0,2,0
grant.3858813,R01AI110482,A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage,3956523,2014-11-05,2014.0,2019-10-31,2019,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,1
grant.3744387,QLK2-CT-1999-01093,A cluster for tuberculosis vaccine development,4812732,2000-02-01,2000.0,2004-01-31,2004,Pasteur Institute; University of Zaragoza; The Francis Crick Institute; London School of Hygiene & Tropical Medicine; University of Surrey; Public Health England; Pasteur Institute of Lille; Helmholtz Centre for Infection Research; Department for Environment Food and Rural Affairs; GlaxoSmithKline (Belgium); Public Health Agency of Sweden; State Serum Institute; Autonomous University of Barcelona; Queen's University Belfast; University of Erlangen-Nuremberg; University of Oxford; French Institute of Health and Medical Research; Sanofi (France); Biomedical Primate Research Centre; Délégation Midi Pyrénées; Imperial College London; Leiden University; Max Planck Institute for Molecular Genetics; University of Basel; Public Health England; Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani; Wageningen University & Research; Royal Veterinary College; University of Zurich,grid.428999.7; grid.11205.37; grid.451388.3; grid.8991.9; grid.5475.3; grid.271308.f; grid.8970.6; grid.7490.a; grid.13689.35; grid.425090.a; grid.419734.c; grid.6203.7; grid.7080.f; grid.4777.3; grid.5330.5; grid.4991.5; grid.7429.8; grid.417924.d; grid.11184.3d; grid.457025.1; grid.7445.2; grid.5132.5; grid.419538.2; grid.6612.3; grid.271308.f; grid.419423.9; grid.4818.5; grid.20931.39; grid.7400.3,France; Spain; United Kingdom; United Kingdom; United Kingdom; United Kingdom; France; Germany; United Kingdom; Belgium; Sweden; Denmark; Spain; United Kingdom; Germany; United Kingdom; France; France; Netherlands; France; United Kingdom; Netherlands; Germany; Switzerland; United Kingdom; Italy; Netherlands; United Kingdom; Switzerland,European Commission,Belgium,32,0,0
grant.3633986,069733/Z/02/Z,Whooping cough vaccine and vaccination in the Netherlands since 1950.,47678,2003-03-01,2003.0,2004-02-29,2004,University of Amsterdam,grid.7177.6,Netherlands,Wellcome Trust,United Kingdom,0,0,0
grant.3493444,R41AI109926,Development of VPL Vaccine for RSV,225000,2014-02-15,2014.0,2016-01-31,2016,Sigmovir Biosystems (United States),grid.422208.e,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.3146991,1315511,SBIR Phase I: Development of Polymer Gel-Based Indicators to Monitor the Exposure of Individual Vaccine Vials to Harmful Temperatures,149999,2013-07-01,2013.0,2013-12-31,2013,,,,Directorate for Engineering,United States,0,0,0
grant.2765536,G0700647,Immune correlates to an inactivated H5N1 vaccine in humans,198866,2007-04-30,2007.0,2008-04-29,2008,Medical Research Council,grid.14105.31,United Kingdom,Medical Research Council,United Kingdom,2,0,0
grant.2711594,Z01BK003016,"Safety, immunogenicity and mechanism of action of DNA va",0,1997-01-01,1997.0,2002-01-01,2002,,,,United States Food and Drug Administration,United States,0,0,0
grant.2692253,U01IP000414,Improving Vaccination Coverage Among Adolescents,1600000,2010-09-01,2010.0,2015-08-31,2015,University of Michigan,grid.214458.e,United States,Centers for Disease Control and Prevention,United States,4,0,0
grant.2687567,U01AI053719,INDO-US Collaboration to Develop Rotavirus Vaccines,1130283,2003-03-01,2003.0,2008-02-29,2008,All India Institute of Medical Sciences,grid.413618.9,India,National Institute of Allergy and Infectious Diseases,United States,2,0,1
grant.2687497,U01AI047976,(HVTN) HIV VACCINE TRIAL UNITS,10162663,2000-06-01,2000.0,2006-05-31,2006,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2668262,RC1AI048864,PULSED ELECTRIC FIELD DELIVERED DENGUE VACCINE,26000,2000-05-03,2000.0,2000-08-31,2000,Cellectis (United States),grid.433243.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2657735,R44AI039865,LYME VACCINE BASED ON BORRELIA DECORIN ADHESIN,0,1996-04-15,1996.0,1999-06-30,1999,AstraZeneca (United States),grid.418152.b,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2641758,R43AI085783,Novel Protein Adjuvant for Flu Vaccines,600000,2010-07-01,2010.0,2013-06-30,2013,,,,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2640474,R43AI043107,HETEROCONJUGATE VACCINES AGAINST HERPES SIMPLEX VIRUS,0,1998-06-01,1998.0,1999-11-30,1999,Cel-Sci (United States),grid.420516.4,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2599383,R21AI073933,Pro-Apoptotic BCG as an HCV vaccine vector,438917,2009-09-26,2009.0,2011-08-31,2011,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2599315,R21AI073240,Vaccines to Generate Neutralizing Anti-HIV Antibodies,378517,2007-07-15,2007.0,2009-06-30,2009,Veterans Medical Research Foundation of San Diego,grid.44214.37,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2598551,R21AI060368,Chimeric Adenovirus Vaccine Vectors for HIV/SIV,510000,2004-04-01,2004.0,2007-03-31,2007,Beth Israel Deaconess Medical Center,grid.239395.7,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2598339,R21AI057004,Enhancing HIV-1 vaccine immunogenicity using hsp70,491313,2003-08-01,2003.0,2006-07-31,2006,Harvard University,grid.38142.3c,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2597759,R21AI048374,EXPRESSION OF SIVmac239 GP120 IN TRANSGENIC MAIZE,300000,2000-08-01,2000.0,2003-07-31,2003,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2583675,R13CA117408,Annual Sabin Colloquium on Cancer Vaccines and Immunotherapy,9000,2005-06-10,2005.0,2006-05-31,2006,Sabin Vaccine Institute,grid.452766.4,United States,National Cancer Institute,United States,0,0,0
grant.2567423,R03AI094159,A novel DNA-launched live attenuated Chikungunya vaccine,174300,2011-09-09,2011.0,2014-08-31,2014,Medigen (United States),grid.421237.1,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2473620,R01CA077523,CANCER VACCINES TO HPV-16 ASSOCIATED TUMOR,490920,1998-04-01,1998.0,2003-01-31,2003,The Wistar Institute,grid.251075.4,United States,National Cancer Institute,United States,1,0,0
grant.2459539,R01AI098933,Advancing a Lead Candidate Hantavirus Pulmonary Syndrome DNA Vaccine,3279471,2012-05-16,2012.0,2018-04-30,2018,Geneva Foundation,grid.417469.9,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2459098,R01AI091493,Functional genomic analysis of the CD8 T cell response to HIV vaccines in,4852474,2010-09-30,2010.0,2017-08-31,2017,Dana-Farber Cancer Institute,grid.65499.37,United States,National Institute of Allergy and Infectious Diseases,United States,13,2,0
grant.2458596,R01AI081886,A Small Animal Model for Viscerotropic Disease to Improve Yellow Fever Vaccine,1719828,2011-07-01,2011.0,2016-06-30,2016,University of Pittsburgh,grid.21925.3d,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2455944,R01AI052337,Appropriate Pneumococcal Vaccination in Infants in Fiji,1168026,2002-09-30,2002.0,2005-09-29,2005,University of Melbourne,grid.1008.9,Australia,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2455051,R01AI047758,DOMAIN-SPECIFIC SEROLOGY FOR SIV/SHIV VACCINE EVALUATION,1322281,2000-09-30,2000.0,2005-05-31,2005,University of Pittsburgh,grid.21925.3d,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2455044,R01AI047735,DETERMINANTS OF VACCINE PROTECTION IN A SIV MODEL,2392170,2000-06-01,2000.0,2007-05-31,2007,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2452208,R01AI031338,Development and Testing of New Tuberculosis Vaccines,6338002,1991-04-01,1991.0,2012-02-28,2012,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,31,6,0
grant.2452138,R01AI030904,Protective CMI mechanisms of a dual-subtype FIV vaccine,4213791,1991-08-01,1991.0,2015-03-31,2015,University of Florida,grid.15276.37,United States,National Institute of Allergy and Infectious Diseases,United States,31,28,0
grant.2439912,P41RR012255,Multiscale Modeling Tools for Structural Biology,10351716,1997-08-15,1997.0,2012-08-31,2012,University of Michigan,grid.214458.e,United States,National Center for Advancing Translational Sciences,United States,193,0,0
grant.8330234,81261120397,应用多价疫苗免疫huCD4/CCR5转基因小鼠筛选广谱抗HIV-1中和性抗体,48429,2013-01-01,2013.0,2013-12-31,2013,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,1,0,0
grant.8211596,39200110,T细胞疫苗及其诱导的抗克隆型T细胞的研究,6808,1993-01-01,1993.0,1995-12-31,1995,Southern Medical University,grid.284723.8,China,National Natural Science Foundation of China,China,0,0,0
grant.8170790,30271215,HIV壳体蛋白疫苗在转基因枸杞根系中的分泌表达,8455,2003-01-01,2003.0,2003-12-31,2003,Shandong Academy of Medical Science,grid.410587.f,China,National Natural Science Foundation of China,China,4,0,0
grant.8169256,30200120,树突状细胞靶向性DNA疫苗治疗哮喘的试验研究,23024,2003-01-01,2003.0,2005-12-31,2005,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,4,0,0
grant.8166485,30000206,基因修饰的肺癌树突状细胞疫苗及其抗癌机制的实验研究,19322,2001-01-01,2001.0,2003-12-31,2003,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,0,0,0
grant.8107435,25782,A New Approach to Immunization Against E. coli Infections in Broilers,0,2002-05-01,2002.0,2005-04-30,2005,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.7707767,639710,Peut-on prévenir la réponse délétère du déoxynivalénol (DON) sur la réponse vaccinale chez le poulet?,19254,2017-04-01,2017.0,2018-03-31,2018,University of Montreal,grid.14848.31,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.7652313,,Development of Novel Vaccine strategies against HIV-1 infection,1875,2008-10-01,2008.0,2008-12-31,2008,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7645924,,Research on the social and cultural aspects of implementing HIV vaccine programs among MSM and FSWs in Asia and Africa,8759,2009-12-01,2009.0,2010-03-31,2010,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7645922,,CIHR/CHVI Team in the soci-cultural aspects of implementing HIV vaccine programs among MSM and FSWs in Asia and Africa,745315,2010-08-01,2010.0,2013-07-31,2013,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7644719,,"Enhancing Care and Prevention in HIV Vaccine Trials: An International, Interdisciplinary Collaboration",8759,2009-12-01,2009.0,2010-03-31,2010,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7643364,,Preventing Respiratory Syncytial Virus (RSV) infection with a novel antigen-adjuvant platform,177122,2013-10-01,2013.0,2015-09-30,2015,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7624864,,"Social, Behavioral and Ethical Challenges of HIV Vaccine Development",25276,2011-02-01,2011.0,2012-01-31,2012,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7622446,,The immunobiology of recombinant adenovirus vaccines,1035844,2000-10-01,2000.0,2011-09-30,2011,McMaster University,grid.25073.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7620844,,"Understanding H1N1 Immunization Knowledge, Attitudes and Behavior in Pregnant Women in British Columbia",56206,2010-03-01,2010.0,2011-02-28,2011,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7618683,,Collaborative vaccine development - SSI (Denmark) and VIDO (Canada),21775,2006-01-01,2006.0,2006-12-31,2006,University of Saskatchewan,grid.25152.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7186510,31300764,海藻酸钠水凝胶包装以提升腺病毒载体流感疫苗免疫保护效率的机制研究,36318,2014-01-01,2014.0,2016-12-31,2016,Guangzhou Institutes of Biomedicine and Health,grid.428926.3,China,National Natural Science Foundation of China,China,1,0,0
grant.7159514,206523/Z/17/Z,"Clinical trial of duration of immunity of the yellow fever vaccine in army recruits, participants of the study “17DD yellow fever vaccine. A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study”, done in 2009",203600,2017-03-27,2017.0,2018-05-31,2018,Oswaldo Cruz Foundation,grid.418068.3,Brazil,Wellcome Trust,United Kingdom,2,0,0
grant.7073217,16-UOA-016,PilVax: a novel peptide delivery strategy for the development of vaccines,574284,2016-07-01,2016.0,2019-07-01,2019,University of Auckland; University of Otago; University of Otago,grid.9654.e; grid.29980.3a; grid.29980.3a,New Zealand; New Zealand; New Zealand,Royal Society of New Zealand,New Zealand,0,0,0
grant.7028964,R21AI130298,Mucosal Single-Cycle Vaccines against Zika Virus,437250,2017-09-05,2017.0,2019-08-31,2019,Mayo Clinic,grid.66875.3a,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.7016683,81373109,同源模建HSV2免疫保护及免疫逃避蛋白的多表位融合疫苗,26031,2014-01-01,2014.0,2014-12-31,2014,Nanjing General Hospital of Nanjing Military Command,grid.440259.e,China,National Natural Science Foundation of China,China,1,0,0
grant.7010204,31200694,免疫原性氨基酸在肿瘤疫苗HER-2/neu设计中的应用及其免疫应答机制研究,32309,2013-01-01,2013.0,2015-12-31,2015,China Pharmaceutical University,grid.254147.1,China,National Natural Science Foundation of China,China,4,0,0
grant.7002558,31100656,汉坦病毒新型VLPs疫苗及其在小鼠中诱导的免疫反应研究,38599,2012-01-01,2012.0,2014-12-31,2014,,,,National Natural Science Foundation of China,China,0,0,0
grant.6988179,41106147,虹彩病毒纳米基因工程疫苗载体构建与跨膜机理研究,40207,2012-01-01,2012.0,2014-12-31,2014,Ministry of Natural Resources,grid.453137.7,China,National Natural Science Foundation of China,China,4,0,0
grant.6894983,NT11541,Vývoj vakcín namířených proti znakům nádorových kmenových buněk,489858,2010-09-01,2010.0,2013-12-31,2013,Institute of Haematology and Blood Transfusion,grid.419035.a,Czechia,Ministry of Health,Czechia,3,0,0
grant.6841109,17K15687,志賀毒素に対するB鎖標的型組換えトキソイドワクチンの分子構築,37533,2017-04-01,2017.0,2019-03-31,2019,University of the Ryukyus,grid.267625.2,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6777237,25866,Feasibility and safety of a WT1-targeted cancer vaccine in patients with malignant mesothelioma and locally advanced breast cancer: an open label phase I trial.,0,2011-01-01,2011.0,2013-12-31,2013,University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp,grid.5284.b; grid.5284.b; grid.5284.b; grid.5284.b; grid.5284.b; grid.5284.b,Belgium; Belgium; Belgium; Belgium; Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.6726168,597476,Australia Fellowship,3734634,2010-01-01,2010.0,2015-12-31,2015,Griffith University,grid.1022.1,Australia,National Health and Medical Research Council,Australia,1,0,0
grant.6720824,264582,Child and Adolescent Immunisation,1587390,2005-01-01,2005.0,2009-12-31,2009,Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute; Murdoch Childrens Research Institute,grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c; grid.1058.c,Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6720627,264574,Therapeutic Cancer Vaccines,135486,2004-01-01,2004.0,2005-12-31,2005,Peter MacCallum Cancer Centre,grid.1055.1,Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6716293,290240,Kunjin replicon based vaccines for HIV,257980,2004-01-01,2004.0,2006-12-31,2006,QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute; QIMR Berghofer Medical Research Institute,grid.1049.c; grid.1049.c; grid.1049.c,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6715153,299907,HIV Infection: Immunology and Vaccine Design,5816677,2004-01-01,2004.0,2008-12-31,2008,University of Melbourne; University of Melbourne; University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9; grid.1008.9; grid.1008.9,Australia; Australia; Australia; Australia,National Health and Medical Research Council,Australia,25,0,0
grant.6713348,224278,A new scrambled antigen vaccine (SAVINE) approach: Proof-of-concept in non-human primates for HIV-1,86359,2003-01-01,2003.0,2005-12-31,2005,Australian National University; Australian National University; Australian National University,grid.1001.0; grid.1001.0; grid.1001.0,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6443782,AAI15039001-1-0-5,Global HIV/AIDS Vaccine Enterprise,958333,2018-01-01,2018.0,2018-12-31,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6381913,1005325,DETECTION AND CONTROL OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND EMERGING VIRAL DISEASES OF SWINE,0,2014-11-17,2014.0,2016-03-31,2016,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.6380616,2016-67016-24890,NATURE`S ADJUVANT: THE EVOLUTIONARY CONSERVED ROLE OF COMPLEMENT COMPONENT 3D (C3D) IN ENHANCING B-CELL RESPONSES,149861,2016-02-15,2016.0,2018-02-14,2018,University of Massachusetts Dartmouth,grid.266686.a,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.6380515,1005150,PATHOGENOMICS OF INFECTIOUS LARYNGOTRACHEITIS VIRUS,0,2014-11-01,2014.0,2019-10-31,2019,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.6158985,26860771,Development study of next generation therapeutic vaccine for clinical application,25531,2014-04-01,2014.0,2018-03-31,2018,Saitama Medical University,grid.410802.f,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6153433,26640099,A molecular mechanism of cancer vaccine enhancement,34407,2014-04-01,2014.0,2016-03-31,2016,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6148084,26560221,Establishment of near infrared laser adjuvants: An exploration of new mechanisms in light reception,33260,2014-04-01,2014.0,2016-03-31,2016,Keio University,grid.26091.3c,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.6146666,26461250,Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats,42919,2014-04-01,2014.0,2017-03-31,2017,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6144510,26330045,Statistical analysis of an influenza infection system,41789,2014-04-01,2014.0,2018-03-31,2018,Kyoto University,grid.258799.8,Japan,Japan Society for the Promotion of Science,Japan,9,0,0
grant.6141219,26305010,Evaluation of novel transmission blocking vaccine antigen using infected patient's blood from endemic area,145009,2014-04-01,2014.0,2017-03-31,2017,Ehime University,grid.255464.4,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6130025,25870715,The development of new angiotensin II receptor vaccine,38399,2013-04-01,2013.0,2016-03-31,2016,Keio University,grid.26091.3c,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6121924,25461598,Analysis of the factor of low immune responses to pneumococcal conjugate vaccine and Hemophilus influenzae type b conjugate vaccine in immunocompromised children,46798,2013-04-01,2013.0,2016-03-31,2016,University of Occupational and Environmental Health Japan,grid.271052.3,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.6118451,25450432,Study of oral vaccine prevent from neosporosis,47999,2013-04-01,2013.0,2016-03-31,2016,Nippon Veterinary and Life Science University,grid.412202.7,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.6090612,24501335,Synergistic enhancement of tumor vaccine efficacy mediated by herbal medicines,45922,2012-04-01,2012.0,2015-03-31,2015,Nippon Medical School,grid.410821.e,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.6090601,24501332,Development of MIF vaccine therapy against inflammation-related colon carcinogenesis,52840,2012-04-01,2012.0,2016-03-31,2016,Hokkai Gakuen University,grid.440874.b,Japan,Japan Society for the Promotion of Science,Japan,4,0,0
grant.6088330,24591283,Generation of new DNA vaccine plasmid for the therapy of Alzheimer's disease,55375,2012-04-01,2012.0,2015-03-31,2015,Tokyo Metropolitan Institute of Medical Science,grid.272456.0,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.6077873,23790516,Development of recombinant vaccine for lassa fever using replication-incompetent rabies viral vector.,53781,2011-01-01,2011.0,2012-12-31,2012,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6065481,23590532,receptor,62753,2011-01-01,2011.0,2013-12-31,2013,National Kinki Chuo Hospital for Chest Disease,grid.415611.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6062567,23590550,Development of a novel vaccine carrier for the next-generation influenza universal vaccine,58158,2011-01-01,2011.0,2013-12-31,2013,Saitama Medical University,grid.410802.f,Japan,Japan Society for the Promotion of Science,Japan,6,0,0
grant.6052099,22791309,The prevention of MRSA prosthetic vascular graft infection by using a DNA vaccine,48220,2010-01-01,2010.0,2011-12-31,2011,Gifu University,grid.256342.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6042942,22592242,Development of cancer peptide vaccine therapy for oral cancer,55299,2010-01-01,2010.0,2012-12-31,2012,Sapporo Medical University,grid.263171.0,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.6039143,22590600,Attitudes Towards and Acceptance of HPV Vaccine in Mothers of Adolescent Girls: Maximizing the Impact of HPV Vaccine in Japan,55299,2010-01-01,2010.0,2012-12-31,2012,Japanese Red Cross Hokkaido College of Nursing,grid.468932.2,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5991816,19791140,Analysis of dendritic cells in gynecologic cancer patients during WT1 peptide vaccine,34312,2007-01-01,2007.0,2008-12-31,2008,Kanazawa University,grid.9707.9,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5882059,15K19950,Elucidation of immunological mechanism in malignant brain tumor of HUVEC vaccine and expansion of adaptation to hemangioblastoma,34532,2015-04-01,2015.0,2018-03-31,2018,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5879816,15K17890,Functional Vaccine Carriers by using Chemically Modified Fullerene Nanostructures,37785,2015-04-01,2015.0,2017-03-31,2017,National Institute for Materials Science,grid.21941.3f,Japan,Japan Society for the Promotion of Science,Japan,9,0,0
grant.5871293,15K07720,Improved safety and immunogenicity of rabies live vaccine by a reverse genetics approach,42591,2015-04-01,2015.0,2018-03-31,2018,Gifu University,grid.256342.4,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.5821105,14370254,Studies on the route of pertussis vaccination and immune response : a fundamental study of intranasaly immunization,64641,2002-01-01,2002.0,2004-12-31,2004,St. Marianna University School of Medicine,grid.412764.2,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5127033,LP160101105,Optimising the efficacy of mycoplasma vaccines in the field,418113,2016-01-01,2016.0,2018-12-31,2018,University of Melbourne,grid.1008.9,Australia,Australian Research Council,Australia,0,0,0
grant.5125629,BB/N022165/1,Improved conjugate vaccines derived from a bacterial immunomodulatory protein,258135,2016-10-09,2016.0,2018-07-08,2018,University of Bath; Newcastle University,grid.7340.0; grid.1006.7,United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,4,0,0
grant.4943714,20374017,高分子避孕疫苗的研究,28229,2004-01-01,2004.0,2006-12-31,2006,,,,National Natural Science Foundation of China,China,0,0,0
grant.4941994,30500560,运用蛋白质组学方法筛选牙周病疫苗候选p.g抗原的反向疫苗学研究,33389,2006-01-01,2006.0,2008-12-31,2008,Xi'an Jiaotong University,grid.43169.39,China,National Natural Science Foundation of China,China,1,0,0
grant.4938852,30500423,多房棘球绦虫重组Bb-EmII/3-10-Em14-3-3疫苗构建及其免疫机制研究,30719,2006-01-01,2006.0,2008-12-31,2008,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,0,0,0
grant.4938364,30500625,实时定量PCR在核酸疫苗生物分布与生物安全性研究中的应用,29382,2006-01-01,2006.0,2008-12-31,2008,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,0,0,0
grant.4937787,30471660,N-甲基-D-天门冬氨酸受体2B亚基表位疫苗的构建及其镇痛效应的研究,26517,2005-01-01,2005.0,2007-12-31,2007,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,1,0,0
grant.4934608,30560146,细粒棘球绦虫终末宿主重组蛋白多价疫苗的构建和免疫保护性研究,30719,2006-01-01,2006.0,2008-12-31,2008,Xinjiang Medical University,grid.13394.3c,China,National Natural Science Foundation of China,China,1,0,0
grant.4926171,30430610,PfCP-2.9疟疾疫苗免疫保护作用机制的研究,182975,2005-01-01,2005.0,2008-12-31,2008,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,6,0,0
grant.4910016,30530660,囊虫DNA疫苗诱导免疫保护机制的蛋白质组学基础,191490,2006-01-01,2006.0,2009-12-31,2009,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,26,0,0
grant.4908338,30440019,CD4+调节T细胞在T细胞疫苗治疗类风关中的作用,9761,2005-01-01,2005.0,2005-12-31,2005,,,,National Natural Science Foundation of China,China,0,0,0
grant.4791473,26436152,Protein lipidation in plants: requirements and potential for the production of lipoprotein vaccines,0,2006-01-01,2006.0,2011-12-31,2011,Technical University of Darmstadt,grid.6546.1,Germany,German Research Foundation,Germany,0,0,0
grant.4675083,180456,"China, bilateral cooperation on fish vaccine development",25186,2006-01-01,2006.0,2008-12-31,2008,Pharmaq (Norway),grid.458841.4,Norway,The Research Council of Norway,Norway,0,0,0
grant.4554277,02/06184-1,"Desenvolvimento de vacina de subunidade para a profilaxia da leptospirose suína, padronização em hamster e avaliação da imunidade ativa e passiva em suínos",0,2002-12-01,2002.0,2005-06-30,2005,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4548758,07/50355-9,Caridad Zayas Vignier | Inst. Finlay - Cuba,0,2007-04-01,2007.0,2007-05-31,2007,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4503412,00/14549-4,Desenvolvimento de vacina contra o estreptococo beta hemolítico do grupo A,0,2002-04-01,2002.0,2006-12-13,2006,Laboratório Teuto (Brazil),grid.501306.1,Brazil,São Paulo Research Foundation,Brazil,1,0,0
grant.4477008,15/07225-3,Synthesis and characterization of conjugates obtained from Streptococcus pneumoniae capsular polysaccharide and PspA as vaccines candidates,0,2015-07-01,2015.0,2017-12-31,2017,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,1,0,0
grant.4426331,W81XWH-11-C-0051,Multiagent Synthetic DNA Vaccines Delivered by Noninvasive Electroporation,69670,2010-10-01,2010.0,2011-09-30,2011,Inovio Pharmaceuticals (United States),grid.421774.3,United States,United States Department of the Army,United States,0,0,0
grant.4388526,W81XWH-04-C-0025,Innovative Manufacturing Techniques for Polysaccharide-Protein Conjugate Vaccines,120000,2003-10-01,2003.0,2004-09-30,2004,,,,United States Department of the Army,United States,0,0,0
grant.4035669,1980,Dendritic cell targeted adenovirus vaccine vector,82810,2006-07-01,2006.0,2008-06-30,2008,University of Saskatchewan; University of Saskatchewan,grid.25152.31; grid.25152.31,Canada; Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.3984049,12/IP/1532,Understanding cellular immunity to Staphylococcus aureus is required for novel anti-S. aureus vaccine design,462857,2013-04-01,2013.0,2017-03-31,2017,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,9,0,0
grant.3983896,12/IA/1421,Modulation of innate and adaptive immunity by particulate adjuvants for improved parenteral and mucosal vaccination,2142816,2013-04-01,2013.0,2018-03-31,2018,Trinity College Dublin,grid.8217.c,Ireland,Science Foundation Ireland,Ireland,27,0,0
grant.3866240,BBS/E/I/00001557,"Development of a BRSV-ISCOM DIVA vaccine and corresponding DIVA test for future creation, identification and protection of BRSV free zones",66784,2012-01-03,2012.0,2015-01-02,2015,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.3865504,BB/L02442X/1,Technical development of a novel vaccine vehicle for cattle pathogens,502470,2014-10-27,2014.0,2017-04-20,2017,University of Edinburgh; Moredun Foundation,grid.4305.2; grid.420013.4,United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,1,0,0
grant.3843118,131266,Development of a novel VLP based vaccine for malaria,237220,2013-08-31,2013.0,2014-08-30,2014,iQur (United Kingdom); University of Oxford,grid.435566.7; grid.4991.5,United Kingdom; United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.3842325,101597,"Staphylococcus aureus Infections - Development of A Novel, Effective Vaccine",3315873,2014-01-01,2014.0,2017-12-31,2017,Absynth Biologics (United Kingdom); University of Sheffield,grid.432017.3; grid.11835.3e,United Kingdom; United Kingdom,Innovate UK,United Kingdom,1,0,0
grant.3841931,131060,Formulation of VZV to protect virus during manufacture and generate a thermo-stable vaccine to ensure market supply,234501,2013-04-30,2013.0,2014-07-30,2014,,,,Innovate UK,United Kingdom,0,0,0
grant.3837227,0228818,A NOVEL VACCINE AGAINST STREPTOCOCCUS EQUI SUBSP. EQUI FOR HORSES,0,2012-03-27,2012.0,2016-09-30,2016,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3834845,ARS-0412008,FOOT-AND-MOUTH DISEASE VIRUS (FMDV) COUNTERMEASURES DISCOVERY,0,2007-10-01,2007.0,2011-10-10,2011,Agricultural Research Service,grid.463419.d,United States,Agricultural Research Service,United States,0,0,0
grant.3833869,0221494,GENERATION AND ANALYSIS OF A RECOMBINANT MAREK'S DISEASE VIRUS WITH MUTATION IN THE MEQ AND RIBONUCLEOTIDE REDUCTASE GENES FOR POTENTIAL USE AS VACCINE.,0,2010-02-25,2010.0,2012-09-30,2012,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3812426,0228717,GENERATION OF A DOUBLE DELETION MUTANT VIRUS TO IMPROVE SAFETY AND EFFICACY OF A MAREK'S DISEASE VACCINE.,0,2012-03-19,2012.0,2016-09-30,2016,Texas A&M University,grid.264756.4,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3756712,QLK2-CT-2001-42293,"Enhancement of nasal vaccination - improved immune protection, safety and cost-effectivness through optimisation of mucosal and nasal delivery system.",20961,2001-11-27,2001.0,2002-04-26,2002,OptiNose (Norway),grid.458628.5,Norway,European Commission,Belgium,0,0,0
grant.3755519,QLK2-CT-2001-01346,Identification of efficacious delivery systems for recombinant and nucleic acid construct vaccines (EFFICACIOUS DELIVERY),1282553,2001-09-01,2001.0,2005-02-28,2005,"Friedrich Loeffler Institute; Queen's University Belfast; Flanders Institute for Biotechnology; University of Veterinary Medicine Vienna; Queen's University Belfast; University of Veterinary Medicine Vienna; University of Bern; French Agency for Food, Environmental and Occupational Health & Safety; University of Tübingen",grid.417834.d; grid.4777.3; grid.11486.3a; grid.6583.8; grid.4777.3; grid.6583.8; grid.5734.5; grid.15540.35; grid.10392.39,Germany; United Kingdom; Belgium; Austria; United Kingdom; Austria; Switzerland; France; Germany,European Commission,Belgium,5,0,0
grant.3755459,QLK2-CT-2002-01249,Novel strategies for a safe rotavirus vaccine,1934701,2002-09-01,2002.0,2006-02-28,2006,Royal Veterinary College; Research Center at Jouy-en-Josas; Instituto de Biologia Experimental Tecnológica; London School of Hygiene & Tropical Medicine; Public Health Agency of Sweden,grid.20931.39; grid.417961.c; grid.7665.2; grid.8991.9; grid.419734.c,United Kingdom; France; Portugal; United Kingdom; Sweden,European Commission,Belgium,4,0,0
grant.3752777,QLK2-CT-2001-30010,Workshop / training courses on vaccine quality control with three rs methods (VAC-TRAIN),94338,2002-03-01,2002.0,2004-02-27,2004,National Institute for Public Health and the Environment; Paul Ehrlich Institut; University of Bern,grid.31147.30; grid.425396.f; grid.5734.5,Netherlands; Germany; Switzerland,European Commission,Belgium,0,0,0
grant.3750411,ICA4-CT-2002-10042,Phase 1/2 clinical testing of clade C-based HIV-1 candidate vaccines in China,1910593,2002-12-01,2002.0,2008-10-31,2008,University of Regensburg; Sorbonne University; Peking Union Medical College Hospital; Chinese Center For Disease Control and Prevention,grid.7727.5; grid.462844.8; grid.413106.1; grid.198530.6,Germany; France; China; China,European Commission,Belgium,0,0,0
grant.3749572,QLG4-CT-2000-00612,European research programme for improved vaccine safety surveillance,1384883,2001-01-01,2001.0,2003-12-31,2003,Public Health Agency of Sweden; National Institute for Health and Welfare; Azienda Sanitaria Locale Alessandria; National Institute for Public Health and the Environment,grid.419734.c; grid.14758.3f; grid.437448.8; grid.31147.30,Sweden; Finland; Italy; Netherlands,European Commission,Belgium,1,0,0
grant.3748922,ICA4-CT-1999-10010,Towards a vaccine against helicobacter pylori,609220,2000-02-01,2000.0,2003-10-31,2003,Novartis (Italy); Peking University; Second Military Medical University; University of Leeds,grid.15585.3c; grid.11135.37; grid.73113.37; grid.9909.9,Italy; China; China; United Kingdom,European Commission,Belgium,16,0,0
grant.3745255,FAIR984087,DNA vaccination of aquaculture fish with emphasis on VHSV in rainbow trout as a model,544766,1999-01-01,1999.0,2001-12-31,2001,Istituto Zooprofilattico Sperimentale delle Venezie; University of Aberdeen; Technical University of Denmark; University of Oslo,grid.419593.3; grid.7107.1; grid.5170.3; grid.5510.1,Italy; United Kingdom; Denmark; Norway,European Commission,Belgium,8,0,0
grant.3742514,ICA4-CT-2000-30015,Development of an improved vaccine against contagious bovine pleuropneumonia,767710,2000-11-01,2000.0,2004-05-31,2004,French Agricultural Research Centre for International Development; University of Bern; Instituto Nacional de Investigação Agrária e Veterinária; Agricultural Research Council of South Africa,grid.8183.2; grid.5734.5; grid.420943.8; grid.428711.9,France; Switzerland; Portugal; South Africa,European Commission,Belgium,6,0,0
grant.3710988,AIR10441,"AN AROMATIC DEPENDENT MUTANT OF AEROMONAS SALMONICIDA AS A LIVE VACCINE FOR FURUNCULOSIS IN SALMONID FISH. STUDIES ON THE IMMUNE RESPONSE OF VACCINATED FISH AND ON THE FATE OF BACTERIA AFTER VACCINATION, IN THE HOST AND IN THE ENVIRONMENT",777730,1993-01-01,1993.0,1996-03-31,1996,Trinity College Dublin; University of Aberdeen; Eurogentec (Belgium),grid.8217.c; grid.7107.1; grid.424726.1,Ireland; United Kingdom; Belgium,European Commission,Belgium,0,0,0
grant.3642631,099899/Z/12/Z,"Development of an effective inactivated rotavirus vaccine (IRV) for developing countries: definition of rationale, business case, technical feasibility and overall development plan.",159617,2013-06-03,2013.0,2015-06-02,2015,GlaxoSmithKline (Italy); GlaxoSmithKline (Italy),grid.425088.3; grid.425088.3,Italy; Italy,Wellcome Trust,United Kingdom,0,0,0
grant.3629180,075468/Z/04/Z,Parasite evolution in response toblood stage candidate malaria vaccines.,226773,2004-10-01,2004.0,2008-09-30,2008,University of Edinburgh,grid.4305.2,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3629179,075468/Z/04/A,Parasite evolution in response toblood stage candidate malaria vaccines.,20935,2005-09-01,2005.0,2008-08-31,2008,University of Edinburgh,grid.4305.2,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3626830,081461/Z/06/Z,"Development and introduction of vaccines against infectious diseases: MMR in the Netherlands, 1973-85  .",50208,2007-02-05,2007.0,2007-11-04,2007,University of Amsterdam,grid.7177.6,Netherlands,Wellcome Trust,United Kingdom,0,0,0
grant.3624329,R43AI108083,Stable Vaccines Delivered on Oral Thin Films,566303,2014-06-15,2014.0,2016-05-31,2016,Aridis Pharmaceuticals (United States),grid.417462.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3579092,DP1093281,Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch,820763,2010-01-01,2010.0,2012-12-31,2012,University of Queensland,grid.1003.2,Australia,Australian Research Council,Australia,9,0,0
grant.3579004,LP0348441,Genomic sequencing and comparative genomic analysis for animal bacterial vaccine discovery,500176,2003-01-01,2003.0,2006-12-31,2006,Murdoch University,grid.1025.6,Australia,Australian Research Council,Australia,1,0,0
grant.3573546,DP1094465,Investigation of the resilience of immune memory to manipulation by pathogens,358142,2010-01-01,2010.0,2012-12-31,2012,University of Melbourne,grid.1008.9,Australia,Australian Research Council,Australia,0,0,0
grant.3571454,DP0879414,Development of a prime-boost anti-cancer vaccine,195078,2008-01-01,2008.0,2010-12-31,2010,University of Western Australia,grid.1012.2,Australia,Australian Research Council,Australia,0,0,0
grant.3571208,LP0667534,Using transgenic plant-based production and delivery systems to develop an avian influenza vaccine,434961,2006-01-01,2006.0,2008-12-31,2008,University of Melbourne,grid.1008.9,Australia,Australian Research Council,Australia,0,0,0
grant.3357900,8711706,Engineering Creativity Award: Development of Small Scale Facilities for Vaccine,90000,1987-09-01,1987.0,1991-01-31,1991,Tufts University,grid.429997.8,United States,Directorate for Engineering,United States,0,0,0
grant.2769793,G0700735,Vectored Blood Stage Malaria Vaccine,1374450,2008-01-01,2008.0,2010-12-31,2010,University of Oxford; University of Oxford,grid.4991.5; grid.4991.5,United Kingdom; United Kingdom,Medical Research Council,United Kingdom,19,0,0
grant.2754972,BBS/E/I/00001461,Towards improved vaccines for control of avian pathogenic Escherichia coli in poultry,316051,2010-01-18,2010.0,2012-07-16,2012,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.2753546,G0600424,The development of a blood-stage vectored vaccine against Plasmodium falciparum malaria,294333,2006-09-04,2006.0,2009-10-03,2009,University of Oxford; Imperial College London; National Cancer Institute; King's College London,grid.4991.5; grid.7445.2; grid.48336.3a; grid.13097.3c,United Kingdom; United Kingdom; United States; United Kingdom,Medical Research Council,United Kingdom,12,0,0
grant.2723261,ZIAAI001053,Imaging Viral Immunity,4418753,2009-01-01,2009.0,2015-01-01,2015,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2718153,Z01HD000375,TRIAL OF A NEW HEMOPHILUS INFLUENZAE TYPE B VACCINE,0,1989-01-01,1989.0,1989-12-31,1989,National Institute of Child Health and Human Development,grid.420089.7,United States,National Institute of Child Health and Human Development,United States,0,0,0
grant.2709746,Z01BA004012,ADVERSE ALLERGIC REACTIONS TO VACCINES,0,1992-01-01,1992.0,1992-12-31,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709229,Z01AI005064,A Phase I Clinical Trial of a Multiclade HIV-1 Vaccine,0,2004-01-01,2004.0,2004-12-31,2004,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2709203,Z01AI005038,Evaluating a Multicomponent Ebola Vaccine In Adult Volun,0,2002-01-01,2002.0,2002-12-31,2002,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2709136,Z01AI001053,Imaging Viral Immunity,616870,2008-01-01,2008.0,2008-12-31,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2708776,Z01AI000672,Chlamydial Immunity and Vaccine Development,1394166,1993-01-01,1993.0,2008-01-01,2008,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,31,0,0
grant.2708519,Z01AI000404,SECOND AND THIRD-GENERATION HEPATITIS B VACCINES,0,1985-01-01,1985.0,1987-01-01,1987,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2706170,Y1AI4866-4-0-1,Malaria Vaccines: Clinical Research and Trial Sites in Endemic Areas,558430,2009-01-01,2009.0,2009-12-31,2009,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2695788,U19AI066332,Plant-derived vaccines against hepatitis C Cooperative *,3561650,2005-08-01,2005.0,2012-07-31,2012,Arizona State University,grid.215654.1,United States,National Institute of Allergy and Infectious Diseases,United States,4,4,0
grant.2641784,R43AI088923,Infectious DNA (i-DNA) Vaccine for Yellow Fever,117986,2011-01-15,2011.0,2012-10-31,2012,Medigen (United States),grid.421237.1,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2641642,R43AI081385,Adjuvant-containing chimeric virus-like particles as improved influenza vaccines,599998,2009-09-01,2009.0,2011-08-31,2011,,,,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2640145,R43AI034670,BOVINE RESPIRATORY SYNCYTIAL VIRUS AS A HUMAN VACCINE,0,1993-09-30,1993.0,1994-09-30,1994,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2639711,R43AG042993,Novel Formulation of Flu Vaccine for the Aged,298738,2012-08-15,2012.0,2014-07-31,2014,,,,National Institute on Aging,United States,2,0,0
grant.2636725,R41CA092964,A Novel Vaccine for Cancer,100000,2001-06-01,2001.0,2003-05-31,2003,,,,National Cancer Institute,United States,0,0,0
grant.2459800,R01AI103341,Mucosal Immunization Against P. aeruginosa by Modified Adenovirus Vectors,1669379,2013-05-16,2013.0,2018-04-30,2018,Cornell University,grid.5386.8,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2458975,R01AI089449,Capsule conjugate vaccines against ETEC and Campylobacter,2886225,2010-06-01,2010.0,2017-05-31,2017,Henry M. Jackson Foundation,grid.201075.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2457552,R01AI069148,Novel Vaccine Strategies Against Ebola Virus,1222614,2008-05-01,2008.0,2012-04-30,2012,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2455420,R01AI049534,Chracteristics of An M. Tuberculosis Derived Vaccine,3442578,2001-04-01,2001.0,2014-06-30,2014,The University of Texas Health Science Center at Houston,grid.267308.8,United States,National Institute of Allergy and Infectious Diseases,United States,17,0,0
grant.2425382,N01AI40072-13-0-1,Production and Testing of a Modified Vaccinia Ankara (MVA) Vaccine,544748,2004-09-30,2004.0,2015-02-28,2015,Bavarian Nordic (Denmark),grid.481585.5,Denmark,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2386508,F32HL010446,GENETIC DETERMINANTS MEDIATING VIRUS INDUCED LUNG INJURY,72612,2000-07-01,2000.0,2001-01-01,2001,University of Virginia,grid.27755.32,United States,National Heart Lung and Blood Institute,United States,2,0,0
grant.2370356,F32AI056828,Improved meningococcal vesicle vaccines,152188,2003-07-01,2003.0,2006-06-30,2006,UCSF Benioff Children's Hospital,grid.414016.6,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2359891,F31AI056672,Predoctoral Fellowship for Minority Students,159864,2003-07-01,2003.0,2007-06-30,2007,University of Pennsylvania,grid.25879.31,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.100054928,A12454,Targeting CD137 to enhance RSV peptide vaccine efficacy in aged mice,100000,2012-07-01,2012.0,2014-06-30,2014,Emory University,grid.189967.8,United States,American Federation for Aging Research,United States,0,0,0
grant.7135136,W81XWH-06-1-0677,Clinical Translation of a Mammaglobin cDNA Vaccine for Breast Cancer Prevention and Therapy,2314243,2004-10-01,2004.0,2005-09-01,2005,Washington University in St. Louis,grid.4367.6,United States,Congressionally Directed Medical Research Programs,United States,7,0,0
grant.3958472,BB/M019152/1,Stabilisation of Newcastle Disease vaccine formulated in sugar-glass on polypropylene membranes,215254,2015-05-31,2015.0,2016-11-30,2016,University of Oxford; Pirbright Institute,grid.4991.5; grid.63622.33,United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.2770973,MR/K015419/1,Clinical assessment of a novel simian adenovirus-vectored influenza vaccine designed to induce broadly protective immunity,1257462,2012-12-01,2012.0,2016-06-29,2016,University of Oxford; Icahn School of Medicine at Mount Sinai,grid.4991.5; grid.59734.3c,United Kingdom; United States,Medical Research Council,United Kingdom,2,0,0
grant.2695840,U19AI082642,Translational Immunology Research and Accelerated [vaccine] Development (TRIAD),12965744,2009-07-20,2009.0,2015-06-30,2015,University of Rhode Island,grid.20431.34,United States,National Institute of Allergy and Infectious Diseases,United States,44,9,0
grant.8594467,fef122ee-3b46-4991-9b52-ff15b1b95127,Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development,0,2015-01-01,2015.0,2018-12-31,2018,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8457856,,Eliciting and identifying broad anti-HIV immune response with a Polyvalent Anti-HIV Vaccine,78252,2015-09-01,2015.0,2016-08-31,2016,Western University,grid.39381.30,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8329770,81161120428,运用新型统计学临床试验设计方法设计中国首次艾滋病疫苗有效性和免疫原性的IIb期临床试验(中美生物医学合作试点项目),47528,2012-01-01,2012.0,2012-12-31,2012,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,1,0,0
grant.8186858,31500751,滤泡辅助T细胞在乙肝疫苗免疫应答中的表型和功能分析及调控机制研究,25476,2016-01-01,2016.0,2018-12-31,2018,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,5,0,0
grant.8184633,31470895,结核亚单位疫苗诱导的记忆性T细胞亚型特征、分化调控及保护效应研究,122035,2015-01-01,2015.0,2018-12-31,2018,Lanzhou University,grid.32566.34,China,National Natural Science Foundation of China,China,7,0,0
grant.8176846,31240084,Notch信号在呼吸道病毒疫苗增强性肺部免疫病理中的作用及机制研究,24213,2013-01-01,2013.0,2013-12-31,2013,Hebei Medical University,grid.256883.2,China,National Natural Science Foundation of China,China,1,0,0
grant.7819398,815645,RNA particles for Preparedness against Infectious Diseases,58998,2018-06-01,2018.0,2018-11-30,2018,,,,European Commission,Belgium,0,0,0
grant.7661394,,Targeted Dendritic Cell Vaccines for Influenza: Providing a vaccine to all 33M Canadians,140064,2007-02-01,2007.0,2009-01-31,2009,University of Alberta,grid.17089.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7651941,,Planning and development of a Sexually Transmitted Infections Vaccine Consortium in British Columbia (STRIVE-BC),7712,2018-05-01,2018.0,2019-04-30,2019,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7641972,,A DNA-Based Universal Seasonal Influenza Vaccine Phase I Safety and Immunogenicity Study,317208,2011-10-01,2011.0,2013-09-30,2013,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7621487,,Development of small molecule viral sensitizers to boost vaccine manufacturing,379009,2012-04-01,2012.0,2015-03-31,2015,University of Ottawa,grid.28046.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7200856,81272844,新型GM-CSF锚定的膀胱癌肿瘤干细胞疫苗的治疗作用及相关机制研究,95274,2013-01-01,2013.0,2016-12-31,2016,Southern Medical University,grid.284723.8,China,National Natural Science Foundation of China,China,14,0,0
grant.7189151,81273322,基于菌影递送系统的梅毒螺旋体新型多表位疫苗的免疫保护效应及机制,63515,2013-01-01,2013.0,2016-12-31,2016,University of South China,grid.412017.1,China,National Natural Science Foundation of China,China,4,0,0
grant.7134188,DAMD17-03-1-0727,The identification of breast tumor antigens targeted by the immune response during tumor rejection,113700,2001-10-01,2001.0,2002-09-01,2002,,,,Congressionally Directed Medical Research Programs,United States,1,0,0
grant.7069383,2012-McClarty,"Sociocultural acceptability of a future HIV vaccine: Perspectives of frontline health care workers in Karnataka, India",26772,2012-07-01,2012.0,2014-06-30,2014,University of Manitoba,grid.21613.37,Canada,Research Manitoba,Canada,0,0,0
grant.7043117,SE3223,Development of an oral BCG vaccine bait formulation for badgers,2763721,2006-01-01,2006.0,2008-12-31,2008,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.7042976,SE2807,Protective immune responses induced by FMDV vaccine in target species and their epidemiological significance,326574,1999-04-01,1999.0,2002-06-30,2002,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,1,0,0
grant.7042975,SE2806,Matching the antigenic properties of footandmouth disease vaccine virus strains with those of field strains,309965,1999-04-01,1999.0,2002-06-30,2002,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.6986688,31200690,伪狂犬病病毒/日本脑炎病毒复制子嵌合疫苗载体的构建及评价,40386,2013-01-01,2013.0,2015-12-31,2015,Harbin Veterinary Research Institute,grid.38587.31,China,National Natural Science Foundation of China,China,10,0,0
grant.6971184,609064,Formulation and optimization studies of spray-drying to prepare a thermally stabilized vaccine model,18857,2016-04-01,2016.0,2017-03-31,2017,McMaster University,grid.25073.33,Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.6950274,5114115F,Development of a murine model of oral adenovirus vectored vaccine.,0,2014-10-01,2014.0,2016-12-31,2016,University of Liège,grid.4861.b,Belgium,Fund for Scientific Research,Belgium,0,0,0
grant.6815040,775611,Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems,56360,2017-06-01,2017.0,2017-10-31,2017,,,,European Commission,Belgium,0,0,0
grant.6728763,137881,Improved vaccines against tuberculosis based on dendritic cell manipulation,146466,2001-01-01,2001.0,2003-12-31,2003,University of Sydney; University of Sydney; University of Sydney,grid.1013.3; grid.1013.3; grid.1013.3,Australia; Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
grant.6718339,350841,Understanding Immune Control of HIV,186576,2005-01-01,2005.0,2007-12-31,2007,UNSW Sydney; UNSW Sydney; UNSW Sydney,grid.1005.4; grid.1005.4; grid.1005.4,Australia; Australia; Australia,National Health and Medical Research Council,Australia,3,0,0
grant.6622479,115850,Manufacturing and Development for Rapid Access Ebola Vaccine (EBOMAN) – Sofia ref.: 115850,1146241,2014-12-01,2014.0,2017-11-30,2017,Bavarian Nordic (Denmark); Janssen (Netherlands); Bavarian Nordic (Denmark),grid.481585.5; grid.497529.4; grid.481585.5,Denmark; Netherlands; Denmark,European Commission,Belgium,0,0,0
grant.6381177,972228,Self-Administered Vaccines Directed Against Plague and MERS,668634,2016-08-31,2016.0,2017-08-30,2017,,,,Innovate UK,United Kingdom,1,0,0
grant.5977328,19659115,アジュバントとして異種抗原を付加したインフルエンザワクチンの開発,19970,2007-01-01,2007.0,2008-12-31,2008,Obihiro University of Agriculture and Veterinary Medicine,grid.412310.5,Japan,Japan Society for the Promotion of Science,Japan,11,0,0
grant.5943537,17590547,The burden of rotavirus diarrhea : Estimating the cumulative incidence among children less than 3 years of age,29044,2005-01-01,2005.0,2007-12-31,2007,Nagasaki University,grid.174567.6,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5941026,17592120,Antitumor immunity by OK-432-conjugated tumor vaccine in mice cancer model,31819,2005-01-01,2005.0,2006-12-31,2006,Matsumoto Dental University,grid.411611.2,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5938747,17659313,造血細胞移植患者に対する、免疫抑制を惹起しない麻疹ワクチンの開発,13255,2005-01-01,2005.0,2006-12-31,2006,Mie University,grid.260026.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5927000,17390126,"Development of heterologous vaccines using MPT51, a novel secretory protein of Mycobacterium tubeiculosis",131014,2005-01-01,2005.0,2007-12-31,2007,Hamamatsu University School of Medicine,grid.505613.4,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5682037,07F07439,クルマエビの検疫関連遺伝子の機能解析,20877,2007-01-01,2007.0,2008-12-31,2008,University of Miyazaki,grid.410849.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5585646,02J09066,細胞内寄生性病原体の免疫回避機構に対応したDNAワクチン・遺伝子治療の戦略的基盤,16608,2002-01-01,2002.0,2003-12-31,2003,Kyushu University,grid.177174.3,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5245885,272201300004I-1-27200004-1,"P187 - MULTIPLY EXPOSED VAGINALLY, UNINFECTED MACAQUE MODEL",245277,2014-09-01,2014.0,2015-05-31,2015,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.5210881,112406,Mucosal vaccine strategies against human papillomavirus and cervical cancer,382433,2006-05-01,2006.0,2009-10-31,2009,University of Lausanne,grid.9851.5,Switzerland,Swiss National Science Foundation,Switzerland,5,0,0
grant.4950921,30870023,新型乳酸菌表面展示系统及其作为疫苗载体的前期基础研究,52354,2009-01-01,2009.0,2011-12-31,2011,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,4,0,0
grant.4899319,ID09-USC-027,Dendritic Cell-Directed Vaccine Against HIV,208017,2010-04-01,2010.0,2012-09-30,2012,University of Southern California,grid.42505.36,United States,California HIV/AIDS Research Program,United States,0,0,0
grant.4674892,192465,Application of Open Source Licensing to Vaccine and Medicine Discovery and Development,451756,2009-01-01,2009.0,2013-12-31,2013,Norwegian Knowledge Centre for the Health Services,grid.425407.0,Norway,The Research Council of Norway,Norway,3,0,0
grant.4662133,237315,Fish Virus Vaccines (ViVaFish),3098696,2014-01-01,2014.0,2018-12-31,2018,Norwegian University of Life Sciences,grid.19477.3c,Norway,The Research Council of Norway,Norway,25,0,0
grant.4640691,185872,Developing vaccines against diarrhea caused by Enterotoxigenic Escherichia coli and Shigella (EntVac),2591738,2008-01-01,2008.0,2013-12-31,2013,University of Bergen,grid.7914.b,Norway,The Research Council of Norway,Norway,11,0,0
grant.4640383,183189,TRUKKET XXXXXXXXXXXElectroporation enhanced technology for delivery of DNA vaccines against brucellosis .........,342470,2007-01-01,2007.0,2011-12-31,2011,,,,The Research Council of Norway,Norway,0,0,0
grant.4538557,06/60941-0,Escalonamento do processo de produção de vacina recombinante contra Rhodococcus equi,0,2008-04-01,2008.0,2010-03-31,2010,,,,São Paulo Research Foundation,Brazil,1,0,0
grant.4425384,N00014-01-M-0178,Prediction of Hyperbaric Oxygen Toxicity,69700,2000-10-01,2000.0,2001-09-30,2001,Vaxin (United States),grid.422117.3,United States,United States Department of the Navy,United States,0,2,0
grant.4241520,R42DA040422,Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction,320176,2015-09-01,2015.0,2017-05-31,2017,Molecular GPS Technologies (United States),grid.281192.1,United States,National Institute on Drug Abuse,United States,1,0,0
grant.3939966,643381,TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development,20608244,2015-01-01,2015.0,2019-06-30,2019,"TuBerculosis Vaccine Initiative; International Tuberculosis Research Center; Imperial College London; University of Geneva; Biomedical Primate Research Centre; University of Cape Town; University Hospital of Lausanne; Swiss Federal Institute of Technology in Zurich; Medical Research Council; Leiden University Medical Center; Pasteur Institute of Lille; International Tuberculosis Research Center; Aston University; Stellenbosch University; Aeras; Department for Environment Food and Rural Affairs; Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani; University of Sydney; Azienda Ospedaliera Universitaria Policlinico ""Paolo Giaccone"" di Palermo; Africa Health Research Institute; Ghent University; National Institute of Health; Paul Ehrlich Institut; Friedrich Loeffler Institute; Azienda Ospedaliera Universitaria Policlinico ""Paolo Giaccone"" di Palermo; University of Strathclyde; Pasteur Institute; French National Centre for Scientific Research; Aeras; Health Sciences Research Institute of the “Germans Trias i Pujol” Foundation; Africa Health Research Institute; Yonsei University; University College Dublin; University of Lausanne; Scientific Institute of Public Health; University of Zaragoza; State Serum Institute; University of Basel; University of Ulm; Université Libre de Bruxelles; Transgene (France); GlaxoSmithKline (Belgium); Department of Health and Social Care; London School of Hygiene & Tropical Medicine; University of Zurich; University of Oxford; Max Planck Society; Bangor University; Yonsei University",grid.425962.e; grid.495992.a; grid.7445.2; grid.8591.5; grid.11184.3d; grid.7836.a; grid.8515.9; grid.5801.c; grid.14105.31; grid.10419.3d; grid.8970.6; grid.495992.a; grid.7273.1; grid.11956.3a; grid.432518.9; grid.13689.35; grid.419423.9; grid.1013.3; grid.412510.3; grid.488675.0; grid.5342.0; grid.416651.1; grid.425396.f; grid.417834.d; grid.412510.3; grid.11984.35; grid.428999.7; grid.4444.0; grid.432518.9; grid.429186.0; grid.488675.0; grid.15444.30; grid.7886.1; grid.9851.5; grid.418170.b; grid.11205.37; grid.6203.7; grid.6612.3; grid.6582.9; grid.4989.c; grid.420228.e; grid.425090.a; grid.57981.32; grid.8991.9; grid.7400.3; grid.4991.5; grid.4372.2; grid.7362.0; grid.15444.30,Netherlands; South Korea; United Kingdom; Switzerland; Netherlands; South Africa; Switzerland; Switzerland; United Kingdom; Netherlands; France; South Korea; United Kingdom; South Africa; United States; United Kingdom; Italy; Australia; Italy; South Africa; Belgium; Italy; Germany; Germany; Italy; United Kingdom; France; France; United States; Spain; South Africa; South Korea; Ireland; Switzerland; Belgium; Spain; Denmark; Switzerland; Germany; Belgium; France; Belgium; United Kingdom; United Kingdom; Switzerland; United Kingdom; Germany; United Kingdom; South Korea,European Commission,Belgium,129,0,0
grant.3857025,272201300004I-0-27200004-1,"P187 - MULTIPLY EXPOSED VAGINALLY, UNINFECTED MACAQUE MODEL",57154,2014-09-01,2014.0,2015-05-31,2015,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3811139,2011-67015-30176,POLYVALENT T CELL MOSAIC VACCINE TO CROSS-PROTECT SWINE AGAINST HETEROLOGOUS PRRSSV STRAINS,495000,2010-09-01,2010.0,2012-08-31,2012,University of Connecticut; University of Connecticut; University of Connecticut,grid.63054.34; grid.63054.34; grid.63054.34,United States; United States; United States,National Institute of Food and Agriculture,United States,2,0,0
grant.3800649,602843,"Developing and Testing a novel, low-cost, effective HOOKworm VACcine to Control Human Hookworm Infection in endemic countries",7056595,2013-10-01,2013.0,2019-03-31,2019,Academic Medical Center; Sabin Vaccine Institute; George Washington University; Leiden University Medical Center; Q-Biologicals (Belgium); Baylor College of Medicine; Pharmidex (United Kingdom); George Washington University; University of Tübingen; Centre de Recherche Médicales de Lambaréné; Sabin Vaccine Institute,grid.5650.6; grid.452766.4; grid.253615.6; grid.10419.3d; grid.425714.1; grid.39382.33; grid.425448.b; grid.253615.6; grid.10392.39; grid.452268.f; grid.452766.4,Netherlands; United States; United States; Netherlands; Belgium; United States; United Kingdom; United States; Germany; Gabon; United States,European Commission,Belgium,0,0,0
grant.3797302,315640,Development of an oral Helicobacter Pylori vaccine,1723265,2012-10-01,2012.0,2014-12-31,2014,Sigmoid Pharma (Ireland); Trinity College Dublin; MediTox (Czechia); University of Gothenburg,grid.426141.4; grid.8217.c; grid.424217.6; grid.8761.8,Ireland; Ireland; Czechia; Sweden,European Commission,Belgium,0,0,0
grant.3797051,601738,"A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines",7064241,2013-10-01,2013.0,2018-09-30,2018,Federal Department of Home Affairs; OZ Biosciences (France); French National Centre for Scientific Research; MediTox (Czechia); University of Bergen; University of Manchester; Tp21 (Germany); Helmholtz Centre for Infection Research,grid.424284.c; grid.437080.8; grid.4444.0; grid.424217.6; grid.7914.b; grid.5379.8; grid.426287.d; grid.7490.a,Switzerland; France; France; Czechia; Norway; United Kingdom; Germany; Germany,European Commission,Belgium,34,0,0
grant.3796233,602167,Innovation Partnership for a Roadmap on Vaccines in Europe,600782,2013-12-01,2013.0,2016-03-31,2016,,,,European Commission,Belgium,2,0,0
grant.3796117,602640,Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure,5464655,2013-11-01,2013.0,2017-10-31,2017,Etna Biotech (Italy); Biomedical Primate Research Centre; Department of Health and Social Care; Etna Biotech (Italy); Instituto de Biologia Experimental Tecnológica; Wageningen University & Research,grid.434329.b; grid.11184.3d; grid.57981.32; grid.434329.b; grid.7665.2; grid.4818.5,Italy; Netherlands; United Kingdom; Italy; Portugal; Netherlands,European Commission,Belgium,4,0,0
grant.3791598,324634,ARCAS: Analysis of the Route to Commercialisation of MVA based influenza  vaccines,198381,2012-12-01,2012.0,2013-11-30,2013,Erasmus University Medical Center; Erasmus University Medical Center,grid.5645.2; grid.5645.2,Netherlands; Netherlands,European Research Council,Belgium,4,0,0
grant.3781384,245266,"Development of Vaccines for bTV, EHDV and AHSV",3996185,2010-02-01,2010.0,2014-01-31,2014,"London School of Hygiene & Tropical Medicine; Kansas State University; French Agency for Food, Environmental and Occupational Health & Safety; Deltamune (South Africa); Pfizer (Spain); Kansas State University; French Agency for Food, Environmental and Occupational Health & Safety; Boehringer Ingelheim (Germany); Friedrich Loeffler Institute; MSD (Netherlands); Boehringer Ingelheim (France); Complutense University of Madrid; Deltamune (South Africa); Ingenasa (Spain); Veterinary and Agrochemical Research Centre; Pirbright Institute; French Agency for Food, Environmental and Occupational Health & Safety; Pfizer (Spain); Wageningen University & Research; London School of Hygiene & Tropical Medicine",grid.8991.9; grid.36567.31; grid.15540.35; grid.463214.6; grid.424551.3; grid.36567.31; grid.15540.35; grid.420061.1; grid.417834.d; grid.420097.8; grid.484445.d; grid.4795.f; grid.463214.6; grid.425091.b; grid.423677.3; grid.63622.33; grid.15540.35; grid.424551.3; grid.4818.5; grid.8991.9,United Kingdom; United States; France; South Africa; Spain; United States; France; Germany; Germany; Netherlands; France; Spain; South Africa; Spain; Belgium; United Kingdom; France; Spain; Netherlands; United Kingdom,European Commission,Belgium,39,0,0
grant.3765546,503240,Mucosal Vaccines for Poverty Related Diseases,20580348,2003-12-01,2003.0,2009-11-30,2009,"Novartis (Italy); St George's, University of London; Max Planck Society; King's College London; National Research Council; Wellcome Sanger Institute; University of Italian Switzerland; ALTA (Italy); German Rheumatism Research Centre; University of Gothenburg; Bernhard Nocht Institute for Tropical Medicine; State Serum Institute; Mario Negri Institute for Pharmacological Research; Institute of Microbiology; University of Florence; Ignace Deen Hospital; University of Lausanne; National Institute of Health; Humanitas Research Hospital; South African Medical Research Council; Armauer Hansen Research Institute; University of Palermo; Public Health England; Trinity College Dublin; University of Siena",grid.15585.3c; grid.264200.2; grid.4372.2; grid.13097.3c; grid.5326.2; grid.10306.34; grid.29078.34; grid.424010.3; grid.418217.9; grid.8761.8; grid.424065.1; grid.6203.7; grid.4527.4; grid.418800.5; grid.8404.8; grid.440582.f; grid.9851.5; grid.416651.1; grid.417728.f; grid.415021.3; grid.418720.8; grid.10776.37; grid.271308.f; grid.8217.c; grid.9024.f,Italy; United Kingdom; Germany; United Kingdom; Italy; United Kingdom; Switzerland; Italy; Germany; Sweden; Germany; Denmark; Italy; Czechia; Italy; Guinea; Switzerland; Italy; Italy; South Africa; Ethiopia; Italy; United Kingdom; Ireland; Italy,European Commission,Belgium,2,0,0
grant.3635549,078108/Z/05/Z,UK HIV Vaccine Consortium report.,164608,2005-07-01,2005.0,2006-06-30,2006,Imperial College London; Imperial College London,grid.7445.2; grid.7445.2,United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3630295,075800/Z/04/Z,Development of effective live vaccines for prevention of anaplasmosis and babesiosis.,1721382,2005-07-01,2005.0,2012-06-30,2012,Washington State University,grid.30064.31,United States,Wellcome Trust,United Kingdom,1,0,0
grant.3630291,075800/Z/04/A,Development of effective live vaccines for prevention of anaplasmosis and babesiosis.,124287,2005-07-01,2005.0,2012-06-30,2012,Washington State University,grid.30064.31,United States,Wellcome Trust,United Kingdom,4,0,0
grant.3628122,075799/Z/04/A,Adapting recombinant anti-tick vaccines to livestock in Africa.,183003,2005-01-01,2005.0,2009-12-31,2009,Utrecht University,grid.5477.1,Netherlands,Wellcome Trust,United Kingdom,0,0,0
grant.3628116,075799/Z/04/Z,Adapting recombinant anti-tick vaccines to livestock in Africa.,1812122,2005-05-01,2005.0,2010-04-30,2010,Utrecht University; Utrecht University; Utrecht University; Utrecht University; Utrecht University; Utrecht University; Utrecht University,grid.5477.1; grid.5477.1; grid.5477.1; grid.5477.1; grid.5477.1; grid.5477.1; grid.5477.1,Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands,Wellcome Trust,United Kingdom,10,0,0
grant.3623723,R01AI113103,Role of Plac8 in natural and vaccine-generated immunity against Chlamydia infections,1859892,2014-07-01,2014.0,2019-06-30,2019,Yale University,grid.47100.32,United States,National Institute of Allergy and Infectious Diseases,United States,5,3,0
grant.2953673,530861,Development of small molecule viral sensitizers to boost vaccine manufacturing,387251,2012-04-01,2012.0,2014-03-31,2014,University of Ottawa; Canadian Institutes of Health Research; Canadian Institutes of Health Research,grid.28046.38; grid.248883.d; grid.248883.d,Canada; Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2766843,BBS/E/I/00001310,Combating highly pathogenic avian influenza: novel vaccination strategies,1011749,2008-02-18,2008.0,2012-08-04,2012,Pirbright Institute; Pirbright Institute; Pirbright Institute,grid.63622.33; grid.63622.33; grid.63622.33,United Kingdom; United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.2711478,Z01BJ003004,AEROSOL INFECTION OF MICE AS A MODEL FOR PERTUSSIS INFEC,0,1995-01-01,1995.0,1999-01-01,1999,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711194,Z01BF003004,IMMUNOGENICITY OF TWO DIFFERENT MEASLES VACCINES IN HAITIAN INFANTS,0,1990-01-01,1990.0,1990-12-31,1990,,,,United States Food and Drug Administration,United States,0,0,0
grant.2710976,Z01BC011062,Development of a Vaccine for HIVAIDS: Cellular Immunity,1266575,2008-01-01,2008.0,2008-12-31,2008,,,,National Cancer Institute,United States,9,0,0
grant.2705299,UM1AI069443,South-West European HIV Vaccine Clinical Trial Unit,743738,2007-02-01,2007.0,2014-01-31,2014,University Hospital of Lausanne,grid.8515.9,Switzerland,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2704638,UC1AI067183,Development of an VEE Replicon Vaccine Against Smallpox,3300000,2005-09-30,2005.0,2009-08-31,2009,AlphaVax (United States),grid.422340.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2704622,UC1AI062567,Development of ProtollinTM Plague Vaccine,7992403,2004-09-30,2004.0,2007-08-31,2007,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2704613,UC1AI062511,An Inactivated Influenza Nasal Powder Vaccine,6061068,2004-09-30,2004.0,2009-08-31,2009,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2695767,U19AI061728,Optimizing the Immunogenicity of MVA-Based AIDS Vaccines,14315660,2004-09-02,2004.0,2009-08-31,2009,Emory University,grid.189967.8,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2688088,U01AI082224,"Development of a Next Generation Anthrax Vaccine, dmPA7909",5351252,2009-09-30,2009.0,2012-08-31,2012,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2688026,U01AI078010,"Dose Optimization, Production &Tox Testing of Replicon-Vaccines for Smallpox",1000000,2008-08-04,2008.0,2011-07-31,2011,AlphaVax (United States),grid.422340.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2687854,U01AI069486,Development of HIV Vaccine Clinical Trials Phase I-II-III in Dominican Republic,2384636,2007-02-15,2007.0,2012-06-30,2012,Instituto Dermatológico y Cirugía de Piel,grid.477459.c,Dominican Republic,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2687829,U01AI069443,South-West European HIV Vaccine Clinical Trial Unit,1749940,2007-02-01,2007.0,2014-01-31,2014,University Hospital of Lausanne,grid.8515.9,Switzerland,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2687735,U01AI061988,Development of Recombinant SARS VLP Vaccines,1040921,2005-02-15,2005.0,2010-01-31,2010,Novavax (United States),grid.436677.7,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2687614,U01AI056410,Preclinical Development of a Recombinant Dengue Vaccine,3269254,2003-09-15,2003.0,2008-02-28,2008,Hawaii Biotech (United States),grid.420613.2,United States,National Institute of Allergy and Infectious Diseases,United States,2,4,0
grant.2666008,R56AI060686,GENERATION OF NOVEL RECOMBINANT RABIES VIRUS VACCINES,312821,2004-07-01,2004.0,2011-09-09,2011,Thomas Jefferson University,grid.265008.9,United States,National Institute of Allergy and Infectious Diseases,United States,10,0,0
grant.2665739,R56AI030904,Protective CMI mechanisms of a dual-subtype FIV vaccine,98672,2008-04-01,2008.0,2008-06-30,2008,University of Florida,grid.15276.37,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2641999,R43AI102318,TITER ON CHIP: ALTERNATIVE TO SRID FOR INFLUENZA VACCINE POTENCY DETERMINATION,600000,2012-05-15,2012.0,2014-07-31,2014,InDevR (United States),grid.420960.9,United States,National Institute of Allergy and Infectious Diseases,United States,3,3,0
grant.2641546,R43AI077229,Potent Vaccine Adjuvant Therapeutic,577222,2009-09-15,2009.0,2012-08-31,2012,ImmuRx (United States),grid.420939.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641131,R43AI058376,Novel Smallpox Vaccine Derived from VV/VAR Immunome,1027407,2005-06-01,2005.0,2009-05-31,2009,EpiVax (United States),grid.421087.8,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2640943,R43AI052886,Development of an Oral Anthrax Vaccine,203609,2002-09-15,2002.0,2005-08-31,2005,TSRL (United States),grid.281449.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2638327,R42AI044520,Non-invasive delivery of skin-targeted tetanus vaccines,565250,1999-05-01,1999.0,2004-05-31,2004,Vaxin (United States),grid.422117.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,6,0
grant.2636466,R41AI073064,A novel vaccine: botulinum neurotoxin subunit on a viral carrier.,669400,2008-04-01,2008.0,2010-09-30,2010,Molecular Targeting Technologies (United States),grid.421557.0,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2636457,R41AI072777,A Novel Therapy for Staphyloccocal Enterotoxin B poisoning,200970,2007-04-15,2007.0,2009-03-31,2009,SoyMeds (United States),grid.422461.7,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2625454,R29AI040572,DELETED PHOP/PHOQ S TYPHI AS A LIVE ORAL VACCINE VECTOR,0,1997-08-01,1997.0,1999-04-14,1999,Massachusetts General Hospital,grid.32224.35,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2605071,R21CA134813,Stress management and vaccine response among women at risk for breast cancer,425920,2009-07-01,2009.0,2012-12-31,2012,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,National Cancer Institute,United States,3,0,1
grant.2601356,R21AI105499,Increasing efficacy of an Adenovirus vaccine targeting Clostridium difficile usin,396546,2013-05-15,2013.0,2016-04-30,2016,Michigan State University,grid.17088.36,United States,National Institute of Allergy and Infectious Diseases,United States,5,1,0
grant.2598512,R21AI059591,Mast Cell Activator as Adjuvant for Biodefense Vaccines,608762,2005-05-01,2005.0,2007-04-30,2007,Duke University,grid.26009.3d,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2598293,R21AI056003,Transdermal vaccine delivery platform technology,711903,2004-09-30,2004.0,2007-05-31,2007,SRI International,grid.98913.3a,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2581944,R13AI098441,HIV Vaccines,20000,2012-03-15,2012.0,2013-02-28,2013,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2581467,R13AI053895,HIV Vaccine Development,12000,2003-03-01,2003.0,2004-02-29,2004,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2580180,R03TW006306,Epitope Driven HIV Vaccine Development AI50528-01A1,120012,2004-07-01,2004.0,2008-06-30,2008,EpiVax (United States),grid.421087.8,United States,Fogarty International Center,United States,1,0,0
grant.2566828,R03AI044648,HIV 1 VACCINE AND IMMUNITY STUDY,144500,1999-09-01,1999.0,2003-08-31,2003,University of Florida,grid.15276.37,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2545177,R01HS021492,Randomized Intervention Trial to Evaluate a Vaccine Social Media Website,495470,2012-09-30,2012.0,2017-07-31,2017,Kaiser Permanente,grid.280062.e,United States,Agency for Healthcare Research and Quality,United States,5,0,0
grant.2477018,R01CA103921,Optimization of Peptide Based Vaccines for Cancer,1249045,2004-09-01,2004.0,2010-08-31,2010,Moffitt Cancer Center,grid.468198.a,United States,National Cancer Institute,United States,27,2,0
grant.2459067,R01AI090691,Generation and Evaluation of Pro-Apoptotic rBCG and Viral Vectors as TB Vaccine C,845161,2010-08-01,2010.0,2014-03-31,2014,Aeras,grid.432518.9,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2458505,R01AI080781,Novel vaccines for broad protection against avian influenza,1634395,2009-03-15,2009.0,2015-02-28,2015,Yale University,grid.47100.32,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2454744,R01AI046320,VACCINE APPROACHES TO PREVENT HIV/AIDS IN CHILDREN,2198199,1999-09-01,1999.0,2005-06-30,2005,"University of California, Davis",grid.27860.3b,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2451211,R01AI025087,DEVELOPMENTAL ASPECTS OF AN IDIOTYPE VACCINE,0,1988-09-30,1988.0,1993-03-31,1993,Roswell Park Cancer Institute,grid.240614.5,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2451063,R01AI024328,CLINICALLY RELEVANT MODELS FOR IDIOTYPE HBSAG VACCINE,0,1987-01-01,1987.0,1989-12-31,1989,Roswell Park Cancer Institute,grid.240614.5,United States,National Institute of Allergy and Infectious Diseases,United States,2,4,0
grant.2435060,P01AI048203,HUMAN IMMUNE RESPONSES TO HPV VACCINES,3289767,2000-07-01,2000.0,2005-06-30,2005,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,10,0,0
grant.2435034,P01AI045142,DEVELOPMENT OF A NOVEL MULTIENVELOPE AIDS VACCINE,7044139,1999-05-15,1999.0,2006-07-31,2006,St. Jude Children's Research Hospital,grid.240871.8,United States,National Institute of Allergy and Infectious Diseases,United States,34,0,1
grant.2409929,K08AI050035,Tuberculosis Vaccine Strategy Using Salmonella Vectors,328849,2001-09-01,2001.0,2004-11-30,2004,Washington University in St. Louis,grid.4367.6,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2359952,F31AI071372,Gene Variation and Responsiveness to Influenza Vaccines,97206,2008-07-01,2008.0,2011-03-31,2011,Baylor College of Medicine,grid.39382.33,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2354952,DP1DA034787,Development of a Practical Heroin-HIV Vaccine,7159204,2012-08-01,2012.0,2019-07-31,2019,Henry M. Jackson Foundation,grid.201075.1,United States,National Institute on Drug Abuse,United States,14,0,0
grant.8550559,W81XWH-19-1-0019,Development of a Modified mRNA-Based Vaccine for Lassa Virus,3033132,2017-10-01,2017.0,2018-09-01,2018,The University of Texas Medical Branch at Galveston,grid.176731.5,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.6661828,165313,"Global mapping of HPV vaccine hesitancy: determinants, monitoring and identification of strategies for effective implementation",0,2017-03-01,2017.0,2018-08-31,2018,,,,Swiss National Science Foundation,Switzerland,0,0,0
grant.4704416,2013/11/B/NZ7/02083,Ocena potencjału epidemicznego szczepów Bordetella pertussis w warunkach obniżonej odpowiedzi poszczepiennej jako element poszukiwania przyczyn obniżonej efektywności szczepień przeciw krztuścowi,126259,2014-07-30,2014.0,2019-03-29,2019,National Institute of Public Health,grid.415789.6,Poland,National Science Center,Poland,0,0,0
grant.7144747,W81XWH-15-1-0451,Clec9A Targeting Antibodies as a New Immunotherapy for Prostate Cancer,530862,2013-10-01,2013.0,2014-09-01,2014,University of Queensland,grid.1003.2,Australia,Congressionally Directed Medical Research Programs,United States,1,0,0
grant.7143376,W81XWH-05-1-0462,Vaccine Immunotherapy for Prostate Cancer,99053,2003-10-01,2003.0,2004-09-01,2004,University of Iowa,grid.214572.7,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7142769,DAMD17-03-1-0050,Xenoantigens as Tumor Antigens for the Development of Prostate Cancer Vaccines,329137,2001-10-01,2001.0,2002-09-01,2002,University of Wisconsin–Madison,grid.14003.36,United States,Congressionally Directed Medical Research Programs,United States,4,0,0
grant.7043118,SE3224,Continuation of the development for vaccines against bovine TB in cattle,14104144,2005-04-01,2005.0,2012-03-31,2012,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,5,0,0
grant.7043103,SE3208,Generation of Vaccine Candidates Against Mycobacterium bovis,2502254,1999-04-01,1999.0,2005-03-31,2005,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,1,0,0
grant.6856356,2008W3KW2A,"""Strategie combinate basate sulla vaccinazione a DNA per curare i carcinomi ErbB-2/neu positivi e le loro recidive""",323895,2008-01-01,2008.0,2010-01-01,2010,University of Turin; University of Turin; University of Turin; University of Turin; University of Turin,grid.7605.4; grid.7605.4; grid.7605.4; grid.7605.4; grid.7605.4,Italy; Italy; Italy; Italy; Italy,"Ministry of Education, Universities and Research",Italy,0,0,0
grant.6671033,9636,Scotia Scholar Award 2014,16322,2014-05-01,2014.0,2016-05-30,2016,Dalhousie University,grid.55602.34,Canada,Nova Scotia Health Research Foundation,Canada,0,0,0
grant.6618513,R43AI131750,Development of polyvalent inactivated rhinovirus vaccine,216388,2017-04-01,2017.0,2018-06-30,2018,Meissa Vaccines (United States),grid.504806.f,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.6416942,ANR-15-CE18-0030,Development of Dendritic Cell-based prophylactic and therapeutic Ebola vaccines,740216,2016-01-01,2016.0,2018-12-31,2018,French Institute of Health and Medical Research,grid.7429.8,France,National Agency for Research,France,0,0,0
grant.6378716,2015-33610-23506,"COMMERCIALIZATION OF A SYNTHETIC, LIVE-ATTENUATED FMDV VACCINE",99811,2015-06-01,2015.0,2016-01-31,2016,Codagenix (United States),grid.450645.6,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3701645,BIOT0256,Development of second generation vaccines against parvoviruses,0,1991-02-01,1991.0,1994-01-31,1994,Ingenasa (Spain); Wageningen University & Research,grid.425091.b; grid.4818.5,Spain; Netherlands,European Commission,Belgium,0,0,0
grant.3499383,BB/L004461/1,13TSB_SynBio: Engineering immune-cell-targeting bacteria to express vaccines from within the body,273897,2013-03-31,2013.0,2014-09-29,2014,University of Birmingham; University of Birmingham,grid.6572.6; grid.6572.6,United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,6,0,0
grant.2723442,ZIAAI005120,ARRA: Clinical Support for Universal Influenza Development,8654779,2010-01-01,2010.0,2010-12-31,2010,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2638362,R42AI081334,Human Rabies Virus Vaccine Development,829600,2008-12-01,2008.0,2015-07-31,2015,Molecular Targeting Technologies (United States),grid.421557.0,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2633208,R36HS020172,Geographic access to care and HPV vaccine uptake among ethnic minority girls,36593,2011-09-01,2011.0,2012-05-31,2012,University of California Los Angeles,grid.19006.3e,United States,Agency for Healthcare Research and Quality,United States,2,0,0
grant.2600460,R21AI090424,Development of a Sublingual Measles Vaccine,439758,2010-06-01,2010.0,2013-05-31,2013,University of Colorado Boulder,grid.266190.a,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2599137,R21AI070538,A tri-antigen nasal anthrax vaccine against toxins and vegetative bacilli,286525,2007-09-20,2007.0,2010-08-31,2010,Oregon State University,grid.4391.f,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2567237,R03AI076091,Cellular Immune Responses Induced by SIVdelta-vif plus IL-15 DNA Vaccine,76000,2008-09-17,2008.0,2010-08-31,2010,"University of California, Davis",grid.27860.3b,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2458846,R01AI085198,The safety of pneumococcal polysaccharide vaccine in children - a followup study.,935655,2010-08-03,2010.0,2012-07-31,2012,Murdoch Childrens Research Institute,grid.1058.c,Australia,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.7145428,DAMD17-03-1-0052,Vaccine Strategies for Tularemia,1850112,2001-10-01,2001.0,2002-09-01,2002,University of California Los Angeles,grid.19006.3e,United States,Congressionally Directed Medical Research Programs,United States,5,2,0
grant.7143720,W81XWH-08-1-0341,Preclinical Evaluation of Antigen-Specific DNA Vaccines as a Treatment for Prostate Cancer,976673,2006-10-01,2006.0,2007-09-01,2007,University of Wisconsin–Madison,grid.14003.36,United States,Congressionally Directed Medical Research Programs,United States,7,2,0
grant.7133861,DAMD17-03-1-0487,Fusions of Breast Carcinoma and Dendritic Cells as a Vaccine for the Treatment of Metastatic Breast Cancer,2039956,2001-10-01,2001.0,2002-09-01,2002,,,,Congressionally Directed Medical Research Programs,United States,1,1,0
grant.7083896,971507,"EML-VAC: Multivalent replicon vaccine against Ebola, Marburg and Lassa viruses",634097,2017-03-31,2017.0,2018-03-30,2018,Imperial College London,grid.7445.2,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.7048257,2016-33610-25690,"COMMERCIALIZATION OF A SYNTHETIC, LIVE-ATTENUATED FMDV VACCINE",1195400,2016-09-01,2016.0,2018-08-31,2018,Codagenix (United States),grid.450645.6,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.6932398,1743455,I-Corps: Enhancing Vaccine Performance,50000,2017-06-15,2017.0,2018-11-30,2018,Purdue University West Lafayette,grid.169077.e,United States,Directorate for Engineering,United States,0,0,0
grant.6434842,,Vacina oral recombinante contra raiva,0,2013-11-11,2013.0,2016-11-30,2016,University of Brasília,grid.7632.0,Brazil,National Council for Scientific and Technological Development,Brazil,0,0,0
grant.5475786,R43AI118189,Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza,590546,2016-07-01,2016.0,2019-06-30,2019,EpiVax (United States),grid.421087.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.4898746,R21AI121586,Development of Structurally Defined QS-17/18-Based Vaccine Adjuvants,396647,2016-03-15,2016.0,2019-02-28,2019,University of Alabama at Birmingham,grid.265892.2,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.4526619,ANR-14-CE15-0017,leveraging On t-cell immune resPonse To Improve influenza VACcines.,671795,2015-02-01,2015.0,2017-01-31,2017,Imaxio (France),grid.503192.c,France,National Agency for Research,France,0,0,0
grant.4242390,R01AI116835,Novel vaccine to enhance breadth of influenza immunity by skin vaccination,2444922,2015-08-12,2015.0,2019-07-31,2019,Georgia State University,grid.256304.6,United States,National Institute of Allergy and Infectious Diseases,United States,16,0,0
grant.4054922,R41AI120353,Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system,224999,2015-05-15,2015.0,2017-10-31,2017,,,,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.3829290,0221845,CONTROL OF INFECTIOUS BRONCHITIS IN POULTRY,0,2010-10-01,2010.0,2015-09-30,2015,Auburn University; Auburn University; Auburn University,grid.252546.2; grid.252546.2; grid.252546.2,United States; United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3728428,BIO4960006,New generation vaccines based on recombinant self-replicating alphavirus rna,0,1996-12-01,1996.0,1999-11-30,1999,Karolinska Institute; University of Groningen; National Institute for Biological Standards and Control; Université Libre de Bruxelles; Catholic University of Louvain,grid.4714.6; grid.4830.f; grid.70909.37; grid.4989.c; grid.7942.8,Sweden; Netherlands; United Kingdom; Belgium; Belgium,European Commission,Belgium,0,0,0
grant.3624085,K23AI114381,Diversity of Immune Responses Elicited by HIV Vaccines,817620,2014-07-01,2014.0,2019-06-30,2019,Beth Israel Deaconess Medical Center,grid.239395.7,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2766618,MC_U137884179,Development of a vaccine against HIV and AIDS,3540942,1998-09-30,1998.0,2010-03-30,2010,MRC Human Immunology Unit; Envigo (United Kingdom); Leiden University Medical Center; University of Barcelona; IDT Biologika (Germany); Imperial College London; Aeras; Defence Science and Technology Laboratory; Academy of Sciences of the Czech Republic; Columbia University; Kumamoto University; Los Alamos National Laboratory; University of Warwick; Commonwealth Scientific and Industrial Research Organisation; Karolinska Institute; International AIDS Vaccine Initiative; Recipharm (Sweden); University of Pittsburgh,grid.173746.0; grid.482881.f; grid.10419.3d; grid.5841.8; grid.498615.7; grid.7445.2; grid.432518.9; grid.417845.b; grid.418095.1; grid.21729.3f; grid.274841.c; grid.148313.c; grid.7372.1; grid.1016.6; grid.4714.6; grid.420368.b; grid.496608.5; grid.21925.3d,United Kingdom; United Kingdom; Netherlands; Spain; Germany; United Kingdom; United States; United Kingdom; Czechia; United States; Japan; United States; United Kingdom; Australia; Sweden; United States; Sweden; United States,Medical Research Council,United Kingdom,52,0,0
grant.2711483,Z01BJ003009,DEVELOPMENT AND EVALUATION OF QUALITY CONTROL METHODS FO,0,1993-01-01,1993.0,1998-01-01,1998,,,,United States Food and Drug Administration,United States,0,0,0
grant.2695668,U19AI028243,DEVELOPMENT OF AN AIDS PROTOTYPE VACCINE USING SIV,0,1989-03-01,1989.0,1998-06-14,1998,University of Pittsburgh,grid.21925.3d,United States,National Institute of Allergy and Infectious Diseases,United States,14,0,0
grant.2688036,U01AI078169,"Development of a Next Generation Anthrax Vaccine, AV7909",2794326,2008-07-01,2008.0,2013-06-30,2013,Emergent Biosolutions (United States),grid.289748.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687950,U01AI074512,Adjuvant Enhanced Antiviral Immunity,8475960,2007-08-01,2007.0,2013-07-31,2013,Colby Pharmaceutical (United States),grid.470267.0,United States,National Institute of Allergy and Infectious Diseases,United States,9,1,0
grant.2687700,U01AI061204,Developing recombinant coronavirus vaccines for SARS,3699069,2004-07-01,2004.0,2010-06-30,2010,University of Arkansas for Medical Sciences,grid.241054.6,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2687360,U01AI037127,Ontogeny of Measles Immunity in Infants,1177779,1994-09-30,1994.0,2011-01-31,2011,Stanford University,grid.168010.e,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2679944,SC3GM081198,Targeting vaccine vectors and antigens to dendritic cells using protein L.,318375,2007-08-01,2007.0,2010-07-31,2010,The University of Texas at San Antonio,grid.215352.2,United States,National Institute of General Medical Sciences,United States,0,0,0
grant.2669267,RC2CA149023,Non-peptidic HIV vaccine,997723,2009-09-30,2009.0,2012-08-31,2012,University of Wisconsin–Madison,grid.14003.36,United States,National Cancer Institute,United States,0,0,0
grant.2666620,R56AI093791,Humoral Immune Responses to Virus-like Particle Vaccine Candidates for RSV,411250,2011-08-01,2011.0,2013-07-31,2013,University of Massachusetts Medical School,grid.168645.8,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2641555,R43AI077406,Enhancement of mucosal antibody responses to HIV vaccine,600000,2008-09-01,2008.0,2010-08-31,2010,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2641424,R43AI071660,Rapid deployment DNA vaccine for pandemic influenza,207016,2007-09-01,2007.0,2009-08-31,2009,Nature Technology Corporation (United States),grid.422377.7,United States,National Institute of Allergy and Infectious Diseases,United States,2,6,0
grant.2641235,R43AI061940,Mucosal modified vaccinina Ankara-based plaque vaccines,667079,2006-03-15,2006.0,2008-11-29,2008,Takeda (United States),grid.419849.9,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2638361,R42AI078631,Delivery system development for a reservoir targeted Lyme disease vaccine,3000000,2008-08-01,2008.0,2017-05-31,2017,,,,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2636978,R41DA016843,A Peptide-Based Vaccine to Nicotine,99510,2004-03-01,2004.0,2006-02-28,2006,,,,National Institute on Drug Abuse,United States,1,0,0
grant.2636590,R41AR056169,Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin,100000,2008-09-05,2008.0,2010-08-31,2010,Vaxin (United States),grid.422117.3,United States,National Institute of Arthritis and Musculoskeletal and Skin Diseases,United States,20,0,0
grant.2636516,R41AI100428,Rational Design of Live Attenuated Influenza A Vaccine Candidates,600000,2012-06-15,2012.0,2014-05-31,2014,Codagenix (United States),grid.450645.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2633028,R36CK000127,Evaluation of Flavivirus Live Attenuated Vaccine Recombination Potential,31834,2009-09-30,2009.0,2010-09-29,2010,The University of Texas Medical Branch at Galveston,grid.176731.5,United States,Centers for Disease Control and Prevention,United States,0,0,0
grant.2632159,R34AI080845,Controlled Trial of Live Attenuated Influenza Vaccine in Very Premature Infants,276534,2009-09-02,2009.0,2011-08-31,2011,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2602760,R21CA075317,POTENTIATION OF CD8+ T CELL RESPONSE TO MELANOMA VACCINE,0,1997-08-15,1997.0,1999-07-31,1999,University of Pittsburgh,grid.21925.3d,United States,National Cancer Institute,United States,2,0,0
grant.2600220,R21AI085380,Laser treatment to enhance therapeutic HPV DNA vaccine potency,462228,2010-06-01,2010.0,2012-05-31,2012,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2599545,R21AI076812,Development and Evaluation of a Dual-Antigen Nasal Brucella Vaccine,418502,2009-07-21,2009.0,2011-06-30,2011,University of Michigan,grid.214458.e,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2599245,R21AI072244,T. cruzi immune evasion factors and vaccine design,356675,2007-07-01,2007.0,2010-06-30,2010,University of Pittsburgh,grid.21925.3d,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2598200,R21AI055289,HIV Vaccines in Th2 Biased Recipients,491375,2003-09-15,2003.0,2006-08-31,2006,Harvard University,grid.38142.3c,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2598185,R21AI054952,Vaccine-enhanced respiratory syncytial virus disease,367875,2004-05-15,2004.0,2005-04-30,2005,Johns Hopkins University,grid.21107.35,United States,National Institute of Allergy and Infectious Diseases,United States,16,0,0
grant.2597362,R21AI042181,Evaluation of Anti-endotoxin Vaccine for Human Use,398399,2002-09-15,2002.0,2003-09-14,2003,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2501723,R01EB006493,Nanocarriers for transcutaneous delivery of vaccines,1982832,2006-04-01,2006.0,2011-01-31,2011,Tulane University,grid.265219.b,United States,National Institute of Biomedical Imaging and Bioengineering,United States,20,0,0
grant.2485752,R01DA017505,An HB Vaccine Model For HIV Vaccine Trials in Drug Users,3349338,2003-09-30,2003.0,2009-06-30,2009,The University of Texas Health Science Center at Houston,grid.267308.8,United States,National Institute on Drug Abuse,United States,6,0,0
grant.2475426,R01CA090562,Polypeptide Vaccine In IL-2 Liposomes For Prostate Ca,1199353,2002-07-01,2002.0,2006-12-31,2006,New York University,grid.137628.9,United States,National Cancer Institute,United States,0,0,0
grant.2459532,R01AI098817,rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses,5335752,2012-05-01,2012.0,2019-04-30,2019,Profectus Biosciences (United States),grid.281295.5,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2459430,R01AI097127,Building novel vaccines on a borrowed coat,2093325,2011-09-15,2011.0,2017-08-31,2017,Rockefeller University,grid.134907.8,United States,National Institute of Allergy and Infectious Diseases,United States,5,1,0
grant.2459193,R01AI093372,Subunit Vaccines for Brucella Pathogens,2188091,2011-05-05,2011.0,2017-04-30,2017,University of Florida,grid.15276.37,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2457778,R01AI072139,New Vaccine against Influenza,1115984,2009-09-11,2009.0,2014-08-31,2014,Texas Tech University Health Sciences Center,grid.416992.1,United States,National Institute of Allergy and Infectious Diseases,United States,6,2,0
grant.2457417,R01AI067874,Collaborative Development of a Vaccine against Cutaneous and Visceral Leishmanias,2189690,2006-05-01,2006.0,2013-04-30,2013,University of Iowa,grid.214572.7,United States,National Institute of Allergy and Infectious Diseases,United States,34,3,0
grant.2456177,R01AI054711,New Approaches to Schistosome vaccine antigen discovery,1437732,2005-04-01,2005.0,2009-12-31,2009,Case Western Reserve University,grid.67105.35,United States,National Institute of Allergy and Infectious Diseases,United States,9,0,0
grant.2455862,R01AI052012,An Envelope Containing HIV Pseudovirion Vaccine,770436,2002-05-01,2002.0,2006-09-29,2006,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2455572,R01AI050483,Poly-functional analyses of vaccine-induced T cell responses,3520665,2001-09-01,2001.0,2012-07-31,2012,Duke University,grid.26009.3d,United States,National Institute of Allergy and Infectious Diseases,United States,15,0,0
grant.2454563,R01AI045168,VACCINE TRIALS USING INDIVIDUAL AND ECOLOGICAL UNITS,870326,2000-04-01,2000.0,2004-07-31,2004,University of Michigan,grid.214458.e,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2453938,R01AI042181,Evaluation of Anti-endotoxin Vaccine for Human Use,1911423,1999-04-15,1999.0,2009-04-30,2009,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,12,1,0
grant.2453675,R01AI040896,FIVDELTAVIF DNA Vaccines with Cytokine Adjuvants,1353871,1997-06-01,1997.0,2006-05-31,2006,"University of California, Davis",grid.27860.3b,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2453157,R01AI037127,Ontogeny of Measles Immunity in Infants,1984483,1994-09-30,1994.0,2010-01-31,2010,Stanford University,grid.168010.e,United States,National Institute of Allergy and Infectious Diseases,United States,10,0,0
grant.2452634,R01AI033575,CONTROLLED RELEASE SYSTEMS AS VACCINE ADJUVANTS,0,1992-09-30,1992.0,1996-05-31,1996,,,,National Institute of Allergy and Infectious Diseases,United States,11,0,0
grant.2449442,R01AI014411,PATHOGENIC ROLE OF H. INFLUENZAE SURFACE PROTEINS,0,1977-06-01,1977.0,1989-03-31,1989,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2449186,R01AI006264,LIVE VIRUS VACCINES AS DOMINANT NEGATIVE MUTANTS,0,1974-09-01,1974.0,1996-05-31,1996,University of Pittsburgh,grid.21925.3d,United States,National Institute of Allergy and Infectious Diseases,United States,36,1,0
grant.2418466,K23CA128927,Survivin &Interferon-alpha as Cancer Vaccine Therapy in Pancreatic Cancer,136080,2008-09-03,2008.0,2009-04-15,2009,The University of Texas MD Anderson Cancer Center,grid.240145.6,United States,National Cancer Institute,United States,2,0,0
grant.7925321,MC_EX_G0701291,Molecular profiling consortium: biomarker identification and interaction analysis of EPI vaccines,979552,2008-03-31,2008.0,2011-03-30,2011,Medical Research Council The Gambia Unit,grid.415063.5,Gambia,Medical Research Council,United Kingdom,7,0,0
grant.2711626,Z01BK005014,Viral Latency and Virus Detection,0,2003-01-01,2003.0,2003-12-31,2003,,,,United States Food and Drug Administration,United States,0,0,0
grant.8519056,,Influenza: making vaccines in plants,0,2013-04-01,2013.0,2014-03-31,2014,McGill University,grid.14709.3b,Canada,Fonds de Recherche du Québec - Santé,Canada,0,0,0
grant.7749733,W81XWH-18-1-0488,GMP Production of Candidate Pan-Group 2 Influenza A Virus Vaccines,5085001,2016-10-01,2016.0,2017-09-01,2017,Icahn School of Medicine at Mount Sinai,grid.59734.3c,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7673664,W81XWH-18-1-0140,Universal Influenza T Cell-Targeted Mucosal Vaccines,276606,2016-10-01,2016.0,2017-09-01,2017,Saint Louis University,grid.262962.b,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.7618456,,Combining oncolytic vaccines (OVax) with surgery and immune modulation to prevent postoperative cancer recurrence and metastases,346000,2015-02-01,2015.0,2018-01-31,2018,Ottawa Hospital,grid.412687.e,Canada,Canadian Cancer Society,Canada,0,0,0
grant.7043121,SE3227,Evaluation of the protection efficacy of vaccines against bovine TB in a natural transmission setting.,12005060,2005-10-01,2005.0,2012-03-31,2012,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,3,0,0
grant.7040510,OD0722,Transmission and VaccineInduced Protection of Marek's Disease,1355228,2013-01-01,2013.0,2016-12-31,2016,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,0,0,0
grant.6460791,F31AI126629,Genetically determined susceptibility to rotavirus and rotavirus vaccine failure in sub-Saharan Africa,64154,2016-09-16,2016.0,2017-11-15,2017,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.6381145,972214,Addresing Efficacy of a Dengue vaccine candidate in a macaque challenge model,660003,2016-09-30,2016.0,2017-09-29,2017,University of Oxford,grid.4991.5,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.5504997,R43AI127050,Multivalent Oral Vaccine against Enterotoxigenic Escherichia coli and Enteric Fevers,591329,2016-08-18,2016.0,2019-07-31,2019,Protein Potential (United States),grid.423438.a,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3703693,MR4*0209,EUROPEAN VACCINE AGAINST AIDS,0,1989-07-01,1989.0,1992-06-30,1992,National Institute for Biological Standards and Control,grid.70909.37,United Kingdom,European Commission,Belgium,0,0,0
grant.2723204,ZIAAI000987,Clinical Trials of  Biodefense Vaccines (Dengue),31443522,2009-01-01,2009.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,26,0,0
grant.2723133,ZIAAI000891,Laboratory And Preclinical Studies Of Flaviviruses,9883449,2009-01-01,2009.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,48,0,0
grant.2710571,Z01BC010597,Vaccine Clinical Trials,0,2005-01-01,2005.0,2005-12-31,2005,,,,National Cancer Institute,United States,8,0,0
grant.2641917,R43AI096683,Rapid  Response Vaccines for Botulinum Neurotoxins,587806,2011-07-22,2011.0,2015-06-30,2015,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2641846,R43AI092917,Adenovirus-vectored RSV vaccine not inhibited by maternal immunity,589058,2012-06-01,2012.0,2014-05-31,2014,GenVec,grid.281217.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641825,R43AI091232,Synthetic Nanoparticle based Universal Influenza Vaccine,598005,2010-07-01,2010.0,2013-06-30,2013,Immunotope (United States),grid.417525.0,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2641582,R43AI078654,Surrogate endpoints for correlating protective immunity in response to influenza,599994,2009-09-01,2009.0,2011-08-31,2011,Molecular GPS Technologies (United States),grid.281192.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2641474,R43AI074119,Adjuvanted Influenza Vaccine,600000,2007-08-01,2007.0,2010-07-31,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641417,R43AI071522,Lyophilization of Plasmodium falciparum sporozoite vaccine,500464,2006-08-15,2006.0,2009-07-31,2009,Sanaria,grid.280962.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2600613,R21AI094074,Enhancing TB vaccine with gene silencing,452375,2012-02-01,2012.0,2015-01-31,2015,University of Massachusetts Medical School,grid.168645.8,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2599420,R21AI074790,A Lassa Vaccine in primates with AIDS,487500,2008-07-01,2008.0,2010-12-30,2010,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2581841,R13AI091178,Immunological Mechanisms of Vaccination,10000,2010-07-01,2010.0,2011-06-30,2011,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2459891,R01AI105206,Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo,2183992,2013-04-01,2013.0,2016-12-31,2016,VaxInnate (United States),grid.438933.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2459207,R01AI093493,A novel anti-spore nasal vaccine for protection from anthrax,3295345,2011-08-19,2011.0,2018-07-31,2018,Loyola University Chicago,grid.164971.c,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2458958,R01AI088754,Novel Bioconjugate Vaccines to Prevent Staphylococcus aureus Infection,3489967,2010-04-01,2010.0,2016-03-31,2016,Brigham and Women's Hospital,grid.62560.37,United States,National Institute of Allergy and Infectious Diseases,United States,8,6,0
grant.8615120,44378,Continuing an education campaign on vaccines and immunization,749630,2002-04-01,2002.0,2003-08-31,2003,Infectious Diseases Society of America,grid.435069.d,United States,Robert Wood Johnson Foundation,United States,0,0,0
grant.8588543,2b92f9bc-7917-4bba-a530-57cc63f9b071,Rationeel ontwerp van een therapeutisch vaccin tegen HIV-1 gebaseerd op een nieuwe formulering van nanopartikel,0,2016-01-01,2016.0,2018-12-31,2018,Institute of Tropical Medicine Antwerp; Institute of Tropical Medicine Antwerp; Institute of Tropical Medicine Antwerp,grid.11505.30; grid.11505.30; grid.11505.30,Belgium; Belgium; Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8573811,436_1,Clinical optimization of an autologous tumour vaccine strategy for the treatment of Chronic Lymphocytic Leukemia,0,2003-09-17,2003.0,2006-09-16,2006,Sunnybrook Health Science Centre,grid.413104.3,Canada,Ontario Institute for Cancer Research,Canada,0,0,0
grant.8458609,,Highly stable trimerization of HIV-1 envelope based antigens will improve their immunogenicity and capacity to elicit a neutralizing antibody responses,16987,2013-09-01,2013.0,2014-08-31,2014,Jewish General Hospital,grid.414980.0,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8457229,,Augmentation of a Canine Melanoma Vaccine with Immunomodulatory Antibodies,13199,2016-05-01,2016.0,2017-04-30,2017,University of Guelph,grid.34429.38,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8343971,81500167,Ad-NK4修饰的树突状细胞疫苗抗骨髓瘤免疫作用研究,26974,2016-01-01,2016.0,2018-12-31,2018,Fujian Medical University,grid.256112.3,China,National Natural Science Foundation of China,China,1,0,0
grant.8340455,81470494,肺动脉高压内皮素ETA受体治疗性疫苗的研制,111357,2015-01-01,2015.0,2018-12-31,2018,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,2,0,0
grant.8339653,81460306,恙虫病东方体Karp株融合抗原的莴苣叶绿体生物封装表达、胶囊化及免疫效应评价,73217,2015-01-01,2015.0,2018-12-31,2018,Hainan Medical University,grid.443397.e,China,National Natural Science Foundation of China,China,3,0,0
grant.8334613,81373316,福氏志贺氏菌多糖结合疫苗的体内生物合成研究,124340,2014-01-01,2014.0,2017-12-31,2017,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,2,0,0
grant.8334535,81373229,丙型肝炎病毒新型疫苗免疫保护机制的研究,108798,2014-01-01,2014.0,2017-12-31,2017,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,5,0,0
grant.8333847,81372470,DEC-205/PLGA-肝素酶CD4+、CD8+T细胞联合表位肽纳米颗粒疫苗的构建及其抗肿瘤免疫效应的实验研究,108798,2014-01-01,2014.0,2017-12-31,2017,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,1,0,0
grant.8329741,81160353,云南省狂犬病毒糖蛋白基因分析及抗原性研究,88425,2012-01-01,2012.0,2015-12-31,2015,Yunnan Institute of Endemic Diseases Control and Prevention,grid.464498.3,China,National Natural Science Foundation of China,China,4,0,0
grant.8328946,81000269,靶向郎格罕氏细胞的Eppin优势表位避孕疫苗的设计与研究,31631,2011-01-01,2011.0,2013-12-31,2013,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,1,0,0
grant.8216959,39700172,人乳头瘤病毒16型预防性疫苗的可行性研究,13283,1998-01-01,1998.0,2000-12-31,2000,Xi'an Jiaotong University,grid.43169.39,China,National Natural Science Foundation of China,China,0,0,0
grant.8214963,39570031,戊型肝炎病毒CDNA基因疫苗的研究,10240,1996-01-01,1996.0,1998-12-31,1998,Peking University,grid.11135.37,China,National Natural Science Foundation of China,China,0,0,0
grant.8214438,39470653,口服缓释长效霍乱微球菌苗的动物实验研究,6604,1995-01-01,1995.0,1997-12-31,1997,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,0,0,0
grant.8207596,38870533,中国与世界气候及农业气候相似研究*3,8616,1989-01-01,1989.0,1991-12-31,1991,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,0,0,0
grant.8184627,31470889,"EV71 VP1""食品级""乳酸菌活载体疫苗及异源抗原联合免疫诱导黏膜和系统免疫的研究",122035,2015-01-01,2015.0,2018-12-31,2018,Nanjing Medical University,grid.89957.3a,China,National Natural Science Foundation of China,China,3,0,0
grant.8184513,31470775,MSP2的抗疟疾疫苗潜能相关性质的分子机制研究,129661,2015-01-01,2015.0,2018-12-31,2018,Anhui University,grid.252245.6,China,National Natural Science Foundation of China,China,6,0,0
grant.8183781,31460664,基于乳腺上皮细胞FcRn胞吞转运途径的金黄色葡萄球菌多价毒力因子疫苗设计及其诱导免疫应答效果的研究,79321,2015-01-01,2015.0,2018-12-31,2018,Inner Mongolia Agricultural University,grid.411638.9,China,National Natural Science Foundation of China,China,0,0,0
grant.8183778,31460661,鹅细小病毒VP3基因与鹅γ干扰素基因重组禽痘病毒的免疫保护作用及其机制研究,80846,2015-01-01,2015.0,2018-12-31,2018,Yanbian University,grid.440752.0,China,National Natural Science Foundation of China,China,0,0,0
grant.8183360,31460242,FcRn介导的抗细粒棘球蚴靶向黏膜疫苗的构建及其增强体液免疫应答的机制研究,79321,2015-01-01,2015.0,2018-12-31,2018,Ningxia Medical University,grid.412194.b,China,National Natural Science Foundation of China,China,0,0,0
grant.8174921,30840073,鼻黏膜接种Aβ亚单位疫苗预防AD的疗效评价及免疫机制分析,13172,2009-01-01,2009.0,2009-12-31,2009,,,,National Natural Science Foundation of China,China,1,0,0
grant.8171709,30371291,新型口服HIV-1粘膜免疫疫苗的研制,25772,2004-01-01,2004.0,2006-12-31,2006,Xi'an Jiaotong University,grid.43169.39,China,National Natural Science Foundation of China,China,0,0,0
grant.8145336,21372145,氟代肿瘤相关糖抗原的化学酶法合成及其在肿瘤糖疫苗中的应用,124340,2014-01-01,2014.0,2017-12-31,2017,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,10,0,0
grant.7767266,W81XWH-17-C-0047,Enhanced HIV Vaccine by CNT-enabled Mucosal Delivery,999998,2016-10-01,2016.0,2017-09-30,2017,Luna Innovations (United States),grid.281080.3,United States,United States Department of the Army,United States,0,0,0
grant.7766966,HDTRA1-17-C-0030,Production of Inactivated Vaccines Using Supralethal Irradiation,990021,2016-10-01,2016.0,2017-09-30,2017,Biological Mimetics (United States); Henry M. Jackson Foundation,grid.465136.3; grid.201075.1,United States; United States,Defense Threat Reduction Agency,United States,0,0,0
grant.7765761,W81XWH-17-C-0037,Passively Regulated Cryogenic (PaRC) Vial System for Vaccine Distribution and Administration,149999,2016-10-01,2016.0,2017-09-30,2017,Mainstream Engineering Corporation (United States),grid.426847.b,United States,United States Department of Defense,United States,0,0,0
grant.7724040,R43AI138612,Surfactant-vesicle based gonorrhea vaccine,268434,2018-08-01,2018.0,2019-07-31,2019,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7667260,,Developing a Chlamydia trachomatis vaccine by optomizing dendritic cell responses.,38403,2005-04-01,2005.0,2006-12-08,2006,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7664869,,Development of Novel Molecular Adjuvants for Genetic Vaccination,91634,2009-10-01,2009.0,2010-09-30,2010,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7656538,,Influenza Vaccine Effectiveness Against Serious Outcomes,87129,2007-02-01,2007.0,2008-01-31,2008,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7651336,,Short Term Travel Grant to Attend AIDS Vaccine 2008 Partner Development Forum,8045,2008-10-01,2008.0,2008-12-31,2008,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7649919,,A Study of an HPV VLP Vaccine in a Cohort of HIV Positive Girls and Women,1306502,2008-04-01,2008.0,2013-03-31,2013,Children's & Women's Health Centre of British Columbia,grid.413941.a,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7640714,,Vaccination during pregnancy: issues in translational ethics and research ethics,13140,2009-06-01,2009.0,2009-08-31,2009,Dalhousie University,grid.55602.34,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7635437,,Towards a Broad-Spectrum Meningococcal Vaccine:  Preparation and validation of modified outer membrane vesicle vaccines.,187131,2008-07-01,2008.0,2011-06-30,2011,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7632116,,Development of a Salmonella Poultry and Human Vaccine based on  Secreted Bacterial Products,129410,2008-01-01,2008.0,2008-12-31,2008,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7624865,,CHVI Team in Social and Behavioral Research on HIV Vaccines,1113619,2011-12-01,2011.0,2016-11-30,2016,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7621645,,Understanding recent influenza drifts and efficacy of new mucosal vaccines,103291,2007-07-01,2007.0,2011-06-30,2011,Laval University,grid.23856.3a,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7209085,81302608,肺递送炭疽疫苗干粉气溶胶用以预防吸入性炭疽的研究,36318,2014-01-01,2014.0,2016-12-31,2016,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,3,0,0
grant.7202920,81470186,"""芳香辟秽""中药作为流感疫苗粘膜佐剂的活性及其鼻粘膜免疫机制研究",46658,2015-01-01,2015.0,2016-12-31,2016,Guangzhou University of Chinese Medicine,grid.411866.c,China,National Natural Science Foundation of China,China,4,0,0
grant.7198131,31302127,乳酸菌菌影作为DNA疫苗包装载体诱导免疫应答的研究,39477,2014-01-01,2014.0,2016-12-31,2016,Northeast Agricultural University,grid.412243.2,China,National Natural Science Foundation of China,China,3,0,0
grant.7189701,81302605,霍乱毒素A、B亚单位增强DNA疫苗免疫效果的佐剂活性和机制研究,36318,2014-01-01,2014.0,2016-12-31,2016,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,3,0,0
grant.7186623,81272325,携带Her2/neu的红细胞作为抗乳腺癌疫苗的作用和免疫机制,111158,2013-01-01,2013.0,2016-12-31,2016,Tongji University,grid.24516.34,China,National Natural Science Foundation of China,China,2,0,0
grant.7181817,31272446,GnIH和INH基因疫苗联合免疫大鼠和牛的效果及作用机制探讨,127034,2013-01-01,2013.0,2016-12-31,2016,Huazhong Agricultural University,grid.35155.37,China,National Natural Science Foundation of China,China,8,0,0
grant.7178941,31272701,基于冷胁迫诱导下相容性溶质胞内积累的鳗弧菌活疫苗冻干耐受分子机制,127034,2013-01-01,2013.0,2016-12-31,2016,East China University of Science and Technology,grid.28056.39,China,National Natural Science Foundation of China,China,2,0,0
grant.7170931,R13AI136747,Progress and Pathways Toward an Effective HIV Vaccine,20400,2017-12-01,2017.0,2018-11-30,2018,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.7140864,W81XWH-12-1-0403,Development of a Recombinant Listeria Monocytogenes Booster Vaccine against Tuberculosis,1155000,2010-10-01,2010.0,2011-09-01,2011,University of California Los Angeles,grid.19006.3e,United States,Congressionally Directed Medical Research Programs,United States,1,0,0
grant.7138381,DAMD17-98-1-8154,Synthesis of Clustered ST-Antigens for the Development of Novel Breast Cancer Vaccines,80000,1996-10-01,1996.0,1997-09-01,1997,Memorial Sloan Kettering Cancer Center,grid.51462.34,United States,Congressionally Directed Medical Research Programs,United States,1,0,0
grant.7125513,2011-06846,Antibody affinity maturation and protective effect of B cell responses elicited by HIV-1 Env vaccination of non-human primates,258340,2012-01-01,2012.0,2013-12-31,2013,Karolinska Institute,grid.4714.6,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7123318,2008-02679,BUILDING BETTER VACCINES; LEARNING FROM VIRUSES,87603,2009-01-01,2009.0,2010-12-31,2010,Karolinska Institute,grid.4714.6,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7119830,2009-06434,Preparation for a phase I/II study of a new TB vaccine candidate,66064,2010-01-01,2010.0,2012-12-31,2012,Karolinska Institute,grid.4714.6,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7107975,SB12-0088,Gastrointestinal viral infections and novel mucosal vaccines,3775742,2013-08-01,2013.0,2018-07-31,2018,University of Gothenburg,grid.8761.8,Sweden,Swedish Foundation for Strategic Research,Sweden,0,0,0
grant.7096947,2015-06247,A cooperative platform for development of Asian and European diagnostics and vaccines for autoimmune diseases,81836,2016-01-01,2016.0,2017-12-31,2017,Karolinska Institute,grid.4714.6,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7095071,2009-03018,Viral Vectors as Recombinant Vaccines,220237,2010-01-01,2010.0,2012-12-31,2012,Karolinska Institute,grid.4714.6,Sweden,Swedish Research Council,Sweden,0,0,0
grant.7043000,SE2917,Improved selection methods for emergency FMD vaccines,609070,2000-07-01,2000.0,2003-06-30,2003,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,1,0,0
grant.7042563,SE0778,Development of strategies for control of classical swine fever by emergency vaccination with live attenuated vaccine,1564750,2004-09-01,2004.0,2010-03-31,2010,Animal and Plant Health Agency,grid.422685.f,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,5,0,0
grant.7024736,31172320,基于大规模PCR技术高通量制备DNA疫苗方法的研究,99678,2012-01-01,2012.0,2015-12-31,2015,Hubei University,grid.34418.3a,China,National Natural Science Foundation of China,China,3,0,0
grant.7022578,81172890,基于诱导和增强黏膜免疫效应的B群流脑疫苗实验研究,83600,2012-01-01,2012.0,2015-12-31,2015,University of South China,grid.412017.1,China,National Natural Science Foundation of China,China,3,0,0
grant.7013810,31201909,牛UK株轮状病毒拮抗Ⅰ型IFN信号转导通路机制的研究,38770,2013-01-01,2013.0,2015-12-31,2015,,,,National Natural Science Foundation of China,China,2,0,0
grant.7012934,81102415,近红外荧光/激光拉曼双模式成像技术用于肿瘤靶向细菌疫苗的体内分布研究,40207,2012-01-01,2012.0,2014-12-31,2014,Yantai Institute of Coastal Zone Research,grid.453127.6,China,National Natural Science Foundation of China,China,6,0,0
grant.6999438,81202015,负载gp96-Ki67肽复合物的DC疫苗对肾癌的抗肿瘤效应研究,37155,2013-01-01,2013.0,2015-12-31,2015,,,,National Natural Science Foundation of China,China,6,0,0
grant.6994947,81202364,HIV-1 gp120与有效病毒亚单位疫苗诱导Tfh细胞活化及抗体生成能力的比较研究,37155,2013-01-01,2013.0,2015-12-31,2015,Harbin Medical University,grid.410736.7,China,National Natural Science Foundation of China,China,2,0,0
grant.6994410,31201904,TLR3配体提高H9亚型禽流感疫苗对鸡的细胞免疫机理研究,37155,2013-01-01,2013.0,2015-12-31,2015,Jiangsu Academy of Agricultural Sciences,grid.454840.9,China,National Natural Science Foundation of China,China,3,0,0
grant.6991532,81201785,新型可降解的HPEI-YS靶向基因疫苗载体用于肿瘤免疫基因治疗的实验研究,37155,2013-01-01,2013.0,2015-12-31,2015,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,7,0,0
grant.6991520,81201866,负性调控骨髓间充质干细胞的FAPα- - 增强多发性骨髓瘤疫苗抗瘤效应的新策略,37155,2013-01-01,2013.0,2015-12-31,2015,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,1,0,0
grant.6991182,31172353,羊传染性脓疱病毒保护性抗原表位筛选及表位作图研究,80386,2012-01-01,2012.0,2015-12-31,2015,,,,National Natural Science Foundation of China,China,1,0,0
grant.6990117,81172257,MMSA-1与DKK1联合多表位疫苗的设计及抗骨髓瘤研究,80386,2012-01-01,2012.0,2015-12-31,2015,Xi'an Jiaotong University,grid.43169.39,China,National Natural Science Foundation of China,China,8,0,0
grant.6983221,81160206,猪带绦虫重组Bb-TSO45W-4B-TSOL18疫苗构建及其免疫机制研究,80386,2012-01-01,2012.0,2015-12-31,2015,Zunyi Medical University,grid.417409.f,China,National Natural Science Foundation of China,China,0,0,0
grant.6983019,31160501,牛源犬新孢子虫NcSRS2-NcGRA7复合基因核酸疫苗与重组腺病毒疫苗的免疫保护作用及其机制研究,83600,2012-01-01,2012.0,2015-12-31,2015,Yanbian University,grid.440752.0,China,National Natural Science Foundation of China,China,1,0,0
grant.6981617,31340036,基于酿酒酵母靶向性递呈和表达的DNA疫苗研究,24405,2014-01-01,2014.0,2014-12-31,2014,Hubei University,grid.34418.3a,China,National Natural Science Foundation of China,China,2,0,0
grant.6980454,31340069,T细胞受体识别肿瘤多肽疫苗的结构和功能研究,22777,2014-01-01,2014.0,2014-12-31,2014,Wuhan University,grid.49470.3e,China,National Natural Science Foundation of China,China,1,0,0
grant.6932286,1742660,I-Corps: Nanotechnology for Boosting Vaccine Efficacy and Longevity,50000,2017-06-15,2017.0,2018-05-31,2018,Georgia Institute of Technology,grid.213917.f,United States,Directorate for Engineering,United States,0,0,0
grant.6891494,GA312/98/0826,"Vývoj nových vakcin pro genovou léčbu zhoubných nádorů, založený na kooperaci APC a TH buněk",97981,1998-01-01,1998.0,2000-12-31,2000,Institute of Molecular Genetics,grid.418827.0,Czechia,Czech Science Foundation,Czechia,0,0,0
grant.6888017,GAP304/10/1951,Nanoliposomy pro vývoj rekombinantních vakcín a cílených imunoterapeutik,574390,2010-01-01,2010.0,2013-12-31,2013,"University of Chemistry and Technology; Institute of Physics; Institute of Organic Chemistry and Biochemistry; Institute of Macromolecular Chemistry; Palacký University, Olomouc; Veterinary Research Institute",grid.448072.d; grid.424881.3; grid.418892.e; grid.424999.b; grid.10979.36; grid.426567.4,Czechia; Czechia; Czechia; Czechia; Czechia; Czechia,Czech Science Foundation,Czechia,22,0,0
grant.6849449,TRAN1-08522,2nd Generation Vaccine for the Treatment of Glioblastoma,3241524,2016-03-16,2016.0,2016-12-31,2016,Stanford University,grid.168010.e,United States,California Institute for Regenerative Medicine,United States,0,0,0
grant.6793067,W81XWH-16-C-0113,Next-Generation Adenovirus Vaccine,1999175,2015-10-01,2015.0,2016-09-30,2016,TechnoVax (United States),grid.438336.9,United States,United States Department of Defense,United States,0,0,0
grant.6759552,13-07-12127,Информационные технологии отбора пациентов онкологического профиля для применения дендритноклеточных вакцин.,0,2013-01-01,2013.0,2013-12-31,2013,,,,Russian Foundation for Basic Research,Russia,1,0,0
grant.6665244,109469/Z/15/Z,Immune-complex mimetics (ICMs): an adjuvant free approach to controlling the major diseases for which no vaccines are available,183896,2016-04-01,2016.0,2018-07-31,2018,Liverpool School of Tropical Medicine,grid.48004.38,United Kingdom,Wellcome Trust,United Kingdom,2,0,0
grant.6663844,349903,Improving cancer vaccines with agonistic antibodies to CD40 and CD27,300000,2015-07-01,2015.0,2018-06-30,2018,University of Virginia,grid.27755.32,United States,Melanoma Research Alliance,United States,0,0,0
grant.6621694,103264,Equipment to Support Prophylactic Antibacterial Vaccine Development,61147,2017-03-01,2017.0,2017-03-30,2017,Absynth Biologics (United Kingdom),grid.432017.3,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.6502258,1815378,Cost effectiveness of poultry vaccination for control of H9N2 avian influenza in Pakistan,0,2016-11-01,2016.0,2019-09-29,2019,Royal Veterinary College; Pirbright Institute,grid.20931.39; grid.63622.33,United Kingdom; United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.6381108,972225,Room temperature stable MVA-GP pox vectored vaccine against CCHF,579002,2016-08-31,2016.0,2017-08-30,2017,,,,Innovate UK,United Kingdom,0,0,0
grant.6239164,62440019,Basic Research on the Development of Recombinant Vaccines for Animals by Genetic Engineering,192015,1987-01-01,1987.0,1990-12-31,1990,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5894519,16500277,Establishment of the screening system of vaccine candidate genes against cysticercosis using Nod-scid mice.,27816,2004-01-01,2004.0,2006-12-31,2006,Tottori University,grid.265107.7,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5838858,15590415,Basic study of gene therapy to hepatitis C virus infection by using virus-like particle.,26803,2003-01-01,2003.0,2004-12-31,2004,Mie University,grid.260026.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5819445,14370589,Development of therapeutic RANKL vaccination approach against inflammatory alveolar-bone-destruction,94681,2002-01-01,2002.0,2003-12-31,2003,Tokyo Medical and Dental University,grid.265073.5,Japan,Japan Society for the Promotion of Science,Japan,2,0,0
grant.5813252,14021068,粘膜ワクチンへの基礎研究:HIV特異的分泌型IgA誘導システムの開発,47922,2002-01-01,2002.0,2002-12-31,2002,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5798285,13671362,Basic and clinical studies for development of peptide vaccine for colorectal cancer,28974,2001-01-01,2001.0,2003-12-31,2003,Kurume University,grid.410781.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5778403,12670795,Comparison of DNA sequences on VZV glycoproteins of the Oka vaccine and parental Oka strains,29755,2000-01-01,2000.0,2001-12-31,2001,Kawasaki Medical School,grid.415086.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5762242,11670765,Study on efficacy and improvement of diphtheria and tetanus toxoids and pertussis (DPT) vaccine,12265,1999-01-01,1999.0,2001-12-31,2001,Kyushu University,grid.177174.3,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5653175,06807027,Development of orally administrable pertussis vaccine,10207,1994-01-01,1994.0,1995-12-31,1995,Nagoya City University,grid.260433.0,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5636461,06670339,Studies on the development of mucosal vaccine adjuvant,22456,1994-01-01,1994.0,1995-12-31,1995,National Institute of Infectious Diseases,grid.410795.e,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5634704,05857191,緑膿菌感染マウスにおける遺伝子操作ワクチンの有効性および免疫学的機序の検討,6297,1993-01-01,1993.0,1993-12-31,1993,Yokohama City University,grid.268441.d,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5602201,04454201,Antigenic diversity and gene sequences of measles virus in the presence of antibodies,53343,1992-01-01,1992.0,1994-12-31,1994,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5537052,619071,Improving a plant vaccine platform modulation of the plant defence system,223348,2015-04-01,2015.0,2018-03-31,2018,Université de Sherbrooke; Medicago (Canada),grid.86715.3d; grid.421219.d,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.5145795,CRUK-A3849,DNA fusion gene vaccines against prostate cancer,0,2003-06-01,2003.0,2008-04-30,2008,University of Southampton,grid.5491.9,United Kingdom,Cancer Research UK,United Kingdom,1,0,0
grant.5018695,81000725,EV71病毒衣壳蛋白VP1基因的优化和免疫原性的研究,31631,2011-01-01,2011.0,2013-12-31,2013,Nanjing Medical University,grid.89957.3a,China,National Natural Science Foundation of China,China,2,0,0
grant.5017925,81000747,协同活化TLR4和TLR9的靶向DC疟疾红外期脂质体疫苗的研究,31631,2011-01-01,2011.0,2013-12-31,2013,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,1,0,0
grant.5009211,31072144,携带TGEV S和PEDV S双基因的减毒沙门氏菌口服疫苗的免疫机制研究,44288,2011-01-01,2011.0,2013-12-31,2013,Sichuan Agricultural University,grid.80510.3c,China,National Natural Science Foundation of China,China,3,0,0
grant.5006128,31000413,DNA-痘病毒疫苗初免加强方案所诱导的高功能亲和力的CD8+T细胞的分子特征,30049,2011-01-01,2011.0,2013-12-31,2013,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,5,0,0
grant.5005113,31000411,细粒棘球绦虫BCG-egG1Y162重组疫苗的构建和保护机制研究,30049,2011-01-01,2011.0,2013-12-31,2013,Xinjiang Medical University,grid.13394.3c,China,National Natural Science Foundation of China,China,10,0,0
grant.5004063,31070815,肿瘤疫苗新型氢氧化铝凝胶/多糖复合佐剂（Al-PS）的免疫机制研究,56942,2011-01-01,2011.0,2013-12-31,2013,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,4,0,0
grant.5001338,31072235,SVCV反向遗传系统的构建及其传送分子疫苗机制研究,52197,2011-01-01,2011.0,2013-12-31,2013,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,0,0,0
grant.4998819,81072494,多基因表达家蚕生物反应器经济高效组装甲型H1N1流感病毒样颗粒及其免疫原性研究,47452,2011-01-01,2011.0,2013-12-31,2013,Nanyang Normal University,grid.453722.5,China,National Natural Science Foundation of China,China,1,0,0
grant.4998575,81072341,TLR3在HBsAg阳性母亲婴儿乙肝疫苗无弱应答中的作用,55361,2011-01-01,2011.0,2013-12-31,2013,Shanxi Medical University,grid.263452.4,China,National Natural Science Foundation of China,China,3,0,0
grant.4995025,31070819,D39△1672缺陷菌株粘膜接种对肺炎链球菌感染的保护作用及机制研究,52197,2011-01-01,2011.0,2013-12-31,2013,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,4,0,0
grant.4986606,30471596,丙型肝炎病毒抗原表位的颗粒化对其免疫原性的影响,23993,2005-01-01,2005.0,2007-12-31,2007,Second Military Medical University,grid.73113.37,China,National Natural Science Foundation of China,China,0,0,0
grant.4984532,81072028,表观遗传修饰的MHC-II基因细胞疫苗治疗胰腺癌的机理研究,15468,2011-01-01,2011.0,2011-12-31,2011,Nantong University,grid.260483.b,China,National Natural Science Foundation of China,China,2,0,0
grant.4981684,30801052,细粒棘球绦虫重组Bb-Eg95-EgA31融合基因疫苗构建及其免疫机制研究,28418,2009-01-01,2009.0,2011-12-31,2011,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,0,0,0
grant.4973116,30772223,靶向肿瘤干细胞的树突细胞疫苗治疗恶性脑胶质瘤的实验及作用机制研究,43790,2008-01-01,2008.0,2010-12-31,2010,Wuhan University,grid.49470.3e,China,National Natural Science Foundation of China,China,2,0,0
grant.4962484,30872788,表达Ag85B、ESAT-6和MPT64基因核酸疫苗免疫应答及免疫保护作用实验研究,50858,2009-01-01,2009.0,2011-12-31,2011,Capital Medical University,grid.24696.3f,China,National Natural Science Foundation of China,China,3,0,0
grant.4961959,30972608,基于蛋白芯片技术的新型乙肝病毒优势表位肽疫苗的研究,52225,2010-01-01,2010.0,2012-12-31,2012,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,2,0,0
grant.4961830,30901082,小反刍兽疫病毒反向遗传操作平台建立及标记疫苗构建,30715,2010-01-01,2010.0,2012-12-31,2012,Harbin Veterinary Research Institute,grid.38587.31,China,National Natural Science Foundation of China,China,2,0,0
grant.4958898,30971246,抑制肾素活性的短肽纳米疫苗研究,49152,2010-01-01,2010.0,2012-12-31,2012,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,1,0,0
grant.4956057,30300257,猪繁殖与呼吸综合征“自杀性”DNA疫苗研究,25772,2004-01-01,2004.0,2006-12-31,2006,Huazhong Agricultural University,grid.35155.37,China,National Natural Science Foundation of China,China,5,0,0
grant.4952485,30371318,重组尿素酶-BCG预防幽门螺杆菌感染的免疫机制,25772,2004-01-01,2004.0,2006-12-31,2006,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,2,0,0
grant.4951856,30801259,我国儿童肺炎链球菌分离株蛋白质抗原的分子流行病学研究,26920,2009-01-01,2009.0,2011-12-31,2011,Capital Medical University,grid.24696.3f,China,National Natural Science Foundation of China,China,2,0,0
grant.4940647,30772538,去除Treg细胞联合IL-15增强DC疫苗的抗肿瘤免疫治疗研究,40870,2008-01-01,2008.0,2010-12-31,2010,Sichuan University,grid.13291.38,China,National Natural Science Foundation of China,China,0,0,0
grant.4938462,30771884,调节性T细胞对血吸虫疫苗保护性效果的影响及机制研究,46710,2008-01-01,2008.0,2010-12-31,2010,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,3,0,0
grant.4934796,30400208,抗消化系恶性肿瘤hTERT广谱疫苗的分子设计及实验研究,26517,2005-01-01,2005.0,2007-12-31,2007,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,1,0,0
grant.4933015,30671924,以沙门菌的菌毛为载体的多价HIV-1疫苗,10514,2007-01-01,2007.0,2007-12-31,2007,Peking University,grid.11135.37,China,National Natural Science Foundation of China,China,0,0,0
grant.4932126,30972585,基于双歧杆菌表达系统的EV71 VP1亚单位口服活疫苗研究,46080,2010-01-01,2010.0,2012-12-31,2012,Chongqing Medical University,grid.203458.8,China,National Natural Science Foundation of China,China,4,0,0
grant.4930753,30901378,慢病毒载体结核病治疗性疫苗的研究,33789,2010-01-01,2010.0,2012-12-31,2012,Fudan University,grid.8547.e,China,National Natural Science Foundation of China,China,3,0,0
grant.4928248,u0772002,肝癌干细胞/DC疫苗增强抗肝癌免疫应答及机制研究,43790,2008-01-01,2008.0,2010-12-31,2010,Sun Yat-sen University,grid.12981.33,China,National Natural Science Foundation of China,China,6,0,0
grant.4927844,30972801,新型佐剂对呼吸道合胞病毒亚单位疫苗增强的肺部免疫病理的免疫调节作用及机制研究,49152,2010-01-01,2010.0,2012-12-31,2012,Hebei Medical University,grid.256883.2,China,National Natural Science Foundation of China,China,3,0,0
grant.4927113,29774034,口服靶向疫苗控制释放的基础研究,20529,1998-01-01,1998.0,2000-12-31,2000,Chengdu Organic Chemicals (China),grid.458550.9,China,National Natural Science Foundation of China,China,5,0,0
grant.4926392,30700741,以病毒样颗粒(VLP)为对照研究重组腺病毒疫苗对诺如病毒(NV)的免疫保护作用,24809,2008-01-01,2008.0,2010-12-31,2010,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,3,0,0
grant.4926144,30672107,新型树突状细胞疫苗治疗前列腺癌及其机制的研究,37946,2007-01-01,2007.0,2009-12-31,2009,Wuhan University,grid.49470.3e,China,National Natural Science Foundation of China,China,9,0,0
grant.4924377,30970639,锦灯笼多糖在核酸疫苗中免疫增强作用的研究,46080,2010-01-01,2010.0,2012-12-31,2012,Northeast Normal University,grid.27446.33,China,National Natural Science Foundation of China,China,5,0,0
grant.4912662,30901263,肠道病毒71型DNA疫苗制备及其免疫效果的优化,27644,2010-01-01,2010.0,2012-12-31,2012,Tongji University,grid.24516.34,China,National Natural Science Foundation of China,China,0,0,0
grant.4912066,30500609,抗宫颈癌穿膜肽融合性疫苗的设计及作用研究,33389,2006-01-01,2006.0,2008-12-31,2008,Third Military Medical University,grid.410570.7,China,National Natural Science Foundation of China,China,2,0,0
grant.4903278,30825045,疫苗的新型靶向输送体系及其机制研究,303623,2009-01-01,2009.0,2012-12-31,2012,Shanghai Jiao Tong University,grid.16821.3c,China,National Natural Science Foundation of China,China,15,0,0
grant.4893254,W81XWH-15-C-0176,Enhanced HIV Vaccine by CNT-enabled Mucosal Delivery,100000,2014-10-01,2014.0,2015-09-30,2015,Luna Innovations (United States),grid.281080.3,United States,United States Department of the Army,United States,0,0,0
grant.4638867,214753,E! 5934 Improved vaccines against intracellular pathogens in aquaculture - combining PHARMAQ and Isconova technology,800810,2011-01-01,2011.0,2014-12-31,2014,Pharmaq (Norway),grid.458841.4,Norway,The Research Council of Norway,Norway,0,0,0
grant.4579336,103365/Z/13/Z,"Clinical development of DB Fusion, a serotype-independent vaccine to prevent Shigella dysentery",3320711,2016-09-20,2016.0,2018-01-05,2018,Program for Appropriate Technology in Health; Program for Appropriate Technology in Health,grid.415269.d; grid.415269.d,United States; United States,Wellcome Trust,United Kingdom,0,0,0
grant.4579119,102051/Z/13/A,Generating and improving novel vaccine candidates targeting multiple stages of Malaria,77464,2014-10-01,2014.0,2017-09-30,2017,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.4550783,02/01294-3,Imunização com a vacina pneumocócica durante a gestação em mulheres infecctadas pelo vírus da imunodeficiência humana (HIV): resposta vacinal materna e transmissão placentária de anticorpos específicos,0,2002-05-01,2002.0,2005-02-28,2005,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,1,0,0
grant.4515357,96/01433-0,Study of the necessary immunological effector mechanisms for the development of vaccine against tuberculosis,0,1996-09-01,1996.0,2002-05-31,2002,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4488747,08/05207-4,Pneumococcal conjugate vaccine: capsular polysaccharide - pneumococcal surface protein A,0,2009-04-01,2009.0,2014-06-30,2014,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,5,0,0
grant.4487266,10/52167-8,"Control of diarrhea induced by enterotoxigenic Escherichia coli (ETEC) strains: vaccine formulations based on the CFA/I fimbriae, CfaE adhesin, heat-labile toxin (LT), and a new vaccine protection experimental model",0,2011-04-01,2011.0,2013-03-31,2013,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,1,0,0
grant.4485815,10/10399-0,Vaccine efficiency test in type 1 bovine Herpesvirus and in types 1 and 2 bovine pestevirus in experimental guinea pig and caprine experimental models,0,2010-10-01,2010.0,2012-09-30,2012,Sao Paulo State University,grid.410543.7,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4481761,12/50362-3,Vacinas para o controle da dengue administradas pelas vias intra-dérmica e transcutânea,0,2013-09-01,2013.0,2015-08-31,2015,GlaxoSmithKline (Brazil),grid.501324.1,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4446596,,"THE OBJECTIVE OF THIS PROJECT IS TO DEVELOP A VACCINE DELIVERY SYSTEM WHICH WILL STIMULATE, RAPIDLY, A STATE OF NON-SPECIFIC PROTECTION WHILE IT ENHANCES THE SPECIFIC IMMUNE RESPONSE TO THE VACCINE AND SHORTENS THE INDUCTION PERIOD FOR DEVELOPMENT OF",50000,1985-10-01,1985.0,1986-09-30,1986,GlaxoSmithKline (United States),grid.418019.5,United States,United States Department of the Army,United States,0,0,0
grant.4369312,W81XWH-12-C-0183,Development of a Recombinant Vaccine Against Streptococcus Pyogenes Infection and Disease,749505,2012-10-01,2012.0,2013-09-30,2013,Purdue University System,grid.411031.6,United States,United States Department of the Army,United States,0,0,0
grant.4119613,9560,Developing a Chlamydia trachomatis vaccine by optimizing dendritic cell responses,10307,2005-04-01,2005.0,2007-06-15,2007,University of British Columbia,grid.17091.3e,Canada,Michael Smith Foundation for Health Research,Canada,0,0,0
grant.4035533,2737,Targeted disabled infectious single cycle (DISC) Bovine Adenovirus (BAdV)-3 as vaccine delivery vector,93816,2013-01-01,2013.0,2014-12-31,2014,University of Saskatchewan; University of Saskatchewan,grid.25152.31; grid.25152.31,Canada; Canada,Saskatchewan Health Research Foundation,Canada,0,0,0
grant.3846713,131053,Feasibility assessment of a novel vaccine platform for the stratified therapeutic vaccine intervention in non-small cell lung cancer.,234506,2013-03-01,2013.0,2014-02-28,2014,Altimmune (United Kingdom),grid.459603.d,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.3840565,2011-33610-30433,POLYVALENT VACCINE TO PROTECT POULTRY FROM AVIAN INFLUENZA,99892,2010-07-01,2010.0,2012-06-30,2012,Medigen (United States),grid.421237.1,United States,National Institute of Food and Agriculture,United States,1,1,0
grant.3833138,2011-33610-30462,DEVELOPMENT OF A SIMPLE KILLED ENTEROTOXIGENIC E. COLI VACCINE FOR WEANED PIGS,100000,2010-09-01,2010.0,2013-08-31,2013,Brookings Institution,grid.282940.5,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3830372,0222973,DESIGN OF LIVE ATTENUATED VACCINIA VIRUS VACCINE VECTORS FOR THE DEVELOPMENT OF POLYVALENT VACCINES,0,2010-10-01,2010.0,2013-09-30,2013,University of Connecticut Health Center,grid.208078.5,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3823937,2008-35204-04626,ANTIGEN DELIVERY SYSTEM FOR ELICITATION OF PROTECTIVE IMMUNITY AGAINST JOHNE?S DISEASE,111497,2011-10-01,2011.0,2013-09-30,2013,Cornell University; Cornell University; Cornell University,grid.5386.8; grid.5386.8; grid.5386.8,United States; United States; United States,National Institute of Food and Agriculture,United States,7,0,0
grant.3815912,2012-67016-30211,DEVELOPMENT OF VIRAL VECTORS FOR POLYVALENT ANIMAL VACCINES,140000,2011-03-15,2011.0,2016-03-14,2016,University of Connecticut,grid.63054.34,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3813523,0212600,EVALUATION OF B. THURENGIENSIS SPORE-BASED VACCINES EXPRESSING ORF-4 AND ORF-5 OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS,0,2007-10-01,2007.0,2008-09-30,2008,University of Missouri; University of Missouri,grid.134936.a; grid.134936.a,United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3811209,ARS-0409755,COUNTERMEASURES TO PREVENT AND CONTROL BRUCELLOSIS IN LIVESTOCK AND WILDLIFE RESERVOIRS,0,2006-11-09,2006.0,2011-11-08,2011,Agricultural Research Service,grid.463419.d,United States,Agricultural Research Service,United States,0,0,0
grant.3806816,R21AI112837,"An unconventional, effector memory T cell vaccine for influenza",489963,2014-08-01,2014.0,2016-07-31,2016,Oregon Health & Science University,grid.5288.7,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.3783912,251456,Investigation of influenza immune responses and vaccine efficacy correlates by global expression profiling and immunological analyses in the ferret model of influenza,322294,2010-09-01,2010.0,2012-08-31,2012,Karolinska Institute; Karolinska Institute,grid.4714.6; grid.4714.6,Sweden; Sweden,European Commission,Belgium,0,0,0
grant.3747160,QLK2-CT-1999-00014,Development of an efficacious vaccine against animal brucellosis that is harmless for humans,1504226,2000-01-01,2000.0,2004-12-31,2004,French Institute of Health and Medical Research; Department for Environment Food and Rural Affairs; University of Cantabria; Veterinary and Agrochemical Research Centre; University of Namur,grid.7429.8; grid.13689.35; grid.7821.c; grid.423677.3; grid.6520.1,France; United Kingdom; Spain; Belgium; Belgium,European Commission,Belgium,13,0,0
grant.3743602,QLK2-CT-1999-00359,A new vaccine strategy against serogroup b meningococcal infection: from antigen discovery to clinical trials,2472345,2000-02-01,2000.0,2003-04-01,2003,GlaxoSmithKline (Belgium); Wise & Munro Learning Research; Public Health England; Public Health England; Oslo University Hospital; Norwegian Institute of Public Health; French Institute of Health and Medical Research; Max Planck Society; Karolinska Institute,grid.425090.a; grid.5474.2; grid.271308.f; grid.271308.f; grid.55325.34; grid.418193.6; grid.7429.8; grid.4372.2; grid.4714.6,Belgium; Netherlands; United Kingdom; United Kingdom; Norway; Norway; France; Germany; Sweden,European Commission,Belgium,0,0,0
grant.3730420,BMH4972167,New mycobacterial tuberculosis antigens for diagnosis and vaccines,0,1997-07-01,1997.0,2000-12-31,2000,Pasteur Institute; University of Surrey; Sanofi (France); State Serum Institute,grid.428999.7; grid.5475.3; grid.417924.d; grid.6203.7,France; United Kingdom; France; Denmark,European Commission,Belgium,0,0,0
grant.3643075,087667/Z/08/Z,Community Engagement and Ethical Practice in Vaccine Research.,47683,2009-04-01,2009.0,2011-04-30,2011,London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,grid.8991.9; grid.8991.9; grid.8991.9,United Kingdom; United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3643010,102051/Z/13/Z,Generating and improving novel vaccine candidates targeting multiple stages of Malaria,234092,2013-10-01,2013.0,2017-12-25,2017,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3640055,092767/Z/10/Z,Statistical analysis and modelling of the effect of conjugate vaccine and systemic capsular antibody on carriage and transmission of Streptococcus pneumoniae in Kenyan children.,143360,2010-09-01,2010.0,2013-02-28,2013,Kenya Medical Research Institute,grid.33058.3d,Kenya,Wellcome Trust,United Kingdom,4,0,0
grant.3639922,091936/Z/10/Z,Novel vaccine against haemorrhagic septicaemia in cattle and buffalo for use by resource poor farmers.,1674934,2011-11-01,2011.0,2014-04-30,2014,Moredun Foundation; Moredun Foundation; Moredun Foundation,grid.420013.4; grid.420013.4; grid.420013.4,United Kingdom; United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,0,0,0
grant.3639862,097171/Z/11/Z,Anaplasmosis vaccine development for west Africa: genetic and immunologic analysis of endemic strains,1132822,2012-08-01,2012.0,2017-07-31,2017,University of Ghana,grid.8652.9,Ghana,Wellcome Trust,United Kingdom,3,0,0
grant.3635735,097113/Z/11/A,Towards the development of a universal influenza vaccine: Investigation of heterosubtypic humoral and cellular immune responses to influenza induced by vaccination with viral,64139,2012-10-01,2012.0,2015-09-30,2015,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,1,0,0
grant.3630957,081835/Z/06/Z,An effectiveness study of 7-valent Pneumococcal Conjugate Vaccine administered through EPI in the Kilifi Demographic Surveillance Survey Area.,2547521,2008-01-01,2008.0,2012-12-31,2012,University of Oxford,grid.4991.5,United Kingdom,Wellcome Trust,United Kingdom,79,0,0
grant.3629169,067697/Z/02/Z,Synthesis of bacterial polysaccharide vaccines in plants.,225600,2003-10-01,2003.0,2006-01-31,2006,University of Leicester; University of Leicester; University of Leicester,grid.9918.9; grid.9918.9; grid.9918.9,United Kingdom; United Kingdom; United Kingdom,Wellcome Trust,United Kingdom,1,0,0
grant.3627644,080929/Z/06/Z,"Longitudinal characterization of immunity induced by a novel TB vaccine, MVA85A, in humans.",275834,2007-01-01,2007.0,2010-12-31,2010,University of Cape Town,grid.7836.a,South Africa,Wellcome Trust,United Kingdom,17,0,0
grant.2815876,496369,Synthetic Toll-like Receptor 4 Agonists as Potential Adjuvants for Use in Animal Vaccines,25272,2011-04-01,2011.0,2012-03-31,2012,Lakehead University; Immunovaccine (Canada),grid.258900.6; grid.420938.4,Canada; Canada,Natural Sciences and Engineering Research Council,Canada,0,0,0
grant.2782054,MC_U190088488,Two Dose E-Z Measles Vaccine Trial: Boosting Of Immune Responses In Bissau,18153,2007-03-31,2007.0,2008-06-29,2008,Medical Research Council The Gambia Unit; Bandim Health Project,grid.415063.5; grid.418811.5,Gambia; Guinea-Bissau,Medical Research Council,United Kingdom,1,0,0
grant.2775543,BBS/E/I/00001463,Development of rationally attenuated live vaccines for effective control of infectious bronchitis,666369,2009-10-07,2009.0,2014-08-03,2014,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,0,0,0
grant.2753642,BBS/E/I/00001482,IAH Jenner Fellowship: Assessing the efficacy of recombinant viral vaccines to induce heterosubtypic immunity to influenza in birds,341100,2010-02-08,2010.0,2012-08-30,2012,Pirbright Institute,grid.63622.33,United Kingdom,Biotechnology and Biological Sciences Research Council,United Kingdom,2,0,0
grant.2711569,Z01BK002017,VACCINE POTENCY:  DEVELOPMENT AND VALIDATION OF IPV ELIS,0,1997-01-01,1997.0,1999-01-01,1999,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711541,Z01BJ007003,Aerosol Infection of Mice as a Model for Pertussis Infec,0,2000-01-01,2000.0,2002-01-01,2002,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711209,Z01BF003019,IN VIVO POTENCY OF INACTIVATED POLIOVIRUS VACCINE,0,1992-01-01,1992.0,1992-12-31,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2709727,Z01BA002031,QUANTITATIVE ANALYSIS OF HIB PS IN DTP-HIB CONJUGATE COMBINED VACCINE,0,1992-01-01,1992.0,1992-12-31,1992,,,,United States Food and Drug Administration,United States,0,0,0
grant.2708830,Z01AI000727,Malaria Vaccine Development Branch (MVDB),0,1995-01-01,1995.0,2006-01-01,2006,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,60,0,0
grant.2704647,UC1AI067251,Development &Manufacture of an MDR Tuberculosis Vaccine,4095564,2005-09-30,2005.0,2010-08-31,2010,Infectious Disease Research Institute,grid.53959.33,United States,National Institute of Allergy and Infectious Diseases,United States,9,2,0
grant.2695923,U19AT006028,Bastyr/UW Oncomycology Translational Research Center,4038890,2010-09-29,2010.0,2015-08-31,2015,Bastyr University,grid.252865.e,United States,National Center for Complementary and Integrative Health,United States,10,0,1
grant.2695778,U19AI065683,Malaria Vaccine Trials in Mali,4748457,2005-09-01,2005.0,2010-06-30,2010,"University of Maryland, Baltimore",grid.411024.2,United States,National Institute of Allergy and Infectious Diseases,United States,32,0,1
grant.2688081,U01AI082197,Multivalent Vaccine for Viral Hemorrhagic Fever,1854702,2009-08-15,2009.0,2012-07-31,2012,The University of Texas Medical Branch at Galveston,grid.176731.5,United States,National Institute of Allergy and Infectious Diseases,United States,6,0,0
grant.2687721,U01AI061361,Recombinant Subunit West Nile Virus Vaccine Development,3615940,2004-09-01,2004.0,2009-06-30,2009,,,,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2687202,U01AI028171,VACCINE DEVELOPMENT FOR IMMUNODEFICIENCY VIRUSES,0,1989-03-01,1989.0,1994-02-28,1994,AstraZeneca (United States),grid.418152.b,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2666811,R56AI105409,Development of Chimeric Vesiculo/Alphaviruses as an Alphavirus Vaccine,1156616,2013-08-08,2013.0,2015-07-31,2015,Yale University,grid.47100.32,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2657817,R44AI045267,SELECTION OF RSV SUBGROUP A &B VACCINE CANDIDATES,750200,1999-08-15,1999.0,2002-08-31,2002,AstraZeneca (United States),grid.418152.b,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2657569,R44AI025232,ORAL MALARIA VACCINE DEVELOPMENT IN A P. BERGHEI MODEL,0,1989-06-01,1989.0,1991-05-31,1991,Pfizer (United States),grid.410513.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2654335,R43IP000002,VACCINE/HEALTH ECONOMICS LINEAR PROGRAMMING SOFTWARE,0,1998-09-30,1998.0,1999-12-31,1999,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2646969,R43DK041168,EFFICACY OF E COLI PILUS VACCINE FOR URINARY INFECTION,0,1990-04-01,1990.0,1990-11-30,1990,,,,National Institute of Diabetes and Digestive and Kidney Diseases,United States,0,0,0
grant.2643965,R43CA081752,A NEW CANDIDATE VACCINE FOR LEUKEMIA AND CANCER,0,1999-09-08,1999.0,2000-06-30,2000,Corixa Corporation,grid.284594.6,United States,National Cancer Institute,United States,0,20,0
grant.2641521,R43AI075921,Development of a Bacterial Ghost DNA vaccine for Influenza using antibody epitope,578126,2007-09-01,2007.0,2010-08-31,2010,Vital Probes (United States),grid.505454.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641308,R43AI065016,Development of a DNA Vaccine Against Influenza Virus,500000,2005-05-01,2005.0,2006-10-31,2006,Vical (United States),grid.422245.7,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2641156,R43AI058535,Synthesis and Optimization of a Malaria Vaccine,130750,2004-03-01,2004.0,2005-02-28,2005,Corden Pharma (United States),grid.432520.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2641134,R43AI058391,Oral Smallpox Vaccine Development,428289,2004-09-01,2004.0,2005-04-30,2005,Incell Corporation (United States),grid.420947.c,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640884,R43AI051918,Needle-Free Delivery of Subunit Rotavirus Vaccines,125499,2003-06-01,2003.0,2005-02-28,2005,Emerging Concepts (United States),grid.450786.8,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2640647,R43AI046821,CD1 PRESENTED VACCINES TO PREVENT CHLAMYDIA INFECTION,127989,2000-07-01,2000.0,2001-06-30,2001,Agenus (United States),grid.420152.0,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640492,R43AI043157,IMPROVING DNA VACCINES FOR HIV1,0,1998-09-30,1998.0,1999-09-29,1999,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640479,R43AI043119,EXPRESSION OF MALARIA MSP-1 P42 C-TERMINAL FRAGMENT,0,1998-03-01,1998.0,1998-12-14,1998,Hawaii Biotech (United States),grid.420613.2,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2640473,R43AI043104,VAGINAL IMMUNIZATION AGAINST URINARY TRACT INFECTIONS,0,1998-08-01,1998.0,1999-05-30,1999,Protein Express (United States),grid.437364.1,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640225,R43AI036799,VACCINE FOR MYCOBACTERIUM TUBERCULOSIS,0,1995-09-30,1995.0,1996-03-31,1996,Corixa Corporation,grid.284594.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640198,R43AI036096,WATER SOLUBLE POLYMER MICROSPHERES AS VACCINE VEHICLES,0,1994-04-15,1994.0,1994-10-15,1994,Celldex Therapeutics (United States),grid.417695.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2639892,R43AI028132,SYNTHETIC GLYCO-CONJUGATE VACCINE AGAINST MENINGOCOCCI,0,1989-06-01,1989.0,1989-11-30,1989,Pfizer (United States),grid.410513.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2639810,R43AI025232,ORAL MALARIA VACCINE DEVELOPMENT INA P BERGHEI MODEL,0,1988-03-01,1988.0,1988-08-31,1988,Pfizer (United States),grid.410513.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2636506,R41AI096706,A novel vaccine against vaginal Chlamydia trachomatis,600000,2012-06-05,2012.0,2015-05-31,2015,EpitoGenesis (United States),grid.428901.6,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2636420,R41AI062482,A novel recombinant vaccine against Cryptococcus.,99999,2004-07-01,2004.0,2006-06-30,2006,Mycologics,grid.288161.4,United States,National Institute of Allergy and Infectious Diseases,United States,0,5,0
grant.2601233,R21AI103480,Identification of protective pneumococcal antigens from a surface protein library,412619,2013-08-16,2013.0,2016-07-31,2016,Boston Children's Hospital,grid.2515.3,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2597386,R21AI042603,TARGETED DELIVERY OF MUSCOSAL HIV1 RNA VACCINE,0,1997-09-30,1997.0,1999-09-29,1999,University System of Maryland,grid.410443.6,United States,National Institute of Allergy and Infectious Diseases,United States,3,1,0
grant.2577671,R03MH057176,"HIV VACCINE VOLUNTEERS--PERSONALITY, MOTIVATION, AND RIS",0,1998-02-15,1998.0,1999-01-31,1999,University of Alabama at Birmingham,grid.265892.2,United States,National Institute of Mental Health,United States,3,0,0
grant.2568118,R03CA053468,CORRELATION OF ANTIBODY RESPONSE TO MELANOMA VACCINE...,0,1991-08-01,1991.0,1993-07-31,1993,New York University,grid.137628.9,United States,National Cancer Institute,United States,5,0,0
grant.2567052,R03AI059234,NASAL ANTHRAX VACCINE DELIVERY FORMULATIONS,96846,2004-04-01,2004.0,2007-03-31,2007,SRI International,grid.98913.3a,United States,National Institute of Allergy and Infectious Diseases,United States,0,1,0
grant.2480171,R01CA136847,Diindolylmethane enhances the efficacy of preventive vaccines in an HPV transgeni,1754766,2009-05-04,2009.0,2014-02-28,2014,Hackensack University Medical Center,grid.239835.6,United States,National Cancer Institute,United States,2,0,0
grant.2467344,R01CA034358,IMMUNOGENICITY OF A POLYVALENT MELANOMA ANTIGEN VACCINE,0,1984-09-01,1984.0,1988-05-31,1988,New York University,grid.137628.9,United States,National Cancer Institute,United States,11,0,0
grant.2456685,R01AI059597,Alphavirus-based Vaccine for Prevention of MPV Infection,1568348,2004-04-01,2004.0,2010-02-28,2010,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,4,2,0
grant.2456117,R01AI054280,Tools for Testing HIV Immune-Control and Vaccine Models,1029043,2003-04-01,2003.0,2010-05-31,2010,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2451240,R01AI025232,ORAL MALARIA VACCINE DEVELOPMENT--P. BERGHEI MODEL,0,1989-06-01,1989.0,1991-05-31,1991,Pfizer (United States),grid.410513.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2424927,N01AI082689,PROTEIN-POLYSACCHARIDE PNEUMOCOCCAL CONJUGATE VACCINES,0,1988-04-01,1988.0,1992-06-30,1992,Pfizer (United States),grid.410513.2,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2370445,F32AI063976,HIV Vaccines via 2G12 Carbohydrate Epitope Mimicry,143200,2005-01-01,2005.0,2007-12-31,2007,Memorial Sloan Kettering Cancer Center,grid.51462.34,United States,National Institute of Allergy and Infectious Diseases,United States,2,2,0
grant.8586139,866570,PnuBioVax™: next-generation vaccine for a personalised and effective immune response against Streptococcus pneumoniae.,57206,2019-05-01,2019.0,2019-09-30,2019,ImmBio (United Kingdom); ImmBio (United Kingdom),grid.434859.7; grid.434859.7,United Kingdom; United Kingdom,European Commission,Belgium,0,0,0
grant.8550870,W81XWH-19-2-0026,Novel Live Vaccines with Modified Lipid A for the Prevention of Shigella Diarrheal Disease,446437,2017-10-01,2017.0,2018-09-01,2018,Geneva Foundation,grid.417469.9,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.8550869,W81XWH-19-2-0025,Novel Live Vaccines with Modified Lipid A for the Prevention of Shigella Diarrheal Disease,1112464,2017-10-01,2017.0,2018-09-01,2018,"University of Maryland, Baltimore",grid.411024.2,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.8458639,,Generation and characterization of a bivalent replication-competent vaccine against Ebola virus and human immunodeficiency virus,13692,2015-05-01,2015.0,2016-04-30,2016,University of Manitoba,grid.21613.37,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8458394,,Unpacking Vaccine Hesitancy among Perinatal Healthcare Providers: Influences on Beliefs and Practices,121458,2017-02-01,2017.0,2019-01-31,2019,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8334271,81372935,登革病毒四价疫苗免疫新策略的研究,108798,2014-01-01,2014.0,2017-12-31,2017,Capital Medical University,grid.24696.3f,China,National Natural Science Foundation of China,China,9,0,0
grant.8185917,31472179,构建新颖的减毒沙门载体递送鸭瘟DNA疫苗,134242,2015-01-01,2015.0,2018-12-31,2018,Southwest University,grid.263906.8,China,National Natural Science Foundation of China,China,12,0,0
grant.8178837,31370929,基于多基因共表达载体的通用型流感疫苗研究,124340,2014-01-01,2014.0,2017-12-31,2017,,,,National Natural Science Foundation of China,China,6,0,0
grant.7664581,,Investigating tropical enteropathy as a cause of oral rotavirus vaccine failure in the developing world,122118,2014-06-01,2014.0,2017-05-31,2017,,,,Canadian Institutes of Health Research,Canada,0,0,0
grant.7647386,,The examination of a novel viral vector and immunogens for HIV/SIV vaccine development in a non-human primate model,54344,2012-05-01,2012.0,2013-10-31,2013,University of Toronto,grid.17063.33,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7642410,,Uptake of The Human Papillomavirus Vaccine in Canada: Barriers and Facilitators.,98354,2008-09-01,2008.0,2011-08-31,2011,McGill University,grid.14709.3b,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7640114,,Dissecting the mechanisms of protection by attenuated Nef-deleted HIV vaccine,87612,2009-03-01,2009.0,2010-02-28,2010,University of Montreal,grid.14848.31,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7636485,,Qualitative and quantitative parameters of correlates of protection in HIV-1 vaccines,118700,2005-04-01,2005.0,2008-03-31,2008,Centre Hospitalier de l’Université de Montréal,grid.410559.c,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7623307,,Accelerated Chlamydia trachomatis Immunoproteomic Vaccine Enterprise,139649,2007-01-01,2007.0,2007-12-31,2007,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7620846,,Increasing HPV vaccine uptake in the school-based program in rural and remote British Columbia,153787,2017-04-01,2017.0,2018-03-31,2018,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.7138827,DAMD17-99-1-9067,Vaccine Development Against Novel Breast Cancer Antigens,315000,1997-10-01,1997.0,1998-09-01,1998,,,,Congressionally Directed Medical Research Programs,United States,1,0,0
grant.7099836,2014-03071,Development of a mucosal vaccine against Helicobacter pylori infection including Phase I clinical testing in India,514197,2015-01-01,2015.0,2018-12-31,2018,University of Gothenburg,grid.8761.8,Sweden,Swedish Research Council,Sweden,4,0,0
grant.7050174,2016-33610-25438,POTENT VACCINE FORMULAS FOR JOHNE`S DISEASE,99846,2016-08-15,2016.0,2017-08-14,2017,Pan Genome Systems (United States); Pan Genome Systems (United States),grid.427099.1; grid.427099.1,United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.7040500,OD0712,New strategies for vaccines against infectious bronchitis and the elucidation of pathogenicity and immunity,1563521,1999-04-01,1999.0,2003-03-31,2003,Pirbright Institute,grid.63622.33,United Kingdom,Department for Environment Food and Rural Affairs,United Kingdom,5,0,0
grant.6996265,31201906,马传染性贫血病毒弱毒疫苗株与强毒株感染对靶细胞作用差异的研究,37155,2013-01-01,2013.0,2015-12-31,2015,Harbin Veterinary Research Institute,grid.38587.31,China,National Natural Science Foundation of China,China,3,0,0
grant.6805630,,Long-term immunogenicity and clinical efficacy of the quadrivalent HPV vaccine in HIV positive girls and women,887063,2014-07-01,2014.0,2018-06-30,2018,University of British Columbia,grid.17091.3e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.6382115,1004788,PROBIOTICS AS TOOLS TO IMPROVE IMMUNE RESPONSE TO VACCINE AGENTS DELIVERED THROUGH THE RESPIRATORY MUCOSAL SURFACE IN FARM ANIMALS,0,2014-10-27,2014.0,2019-09-30,2019,,,,National Institute of Food and Agriculture,United States,0,0,0
grant.6224508,60860031,"Preventive measurement for vaccine brak of Marek's Disease, Divelopment of the vaccine in particular",174057,1985-01-01,1985.0,1987-12-31,1987,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.6004587,20658069,抗体依存性感染増強現象を利用したアジュバントの開発,34590,2008-01-01,2008.0,2009-12-31,2009,Hokkaido University,grid.39158.36,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5910597,16K08033,ネオスポラ症をモデルとした経口投与型藻類クラミドモナスワクチンの作出,44737,2016-04-01,2016.0,2019-03-31,2019,Nippon Veterinary and Life Science University,grid.412202.7,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5802355,13670505,HCV感染チンパンジーに対するHCVDNAワクチンの効果に関する研究,16214,2001-01-01,2001.0,2002-12-31,2002,Nagoya University,grid.27476.30,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5800369,13671671,Active specific immunotherapy with MN\CA IX antigen peptide vaccines for renal cell carcinoma,29185,2001-01-01,2001.0,2002-12-31,2002,Nara Medical University,grid.410814.8,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5796849,13771257,歯周病原性菌のシステインプロテアーゼを標的としたDNAワクチンの開発,17021,2001-01-01,2001.0,2002-12-31,2002,Osaka University,grid.136593.b,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5754852,10J05592,ナノテクノロジーを用いた次世代経鼻ワクチン開発と、それによる免疫誘導機序の解明,25518,2010-01-01,2010.0,2012-12-31,2012,University of Tokyo,grid.26999.3d,Japan,Japan Society for the Promotion of Science,Japan,3,0,0
grant.5750850,11470381,Molecular and immunological analysis of periodontopathic bacterial attachment factors,92901,1999-01-01,1999.0,2001-12-31,2001,Tokyo Dental College,grid.265070.6,Japan,Japan Society for the Promotion of Science,Japan,1,0,0
grant.5716915,09J06197,自然免疫制御による呼吸器疾患の予防およびワクチン開発,32997,2009-01-01,2009.0,2012-12-31,2012,Tohoku University,grid.69566.3a,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5637120,06670765,ロタウイルスワクチン株の野生株との遺伝子交雑体の解析,18587,1994-01-01,1994.0,1994-12-31,1994,Akita University,grid.251924.9,Japan,Japan Society for the Promotion of Science,Japan,0,0,0
grant.5503915,K22AI118421,Development of Immune-Modulated HIV Vaccines,270000,2016-08-15,2016.0,2018-07-31,2018,Northwestern University,grid.16753.36,United States,National Institute of Allergy and Infectious Diseases,United States,10,0,0
grant.5349803,11-08-01245,Разработка и применение новых технологий при конструировании диагностических и вакцинных препаратов против лихорадки долины Рифт,0,2011-01-01,2011.0,2011-12-31,2011,,,,Russian Foundation for Basic Research,Russia,0,0,0
grant.5054576,R43DK109746,Improving the efficacy of hepatitis B prophylactic vaccines,146776,2016-04-15,2016.0,2017-03-31,2017,Applied Biotechnology Institute,grid.426798.6,United States,National Institute of Diabetes and Digestive and Kidney Diseases,United States,0,0,0
grant.4942762,254907,Veien til vellykket DNA-vaksinering av laks mot virussykdommer,399400,2016-01-01,2016.0,2018-12-31,2018,The Arctic University of Norway,grid.10919.30,Norway,The Research Council of Norway,Norway,2,0,0
grant.4895796,14-15-00391,Development of methods for enhancement of nucleic acids-based antiviral vaccines immunogenicity,0,2014-01-01,2014.0,2016-12-31,2016,Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences,grid.419647.9,Russia,Russian Science Foundation,Russia,2,0,0
grant.4694512,5-2008-792,DENDRITIC CELL ARRAYS FOR T1D NANOPARTICLE-BASED VACCINE DEVELOPMENT,110000,2008-09-01,2008.0,2010-02-28,2010,University of Florida,grid.15276.37,United States,Juvenile Diabetes Research Foundation,United States,0,0,0
grant.4679006,174220,"EFFEKTIVE VAKSINER OG VAKSINESTRATEGIER FOR TORSK, FOKUS PÅ BAKTERIELLE AGENS",176680,2005-01-01,2005.0,2009-12-31,2009,Pharmaq (Norway),grid.458841.4,Norway,The Research Council of Norway,Norway,0,0,0
grant.4660408,184634,"Vibriosis and furunculosis vaccines for Atlantic cod: efficacy, protective antigens and specific immune responses",1278115,2007-01-01,2007.0,2012-12-31,2012,Nofima,grid.22736.32,Norway,The Research Council of Norway,Norway,4,0,0
grant.4659393,220829,Meningococcal vaccines for Africa: Impact of MenAfriVac on serogroup A transmission and clinical evaluation of a new protein-based vaccine,2359049,2012-01-01,2012.0,2017-12-31,2017,Norwegian Institute of Public Health,grid.418193.6,Norway,The Research Council of Norway,Norway,11,0,0
grant.4646343,172508,Novel strategies for immunisation against intracellular pathogens of Atlantic salmon,1083337,2006-01-01,2006.0,2010-12-31,2010,The Arctic University of Norway,grid.10919.30,Norway,The Research Council of Norway,Norway,7,0,0
grant.4645097,179348,Project establishment: Development of vaccine(s) against infections with diarrheagenic Escherichia coli and Shigella,48986,2006-01-01,2006.0,2007-12-31,2007,University of Bergen,grid.7914.b,Norway,The Research Council of Norway,Norway,0,0,0
grant.4642173,182035,Immunisation strategies against viral pathogens of Atlantic salmon,1167454,2007-01-01,2007.0,2011-12-31,2011,Norwegian University of Life Sciences,grid.19477.3c,Norway,The Research Council of Norway,Norway,11,0,0
grant.4534271,07/05353-8,Efeito modulador de estratégias vacinais para tuberculose na encefalite autoimune experimental (EAE),0,2007-11-01,2007.0,2009-10-31,2009,Sao Paulo State University,grid.410543.7,Brazil,São Paulo Research Foundation,Brazil,1,0,0
grant.4475728,12/10642-7,Genomic characterization of the Bordetella pertussis strain used to produce the anti-pertussis vaccine at Butantan Institute,0,2012-10-01,2012.0,2015-09-30,2015,Secretaria da Saúde,grid.419716.c,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.4472767,12/10409-0,Studies of the immunogenic and protective properties of third generation vaccines against american tegumentar leishmaniasis,0,2012-09-01,2012.0,2014-08-31,2014,University of Sao Paulo,grid.11899.38,Brazil,São Paulo Research Foundation,Brazil,2,0,0
grant.4274070,696568,Commercialisation of a world changing invention for the stabilisation and delivery of vaccines,55489,2015-09-01,2015.0,2015-10-31,2015,,,,European Commission,Belgium,0,0,0
grant.4057204,659615,Structural Vaccinology in the design of bionanoparticles with multi-copy antigen display for vaccines with enhanced efficacy,187122,2015-06-15,2015.0,2017-06-14,2017,GlaxoSmithKline (Italy),grid.425088.3,Italy,European Commission,Belgium,3,0,0
grant.3953270,2012-67015-19505,INNOVATIVE STRATEGIES TO ENHANCE PRRSV SPECIFIC INNATE AND MUCOSAL IMMUNITY: IMPLICATION FOR DEVELOPMENT OF BROADLY PROTECTIVE PRRS VACCINE,61812,2014-09-01,2014.0,2015-08-31,2015,South Dakota State University; South Dakota State University; South Dakota State University; South Dakota State University; South Dakota State University,grid.263791.8; grid.263791.8; grid.263791.8; grid.263791.8; grid.263791.8,United States; United States; United States; United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3945629,1002248,ROLE OF M-PROTEIN IN PROTECTION AND VIRULENCE OF STREPTOCOCCUS EQUI SUBSP. EQUI,0,2013-12-15,2013.0,2015-09-30,2015,University of Illinois at Urbana Champaign,grid.35403.31,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3939603,643558,Eliciting Mucosal Immunity to Tuberculosis,9051385,2015-01-01,2015.0,2019-06-30,2019,"St George's, University of London; University of Rome Tor Vergata; Department of Health and Social Care; Karolinska Institute; Institute of Microbiology; Instituto Nacional de Saúde; Stockholm University; Lionex (Germany); Spanish National Research Council; Health Sciences Research Institute of the “Germans Trias i Pujol” Foundation; Azienda Ospedaliera Universitaria Policlinico ""Paolo Giaccone"" di Palermo; University of Vigo; King's College London",grid.264200.2; grid.6530.0; grid.57981.32; grid.4714.6; grid.418800.5; grid.419229.5; grid.10548.38; grid.425267.0; grid.4711.3; grid.429186.0; grid.412510.3; grid.6312.6; grid.13097.3c,United Kingdom; Italy; United Kingdom; Sweden; Czechia; Mozambique; Sweden; Germany; Spain; Spain; Italy; Spain; United Kingdom,European Commission,Belgium,17,0,0
grant.3847452,720371,Star ID (Star Intradermal),292456,2013-09-30,2013.0,2015-06-29,2015,,,,Innovate UK,United Kingdom,0,0,0
grant.3847218,710349,"Developing Stable Liquid Pandemic Influenza Vaccines to Improve Shelf Life, Facilitate Distribution, and Increase Pandemic Preparedness",150083,2013-06-30,2013.0,2014-06-29,2014,Arecor (United Kingdom),grid.428042.8,United Kingdom,Innovate UK,United Kingdom,0,0,0
grant.3839140,2013-67015-20476,UNIVERSAL FLU VACCINE BY A NOROVIRUS P PARTICLE PLATFORM,2200000,2012-04-15,2012.0,2015-04-14,2015,The Ohio State University; The Ohio State University,grid.261331.4; grid.261331.4,United States; United States,National Institute of Food and Agriculture,United States,11,1,0
grant.3836265,2011-67021-30172,PEPTIDE NANOPARTICLES AS NOVEL IMMUNOGENS: DESIGN AND ANALYSIS OF AVIAN INFLUENZA VACCINE,499943,2010-01-15,2010.0,2014-01-14,2014,University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut,grid.63054.34; grid.63054.34; grid.63054.34; grid.63054.34,United States; United States; United States; United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3816560,2009-65119-05921,COMPETITION FOR ANTERIOR PLASMA CELL NICHES DETERMINES THE SUCCESS OF VACCINES,375000,2009-08-01,2009.0,2012-07-31,2012,University of Massachusetts Dartmouth,grid.266686.a,United States,National Institute of Food and Agriculture,United States,0,0,0
grant.3800484,602437,Development of a universal influenza vaccine based on tandem core technology,3766138,2013-09-01,2013.0,2017-03-31,2017,University College London; Latvian Biomedical Research and Study Centre; University College London; iQur (United Kingdom); iQur (United Kingdom); Institut Català de la Salut; Luxembourg Institute of Health; University of Leeds,grid.83440.3b; grid.419210.f; grid.83440.3b; grid.435566.7; grid.435566.7; grid.22061.37; grid.451012.3; grid.9909.9,United Kingdom; Latvia; United Kingdom; United Kingdom; United Kingdom; Spain; Luxembourg; United Kingdom,European Commission,Belgium,2,0,0
grant.3800251,602999,Reach  α-synuclein-dependent neurodegeneration: clinical development of therapeutic AFFITOPE vaccines for Parkinson’s disease and multisystem atrophy,7080653,2013-10-01,2013.0,2017-09-30,2017,AFFiRiS (Austria); French Institute of Health and Medical Research; Jülich Research Centre; Biolution (Austria); Centre Hospitalier Universitaire de Toulouse; Innsbruck Medical University; Centre Hospitalier Universitaire de Bordeaux,grid.452292.a; grid.7429.8; grid.8385.6; grid.424146.1; grid.411175.7; grid.5361.1; grid.42399.35,Austria; France; Germany; Austria; France; Austria; France,European Commission,Belgium,4,0,0
grant.3798782,304815,Clinical development of a VAR2CSA-based placental malaria vaccine,7178411,2013-03-01,2013.0,2017-02-28,2017,University of Copenhagen; ExpreS2ion Biotechnologies (Denmark); University of Tübingen; Institute of Research for Development; University of Copenhagen; ExpreS2ion Biotechnologies (Denmark); Université d'Abomey-Calavi,grid.5254.6; grid.498308.e; grid.10392.39; grid.4399.7; grid.5254.6; grid.498308.e; grid.412037.3,Denmark; Denmark; Germany; France; Denmark; Denmark; Benin,European Commission,Belgium,11,0,0
grant.3796896,607690,Universal Flu Vaccine,4833804,2013-11-01,2013.0,2018-02-28,2018,University of Gothenburg; Mivac Development (Sweden); Mivac Development (Sweden); European Institute of Oncology; University of Lille; Flanders Institute for Biotechnology; Retroscreen Virology (United Kingdom); King's College London,grid.8761.8; grid.451585.8; grid.451585.8; grid.15667.33; grid.503422.2; grid.11486.3a; grid.425987.5; grid.13097.3c,Sweden; Sweden; Sweden; Italy; France; Belgium; United Kingdom; United Kingdom,European Commission,Belgium,5,0,0
grant.3795062,602012,Universal Influenza Vaccines Secured,7030446,2013-10-01,2013.0,2018-03-31,2018,University of Groningen; Peptcell (United Kingdom); Norwegian Institute of Public Health; Department of Health and Social Care; Robert Koch Institute; State Serum Institute; University Medical Center Groningen; Department of Health and Social Care; Novavax (Sweden); University of Gothenburg; Retroscreen Virology (United Kingdom); Peptcell (United Kingdom); National Center for Epidemiology; University of Groningen,grid.4830.f; grid.476606.5; grid.418193.6; grid.57981.32; grid.13652.33; grid.6203.7; grid.4494.d; grid.57981.32; grid.425310.1; grid.8761.8; grid.425987.5; grid.476606.5; grid.419249.3; grid.4830.f,Netherlands; United Kingdom; Norway; United Kingdom; Germany; Denmark; Netherlands; United Kingdom; Sweden; Sweden; United Kingdom; United Kingdom; Hungary; Netherlands,European Commission,Belgium,15,0,0
grant.3778054,37200,Mucosal nano vaccine candidate for HIV,2101788,2007-01-01,2007.0,2010-06-30,2010,"St George's, University of London; Hospital Clinic of Barcelona; Palacký University, Olomouc; Sorbonne University; Charité – University Medicine Berlin; French National Centre for Scientific Research; Atomic Energy and Alternative Energies Commission",grid.264200.2; grid.410458.c; grid.10979.36; grid.462844.8; grid.6363.0; grid.4444.0; grid.5583.b,United Kingdom; Spain; Czechia; France; Germany; France; France,European Commission,Belgium,1,0,0
grant.3776776,36615,Use of CpG oligodeoxynucleotides to improve the immunogenicity of vaccines,106995,2006-04-01,2006.0,2008-03-31,2008,Bilkent University; Bilkent University,grid.18376.3b; grid.18376.3b,Turkey; Turkey,European Commission,Belgium,5,0,0
grant.3776766,223532,"Optimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges",1273485,2009-02-01,2009.0,2012-01-31,2012,Biomedical Primate Research Centre; Fondation Mérieux; University of Geneva; State Serum Institute; Fondation Mérieux; Wageningen University & Research; TuBerculosis Vaccine Initiative; World Health Organization,grid.11184.3d; grid.434215.5; grid.8591.5; grid.6203.7; grid.434215.5; grid.4818.5; grid.425962.e; grid.3575.4,Netherlands; France; Switzerland; Denmark; France; Netherlands; Netherlands; Switzerland,European Commission,Belgium,2,0,0
grant.3775456,227056,Plant Production of Vaccines,2735563,2009-01-01,2009.0,2011-12-31,2011,John Innes Centre; All-Russian Research Institute for Animal Health; Wageningen University & Research; Russian Academy of Sciences; John Innes Centre; National Research Council; Research Institute of Influenza; University of Cape Town; Moscow State University; Spanish National Research Council; James Hutton Institute; Research Institute of Influenza; All-Russian Research Institute for Animal Health; Russian Academy of Sciences; Plovdiv University,grid.14830.3e; grid.494067.8; grid.4818.5; grid.4886.2; grid.14830.3e; grid.5326.2; grid.452514.3; grid.7836.a; grid.14476.30; grid.4711.3; grid.43641.34; grid.452514.3; grid.494067.8; grid.4886.2; grid.11187.3e,United Kingdom; Russia; Netherlands; Russia; United Kingdom; Italy; Russia; South Africa; Russia; Spain; United Kingdom; Russia; Russia; Russia; Bulgaria,European Commission,Belgium,17,0,0
grant.3769804,12161,Vaccine Strategies for Combined Targeting of Innate and Adaptive Immune Pathways,1269603,2005-05-01,2005.0,2007-04-30,2007,Karolinska Institute; Spanish National Research Council; French Institute of Health and Medical Research; Karolinska Institute,grid.4714.6; grid.4711.3; grid.7429.8; grid.4714.6,Sweden; Spain; France; Sweden,European Commission,Belgium,0,0,0
grant.3749469,FMBI983217,An investigation into the incorporation and release of vaccines from polylactid acid microspheres,0,1998-11-02,1998.0,1999-11-01,1999,University College London,grid.83440.3b,United Kingdom,European Commission,Belgium,1,0,0
grant.3736252,IC18970254,Development of tuberculosis vaccine with consistent efficacy in differentregions of the world,0,1998-01-01,1998.0,2000-12-31,2000,State Serum Institute; Armauer Hansen Research Institute; Norwegian Institute of Public Health; University of Oslo; University of Porto,grid.6203.7; grid.418720.8; grid.418193.6; grid.5510.1; grid.5808.5,Denmark; Ethiopia; Norway; Norway; Portugal,European Commission,Belgium,0,0,0
grant.3721586,IC18950025,Evaluation of respiratory vaccines for children in South East Asia. Streptococcus pneumoniae (and Hib) conjugate vaccincs in prevention of childhood pneumonia in developing countries,0,1996-01-01,1996.0,1997-12-31,1997,National Institute for Health and Welfare; Research Institute for Tropical Medicine; University of Copenhagen,grid.14758.3f; grid.437564.7; grid.5254.6,Finland; Philippines; Denmark,European Commission,Belgium,0,0,0
grant.3135164,1158807,"I-Corps: SwiftVax - A Green Manufacturing Platform for Faster, Cheaper, and Scalable Vaccine Manufacturing",50000,2011-10-01,2011.0,2013-03-31,2013,"University of California, Davis",grid.27860.3b,United States,Directorate for Engineering,United States,0,0,0
grant.2766098,MC_U190088487,Two Dose E-Z Measles Vaccine Trial: Boosting of Immune Responses,502767,2007-03-31,2007.0,2008-06-29,2008,Medical Research Council The Gambia Unit; Bandim Health Project,grid.415063.5; grid.418811.5,Gambia; Guinea-Bissau,Medical Research Council,United Kingdom,5,0,0
grant.2765030,BBS/E/J/000CA374,Plant Production of Vaccines,612654,2009-01-01,2009.0,2011-12-31,2011,John Innes Centre; National Center for Biotechnology; Research Institute of Influenza; Russian Academy of Sciences; All-Russian Research Institute for Animal Health; Wageningen University & Research; Medical University Plovdiv; PA Consulting Group; University of Turin; James Hutton Institute; University of Cape Town,grid.14830.3e; grid.428469.5; grid.452514.3; grid.4886.2; grid.494067.8; grid.4818.5; grid.35371.33; grid.437091.8; grid.7605.4; grid.43641.34; grid.7836.a,United Kingdom; Spain; Russia; Russia; Russia; Netherlands; Bulgaria; United Kingdom; Italy; United Kingdom; South Africa,Biotechnology and Biological Sciences Research Council,United Kingdom,7,0,0
grant.2726426,ZIBAI005121,Production of a Broadly Neutralizing HIV Antibodies,70558096,2011-01-01,2011.0,2018-01-01,2018,National Institute of Allergy and Infectious Diseases,grid.419681.3,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2711566,Z01BK002014,IMMUNOPATHOGENESIS OF RUBELLA VIRUS ASSOCIATED AUTOIMMUN,0,1997-01-01,1997.0,1998-01-01,1998,,,,United States Food and Drug Administration,United States,0,0,0
grant.2711200,Z01BF003010,IMMUNIZATION OF SIX AND NINE MONTH OLD INFANTS AGAINST MEASLES,0,1991-01-01,1991.0,1991-12-31,1991,,,,United States Food and Drug Administration,United States,0,0,0
grant.2704629,UC1AI062634,Novel cell-culture derived split influenza vaccine,3489073,2004-09-01,2004.0,2006-10-31,2006,GlaxoSmithKline (United States),grid.418019.5,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2704602,UC1AI049509,Production of Non-Egg grown Influenza Vaccines,848254,2000-09-30,2000.0,2005-08-31,2005,Novavax (United States),grid.436677.7,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2692264,U01IP000466,Core_Prospective population-based estimation of influenza vaccine effectiveness a,4101223,2011-07-01,2011.0,2016-07-31,2016,Kaiser Foundation Health Plan,grid.414864.b,United States,Centers for Disease Control and Prevention,United States,24,0,0
grant.2689373,U01CI000347,Avian Flu A/H5N1 Vaccine Development in Vietnam,0,2006-01-25,2006.0,2009-01-24,2009,,,,Centers for Disease Control and Prevention,United States,0,0,0
grant.2688035,U01AI078073,Multi-gene Subunit Vaccine Platform Against Y. pestis,1653159,2008-09-15,2008.0,2013-08-31,2013,University of Massachusetts Medical School,grid.168645.8,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2687963,U01AI074578,Production of an NP-ISS conjugate vaccine to combat pandemic influenza.,3216687,2007-08-15,2007.0,2009-07-31,2009,Dynavax Technologies (United States),grid.418630.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687948,U01AI074508,Non-Viral Pandemic Influenza Vaccine Development,2388206,2007-09-15,2007.0,2010-08-31,2010,Molecular GPS Technologies (United States),grid.281192.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,1,0
grant.2687707,U01AI061253,Development of a vaccine for Ebola virus in plant system,2876373,2005-03-15,2005.0,2010-02-28,2010,Arizona State University,grid.215654.1,United States,National Institute of Allergy and Infectious Diseases,United States,6,3,0
grant.2687655,U01AI057249,Influenza DNA Vaccine for Biodefense/Pandemic Readiness,818377,2003-08-15,2003.0,2004-05-17,2004,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2687645,U01AI056536,Multi-gene plague vaccine with expanded protection,1089169,2003-09-30,2003.0,2006-08-31,2006,University of Massachusetts Medical School,grid.168645.8,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2658044,R44AI071634,Evaluation and Production of a Multivalent Adenoviral Plague Vaccine,2923479,2006-07-01,2006.0,2016-06-30,2016,Norwell (Norway),grid.458549.1,Norway,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2657851,R44AI047641,Transcriptionally Active PCR to Improve DNA Vaccines,1848292,2000-06-01,2000.0,2007-06-30,2007,Genlantis (United States),grid.421709.9,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2657802,R44AI043830,MALARIA VACCINE,856254,1998-08-01,1998.0,2002-06-30,2002,,,,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2657756,R44AI040798,DEVELOPMENT OF LIPID VACCINES FOR TUBERCULOSIS,420908,1997-08-01,1997.0,2001-07-31,2001,Agenus (United States),grid.420152.0,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2650996,R43GM101737,Use of Spray-Drying as a Manufacturing Process for Oral Adenovirus Vaccine,298464,2012-09-24,2012.0,2014-09-23,2014,PaxVax (United States),grid.437314.6,United States,National Institute of General Medical Sciences,United States,0,0,0
grant.2645340,R43CA136357,Multivalent HPV Capsomere Vaccines,373315,2008-09-26,2008.0,2010-09-25,2010,Takeda (United States),grid.419849.9,United States,National Cancer Institute,United States,0,0,0
grant.2644024,R43CA082952,THERAPEUTIC DNA VACCINES TO TREAT B CELL LYMPHOMA,281484,1999-07-01,1999.0,2001-06-30,2001,Vical (United States),grid.422245.7,United States,National Cancer Institute,United States,0,0,0
grant.2641283,R43AI063830,Influenza Virus-like Particles As Vaccines,1010042,2005-05-01,2005.0,2007-12-31,2007,TechnoVax (United States),grid.438336.9,United States,National Institute of Allergy and Infectious Diseases,United States,1,7,0
grant.2641280,R43AI063820,A Mucosal Vaccine for HSV-2,583103,2006-04-01,2006.0,2008-03-31,2008,Biomedical Research Models (United States),grid.423392.d,United States,National Institute of Allergy and Infectious Diseases,United States,2,7,0
grant.2640997,R43AI053976,Novel Delivery of a New Vaccine for Tuberculosis,189617,2003-02-01,2003.0,2003-11-30,2003,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640928,R43AI052669,Development of an Intranasal Rotavirus Subunit Vaccine,100000,2002-07-15,2002.0,2003-03-14,2003,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640815,R43AI050324,A Max-Ad Vaccine for Mucosal Immunity to HIV,400000,2001-09-30,2001.0,2003-03-31,2003,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2640772,R43AI049051,DESIGN &DEVELOPMENT OF A MULTIEPITOPE VACCINE: MALARIA,302335,2001-06-01,2001.0,2002-05-31,2002,Takeda (United States),grid.419849.9,United States,National Institute of Allergy and Infectious Diseases,United States,2,3,0
grant.2640696,R43AI047558,Noninvasive delivery of skin-targeted anthrax vaccines,100000,2001-09-01,2001.0,2003-02-28,2003,Vaxin (United States),grid.422117.3,United States,National Institute of Allergy and Infectious Diseases,United States,6,4,0
grant.2640674,R43AI047506,EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS,177172,2001-09-30,2001.0,2003-09-30,2003,Hawaii Biotech (United States),grid.420613.2,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2640635,R43AI046198,NONINVASIVE DELIVERY OF SKIN-TARGETED RABIES VACCINES,100000,2001-09-30,2001.0,2003-03-29,2003,Vaxin (United States),grid.422117.3,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2640537,R43AI043816,POLYMERS FOR AUGMENTING R BOTULINUM VACCINE EFFICACY,0,1998-09-30,1998.0,1999-09-30,1999,Poly Med (United States),grid.423208.f,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2636444,R41AI068290,New attenuated anthrax vaccine,865145,2006-08-01,2006.0,2010-07-31,2010,,,,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2632162,R34AI081875,Recombinant hPIV3 and RSV Sendai Virus Vaccine Phase I Clinical Trial Development,126000,2009-09-23,2009.0,2010-08-31,2010,St. Jude Children's Research Hospital,grid.240871.8,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2631500,R33AI073182,BCG as an HIV vaccine vector,960732,2007-07-01,2007.0,2012-08-31,2012,University of Cape Town,grid.7836.a,South Africa,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2604709,R21CA127181,Exploiting the Unique T Cell Response to CMV for a Cancer Vaccine,369570,2009-04-01,2009.0,2011-03-31,2011,Oregon Health & Science University,grid.5288.7,United States,National Cancer Institute,United States,2,0,0
grant.2601355,R21AI105479,Rabbit model to assess reactogenicity and immunogenicity of Salmonella vaccines,423938,2013-02-01,2013.0,2016-01-31,2016,Arizona State University,grid.215654.1,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2600357,R21AI088450,E. coli O157:  H7 Vaccine Development,420750,2011-09-27,2011.0,2014-11-30,2014,The University of Texas Medical Branch at Galveston,grid.176731.5,United States,National Institute of Allergy and Infectious Diseases,United States,3,0,0
grant.2599306,R21AI073182,BCG as an HIV vaccine vector,294015,2007-07-01,2007.0,2009-06-30,2009,University of Cape Town,grid.7836.a,South Africa,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2598906,R21AI065591,Avian Influenza Virus Vaccines Bearing Immunomodulators,392593,2006-04-01,2006.0,2009-03-31,2009,Virginia Tech,grid.438526.e,United States,National Institute of Allergy and Infectious Diseases,United States,4,0,0
grant.2598853,R21AI064898,Vaccine potential of promiscuous mycobacterial peptides,363766,2006-03-01,2006.0,2009-02-28,2009,The University of Texas Health Science Center at Tyler,grid.267310.1,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2598797,R21AI064179,Novel Adjuvant Formulations for Genetic Vaccines,399165,2006-06-01,2006.0,2009-11-30,2009,The University of Texas at Austin,grid.89336.37,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2598470,R21AI059225,Development of a New Tularemia Vaccine,616668,2005-07-15,2005.0,2009-06-30,2009,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2598285,R21AI055946,New genetic vaccine to protect aganist botulism,630000,2003-08-01,2003.0,2007-07-31,2007,University of Rochester,grid.16416.34,United States,National Institute of Allergy and Infectious Diseases,United States,5,1,0
grant.2598003,R21AI053346,Immunodominant epitopes of a smallpox vaccine in humans,412295,2002-09-01,2002.0,2004-08-31,2004,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2597976,R21AI052842,TNFSF APC activators for HIV Vaccines,422100,2002-09-01,2002.0,2005-08-31,2005,Veterans Medical Research Foundation of San Diego,grid.44214.37,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.2597911,R21AI051561,Pro-Apoptotic Tuberculosis Vaccine,305965,2002-06-15,2002.0,2003-05-31,2003,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2597795,R21AI049135,TRANSCRIPTION-REGULATING VECTORS FOR ANTIVIRAL VACCINES,458313,2001-07-01,2001.0,2004-06-30,2004,University of California Los Angeles,grid.19006.3e,United States,National Institute of Allergy and Infectious Diseases,United States,13,0,0
grant.2597419,R21AI042688,"NOVEL, LIVE, RECOMBINANT YEAST BASED HIV VACCINE",0,1997-09-30,1997.0,2000-09-29,2000,University of Colorado Anschutz Medical Campus,grid.430503.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,7,0
grant.2597353,R21AI041914,Oral Vaccine-Induced Cellular Immunity Against HIV-1,371250,2001-09-30,2001.0,2003-09-29,2003,University System of Maryland,grid.410443.6,United States,National Institute of Allergy and Infectious Diseases,United States,8,0,0
grant.2585998,R13FD004836,Annual Conference on Vaccine Research,50000,2013-04-22,2013.0,2018-04-07,2018,,,,United States Food and Drug Administration,United States,0,0,0
grant.2581500,R13AI058748,Conference HIV Vaccine Development Progress &Prospects,20000,2004-04-01,2004.0,2005-03-31,2005,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2581365,R13AI044741,CONFERENCE ON HIV VACCINE DEVELOPMENT,0,1999-01-07,1999.0,2000-01-06,2000,Keystone Symposia On Molecular and Cellular Biology,grid.280268.6,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2566930,R03AI054174,Host SNPs and Altered Responses to Influenza Vaccine,151000,2003-05-01,2003.0,2006-04-30,2006,Vanderbilt University,grid.152326.1,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2471015,R01CA056059,GANGLIOSIDE MEDIATED IMMUNOTHERAPY OF CANCER,0,1992-03-01,1992.0,1996-02-29,1996,Saint John's Health Center,grid.416507.1,United States,National Cancer Institute,United States,6,5,0
grant.2459743,R01AI102693,NKT cells as modulators of AIDS vaccine efficacy,3203238,2012-06-19,2012.0,2018-05-31,2018,Tulane University,grid.265219.b,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2459536,R01AI098884,Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive,5754468,2012-05-01,2012.0,2018-04-30,2018,Protein Potential (United States),grid.423438.a,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2458866,R01AI085622,Novel Adjuvant Discovery in Vaccine Therapy,3423141,2010-06-01,2010.0,2015-05-31,2015,Memorial Sloan Kettering Cancer Center,grid.51462.34,United States,National Institute of Allergy and Infectious Diseases,United States,10,1,0
grant.2457499,R01AI068769,QUALITATIVE NATURE OF ANTIBODIES TO HCV GLYCOPROTEIN SUBUNIT VACCINE IN HUMANS,1282020,2006-05-01,2006.0,2012-04-30,2012,Saint Louis University,grid.262962.b,United States,National Institute of Allergy and Infectious Diseases,United States,11,0,0
grant.2456659,R01AI059396,Vaccine Development in Leishmaniasis,1179438,2004-04-01,2004.0,2008-03-31,2008,University of Pennsylvania,grid.25879.31,United States,National Institute of Allergy and Infectious Diseases,United States,5,0,0
grant.2456070,R01AI053593,The Immunobiology of the Hemoglobin Receptor of H. ducreyi,1514433,2003-02-01,2003.0,2011-08-31,2011,University of North Carolina at Chapel Hill,grid.10698.36,United States,National Institute of Allergy and Infectious Diseases,United States,1,0,0
grant.2453081,R01AI036516,SALMONELLA VECTORED MULTIVALENT VACCINES,0,1994-09-01,1994.0,1999-05-31,1999,University of Washington,grid.34477.33,United States,National Institute of Allergy and Infectious Diseases,United States,0,0,0
grant.2435196,P01AI082282,Correlates of protection against SIV/SHIV challenge,5581859,2009-09-01,2009.0,2012-08-31,2012,The Wistar Institute,grid.251075.4,United States,National Institute of Allergy and Infectious Diseases,United States,8,4,0
grant.2434960,P01AI035365,LIVE ATTENUATED MULTIPLY DELETED HIV1 VACCINE FOR AIDS,8458070,1994-02-15,1994.0,2005-07-31,2005,Harvard University,grid.38142.3c,United States,National Institute of Allergy and Infectious Diseases,United States,28,0,0
grant.2424625,N01AI045200,STATISTICAL &CLINICAL COORDINATING CENTER (SC),852857,1994-03-15,1994.0,2000-09-29,2000,Fred Hutchinson Cancer Research Center,grid.270240.3,United States,National Institute of Allergy and Infectious Diseases,United States,121,0,0
grant.2424575,N01AI035166,CORE IMMUN. LAB FOR ASSESS. OF AIDS VACCINES IN PRIMATES,0,1993-06-30,1993.0,1998-07-31,1998,Beth Israel Deaconess Medical Center,grid.239395.7,United States,National Institute of Allergy and Infectious Diseases,United States,7,0,0
grant.2420915,K24CA085218,MIDCAREER INVESTIGATOR AWARD IN PATIENT ORIENTED RESEARC,570888,2000-07-05,2000.0,2005-06-30,2005,University of Washington,grid.34477.33,United States,National Cancer Institute,United States,27,4,0
grant.2410235,K08AI083079,Induction of Mucosal Cellular Immunity by HIV-1 Vaccine Vectors,253260,2009-07-01,2009.0,2014-05-31,2014,Beth Israel Deaconess Medical Center,grid.239395.7,United States,National Institute of Allergy and Infectious Diseases,United States,2,0,0
grant.100071932,V2016-011,A novel polyvalent vaccine against EBV+ lymphoma,200000,2016-11-01,2016.0,2018-10-31,2018,City Of Hope National Medical Center,grid.410425.6,United States,V Foundation for Cancer Research,United States,0,0,0
grant.8594124,e3d487fd-4649-480b-8277-8c2742712374,BIOVACSAFE – Biomarkers for enhanced vaccine safety,0,2012-03-01,2012.0,2018-02-28,2018,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8591790,35c7e654-0654-49b6-84ff-091316d4b012,"Innovation Mandate Phase 1 Sebastiaan Theuns 150269 (resubmission 140777): Development of a roaal attenuated rotavirus vaccines for gilts, sows and piglets to prevent farrowing and weaning diarrhea",0,2015-08-01,2015.0,2017-07-31,2017,Ghent University,grid.5342.0,Belgium,Belgian Federal Science Policy Office,Belgium,0,0,0
grant.8550889,W81XWH-19-1-0027,Development of a Recombinant VSV-Based Vaccine for Lassa Fever,1864897,2017-10-01,2017.0,2018-09-01,2018,The University of Texas Medical Branch at Galveston,grid.176731.5,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.8550496,W81XWH-19-1-0028,Development of a Recombinant VSV-Based Vaccine for Nipah Virus,1864897,2017-10-01,2017.0,2018-09-01,2018,The University of Texas Medical Branch at Galveston,grid.176731.5,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.8472155,W81XWH-19-1-0208,Vaccines for Pseudomonas aeruginosa,1883749,2017-10-01,2017.0,2018-09-01,2018,Boston Children's Hospital,grid.2515.3,United States,Congressionally Directed Medical Research Programs,United States,0,0,0
grant.8456826,,The Road Ahead: HIV Vaccines,11311,2016-04-01,2016.0,2017-03-31,2017,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8456825,,"HIV Vaccines: Progress, Failures and New Directions",14657,2018-05-01,2018.0,2019-04-30,2019,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8456820,,HIV Vaccines: Where do we go next?,15405,2017-11-01,2017.0,2018-10-31,2018,Ottawa Hospital,grid.412687.e,Canada,Canadian Institutes of Health Research,Canada,0,0,0
grant.8219774,39970353,表达人精子膜蛋白的沙门氏菌的制备及免疫应答的研究,14488,2000-01-01,2000.0,2002-12-31,2002,,,,National Natural Science Foundation of China,China,0,0,0
grant.8215413,39570547,猪伪狂犬病和细小病毒基因工程疫苗的研究,10844,1996-01-01,1996.0,1998-12-31,1998,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,0,0,0
grant.8173004,30570043,猪圆环病毒活疫苗载体的构建及免疫原性分析,34725,2006-01-01,2006.0,2008-12-31,2008,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,3,0,0
grant.8171715,30371326,利用人体天然抗体治疗肿瘤,24980,2004-01-01,2004.0,2007-12-31,2007,Sun Yat-sen University,grid.12981.33,China,National Natural Science Foundation of China,China,1,0,0
grant.8171555,30370075,人结核杆菌多抗原基因重组BCG疫苗的研究,9664,2004-01-01,2004.0,2004-12-31,2004,Huazhong University of Science and Technology,grid.33199.31,China,National Natural Science Foundation of China,China,0,0,0
grant.8170908,30271355,IL-15cDNA协同HPV16E6E7新型rAAV疫苗的抗肿瘤免疫研究,23024,2003-01-01,2003.0,2005-12-31,2005,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,1,0,0
grant.8170796,30271222,手性多重抗原肽疫苗的制备及实验研究,24240,2003-01-01,2003.0,2005-12-31,2005,Jilin University,grid.64924.3d,China,National Natural Science Foundation of China,China,0,0,0
grant.8170794,30271220,口蹄疫DNA疫苗粘膜免疫效果的研究,21815,2003-01-01,2003.0,2005-12-31,2005,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,1,0,0
grant.8170663,30271016,鱼类淋巴囊肿病毒中和单克隆抗体研制及其流行病学研究,21815,2003-01-01,2003.0,2005-12-31,2005,Ocean University of China,grid.4422.0,China,National Natural Science Foundation of China,China,9,0,0
grant.8170645,30270991,伊氏锥虫VSG抗原库建立及其免疫保护机理,27267,2003-01-01,2003.0,2005-12-31,2005,China Agricultural University,grid.22935.3f,China,National Natural Science Foundation of China,China,5,0,0
grant.8170640,30270983,马立克氏病疫苗二次免疫增强抗肿瘤免疫机理的研究,21815,2003-01-01,2003.0,2005-12-31,2005,Yangzhou University,grid.268415.c,China,National Natural Science Foundation of China,China,1,0,0
grant.8170373,30270594,幽门螺杆菌疫苗免疫保护机制的研究,23024,2003-01-01,2003.0,2005-12-31,2005,Shanghai Jiao Tong University,grid.16821.3c,China,National Natural Science Foundation of China,China,1,0,0
grant.8169342,30200245,基于Ii分子的HCV-NS3 Th1表位基因疫苗的设计及功能研究,25451,2003-01-01,2003.0,2005-12-31,2005,Academy of Military Medical Sciences,grid.410740.6,China,National Natural Science Foundation of China,China,1,0,0
grant.8169087,30171057,利用生物降解微球制做抗癌症双功能融合蛋白免疫疫苗,21740,2002-01-01,2002.0,2004-12-31,2004,Tsinghua University,grid.12527.33,China,National Natural Science Foundation of China,China,0,0,0
grant.8169047,30171010,以减毒沙门氏菌为载体二价防龋DNA疫苗实验研究,21740,2002-01-01,2002.0,2004-12-31,2004,Shandong University,grid.27255.37,China,National Natural Science Foundation of China,China,3,0,0
grant.8168649,30170440,谷氨酸脱羧酶DNA疫苗预防胰岛炎研究,20536,2002-01-01,2002.0,2004-12-31,2004,Central South University,grid.216417.7,China,National Natural Science Foundation of China,China,0,0,0
grant.8168333,30160086,转基因植物可食嵌合体防龋疫苗的研究,23006,2002-01-01,2002.0,2005-12-31,2005,Zunyi Medical University,grid.417409.f,China,National Natural Science Foundation of China,China,0,0,0
grant.8167459,30070718,间日疟原虫传播阻断疫苗候选蛋白Pvs25和Pvs28基因的克隆和表达,18114,2001-01-01,2001.0,2003-12-31,2003,China Medical University,grid.412449.e,China,National Natural Science Foundation of China,China,1,0,0
grant.8167453,30070711,CpG寡核苷酸作为人用疫苗佐剂的研究,19322,2001-01-01,2001.0,2003-12-31,2003,Chinese Center For Disease Control and Prevention,grid.198530.6,China,National Natural Science Foundation of China,China,0,0,0
grant.8108168,16770,"Investigation of porcine reproductive and respiratory syndrome: chronic losses, vaccine use and export markets.",0,1997-05-01,1997.0,1999-04-30,1999,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8107600,25670,PRRS Virus:  The Implications for the Breeding Herd,0,2001-05-01,2001.0,2006-04-30,2006,University of Guelph,grid.34429.38,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.8106422,FS2011-1105,Subunit vaccines directed against Salmonella Enteritidis in poultry,0,2012-04-02,2012.0,2014-12-31,2014,University of Saskatchewan,grid.25152.31,Canada,"Ministry of Agriculture, Food and Rural Affairs",Canada,0,0,0
grant.7923972,18/24390-6,Avaliação das estratégias de vacinação para a gripe: impacto da mutação viral,0,2019-02-02,2019.0,2019-02-16,2019,Sao Paulo State University,grid.410543.7,Brazil,São Paulo Research Foundation,Brazil,0,0,0
grant.7878131,1060433,Hepatitis C vaccines,353299,2014-01-01,2014.0,2018-12-31,2018,University of Melbourne; University of Melbourne,grid.1008.9; grid.1008.9,Australia; Australia,National Health and Medical Research Council,Australia,0,0,0
